<SEC-DOCUMENT>0001824293-23-000147.txt : 20230814
<SEC-HEADER>0001824293-23-000147.hdr.sgml : 20230814
<ACCEPTANCE-DATETIME>20230814080845
ACCESSION NUMBER:		0001824293-23-000147
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		67
CONFORMED PERIOD OF REPORT:	20230630
FILED AS OF DATE:		20230814
DATE AS OF CHANGE:		20230814

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GRI BIO, Inc.
		CENTRAL INDEX KEY:			0001824293
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				824369909
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40034
		FILM NUMBER:		231166435

	BUSINESS ADDRESS:	
		STREET 1:		2223 AVENIDA DE LA PLAYA
		STREET 2:		SUITE 208
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
		BUSINESS PHONE:		(619) 400-1171

	MAIL ADDRESS:	
		STREET 1:		2223 AVENIDA DE LA PLAYA
		STREET 2:		SUITE 208
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Vallon Pharmaceuticals, Inc.
		DATE OF NAME CHANGE:	20200910
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ck0001824293-20230630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with the Workiva Platform--><!--Copyright 2023 Workiva--><!--r:03e6aede-a80d-4c93-aec7-6df3e5ac1c16,g:d01e6060-7205-4c9b-8c6f-b994c931683b,d:ed77ea4fb48541edb9612582cb5c50b7--><html xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ck0001824293="http://www.vallon-pharma.com/20230630" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:srt="http://fasb.org/srt/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ck0001824293-20230630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-29">0001824293</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" id="f-30">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-31">2023</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-32">Q2</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-33">FALSE</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="c-41" decimals="4" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="f-259">0.0333</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ck0001824293-20230630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-08-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-04-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-21</xbrli:startDate><xbrli:endDate>2023-04-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-21</xbrli:startDate><xbrli:endDate>2023-04-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ck0001824293:GRIBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-21</xbrli:startDate><xbrli:endDate>2023-04-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ck0001824293:StockSubjectToPutRightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ck0001824293:StockSubjectToPutRightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ck0001824293:ConvertiblePromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ck0001824293:ConvertiblePromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:ExchangeWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-04-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ck0001824293:WarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ck0001824293:WarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ck0001824293:WarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-13</xbrli:startDate><xbrli:endDate>2022-12-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-13</xbrli:startDate><xbrli:endDate>2022-12-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-14</xbrli:startDate><xbrli:endDate>2022-12-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-09</xbrli:startDate><xbrli:endDate>2023-03-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:BridgeWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:BridgeWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-14</xbrli:startDate><xbrli:endDate>2022-12-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:BridgeWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-09</xbrli:startDate><xbrli:endDate>2023-03-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:TEPNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:TEPNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:TEPNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:TEPNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:CallOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:TEPNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:TEPNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:TEPNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:TEPNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:TEPNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:TEPNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:TEPNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:PutOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesA1WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesA2WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesTWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesA1WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesA2WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:EquityWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:BridgeWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:ExchangeWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:BridgeWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:BankerWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:BankerWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:BankerWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:EquityWarrantsExchangeWarrantsAndBankerWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:EquityWarrantsExchangeWarrantsAndBankerWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:EquityWarrantsExchangeWarrantsAndBankerWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:EquityWarrantsExchangeWarrantsAndBankerWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInNovember2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInDecember2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInJune2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInFebruary2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInMay2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInJuly2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInApril2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringIn60MonthsAfterRegistrationDateOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringIn60MonthsAfterRegistrationDateOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringIn60MonthsAfterRegistrationDateTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringIn60MonthsAfterRegistrationDateTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringIn24MonthsAfterRegistrationDateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringIn24MonthsAfterRegistrationDateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ck0001824293:PrivateGRIPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ck0001824293:AmendedAndRestated2018EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-21</xbrli:startDate><xbrli:endDate>2023-04-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ck0001824293:AmendedAndRestated2018EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ck0001824293:AmendedAndRestated2018EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ck0001824293:A2018EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ck0001824293:AmendedAndRestated2018EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ck0001824293:FormerChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-21</xbrli:startDate><xbrli:endDate>2023-04-21</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ied77ea4fb48541edb9612582cb5c50b7_1"></div><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ied77ea4fb48541edb9612582cb5c50b7_7">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:2.5pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">____________________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1"><ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-2">10-Q</ix:nonNumeric></ix:nonNumeric></span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">____________________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.150%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="f-3">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the quarterly period ended </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-4"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-5">June 30, 2023</ix:nonNumeric></ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.150%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-6">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the transition period from_________to_________</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number:&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-7">001-40034</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">____________________________________</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><img src="ck0001824293-20230630_g1.jpg" alt="GRI_ LOGO SELECT_ColorJPG.jpg" style="height:101px;margin-bottom:5pt;vertical-align:text-bottom;width:201px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-8">GRI BIO, INC.</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in its Charter)</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">____________________________________</span></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.622%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-9">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-10">82-4369909</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(State or other jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">incorporation or organization)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Identification No.)&#160;</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-11">2223 Avenida de la Playa</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-12">#208</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-13">La Jolla</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-14">CA</ix:nonNumeric>  <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-15">92037</ix:nonNumeric></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Address of principal executive offices, including zip code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> (<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-16">619</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-17">400-1170</ix:nonNumeric></span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:8pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.513%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-18">Common Stock, par value $0.0001<br/>per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-19">GRI</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-20">The Nasdaq</ix:nonNumeric> Capital Market</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-21">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-22">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ied77ea4fb48541edb9612582cb5c50b7_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</span></div><div style="margin-bottom:8pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">o</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-23">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-24">x</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="f-25">x</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityExTransitionPeriod" format="ixt:fixed-false" id="f-26">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-27">x</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of August 6, 2023, <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-28">2,956,354</ix:nonFraction> shares of the Registrant&#8217;s common stock were outstanding.</span></div><div style="margin-bottom:8pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div></div><div id="ied77ea4fb48541edb9612582cb5c50b7_7"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ied77ea4fb48541edb9612582cb5c50b7_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-bottom:8pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#ied77ea4fb48541edb9612582cb5c50b7_13">PART&#160;I. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#ied77ea4fb48541edb9612582cb5c50b7_13">FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ied77ea4fb48541edb9612582cb5c50b7_13">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ied77ea4fb48541edb9612582cb5c50b7_16">Item&#160;1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ied77ea4fb48541edb9612582cb5c50b7_16">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ied77ea4fb48541edb9612582cb5c50b7_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated <a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ied77ea4fb48541edb9612582cb5c50b7_19">Balance Sheets as of </a>June 30, 2023<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ied77ea4fb48541edb9612582cb5c50b7_19"> (unaudited) and </a>December 31, 2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ied77ea4fb48541edb9612582cb5c50b7_19">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Operations (unaudited) for the three and six <a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ied77ea4fb48541edb9612582cb5c50b7_22">months ended</a> June 30, 2023<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ied77ea4fb48541edb9612582cb5c50b7_22"> and</a> 2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ied77ea4fb48541edb9612582cb5c50b7_22">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ied77ea4fb48541edb9612582cb5c50b7_25">Consolidated </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ied77ea4fb48541edb9612582cb5c50b7_25">Statements of Changes in Stockholders&#8217; Equity</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ied77ea4fb48541edb9612582cb5c50b7_25"> (Deficit)</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ied77ea4fb48541edb9612582cb5c50b7_25"> (unaudited) for the </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ied77ea4fb48541edb9612582cb5c50b7_25">thre</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ied77ea4fb48541edb9612582cb5c50b7_25">e and </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ied77ea4fb48541edb9612582cb5c50b7_25">six</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ied77ea4fb48541edb9612582cb5c50b7_25"> months ended </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ied77ea4fb48541edb9612582cb5c50b7_25">June 30, 2023</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ied77ea4fb48541edb9612582cb5c50b7_25"> </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ied77ea4fb48541edb9612582cb5c50b7_25">and </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ied77ea4fb48541edb9612582cb5c50b7_25">2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ied77ea4fb48541edb9612582cb5c50b7_25">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Cash Flows (unaudited) for the six months ended June 30, 2023<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ied77ea4fb48541edb9612582cb5c50b7_28"> and </a>2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ied77ea4fb48541edb9612582cb5c50b7_28">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ied77ea4fb48541edb9612582cb5c50b7_31">Notes to Unaudited Interi</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ied77ea4fb48541edb9612582cb5c50b7_31">m</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ied77ea4fb48541edb9612582cb5c50b7_31"> Consolidate</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ied77ea4fb48541edb9612582cb5c50b7_31">d</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ied77ea4fb48541edb9612582cb5c50b7_31"> </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ied77ea4fb48541edb9612582cb5c50b7_31">F</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ied77ea4fb48541edb9612582cb5c50b7_31">inancial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ied77ea4fb48541edb9612582cb5c50b7_31">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ied77ea4fb48541edb9612582cb5c50b7_79">Item&#160;2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ied77ea4fb48541edb9612582cb5c50b7_79">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ied77ea4fb48541edb9612582cb5c50b7_79">19</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ied77ea4fb48541edb9612582cb5c50b7_103">Item&#160;3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ied77ea4fb48541edb9612582cb5c50b7_103">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ied77ea4fb48541edb9612582cb5c50b7_103">25</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ied77ea4fb48541edb9612582cb5c50b7_106">Item&#160;4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ied77ea4fb48541edb9612582cb5c50b7_106">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ied77ea4fb48541edb9612582cb5c50b7_106">25</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#ied77ea4fb48541edb9612582cb5c50b7_109">PART&#160;II. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#ied77ea4fb48541edb9612582cb5c50b7_109">OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ied77ea4fb48541edb9612582cb5c50b7_109">26</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ied77ea4fb48541edb9612582cb5c50b7_112">Item&#160;1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ied77ea4fb48541edb9612582cb5c50b7_112">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ied77ea4fb48541edb9612582cb5c50b7_112">26</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ied77ea4fb48541edb9612582cb5c50b7_115">Item&#160;1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ied77ea4fb48541edb9612582cb5c50b7_115">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ied77ea4fb48541edb9612582cb5c50b7_115">26</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ied77ea4fb48541edb9612582cb5c50b7_130">Item&#160;6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ied77ea4fb48541edb9612582cb5c50b7_130">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ied77ea4fb48541edb9612582cb5c50b7_130">27</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ied77ea4fb48541edb9612582cb5c50b7_133">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ied77ea4fb48541edb9612582cb5c50b7_133">29</a></span></div></td></tr></table></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><div id="ied77ea4fb48541edb9612582cb5c50b7_13"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ied77ea4fb48541edb9612582cb5c50b7_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I&#8212;FINANCIAL INFORMATION</span></div><div id="ied77ea4fb48541edb9612582cb5c50b7_16"></div><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Financial Statements.</span></div><div id="ied77ea4fb48541edb9612582cb5c50b7_19"></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GRI Bio, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.166%"><tr><td style="width:1.0%"></td><td style="width:71.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.360%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-34">4,799</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="f-35">9</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="f-36">793</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="f-37">303</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-38">5,592</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" scale="3" id="f-39">312</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-40">9</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-41">4</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="f-42">41</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="f-43">67</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-44">5,642</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" scale="3" id="f-45">383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and stockholders' equity (deficit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsPayableCurrent" scale="3" id="f-46">307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-47">1,294</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-48">1,193</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="f-49">36</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advances from employees</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ck0001824293:EmployeeAdvancesCurrent" format="ixt:fixed-zero" scale="3" id="f-50">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ck0001824293:EmployeeAdvancesCurrent" scale="3" id="f-51">5</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" id="f-52">63</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:WarrantsAndRightsOutstanding" format="ixt:fixed-zero" scale="3" id="f-53">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bridge promissory note, net</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:NotesPayableCurrent" format="ixt:fixed-zero" scale="3" id="f-54">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:NotesPayableCurrent" scale="3" id="f-55">602</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, current</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-56">41</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-57">57</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-58">1,604</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-59">1,994</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, non-current</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="f-60">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="f-61">14</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-62">1,604</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-63">2,008</ix:nonFraction></span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 11)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-3" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-64"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-65"></ix:nonFraction></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders' equity (deficit):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, <ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-66"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-67">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-68"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-69">250,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of June&#160;30, 2023 and December&#160;31, 2022; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-70"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-71">2,956,354</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-72"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-73">999,748</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of June&#160;30, 2023 and December&#160;31, 2022, respectively</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockValueOutstanding" format="ixt:fixed-zero" scale="3" id="f-74">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValueOutstanding" format="ixt:fixed-zero" scale="3" id="f-75">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in-capital</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-76">31,430</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-77">16,871</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-78">27,392</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-79">18,496</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity (deficit)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-80">4,038</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-81">1,625</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity (deficit)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-82">5,642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="f-83">383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to unaudited interim consolidated financial statements.</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="ied77ea4fb48541edb9612582cb5c50b7_22"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ied77ea4fb48541edb9612582cb5c50b7_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GRI Bio, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Operations</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:8pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.043%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.352%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.352%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.352%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.954%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:10pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="f-84">880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="f-85">59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="f-86">997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="f-87">119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-88">5,054</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="f-89">130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-90">5,926</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="f-91">268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28.35pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-92">5,934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingExpenses" scale="3" id="f-93">189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-94">6,923</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingExpenses" scale="3" id="f-95">387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-96">5,934</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" scale="3" id="f-97">189</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-98">6,923</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" scale="3" id="f-99">387</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant liability</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ck0001824293:ChangeInFairValueOfWarrantLiability" scale="3" id="f-100">122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ck0001824293:ChangeInFairValueOfWarrantLiability" format="ixt:fixed-zero" scale="3" id="f-101">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ck0001824293:ChangeInFairValueOfWarrantLiability" scale="3" id="f-102">122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ck0001824293:ChangeInFairValueOfWarrantLiability" format="ixt:fixed-zero" scale="3" id="f-103">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="f-104">934</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="f-105">106</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="f-106">2,095</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="f-107">210</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-108">6,746</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="f-109">295</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-110">8,896</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="f-111">597</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share of common stock, basic and diluted</span></div></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-112"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-113">2.79</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-114"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-115">0.35</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-116"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-117">5.23</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-118"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-119">0.70</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-120"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-121">2,417,785</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-122"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-123">851,419</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-124"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-125">1,701,864</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-126"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-127">851,419</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to unaudited interim consolidated financial statements.</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="ied77ea4fb48541edb9612582cb5c50b7_25"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ied77ea4fb48541edb9612582cb5c50b7_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GRI Bio, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Changes in Stockholders&#8217; Equity (Deficit)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except shares)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:8pt;margin-top:12pt"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.493%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.024%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.024%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.354%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.083%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.470%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.896%"></td><td style="width:0.1%"></td></tr><tr style="height:26pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Redeemable Convertible Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common&#160;Stock</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additional&#160;Paid-in Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Stockholders&#8217; Deficit</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance,&#160;December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-128">7,816</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="f-129">124</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-130">851,419</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-131">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-132">10,430</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-133">15,278</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-134">4,848</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="f-135">302</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="f-136">302</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-137">7,816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="f-138">124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-139">851,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-140">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-141">10,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-142">15,580</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-143">5,150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="f-144">295</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="f-145">295</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-19" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-146">7,816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="f-147">124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-20" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-148">851,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-149">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-150">10,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-151">15,875</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-152">5,445</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.493%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.024%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.024%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.354%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.083%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.470%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.896%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Redeemable Convertible Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common&#160;Stock</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additional&#160;Paid-in Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Stockholders&#8217; Equity (Deficit)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance,&#160;December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-23" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-153">999,748</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-154">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-155">16,871</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-156">18,496</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-157">1,625</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-158">13</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-159">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted stock vesting</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-28" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="f-160">467</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrant issuance</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="f-161">532</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="f-162">532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-163">2,150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-164">2,150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, March 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-30" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-165">1,000,215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-166">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-167">17,416</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-168">20,646</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-169">3,230</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-170">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-171">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted stock vesting</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-35" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="f-172">164,038</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrant exercise</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-35" decimals="INF" name="ck0001824293:StockIssuedDuringPeriodSharesWarrantExercise" format="ixt:num-dot-decimal" scale="0" id="f-173">43,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="ck0001824293:StockIssuedDuringPeriodValueWarrantExercises" scale="3" id="f-174">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ck0001824293:StockIssuedDuringPeriodValueWarrantExercises" scale="3" id="f-175">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock in pre-closing financing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-35" decimals="INF" name="ck0001824293:StockIssuedDuringPeriodSharesPreClosingFinancing" format="ixt:num-dot-decimal" scale="0" id="f-176">1,214,912</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="ck0001824293:StockIssuedDuringPeriodValuePreClosingFinancing" format="ixt:num-dot-decimal" scale="3" id="f-177">11,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ck0001824293:StockIssuedDuringPeriodValuePreClosingFinancing" format="ixt:num-dot-decimal" scale="3" id="f-178">11,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for settlement of bridge note</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-35" decimals="INF" name="ck0001824293:StockIssuedDuringPeriodSharesSettlementOfDebt" format="ixt:num-dot-decimal" scale="0" id="f-179">54,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="ck0001824293:StockIssuedDuringPeriodValueSettlementOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-180">3,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ck0001824293:StockIssuedDuringPeriodValueSettlementOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-181">3,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for reverse recapitalization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-35" decimals="INF" name="ck0001824293:StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses" format="ixt:num-dot-decimal" scale="0" id="f-182">30,542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="ck0001824293:StockIssuedDuringPeriodValueReverseRecapitalizationExpenses" format="ixt:num-dot-decimal" scale="3" id="f-183">1,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ck0001824293:StockIssuedDuringPeriodValueReverseRecapitalizationExpenses" format="ixt:num-dot-decimal" scale="3" id="f-184">1,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock to Vallon stockholders in reverse recapitalization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-35" decimals="INF" name="ck0001824293:StockIssuedDuringPeriodSharesReverseRecapitalization" format="ixt:num-dot-decimal" scale="0" id="f-185">448,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" sign="-" name="ck0001824293:StockIssuedDuringPeriodValueReverseRecapitalization" format="ixt:num-dot-decimal" scale="3" id="f-186">2,940</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="ck0001824293:StockIssuedDuringPeriodValueReverseRecapitalization" format="ixt:num-dot-decimal" scale="3" id="f-187">2,940</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-188">6,746</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-189">6,746</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-37" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-190">2,956,354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-191">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-192">31,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-193">27,392</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-194">4,038</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to unaudited interim consolidated financial statements. </span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="ied77ea4fb48541edb9612582cb5c50b7_28"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ied77ea4fb48541edb9612582cb5c50b7_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GRI Bio, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:8pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-195">8,896</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="f-196">597</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Depreciation" scale="3" id="f-197">2</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Depreciation" scale="3" id="f-198">1</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt discounts and issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="f-199">2,104</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:fixed-zero" scale="3" id="f-200">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" scale="3" id="f-201">26</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="f-202">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of warrant liability</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="f-203">63</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:fixed-zero" scale="3" id="f-204">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reduction in operating right of use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="f-205">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="f-206">23</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-207">750</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-208">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-209">4,179</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="f-210">79</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-211">1,157</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="f-212">409</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="f-213">30</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="f-214">23</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-215">2,119</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="f-216">116</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-217">8</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-218">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash used in investing activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="f-219">8</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:fixed-zero" scale="3" id="f-220">&#8212;</ix:nonFraction></span></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Advances from employees</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ck0001824293:ProceedsFromAdvancesFromEmployees" scale="3" id="f-221">190</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ck0001824293:ProceedsFromAdvancesFromEmployees" scale="3" id="f-222">35</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayment of advances from employees</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ck0001824293:RepaymentOfAdvancesFromEmployees" scale="3" id="f-223">195</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ck0001824293:RepaymentOfAdvancesFromEmployees" format="ixt:fixed-zero" scale="3" id="f-224">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock in pre-closing financing</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-225">12,250</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-226">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from issuance of bridge promissory note</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromNotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-227">1,250</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromNotesPayable" format="ixt:fixed-zero" scale="3" id="f-228">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from warrant exercise</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="f-229">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:fixed-zero" scale="3" id="f-230">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net liabilities assumed in connection with reverse recapitalization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ck0001824293:NetLiabilitiesAssumedInConnectionWithReverseRecapitalization" format="ixt:num-dot-decimal" scale="3" id="f-231">2,939</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ck0001824293:NetLiabilitiesAssumedInConnectionWithReverseRecapitalization" format="ixt:fixed-zero" scale="3" id="f-232">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payment of reverse recapitalization costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ck0001824293:PaymentOfReverseRecapitalizationCosts" format="ixt:num-dot-decimal" scale="3" id="f-233">2,984</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ck0001824293:PaymentOfReverseRecapitalizationCosts" format="ixt:fixed-zero" scale="3" id="f-234">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payment of deferred stock issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="f-235">517</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:fixed-zero" scale="3" id="f-236">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payment of debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="f-237">150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:fixed-zero" scale="3" id="f-238">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-239">6,917</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="f-240">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-241">4,790</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="f-242">81</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-243">9</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-244">90</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-245">4,799</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-246">9</ix:nonFraction></span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplemental disclosure of non-cash financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Issuance of stock for repayment of bridge promissory note</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ck0001824293:StockIssuedForRepaymentOfNotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-247">3,333</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ck0001824293:StockIssuedForRepaymentOfNotesPayable" format="ixt:fixed-zero" scale="3" id="f-248">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Recognition of debt discount and additional paid-in-capital for issuance of warrants in connection with the<br/>&#160;&#160;issuance of promissory notes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ck0001824293:DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants" scale="3" id="f-249">532</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ck0001824293:DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants" format="ixt:fixed-zero" scale="3" id="f-250">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Issuance of stock for payment of reverse recapitalization costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ck0001824293:StockIssuedForPaymentOfReverseRecapitalizationCosts" format="ixt:num-dot-decimal" scale="3" id="f-251">1,875</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ck0001824293:StockIssuedForPaymentOfReverseRecapitalizationCosts" format="ixt:fixed-zero" scale="3" id="f-252">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Issuance of warrants for payment of stock issuance costs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ck0001824293:WarrantsIssued" scale="3" id="f-253">18</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-7" xsi:nil="true" name="ck0001824293:WarrantsIssued" id="f-254"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Merger costs included in accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ck0001824293:NoncashMergerRelatedCostsFinancingActivities" scale="3" id="f-255">72</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ck0001824293:NoncashMergerRelatedCostsFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-256">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to unaudited interim consolidated financial statements.</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="ied77ea4fb48541edb9612582cb5c50b7_31"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ied77ea4fb48541edb9612582cb5c50b7_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GRI Bio, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Interim Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div id="ied77ea4fb48541edb9612582cb5c50b7_34"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:NatureOfOperations" id="f-257" continuedAt="f-257-1" escape="true">ORGANIZATION AND DESCRIPTION OF BUSINESS</ix:nonNumeric></span></div><ix:continuation id="f-257-1"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GRI Bio, Inc. (GRI or the Company), based in La Jolla, CA, was incorporated in Delaware in May 2009, which is the date of inception.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GRI is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies that target serious diseases associated with dysregulated immune responses leading to inflammatory, fibrotic, and autoimmune disorders. The Company&#8217;s goal is to be an industry leader in developing therapies to treat these diseases and to improve the lives of patients suffering from such diseases. The Company&#8217;s lead product candidate, GRI-0621, is an oral inhibitor of type 1 Natural Killer T (iNKT I) cells and is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis (IPF). The Company&#8217;s product candidate portfolio also includes GRI-0803 and a proprietary library of 500+ compounds. GRI-0803, the lead molecule selected from the library, is a novel oral agonist of type 2 Natural Killer T (NKT II) cells and is being developed for the treatment of autoimmune disorders, with much of its preclinical work in Systemic Lupus Erythematosus Disease (SLE) or lupus and multiple sclerosis (MS).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reverse Merger with Vallon Pharmaceuticals, Inc.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 21, 2023, the Company (formerly Vallon Pharmaceuticals, Inc.(Vallon)) consummated a merger with GRI Bio Operations, Inc. (formerly GRI Bio, Inc.) (Private GRI) pursuant to an Agreement and Plan of Merger, as amended (the Merger Agreement), by and among the Company, Private GRI and Vallon Merger Sub, Inc. (Merger Sub), a Delaware corporation and wholly-owned subsidiary of the Company (Note 4). The Merger Agreement provided for the merger of Merger Sub with and into Private GRI, with Private GRI surviving the merger as a wholly-owned subsidiary of the Company (the Merger). In connection with the closing of the Merger (the Closing), the Company amended its certificate of incorporation and bylaws to change its name from &#8220;Vallon Pharmaceuticals, Inc.&#8221; to &#8220;GRI Bio, Inc.&#8221; In addition, prior to the effective time of the Merger (the Effective Time), the Company effected a reverse stock split of the Company&#8217;s common stock at a ratio of 1 for 30 (the Reverse Stock Split). At the Effective Time, each share of Private GRI&#8217;s common stock outstanding immediately prior to the Effective Time automatically converted solely into the right to receive a number of shares of the Company's common stock equal to <ix:nonFraction unitRef="number" contextRef="c-40" decimals="4" name="ck0001824293:CommonStockExchangeRatio" scale="0" id="f-258">0.0374</ix:nonFraction> (the Exchange Ratio).</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as otherwise indicated or as the context requires, references herein to &#8220;GRI Bio,&#8221; the &#8220;Company,&#8221; or the &#8220;Combined Company,&#8221; refer to GRI Bio, Inc. on a post-Merger basis, and references to &#8220;Private GRI&#8221; refer to the business of  GRI Bio, Inc. prior to the completion of the Merger. References to &#8220;Vallon&#8221; refer to Vallon Pharmaceuticals, Inc. prior to the completion of the Merger.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 4, the Merger was accounted for as reverse recapitalization under which the historical financial statements of the Company prior to the Merger are the historical financial statements of the accounting acquirer, Private GRI. All common stock, per share and related information presented in the consolidated financial statements and notes prior to the Merger has been retroactively adjusted to reflect the Exchange Ratio and Reverse Stock Split for all periods presented, to the extent applicable.</span></div></ix:continuation><div id="ied77ea4fb48541edb9612582cb5c50b7_40"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock" id="f-260" continuedAt="f-260-1" escape="true">LIQUIDITY</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-260-1" continuedAt="f-260-2">These financial statements have been prepared on the basis that the Company is a going concern, which contemplates, among other things, the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has not generated any significant revenues from operations since inception and does not expect to do so in the foreseeable future. The Company has incurred operating losses since its inception in 2009 and as a result has incurred $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-261">27,392</ix:nonFraction> in accumulated deficit through June&#160;30, 2023. The Company has financed its working capital requirements to date through the issuance of equity and debt securities. As of June&#160;30, 2023, the Company had cash of approximately $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-262">4,799</ix:nonFraction>. </ix:continuation></span></div><div style="margin-bottom:8pt;margin-top:8pt"><span><br/></span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ied77ea4fb48541edb9612582cb5c50b7_7">Table of Contents</a></span></div></div><ix:continuation id="f-260-2"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with signing the Merger Agreement, Vallon, Private GRI and the Investor entered the Equity SPA pursuant to which the Investor agreed to invest $<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:InvestmentCompanyCommittedCapital" format="ixt:num-dot-decimal" scale="3" id="f-263">12,250</ix:nonFraction> in cash and cancel any outstanding principal and accrued interest on the Bridge Notes in return for the issuance of shares of Private GRI common stock immediately prior to the consummation of the Merger. Pursuant to the Equity SPA, immediately prior to the Closing, Private GRI issued <ix:nonFraction unitRef="shares" contextRef="c-43" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-264">6,787,219</ix:nonFraction> shares of Private GRI common stock (the Initial Shares) to the Investor and <ix:nonFraction unitRef="shares" contextRef="c-44" decimals="INF" name="ck0001824293:CommonStockHeldIntoEscrowAccount" format="ixt:num-dot-decimal" scale="0" id="f-265">27,148,877</ix:nonFraction> shares of Private GRI common stock (the Additional Shares) into escrow with an escrow agent for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-266">11,704</ix:nonFraction>, after deducting offering expenses of $<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ck0001824293:StockIssuanceCostsOfferingExpenses" scale="3" id="f-267">546</ix:nonFraction>.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the closing, pursuant to the Merger, the Initial Shares converted into an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-45" decimals="INF" name="us-gaap:ConversionOfStockSharesConverted1" format="ixt:num-dot-decimal" scale="0" id="f-268">253,842</ix:nonFraction> shares of the Company&#8217;s common stock and the Additional Shares converted into an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-45" decimals="INF" name="ck0001824293:ConversionOfStockAdditionalSharesConverted" format="ixt:num-dot-decimal" scale="0" id="f-269">1,015,368</ix:nonFraction> shares of the Company&#8217;s common stock. On May 8, 2023, in accordance with the terms of the Equity SPA, the Company and the Investor authorized the escrow agent to, subject to beneficial ownership limitations, disburse to the Investor all of the shares of the Company&#8217;s common stock issued in exchange for the Additional Shares. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the Company&#8217;s current operating plan, the Company believes that its existing cash and cash equivalents, which include the proceeds from the Equity SPA, will be sufficient to fund its operating expenses and capital expenditure requirements for twelve months from the date of the Merger (Note 4), not including the exercise of the Series T Warrants (the Series T Warrant Exercises). </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to continue as a going concern is dependent on its ability to raise additional capital to fund its business activities, including its research and development program. The Company intends to raise capital through additional issuances of common stock and/or short-term or long-term notes, but there can be no assurances any such financing will be available when needed or that the Company&#8217;s research and development efforts will be successful. If the Company is not able to obtain additional financing on acceptable terms and in the amounts necessary to fully fund its future operating requirements, it may be forced to reduce or discontinue its operations entirely. Therefore, there is substantial doubt about the Company&#8217;s ability to continue as a going concern. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from this uncertainty.</span></div></ix:continuation><div id="ied77ea4fb48541edb9612582cb5c50b7_43"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="f-270" continuedAt="f-270-1" escape="true">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="f-270-1" continuedAt="f-270-2"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-271" escape="true">The accompanying unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial periods and pursuant to the rules of the Securities and Exchange Commission (the SEC). Any reference in the accompanying unaudited interim financial statements to &#8220;authoritative guidance&#8221; is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB). The December&#160;31, 2022 balance sheet was derived from the Company&#8217;s audited financial statements.</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the unaudited interim financial statements furnished herein include all normal and recurring adjustments considered necessary to present fairly the Company&#8217;s financial position as of June&#160;30, 2023, and the results of operations and stockholders&#8217; deficit for the three and six months ended June&#160;30, 2023 and 2022 and cash flows for the three and six months ended June&#160;30, 2023 and 2022. Results of operations for the three and six months ended June&#160;30, 2023, are not necessarily indicative of the operating results that may be expected for the year ending December 31, 2023. The unaudited interim financial statements, presented herein, do not contain the required disclosures under GAAP for annual financial statements. The accompanying unaudited interim financial statements should be read in conjunction with the annual audited financial statements and related notes as of and for the year ended December&#160;31, 2022, which are included as Exhibit 99.2 of Amendment No. 2 to the Current Report on Form 8-K filed with the SEC on July 6, 2023. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-272" continuedAt="f-272-1" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates and assumptions are primarily made in relation to the valuation of share options, the embedded derivative of convertible notes, warrant issuance and subsequent revaluations, valuation allowances relating to deferred tax assets, revenue recognition, accrued expenses and estimation of the incremental borrowing rate for the finance lease. If actual results differ from the Company&#8217;s estimates, or to the extent these estimates are adjusted </span></div></ix:nonNumeric></ix:continuation><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ied77ea4fb48541edb9612582cb5c50b7_7">Table of Contents</a></span></div></div><ix:continuation id="f-270-2" continuedAt="f-270-3"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-272-1">in future periods, the Company&#8217;s results of operations could either benefit from, or be adversely affected by, any such change in estimate.</ix:continuation></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-273" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents are highly-liquid investments that are readily convertible into cash with original maturities of three months or less when purchased and as of June&#160;30, 2023 and  December&#160;31, 2022 included investments in money market funds. The Company maintains its cash and cash equivalent balances at domestic financial institutions. Bank deposits with US banks are insured up to $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashFDICInsuredAmount" scale="3" id="f-274">250</ix:nonFraction> by the Federal Deposits Insurance Corporation. The Company had an uninsured cash balances of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashUninsuredAmount" format="ixt:num-dot-decimal" scale="3" id="f-275">4,302</ix:nonFraction> at June&#160;30, 2023. The Company&#8217;s cash balance as of December&#160;31, 2022 was fully insured.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="f-276" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (ASC 820) establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The three levels of fair value hierarchy defined by ASC 820 are described below:</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:67.5pt;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liabilities.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2023, the Company&#8217;s financial instruments included cash, cash equivalents, prepaid expenses and other current assets, accounts payable, accrued expenses and certain liability classified warrants. The carrying amounts reported in the balance sheets for cash, cash equivalents, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair value based on the short-term maturity of these instruments. The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. At June&#160;30, 2023, there were no financial assets or liabilities measured at fair value on a recurring basis other than the liability classified warrants.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, Vallon issued warrants in connection with a securities purchase agreement. Vallon evaluated the warrants in accordance with ASC 815-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 815-40), and concluded that a provision in the warrants related to the reduction of the exercise price in certain circumstances precludes the warrants from being accounted for as components of equity. As a result, the warrants are recorded as a liability on the balance sheet. Vallon recorded the fair value of the warrants upon issuance using a Black-Scholes valuation model. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to revalue the warrants at each reporting date with any changes in fair value recorded in its statement of operations. The valuation of the warrants is considered under Level 3 of the fair value hierarchy due to the need to use assumptions in the valuation that are both significant to the fair value measurement and unobservable. The change in the fair value of the Level 3 warrants liabilities is reflected in the statement of operations for the six months ended June&#160;30, 2023.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:DeferredChargesPolicyTextBlock" id="f-277" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred Stock Issuance Costs</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred stock issuance costs represent incremental legal costs incurred that are directly attributable to proposed offerings of securities. The costs are charged against the gross proceeds of the respective offering upon closing.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtPolicyTextBlock" id="f-278" continuedAt="f-278-1" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt Discounts</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The relative fair values of warrants and common shares issued and call option rights assigned in connection with principal advances under promissory notes, the increases in fair values of embedded conversion options in connection with convertible promissory note </span></div></ix:nonNumeric></ix:continuation><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ied77ea4fb48541edb9612582cb5c50b7_7">Table of Contents</a></span></div></div><ix:continuation id="f-270-3"><ix:continuation id="f-278-1"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">modifications, and the intrinsic values of non-contingent beneficial conversion features were recorded as debt discounts that are amortized as additional interest expense over the estimated terms of the notes using the effective interest method.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt Issuance Costs</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt issuance costs represent incremental legal costs and other costs incurred that are directly attributable to issuing debt. The costs are included as a direct reduction of the carrying amount of the respective liability and are amortized as additional interest expense over the estimated term of the debt using the effective interest method.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-279" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes expense for employee and non-employee stock-based compensation in accordance with ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 718). ASC 718 requires that such transactions be accounted for using a fair value-based method. The estimated fair value of the options is amortized over the vesting period, based on the fair value of the options on the date granted, and is calculated using the Black-Scholes option-pricing model. The Company accounts for forfeitures as incurred. In considering the fair value of the underlying stock when the Company granted options, the Company considered several factors including the fair values established by market transactions. Stock option-based compensation includes estimates and judgments of when stock options might be exercised and stock price volatility. The timing of option exercises is out of the Company's control and depends upon a number of factors including the Company's market value and the financial objectives of the option holders. These estimates can have a material impact on the stock compensation expense but will have no impact on the cash flows. The estimation of share-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from original estimates, such </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amounts are recorded as a cumulative adjustment in the period the estimates are revised. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the expected term, rather than the contractual term, for both employee and consultant options issued.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-280" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Loss Per Common Share</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per common share are calculated by dividing the net loss by the applicable weighted-average number of common shares outstanding during the period. As the Company had a net loss in each of the three and six months ended June&#160;30, 2023 and 2022, diluted net loss per common share is the same as basic net loss per common share for the period because the effects of potentially dilutive securities are antidilutive.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-281" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock equivalents excluded from the diluted net loss per common share calculations are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-46" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-282">100,459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-47" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-283">89,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-48" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-284">3,688,449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-49" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-285">10,067</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock with repurchase rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-50" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-286">164,038</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-51" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-287">164,038</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock subject to put right</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-52" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="f-288">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-53" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-289">7,816</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible promissory note</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-54" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="f-290">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-55" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-291">143,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-292">3,952,946</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-293">414,937</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-294" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considered the applicability and impact of all ASUs issued during the quarter ended June&#160;30, 2023 and each was determined to be either not applicable or expected to have minimal impact on these financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="ied77ea4fb48541edb9612582cb5c50b7_579"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ied77ea4fb48541edb9612582cb5c50b7_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="f-295" continuedAt="f-295-1" escape="true">MERGER WITH VALLON</ix:nonNumeric></span></div><ix:continuation id="f-295-1" continuedAt="f-295-2"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 21, 2023, pursuant to the Merger Agreement, Merger Sub was merged with and into Private GRI, with Private GRI surviving the Merger as a wholly owned subsidiary of the Company. In connection with the Closing, the Company amended its certificate of incorporation and bylaws to change its name from &#8220;Vallon Pharmaceuticals, Inc.&#8221; to &#8220;GRI Bio, Inc.&#8221;</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the Effective Time:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Each share of Private GRI&#8217;s common stock outstanding immediately prior to the Effective Time, including any shares of Private GRI&#8217;s common stock  issued pursuant to the Equity SPA automatically converted solely into the right to receive a number of shares of the Company&#8217;s common stock equal to the Exchange Ratio.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Each option to purchase shares of Private GRI&#8217;s common stock (each, a GRI Option) outstanding and unexercised immediately prior to the Effective Time under the GRI Bio, Inc. 2015 Equity Incentive Plan (the GRI Plan), whether or not vested, converted into and became an option to purchase shares of the Company&#8217;s common stock, and the Company assumed the GRI Plan and each such GRI Option in accordance with the terms of the GRI Plan (the Assumed Options). The number of shares of he Company&#8217;s common stock subject to each Assumed Option was determined by multiplying (i) the number of shares of Private GRI&#8217;s common stock that were subject to such GRI Option, as in effect immediately prior to the Effective Time, by (ii) the Exchange Ratio, and rounding the resulting number down to the nearest whole number of shares of he Company&#8217;s common stock. The per share exercise price for the he Company&#8217;s common stock issuable upon exercise of each Assumed Option was determined by dividing (A) the per share exercise price of such Assumed Option, as in effect immediately prior to the Effective Time, by (B) the Exchange Ratio and rounding the resulting per share exercise price up to the nearest whole cent. Any restriction on the exercise of any Assumed Option continued in full force and effect and the term, exercisability, vesting schedule, and any other provisions of such Assumed Option otherwise remained unchanged.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Each warrant to purchase shares of Private GRI&#8217;s common stock outstanding immediately prior to the Effective Time other than the Bridge Warrants (as defined below) (the GRI Warrants), was assumed by the Company and converted into a warrant to purchase shares of the Company&#8217;s common stock (the Assumed Warrants) and thereafter (i) each Assumed Warrant became exercisable solely for shares of the Company&#8217;s common stock; (ii) the number of shares of the Company&#8217;s common stock subject to each Assumed Warrant was determined by multiplying (A) the number of shares of Private GRI&#8217;s common stock that were subject to such GRI Warrant, as in effect immediately prior to the Effective Time, by (B) the Exchange Ratio, and rounding the resulting number down to the nearest whole number of shares of the Company&#8217;s common stock; (iii) the per share exercise price for shares of the Company&#8217;s common stock issuable upon exercise of each Assumed Warrant was determined by dividing (A) the exercise price per share of Private GRI&#8217;s common stock subject to such GRI Warrant, as in effect immediately prior to the Effective Time, by (B) the Exchange Ratio, and rounding the resulting exercise price up to the nearest whole cent. </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Bridge Warrants (Note 8) were exchanged for warrants (the Exchange Warrants) to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-56" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-296">421,589</ix:nonFraction> shares of the Company&#8217;s common stock. The Exchange Warrants contain substantively similar terms to the Bridge Warrants, and have an initial exercise price equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-56" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-297">14.73</ix:nonFraction> per share.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All rights with respect to Private GRI restricted stock awards were assumed by the Company and converted into Company restricted stock awards with the number of shares subject to each restricted stock award multiplied by the Exchange Ratio and rounding the resulting number down to the nearest whole number of shares of the Company&#8217;s common stock. The term, exercisability, vesting schedule and other provisions of the Private GRI restricted stock awards otherwise remained unchanged.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Merger is accounted for as a reverse recapitalization under U.S. GAAP because the primary assets of Vallon were cash and cash equivalents. For accounting purposes, GRI has been determined to be the accounting acquirer based upon the terms of the Merger and other factors including: (i)  the equity holders of Private GRI immediately prior to the Merger owned, or held rights to acquire, in the aggregate approximately <ix:nonFraction unitRef="number" contextRef="c-57" decimals="2" name="ck0001824293:CommonStockOwnershipPercentage" scale="-2" id="f-298">85</ix:nonFraction>% of the outstanding shares of the Company&#8217;s common stock and the Company&#8217;s stockholders immediately prior to the Merger owned approximately <ix:nonFraction unitRef="number" contextRef="c-58" decimals="2" name="ck0001824293:CommonStockOwnershipPercentage" scale="-2" id="f-299">15</ix:nonFraction>% of the outstanding shares of the Company&#8217;s common stock (ii) Private GRI holds the majority (4 out of 5) of board seats of the combined company, and (iii) Private GRI&#8217;s management holds the majority of </span></div></ix:continuation><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ied77ea4fb48541edb9612582cb5c50b7_7">Table of Contents</a></span></div></div><ix:continuation id="f-295-2" continuedAt="f-295-3"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">key positions in the management of the combined company. Immediately after the Merger, there were <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-300"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-301">2,956,354</ix:nonFraction></ix:nonFraction> shares of the Company&#8217;s common stock outstanding.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" id="f-302" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the net liabilities assumed in the Merger:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">April 21, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="3" id="f-303">941</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" scale="3" id="f-304">310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="ck0001824293:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses" format="ixt:num-dot-decimal" scale="3" id="f-305">4,190</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net liabilities assumed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" sign="-" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="f-306">2,939</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plus: Transaction costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" format="ixt:num-dot-decimal" scale="3" id="f-307">2,984</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net liabilities assumed plus transaction costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" sign="-" name="ck0001824293:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts" format="ixt:num-dot-decimal" scale="3" id="f-308">5,923</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-295-3">In addition to the transactions costs noted above, at the Effective Time, <ix:nonFraction unitRef="shares" contextRef="c-41" decimals="INF" name="ck0001824293:StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses" format="ixt:num-dot-decimal" scale="0" id="f-309">30,542</ix:nonFraction> shares of the Company&#8217;s common stock were issued to Private GRI&#8217;s financial advisor for services related to the Merger.</ix:continuation> </span></div><div id="ied77ea4fb48541edb9612582cb5c50b7_49"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-310" continuedAt="f-310-1" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:continuation id="f-310-1" continuedAt="f-310-2"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the guidance in ASC 820 to account for financial assets and liabilities measured on a recurring basis. Fair value is measured as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses a fair value hierarchy, which distinguishes between assumptions based on market data (observable inputs) and an entity's own assumptions (unobservable inputs). The guidance requires that fair value measurements be classified and disclosed in one of the following 3 categories:</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:67.5pt;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liabilities; and</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each reporting period. There were no transfers between Level 1, 2 and 3 during the six months ended June&#160;30, 2023.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="f-311" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents, for each of the fair value hierarchy levels required under ASC 820, the Company&#8217;s liabilities that are measured at fair value on a recurring basis at June&#160;30, 2023:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.098%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets (Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Other Observable Inputs (Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Other Unobservable Inputs (Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:WarrantsAndRightsOutstanding" format="ixt:fixed-zero" scale="3" id="f-312">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:WarrantsAndRightsOutstanding" format="ixt:fixed-zero" scale="3" id="f-313">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" id="f-314">63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-315">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-316">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="f-317">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ied77ea4fb48541edb9612582cb5c50b7_7">Table of Contents</a></span></div></div><ix:continuation id="f-310-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="f-318" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes is the fair value of the Level 3 liability:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.984%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Warrant Liability </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value as of December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.6pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="f-319">185</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="f-320">122</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value as of June&#160;30, 2023</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.6pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="f-321">63</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="f-322" continuedAt="f-322-1" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes valuation model was used to estimate the fair value of the warrants with the following weighted-average assumptions:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.288%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-66" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-323">167.1</ix:nonFraction>&#160;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-67" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-324">139.9</ix:nonFraction>&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-68" decimals="1" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="f-325">2.5</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-69" decimals="1" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="f-326">2.5</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-70" decimals="INF" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-327">0.0</ix:nonFraction>&#160;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-71" decimals="INF" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-328">0.0</ix:nonFraction>&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-72" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-329">4.68</ix:nonFraction>&#160;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-73" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-330">4.32</ix:nonFraction>&#160;%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ied77ea4fb48541edb9612582cb5c50b7_549"></div><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="f-331" continuedAt="f-331-1" escape="true">PROPERTY AND EQUIPMENT</ix:nonNumeric></span></div><ix:continuation id="f-331-1"><div style="margin-bottom:8pt"><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-332" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.512%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-333">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-334">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-335">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-336">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-337">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-338">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="f-339">24</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="f-340">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-341">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-342">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense related to property and equipment was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Depreciation" scale="3" id="f-343">2</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Depreciation" scale="3" id="f-344">1</ix:nonFraction> for the six months ended June&#160;30, 2023 and 2022, respectively.</span></div></ix:continuation><div id="ied77ea4fb48541edb9612582cb5c50b7_52"></div><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="f-345" continuedAt="f-345-1" escape="true">ACCRUED EXPENSES</ix:nonNumeric></span></div><ix:continuation id="f-345-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="f-346" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following:</span></div><div style="margin-bottom:8pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ck0001824293:AccruedResearchAndDevelopmentCostsCurrent" scale="3" id="f-347">143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ck0001824293:AccruedResearchAndDevelopmentCostsCurrent" format="ixt:fixed-zero" scale="3" id="f-348">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ck0001824293:AccruedGeneralAndAdministrativeExpensesCurrent" scale="3" id="f-349">188</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ck0001824293:AccruedGeneralAndAdministrativeExpensesCurrent" format="ixt:fixed-zero" scale="3" id="f-350">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and related</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="f-351">862</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="f-352">36</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-353">1,193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="f-354">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ied77ea4fb48541edb9612582cb5c50b7_55"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-355" continuedAt="f-355-1" escape="true">PROMISSORY NOTES</ix:nonNumeric></span></div><ix:continuation id="f-355-1" continuedAt="f-355-2"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bridge Financing</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with signing the Merger Agreement, Private GRI entered into a Securities Purchase Agreement, dated as of December 13, 2022 (Bridge SPA), with Altium Growth Fund, LP (the Investor), pursuant to which Private GRI issued senior secured promissory notes (Bridge Notes) in the aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="f-356">3,333</ix:nonFraction>, in exchange for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="ck0001824293:DebtInstrumentAggregatePurchasePrice" format="ixt:num-dot-decimal" scale="3" id="f-357">2,500</ix:nonFraction>. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Bridge Notes were issued in <ix:nonFraction unitRef="number" contextRef="c-80" decimals="INF" name="ck0001824293:DebtInstrumentNumberOfClosings" format="ixt-sec:numwordsen" scale="0" id="f-358">two</ix:nonFraction> closings: (i) the first closing for $<ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="f-359">1,667</ix:nonFraction> in aggregate principal amount (in exchange for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="ck0001824293:DebtInstrumentAggregatePurchasePrice" format="ixt:num-dot-decimal" scale="3" id="f-360">1,250</ix:nonFraction>) closed on December 14, 2022; and (ii) the second closing for $<ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="f-361">1,667</ix:nonFraction> in aggregate principal amount (in exchange for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="ck0001824293:DebtInstrumentAggregatePurchasePrice" format="ixt:num-dot-decimal" scale="3" id="f-362">1,250</ix:nonFraction>) closed on March 9, 2023. The Bridge Notes were secured by a lien on all of the Company&#8217;s assets. </span></div></ix:continuation><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ied77ea4fb48541edb9612582cb5c50b7_7">Table of Contents</a></span></div></div><ix:continuation id="f-355-2" continuedAt="f-355-3"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, upon the funding of each tranche, the Investor received warrants to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-85" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-363">1,252,490</ix:nonFraction> shares of the Company&#8217;s common stock (the Bridge Warrants). The Bridge Warrants had an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-85" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-364">1.33</ix:nonFraction> per share, were exercisable at any time on or after the applicable issuance date and had a term of <ix:nonNumeric contextRef="c-85" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durmonth" id="f-365">60</ix:nonNumeric> months from the date all shares underlying the Bridge Warrants were freely tradable. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $<ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="ck0001824293:DebtInstrumentAggregatePurchasePrice" format="ixt:num-dot-decimal" scale="3" id="f-366">1,250</ix:nonFraction> of proceeds from the first closing were allocated to the Bridge Notes and Bridge Warrants based on their relative fair values as of the commitment date, resulting in an allocation of $<ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:ProceedsFromNotesPayable" scale="3" id="f-367">679</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:ProceedsFromNotesPayable" scale="3" id="f-368">571</ix:nonFraction>, respectively. The $<ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="ck0001824293:DebtInstrumentAggregatePurchasePrice" format="ixt:num-dot-decimal" scale="3" id="f-369">1,250</ix:nonFraction> of proceeds from the second closing were allocated to the Bridge Notes and Bridge Warrants based on their relative fair values as of the commitment date, resulting in an allocation of $<ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:ProceedsFromNotesPayable" scale="3" id="f-370">718</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:ProceedsFromNotesPayable" scale="3" id="f-371">532</ix:nonFraction>, respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the Bridge SPA, and also in connection with signing the Merger Agreement, Vallon, Private GRI and the Investor entered into the Equity SPA (Note 9) pursuant to which the Investor agreed to invest $<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:InvestmentCompanyCommittedCapital" format="ixt:num-dot-decimal" scale="3" id="f-372">12,250</ix:nonFraction> in cash and cancel any outstanding principal and accrued interest on the Bridge Notes in return for the issuance of shares of Private GRI&#8217;s common stock immediately prior to the consummation of the Merger. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 21, 2023, the Company completed the Merger and the outstanding principal and accrued interest on the Bridge Notes was cancelled and the Bridge Warrants were exchanged for the Exchange Warrants. The Exchange Warrants contain substantively similar terms to the Bridge Warrants, and have an initial exercise price equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-56" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-373">14.73</ix:nonFraction> per share subject to adjustments for splits and recapitalization events.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Bridge Notes were accounted for as share-settled debt under the accounting guidance in ASC 835-30 and, as such, the initial net carrying amounts were accreted to the redemption amounts using the effective interest method. The Company incurred debt issuance costs of $<ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:DeferredFinanceCostsGross" scale="3" id="f-374">205</ix:nonFraction> during the year ended December&#160;31, 2022 and $<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:DeferredFinanceCostsGross" scale="3" id="f-375">90</ix:nonFraction> during the six months ended June&#160;30, 2023 related to its issuance of debt under the Bridge SPA. Unamortized debt discounts and debt issuance costs totaled $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="f-376">1,065</ix:nonFraction> as of December&#160;31, 2022. Interest expense stemming from amortization of debt discounts and issuance costs was $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="f-377">1,161</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="f-378">2,104</ix:nonFraction> for the three and six months ended June&#160;30, 2023, respectively.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">TEP Note</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, Private GRI and TEP Biotech, LLC (TEP) entered into a convertible note and warrant purchase agreement pursuant to which TEP agreed to fund up to $<ix:nonFraction unitRef="usd" contextRef="c-90" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="f-379">5,000</ix:nonFraction> to Private GRI in exchange for a convertible promissory note (the TEP Note) and a warrant to purchase up to <ix:nonFraction unitRef="shares" contextRef="c-91" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-380">25,245</ix:nonFraction> shares of Private GRI&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-91" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-381">0.27</ix:nonFraction> per share. The TEP Note was secured by Private GRI&#8217;s assets and accrued simple interest on the outstanding principal balance at a rate of <ix:nonFraction unitRef="number" contextRef="c-90" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-382">12</ix:nonFraction>% per annum. The total outstanding principal and accrued interest balance was initially due on the earlier of Private GRI&#8217;s next financing, as defined, and May 2, 2020. The initial $<ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:ProceedsFromNotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-383">2,500</ix:nonFraction> tranche under the TEP Note was funded upon execution of the agreement in November 2018. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, Private GRI and TEP amended the TEP Note. In lieu of TEP funding the second $<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="f-384">2,500</ix:nonFraction> tranche, TEP made a first additional advance of $<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="us-gaap:ProceedsFromNotesPayable" scale="3" id="f-385">500</ix:nonFraction> to Private GRI in exchange for a convertible promissory note, a warrant to purchase up to <ix:nonFraction unitRef="shares" contextRef="c-95" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-386">17,269</ix:nonFraction> shares of Private GRI&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-95" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-387">0.27</ix:nonFraction> per share, and the assignment of Private GRI&#8217;s rights under a certain call option agreement. The call option agreement, which was entered into in 2015, provided Private GRI with the right to repurchase up to <ix:nonFraction unitRef="shares" contextRef="c-96" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-388">39,720</ix:nonFraction> shares of Private GRI&#8217;s common stock held by the counterparty for $<ix:nonFraction unitRef="usdPerShare" contextRef="c-96" decimals="2" name="ck0001824293:CallOptionPrice" scale="0" id="f-389">26.74</ix:nonFraction> per share at any time before April 1, 2025. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, the TEP Note maturity date was extended to August 31, 2020, and in March 2021, TEP agreed to forbear on its available right to exercise remedies on account of Private GRI&#8217;s failure to pay the past due principal and accrued interest balance until October 31, 2021.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, Private GRI and TEP amended the TEP Note, and TEP agreed to make a second additional advance of $<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:ProceedsFromNotesPayable" scale="3" id="f-390">500</ix:nonFraction> to Private GRI in exchange for a convertible promissory note with separate, modified conversion options. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, Private GRI and TEP further amended the TEP Note, and TEP agreed to make a third additional advance of $<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:ProceedsFromNotesPayable" scale="3" id="f-391">125</ix:nonFraction> to Private GRI in exchange for a convertible promissory note and a warrant to purchase up to <ix:nonFraction unitRef="shares" contextRef="c-99" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-392">1,169</ix:nonFraction> shares of Private GRI&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-99" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-393">0.27</ix:nonFraction> per share.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, Private GRI and TEP entered into a conversion agreement pursuant to which, effective upon the full execution of the Merger Agreement (Note 4), $<ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="ck0001824293:DebtConversionConvertedInstrumentPrincipalAmountOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-394">3,500</ix:nonFraction> of outstanding principal under the TEP Note together with $<ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="ck0001824293:DebtConversionConvertedInstrumentAmountOfInterest" scale="3" id="f-395">650</ix:nonFraction> of related accrued interest was to </span></div></ix:continuation><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ied77ea4fb48541edb9612582cb5c50b7_7">Table of Contents</a></span></div></div><ix:continuation id="f-355-3"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">automatically convert into <ix:nonFraction unitRef="shares" contextRef="c-101" decimals="INF" name="ck0001824293:DebtInstrumentConvertibleSharesIssuedUponConversion" format="ixt:num-dot-decimal" scale="0" id="f-396">155,210</ix:nonFraction> shares of Private GRI&#8217;s common stock at a conversion price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-101" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="f-397">26.74</ix:nonFraction> per share. Further, upon the closing of the first tranche of the Bridge Notes, Private GRI was to repay, in cash, the $<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="f-398">125</ix:nonFraction> third additional advance under the TEP Note along with the $<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="us-gaap:InterestPayableCurrentAndNoncurrent" scale="3" id="f-399">15</ix:nonFraction> of related accrued interest. Upon issuance of the <ix:nonFraction unitRef="shares" contextRef="c-101" decimals="INF" name="ck0001824293:DebtInstrumentConvertibleSharesIssuedUponConversion" format="ixt:num-dot-decimal" scale="0" id="f-400">155,210</ix:nonFraction> conversion shares and payment of the $<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="ck0001824293:LongTermDebtIncludingInterest" scale="3" id="f-401">140</ix:nonFraction> principal and accrued interest balance, Private GRI would fully satisfy all of its obligations under the TEP Note.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, upon the full execution of the Merger Agreement and the closing of the first tranche of the Bridge Notes Private GRI issued the <ix:nonFraction unitRef="shares" contextRef="c-103" decimals="INF" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" format="ixt:num-dot-decimal" scale="0" id="f-402">155,210</ix:nonFraction> conversion shares and paid the $<ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="us-gaap:RepaymentsOfNotesPayable" scale="3" id="f-403">140</ix:nonFraction> principal and accrued interest balance as per the terms of the conversion agreement. The share numbers and exercise or conversion prices in this section of Note 8 entitled &#8220;TEP Note&#8221; reflect the Exchange Ratio retroactively.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the conversion, the $<ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:num-dot-decimal" scale="3" id="f-404">4,150</ix:nonFraction> of converted principal and accrued interest, along with $<ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="ck0001824293:AccruedInterestForfeited" scale="3" id="f-405">863</ix:nonFraction> of related forfeited accrued interest through the conversion date, were credited to stockholders&#8217; deficit. Interest expense recognized on the TEP Note was $<ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="us-gaap:InterestExpenseBorrowings" scale="3" id="f-406">107</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="us-gaap:InterestExpenseBorrowings" scale="3" id="f-407">210</ix:nonFraction> for the three and six months ended June&#160;30, 2022.</span></div></ix:continuation><div id="ied77ea4fb48541edb9612582cb5c50b7_58"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-408" continuedAt="f-408-1" escape="true">STOCKHOLDERS&#8217; EQUITY </ix:nonNumeric></span></div><ix:continuation id="f-408-1" continuedAt="f-408-2"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with signing the Merger Agreement, Vallon, Private GRI and the Investor entered the Equity SPA pursuant to which the Investor agreed to invest $<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:InvestmentCompanyCommittedCapital" format="ixt:num-dot-decimal" scale="3" id="f-409">12,250</ix:nonFraction> in cash and cancel any outstanding principal and accrued interest on the Bridge Notes in return for the issuance of shares of Private GRI&#8217;s common stock immediately prior to the consummation of the Merger. Pursuant to the Equity SPA, immediately prior to the Closing, Private GRI issued <ix:nonFraction unitRef="shares" contextRef="c-43" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-410">6,787,219</ix:nonFraction> shares of Private GRI&#8217;s common stock (the Initial Shares) to the Investor and <ix:nonFraction unitRef="shares" contextRef="c-44" decimals="INF" name="ck0001824293:CommonStockHeldIntoEscrowAccount" format="ixt:num-dot-decimal" scale="0" id="f-411">27,148,877</ix:nonFraction> shares of Private GRI&#8217;s common stock (the Additional Shares) into escrow with an escrow agent for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-412">11,704</ix:nonFraction>, after deducting offering expenses of $<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ck0001824293:StockIssuanceCostsOfferingExpenses" scale="3" id="f-413">546</ix:nonFraction>.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the closing, pursuant to the Merger, the Initial Shares converted into an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-45" decimals="INF" name="us-gaap:ConversionOfStockSharesConverted1" format="ixt:num-dot-decimal" scale="0" id="f-414">253,842</ix:nonFraction> shares of the Company&#8217;s common stock and the Additional Shares converted into an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-45" decimals="INF" name="ck0001824293:ConversionOfStockAdditionalSharesConverted" format="ixt:num-dot-decimal" scale="0" id="f-415">1,015,368</ix:nonFraction> shares of the Company&#8217;s common stock. On May 8, 2023, in accordance with the terms of the Equity SPA, the Company and the Investor authorized the escrow agent to, subject to beneficial ownership limitations, disburse to the Investor all of the shares of the Company&#8217;s common stock issued in exchange for the Additional Shares. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Redeemable Common Stock</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, Private GRI entered into an agreement with a stockholder pursuant to which the stockholder had the right to require Private GRI to purchase all or a portion of <ix:nonFraction unitRef="shares" contextRef="c-107" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-416">7,816</ix:nonFraction> shares of Private GRI&#8217;s common stock held by the stockholder for $<ix:nonFraction unitRef="usdPerShare" contextRef="c-107" decimals="2" name="ck0001824293:PutOptionSharePrice" scale="0" id="f-417">15.88</ix:nonFraction> per share (the Put Right). The Put Right was exercisable (i) for a period commencing thirty days prior to the day Private GRI completed an equity or debt financing and ending fifteen business days thereafter, or (ii) at any time following a breach of the agreement by Private GRI.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management assessed the Put Right and determined that (i) it was not freestanding and, therefore, was not required to be classified as a liability and (ii) it could be exercised by the stockholder at any time, which was not within Private GRI&#8217;s control. Therefore, the common shares subject to the Put Right were classified in mezzanine equity. In December 2022, the stockholder exercised the Put Right and Private GRI redeemed the <ix:nonFraction unitRef="shares" contextRef="c-103" decimals="INF" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="f-418">7,816</ix:nonFraction> shares of Private GRI&#8217;s common stock for $<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="3" id="f-419">124</ix:nonFraction> ($<ix:nonFraction unitRef="usdPerShare" contextRef="c-103" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="f-420">15.88</ix:nonFraction> per share). The redeemed shares were retired by Private GRI. The share numbers and exercise or conversion prices in this section of Note 9 entitled &#8220;Redeemable Common Stock&#8221; reflect the Exchange Ratio retroactively.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Warrants</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Equity SPA, on May 8, 2023, the Company issued to the Investor (i) Series A-1 Warrants to purchase <ix:nonFraction unitRef="shares" contextRef="c-108" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-421">1,269,210</ix:nonFraction> shares of the Company&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-108" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-422">13.51</ix:nonFraction>, (ii) Series A-2 Warrants to purchase <ix:nonFraction unitRef="shares" contextRef="c-109" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-423">1,142,289</ix:nonFraction> shares of the Company&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-109" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-424">14.74</ix:nonFraction> , and (iii) Series T Warrants to purchase (x) <ix:nonFraction unitRef="shares" contextRef="c-110" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-425">814,467</ix:nonFraction> shares of the Company&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-110" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-426">12.28</ix:nonFraction> and (y) upon exercise of the Series T Warrants, <ix:nonFraction unitRef="shares" contextRef="c-111" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-427"><ix:nonFraction unitRef="shares" contextRef="c-112" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-428">814,467</ix:nonFraction></ix:nonFraction> additional Series </span></div></ix:continuation><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ied77ea4fb48541edb9612582cb5c50b7_7">Table of Contents</a></span></div></div><ix:continuation id="f-408-2"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A-1 Warrants and Series A-2 Warrants, each to purchase <ix:nonFraction unitRef="shares" contextRef="c-111" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-429"><ix:nonFraction unitRef="shares" contextRef="c-112" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-430">814,467</ix:nonFraction></ix:nonFraction> shares of the Company&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-111" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-431">13.51</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-112" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-432">14.74</ix:nonFraction>, respectively (collectively, the Equity Warrants). </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Series A-1 Warrants have a term of <ix:nonNumeric contextRef="c-108" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durmonth" id="f-433">60</ix:nonNumeric> months from the date all shares underlying the Series A-1 Warrants are freely tradable. The A-2 warrants have a <ix:nonNumeric contextRef="c-109" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen" id="f-434">2-year</ix:nonNumeric> term and expire in June 2025. Series T Warrants have a term of <ix:nonNumeric contextRef="c-110" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durmonth" id="f-435">24</ix:nonNumeric> months from the date all shares underlying Series T Warrants are freely tradable. The Company may force the exercise of the Series T Warrants subject to the satisfaction of certain equity conditions. The Equity Warrants include certain contingent cashless exercise features and contain certain other rights with regard to asset distributions and fundamental transactions. The exercise price of the Series A-1 Warrants is subject to adjustment for certain dilutive issuances, and all of the Equity Warrants are subject to standard antidilution adjustments. All of the Equity Warrants were outstanding as of June&#160;30, 2023. The Equity Warrants were classified as equity and the allocated fair value of $<ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:WarrantsAndRightsOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-436">5,675</ix:nonFraction> is included in additional paid in capital.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Bridge SPA, upon the funding of each tranche of the Bridge Note, the Investor  received the Bridge Warrants. The Bridge Warrants had an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-114" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-437">1.33</ix:nonFraction> per share, were exercisable at any time on or after the applicable issuance date and had a term of <ix:nonNumeric contextRef="c-114" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durmonth" id="f-438">60</ix:nonNumeric> months from the date all shares underlying the Bridge Warrants are freely tradable. Upon the completion of the Merger the Bridge Warrants were exchanged for the Exchange Warrants to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-114" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-439">421,589</ix:nonFraction> shares of the Company&#8217;s common stock. The Exchange Warrants contain substantively similar terms to the Bridge Warrants, and have an initial exercise price equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-115" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-440">14.73</ix:nonFraction> per share subject to adjustments for splits and recapitalization events. All of the Bridge Warrants were outstanding as of June&#160;30, 2023. The Bridge Warrants were classified as equity and the allocated fair value of $<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-3" name="us-gaap:WarrantsAndRightsOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-441">2,860</ix:nonFraction> is included in additional paid in capital.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Closing, Private GRI granted its financial advisor warrants (the Advisor Warrants) to purchase shares of Private GRI&#8217;s common stock, which, at the Effective Time, became exercisable for an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-117" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-442">2,402</ix:nonFraction> shares of the Company&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-117" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-443">61.39</ix:nonFraction> per share. The Advisor Warrants have a <ix:nonNumeric contextRef="c-118" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen" id="f-444">five-year</ix:nonNumeric> term. All of the Advisor Warrants were outstanding as of June 30, 2023. The Advisor Warrants were classified as equity and the fair value of $<ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-3" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" id="f-445">18</ix:nonFraction> is included in additional paid in capital. </span></div><ix:continuation id="f-322-1"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes option-pricing model was used to estimate the fair value of the Equity Warrants, the Exchange Warrants and the Advisor Warrants with the following weighted-average assumptions:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-120" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-446">167.6</ix:nonFraction>&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-121" decimals="2" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="f-447">1.69</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-122" decimals="2" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-448">0.0</ix:nonFraction>&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-123" decimals="5" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-449">4.37</ix:nonFraction>&#160;%</span></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="f-450" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2023, the Company had the following warrants outstanding to purchase common stock. </span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercise Price per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expiration Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-124" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-451">8,629</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-124" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-452">34.76</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-125" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-453">1,438</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-125" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-454">34.76</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-126" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-455">1,142,289</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-126" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-456">14.74</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-127" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-457">3,758</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-127" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-458">300.00</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-128" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-459">24,667</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-128" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-460">28.15</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2027</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-129" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-461">1,168</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-129" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-462">0.01</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-130" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-463">2,402</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-130" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-464">61.39</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2028</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-131" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-465">421,590</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-131" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-466">14.73</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-132" name="ck0001824293:ClassOfWarrantOrRightExpirationPeriod" format="ixt-sec:durmonth" id="f-467">60</ix:nonNumeric> months after registration date</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-133" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-468">1,269,210</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-133" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-469">13.51</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-134" name="ck0001824293:ClassOfWarrantOrRightExpirationPeriod" format="ixt-sec:durmonth" id="f-470">60</ix:nonNumeric> months after registration date</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-135" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-471">814,467</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-135" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-472">12.28</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-136" name="ck0001824293:ClassOfWarrantOrRightExpirationPeriod" format="ixt-sec:durmonth" id="f-473">24</ix:nonNumeric> months after registration date</span></div></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><div id="ied77ea4fb48541edb9612582cb5c50b7_61"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ied77ea4fb48541edb9612582cb5c50b7_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-474" continuedAt="f-474-1" escape="true">STOCK-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="f-474-1" continuedAt="f-474-2"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2015 Equity Incentive Plan</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Private GRI adopted the GRI Bio, Inc. 2015 Equity Incentive Plan, as amended (the Private GRI Plan), that provided Private GRI with the ability to grant stock options, restricted stock awards and other equity-based awards to employees, directors, and consultants. Stock options granted under the Private GRI Plan generally had a contractual life of up to <ix:nonNumeric contextRef="c-137" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="f-475">10</ix:nonNumeric> years. Upon completion of the Merger, the Company assumed the Private GRI Plan and the outstanding and unexercised options issued thereunder, and ceased granting awards under the Private GRI Plan.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amended and Restated 2018 Equity Incentive Plan</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 21, 2023, the stockholders of the Company approved the Amended and Restated GRI Bio, Inc. 2018 Equity Incentive Plan, formerly the Vallon Pharmaceuticals, Inc. 2018 Equity Incentive Plan (the A&amp;R 2018 Plan). The A&amp;R 2018 Plan had previously been approved by the Company&#8217;s board of directors, subject to stockholder approval. The A&amp;R 2018 Plan became effective on April 21, 2023, with the stockholders approving the amendment to the A&amp;R 2018 Plan to, among other things, (i) to increase the aggregate number of shares by </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-138" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-476">168,905</ix:nonFraction> shares to <ix:nonFraction unitRef="shares" contextRef="c-139" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-477">216,666</ix:nonFraction> shares of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company&#8217;s common stock </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for issuance as awards under the A&amp;R 2018 Plan, (ii) to extend the term of the A&amp;R 2018 Plan through January 1, 2033, (iii) to prohibit any action that would be treated as a &#8220;repricing&#8221; of an award without further approval by the stockholders of Company, and (iv) to revise the limits on awards to non-employee directors.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The A&amp;R 2018 Plan provides the Company with the ability to grant stock options, restricted stock and other equity-based awards to employees, directors and consultants. Stock options granted by Vallon generally have a contractual life of up to <ix:nonNumeric contextRef="c-140" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="f-478">10</ix:nonNumeric> years. As of June&#160;30, 2023, <ix:nonFraction unitRef="shares" contextRef="c-141" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-479">100,459</ix:nonFraction> shares of the Company's common stock were authorized to be issued under the A&amp;R 2018 Plan, and <ix:nonFraction unitRef="shares" contextRef="c-142" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-480">116,207</ix:nonFraction> shares were reserved for future awards under the A&amp;R 2018 Plan. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-481" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation related to stock options issued under the A&amp;R 2018 Plan in the following expense categories of its accompanying statements of operations for the three and six months ended June&#160;30, 2023 and 2022:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="f-482">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="f-483">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="f-484">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="f-485">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-486">13</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="f-487">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-488">26</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="f-489">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-490">13</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="f-491">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-492">26</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="f-493">&#8212;</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures equity-based awards granted to employees, and non-employees based on their fair value on the date of the grant and recognizes compensation expense for those awards over the requisite service period or performance-based period, which is generally the vesting period of the respective award. The measurement date for service-based equity awards is the date of grant, and equity-based compensation costs are recognized as expense over the requisite service period, which is the vesting period for certain </span></div></ix:continuation><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ied77ea4fb48541edb9612582cb5c50b7_7">Table of Contents</a></span></div></div><ix:continuation id="f-474-2" continuedAt="f-474-3"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">performance-based awards. The Company records expense for performance-based awards if it concludes that it is probable that the performance condition will be achieved.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-494" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below represents the activity of stock options granted to employees and non-employees for the six months ended June&#160;30, 2023:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted average remaining contractual term&#160;(years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-495">112,612</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-496">39.77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-151" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-497">4.71</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="0" id="f-498">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-499">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="f-500">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-501">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/Cancelled</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-502">12,153</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-503">130.84</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-504">100,459</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-505">28.75</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-506">4.73</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2023</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-507">100,459</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-508">28.75</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-509">4.73</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-510" escape="true"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes option-pricing model was used to estimate the grant date fair value of each stock option grant at the time of grant using the following weighted-average assumptions:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-152" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-511">90.39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-152" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-512">5.98</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-152" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-513">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-152" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-514">2.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of option on grant date</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-153" decimals="2" name="us-gaap:SharePrice" scale="0" id="f-515">3.86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="0" id="f-516">No</ix:nonFraction> options were granted during the six months ended June&#160;30, 2023. </span></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-474-3">As of June&#160;30, 2023, the unrecognized compensation cost related to unvested stock options expected to vest was $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="3" id="f-517">280</ix:nonFraction>. This unrecognized compensation is expected to be recognized over a weighted-average amortization period of <ix:nonNumeric contextRef="c-154" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-518">3.35</ix:nonNumeric> years.</ix:continuation> </span></div><div id="ied77ea4fb48541edb9612582cb5c50b7_70"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-519" continuedAt="f-519-1" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="f-519-1" continuedAt="f-519-2"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employment Agreements</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into employment contracts with its officers that provide for severance and continuation of benefits in the event of termination of employment by the Company without cause or by the employee for good reason. In addition, in the event of termination of employment following a change in control, the vesting of certain equity awards may be accelerated.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Separation and Release Agreement</span></div></ix:continuation><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-519-2">In connection with the resignation of David Baker, the Company&#8217;s Former Chief Executive Officer, pursuant to the Merger, the Company and Mr. Baker entered into a Separation and Release Agreement on April 21, 2023 (the Separation Agreement). Pursuant to the terms of the Separation Agreement and his employment agreement, Mr. Baker will receive continuation of his current salary and certain COBRA benefits for <ix:nonNumeric contextRef="c-155" name="ck0001824293:COBRABenefitsPaymentPeriod" format="ixt-sec:durmonth" id="f-520">18</ix:nonNumeric> months payable in accordance with the Company&#8217;s payroll practices. Mr. Baker also received a lump sum payment equal to <ix:nonFraction unitRef="number" contextRef="c-155" decimals="INF" name="ck0001824293:PercentageOfTargetBonus" scale="-2" id="f-521">150</ix:nonFraction>% of his target bonus and agreed to reduce amounts payable with respect to certain future milestone payments.</ix:continuation> </span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><div id="ied77ea4fb48541edb9612582cb5c50b7_79"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ied77ea4fb48541edb9612582cb5c50b7_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the Company&#8217;s financial statements and the related notes appearing elsewhere in this Quarterly Report on Form 10-Q, the audited financial statements (and notes thereto, management&#8217;s discussion and analysis of financial condition and results of operations for the year ended December 31, 2022, included in Vallon&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on February 24, 2023, and Private GRI&#8217;s financial statements and related notes which are filed as Exhibit 99.1 of Amendment No. 2 to the Current Report on Form 8-K filed with the SEC on July 6, 2023. Some of the information contained in this discussion and analysis, including information with respect to GRI&#8217;s plans and strategy for its business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set out under the section entitled &#8220;Risk Factors&#8221; which is included in the Quarterly Report on Form 10-Q filed by the Combined Company, GRI&#8217;s actual results could differ materially from the results described in or implied by these forward-looking statements. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Except as otherwise indicated, references herein to &#8220;GRI Bio,&#8221; the &#8220;Company,&#8221; or the &#8220;Combined Company,&#8221; refer to GRI Bio, Inc. on a post-Merger basis, and references to &#8220;Private GRI&#8221; refer to the business of  GRI Bio, Inc. prior to the completion of the Merger. References to &#8220;Vallon&#8221; refer to Vallon Pharmaceuticals, Inc. prior to the completion of the Merger.</span></div><div id="ied77ea4fb48541edb9612582cb5c50b7_82"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies that target serious diseases associated with dysregulated immune responses leading to inflammatory, fibrotic, and autoimmune disorders. Our goal is to be an industry leader in developing therapies to treat these diseases and to improve the lives of patients suffering from such diseases.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead product candidate, GRI-0621, is an oral inhibitor of type 1 Natural Killer T (iNKT) cells. GRI-0621 is also an oral formulation of tazarotene, a synthetic retinoid acid receptor (RAR)-beta and gamma selective agonist, that is approved in the United States for topical treatment of psoriasis and acne. As of March 31, 2023, it has been evaluated in over 1,700 patients as an oral product for up to 52-weeks. We are developing GRI-0621 for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis (IPF), a life-threatening progressive fibrotic disease of the lung that affects approximately 140,000 people in the United States, with up to 40,000 new cases per year in the United States and some estimate that IPF affects 3 million globally. While there are currently two approved therapies for the treatment of lung fibrosis, neither has been associated with improvements in overall survival, and both therapies have been associated with significant side effects leading to poor therapeutic adherence. In preliminary data from our trials to date with GRI-0621, and earlier trials with oral tazarotene, we have observed GRI-0621 to be well-tolerated and to inhibit iNKT cell activity in subjects. We and others have shown that activated iNKT are upregulated in IPF, primary sclerosing cholangitis (PSC), non-alcoholic steatohepatitis (NASH), alcoholic liver disease (ALD), Systemic Lupus Erythematosus Disease (SLE), multiple sclerosis (MS), ulcerative colitis (UC) patients as well as other indications. In these patients activated iNKT cells are correlated with more severe disease. We are initiating a Phase 2a trial in 36 IPF patients in the second half of 2023 and expects topline results from this trial to be available in the second half of 2024.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidate portfolio also includes GRI-0803 and a proprietary library of 500+ compounds. GRI-0803, the lead molecule selected from the library, is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells. We are developing GRI-0803 for the treatment of autoimmune disorders, with much of our preclinical work in SLE or lupus and MS. In lupus, the immune system mistakenly attacks its own healthy tissues, especially joints and skin, but can affect almost every organ and tissue of the body. The condition can be fatal, and often causes debilitating bouts of fatigue and pain that prevent nearly half of adult patients from working. Lupus affects between 160,000 - 200,000 patients in the United States, with around 80,000 &#8211; 100,000 patients in the United States suffering from kidney nephritis, one of the most serious manifestations of SLE, typically within five years of diagnosis. There is no cure for lupus, but medical interventions and lifestyle changes can help control it. SLE treatment consists primarily of immunosuppressive drugs that inhibit the activity of the immune system. Only two drugs have been approved for lupus in the past 50 years, and new treatment options are sorely needed. Subject to IND clearance, we intend to evaluate GRI-0803 in a Phase 1a and 1b trial initially targeting SLE. We expect to file an IND with respect to this Phase 1a and 1b trial in the first half of 2024. We will continue to evaluate indications to select the best fit for further development of the program, but our initial focus is on lupus.</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ied77ea4fb48541edb9612582cb5c50b7_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Merger with Vallon Pharmaceuticals, Inc. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 21, 2023, the Company (formerly Vallon Pharmaceuticals, Inc.) consummated a merger with GRI Bio Operations, Inc. (formerly GRI Bio, Inc.) (Private GRI) pursuant to an Agreement and Plan of Merger, as amended (the Merger Agreement), by and among the Company, Private GRI and Vallon Merger Sub, Inc. (Merger Sub), a Delaware corporation and wholly-owned subsidiary of the Company. The Merger Agreement provided for the merger of Merger Sub with and into Private GRI, with Private GRI continuing as a wholly-owned subsidiary of the Company and the surviving corporation of the merger (the Merger). In connection with the closing of the Merger (the Closing), the Company amended its certificate of incorporation and bylaws to change its name from &#8220;Vallon Pharmaceuticals, Inc.&#8221; to &#8220;GRI Bio, Inc.&#8221;</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with signing the Merger Agreement, Private GRI entered into a Securities Purchase Agreement, dated as of December 13, 2022 (the Bridge SPA), with Altium Growth Fund, LP (the Investor), pursuant to which Private GRI issued senior secured promissory notes (the Bridge Notes) in the aggregate principal amount of $3.3 million, in exchange for an aggregate purchase price of $2.5 million. The Bridge Notes were issued in two closings: (i) the first closing for $1.67 million in aggregate principal amount (in exchange for an aggregate purchase price of $1.25 million) closed on December 14, 2022; and (ii) the second closing for $1.67 million in aggregate principal amount (in exchange for an aggregate purchase price of $1.25 million) closed on March 9, 2023. In addition, upon the funding of each tranche, the Investor received warrants to purchase an aggregate of 1,252,490 shares of Private GRI&#8217;s common stock (the Bridge Warrants).</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the Bridge SPA, and also in connection with signing the Merger Agreement, the Company, Private GRI and the Investor entered into a Securities Purchase Agreement on December 13, 2022 (the Equity SPA) pursuant to which the Investor agreed to invest $12.25 million in cash and cancel any outstanding principal and accrued interest on the Bridge Notes in return for the issuance of shares of Private GRI&#8217;s common stock immediately prior to the consummation of the Merger.  Pursuant to the Equity SPA, immediately prior to the Closing, Private GRI issued 6,787,219 shares of Private GRI&#8217;s common stock  (the Initial Shares) to the Investor and 27,148,877 shares of Company common stock (the Additional Shares) into escrow with an escrow agent. At the closing, pursuant to the Merger, the Initial Shares converted into an aggregate of 253,842 shares of the Company&#8217;s common stock  and the Additional Shares converted into an aggregate of 1,015,368 shares of the Company&#8217;s common stock . On May 8, 2023, in accordance with the terms of the Equity SPA, the Company and the Investor authorized the escrow agent to, subject to beneficial ownership limitations, disburse to the Investor all of the shares of the Company&#8217;s common stock  issued in exchange for the Additional Shares.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Equity SPA, on May 8, 2023, the Company issued to the Investor (i) Series A-1 Warrants to purchase 1,269,210 shares of the Company&#8217;s common stock  with an initial exercise price of $13.51 per share, (ii) Series A-2 Warrants to purchase 1,142,289 shares of the Company&#8217;s common stock  with an initial exercise price of $14.74 per share, and (iii) Series T Warrants to purchase at an exercise price of $12.28 per share (x) 814,467 shares of the Company&#8217;s common stock and (y) upon exercise of the Series T Warrants, an additional amount of Series A-1 Warrants and Series A-2 Warrants, each to purchase 814,467 shares of the Company&#8217;s common stock (collectively, the Equity Warrants).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the completion of the Merger, the outstanding principal and accrued interest on the Bridge Notes was cancelled and the Bridge Warrants were exchanged for warrants (the Exchange Warrants) to purchase an aggregate of 421,589 shares of the Company&#8217;s common stock .</span></div><div id="ied77ea4fb48541edb9612582cb5c50b7_85"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Operations Overview</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include personnel costs associated with research and development activities, including third party contractors to perform research, conduct clinical trials and manufacture drug supplies and materials. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development expenses have consisted primarily of costs related to our development program for our lead product candidate GRI-0621. These expenses include:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">employee-related expenses, such as salaries, bonuses and benefits, consultant-related expenses such as consultant fees and bonuses, stock-based compensation, overhead-related expenses and travel-related expenses for our research and development personnel; and</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ied77ea4fb48541edb9612582cb5c50b7_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">expenses incurred under agreements with CROs, CMOs and research laboratories in connection with our preclinical development, process development, manufacturing and clinical development activities as well as consultants that support the implementation of our clinical and non-clinical studies.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although our direct research and development expenses are tracked by product candidate, we do not allocate employee costs and costs associated with our discovery efforts, laboratory supplies and facilities, including other indirect costs, to specific product candidates as these costs are deployed across multiple programs. We expect our research and development expenses to increase over the next several years as we conduct our planned clinical and preclinical activities for our product candidates.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of compensation and consulting related expenses for executives and other administrative personnel, professional fees and other corporate expenses, including legal and accounting fees, travel expenses, facilities-related expenses, and consulting services relating to corporate matters.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our general and administrative expenses will increase substantially as we incur costs associated with being a public company, including expenses related to services associated with maintaining compliance with The Nasdaq Capital Market and SEC requirements, directors&#8217; and officers&#8217; insurance, legal and accounting costs and investor relations costs, as well as an increase in personnel expenses as we hire additional personnel.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrant Liability</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, Vallon issued warrants in connection with a securities purchase agreement. Vallon evaluated the warrants in accordance with ASC 815-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 815-40), and concluded that a provision in the warrants related to the reduction of the exercise price in certain circumstances precludes the warrants from being accounted for as components of equity. As a result, the warrants were measured the fair value  upon issuance using a Black-Scholes valuation model and are recorded as a liability on the balance sheet. The fair value of the warrants is measured at each reporting date and changes in fair value are recognized in the consolidated statements of operations in the period of change. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense, net</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense consists of amortization of debt discounts, debt issuance costs and interest expense related to the TEP Notes and the Bridge Notes.</span></div><div id="ied77ea4fb48541edb9612582cb5c50b7_88"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Three Months Ended June&#160;30, 2023 and 2022 </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of our operations for the periods indicated (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">880&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,054&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,934</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,934)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(189)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(934)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,746)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(295)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ied77ea4fb48541edb9612582cb5c50b7_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $0.9 million and $0.1 million for the three months ended June&#160;30, 2023 and 2022, respectively. The $0.8 million increase in research and development expenses was primarily due to increases of $0.4 million in expenses related to the development program of GRI-0621, $0.2 million in consulting fees and $0.2 million in personnel expenses. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $5.1 million and $0.1 million for the three months ended June&#160;30, 2023 and 2022, respectively. The $5.0 million increase was primarily related to increased costs for professional fees, including legal, accounting and investment banking fees associated with the Merger of $3.8 million, personnel expenses of $0.8 million as a result of increased headcount, and increases in consulting, administrative and insurance expenses of $0.3 million as a result of operating as a public company.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in Fair Value of Warrant Liability </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in fair value of $0.1 million represents a decrease in the fair value of the warrants outstanding during the three months ended June&#160;30, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense, net</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense, net, was $0.9 million and $0.1 million for the three months ended June&#160;30, 2023 and 2022, respectively and related to the outstanding promissory notes. The increase in interest expense, net, was due to interest related to the Bridge Notes.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Six Months Ended June&#160;30, 2023 and 2022 </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of our operations for the periods indicated (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,926&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,923</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,923)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(387)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,095)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(210)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,896)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(597)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $1.0 million and $0.1 million for the six months ended June&#160;30, 2023 and 2022, respectively. The $0.9 million increase in research and development expenses was primarily due to </span><span style="background-color:#fff7c3;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ncreases of $0.4 million in expenses related to the development program of GRI-0621, $0.3 million in consulting fees and $0.2 million in personnel expenses. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $5.9 million and $0.3 million for the six months ended June&#160;30, 2023 and 2022, respectively. The $5.6 million increase was primarily related to increased costs for professional fees, including legal, accounting and investment banking fees associated with the Merger of $4.5 million, personnel expenses of $0.8 million as a result of increased headcount, and increases in consulting, administrative and insurance expenses of  $0.3 million as a result of operating as a public company.</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ied77ea4fb48541edb9612582cb5c50b7_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in Fair Value of Warrant Liability</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in fair value of $0.1 million represents an increase in the fair value of the warrants outstanding during the six months ended June&#160;30, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense, net</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense, net, was $2.1 million and $0.2 million for the six months ended June&#160;30, 2023 and 2022, respectively, and related to the outstanding promissory notes. The increase in interest expense, net, was due to interest related to the Bridge Notes. </span></div><div id="ied77ea4fb48541edb9612582cb5c50b7_91"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we have incurred losses and expect to continue to incur losses for the foreseeable future. We incurred net losses of $8.9 million and $0.6 million for the six months ended June&#160;30, 2023 and 2022, respectively. As of June&#160;30, 2023, we had an accumulated deficit of $27.4 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have financed our working capital requirements to date through the issuance of common stock, warrants, convertible notes and promissory notes. As of June&#160;30, 2023, we had $4.8 million in cash. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for the periods indicated (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,119)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(116)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,790&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows from Operating Activities</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June&#160;30, 2023 and 2022, $2.1 million was provided by and $0.1 million was used in operating activities, respectively. The $2.0&#160;million increase was primarily due to a $8.3&#160;million increase in net loss and a $0.7&#160;million decrease in prepaid and other assets, offset by an increase in non-cash adjustments of $2.1 million related to the amortization of debt discounts and debt issuance costs and $0.1 million related to the revaluation of the warrant liability, as well as a $4.1&#160;million increase in accounts payable and a $0.7&#160;million increase in accrued expenses. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows from Investing Activities</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $8 thousand for the six months ended June&#160;30, 2023, which was related to the purchase of computer equipment.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows from Financing Activities</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $6.9 million for the six months ended June&#160;30, 2023. The $6.9 million increase was primarily due to $12.3 million of proceeds from the Equity SPA and $1.3 million of proceeds from the funding of the second tranche of the Bridge Notes. The increase was offset by $2.9 million of net liabilities assumed in the connection with the Merger, $3.0 million in costs associated with the Merger, the payment of $0.5 million of debt issuance costs related to the Bridge Notes and $0.1 million of stock issuance costs related the Equity SPA. </span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ied77ea4fb48541edb9612582cb5c50b7_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Securities Purchase Agreement</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with signing the Merger Agreement, Vallon, Private GRI and the Investor entered the Equity SPA pursuant to which the Investor agreed to invest $12,250 in cash and cancel any outstanding principal and accrued interest on the Bridge Notes in return for the issuance of shares of Private GRI&#8217;s common stock immediately prior to the consummation of the Merger. Pursuant to the Equity SPA, immediately prior to the Closing, Private GRI issued 6,787,219 shares of Private GRI&#8217;s common stock (the Initial Shares) to the Investor and 27,148,877 shares of Private GRI&#8217;s common stock (the Additional Shares) into escrow with an escrow agent for net proceeds of $11,704, after deducting offering expenses of $546.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the closing, pursuant to the Merger, the Initial Shares converted into an aggregate of 253,842 shares of the Company&#8217;s common stock and the Additional Shares converted into an aggregate of 1,015,368 shares of the Company&#8217;s common stock . On May 8, 2023, in accordance with the terms of the Equity SPA, we, along with the Investor, authorized the escrow agent to, subject to beneficial ownership limitations, disburse to the Investor all of the shares of the Company&#8217;s common stock  issued in exchange for the Additional Shares. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Funding Requirements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net losses were $8.9 million and $0.6 million for the six months ended June&#160;30, 2023 and 2022, respectively. As of June&#160;30, 2023, we had $4.8 million in cash and an accumulated deficit of $27.4 million. We expect to devote substantial financial resources to our planned activities, particularly as we prepare for, initiate, and conduct our planned clinical trials of GRI-0621 and GRI-0803, advance our discovery programs and continue our product development efforts. In addition, we expect to incur additional costs associated with operating as a public company. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our current operating plan, we believe that our existing cash and cash equivalents, which include the proceeds from the Equity SPA, will be sufficient to fund our operating expenses and capital expenditure requirements for twelve months from the date of the Merger, not including the exercise of the Series T Warrants (the Series T Warrant Exercises). </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to secure adequate additional funding, we will need to reevaluate our operating plans and may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, delay, scale back or eliminate some or all of our development programs, or relinquish rights to our technology on less favorable terms than we would otherwise choose. These actions could materially impact our business, results of operations and future prospects. In addition, attempting to secure additional financing may divert the time and attention of management from day-to-day activities and distract from our discovery and product development efforts. As a result, there is substantial doubt about our ability to continue as a going concern. We expect to continue to incur significant and increasing operating losses at least for the foreseeable future. We do not expect to generate product revenue unless and until we successfully complete development, obtain regulatory approval for, and successfully commercialize our current, or any future, product candidates.</span></div><div id="ied77ea4fb48541edb9612582cb5c50b7_94"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not party to any off-balance sheet transactions. We have no guarantees or obligations other than those which arise out of normal business operations.</span></div><div id="ied77ea4fb48541edb9612582cb5c50b7_97"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of its financial condition and results of operations is based on its unaudited interim financial statements, which have been prepared in accordance with GAAP. The preparation of these condensed financial statements requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Management evaluates these estimates and judgments on an ongoing basis. Management bases its estimates on historical experience and on various other factors that it believes are reasonable under the circumstances. Actual results could differ from those estimates.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our significant accounting policies are described in more detail in Note 1, &#8220;The Company and a Summary of its Significant Accounting Policies&#8221;, in the notes to its financial statements as of and for the years ended December&#160;31, 2022 and 2021, which is Exhibit 99.2 of Amendment No. 2 to the Current Report on Form 8-K filed with the SEC on July 6, 2023. </span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><div id="ied77ea4fb48541edb9612582cb5c50b7_100"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ied77ea4fb48541edb9612582cb5c50b7_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Emerging Growth Company Status</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and may remain an emerging growth company for up to five years. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not applicable to emerging growth companies. These exemptions include:</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduced disclosure about our executive compensation arrangements;</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">no non-binding stockholder advisory votes on executive compensation or golden parachute arrangements; and</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have taken advantage of reduced reporting requirements in this report and may continue to do so until such time that we are no longer an emerging growth company. We will remain an &#8220;emerging growth company&#8221; until the earliest of (a) the last day of the fiscal year in which we have total annual gross revenues of $1.235 billion or more, (b) December 31, 2026, the last day of the fiscal year following the fifth anniversary of the completion of the IPO, (c) the date on which we have issued more than $1.0 billion in nonconvertible debt during the previous three years or (d) the date on which we are deemed to be a large accelerated filer under the rules of the SEC. Section&#160;107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period for complying with new or revised accounting standards. </span></div><div id="ied77ea4fb48541edb9612582cb5c50b7_103"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable to a smaller reporting company.</span></div><div id="ied77ea4fb48541edb9612582cb5c50b7_106"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management&#8217;s Evaluation of our Disclosure Controls and Procedures</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Chief Executive Officer and Chief Financial Officer evaluated the effectiveness of its disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e)) of the Securities Exchange Act of 1934 (the Exchange Act)) as of June&#160;30, 2023. We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in its periodic and current reports that we file with the SEC is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the evaluation of our disclosure controls and procedures as of June&#160;30, 2023, our Chief Executive Officer and Chief Financial Officer have concluded that, as of such date, our disclosure controls and procedures, as defined above, are effective.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred during the fiscal quarter covered by this report that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.</span></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="ied77ea4fb48541edb9612582cb5c50b7_109"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ied77ea4fb48541edb9612582cb5c50b7_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II&#8212;OTHER INFORMATION</span></div><div id="ied77ea4fb48541edb9612582cb5c50b7_112"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ied77ea4fb48541edb9612582cb5c50b7_115"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes from the risk factors previously disclosed in Vallon&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2022 and in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2023.</span></div><div id="ied77ea4fb48541edb9612582cb5c50b7_118"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Securities.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ied77ea4fb48541edb9612582cb5c50b7_121"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ied77ea4fb48541edb9612582cb5c50b7_124"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ied77ea4fb48541edb9612582cb5c50b7_127"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 10, 2023, our Compensation Committee ratified and approved, effective as of July 1, 2023, an employment agreement with Albert Agro, M.D. (the Employment Agreement), which superseded the previous consulting agreement by and between the Company and Dr. Agro, and includes the following terms: </span></div><div style="margin-bottom:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226; an annual base salary of $325,000 (the Annual Base Salary); and </span></div><div style="margin-bottom:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226; an annual target cash bonus of 35%.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Employment Agreement also provide that if the Company terminates Dr. Agro's employment without &#8220;cause&#8221; or if Dr. Agro resigns his employment for &#8220;good reason,&#8221; each as defined in the Employment Agreement, Dr. Agro will be entitled to receive salary continuation and COBRA premium reimbursement for twelve months. In the case of a termination without cause or resignation for good reason that occurs during the period beginning upon the occurrence of a &#8220;change in control&#8221; (as defined in the Employment Agreement) and ending twelve months thereafter, (a) these severance-related periods will be increased to 18 months, (b) all unvested equity awards will automatically accelerate, (c) all vested stock options will remain exercisable for the full duration of their term, and (d) Dr. Agro will receive an additional payment equivalent to 1.5 times his Annual Base Salary.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing description of the Employment Agreement contained herein does not purport to be complete and is qualified in its entirety by reference to the text of the Employment Agreement that is filed herewith as Exhibit 10.6.</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><div id="ied77ea4fb48541edb9612582cb5c50b7_130"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="-sec-extract:summary;margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ied77ea4fb48541edb9612582cb5c50b7_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits.</span></div><div style="margin-bottom:8pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.872%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.322%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed Herewith</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference File No. </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date Filed</span></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1824293/000182429323000073/ex31_arcoi.htm">Certificate of Incorporation of GRI Bio, Inc., as amended.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-40034</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/21/2023</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1824293/000182429323000073/ex32_amendedandrestatedbyl.htm">Amended and Restated Bylaws.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-40034</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5/26/2023</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1824293/000182429323000121/gribioinc-argribioinc2018e.htm">A&amp;R 2018 Equity Incentive Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-40034</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5/15/2023</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1824293/000162828023004948/exhibit1040-sx4a3.htm">Employment Agreement, by and between GRI Bio, Inc. and Marc Hertz, Ph.D., dated as of February 20, 2023.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-4/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333-268977</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/24/2023</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1824293/000162828023004948/exhibit1041-sx4a3.htm">Employment Agreement, by and between GRI Bio, Inc. and Leanne M. Kelly, dated as of February 20, 2023.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-4/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333-268977</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/24/2023</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1824293/000162828023004948/exhibit1042-sx4a3.htm">Employment Agreement, by and between GRI Bio, Inc. and Vipin Kumar Chaturvedi dated as of February 20, 2023. </a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-4/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333-268977</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/24/2023</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.4#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1824293/000182429323000073/ex105_consultingagreement-.htm">Consulting Agreement, by and between GRI Bio, Inc. and Albert Agro, Ph.D., dated as of January 9, 2023.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-40034</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/21/2023</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.5#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1824293/000182429323000073/ex109_separationagreementb.htm">Separation Agreement, by and between GRI Bio, Inc. and David Baker, dated as of April 21, 2023</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-40034</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/21/2023</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.6#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex106_aagroemploymentagree.htm">Employment Agreement, by and between GRI Bio, Inc. and Albert Agro, Ph.D., dated as of July 1, 2023.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex311_ceo302cert63023.htm">Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex312_cfo302cert63023.htm">Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex321_ceosection906cert630.htm">Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex322_cfosection906cert630.htm">Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">iXBRL Instance Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">iXBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">iXBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">iXBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">iXBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">iXBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">____________________________________</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unless otherwise indicated, exhibits are filed herewith.</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="-sec-extract:summary;margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ied77ea4fb48541edb9612582cb5c50b7_7">Table of Contents</a></span></div></div><div style="padding-left:18pt;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"><tr><td style="width:0.1%"></td><td style="width:2.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.774%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.933%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.933%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.936%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicates a management contract or any compensatory plan, contract or arrangement.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">This certification will not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, except to the extent specifically incorporated by reference into such filing.</span></td></tr></table></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><div id="ied77ea4fb48541edb9612582cb5c50b7_133"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ied77ea4fb48541edb9612582cb5c50b7_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.352%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.815%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GRI BIO, INC.</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: August 14, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Leanne M. Kelly</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name: Leanne M. Kelly</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title: Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</span></td></tr></table></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>2
<FILENAME>ex106_aagroemploymentagree.htm
<DESCRIPTION>EX-10.6
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i92a9112eeda24559a0bb5f2b3e427a50_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.6</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EMPLOYMENT AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This EMPLOYMENT AGREEMENT (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is made as of the 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> day of July, 2023 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), between GRI Bio, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and Albert Agro, PhD. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and shall become effective on the date provided herein. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> WHEREAS, the Company and Executive, in connection with the Merger, entered into a Consulting Agreement dated as of January 9, 2023 (the &#8220;Consulting Agreement&#8221;)&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, the Company and Executive wish to enter into this Employment Agreement that will supersede the Consulting Agreement in all respects.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOW THEREFORE, in consideration of the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and Executive agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.&#160;&#160;&#160;&#160;Employment Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company shall employ Executive, and Executive accepts employment with the Company, upon the terms and subject to the conditions set forth in this Agreement, for the period beginning on the Effective Date and ending on the Date of Termination (as defined in Section 4(e) of this Agreement) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.&#160;&#160;&#160;&#160;Terms of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Position and Duties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  During the Term, Executive shall be employed by the Company as Chief Medical Officer and shall have such duties, responsibilities and authorities as are customarily associated with his position and such additional duties and responsibilities consistent with his position as may, from time to time, be properly and lawfully assigned to him.  Executive shall report to the Company&#8217;s Chief Executive Officer (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">CEO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Executive shall act at all times in compliance in all respects with the policies, rules and decisions adopted from time to time by the Company and perform all of the duties and obligations required of him by this Agreement in a loyal and conscientious manner.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Engaging in Other Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  During the Term, Executive shall devote his full time and attention to the Company and its affiliates and shall not be employed by or provide services to any other person or entity, except that Executive may devote ten percent (10%) of his working time to certain consulting projects he has disclosed to the Company, which projects are expected to be completed by December 31, 2023.  During the Term, it shall not be a violation of this Agreement for Executive, subject to the requirements of Section 8 hereof, to (i) serve on civic, charitable or religious boards or engage in other activities for such organizations, (ii) with the consent of the Company&#8217;s Board of Directors (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), which consent shall not be unreasonably withheld, serve on up to one corporate board unrelated to the Company (and retain all compensation in whatever form for such service), and (iii) manage personal investments, so long as such activities (individually or in the aggregate) do not interfere with the performance of Executive's responsibilities as set forth in Sections 2(a) or 2(b) of this Agreement or Executive's fiduciary duties to the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Location</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive&#8217;s primary work location shall be from the New York City home office.  Executive may be required to travel from time to time to the Company&#8217;s San Diego office, the expenses for which shall be reimbursed pursuant to Company policy.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.&#160;&#160;&#160;&#160;Compensation and Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  During the Term, the Company shall pay Executive an annualized base salary (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Annual Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) of $325,000, payable in regular installments in accordance with the Company's normal payroll practices, and subject to usual payroll deductions.  During </font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Term, the Annual Base Salary shall be reviewed by the Board or a committee thereof at such time as the salaries of other senior executives of the Company are reviewed generally, but no less frequently than once a year.  The Annual Base Salary shall not be reduced other than in connection with an across-the-board salary reduction which applies in a comparable manner to other senior executives of the Company.  If so increased or reduced, then such adjusted salary will thereafter be the Annual Base Salary for all purposes under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Performance Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive shall be eligible to receive a performance bonus, the earning of which shall be subject to the discretion and determination of the Board or a committee thereof (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Performance Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) in an amount equal to thirty-five percent (35%) of Executive&#8217;s Annual Base Salary. The determination of the amount, if any, of the Performance Bonus each year shall be made no later than sixty (60) days following the conclusion of each applicable year of the Term, and shall be paid, if at all, within sixty (60) days of such determination. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">PTO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  During the Term, Executive shall be eligible for at least four (4) weeks paid time off (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">PTO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) per year in accordance with the Company's policies in effect from time to time.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Expense Reimbursement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive shall be reimbursed for all reasonable travel and other out-of-pocket expenses actually and properly incurred by Executive prior to and during the Term in connection with carrying out her duties hereunder in accordance with the Company's policies in effect from time to time for its senior executives generally.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  During the Term, Executive shall be eligible to participate in all welfare, perquisite, fringe benefit, insurance, retirement and other benefit plans, practices, policies and programs, maintained by the Company and its affiliates applicable to senior executives of the Company generally, in each case as amended from time to time. In the event the Company does not purchase a policy of long-term disability insurance, the Company will reimburse Executive for his purchase of such a policy, up to a maximum annual amount of $7,500.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.&#160;&#160;&#160;&#160;Termination of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Death and Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive's employment shall terminate automatically upon Executive's death.  If the Company determines in good faith that the Disability (as defined below) of Executive has occurred during the Term, it may give to Executive written notice in accordance with Section 11 of this Agreement of its intention to terminate Executive's employment&#59; provided that (i) such notice is provided no later than 150 calendar days following the determination of Executive's Disability, and (ii) Executive has not returned to full-time employment during the period between such determination and the giving of such notice.  In such event, Executive's employment shall terminate effective on the 30th calendar day after receipt of such notice by Executive (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Disability Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), provided that, within the 30 calendar days after such receipt, Executive shall not have returned to full-time performance of Executive's duties.  For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the inability of Executive to perform the essential duties of the position held by Executive by reason of any medically determined physical or mental impairment that is reasonably expected to result in death or lasts for 120 calendar days in any one-year period, all as determined by an independent licensed physician mutually acceptable to the Company and Executive or Executive's legal representative.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive's employment with the Company may be terminated by the Company with or without Cause.  For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean&#58; (i) the continued failure of Executive to perform Executive's duties as set forth in Section 2 hereof or Executive's material disregard of the reasonable and lawful directives of the Company (in each case other than any such failure resulting from any medically determined physical or mental </font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">impairment) that is not cured by Executive within 20 calendar days after a written demand for performance is delivered to Executive by the Company which specifically identifies the manner in which the Company believes that Executive has not performed Executive's duties or disregarded a directive of the CEO&#59; (ii) Executive's commission of any material act of fraud, misappropriation or embezzlement against or in connection with the Company or any of its affiliates or their respective businesses or operations&#59; (iii) Executive's commission of, or indictment for or otherwise being formally charged with, any crime involving dishonesty or for any felony&#59; (iv) the engaging by Executive in misconduct that is materially detrimental to the financial condition or business reputation of the Company or any of its affiliates, including due to any adverse publicity&#59; or (v) a material breach by Executive of his obligations under Section 8, or his representations under Section 9, of this Agreement.  In addition to the notice and opportunity to cure set forth in subsection (i) above, to the extent that any of the grounds set forth in subsections (iv) or (v) above is capable of being cured, the Company shall not have Cause unless it has furnished Executive with written notice specifically identifying the conduct allegedly giving rise to Cause, and he has failed to cure such ground within 20 days of the delivery of such notice.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive's employment with the Company may be terminated by Executive with or without Good Reason.  For purposes of this Agreement, &#8220;Good Reason&#8221; shall mean the occurrence of any of the following without Executive's consent&#58;  (i) a material reduction by the Company of Executive's title, duties, responsibilities, authority or reporting relationship set forth in Section 2(a)&#59; (ii) a material reduction by the Company of Executive's Annual Base Salary&#59; (iii) a material breach of the Company of this Agreement&#59; or (iv) a material change in geographic location at which Executive must principally perform services under this Agreement from the location at which Executive was principally employed.  A termination of Executive's employment by Executive under Sections 4(c)(i), (ii),(iii) or (iv) shall not be deemed to be for Good Reason unless (x) Executive gives notice to the Company of the existence of the event or condition constituting Good Reason within 30 calendar days after becoming aware of the initial occurrence or existence of such event or condition, and (y) the Company fails to cure such event or condition within 30 calendar days after receiving such notice.  Additionally, Executive must terminate his employment within 90 calendar days after the initial occurrence of the circumstance constituting Good Reason for such termination to be &#8220;Good Reason&#8221; hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notice of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any termination by the Company for Cause, or by Executive for Good Reason, shall be communicated by Notice of Termination to the other party in accordance with Section 11.  For purposes of this Agreement, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notice of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a written notice which (i) indicates the specific termination provision in this Agreement relied upon, (ii) to the extent applicable, sets forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of Executive's employment under the provision so indicated, and (iii) if the Date of Termination (as defined below) is other than the date of receipt of such notice, specifies the Date of Termination.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Date of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Date of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, as applicable, the date of Executive's death, the Disability Effective Date, or the date on which the termination of Executive's employment by the Company for Cause or without Cause or by Executive for Good Reason or without Good Reason is effective.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Resignation from All Positions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any other provision of this Agreement, upon the termination of Executive's employment for any reason, unless otherwise requested by the CEO, Executive shall immediately resign from all positions that he holds or has ever held with the Company and its affiliates, including the boards of directors or committees of the Company's affiliates.  Executive hereby agrees to execute any and all documentation to effectuate such resignations upon request by the Company, but he shall be treated for all purposes as having so resigned upon termination of his employment, regardless of when or whether he executes any such documentation.</font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.&#160;&#160;&#160;&#160;Severance Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Any Termination of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If, during or at the expiration of the Term, Executive's employment with the Company and its affiliates shall terminate for any reason or no reason, then&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Accrued Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company shall pay, or cause to be paid, to Executive the sum of&#58;  (A) the portion of Executive's Annual Base Salary earned through the Date of Termination, to the extent not previously paid, (B) the amount of the Performance Bonus that the Board of Directors (or subcommittee thereof) has decided has been earned by Executive preceding the Date of Termination, but has not yet been paid to Executive, and (C) any unreimbursed business expenses to the extent reimbursable in accordance with the Company's reimbursement policies (the sum of the amounts described in clauses (A) through and including (C) shall be referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Accrued Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  The Accrued Benefits shall be paid to Executive in a single lump sum within 30 calendar days after the Date of Termination or such earlier date if required by law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Other Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  To the extent not previously paid or provided, the Company shall pay or provide, or cause to be paid or provided, to Executive (or his estate) any other amounts or benefits (including, as applicable, any payment of long-term incentive awards) required to be paid or provided or which Executive is eligible to receive under any plan, program, policy or practice or contract or agreement of the Company, including any benefits to which Executive is entitled under COBRA (such other amounts and benefits described in this Section 5(a)(ii) shall be hereinafter referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Other Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) in accordance with the terms and normal procedures of each such plan, program, policy or practice or contract or agreement, based on accrued and vested benefits through the Date of Termination.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Good Reason, Other than for Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If, during the Term, the Company shall terminate Executive's employment other than for Disability or Cause, or if Executive shall terminate employment for Good Reason, then, in addition to providing the Accrued Benefits and Other Benefits, as set forth in Section 5(a) above, and subject to Sections 6 and 8(f) below, the Company shall pay or provide the following amounts and benefits to Executive&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Severance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company shall continue to pay to Executive the Annual Base Salary, as of the Date of Termination, for the period beginning on the Date of Termination and ending twelve (12) months thereafter (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Severance Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), which shall be payable over the Severance Period in regular installments in accordance with the Company's normal payroll practices as they may exist from time to time, with the installments that otherwise would be paid prior to the first payroll date following the date the Release described in Section 6 becomes effective and irrevocable in accordance with its terms (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Release Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) being paid (without interest) on such payroll date in a lump sum and the remaining installments being paid as otherwise scheduled assuming payments had begun immediately after the Date of Termination.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Continued Health Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If Executive elects COBRA coverage under the applicable medical and dental plans of the Company, the Company will subsidize a portion of the applicable monthly COBRA premium during the Severance Period, so that Executive will only be required to pay the premiums applicable to continuing employees during that time&#59; provided that such subsidy shall cease on the date on which Executive becomes eligible for medical and dental coverage from a third party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Performance Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive will be eligible to receive the Performance Bonus for the fiscal year during which the Date of Termination occurs, based on actual performance results during the entire fiscal year and without regard to any discretionary adjustments that have the effect of reducing the amount of the Performance Bonus (other than </font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">discretionary adjustments applicable to all senior executives who did not terminate employment), pro-rated based on the number of days in the Company's fiscal year through (and including) the Date of Termination (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Pro-Rated Performance Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), which, if earned, shall be payable in a single lump sum at the same time that payments are made to other participants in the annual bonus plan for that fiscal year&#59; provided, however, that Executive shall be entitled to such a Pro-Rated Performance Bonus only if Executive was employed by the Company for at least six months during the fiscal year in which the Date of Termination occurred.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Good Reason, Other than for Cause During the Change in Control Protection Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If, during the Term and during the period beginning upon the occurrence of a &#8220;Change in Control&#8221; (as defined in the Equity Plan) and ending on the first anniversary of the occurrence of the Change in Control (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Change in Control Protection Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), the Company shall terminate Executive's employment other than for Disability or Cause, or if Executive shall terminate employment for Good Reason, then, in addition to providing the Accrued Benefits and Other Benefits, as set forth in Section 5(a) above, and subject to Sections 6 and 8(f) below, the Company shall pay or provide the benefits set forth in Section 5(b) except that Executive shall receive a lump sum amount equivalent to 1.5 times his Annual Base Salary (in lieu of the amount paid during the Severance Period as provided in Section 5(b)), and the Performance Bonus, which shall not be pro-rated, within fourteen (14) business days of the effective date of the Release provided for in Section 6 and Executive shall thereafter be entitled to 18 months of subsidized COBRA premiums. In addition, and notwithstanding anything contained in the applicable Company equity plan and award agreements to the contrary, all outstanding and unvested equity awards of the Company granted to Executive shall become immediately vested and exercisable upon such date of termination.  In addition, all outstanding and vested Company stock options (including those that vest pursuant to the operation of the immediately preceding sentence) will remain exercisable for the full duration of their term.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 280G</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding anything in this Agreement to the contrary, in the event it shall be determined that any accrual, acceleration, payment, benefit or distribution by the Company or any of its affiliated companies to or for the benefit of Executive (whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise) (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) would be an excess parachute payment within the meaning of section 280G of the Internal Revenue Code of 1986, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) (such excess only, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Excess Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), then Executive shall forfeit all Excess Payments if the after-tax value to Executive of the Payments, as reduced by such forfeiture, would be greater than the after-tax value to Executive of the Payments absent such forfeiture.  The forfeiture of Excess Payments, if applicable, shall be applied to the severance described in Section 5(c) hereof, then to cancellation of accelerated vesting of performance-based equity awards (based on the reverse order of the date of grant), then to cancellation of accelerated vesting of other equity awards (based on the reverse order of the date of grant), and then to any other Payments on a pro-rata basis.  All determinations required to be made under this Section 5(d), including whether and when a Payment is subject to section 280G of the Code, and the value of a Payment for purposes of section 280G of the Code, and the assumptions to be utilized in arriving at such determination, shall be made by an accounting firm with expertise in such matters designated by the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Accounting Firm</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  The Company will direct the Accounting Firm to provide its determination and detailed supporting calculations both to the Company and Executive within 15 business days after the date of the event giving rise to the Payment or such other time as is requested by the Company.  Any determination by the Accounting Firm shall be binding upon the Company and Executive.  All fees and expenses of the Accounting Firm for services performed pursuant to this Section 5(d) shall be borne solely by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.&#160;&#160;&#160;&#160;Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding anything contained herein to the contrary, the Company shall not be obligated to make any payment or provide any benefit under Section 5(b) or 5(c) hereof unless&#58;  (a) Executive or Executive's legal representative first executes within 21 calendar days after the Date of Termination (or such longer period as required by applicable law) </font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a release of claims (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59; (b) Executive does not revoke the Release&#59; and (c) the Release becomes effective and irrevocable in accordance with its terms.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.&#160;&#160;&#160;&#160;Full Settlement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company's obligation to make the payments provided for in this Employment Agreement and otherwise to perform its obligations hereunder shall not be affected by any set-off, counterclaim, recoupment, defense or other claim, right or action which the Company or any of its affiliates may have against Executive or others, except as otherwise may be provided in Section 8 hereof.  In no event shall Executive be obligated to seek other employment or take any other action by way of mitigation of the amounts payable to Executive under any of the provisions of this Agreement and such amounts shall not be reduced whether or not Executive obtains other employment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.&#160;&#160;&#160;&#160;Executive&#8217;s Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  During the Term and thereafter, Executive agrees to keep secret and confidential, and not to use or disclose to any third parties, except as directly required for Executive to perform Executive's responsibilities for the Company under this Agreement, any of the Company's Confidential Information (as defined in paragraph (l) below) acquired by Executive during the course of, or in connection with, Executive's employment with the Company.  Executive acknowledges that the Confidential Information is the exclusive property of the Company.  Upon termination of Executive's employment with the Company, for any reason, or at the request of the Company at any time, Executive shall promptly return to the Company all property then in Executive's possession, custody or control belonging to the Company, including all Confidential Information.  Executive shall not retain any copies of correspondence, memoranda, reports, notebooks, drawings, photographs or other documents in any form whatsoever (including information contained in computer or other electronic memory or on any computer or electronic storage device) relating in any way to the affairs of the Company and which were entrusted to Executive or obtained by Executive at any time during the Term.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Assignment of Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive shall promptly disclose to the Company and hereby assigns and transfers to the Company all of Executive's right, title and interest in and to&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;any and all patents, inventions, discoveries, concepts, processes, methods, formulas, techniques, trade secrets, know-how, and related rights, whether or not patentable&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;any and all copyrights and works of authorship, whether or not copyrightable, if and only to the extent that such intellectual property was conceived, created or reduced to tangible form by Executive in the course of performing her duties for the Company, and either relates to the business of the Company, or was conceived, created or reduced to tangible form with the use or assistance of the Company's facilities, materials or personnel.  Without limiting the generality of the foregoing, this assignment requirement applies to applications for U.S. or foreign letters patent and copyright registration granted upon such inventions, discoveries, and works of authorship and similar items as hereinabove set forth.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;Executive shall deliver to the Company any and all instruments necessary to confirm complete ownership by the Company of any and all rights as described above, and upon the failure of Executive to furnish such documents, this Agreement shall constitute such documentation for all purposes.  Executive further agrees during and after Executive's employment by the Company, to cooperate fully, including giving testimony in support of Executive's inventorship, as may be necessary in the opinion of the Company to obtain and&#47;or maintain letters patent and to vest the entire ownership of such letters patent with the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Disparagement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive agrees that he will not do or say anything that could reasonably be expected to disparage or impact negatively the name or reputation in the </font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">marketplace of the Company or any of its affiliates, employees, officers, directors, stockholders, members, principals or assigns.  Subject to Executive's continuing obligations to comply with Section 8(a) (Confidential Information) hereof, nothing in this Section 8(f) shall preclude Executive from responding truthfully to any legal process or truthfully testifying in a legal or regulatory proceeding, provided that, to the extent permitted by law and Section 8(i) hereof, Executive promptly informs the Company of any such obligation prior to participating in any such proceedings.  The Company, defined for purposes of this Section 8(f) as the Board and its individual members, agrees in turn that it will not do or say anything that could reasonably be expected to disparage or impact negatively the name or reputation in the marketplace of Executive, provided that nothing in this Section 8(f) shall prevent the Company from responding truthfully to any legal process or truthfully testifying in a legal or regulatory proceeding.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Divisible Provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The individual terms and provisions of this Section 8 are intended to be separate and divisible provisions and if, for any reason, any one or more of them is held to be invalid or unenforceable, neither the validity nor the enforceability of any other provision of this Section 8 shall thereby be affected.  It is the intention of Executive and the Company that the potential restrictions on Executive's solicitation and future employment imposed by this Section 8 be reasonable in both duration and geographic scope and in all other respects.  If for any reason any court of competent jurisdiction shall find any provisions of this Section 8 unreasonable in duration or geographic scope or otherwise, Executive and the Company agree that the restrictions and prohibitions contained herein may be modified by a court of competent jurisdiction and shall be effective to the fullest extent allowed under applicable law in such jurisdiction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Injunctive Relief and Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In event of a breach or threatened breach of any of Executive's duties and obligations under this Section 8, the Company shall be entitled, in addition to any other legal or equitable remedies it may have in connection therewith (including any right to damages it may suffer), to (i) seek temporary, preliminary and permanent injunctive relief restraining such breach or threatened breach, (ii) cease making payments or providing benefits under Section 5 of this Agreement (other than paragraph 5(a) thereof), and (iii) seek any other relief obtainable through statutory or common law means (including, but not limited to, applicable trade secrets law).  Executive hereby expressly acknowledges that the harm that might result to the Company's business as a result of any noncompliance by Executive with the provisions of this Section 8 may be largely irreparable.  The restrictions stated in this Section 8 are in addition to and not in lieu of protections afforded to trade secrets and confidential information under applicable law.  Nothing in this Section 8 is intended to or shall be interpreted as diminishing or otherwise limiting the Company's right under applicable law to protect its trade secrets and confidential information.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Protected Activity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Nothing contained in this Agreement, or any other agreement, policy, practice, procedure, directive or instruction maintained by the Company shall prohibit Executive from reporting possible violations of federal, state or local laws or regulations to any federal, state or local governmental agency or commission (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Government Agency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) or from making other disclosures that are protected under the whistleblower provisions of federal, state or local laws or regulations.  Executive does not need prior authorization of any kind to make any such reports or disclosures to any Government Agency and Executive is not required to notify the Company that Executive has made such reports or disclosures.  Nothing in this Agreement limits any right Executive may have to receive a whistleblower award or bounty for information provided to any Government Agency.  Executive hereby acknowledges that the Company has informed Executive, in accordance with 18 U.S.C. &#167; 1833(b), that Executive may not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret where the disclosure&#58;  (i) is made in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, and solely for the purpose of reporting or investigating a suspected violation of law&#59; or (ii) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.</font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notification&#47;Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  To enable the Company to monitor Executive's compliance with the obligations imposed by this Section 8, Executive agrees to inform the Company of the identity of any subsequent employer and Executive's new job title.  Executive agrees that he will disclose the existence of this Section 8 to any subsequent employer.  Following the expiration of the Term or this Agreement, this Section 8 shall survive and be of full force and effect.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  As used in this Section 8, the following definitions shall apply </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Company and its subsidiaries and affiliates.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means information pertaining to the business of the Company that is generally not known to or readily ascertainable to the industry in which the Company competes, and that gives or tends to give the Company a competitive advantage over persons who do not possess such information or the secrecy of which is otherwise of value to the Company in the conduct of its business regardless of when and by whom such information was developed or acquired, and regardless of whether any of these are described in writing, copyrightable or considered copyrightable, patentable or considered patentable.  Confidential Information includes, but is not limited to, the Company's trade secrets, financial information or plans, pricing and profit information, sales and marketing information or plans, business or strategic plans, information concerning methods of operation, proprietary systems or software, legal or regulatory information, cost and pricing information or policies, information concerning new or potential products or markets, clinical data, medical or other data relating to participants in clinical trials, or research and&#47;or analysis, information related to present and potential customers, vendors and suppliers (including, but not limited to, lists, contact information, requirements, contract terms, and pricing), methods of operations, research and development, product information, business technical information, including technical data, techniques, solutions, test methods, quality control systems, processes, design specifications, technical formulas, procedures and information, all agreements, schematics, manuals, studies, reports, and statistical information relating to the Company, all formulations, database files, information technology, strategic alliances, products, services, programs and processes used or sold, and all software licensed or developed by the Company, computer programs, systems and&#47;or software, ideas, inventions, business information, know-how, improvements, designs, redesigns, creations, discoveries and developments of the Company.  Confidential Information includes all forms of the information, whether oral, written or contained in electronic or any other format.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.&#160;&#160;&#160;&#160;Representations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive hereby represents and warrants to the Company that Executive is not party to any contract, understanding, agreement or policy, whether or not written, with his current employer (or any other previous employer) or otherwise, that would be breached by Executive's entering into, or performing services under, this Agreement.  Executive further represents that he has disclosed to the Company in writing all material threatened, pending, or actual claims against Executive that are unresolved and still outstanding as of the Effective Date, in each case of which he is aware, resulting or arising from his service with his current employer (or any other previous employer) or his membership on any boards of directors.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.&#160;&#160;&#160;&#160;Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  During the Term and thereafter, Executive shall cooperate with the Company and its affiliates, without additional consideration, in any internal investigation or administrative, regulatory, or judicial proceeding as reasonably requested by the Company including, without limitation, Executive's being available to the Company and its affiliates upon reasonable notice for interviews and factual investigations, appearing at the Company's request to give testimony without requiring service of a subpoena or other legal process, volunteering to the Company all pertinent information, and turning over to the Company all relevant documents that are or may come into Executive's possession, all at times and on schedules that are reasonably consistent with Executive's other permitted activities and commitments and otherwise taking into account Executive's reasonable business obligations.  Executive shall be reimbursed for the reasonable expenses Executive incurs in connection with any such cooperation and&#47;or </font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">assistance. Executive shall also receive from the Company hourly compensation equal to the Annual Base Salary immediately prior to the Date of Termination divided by 2,200 hours, in each case in connection with any assistance or cooperation that occurs after the Date of Termination.  Any such reimbursements or per diem compensation shall be paid to Executive no later than the 15th day of the month immediately following the month in which such expenses were incurred or such cooperation and&#47;or assistance was provided (subject to Executive&#8217;s timely submission to the Company of proper documentation with respect thereto).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.&#160;&#160;&#160;&#160;Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any notice provided for in this Agreement shall be in writing and shall be either personally delivered, sent by electronic mail, or sent by reputable overnight carrier, in each case with proof of receipt, to the recipient.  Notices to Executive shall be sent to the address of Executive most recently provided to the Company.  Notices to the Company should be sent to the attention of the Company&#8217;s Chief Executive Officer.  Any notice under this Agreement will be deemed to have been given when so delivered or sent (subject to proof of delivery and receipt).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12.&#160;&#160;&#160;&#160;Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The invalidity or unenforceability of any particular provision in this Agreement shall not affect the other provisions hereof, and this Agreement shall be construed in all respects as if the invalid or unenforceable provision were omitted.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.&#160;&#160;&#160;&#160;Complete Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement embodies the complete agreement and understanding between the parties with respect to the subject matter hereof and effective as of its date supersedes and preempts any prior understandings, agreements (including without limitation the Consulting Agreement) or representations by or between the parties, written or oral, which may have related to the subject matter hereof in any way.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">14.&#160;&#160;&#160;&#160;Withholding of Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company and its affiliates may withhold from any amounts payable under this Agreement all federal, state, city or other taxes as the Company and its affiliates are required to withhold pursuant to any law or government regulation or ruling.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">15.&#160;&#160;&#160;&#160;Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;This Agreement is personal to Executive, and, without the prior written consent of the Company, shall not be assignable by Executive other than by will or the laws of descent and distribution.  This Agreement shall inure to the benefit of and be enforceable by Executive&#8217;s legal representatives.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;This Agreement shall inure to the benefit of and be binding upon the Company and its successors and assigns.  Except as provided in Section 15(c), without the prior written consent of Executive this Agreement shall not be assignable by the Company, except to an affiliate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;The Company will require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business and&#47;or assets of the Company to assume expressly and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such succession had taken place.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Company as hereinbefore defined and any successor to its business and&#47;or assets as aforesaid that assumes and agrees to perform this Agreement by operation of law or otherwise.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.&#160;&#160;&#160;&#160;Choice of Law&#47;Dispute Resolution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement shall be governed, construed, interpreted and enforced in accordance with the substantive laws of the State of New York, without regard to conflicts of law principles.  The parties shall execute simultaneously herewith a mutual agreement to arbitrate claims, which arbitration shall take place in New York. </font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">17.&#160;&#160;&#160;&#160;Amendment and Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The provisions of this Agreement may be amended or waived only with the prior written consent of the Company and Executive, and no course of conduct or failure or delay in enforcing the provisions of this Agreement shall affect the validity, binding effect or enforceability of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">18.&#160;&#160;&#160;&#160;Section 409A Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">In General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The intent of the parties is that payments and benefits under this Agreement comply with Section 409A of the Code (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) or are exempt therefrom and, accordingly, to the maximum extent permitted, this Agreement shall be interpreted and administered so as to be in compliance therewith.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Separation from Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  A termination of employment shall not be deemed to have occurred for purposes of any provision of this Agreement providing for the payment of any amounts or benefits subject to Section 409A upon or following a termination of employment un-less such termination is also a &#8220;separation from service&#8221; within the meaning of Section 409A, and for purposes of any such provision of this Agreement, references to a &#8220;termination,&#8221; &#8220;termination of employment&#8221; or like terms shall mean &#8220;separation from service&#8221; within the meaning of Section 409A.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Reimbursements or In-Kind Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  With regard to any provision herein that provides for reimbursement of costs and expenses or in-kind benefits, except as permitted by Section 409A&#58;  (i) the right to reimbursement or in-kind benefits shall not be subject to liquidation or exchange for another benefit&#59; (ii) the amount of expenses eligible for reimbursement, or in-kind benefits, provided during any taxable year shall not affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other taxable year&#59; and (iii) such payments shall be made on or before the last day of Executive's taxable year following the taxable year in which the expense occurred, or such earlier date as required hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Six Month Delay</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding anything contained in this Agreement to the contrary, if Executive is a &#8220;specified employee,&#8221; as determined under the Company's policy for identifying specified employees on the Date of Termination, then to the extent required in order to comply with Section 409A, all payments, benefits or reimbursements paid or provided under this Agreement that constitute a &#8220;deferral of compensation&#8221; within the meaning of Section 409A, that are provided as a result of a &#8220;separation from service&#8221; within the meaning of Section 409A and that would otherwise be paid or provided during the first six months following such Date of Termination shall be accumulated through and paid or provided (without interest), within 20 calendar days after the first business day that is more than six months after the date of her separation from service (or, if Executive dies during such six-month period, within 20 calendar days after Executive's death).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Payment Dates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event the payment period under this Agreement for any nonqualified deferred compensation commences in one calendar year and ends in a second calendar year, the payments shall not be paid (or installments commenced) until the later of the first payroll date of the second calendar year, or the date that such Release becomes effective and irrevocable, to the extent necessary to comply with Section 409A.  For purposes of Section 409A, Executive&#8217;s right to receive any &#8220;installment&#8221; payments pursuant to this Agreement shall be treated as a right to receive a series of separate and distinct payments.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">19.&#160;&#160;&#160;&#160;Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement.  A signed copy of this Agreement delivered by electronic mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.</font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">GRI BIO, INC.</font></div><div style="text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; W. Marc Hertz&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;  W. Marc Hertz</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Its&#58;  President &#38; CEO</font></div><div style="margin-bottom:24pt;padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">EXECUTIVE</font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Albert Agro, Ph.D.&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Albert Agro, Ph.D.</font></div><div style="margin-bottom:12pt;text-align:justify"><img alt="image_0.jpg" src="image_0.jpg" style="height:28px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>ex311_ceo302cert63023.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i4c58a976808041bbb69e86d4f1c96038_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit 31.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:8pt"><font><br></font></div><div style="margin-top:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I, W. Marc Hertz, certify that&#58;</font></div><div style="margin-top:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended June&#160;30, 2023 of GRI Bio, Inc.&#59;</font></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.726%"><tr><td style="width:1.0%"></td><td style="width:31.191%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.352%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; August&#160;14, 2023</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; W. Marc Hertz</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">W. Marc Hertz</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>ex312_cfo302cert63023.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="iff48f764c51f43d586fa777eb5efa290_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit 31.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:8pt"><font><br></font></div><div style="margin-top:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I, Leanne M. Kelly, certify that&#58;</font></div><div style="margin-top:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended June&#160;30, 2023 of GRI Bio, Inc.&#59;</font></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.299%"><tr><td style="width:1.0%"></td><td style="width:29.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.435%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; August&#160;14, 2023</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Leanne M. Kelly</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Leanne M. Kelly</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>ex321_ceosection906cert630.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i1baf6d9c8b6f4dd1b55c411966fab758_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit 32.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I, W. Marc Hertz, President and Chief Executive Officer of GRI Bio, Inc. (the &#8220;Company&#8221;), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">the Quarterly Report on Form 10-Q of the Company for the quarter ended June&#160;30, 2023 (the &#8220;Quarterly Report&#8221;) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">the information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein.</font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.281%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.361%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; August&#160;14, 2023</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; W. Marc Hertz</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">W. Marc Hertz</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>ex322_cfosection906cert630.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i20b989d822164af6877c8cd52bf39cc8_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit 32.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I, Leanne M. Kelly,  Chief Financial Officer of GRI Bio, Inc. (the &#8220;Company&#8221;), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">the Quarterly Report on Form 10-Q of the Company for the quarter ended June&#160;30, 2023 (the &#8220;Quarterly Report&#8221;) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">the information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein.</font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.683%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.360%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; August&#160;14, 2023</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Leanne M. Kelly</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Leanne M. Kelly</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>ck0001824293-20230630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:03e6aede-a80d-4c93-aec7-6df3e5ac1c16,g:d01e6060-7205-4c9b-8c6f-b994c931683b-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ck0001824293="http://www.vallon-pharma.com/20230630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.vallon-pharma.com/20230630">
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ck0001824293-20230630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ck0001824293-20230630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ck0001824293-20230630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ck0001824293-20230630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.vallon-pharma.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets">
        <link:definition>0000002 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.vallon-pharma.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperations" roleURI="http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations">
        <link:definition>0000004 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofChangesinStockholdersEquityDeficit" roleURI="http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit">
        <link:definition>0000005 - Statement - Consolidated Statements of Changes in Stockholders&#8217; Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>0000006 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDDESCRIPTIONOFBUSINESS" roleURI="http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS">
        <link:definition>0000007 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LIQUIDITY" roleURI="http://www.vallon-pharma.com/role/LIQUIDITY">
        <link:definition>0000008 - Disclosure - LIQUIDITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>0000009 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MERGERWITHVALLON" roleURI="http://www.vallon-pharma.com/role/MERGERWITHVALLON">
        <link:definition>0000010 - Disclosure - MERGER WITH VALLON</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTS" roleURI="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTS">
        <link:definition>0000011 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENT" roleURI="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENT">
        <link:definition>0000012 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSES" roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSES">
        <link:definition>0000013 - Disclosure - ACCRUED EXPENSES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROMISSORYNOTES" roleURI="http://www.vallon-pharma.com/role/PROMISSORYNOTES">
        <link:definition>0000014 - Disclosure - PROMISSORY NOTES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITY" roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITY">
        <link:definition>0000015 - Disclosure - STOCKHOLDERS&#8217; EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATION" roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION">
        <link:definition>0000016 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>0000017 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>9954701 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables">
        <link:definition>9954702 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MERGERWITHVALLONTables" roleURI="http://www.vallon-pharma.com/role/MERGERWITHVALLONTables">
        <link:definition>9954703 - Disclosure - MERGER WITH VALLON (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSTables" roleURI="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSTables">
        <link:definition>9954704 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTTables" roleURI="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTTables">
        <link:definition>9954705 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESTables" roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables">
        <link:definition>9954706 - Disclosure - ACCRUED EXPENSES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYTables" roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYTables">
        <link:definition>9954707 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONTables" roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables">
        <link:definition>9954708 - Disclosure - STOCK-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails" roleURI="http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails">
        <link:definition>9954709 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LIQUIDITYDetails" roleURI="http://www.vallon-pharma.com/role/LIQUIDITYDetails">
        <link:definition>9954710 - Disclosure - LIQUIDITY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails">
        <link:definition>9954711 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails" roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails">
        <link:definition>9954712 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Diluted Net Loss Per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MERGERWITHVALLONNarrativeDetails" roleURI="http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails">
        <link:definition>9954713 - Disclosure - MERGER WITH VALLON - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails" roleURI="http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails">
        <link:definition>9954714 - Disclosure - MERGER WITH VALLON - Schedule of the Net Liabilities Assumed in the Merger (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails_1" roleURI="http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails_1">
        <link:definition>9954714 - Disclosure - MERGER WITH VALLON - Schedule of the Net Liabilities Assumed in the Merger (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails" roleURI="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails">
        <link:definition>9954715 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Fair Value, Liabilities Measured on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails" roleURI="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails">
        <link:definition>9954716 - Disclosure - FAIR VALUE MEASUREMENTS - Liability Measured at Estimated Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails" roleURI="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails">
        <link:definition>9954717 - Disclosure - FAIR VALUE MEASUREMENTS - Derivative Liability Measurement Inputs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" roleURI="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails">
        <link:definition>9954718 - Disclosure - PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTNarrativeDetails" roleURI="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTNarrativeDetails">
        <link:definition>9954719 - Disclosure - PROPERTY AND EQUIPMENT - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESDetails" roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails">
        <link:definition>9954720 - Disclosure - ACCRUED EXPENSES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROMISSORYNOTESBridgeFinancingDetails" roleURI="http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails">
        <link:definition>9954721 - Disclosure - PROMISSORY NOTES - Bridge Financing (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROMISSORYNOTESTEPNoteDetails" roleURI="http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails">
        <link:definition>9954722 - Disclosure - PROMISSORY NOTES - TEP Note (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYNarrativeDetails" roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails">
        <link:definition>9954723 - Disclosure - STOCKHOLDERS&#8217; EQUITY - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails" roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails">
        <link:definition>9954724 - Disclosure - STOCKHOLDERS&#8217; EQUITY - Estimate of the Fair Value of the Warrants and Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails" roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails">
        <link:definition>9954725 - Disclosure - STOCKHOLDERS&#8217; EQUITY - Schedule of Warrants Outstanding to Purchase Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONNarrativeDetails" roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails">
        <link:definition>9954726 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails" roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails">
        <link:definition>9954727 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails" roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails">
        <link:definition>9954728 - Disclosure - STOCK-BASED COMPENSATION - Activity of Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails" roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails">
        <link:definition>9954729 - Disclosure - STOCK-BASED COMPENSATION - Assumptions Used to Estimate Fair Value of Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESDetails" roleURI="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails">
        <link:definition>9954730 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember" abstract="true" name="AmendedAndRestated2018EquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" abstract="false" name="AccruedResearchAndDevelopmentCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringInApril2028Member" abstract="true" name="WarrantsExpiringInApril2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt" abstract="false" name="StockIssuedDuringPeriodSharesSettlementOfDebt" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringInJune2025Member" abstract="true" name="WarrantsExpiringInJune2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_A2018EquityIncentivePlanMember" abstract="true" name="A2018EquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ck0001824293_PercentageOfTargetBonus" abstract="false" name="PercentageOfTargetBonus" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization" abstract="false" name="StockIssuedDuringPeriodValueReverseRecapitalization" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_PaymentOfReverseRecapitalizationCosts" abstract="false" name="PaymentOfReverseRecapitalizationCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_BridgeWarrantsMember" abstract="true" name="BridgeWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_ConversionOfStockAdditionalSharesConverted" abstract="false" name="ConversionOfStockAdditionalSharesConverted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts" abstract="false" name="StockIssuedForPaymentOfReverseRecapitalizationCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses" abstract="false" name="StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ck0001824293_WarrantLiabilityMember" abstract="true" name="WarrantLiabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ck0001824293_DebtInstrumentNumberOfClosings" abstract="false" name="DebtInstrumentNumberOfClosings" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ck0001824293_RepaymentOfAdvancesFromEmployees" abstract="false" name="RepaymentOfAdvancesFromEmployees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_StockSubjectToPutRightMember" abstract="true" name="StockSubjectToPutRightMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_TEPNoteMember" abstract="true" name="TEPNoteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_ExchangeWarrantsMember" abstract="true" name="ExchangeWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants" abstract="false" name="DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_FormerChiefExecutiveOfficerMember" abstract="true" name="FormerChiefExecutiveOfficerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_LongTermDebtIncludingInterest" abstract="false" name="LongTermDebtIncludingInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_StockIssuanceCostsOfferingExpenses" abstract="false" name="StockIssuanceCostsOfferingExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_CommonStockHeldIntoEscrowAccount" abstract="false" name="CommonStockHeldIntoEscrowAccount" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt" abstract="false" name="StockIssuedDuringPeriodValueSettlementOfDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_DebtConversionConvertedInstrumentAmountOfInterest" abstract="false" name="DebtConversionConvertedInstrumentAmountOfInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringInDecember2023Member" abstract="true" name="WarrantsExpiringInDecember2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_DebtConversionConvertedInstrumentPrincipalAmountOfDebt" abstract="false" name="DebtConversionConvertedInstrumentPrincipalAmountOfDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" abstract="false" name="AccruedGeneralAndAdministrativeExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_EmployeeAdvancesCurrent" abstract="false" name="EmployeeAdvancesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_StockIssuedDuringPeriodValueWarrantExercises" abstract="false" name="StockIssuedDuringPeriodValueWarrantExercises" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise" abstract="false" name="StockIssuedDuringPeriodSharesWarrantExercise" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringInMay2027Member" abstract="true" name="WarrantsExpiringInMay2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateOneMember" abstract="true" name="WarrantsExpiringIn60MonthsAfterRegistrationDateOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing" abstract="false" name="StockIssuedDuringPeriodValuePreClosingFinancing" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing" abstract="false" name="StockIssuedDuringPeriodSharesPreClosingFinancing" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ck0001824293_EquityWarrantsExchangeWarrantsAndBankerWarrantsMember" abstract="true" name="EquityWarrantsExchangeWarrantsAndBankerWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringInNovember2023Member" abstract="true" name="WarrantsExpiringInNovember2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization" abstract="false" name="NetLiabilitiesAssumedInConnectionWithReverseRecapitalization" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_StockIssuedForRepaymentOfNotesPayable" abstract="false" name="StockIssuedForRepaymentOfNotesPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_ConvertiblePromissoryNoteMember" abstract="true" name="ConvertiblePromissoryNoteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_DebtInstrumentAggregatePurchasePrice" abstract="false" name="DebtInstrumentAggregatePurchasePrice" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_NoncashMergerRelatedCostsFinancingActivities" abstract="false" name="NoncashMergerRelatedCostsFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_ProceedsFromAdvancesFromEmployees" abstract="false" name="ProceedsFromAdvancesFromEmployees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateTwoMember" abstract="true" name="WarrantsExpiringIn60MonthsAfterRegistrationDateTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_ClassOfWarrantOrRightExpirationPeriod" abstract="false" name="ClassOfWarrantOrRightExpirationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ck0001824293_SeriesA1WarrantsMember" abstract="true" name="SeriesA1WarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringInFebruary2026Member" abstract="true" name="WarrantsExpiringInFebruary2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_BridgeSecuritiesPurchaseAgreementMember" abstract="true" name="BridgeSecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ck0001824293_PrivateGRIPlanMember" abstract="true" name="PrivateGRIPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_PrivateGRIMember" abstract="true" name="PrivateGRIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringIn24MonthsAfterRegistrationDateMember" abstract="true" name="WarrantsExpiringIn24MonthsAfterRegistrationDateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_BankerWarrantsMember" abstract="true" name="BankerWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_CommonStockOwnershipPercentage" abstract="false" name="CommonStockOwnershipPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ck0001824293_AccruedInterestForfeited" abstract="false" name="AccruedInterestForfeited" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses" abstract="false" name="StockIssuedDuringPeriodValueReverseRecapitalizationExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization" abstract="false" name="StockIssuedDuringPeriodSharesReverseRecapitalization" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ck0001824293_PutOptionSharePrice" abstract="false" name="PutOptionSharePrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="ck0001824293_EquityWarrantsMember" abstract="true" name="EquityWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_WarrantsIssued" abstract="false" name="WarrantsIssued" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_COBRABenefitsPaymentPeriod" abstract="false" name="COBRABenefitsPaymentPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ck0001824293_SeriesA2WarrantsMember" abstract="true" name="SeriesA2WarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ck0001824293_CallOptionPrice" abstract="false" name="CallOptionPrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="ck0001824293_CommonStockExchangeRatio" abstract="false" name="CommonStockExchangeRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ck0001824293_SeriesTWarrantsMember" abstract="true" name="SeriesTWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringInJuly2027Member" abstract="true" name="WarrantsExpiringInJuly2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_ChangeInFairValueOfWarrantLiability" abstract="false" name="ChangeInFairValueOfWarrantLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_GRIBioIncMember" abstract="true" name="GRIBioIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ck0001824293_DebtInstrumentConvertibleSharesIssuedUponConversion" abstract="false" name="DebtInstrumentConvertibleSharesIssuedUponConversion" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>ck0001824293-20230630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:03e6aede-a80d-4c93-aec7-6df3e5ac1c16,g:d01e6060-7205-4c9b-8c6f-b994c931683b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_8f38d660-5109-4b68-bc01-1c637e49ee37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_78dae5a3-d718-4586-958e-542f13ad27a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8f38d660-5109-4b68-bc01-1c637e49ee37" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_78dae5a3-d718-4586-958e-542f13ad27a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a8203311-7f06-4330-a6bd-a26f3bb1c138" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8f38d660-5109-4b68-bc01-1c637e49ee37" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a8203311-7f06-4330-a6bd-a26f3bb1c138" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_4282a609-4c2b-44e1-9780-9158e287bd45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_328c4192-dd15-4e2a-b12e-67aa21bb61c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4282a609-4c2b-44e1-9780-9158e287bd45" xlink:to="loc_us-gaap_AccountsPayableCurrent_328c4192-dd15-4e2a-b12e-67aa21bb61c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_00aaa21b-7938-4ea8-9eeb-c3261636aa98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4282a609-4c2b-44e1-9780-9158e287bd45" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_00aaa21b-7938-4ea8-9eeb-c3261636aa98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_5369a89c-c013-429a-a5c0-7c72de640a5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4282a609-4c2b-44e1-9780-9158e287bd45" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_5369a89c-c013-429a-a5c0-7c72de640a5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_EmployeeAdvancesCurrent_0807a86b-db95-4b55-9f29-dd62095b1ad2" xlink:href="ck0001824293-20230630.xsd#ck0001824293_EmployeeAdvancesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4282a609-4c2b-44e1-9780-9158e287bd45" xlink:to="loc_ck0001824293_EmployeeAdvancesCurrent_0807a86b-db95-4b55-9f29-dd62095b1ad2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_cc44df45-d9fc-4c47-8cc4-41aa7d05c3b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4282a609-4c2b-44e1-9780-9158e287bd45" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_cc44df45-d9fc-4c47-8cc4-41aa7d05c3b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_e0da4f48-fd5e-4931-9c2b-7ab6b3beb87f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4282a609-4c2b-44e1-9780-9158e287bd45" xlink:to="loc_us-gaap_NotesPayableCurrent_e0da4f48-fd5e-4931-9c2b-7ab6b3beb87f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_3265f511-1403-4ef0-b6c9-2681182d4817" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_861357c5-8adc-469c-b9eb-d6793479b48f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_3265f511-1403-4ef0-b6c9-2681182d4817" xlink:to="loc_us-gaap_Liabilities_861357c5-8adc-469c-b9eb-d6793479b48f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7608d90d-a953-4427-8bdb-42af14ac9e59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_3265f511-1403-4ef0-b6c9-2681182d4817" xlink:to="loc_us-gaap_StockholdersEquity_7608d90d-a953-4427-8bdb-42af14ac9e59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_bfdf7b80-6ff9-4b6a-8674-3f1349642e0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_3265f511-1403-4ef0-b6c9-2681182d4817" xlink:to="loc_us-gaap_CommitmentsAndContingencies_bfdf7b80-6ff9-4b6a-8674-3f1349642e0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_5328bf37-c60c-4cd2-a935-489b5bcb4c57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_819f1680-0789-41fe-bc84-25410fe02577" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_5328bf37-c60c-4cd2-a935-489b5bcb4c57" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_819f1680-0789-41fe-bc84-25410fe02577" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_899ebdda-6a2d-4912-981e-570cb25a6691" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_5328bf37-c60c-4cd2-a935-489b5bcb4c57" xlink:to="loc_us-gaap_LiabilitiesCurrent_899ebdda-6a2d-4912-981e-570cb25a6691" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4e3d2285-9202-4eec-a352-ef2352bd9a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_18a04c7e-dafe-4cca-adcb-734458905034" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4e3d2285-9202-4eec-a352-ef2352bd9a8e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_18a04c7e-dafe-4cca-adcb-734458905034" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_8b9bf477-f666-4891-815c-3b2a2316a3de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4e3d2285-9202-4eec-a352-ef2352bd9a8e" xlink:to="loc_us-gaap_CommonStockValueOutstanding_8b9bf477-f666-4891-815c-3b2a2316a3de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_34aa2195-9024-47e5-b44c-718004ac7906" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4e3d2285-9202-4eec-a352-ef2352bd9a8e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_34aa2195-9024-47e5-b44c-718004ac7906" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_9d3a5c03-1dfc-46a3-be87-432a7e395888" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_fdf70623-5e6e-4f82-86b2-0d41a58c2f2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9d3a5c03-1dfc-46a3-be87-432a7e395888" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_fdf70623-5e6e-4f82-86b2-0d41a58c2f2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_e48989da-b6df-412c-be9f-5b07f7e13490" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9d3a5c03-1dfc-46a3-be87-432a7e395888" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_e48989da-b6df-412c-be9f-5b07f7e13490" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_053d788e-b93a-4fcd-b5b8-a0d68f228552" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9d3a5c03-1dfc-46a3-be87-432a7e395888" xlink:to="loc_us-gaap_AssetsCurrent_053d788e-b93a-4fcd-b5b8-a0d68f228552" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#ConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7a9a0c33-99ad-4131-820d-90d1bbc2c2f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_2fcf221a-088b-4f32-9358-6ff864c855ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_7a9a0c33-99ad-4131-820d-90d1bbc2c2f5" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_2fcf221a-088b-4f32-9358-6ff864c855ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_271e0730-7504-4b74-821e-2a5709c83634" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_7a9a0c33-99ad-4131-820d-90d1bbc2c2f5" xlink:to="loc_us-gaap_OperatingIncomeLoss_271e0730-7504-4b74-821e-2a5709c83634" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ChangeInFairValueOfWarrantLiability_0b91dbe4-0430-4b5e-828f-585327f2c720" xlink:href="ck0001824293-20230630.xsd#ck0001824293_ChangeInFairValueOfWarrantLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_7a9a0c33-99ad-4131-820d-90d1bbc2c2f5" xlink:to="loc_ck0001824293_ChangeInFairValueOfWarrantLiability_0b91dbe4-0430-4b5e-828f-585327f2c720" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a8d040d3-685e-424f-9636-019a3633166f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_d12218ef-89b7-4314-b613-d04b4475f2e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_a8d040d3-685e-424f-9636-019a3633166f" xlink:to="loc_us-gaap_OperatingExpenses_d12218ef-89b7-4314-b613-d04b4475f2e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_a2ce5df9-9cd1-4ebd-acdd-761956807209" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_19ead897-454e-4739-8827-7ca53b28b253" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a2ce5df9-9cd1-4ebd-acdd-761956807209" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_19ead897-454e-4739-8827-7ca53b28b253" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_f8407753-5209-42e7-bd3d-a4716d170295" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a2ce5df9-9cd1-4ebd-acdd-761956807209" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_f8407753-5209-42e7-bd3d-a4716d170295" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3fa6c675-6a8f-43b3-a682-1902ac8a83e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ff96798c-27af-4fa9-b195-f03c79a3b29f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3fa6c675-6a8f-43b3-a682-1902ac8a83e1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ff96798c-27af-4fa9-b195-f03c79a3b29f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_bf505e3b-c3e1-4efa-b173-9f80ee2cb3fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3fa6c675-6a8f-43b3-a682-1902ac8a83e1" xlink:to="loc_us-gaap_Depreciation_bf505e3b-c3e1-4efa-b173-9f80ee2cb3fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_40ab4fdf-0b2a-442a-b1ef-b6b21084fe11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3fa6c675-6a8f-43b3-a682-1902ac8a83e1" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_40ab4fdf-0b2a-442a-b1ef-b6b21084fe11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_78d5c078-4940-4412-9754-b85d0c9f0f12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3fa6c675-6a8f-43b3-a682-1902ac8a83e1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_78d5c078-4940-4412-9754-b85d0c9f0f12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_55e08504-6f6b-48f3-8bba-97ddc7dd2678" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3fa6c675-6a8f-43b3-a682-1902ac8a83e1" xlink:to="loc_us-gaap_ShareBasedCompensation_55e08504-6f6b-48f3-8bba-97ddc7dd2678" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_a0657f1d-35b1-4485-af42-863c184e0d75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3fa6c675-6a8f-43b3-a682-1902ac8a83e1" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_a0657f1d-35b1-4485-af42-863c184e0d75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_fafc0d8c-74bd-42ea-b2c3-9ce6804df07a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3fa6c675-6a8f-43b3-a682-1902ac8a83e1" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_fafc0d8c-74bd-42ea-b2c3-9ce6804df07a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cca59e25-d6f6-4b64-9c7c-8ccb66b09b54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3fa6c675-6a8f-43b3-a682-1902ac8a83e1" xlink:to="loc_us-gaap_NetIncomeLoss_cca59e25-d6f6-4b64-9c7c-8ccb66b09b54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_8cfd6a39-d2ef-4b61-91eb-7facc41ea5dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3fa6c675-6a8f-43b3-a682-1902ac8a83e1" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_8cfd6a39-d2ef-4b61-91eb-7facc41ea5dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_4829267e-5ebf-434e-9963-dfdceb6128da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3fa6c675-6a8f-43b3-a682-1902ac8a83e1" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_4829267e-5ebf-434e-9963-dfdceb6128da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0d5333ff-33c4-41c9-8471-087e70da7c81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_1f7a7e64-529c-433a-8a9e-2472ffeaf614" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0d5333ff-33c4-41c9-8471-087e70da7c81" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_1f7a7e64-529c-433a-8a9e-2472ffeaf614" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ProceedsFromAdvancesFromEmployees_bff2e639-0574-4489-a1f0-8987db1cd3a0" xlink:href="ck0001824293-20230630.xsd#ck0001824293_ProceedsFromAdvancesFromEmployees"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0d5333ff-33c4-41c9-8471-087e70da7c81" xlink:to="loc_ck0001824293_ProceedsFromAdvancesFromEmployees_bff2e639-0574-4489-a1f0-8987db1cd3a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PaymentOfReverseRecapitalizationCosts_f71fa825-98d0-4bb5-93be-411ad550bc83" xlink:href="ck0001824293-20230630.xsd#ck0001824293_PaymentOfReverseRecapitalizationCosts"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0d5333ff-33c4-41c9-8471-087e70da7c81" xlink:to="loc_ck0001824293_PaymentOfReverseRecapitalizationCosts_f71fa825-98d0-4bb5-93be-411ad550bc83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization_8ff0343a-fb79-4fe5-8bc6-ac83af217272" xlink:href="ck0001824293-20230630.xsd#ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0d5333ff-33c4-41c9-8471-087e70da7c81" xlink:to="loc_ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization_8ff0343a-fb79-4fe5-8bc6-ac83af217272" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_26d16342-a941-4b7f-b63b-2dd89cc9eee8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0d5333ff-33c4-41c9-8471-087e70da7c81" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_26d16342-a941-4b7f-b63b-2dd89cc9eee8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_071e6156-8b26-4827-be27-cae222cf3a21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0d5333ff-33c4-41c9-8471-087e70da7c81" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_071e6156-8b26-4827-be27-cae222cf3a21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_5792cee8-89d0-4c90-8c7f-c89b78a80987" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0d5333ff-33c4-41c9-8471-087e70da7c81" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_5792cee8-89d0-4c90-8c7f-c89b78a80987" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_8b97f9fe-556c-48a9-a2b0-1d8db2892d27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0d5333ff-33c4-41c9-8471-087e70da7c81" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_8b97f9fe-556c-48a9-a2b0-1d8db2892d27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_RepaymentOfAdvancesFromEmployees_1f13204f-316f-4d62-aefd-239dd7da2e19" xlink:href="ck0001824293-20230630.xsd#ck0001824293_RepaymentOfAdvancesFromEmployees"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0d5333ff-33c4-41c9-8471-087e70da7c81" xlink:to="loc_ck0001824293_RepaymentOfAdvancesFromEmployees_1f13204f-316f-4d62-aefd-239dd7da2e19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0b6cb5f6-d476-4212-99df-34e6ffb65277" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_64d19340-adf6-45d0-80e1-780948a9ea82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0b6cb5f6-d476-4212-99df-34e6ffb65277" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_64d19340-adf6-45d0-80e1-780948a9ea82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_75a38b3d-02c6-4ecb-b708-81293f65ece2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0b6cb5f6-d476-4212-99df-34e6ffb65277" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_75a38b3d-02c6-4ecb-b708-81293f65ece2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1355bfb8-d829-433d-af13-6044fab74980" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0b6cb5f6-d476-4212-99df-34e6ffb65277" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1355bfb8-d829-433d-af13-6044fab74980" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_68482d43-ead2-418e-aa70-1c606002347c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_afae2876-8c95-4c61-8ac7-04e271298466" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_68482d43-ead2-418e-aa70-1c606002347c" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_afae2876-8c95-4c61-8ac7-04e271298466" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_4d1e13a3-f8ec-4a2a-9c23-be12ec73bb1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses_f98feb93-a5e7-483f-accc-8f8ab7a5231e" xlink:href="ck0001824293-20230630.xsd#ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_4d1e13a3-f8ec-4a2a-9c23-be12ec73bb1e" xlink:to="loc_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses_f98feb93-a5e7-483f-accc-8f8ab7a5231e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_2afe9396-5261-4318-b777-f7b43af9e88b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_4d1e13a3-f8ec-4a2a-9c23-be12ec73bb1e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_2afe9396-5261-4318-b777-f7b43af9e88b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_9914de2a-4407-427c-9c07-b451f0912f12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_4d1e13a3-f8ec-4a2a-9c23-be12ec73bb1e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_9914de2a-4407-427c-9c07-b451f0912f12" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails_1" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails_1"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_bbeba639-abe5-4826-b0c3-cb5bbf753d60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts_5b887931-c233-47d1-887e-654c25f3ee0a" xlink:href="ck0001824293-20230630.xsd#ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_bbeba639-abe5-4826-b0c3-cb5bbf753d60" xlink:to="loc_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts_5b887931-c233-47d1-887e-654c25f3ee0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_10384e76-eea2-4651-96d8-b7630014f59f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_bbeba639-abe5-4826-b0c3-cb5bbf753d60" xlink:to="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_10384e76-eea2-4651-96d8-b7630014f59f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_508f18f1-8a6a-49a1-bf12-86428ef8e414" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_e8e6d498-e4ef-4d25-bc77-b592ad7d196d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_508f18f1-8a6a-49a1-bf12-86428ef8e414" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_e8e6d498-e4ef-4d25-bc77-b592ad7d196d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8b218241-0f7f-4b27-ab58-0445f6800f86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_707d47ff-17f3-4182-b05a-c9165c894d97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_8b218241-0f7f-4b27-ab58-0445f6800f86" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_707d47ff-17f3-4182-b05a-c9165c894d97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_435ad57a-5b0b-4bfc-af8f-c5be998ac29d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_8b218241-0f7f-4b27-ab58-0445f6800f86" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_435ad57a-5b0b-4bfc-af8f-c5be998ac29d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#ACCRUEDEXPENSESDetails"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_2a3495c7-3971-4d97-9339-2054db263c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_1f0f05f6-ec84-4f1b-8fd3-54b75aea0a90" xlink:href="ck0001824293-20230630.xsd#ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_2a3495c7-3971-4d97-9339-2054db263c1e" xlink:to="loc_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_1f0f05f6-ec84-4f1b-8fd3-54b75aea0a90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_2db4ac45-5bc6-4cba-8928-73b87c6786e8" xlink:href="ck0001824293-20230630.xsd#ck0001824293_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_2a3495c7-3971-4d97-9339-2054db263c1e" xlink:to="loc_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_2db4ac45-5bc6-4cba-8928-73b87c6786e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_913d6778-4628-46c9-877e-93e56ccefe3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_2a3495c7-3971-4d97-9339-2054db263c1e" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_913d6778-4628-46c9-877e-93e56ccefe3a" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>ck0001824293-20230630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:03e6aede-a80d-4c93-aec7-6df3e5ac1c16,g:d01e6060-7205-4c9b-8c6f-b994c931683b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#ConsolidatedStatementsofChangesinStockholdersEquityDeficit"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_89814d09-5485-49d4-b7d6-9285882b7d24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_99430293-7458-4c36-aa54-209a433dff31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_89814d09-5485-49d4-b7d6-9285882b7d24" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_99430293-7458-4c36-aa54-209a433dff31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_0d0af341-f9b2-49fa-9efd-840544f8a5e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_99430293-7458-4c36-aa54-209a433dff31" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_0d0af341-f9b2-49fa-9efd-840544f8a5e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_d3b0113e-2ad3-4db8-8d74-d1dc3bf80683" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_99430293-7458-4c36-aa54-209a433dff31" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_d3b0113e-2ad3-4db8-8d74-d1dc3bf80683" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_12fdbe09-915b-4581-ac46-8711cb283b62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_b3f2909e-c9c5-498f-95dd-77009fbce085" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2059571e-f224-4959-9bd2-f55b89720978" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_89814d09-5485-49d4-b7d6-9285882b7d24" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2059571e-f224-4959-9bd2-f55b89720978" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_7d894df8-88a8-4028-af85-0bd4dd53e3b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2059571e-f224-4959-9bd2-f55b89720978" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_7d894df8-88a8-4028-af85-0bd4dd53e3b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8ea002dd-1910-41fa-841a-dce282539e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2059571e-f224-4959-9bd2-f55b89720978" xlink:to="loc_us-gaap_StockholdersEquity_8ea002dd-1910-41fa-841a-dce282539e5a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_a31be54a-f424-4803-a98f-a713cda6caf9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2059571e-f224-4959-9bd2-f55b89720978" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_a31be54a-f424-4803-a98f-a713cda6caf9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c27681a3-58ae-45fe-ac7b-4bda2229ef6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2059571e-f224-4959-9bd2-f55b89720978" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c27681a3-58ae-45fe-ac7b-4bda2229ef6e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_88eb7a37-8b84-4a5e-bb56-b6f37c384e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2059571e-f224-4959-9bd2-f55b89720978" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_88eb7a37-8b84-4a5e-bb56-b6f37c384e4e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise_2612507a-9e64-42c8-aa9f-2a52cd2bf6fc" xlink:href="ck0001824293-20230630.xsd#ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2059571e-f224-4959-9bd2-f55b89720978" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise_2612507a-9e64-42c8-aa9f-2a52cd2bf6fc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValueWarrantExercises_ad3117f6-9125-4a14-a270-1b68fcd36f11" xlink:href="ck0001824293-20230630.xsd#ck0001824293_StockIssuedDuringPeriodValueWarrantExercises"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2059571e-f224-4959-9bd2-f55b89720978" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodValueWarrantExercises_ad3117f6-9125-4a14-a270-1b68fcd36f11" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing_21a91c78-b9d7-4b4a-8106-46fe6331da9d" xlink:href="ck0001824293-20230630.xsd#ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2059571e-f224-4959-9bd2-f55b89720978" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing_21a91c78-b9d7-4b4a-8106-46fe6331da9d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing_119b7577-51a9-4801-be3b-129e528749f7" xlink:href="ck0001824293-20230630.xsd#ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2059571e-f224-4959-9bd2-f55b89720978" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing_119b7577-51a9-4801-be3b-129e528749f7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt_7fb3bfd6-9cc0-43b8-b083-af47530638ac" xlink:href="ck0001824293-20230630.xsd#ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2059571e-f224-4959-9bd2-f55b89720978" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt_7fb3bfd6-9cc0-43b8-b083-af47530638ac" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt_5cc8f6a7-10c5-4f8d-a49e-02b543e35ddd" xlink:href="ck0001824293-20230630.xsd#ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2059571e-f224-4959-9bd2-f55b89720978" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt_5cc8f6a7-10c5-4f8d-a49e-02b543e35ddd" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses_8a5b25f9-db37-4fac-928f-ff9586e7314e" xlink:href="ck0001824293-20230630.xsd#ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2059571e-f224-4959-9bd2-f55b89720978" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses_8a5b25f9-db37-4fac-928f-ff9586e7314e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses_c20342e6-6852-4983-bd81-4fcb8d7ab6fa" xlink:href="ck0001824293-20230630.xsd#ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2059571e-f224-4959-9bd2-f55b89720978" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses_c20342e6-6852-4983-bd81-4fcb8d7ab6fa" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization_c5bfb067-a871-4b6d-8ac0-851ff48f9390" xlink:href="ck0001824293-20230630.xsd#ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2059571e-f224-4959-9bd2-f55b89720978" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization_c5bfb067-a871-4b6d-8ac0-851ff48f9390" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization_2a89f092-a94e-4e73-89d7-d3919e51a92e" xlink:href="ck0001824293-20230630.xsd#ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2059571e-f224-4959-9bd2-f55b89720978" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization_2a89f092-a94e-4e73-89d7-d3919e51a92e" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_833737f9-6483-4a95-9e8b-66a77a0b5623" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2059571e-f224-4959-9bd2-f55b89720978" xlink:to="loc_us-gaap_NetIncomeLoss_833737f9-6483-4a95-9e8b-66a77a0b5623" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_dee828d7-9fd4-4762-ad22-60e6375a8291" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_63e50c64-4c7b-4d9e-a8ae-214c659b3b54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_cedd3b61-9766-45d5-8535-5b721fbd7824" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_89814d09-5485-49d4-b7d6-9285882b7d24" xlink:to="loc_us-gaap_StatementTable_cedd3b61-9766-45d5-8535-5b721fbd7824" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e771519f-a0d7-4829-97ca-80093461d6d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_cedd3b61-9766-45d5-8535-5b721fbd7824" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e771519f-a0d7-4829-97ca-80093461d6d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e771519f-a0d7-4829-97ca-80093461d6d3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e771519f-a0d7-4829-97ca-80093461d6d3" xlink:to="loc_us-gaap_EquityComponentDomain_e771519f-a0d7-4829-97ca-80093461d6d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f5897778-8aac-4bbb-87ce-897aa5635fed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e771519f-a0d7-4829-97ca-80093461d6d3" xlink:to="loc_us-gaap_EquityComponentDomain_f5897778-8aac-4bbb-87ce-897aa5635fed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_1add51ae-c9da-413d-9b7e-38dfb5f2af98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f5897778-8aac-4bbb-87ce-897aa5635fed" xlink:to="loc_us-gaap_CommonStockMember_1add51ae-c9da-413d-9b7e-38dfb5f2af98" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_bf082b08-5610-4c35-8000-3aea7231bbf4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f5897778-8aac-4bbb-87ce-897aa5635fed" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_bf082b08-5610-4c35-8000-3aea7231bbf4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_92d6958a-8c3f-44f4-8acb-bc9189460f6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f5897778-8aac-4bbb-87ce-897aa5635fed" xlink:to="loc_us-gaap_RetainedEarningsMember_92d6958a-8c3f-44f4-8acb-bc9189460f6b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/LIQUIDITYDetails" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#LIQUIDITYDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/LIQUIDITYDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_2a9d5fe8-62d4-4941-af27-9d784acc2cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentCompanyCommittedCapital_4db452ba-62a1-4694-9036-a9e274e80201" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentCompanyCommittedCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2a9d5fe8-62d4-4941-af27-9d784acc2cd7" xlink:to="loc_us-gaap_InvestmentCompanyCommittedCapital_4db452ba-62a1-4694-9036-a9e274e80201" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_40338850-0c0d-49fb-a11c-b826bc1f177b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2a9d5fe8-62d4-4941-af27-9d784acc2cd7" xlink:to="loc_us-gaap_CommonStockSharesIssued_40338850-0c0d-49fb-a11c-b826bc1f177b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_CommonStockHeldIntoEscrowAccount_67a4ecbf-831b-476f-90b9-f6ad3dea5cd5" xlink:href="ck0001824293-20230630.xsd#ck0001824293_CommonStockHeldIntoEscrowAccount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2a9d5fe8-62d4-4941-af27-9d784acc2cd7" xlink:to="loc_ck0001824293_CommonStockHeldIntoEscrowAccount_67a4ecbf-831b-476f-90b9-f6ad3dea5cd5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_82771355-9ce7-4c0a-a8b2-ccef4103b804" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2a9d5fe8-62d4-4941-af27-9d784acc2cd7" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_82771355-9ce7-4c0a-a8b2-ccef4103b804" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_14864c02-3239-4ba3-bd3d-617ef6cea5a7" xlink:href="ck0001824293-20230630.xsd#ck0001824293_StockIssuanceCostsOfferingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2a9d5fe8-62d4-4941-af27-9d784acc2cd7" xlink:to="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_14864c02-3239-4ba3-bd3d-617ef6cea5a7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_a76b7252-16a6-4638-ac02-c4d765d5fe26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2a9d5fe8-62d4-4941-af27-9d784acc2cd7" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_a76b7252-16a6-4638-ac02-c4d765d5fe26" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ConversionOfStockAdditionalSharesConverted_0e2b9e81-af18-4deb-9834-3cef8fee86a0" xlink:href="ck0001824293-20230630.xsd#ck0001824293_ConversionOfStockAdditionalSharesConverted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2a9d5fe8-62d4-4941-af27-9d784acc2cd7" xlink:to="loc_ck0001824293_ConversionOfStockAdditionalSharesConverted_0e2b9e81-af18-4deb-9834-3cef8fee86a0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f4ba456c-d167-44ad-a50d-72a9eaec7f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2a9d5fe8-62d4-4941-af27-9d784acc2cd7" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f4ba456c-d167-44ad-a50d-72a9eaec7f2b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1b8086d3-aeec-42d6-9a9f-dc35fcfe3691" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f4ba456c-d167-44ad-a50d-72a9eaec7f2b" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1b8086d3-aeec-42d6-9a9f-dc35fcfe3691" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_1b8086d3-aeec-42d6-9a9f-dc35fcfe3691_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1b8086d3-aeec-42d6-9a9f-dc35fcfe3691" xlink:to="loc_us-gaap_RelatedPartyDomain_1b8086d3-aeec-42d6-9a9f-dc35fcfe3691_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_8b83742b-1b30-4489-a545-a8b3d3fc4e94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1b8086d3-aeec-42d6-9a9f-dc35fcfe3691" xlink:to="loc_us-gaap_RelatedPartyDomain_8b83742b-1b30-4489-a545-a8b3d3fc4e94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestorMember_8e0824ca-04f0-415e-82d6-348d163df07f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_8b83742b-1b30-4489-a545-a8b3d3fc4e94" xlink:to="loc_us-gaap_InvestorMember_8e0824ca-04f0-415e-82d6-348d163df07f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_773c6d8a-2829-4bba-9f62-941b1799a9b4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f4ba456c-d167-44ad-a50d-72a9eaec7f2b" xlink:to="loc_dei_LegalEntityAxis_773c6d8a-2829-4bba-9f62-941b1799a9b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_773c6d8a-2829-4bba-9f62-941b1799a9b4_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_773c6d8a-2829-4bba-9f62-941b1799a9b4" xlink:to="loc_dei_EntityDomain_773c6d8a-2829-4bba-9f62-941b1799a9b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_3eeb9cc1-f9ff-4342-b175-dd41dba7ebfb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_773c6d8a-2829-4bba-9f62-941b1799a9b4" xlink:to="loc_dei_EntityDomain_3eeb9cc1-f9ff-4342-b175-dd41dba7ebfb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PrivateGRIMember_020651ba-93d3-404f-bab7-543abcff5dfa" xlink:href="ck0001824293-20230630.xsd#ck0001824293_PrivateGRIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_3eeb9cc1-f9ff-4342-b175-dd41dba7ebfb" xlink:to="loc_ck0001824293_PrivateGRIMember_020651ba-93d3-404f-bab7-543abcff5dfa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_79841a28-dbfe-4ec5-8dff-e2255ac3e5ce" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f4ba456c-d167-44ad-a50d-72a9eaec7f2b" xlink:to="loc_srt_CounterpartyNameAxis_79841a28-dbfe-4ec5-8dff-e2255ac3e5ce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_79841a28-dbfe-4ec5-8dff-e2255ac3e5ce_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_79841a28-dbfe-4ec5-8dff-e2255ac3e5ce" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_79841a28-dbfe-4ec5-8dff-e2255ac3e5ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_71c0c583-6218-4721-a9b3-ce17a70dec79" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_79841a28-dbfe-4ec5-8dff-e2255ac3e5ce" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_71c0c583-6218-4721-a9b3-ce17a70dec79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_GRIBioIncMember_9b31bf4b-4816-4599-b8ed-33d8085ecd6b" xlink:href="ck0001824293-20230630.xsd#ck0001824293_GRIBioIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_71c0c583-6218-4721-a9b3-ce17a70dec79" xlink:to="loc_ck0001824293_GRIBioIncMember_9b31bf4b-4816-4599-b8ed-33d8085ecd6b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b8216ae5-52b7-4dca-baf1-b77862d0ac89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f4ba456c-d167-44ad-a50d-72a9eaec7f2b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b8216ae5-52b7-4dca-baf1-b77862d0ac89" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b8216ae5-52b7-4dca-baf1-b77862d0ac89_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b8216ae5-52b7-4dca-baf1-b77862d0ac89" xlink:to="loc_us-gaap_EquityComponentDomain_b8216ae5-52b7-4dca-baf1-b77862d0ac89_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f8cb03ba-3653-458f-8283-fb3804b491ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b8216ae5-52b7-4dca-baf1-b77862d0ac89" xlink:to="loc_us-gaap_EquityComponentDomain_f8cb03ba-3653-458f-8283-fb3804b491ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_5fc8bbe2-6219-4168-9465-8165f8583afa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f8cb03ba-3653-458f-8283-fb3804b491ac" xlink:to="loc_us-gaap_CommonStockMember_5fc8bbe2-6219-4168-9465-8165f8583afa" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ef97fa5b-acba-4bb6-a5f9-9d09fe9ff7f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6c67e785-cea8-44f9-a393-be227be6b232" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ef97fa5b-acba-4bb6-a5f9-9d09fe9ff7f3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6c67e785-cea8-44f9-a393-be227be6b232" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8ce62d65-b5c0-4df8-a8a3-393540344375" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ef97fa5b-acba-4bb6-a5f9-9d09fe9ff7f3" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8ce62d65-b5c0-4df8-a8a3-393540344375" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_55e6b29b-db7f-420e-9e60-a6c2fd5db180" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8ce62d65-b5c0-4df8-a8a3-393540344375" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_55e6b29b-db7f-420e-9e60-a6c2fd5db180" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_55e6b29b-db7f-420e-9e60-a6c2fd5db180_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_55e6b29b-db7f-420e-9e60-a6c2fd5db180" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_55e6b29b-db7f-420e-9e60-a6c2fd5db180_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_dd242a3a-9ea5-4e5d-94c1-180d1d8d34cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_55e6b29b-db7f-420e-9e60-a6c2fd5db180" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_dd242a3a-9ea5-4e5d-94c1-180d1d8d34cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e54268a7-a695-44f7-809a-3bbefb1a8722" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_dd242a3a-9ea5-4e5d-94c1-180d1d8d34cd" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e54268a7-a695-44f7-809a-3bbefb1a8722" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_285b9416-0a72-4c6e-9019-74d63f12a15a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_dd242a3a-9ea5-4e5d-94c1-180d1d8d34cd" xlink:to="loc_us-gaap_WarrantMember_285b9416-0a72-4c6e-9019-74d63f12a15a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_6cf13921-140d-410f-9e87-1af2d1a4342b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_dd242a3a-9ea5-4e5d-94c1-180d1d8d34cd" xlink:to="loc_us-gaap_RestrictedStockMember_6cf13921-140d-410f-9e87-1af2d1a4342b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockSubjectToPutRightMember_0203f5bd-6862-4eed-a1bb-29e72600cec9" xlink:href="ck0001824293-20230630.xsd#ck0001824293_StockSubjectToPutRightMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_dd242a3a-9ea5-4e5d-94c1-180d1d8d34cd" xlink:to="loc_ck0001824293_StockSubjectToPutRightMember_0203f5bd-6862-4eed-a1bb-29e72600cec9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ConvertiblePromissoryNoteMember_5769fd83-a605-4d73-93f3-78428c490497" xlink:href="ck0001824293-20230630.xsd#ck0001824293_ConvertiblePromissoryNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_dd242a3a-9ea5-4e5d-94c1-180d1d8d34cd" xlink:to="loc_ck0001824293_ConvertiblePromissoryNoteMember_5769fd83-a605-4d73-93f3-78428c490497" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#MERGERWITHVALLONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_cc6796a0-2ddc-4617-b3ad-393a0549339e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1b29c2af-aa46-4d5c-943d-19206a8eec27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cc6796a0-2ddc-4617-b3ad-393a0549339e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1b29c2af-aa46-4d5c-943d-19206a8eec27" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_4f84962d-872d-45b1-bb64-97cda69372ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cc6796a0-2ddc-4617-b3ad-393a0549339e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_4f84962d-872d-45b1-bb64-97cda69372ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_CommonStockOwnershipPercentage_ab7fc6bf-0b3d-4c73-9309-563840b052d2" xlink:href="ck0001824293-20230630.xsd#ck0001824293_CommonStockOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cc6796a0-2ddc-4617-b3ad-393a0549339e" xlink:to="loc_ck0001824293_CommonStockOwnershipPercentage_ab7fc6bf-0b3d-4c73-9309-563840b052d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_95f83a81-66fb-4e4c-902d-4d802285523d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cc6796a0-2ddc-4617-b3ad-393a0549339e" xlink:to="loc_us-gaap_CommonStockSharesIssued_95f83a81-66fb-4e4c-902d-4d802285523d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses_11121536-ffc6-4ae8-ad3c-41e20aaeb546" xlink:href="ck0001824293-20230630.xsd#ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cc6796a0-2ddc-4617-b3ad-393a0549339e" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses_11121536-ffc6-4ae8-ad3c-41e20aaeb546" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b69adb0f-1bb9-4e84-bd1f-c8f5605059e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cc6796a0-2ddc-4617-b3ad-393a0549339e" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b69adb0f-1bb9-4e84-bd1f-c8f5605059e2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_80840bb8-903a-4e82-a281-adafc32aae5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b69adb0f-1bb9-4e84-bd1f-c8f5605059e2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_80840bb8-903a-4e82-a281-adafc32aae5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_80840bb8-903a-4e82-a281-adafc32aae5b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_80840bb8-903a-4e82-a281-adafc32aae5b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_80840bb8-903a-4e82-a281-adafc32aae5b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_f9c31ac0-7dcd-4303-939d-2f45260fe294" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_80840bb8-903a-4e82-a281-adafc32aae5b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_f9c31ac0-7dcd-4303-939d-2f45260fe294" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ExchangeWarrantsMember_cfba75e4-1861-405d-a749-8db084c83307" xlink:href="ck0001824293-20230630.xsd#ck0001824293_ExchangeWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_f9c31ac0-7dcd-4303-939d-2f45260fe294" xlink:to="loc_ck0001824293_ExchangeWarrantsMember_cfba75e4-1861-405d-a749-8db084c83307" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_cc2b05cc-6ff0-4176-b71b-1541d568ca2f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b69adb0f-1bb9-4e84-bd1f-c8f5605059e2" xlink:to="loc_dei_LegalEntityAxis_cc2b05cc-6ff0-4176-b71b-1541d568ca2f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_cc2b05cc-6ff0-4176-b71b-1541d568ca2f_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_cc2b05cc-6ff0-4176-b71b-1541d568ca2f" xlink:to="loc_dei_EntityDomain_cc2b05cc-6ff0-4176-b71b-1541d568ca2f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_0e6a1227-500c-4ea8-9385-a22abbc70191" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_cc2b05cc-6ff0-4176-b71b-1541d568ca2f" xlink:to="loc_dei_EntityDomain_0e6a1227-500c-4ea8-9385-a22abbc70191" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PrivateGRIMember_9d93492b-f46d-4f23-8123-9b2d96f53d09" xlink:href="ck0001824293-20230630.xsd#ck0001824293_PrivateGRIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_0e6a1227-500c-4ea8-9385-a22abbc70191" xlink:to="loc_ck0001824293_PrivateGRIMember_9d93492b-f46d-4f23-8123-9b2d96f53d09" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_403b6cb1-cb16-446f-a3b5-a7a18d46fe8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_c9f056a1-c9ed-4734-827b-a4a652439b15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_403b6cb1-cb16-446f-a3b5-a7a18d46fe8f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_c9f056a1-c9ed-4734-827b-a4a652439b15" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_2ad10dca-d1f0-4e9b-996a-3a7415798639" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_403b6cb1-cb16-446f-a3b5-a7a18d46fe8f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_2ad10dca-d1f0-4e9b-996a-3a7415798639" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses_d72e28fd-5ff1-4a70-babd-53fe5ba26790" xlink:href="ck0001824293-20230630.xsd#ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_403b6cb1-cb16-446f-a3b5-a7a18d46fe8f" xlink:to="loc_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses_d72e28fd-5ff1-4a70-babd-53fe5ba26790" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_a9df73f8-731e-44a0-b438-4b8890f865c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_403b6cb1-cb16-446f-a3b5-a7a18d46fe8f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_a9df73f8-731e-44a0-b438-4b8890f865c0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_de161cb4-fbe5-4e42-b288-9988c47f7255" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_403b6cb1-cb16-446f-a3b5-a7a18d46fe8f" xlink:to="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_de161cb4-fbe5-4e42-b288-9988c47f7255" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts_00ad90be-66dd-4bdb-93bb-ca3cf286ddd5" xlink:href="ck0001824293-20230630.xsd#ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_403b6cb1-cb16-446f-a3b5-a7a18d46fe8f" xlink:to="loc_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts_00ad90be-66dd-4bdb-93bb-ca3cf286ddd5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0bbfdcd8-4e1f-4ec7-a7e1-f4a1374a1dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_403b6cb1-cb16-446f-a3b5-a7a18d46fe8f" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0bbfdcd8-4e1f-4ec7-a7e1-f4a1374a1dbd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_bded7499-782d-4f2e-aa66-2a8d2987b929" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0bbfdcd8-4e1f-4ec7-a7e1-f4a1374a1dbd" xlink:to="loc_dei_LegalEntityAxis_bded7499-782d-4f2e-aa66-2a8d2987b929" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_bded7499-782d-4f2e-aa66-2a8d2987b929_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_bded7499-782d-4f2e-aa66-2a8d2987b929" xlink:to="loc_dei_EntityDomain_bded7499-782d-4f2e-aa66-2a8d2987b929_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_14b0f557-47a1-4767-ade8-839dfe48f424" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_bded7499-782d-4f2e-aa66-2a8d2987b929" xlink:to="loc_dei_EntityDomain_14b0f557-47a1-4767-ade8-839dfe48f424" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PrivateGRIMember_381d3116-cd50-4e82-b32f-2609879ad31a" xlink:href="ck0001824293-20230630.xsd#ck0001824293_PrivateGRIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_14b0f557-47a1-4767-ade8-839dfe48f424" xlink:to="loc_ck0001824293_PrivateGRIMember_381d3116-cd50-4e82-b32f-2609879ad31a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_33da1d0f-8d46-49cf-854c-d59f1e99a733" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_7809fbe5-acab-4f68-bc30-513375fc636a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_33da1d0f-8d46-49cf-854c-d59f1e99a733" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_7809fbe5-acab-4f68-bc30-513375fc636a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_b1d044d6-f6f4-48df-8385-638df4a807d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_33da1d0f-8d46-49cf-854c-d59f1e99a733" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_b1d044d6-f6f4-48df-8385-638df4a807d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f5a81ec4-222d-41f1-9c18-7e31f13604e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_33da1d0f-8d46-49cf-854c-d59f1e99a733" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f5a81ec4-222d-41f1-9c18-7e31f13604e7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6ebc41ac-60df-4fcd-bb59-a6cba6a5a45a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f5a81ec4-222d-41f1-9c18-7e31f13604e7" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6ebc41ac-60df-4fcd-bb59-a6cba6a5a45a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6ebc41ac-60df-4fcd-bb59-a6cba6a5a45a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6ebc41ac-60df-4fcd-bb59-a6cba6a5a45a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6ebc41ac-60df-4fcd-bb59-a6cba6a5a45a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b0c0b1d6-8074-4a0c-a2ec-f8c8c9376725" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6ebc41ac-60df-4fcd-bb59-a6cba6a5a45a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b0c0b1d6-8074-4a0c-a2ec-f8c8c9376725" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_1179c5ba-14ef-437c-8068-ceadef6a8c14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b0c0b1d6-8074-4a0c-a2ec-f8c8c9376725" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_1179c5ba-14ef-437c-8068-ceadef6a8c14" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_0a5733a4-5f0e-4c10-b5fc-93394c94e443" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b0c0b1d6-8074-4a0c-a2ec-f8c8c9376725" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_0a5733a4-5f0e-4c10-b5fc-93394c94e443" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_3fed1346-540f-4c9f-9c48-66486fa749fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b0c0b1d6-8074-4a0c-a2ec-f8c8c9376725" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_3fed1346-540f-4c9f-9c48-66486fa749fb" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_125522e7-f7c7-4b01-bb1e-512c58c156c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_a55f38f7-d375-4eac-8caf-d62a89c5c634" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_125522e7-f7c7-4b01-bb1e-512c58c156c9" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_a55f38f7-d375-4eac-8caf-d62a89c5c634" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_e28d0aec-457b-47d9-b75c-bdfc9c760473" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_125522e7-f7c7-4b01-bb1e-512c58c156c9" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_e28d0aec-457b-47d9-b75c-bdfc9c760473" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_f9524ddc-be4c-454b-997b-681612bd1da0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6e302855-63e1-4c21-bb07-899016d8f521" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_125522e7-f7c7-4b01-bb1e-512c58c156c9" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6e302855-63e1-4c21-bb07-899016d8f521" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_91ab8480-15c3-4bc2-b84d-6e316b689557" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6e302855-63e1-4c21-bb07-899016d8f521" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_91ab8480-15c3-4bc2-b84d-6e316b689557" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_91ab8480-15c3-4bc2-b84d-6e316b689557_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_91ab8480-15c3-4bc2-b84d-6e316b689557" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_91ab8480-15c3-4bc2-b84d-6e316b689557_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_f34c4a7f-fdde-44a8-b68c-0c35410cb6c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_91ab8480-15c3-4bc2-b84d-6e316b689557" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_f34c4a7f-fdde-44a8-b68c-0c35410cb6c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantLiabilityMember_00108544-eaed-46d5-98af-a621208d9d9c" xlink:href="ck0001824293-20230630.xsd#ck0001824293_WarrantLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_f34c4a7f-fdde-44a8-b68c-0c35410cb6c6" xlink:to="loc_ck0001824293_WarrantLiabilityMember_00108544-eaed-46d5-98af-a621208d9d9c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_4b409d48-769f-4f71-b3ba-eb1c4915695f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_07b04a84-5f82-4702-a540-3f1749aa3f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_4b409d48-769f-4f71-b3ba-eb1c4915695f" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_07b04a84-5f82-4702-a540-3f1749aa3f0e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_9690a931-9517-43d6-9950-a9373c2d31dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_4b409d48-769f-4f71-b3ba-eb1c4915695f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_9690a931-9517-43d6-9950-a9373c2d31dd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_99a5e71e-9b73-41a0-9a36-b4bc35410727" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_9690a931-9517-43d6-9950-a9373c2d31dd" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_99a5e71e-9b73-41a0-9a36-b4bc35410727" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_99a5e71e-9b73-41a0-9a36-b4bc35410727_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_99a5e71e-9b73-41a0-9a36-b4bc35410727" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_99a5e71e-9b73-41a0-9a36-b4bc35410727_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_4002af23-ffcd-436e-8e3f-da24ca2b21c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_99a5e71e-9b73-41a0-9a36-b4bc35410727" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_4002af23-ffcd-436e-8e3f-da24ca2b21c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_ee4673fb-b2de-4ed0-b740-f37607701896" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_4002af23-ffcd-436e-8e3f-da24ca2b21c1" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_ee4673fb-b2de-4ed0-b740-f37607701896" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_94f4a53d-84d9-4466-ade3-135ef8700218" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_4002af23-ffcd-436e-8e3f-da24ca2b21c1" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_94f4a53d-84d9-4466-ade3-135ef8700218" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_d0dc48bf-b8de-4fd2-a562-6eaa84ce3d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_4002af23-ffcd-436e-8e3f-da24ca2b21c1" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_d0dc48bf-b8de-4fd2-a562-6eaa84ce3d3c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_d6b3f375-c90c-4b98-9df7-c9c09a89bc6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_4002af23-ffcd-436e-8e3f-da24ca2b21c1" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_d6b3f375-c90c-4b98-9df7-c9c09a89bc6e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_abe59681-28b9-4083-b6a5-a351fd379727" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_9690a931-9517-43d6-9950-a9373c2d31dd" xlink:to="loc_srt_RangeAxis_abe59681-28b9-4083-b6a5-a351fd379727" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_abe59681-28b9-4083-b6a5-a351fd379727_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_abe59681-28b9-4083-b6a5-a351fd379727" xlink:to="loc_srt_RangeMember_abe59681-28b9-4083-b6a5-a351fd379727_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5d607a7b-c5ba-4e73-a6bb-75235c63f8b7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_abe59681-28b9-4083-b6a5-a351fd379727" xlink:to="loc_srt_RangeMember_5d607a7b-c5ba-4e73-a6bb-75235c63f8b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_64f7f2a7-2cc1-4bff-bd65-7585ede780d9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5d607a7b-c5ba-4e73-a6bb-75235c63f8b7" xlink:to="loc_srt_WeightedAverageMember_64f7f2a7-2cc1-4bff-bd65-7585ede780d9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_984193bc-2545-4189-9c70-1f54337a5289" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_d5c82eb3-838c-4864-92a1-573c393f5497" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_984193bc-2545-4189-9c70-1f54337a5289" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_d5c82eb3-838c-4864-92a1-573c393f5497" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6c6a4e09-92a1-404d-8990-c6d6abf9df9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_984193bc-2545-4189-9c70-1f54337a5289" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6c6a4e09-92a1-404d-8990-c6d6abf9df9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5fc0a109-002e-4a73-bffc-be836b567921" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_984193bc-2545-4189-9c70-1f54337a5289" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_5fc0a109-002e-4a73-bffc-be836b567921" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f025aef7-f5ef-430d-ab99-d2b7e90a0ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_984193bc-2545-4189-9c70-1f54337a5289" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f025aef7-f5ef-430d-ab99-d2b7e90a0ab2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7eb928ea-983d-4c4a-aeaa-2aacb3c9b743" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f025aef7-f5ef-430d-ab99-d2b7e90a0ab2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7eb928ea-983d-4c4a-aeaa-2aacb3c9b743" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7eb928ea-983d-4c4a-aeaa-2aacb3c9b743_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7eb928ea-983d-4c4a-aeaa-2aacb3c9b743" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7eb928ea-983d-4c4a-aeaa-2aacb3c9b743_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3f5e9b59-12e8-47d5-9fc7-d9a7eb361e13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7eb928ea-983d-4c4a-aeaa-2aacb3c9b743" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3f5e9b59-12e8-47d5-9fc7-d9a7eb361e13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_5cc91dee-ef3a-4915-a305-784c91770fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3f5e9b59-12e8-47d5-9fc7-d9a7eb361e13" xlink:to="loc_us-gaap_ComputerEquipmentMember_5cc91dee-ef3a-4915-a305-784c91770fb0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_eb141b76-b942-417b-97c5-981e8689d7b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3f5e9b59-12e8-47d5-9fc7-d9a7eb361e13" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_eb141b76-b942-417b-97c5-981e8689d7b3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#PROMISSORYNOTESBridgeFinancingDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_fa3e330c-2fd1-49bb-be20-bf180956aaad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_3458f91f-ca75-4f87-93ce-ce38396a8a53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fa3e330c-2fd1-49bb-be20-bf180956aaad" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_3458f91f-ca75-4f87-93ce-ce38396a8a53" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtInstrumentAggregatePurchasePrice_ec3609ff-0371-4781-bf63-5af1ae7018e7" xlink:href="ck0001824293-20230630.xsd#ck0001824293_DebtInstrumentAggregatePurchasePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fa3e330c-2fd1-49bb-be20-bf180956aaad" xlink:to="loc_ck0001824293_DebtInstrumentAggregatePurchasePrice_ec3609ff-0371-4781-bf63-5af1ae7018e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtInstrumentNumberOfClosings_dc938bd0-99bd-4550-bde2-cc144cd7d142" xlink:href="ck0001824293-20230630.xsd#ck0001824293_DebtInstrumentNumberOfClosings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fa3e330c-2fd1-49bb-be20-bf180956aaad" xlink:to="loc_ck0001824293_DebtInstrumentNumberOfClosings_dc938bd0-99bd-4550-bde2-cc144cd7d142" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_31a69fcb-c802-4fcd-a53d-694250109710" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fa3e330c-2fd1-49bb-be20-bf180956aaad" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_31a69fcb-c802-4fcd-a53d-694250109710" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_67b6de13-6fde-41f0-90ad-1cafa4ce0ef5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fa3e330c-2fd1-49bb-be20-bf180956aaad" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_67b6de13-6fde-41f0-90ad-1cafa4ce0ef5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_64914d51-c7db-42dc-b3a1-c61109770207" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fa3e330c-2fd1-49bb-be20-bf180956aaad" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_64914d51-c7db-42dc-b3a1-c61109770207" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_498e6b46-ccd3-421e-b6f0-dac5177e801c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fa3e330c-2fd1-49bb-be20-bf180956aaad" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_498e6b46-ccd3-421e-b6f0-dac5177e801c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentCompanyCommittedCapital_e7c7064a-18c4-4fdc-babb-207a80f529f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentCompanyCommittedCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fa3e330c-2fd1-49bb-be20-bf180956aaad" xlink:to="loc_us-gaap_InvestmentCompanyCommittedCapital_e7c7064a-18c4-4fdc-babb-207a80f529f8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_05e629ef-8e60-4ad9-81b1-a4389c61ca38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fa3e330c-2fd1-49bb-be20-bf180956aaad" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_05e629ef-8e60-4ad9-81b1-a4389c61ca38" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_6cb278d3-c1f3-4310-bc92-bb6721e2caf5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fa3e330c-2fd1-49bb-be20-bf180956aaad" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_6cb278d3-c1f3-4310-bc92-bb6721e2caf5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_208b9679-5808-41bd-8070-29a3c7920dce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fa3e330c-2fd1-49bb-be20-bf180956aaad" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_208b9679-5808-41bd-8070-29a3c7920dce" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_48098f31-66f3-4622-b639-ff72f8a45370" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fa3e330c-2fd1-49bb-be20-bf180956aaad" xlink:to="loc_us-gaap_DebtInstrumentTable_48098f31-66f3-4622-b639-ff72f8a45370" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_48f987f7-ade5-4150-8c3a-6bcae309dee0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_48098f31-66f3-4622-b639-ff72f8a45370" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_48f987f7-ade5-4150-8c3a-6bcae309dee0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_48f987f7-ade5-4150-8c3a-6bcae309dee0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_48f987f7-ade5-4150-8c3a-6bcae309dee0" xlink:to="loc_us-gaap_RelatedPartyDomain_48f987f7-ade5-4150-8c3a-6bcae309dee0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_aacb88b2-b444-41e1-824d-714cc5da5fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_48f987f7-ade5-4150-8c3a-6bcae309dee0" xlink:to="loc_us-gaap_RelatedPartyDomain_aacb88b2-b444-41e1-824d-714cc5da5fb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestorMember_915f3108-859e-4782-9679-d8caa4794a81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_aacb88b2-b444-41e1-824d-714cc5da5fb1" xlink:to="loc_us-gaap_InvestorMember_915f3108-859e-4782-9679-d8caa4794a81" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_522143f5-cd12-4f9b-af85-359294aff89a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_48098f31-66f3-4622-b639-ff72f8a45370" xlink:to="loc_dei_LegalEntityAxis_522143f5-cd12-4f9b-af85-359294aff89a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_522143f5-cd12-4f9b-af85-359294aff89a_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_522143f5-cd12-4f9b-af85-359294aff89a" xlink:to="loc_dei_EntityDomain_522143f5-cd12-4f9b-af85-359294aff89a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_cf5ccf95-e984-4b59-a542-88ad3fac406e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_522143f5-cd12-4f9b-af85-359294aff89a" xlink:to="loc_dei_EntityDomain_cf5ccf95-e984-4b59-a542-88ad3fac406e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PrivateGRIMember_272c0be0-7d63-4907-a84b-44285cfa5287" xlink:href="ck0001824293-20230630.xsd#ck0001824293_PrivateGRIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_cf5ccf95-e984-4b59-a542-88ad3fac406e" xlink:to="loc_ck0001824293_PrivateGRIMember_272c0be0-7d63-4907-a84b-44285cfa5287" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ba4fa794-79b6-4a4d-a9de-7cfaba0b2deb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_48098f31-66f3-4622-b639-ff72f8a45370" xlink:to="loc_us-gaap_DebtInstrumentAxis_ba4fa794-79b6-4a4d-a9de-7cfaba0b2deb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ba4fa794-79b6-4a4d-a9de-7cfaba0b2deb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_ba4fa794-79b6-4a4d-a9de-7cfaba0b2deb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ba4fa794-79b6-4a4d-a9de-7cfaba0b2deb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_abd714ee-3cdb-449a-866d-22e7c0b34893" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_ba4fa794-79b6-4a4d-a9de-7cfaba0b2deb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_abd714ee-3cdb-449a-866d-22e7c0b34893" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_BridgeSecuritiesPurchaseAgreementMember_74169f1e-1b3f-4fb9-aef2-95cb13cabb46" xlink:href="ck0001824293-20230630.xsd#ck0001824293_BridgeSecuritiesPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_abd714ee-3cdb-449a-866d-22e7c0b34893" xlink:to="loc_ck0001824293_BridgeSecuritiesPurchaseAgreementMember_74169f1e-1b3f-4fb9-aef2-95cb13cabb46" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_08386d39-48df-4ac4-969d-0c7c4fc9b073" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_48098f31-66f3-4622-b639-ff72f8a45370" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_08386d39-48df-4ac4-969d-0c7c4fc9b073" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_08386d39-48df-4ac4-969d-0c7c4fc9b073_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_08386d39-48df-4ac4-969d-0c7c4fc9b073" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_08386d39-48df-4ac4-969d-0c7c4fc9b073_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_a2a15dea-4b6b-4241-a7fc-a5452dcb32fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_08386d39-48df-4ac4-969d-0c7c4fc9b073" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_a2a15dea-4b6b-4241-a7fc-a5452dcb32fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_BridgeWarrantsMember_e6466a92-d589-46c7-8d89-46a16adb1db3" xlink:href="ck0001824293-20230630.xsd#ck0001824293_BridgeWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a2a15dea-4b6b-4241-a7fc-a5452dcb32fd" xlink:to="loc_ck0001824293_BridgeWarrantsMember_e6466a92-d589-46c7-8d89-46a16adb1db3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ExchangeWarrantsMember_fb1ecba8-1165-461c-8038-065a860d2195" xlink:href="ck0001824293-20230630.xsd#ck0001824293_ExchangeWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a2a15dea-4b6b-4241-a7fc-a5452dcb32fd" xlink:to="loc_ck0001824293_ExchangeWarrantsMember_fb1ecba8-1165-461c-8038-065a860d2195" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_e9952567-ab09-4bfe-affc-7cdc02612bab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_48098f31-66f3-4622-b639-ff72f8a45370" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_e9952567-ab09-4bfe-affc-7cdc02612bab" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_e9952567-ab09-4bfe-affc-7cdc02612bab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_e9952567-ab09-4bfe-affc-7cdc02612bab" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_e9952567-ab09-4bfe-affc-7cdc02612bab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_c642794e-623f-4662-957a-bc8ea8074ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_e9952567-ab09-4bfe-affc-7cdc02612bab" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_c642794e-623f-4662-957a-bc8ea8074ba7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CallOptionMember_3e2f34e2-225e-472e-b77f-9992ecc8f161" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CallOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_c642794e-623f-4662-957a-bc8ea8074ba7" xlink:to="loc_us-gaap_CallOptionMember_3e2f34e2-225e-472e-b77f-9992ecc8f161" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#PROMISSORYNOTESTEPNoteDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_bd0ff465-b1f5-4034-8212-772fb54a66e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_cb798637-f443-40f5-96cf-043f733aa292" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bd0ff465-b1f5-4034-8212-772fb54a66e9" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_cb798637-f443-40f5-96cf-043f733aa292" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_39336a35-9daf-4eb5-afa4-ec5a02cafdcc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bd0ff465-b1f5-4034-8212-772fb54a66e9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_39336a35-9daf-4eb5-afa4-ec5a02cafdcc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_86c2432f-b93d-4081-b080-b02e68173224" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bd0ff465-b1f5-4034-8212-772fb54a66e9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_86c2432f-b93d-4081-b080-b02e68173224" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_92223f24-83db-43f1-96c6-274ca14a4bcf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bd0ff465-b1f5-4034-8212-772fb54a66e9" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_92223f24-83db-43f1-96c6-274ca14a4bcf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_caa70a18-f4c0-4783-9607-39670a8af446" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bd0ff465-b1f5-4034-8212-772fb54a66e9" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_caa70a18-f4c0-4783-9607-39670a8af446" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_1994dc81-f55b-4b2b-8c7f-aa9524b2696a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bd0ff465-b1f5-4034-8212-772fb54a66e9" xlink:to="loc_us-gaap_CommonStockSharesIssued_1994dc81-f55b-4b2b-8c7f-aa9524b2696a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_CallOptionPrice_12e67977-a688-4112-961e-0115debd3b10" xlink:href="ck0001824293-20230630.xsd#ck0001824293_CallOptionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bd0ff465-b1f5-4034-8212-772fb54a66e9" xlink:to="loc_ck0001824293_CallOptionPrice_12e67977-a688-4112-961e-0115debd3b10" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtConversionConvertedInstrumentPrincipalAmountOfDebt_e804bd4a-33c7-490f-893b-cfd44c9423ca" xlink:href="ck0001824293-20230630.xsd#ck0001824293_DebtConversionConvertedInstrumentPrincipalAmountOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bd0ff465-b1f5-4034-8212-772fb54a66e9" xlink:to="loc_ck0001824293_DebtConversionConvertedInstrumentPrincipalAmountOfDebt_e804bd4a-33c7-490f-893b-cfd44c9423ca" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtConversionConvertedInstrumentAmountOfInterest_524abc58-04bb-427b-bfe4-5eaf196df2c5" xlink:href="ck0001824293-20230630.xsd#ck0001824293_DebtConversionConvertedInstrumentAmountOfInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bd0ff465-b1f5-4034-8212-772fb54a66e9" xlink:to="loc_ck0001824293_DebtConversionConvertedInstrumentAmountOfInterest_524abc58-04bb-427b-bfe4-5eaf196df2c5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtInstrumentConvertibleSharesIssuedUponConversion_394fbc27-15b2-409e-a26c-794b09b79b2f" xlink:href="ck0001824293-20230630.xsd#ck0001824293_DebtInstrumentConvertibleSharesIssuedUponConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bd0ff465-b1f5-4034-8212-772fb54a66e9" xlink:to="loc_ck0001824293_DebtInstrumentConvertibleSharesIssuedUponConversion_394fbc27-15b2-409e-a26c-794b09b79b2f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_b1c99be2-a790-471b-97cf-6ab297b1c843" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bd0ff465-b1f5-4034-8212-772fb54a66e9" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_b1c99be2-a790-471b-97cf-6ab297b1c843" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_ba2cfe5d-b193-4eb1-a538-0f1c3dd0b1e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bd0ff465-b1f5-4034-8212-772fb54a66e9" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_ba2cfe5d-b193-4eb1-a538-0f1c3dd0b1e4" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_b2afd63e-053b-479a-8c21-41baeda9c2b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bd0ff465-b1f5-4034-8212-772fb54a66e9" xlink:to="loc_us-gaap_InterestPayableCurrentAndNoncurrent_b2afd63e-053b-479a-8c21-41baeda9c2b1" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_LongTermDebtIncludingInterest_07540518-aeb4-47fd-9949-f1e9586acf07" xlink:href="ck0001824293-20230630.xsd#ck0001824293_LongTermDebtIncludingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bd0ff465-b1f5-4034-8212-772fb54a66e9" xlink:to="loc_ck0001824293_LongTermDebtIncludingInterest_07540518-aeb4-47fd-9949-f1e9586acf07" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_e924195a-60b5-4b9b-b857-cd759dbad981" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bd0ff465-b1f5-4034-8212-772fb54a66e9" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_e924195a-60b5-4b9b-b857-cd759dbad981" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_d06cae26-04ac-47d1-9d46-6fc1ef789cd5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bd0ff465-b1f5-4034-8212-772fb54a66e9" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_d06cae26-04ac-47d1-9d46-6fc1ef789cd5" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_b22db6b7-2660-4c5b-8c52-04fd02e77920" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bd0ff465-b1f5-4034-8212-772fb54a66e9" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_b22db6b7-2660-4c5b-8c52-04fd02e77920" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedInterestForfeited_39ad243b-7a8e-48c9-8087-ad29ea54ea10" xlink:href="ck0001824293-20230630.xsd#ck0001824293_AccruedInterestForfeited"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bd0ff465-b1f5-4034-8212-772fb54a66e9" xlink:to="loc_ck0001824293_AccruedInterestForfeited_39ad243b-7a8e-48c9-8087-ad29ea54ea10" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseBorrowings_d56e0d57-1e23-4eb6-a32d-8320bd2b9ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bd0ff465-b1f5-4034-8212-772fb54a66e9" xlink:to="loc_us-gaap_InterestExpenseBorrowings_d56e0d57-1e23-4eb6-a32d-8320bd2b9ca6" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_6a2eb2eb-3268-4db0-a8f2-5e3d607a6e24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bd0ff465-b1f5-4034-8212-772fb54a66e9" xlink:to="loc_us-gaap_DebtInstrumentTable_6a2eb2eb-3268-4db0-a8f2-5e3d607a6e24" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_64e1dd82-41b9-4f80-bde3-5c68de58ee3a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6a2eb2eb-3268-4db0-a8f2-5e3d607a6e24" xlink:to="loc_dei_LegalEntityAxis_64e1dd82-41b9-4f80-bde3-5c68de58ee3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_64e1dd82-41b9-4f80-bde3-5c68de58ee3a_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_64e1dd82-41b9-4f80-bde3-5c68de58ee3a" xlink:to="loc_dei_EntityDomain_64e1dd82-41b9-4f80-bde3-5c68de58ee3a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a715b86e-5cd7-47ee-8428-943e0bcfb9be" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_64e1dd82-41b9-4f80-bde3-5c68de58ee3a" xlink:to="loc_dei_EntityDomain_a715b86e-5cd7-47ee-8428-943e0bcfb9be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PrivateGRIMember_7c901227-db39-4c4c-953c-13011bd985c0" xlink:href="ck0001824293-20230630.xsd#ck0001824293_PrivateGRIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_a715b86e-5cd7-47ee-8428-943e0bcfb9be" xlink:to="loc_ck0001824293_PrivateGRIMember_7c901227-db39-4c4c-953c-13011bd985c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c3502be3-3e30-445d-a3bd-b94df0a39878" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6a2eb2eb-3268-4db0-a8f2-5e3d607a6e24" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c3502be3-3e30-445d-a3bd-b94df0a39878" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c3502be3-3e30-445d-a3bd-b94df0a39878_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c3502be3-3e30-445d-a3bd-b94df0a39878" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c3502be3-3e30-445d-a3bd-b94df0a39878_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2c44a0ae-50a8-4ab9-9447-e3009c6b433d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c3502be3-3e30-445d-a3bd-b94df0a39878" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2c44a0ae-50a8-4ab9-9447-e3009c6b433d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_d7dd95cf-e5ad-4b4e-94c5-7f30e02cb930" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2c44a0ae-50a8-4ab9-9447-e3009c6b433d" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_d7dd95cf-e5ad-4b4e-94c5-7f30e02cb930" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_af7c09ea-44a4-4532-ba0a-e335deda2209" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6a2eb2eb-3268-4db0-a8f2-5e3d607a6e24" xlink:to="loc_us-gaap_DebtInstrumentAxis_af7c09ea-44a4-4532-ba0a-e335deda2209" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_af7c09ea-44a4-4532-ba0a-e335deda2209_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_af7c09ea-44a4-4532-ba0a-e335deda2209" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_af7c09ea-44a4-4532-ba0a-e335deda2209_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_946ccce6-acf1-4274-9f80-5415b9dc4644" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_af7c09ea-44a4-4532-ba0a-e335deda2209" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_946ccce6-acf1-4274-9f80-5415b9dc4644" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_TEPNoteMember_ccfb3baa-50a3-4973-aea6-b992530bbc88" xlink:href="ck0001824293-20230630.xsd#ck0001824293_TEPNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_946ccce6-acf1-4274-9f80-5415b9dc4644" xlink:to="loc_ck0001824293_TEPNoteMember_ccfb3baa-50a3-4973-aea6-b992530bbc88" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_579285a5-2bbc-466a-a46e-315083e31e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6a2eb2eb-3268-4db0-a8f2-5e3d607a6e24" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_579285a5-2bbc-466a-a46e-315083e31e5e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_579285a5-2bbc-466a-a46e-315083e31e5e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_579285a5-2bbc-466a-a46e-315083e31e5e" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_579285a5-2bbc-466a-a46e-315083e31e5e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_ab10417e-f25b-46a6-9155-668154e07740" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_579285a5-2bbc-466a-a46e-315083e31e5e" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_ab10417e-f25b-46a6-9155-668154e07740" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CallOptionMember_93be3bb7-10d5-42d1-8a6c-a23a591b2d86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CallOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_ab10417e-f25b-46a6-9155-668154e07740" xlink:to="loc_us-gaap_CallOptionMember_93be3bb7-10d5-42d1-8a6c-a23a591b2d86" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#STOCKHOLDERSEQUITYNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_e16c4385-2706-493b-ae6d-a4b0647eb747" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentCompanyCommittedCapital_8865f77c-262d-4a65-85a1-0b83fe081b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentCompanyCommittedCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e16c4385-2706-493b-ae6d-a4b0647eb747" xlink:to="loc_us-gaap_InvestmentCompanyCommittedCapital_8865f77c-262d-4a65-85a1-0b83fe081b1e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_3a07aed2-54b5-4a55-8207-21ec97ba970c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e16c4385-2706-493b-ae6d-a4b0647eb747" xlink:to="loc_us-gaap_CommonStockSharesIssued_3a07aed2-54b5-4a55-8207-21ec97ba970c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_CommonStockHeldIntoEscrowAccount_1e065012-fc13-4b5a-89a9-07552e94281d" xlink:href="ck0001824293-20230630.xsd#ck0001824293_CommonStockHeldIntoEscrowAccount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e16c4385-2706-493b-ae6d-a4b0647eb747" xlink:to="loc_ck0001824293_CommonStockHeldIntoEscrowAccount_1e065012-fc13-4b5a-89a9-07552e94281d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_a3f0728e-de24-4024-93e4-9bced53306b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e16c4385-2706-493b-ae6d-a4b0647eb747" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_a3f0728e-de24-4024-93e4-9bced53306b7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_b74ba374-50fe-4582-a1e7-77dfb8384fbf" xlink:href="ck0001824293-20230630.xsd#ck0001824293_StockIssuanceCostsOfferingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e16c4385-2706-493b-ae6d-a4b0647eb747" xlink:to="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_b74ba374-50fe-4582-a1e7-77dfb8384fbf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_f5bb7e3f-21d8-4b27-a350-66d76375989f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e16c4385-2706-493b-ae6d-a4b0647eb747" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_f5bb7e3f-21d8-4b27-a350-66d76375989f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ConversionOfStockAdditionalSharesConverted_720ee1e8-78cb-4643-8b78-78c4b23a7420" xlink:href="ck0001824293-20230630.xsd#ck0001824293_ConversionOfStockAdditionalSharesConverted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e16c4385-2706-493b-ae6d-a4b0647eb747" xlink:to="loc_ck0001824293_ConversionOfStockAdditionalSharesConverted_720ee1e8-78cb-4643-8b78-78c4b23a7420" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PutOptionSharePrice_134ff5c1-3ed8-4ac8-b517-3a25b57d8ba7" xlink:href="ck0001824293-20230630.xsd#ck0001824293_PutOptionSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e16c4385-2706-493b-ae6d-a4b0647eb747" xlink:to="loc_ck0001824293_PutOptionSharePrice_134ff5c1-3ed8-4ac8-b517-3a25b57d8ba7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_0226e1ca-fc08-41b2-8b0c-465722c33b94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e16c4385-2706-493b-ae6d-a4b0647eb747" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_0226e1ca-fc08-41b2-8b0c-465722c33b94" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_7504b885-20e7-4f7d-9e2f-58e507870e86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e16c4385-2706-493b-ae6d-a4b0647eb747" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_7504b885-20e7-4f7d-9e2f-58e507870e86" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_2ae2b5f1-9e5e-4600-a90b-c09f18227f0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e16c4385-2706-493b-ae6d-a4b0647eb747" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_2ae2b5f1-9e5e-4600-a90b-c09f18227f0c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7fb118b4-ad59-4fc2-bd51-621a3d296944" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e16c4385-2706-493b-ae6d-a4b0647eb747" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7fb118b4-ad59-4fc2-bd51-621a3d296944" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_b69e2c16-36ad-4db7-ade5-e8c57bfdaff3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e16c4385-2706-493b-ae6d-a4b0647eb747" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_b69e2c16-36ad-4db7-ade5-e8c57bfdaff3" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_752a9f02-c88f-49e6-aa5b-e4e644c72966" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e16c4385-2706-493b-ae6d-a4b0647eb747" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_752a9f02-c88f-49e6-aa5b-e4e644c72966" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_71a5ca6c-06d4-45e9-b0ae-239c379bc72c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e16c4385-2706-493b-ae6d-a4b0647eb747" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_71a5ca6c-06d4-45e9-b0ae-239c379bc72c" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_b0fbec80-4730-4fbf-ba96-672510093961" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e16c4385-2706-493b-ae6d-a4b0647eb747" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_b0fbec80-4730-4fbf-ba96-672510093961" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_42d3c094-3720-4d08-97f2-866eaf19f9cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_e16c4385-2706-493b-ae6d-a4b0647eb747" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_42d3c094-3720-4d08-97f2-866eaf19f9cc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e4a3e89c-4f2e-4f26-bbd1-5299fa803264" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_42d3c094-3720-4d08-97f2-866eaf19f9cc" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e4a3e89c-4f2e-4f26-bbd1-5299fa803264" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_e4a3e89c-4f2e-4f26-bbd1-5299fa803264_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e4a3e89c-4f2e-4f26-bbd1-5299fa803264" xlink:to="loc_us-gaap_RelatedPartyDomain_e4a3e89c-4f2e-4f26-bbd1-5299fa803264_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_187d771d-a83a-4055-b81d-8eaa488867f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e4a3e89c-4f2e-4f26-bbd1-5299fa803264" xlink:to="loc_us-gaap_RelatedPartyDomain_187d771d-a83a-4055-b81d-8eaa488867f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestorMember_e79c876c-e28b-442e-8fdc-3deae66230c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_187d771d-a83a-4055-b81d-8eaa488867f5" xlink:to="loc_us-gaap_InvestorMember_e79c876c-e28b-442e-8fdc-3deae66230c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_e8a06195-df62-481a-97e5-5affc59ee4c1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_42d3c094-3720-4d08-97f2-866eaf19f9cc" xlink:to="loc_dei_LegalEntityAxis_e8a06195-df62-481a-97e5-5affc59ee4c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e8a06195-df62-481a-97e5-5affc59ee4c1_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_e8a06195-df62-481a-97e5-5affc59ee4c1" xlink:to="loc_dei_EntityDomain_e8a06195-df62-481a-97e5-5affc59ee4c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_199df398-f691-4588-8029-88af4ce6ba04" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_e8a06195-df62-481a-97e5-5affc59ee4c1" xlink:to="loc_dei_EntityDomain_199df398-f691-4588-8029-88af4ce6ba04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PrivateGRIMember_ec0e24c9-1e20-44c3-8532-a5a02bd11a0b" xlink:href="ck0001824293-20230630.xsd#ck0001824293_PrivateGRIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_199df398-f691-4588-8029-88af4ce6ba04" xlink:to="loc_ck0001824293_PrivateGRIMember_ec0e24c9-1e20-44c3-8532-a5a02bd11a0b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_593736c3-406c-4805-853a-4efb5860fd36" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_42d3c094-3720-4d08-97f2-866eaf19f9cc" xlink:to="loc_srt_CounterpartyNameAxis_593736c3-406c-4805-853a-4efb5860fd36" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_593736c3-406c-4805-853a-4efb5860fd36_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_593736c3-406c-4805-853a-4efb5860fd36" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_593736c3-406c-4805-853a-4efb5860fd36_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8b124c87-6eb3-41d3-8705-2b6ed5147ed8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_593736c3-406c-4805-853a-4efb5860fd36" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8b124c87-6eb3-41d3-8705-2b6ed5147ed8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_GRIBioIncMember_04abe490-b469-4a82-bc49-aa9a0a4a91d4" xlink:href="ck0001824293-20230630.xsd#ck0001824293_GRIBioIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8b124c87-6eb3-41d3-8705-2b6ed5147ed8" xlink:to="loc_ck0001824293_GRIBioIncMember_04abe490-b469-4a82-bc49-aa9a0a4a91d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1578c88c-fd17-4796-a60d-219b0ae7f3a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_42d3c094-3720-4d08-97f2-866eaf19f9cc" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1578c88c-fd17-4796-a60d-219b0ae7f3a9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1578c88c-fd17-4796-a60d-219b0ae7f3a9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1578c88c-fd17-4796-a60d-219b0ae7f3a9" xlink:to="loc_us-gaap_EquityComponentDomain_1578c88c-fd17-4796-a60d-219b0ae7f3a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_55f62138-16cf-4099-90d9-f8040d9432bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1578c88c-fd17-4796-a60d-219b0ae7f3a9" xlink:to="loc_us-gaap_EquityComponentDomain_55f62138-16cf-4099-90d9-f8040d9432bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9bc8db19-2a01-4803-92bb-16d2f2f5e047" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_55f62138-16cf-4099-90d9-f8040d9432bb" xlink:to="loc_us-gaap_CommonStockMember_9bc8db19-2a01-4803-92bb-16d2f2f5e047" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_b0fd8993-561a-420f-acea-0e248d67cec5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_55f62138-16cf-4099-90d9-f8040d9432bb" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_b0fd8993-561a-420f-acea-0e248d67cec5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_aba0789e-ae35-4b44-8606-3364da358133" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_42d3c094-3720-4d08-97f2-866eaf19f9cc" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_aba0789e-ae35-4b44-8606-3364da358133" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_aba0789e-ae35-4b44-8606-3364da358133_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_aba0789e-ae35-4b44-8606-3364da358133" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_aba0789e-ae35-4b44-8606-3364da358133_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_9e10fd55-14b9-43a8-bbdc-3fdf741d0e29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_aba0789e-ae35-4b44-8606-3364da358133" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_9e10fd55-14b9-43a8-bbdc-3fdf741d0e29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PutOptionMember_44710eb1-79f0-4ba0-bf4e-d01c8d6f80aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PutOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_9e10fd55-14b9-43a8-bbdc-3fdf741d0e29" xlink:to="loc_us-gaap_PutOptionMember_44710eb1-79f0-4ba0-bf4e-d01c8d6f80aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_8b2277a4-a8c0-4abe-8d34-ef85c37ac208" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_42d3c094-3720-4d08-97f2-866eaf19f9cc" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_8b2277a4-a8c0-4abe-8d34-ef85c37ac208" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_8b2277a4-a8c0-4abe-8d34-ef85c37ac208_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_8b2277a4-a8c0-4abe-8d34-ef85c37ac208" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_8b2277a4-a8c0-4abe-8d34-ef85c37ac208_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_7814e58f-a425-4292-b7ca-709e20cdf913" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_8b2277a4-a8c0-4abe-8d34-ef85c37ac208" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_7814e58f-a425-4292-b7ca-709e20cdf913" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_EquityWarrantsMember_aedac41b-62e8-4b45-ade3-776e7b690150" xlink:href="ck0001824293-20230630.xsd#ck0001824293_EquityWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7814e58f-a425-4292-b7ca-709e20cdf913" xlink:to="loc_ck0001824293_EquityWarrantsMember_aedac41b-62e8-4b45-ade3-776e7b690150" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesA1WarrantsMember_7c830927-27b2-4a0a-baa3-3985200fed13" xlink:href="ck0001824293-20230630.xsd#ck0001824293_SeriesA1WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ck0001824293_EquityWarrantsMember_aedac41b-62e8-4b45-ade3-776e7b690150" xlink:to="loc_ck0001824293_SeriesA1WarrantsMember_7c830927-27b2-4a0a-baa3-3985200fed13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesA2WarrantsMember_ea6056cc-c1c8-4ad1-8a16-1f9a7c5d22cb" xlink:href="ck0001824293-20230630.xsd#ck0001824293_SeriesA2WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ck0001824293_EquityWarrantsMember_aedac41b-62e8-4b45-ade3-776e7b690150" xlink:to="loc_ck0001824293_SeriesA2WarrantsMember_ea6056cc-c1c8-4ad1-8a16-1f9a7c5d22cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesTWarrantsMember_a8035183-f4e6-409d-9ac0-f11e4930cfc7" xlink:href="ck0001824293-20230630.xsd#ck0001824293_SeriesTWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7814e58f-a425-4292-b7ca-709e20cdf913" xlink:to="loc_ck0001824293_SeriesTWarrantsMember_a8035183-f4e6-409d-9ac0-f11e4930cfc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_BridgeWarrantsMember_14c1e2b6-8c0a-4645-affa-40e33aa59fd2" xlink:href="ck0001824293-20230630.xsd#ck0001824293_BridgeWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7814e58f-a425-4292-b7ca-709e20cdf913" xlink:to="loc_ck0001824293_BridgeWarrantsMember_14c1e2b6-8c0a-4645-affa-40e33aa59fd2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_BankerWarrantsMember_76f3c348-14ab-4ca4-8382-c8d3ef7de23b" xlink:href="ck0001824293-20230630.xsd#ck0001824293_BankerWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7814e58f-a425-4292-b7ca-709e20cdf913" xlink:to="loc_ck0001824293_BankerWarrantsMember_76f3c348-14ab-4ca4-8382-c8d3ef7de23b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ExchangeWarrantsMember_db34d1e1-0905-4c05-914f-0699d30d7e49" xlink:href="ck0001824293-20230630.xsd#ck0001824293_ExchangeWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7814e58f-a425-4292-b7ca-709e20cdf913" xlink:to="loc_ck0001824293_ExchangeWarrantsMember_db34d1e1-0905-4c05-914f-0699d30d7e49" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_f78767cb-3554-4a40-badc-49ea3416de22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_a3f7244b-c6e0-4526-844a-9aa1770cc6e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f78767cb-3554-4a40-badc-49ea3416de22" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_a3f7244b-c6e0-4526-844a-9aa1770cc6e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_08d7d174-f818-4495-a515-bbd4c1f4bf78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_f78767cb-3554-4a40-badc-49ea3416de22" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_08d7d174-f818-4495-a515-bbd4c1f4bf78" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1bc42567-d2c6-413b-85b3-80839f4006f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_08d7d174-f818-4495-a515-bbd4c1f4bf78" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1bc42567-d2c6-413b-85b3-80839f4006f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1bc42567-d2c6-413b-85b3-80839f4006f9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1bc42567-d2c6-413b-85b3-80839f4006f9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1bc42567-d2c6-413b-85b3-80839f4006f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_54b7ce54-b6c5-407d-ad3b-737d2302cc18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1bc42567-d2c6-413b-85b3-80839f4006f9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_54b7ce54-b6c5-407d-ad3b-737d2302cc18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_EquityWarrantsExchangeWarrantsAndBankerWarrantsMember_925c2198-ad5e-40a9-931f-1db6011b4ba9" xlink:href="ck0001824293-20230630.xsd#ck0001824293_EquityWarrantsExchangeWarrantsAndBankerWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_54b7ce54-b6c5-407d-ad3b-737d2302cc18" xlink:to="loc_ck0001824293_EquityWarrantsExchangeWarrantsAndBankerWarrantsMember_925c2198-ad5e-40a9-931f-1db6011b4ba9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_4ffd7967-8309-40ab-a8ee-60440daa482e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_08d7d174-f818-4495-a515-bbd4c1f4bf78" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_4ffd7967-8309-40ab-a8ee-60440daa482e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_4ffd7967-8309-40ab-a8ee-60440daa482e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_4ffd7967-8309-40ab-a8ee-60440daa482e" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_4ffd7967-8309-40ab-a8ee-60440daa482e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_09f78a13-0aa6-4814-97e1-b1507f4e510f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_4ffd7967-8309-40ab-a8ee-60440daa482e" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_09f78a13-0aa6-4814-97e1-b1507f4e510f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_d52fd909-2dd4-48b9-a166-1d45c363ace8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_09f78a13-0aa6-4814-97e1-b1507f4e510f" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_d52fd909-2dd4-48b9-a166-1d45c363ace8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_97bf6755-a393-4783-a90e-e9cdd9e744be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_09f78a13-0aa6-4814-97e1-b1507f4e510f" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_97bf6755-a393-4783-a90e-e9cdd9e744be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_31037f18-296e-4723-942e-4a2789a3a71a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_09f78a13-0aa6-4814-97e1-b1507f4e510f" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_31037f18-296e-4723-942e-4a2789a3a71a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_40afae91-28e9-4d33-92d8-5d4c30032bad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_09f78a13-0aa6-4814-97e1-b1507f4e510f" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_40afae91-28e9-4d33-92d8-5d4c30032bad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_293040d6-746e-4944-9371-5cc4491e8849" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_08d7d174-f818-4495-a515-bbd4c1f4bf78" xlink:to="loc_srt_RangeAxis_293040d6-746e-4944-9371-5cc4491e8849" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_293040d6-746e-4944-9371-5cc4491e8849_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_293040d6-746e-4944-9371-5cc4491e8849" xlink:to="loc_srt_RangeMember_293040d6-746e-4944-9371-5cc4491e8849_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_62808ff2-a326-4619-92f0-b926ecb70bad" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_293040d6-746e-4944-9371-5cc4491e8849" xlink:to="loc_srt_RangeMember_62808ff2-a326-4619-92f0-b926ecb70bad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_c38a4cc1-403e-4ff1-acc5-8bd849e05ed1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_62808ff2-a326-4619-92f0-b926ecb70bad" xlink:to="loc_srt_WeightedAverageMember_c38a4cc1-403e-4ff1-acc5-8bd849e05ed1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_eb448efe-178a-4afd-bbe8-9b3b8117c662" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_2c23181b-574c-4bff-bdc2-db318ba37b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_eb448efe-178a-4afd-bbe8-9b3b8117c662" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_2c23181b-574c-4bff-bdc2-db318ba37b5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6663ec19-0344-49bb-b8ba-676d2ac193f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_eb448efe-178a-4afd-bbe8-9b3b8117c662" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6663ec19-0344-49bb-b8ba-676d2ac193f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ClassOfWarrantOrRightExpirationPeriod_c4d1e32a-c215-4d16-882e-07860c1b92c2" xlink:href="ck0001824293-20230630.xsd#ck0001824293_ClassOfWarrantOrRightExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_eb448efe-178a-4afd-bbe8-9b3b8117c662" xlink:to="loc_ck0001824293_ClassOfWarrantOrRightExpirationPeriod_c4d1e32a-c215-4d16-882e-07860c1b92c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_545ef646-79dd-43b5-b172-560874486ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_eb448efe-178a-4afd-bbe8-9b3b8117c662" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_545ef646-79dd-43b5-b172-560874486ccd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_ed2295d8-6604-4390-a94e-caa23139ab60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_545ef646-79dd-43b5-b172-560874486ccd" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_ed2295d8-6604-4390-a94e-caa23139ab60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_ed2295d8-6604-4390-a94e-caa23139ab60_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_ed2295d8-6604-4390-a94e-caa23139ab60" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_ed2295d8-6604-4390-a94e-caa23139ab60_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_8fc2ae7f-4068-4b7a-8f7a-008663415a24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_ed2295d8-6604-4390-a94e-caa23139ab60" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_8fc2ae7f-4068-4b7a-8f7a-008663415a24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInNovember2023Member_7fad6166-0b19-4f2e-8178-2caaee13ed2f" xlink:href="ck0001824293-20230630.xsd#ck0001824293_WarrantsExpiringInNovember2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8fc2ae7f-4068-4b7a-8f7a-008663415a24" xlink:to="loc_ck0001824293_WarrantsExpiringInNovember2023Member_7fad6166-0b19-4f2e-8178-2caaee13ed2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInDecember2023Member_f74ac5dc-c6a5-4334-83ea-84778124eb90" xlink:href="ck0001824293-20230630.xsd#ck0001824293_WarrantsExpiringInDecember2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8fc2ae7f-4068-4b7a-8f7a-008663415a24" xlink:to="loc_ck0001824293_WarrantsExpiringInDecember2023Member_f74ac5dc-c6a5-4334-83ea-84778124eb90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInJune2025Member_b5ebd0d8-0500-4814-ac01-a1ef13d27811" xlink:href="ck0001824293-20230630.xsd#ck0001824293_WarrantsExpiringInJune2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8fc2ae7f-4068-4b7a-8f7a-008663415a24" xlink:to="loc_ck0001824293_WarrantsExpiringInJune2025Member_b5ebd0d8-0500-4814-ac01-a1ef13d27811" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInFebruary2026Member_c47f0dfe-7f17-4914-9c6d-1c3ffd42969b" xlink:href="ck0001824293-20230630.xsd#ck0001824293_WarrantsExpiringInFebruary2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8fc2ae7f-4068-4b7a-8f7a-008663415a24" xlink:to="loc_ck0001824293_WarrantsExpiringInFebruary2026Member_c47f0dfe-7f17-4914-9c6d-1c3ffd42969b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInMay2027Member_b3dc4aca-fca1-4893-a8d5-ef3b8f81653a" xlink:href="ck0001824293-20230630.xsd#ck0001824293_WarrantsExpiringInMay2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8fc2ae7f-4068-4b7a-8f7a-008663415a24" xlink:to="loc_ck0001824293_WarrantsExpiringInMay2027Member_b3dc4aca-fca1-4893-a8d5-ef3b8f81653a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInJuly2027Member_2ec68bb9-95a9-4013-ab1e-5d2acb5bf276" xlink:href="ck0001824293-20230630.xsd#ck0001824293_WarrantsExpiringInJuly2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8fc2ae7f-4068-4b7a-8f7a-008663415a24" xlink:to="loc_ck0001824293_WarrantsExpiringInJuly2027Member_2ec68bb9-95a9-4013-ab1e-5d2acb5bf276" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInApril2028Member_e45a4b0c-7252-492e-817a-9222f828fda8" xlink:href="ck0001824293-20230630.xsd#ck0001824293_WarrantsExpiringInApril2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8fc2ae7f-4068-4b7a-8f7a-008663415a24" xlink:to="loc_ck0001824293_WarrantsExpiringInApril2028Member_e45a4b0c-7252-492e-817a-9222f828fda8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateOneMember_126cedcd-ece4-4399-84c1-2bb2b7fe7354" xlink:href="ck0001824293-20230630.xsd#ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8fc2ae7f-4068-4b7a-8f7a-008663415a24" xlink:to="loc_ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateOneMember_126cedcd-ece4-4399-84c1-2bb2b7fe7354" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateTwoMember_892d7360-d051-491c-8ddb-ec66012c1117" xlink:href="ck0001824293-20230630.xsd#ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8fc2ae7f-4068-4b7a-8f7a-008663415a24" xlink:to="loc_ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateTwoMember_892d7360-d051-491c-8ddb-ec66012c1117" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringIn24MonthsAfterRegistrationDateMember_cde8cb4b-a562-4c5f-a785-53b6b19cec02" xlink:href="ck0001824293-20230630.xsd#ck0001824293_WarrantsExpiringIn24MonthsAfterRegistrationDateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8fc2ae7f-4068-4b7a-8f7a-008663415a24" xlink:to="loc_ck0001824293_WarrantsExpiringIn24MonthsAfterRegistrationDateMember_cde8cb4b-a562-4c5f-a785-53b6b19cec02" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#STOCKBASEDCOMPENSATIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e8ededea-06a2-4608-b5a1-83ee4d849163" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_771bd6b8-70de-4799-a66f-522910d1eb03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e8ededea-06a2-4608-b5a1-83ee4d849163" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_771bd6b8-70de-4799-a66f-522910d1eb03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_d99cf6dc-6d19-49fb-b43d-35569b7faaca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e8ededea-06a2-4608-b5a1-83ee4d849163" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_d99cf6dc-6d19-49fb-b43d-35569b7faaca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_3ed7da2e-c860-4a9d-981d-df8f3f9f811a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e8ededea-06a2-4608-b5a1-83ee4d849163" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_3ed7da2e-c860-4a9d-981d-df8f3f9f811a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_bbd029af-03b6-4137-9745-b1988933b766" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e8ededea-06a2-4608-b5a1-83ee4d849163" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_bbd029af-03b6-4137-9745-b1988933b766" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c08ed77e-97c7-4a2e-866a-ca733a9a90f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e8ededea-06a2-4608-b5a1-83ee4d849163" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c08ed77e-97c7-4a2e-866a-ca733a9a90f9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_f78a4bd6-28ef-404e-8568-2858551dadb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e8ededea-06a2-4608-b5a1-83ee4d849163" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_f78a4bd6-28ef-404e-8568-2858551dadb9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_396154b7-d75e-48ee-bbef-33818af36044" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e8ededea-06a2-4608-b5a1-83ee4d849163" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_396154b7-d75e-48ee-bbef-33818af36044" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8b6d2491-0b51-43a5-9186-3e2ee22d6306" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e8ededea-06a2-4608-b5a1-83ee4d849163" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8b6d2491-0b51-43a5-9186-3e2ee22d6306" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_7a581c1f-304d-4ead-a7a5-b004588a06f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8b6d2491-0b51-43a5-9186-3e2ee22d6306" xlink:to="loc_us-gaap_PlanNameAxis_7a581c1f-304d-4ead-a7a5-b004588a06f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_7a581c1f-304d-4ead-a7a5-b004588a06f7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_7a581c1f-304d-4ead-a7a5-b004588a06f7" xlink:to="loc_us-gaap_PlanNameDomain_7a581c1f-304d-4ead-a7a5-b004588a06f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_b8a78a2a-d955-4d26-8c39-cad794d6b7bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_7a581c1f-304d-4ead-a7a5-b004588a06f7" xlink:to="loc_us-gaap_PlanNameDomain_b8a78a2a-d955-4d26-8c39-cad794d6b7bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PrivateGRIPlanMember_f4460526-3890-41b2-a52d-a61fe0709889" xlink:href="ck0001824293-20230630.xsd#ck0001824293_PrivateGRIPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_b8a78a2a-d955-4d26-8c39-cad794d6b7bc" xlink:to="loc_ck0001824293_PrivateGRIPlanMember_f4460526-3890-41b2-a52d-a61fe0709889" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember_72c2931a-0ba5-4a49-b0dd-441351f7c76b" xlink:href="ck0001824293-20230630.xsd#ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_b8a78a2a-d955-4d26-8c39-cad794d6b7bc" xlink:to="loc_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember_72c2931a-0ba5-4a49-b0dd-441351f7c76b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_A2018EquityIncentivePlanMember_9f2747d0-4a22-4989-ab0c-73a48266528d" xlink:href="ck0001824293-20230630.xsd#ck0001824293_A2018EquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_b8a78a2a-d955-4d26-8c39-cad794d6b7bc" xlink:to="loc_ck0001824293_A2018EquityIncentivePlanMember_9f2747d0-4a22-4989-ab0c-73a48266528d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_75227934-9c31-4ca5-9cdb-5a1b4a110a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8b6d2491-0b51-43a5-9186-3e2ee22d6306" xlink:to="loc_us-gaap_AwardTypeAxis_75227934-9c31-4ca5-9cdb-5a1b4a110a5a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_75227934-9c31-4ca5-9cdb-5a1b4a110a5a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_75227934-9c31-4ca5-9cdb-5a1b4a110a5a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_75227934-9c31-4ca5-9cdb-5a1b4a110a5a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9478b101-88e8-4f46-b4f4-4cebe4507931" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_75227934-9c31-4ca5-9cdb-5a1b4a110a5a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9478b101-88e8-4f46-b4f4-4cebe4507931" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f20e074d-58fe-4ca1-b16e-aed7ff92c03d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9478b101-88e8-4f46-b4f4-4cebe4507931" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f20e074d-58fe-4ca1-b16e-aed7ff92c03d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5a5d3116-a542-4285-9af0-98b5b52e3e57" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8b6d2491-0b51-43a5-9186-3e2ee22d6306" xlink:to="loc_srt_RangeAxis_5a5d3116-a542-4285-9af0-98b5b52e3e57" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5a5d3116-a542-4285-9af0-98b5b52e3e57_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5a5d3116-a542-4285-9af0-98b5b52e3e57" xlink:to="loc_srt_RangeMember_5a5d3116-a542-4285-9af0-98b5b52e3e57_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9379951b-1365-48a2-b86b-19843933a23c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5a5d3116-a542-4285-9af0-98b5b52e3e57" xlink:to="loc_srt_RangeMember_9379951b-1365-48a2-b86b-19843933a23c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_152ba797-7fd6-40cb-b929-696591666733" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9379951b-1365-48a2-b86b-19843933a23c" xlink:to="loc_srt_MaximumMember_152ba797-7fd6-40cb-b929-696591666733" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d1b69135-a7e9-43d7-a1dc-c03925a80e75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3fea8e52-bc7b-40d7-8792-e6b9aea2695b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d1b69135-a7e9-43d7-a1dc-c03925a80e75" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_3fea8e52-bc7b-40d7-8792-e6b9aea2695b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0ad823ba-8459-416a-81d6-d4e4f6bf2c37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d1b69135-a7e9-43d7-a1dc-c03925a80e75" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0ad823ba-8459-416a-81d6-d4e4f6bf2c37" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_39da766b-9501-49ce-814b-7c5b8a52f782" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0ad823ba-8459-416a-81d6-d4e4f6bf2c37" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_39da766b-9501-49ce-814b-7c5b8a52f782" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_39da766b-9501-49ce-814b-7c5b8a52f782_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_39da766b-9501-49ce-814b-7c5b8a52f782" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_39da766b-9501-49ce-814b-7c5b8a52f782_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_35768666-310e-4b8e-8429-923e285b9043" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_39da766b-9501-49ce-814b-7c5b8a52f782" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_35768666-310e-4b8e-8429-923e285b9043" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4a652576-6b39-4f22-83ab-73a1e8c751ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_35768666-310e-4b8e-8429-923e285b9043" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4a652576-6b39-4f22-83ab-73a1e8c751ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1a2eabc7-fa3a-4436-8ecb-90f064727064" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_35768666-310e-4b8e-8429-923e285b9043" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1a2eabc7-fa3a-4436-8ecb-90f064727064" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0dcd956d-3d13-4d5d-bbfe-040b2fcf5462" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7ef47a86-ff35-45a0-890d-6708631173b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0dcd956d-3d13-4d5d-bbfe-040b2fcf5462" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7ef47a86-ff35-45a0-890d-6708631173b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_5089bc03-7eab-408b-af54-0f5be236b17e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0dcd956d-3d13-4d5d-bbfe-040b2fcf5462" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_5089bc03-7eab-408b-af54-0f5be236b17e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3629e965-8525-4464-a770-cdc7590bb8cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0dcd956d-3d13-4d5d-bbfe-040b2fcf5462" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3629e965-8525-4464-a770-cdc7590bb8cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_a1602c34-1f2c-4c6f-8ae3-9fcbf16c9e28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0dcd956d-3d13-4d5d-bbfe-040b2fcf5462" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_a1602c34-1f2c-4c6f-8ae3-9fcbf16c9e28" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_a2084c9b-def6-4607-aef3-2e932178dad3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0dcd956d-3d13-4d5d-bbfe-040b2fcf5462" xlink:to="loc_us-gaap_SharePrice_a2084c9b-def6-4607-aef3-2e932178dad3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e517b0d6-07df-4925-87f2-246cd2a7923e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0dcd956d-3d13-4d5d-bbfe-040b2fcf5462" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e517b0d6-07df-4925-87f2-246cd2a7923e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0fd73c3a-fe62-405d-b6b0-392a9ec4f12a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e517b0d6-07df-4925-87f2-246cd2a7923e" xlink:to="loc_us-gaap_AwardTypeAxis_0fd73c3a-fe62-405d-b6b0-392a9ec4f12a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0fd73c3a-fe62-405d-b6b0-392a9ec4f12a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0fd73c3a-fe62-405d-b6b0-392a9ec4f12a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0fd73c3a-fe62-405d-b6b0-392a9ec4f12a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d51a195d-859a-48e1-b3f4-c6fa2bdb43b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0fd73c3a-fe62-405d-b6b0-392a9ec4f12a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d51a195d-859a-48e1-b3f4-c6fa2bdb43b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2ada04c6-9454-4743-bebe-2f61b3c8c5c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d51a195d-859a-48e1-b3f4-c6fa2bdb43b0" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2ada04c6-9454-4743-bebe-2f61b3c8c5c3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_bfe76ad1-689e-46cb-8ab9-e1a5ea7dc446" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_COBRABenefitsPaymentPeriod_bd2f15d2-8615-4c99-b9bd-13d0aec88f22" xlink:href="ck0001824293-20230630.xsd#ck0001824293_COBRABenefitsPaymentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_bfe76ad1-689e-46cb-8ab9-e1a5ea7dc446" xlink:to="loc_ck0001824293_COBRABenefitsPaymentPeriod_bd2f15d2-8615-4c99-b9bd-13d0aec88f22" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PercentageOfTargetBonus_9c8816b2-b54b-46b4-8c1b-14398e8ccdba" xlink:href="ck0001824293-20230630.xsd#ck0001824293_PercentageOfTargetBonus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_bfe76ad1-689e-46cb-8ab9-e1a5ea7dc446" xlink:to="loc_ck0001824293_PercentageOfTargetBonus_9c8816b2-b54b-46b4-8c1b-14398e8ccdba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_4f90d5f3-5fec-486c-bd97-26ddfe738aec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_bfe76ad1-689e-46cb-8ab9-e1a5ea7dc446" xlink:to="loc_us-gaap_LossContingenciesTable_4f90d5f3-5fec-486c-bd97-26ddfe738aec" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_cd58b33a-b8f6-4917-a5f2-53e1fa17439e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_4f90d5f3-5fec-486c-bd97-26ddfe738aec" xlink:to="loc_srt_TitleOfIndividualAxis_cd58b33a-b8f6-4917-a5f2-53e1fa17439e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_cd58b33a-b8f6-4917-a5f2-53e1fa17439e_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_cd58b33a-b8f6-4917-a5f2-53e1fa17439e" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_cd58b33a-b8f6-4917-a5f2-53e1fa17439e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_bed2bf16-fb3e-4f35-9d15-e351a941a543" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_cd58b33a-b8f6-4917-a5f2-53e1fa17439e" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_bed2bf16-fb3e-4f35-9d15-e351a941a543" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_FormerChiefExecutiveOfficerMember_612f9f79-4dd2-40eb-ba0e-6376842043db" xlink:href="ck0001824293-20230630.xsd#ck0001824293_FormerChiefExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_bed2bf16-fb3e-4f35-9d15-e351a941a543" xlink:to="loc_ck0001824293_FormerChiefExecutiveOfficerMember_612f9f79-4dd2-40eb-ba0e-6376842043db" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>ck0001824293-20230630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:03e6aede-a80d-4c93-aec7-6df3e5ac1c16,g:d01e6060-7205-4c9b-8c6f-b994c931683b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_11fc2793-1d8f-4b96-b2e1-dde9ce7e7f7a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in operating right of use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses_553fe04a-e214-4b03-83aa-a968096878ab_terseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for reverse recapitalization expenses</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses_label_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Reverse Recapitalization Expenses</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Reverse Recapitalization Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses" xlink:href="ck0001824293-20230630.xsd#ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses" xlink:to="lab_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_d12599b6-170d-4123-9346-ef62159d4495_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing_095326ad-1e95-4b8f-8c6f-db36b3587554_terseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in pre-closing financing (in shares)</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing_label_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Pre-closing Financing</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Pre-closing Financing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing" xlink:href="ck0001824293-20230630.xsd#ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing" xlink:to="lab_ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredChargesPolicyTextBlock_aa1ab785-41e0-4527-ac76-1eafed2b17f6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Stock Issuance Costs</link:label>
    <link:label id="lab_us-gaap_DeferredChargesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Charges, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredChargesPolicyTextBlock" xlink:to="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_bd6a9e59-9235-477d-a671-04ce6d495ce8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_d28070fa-1ef8-4d9e-a623-ca9c0aa5c973_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_518630d3-ebdb-40e3-9116-3dff5697aefa_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_b02ea102-a5a1-4d3c-a8ef-fc54f8d524b9_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_17de46e9-2a49-4915-9f92-17e9eb74a60d_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_TEPNoteMember_a1be34be-34ea-427d-915b-ae891d89c40e_terseLabel_en-US" xlink:label="lab_ck0001824293_TEPNoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TEP Note</link:label>
    <link:label id="lab_ck0001824293_TEPNoteMember_label_en-US" xlink:label="lab_ck0001824293_TEPNoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TEP Note [Member]</link:label>
    <link:label id="lab_ck0001824293_TEPNoteMember_documentation_en-US" xlink:label="lab_ck0001824293_TEPNoteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TEP Note</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_TEPNoteMember" xlink:href="ck0001824293-20230630.xsd#ck0001824293_TEPNoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_TEPNoteMember" xlink:to="lab_ck0001824293_TEPNoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_65f7a4de-2ce5-4ae6-83f5-fde03763d211_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPayableCurrentAndNoncurrent_b480556a-041e-42e1-bd2e-6c15ad8546e4_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a6acf5c0-6bc2-4a2d-b55e-afb3c4723433_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_ec1f7834-3429-4cd0-bc0c-b6cf62ab6cd3_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_0450214a-e69e-4ced-b5f3-fdca6cec061a_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock awards, contractual life (up to)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_2f287e17-1416-49df-91c3-1c87fd8a6812_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringInMay2027Member_ea898a11-f5c9-411e-b41a-d7f4ac275c09_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInMay2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring In May 2027</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInMay2027Member_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInMay2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring In May 2027 [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInMay2027Member_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInMay2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring In May 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInMay2027Member" xlink:href="ck0001824293-20230630.xsd#ck0001824293_WarrantsExpiringInMay2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringInMay2027Member" xlink:to="lab_ck0001824293_WarrantsExpiringInMay2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_e9b82709-dd6e-48db-88e7-1d779a4db6e5_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash financing activities:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_eea5ab2e-c740-40e6-966d-e5e7588cfded_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Award Types</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_056dfc6b-ff8e-4a81-889e-cd9dfd5c8045_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PROMISSORY NOTES</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_e7cc5cff-a4af-471f-8381-db16eb5340c7_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_ChangeInFairValueOfWarrantLiability_7e553f24-14b9-4274-a21c-2363779fb40a_terseLabel_en-US" xlink:label="lab_ck0001824293_ChangeInFairValueOfWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of warrant liability</link:label>
    <link:label id="lab_ck0001824293_ChangeInFairValueOfWarrantLiability_label_en-US" xlink:label="lab_ck0001824293_ChangeInFairValueOfWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Fair Value Of Warrant Liability</link:label>
    <link:label id="lab_ck0001824293_ChangeInFairValueOfWarrantLiability_documentation_en-US" xlink:label="lab_ck0001824293_ChangeInFairValueOfWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Fair Value Of Warrant Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ChangeInFairValueOfWarrantLiability" xlink:href="ck0001824293-20230630.xsd#ck0001824293_ChangeInFairValueOfWarrantLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_ChangeInFairValueOfWarrantLiability" xlink:to="lab_ck0001824293_ChangeInFairValueOfWarrantLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_DebtInstrumentNumberOfClosings_8c087fe6-f32c-4abd-8c52-e00b00b0ad7b_terseLabel_en-US" xlink:label="lab_ck0001824293_DebtInstrumentNumberOfClosings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of closings</link:label>
    <link:label id="lab_ck0001824293_DebtInstrumentNumberOfClosings_label_en-US" xlink:label="lab_ck0001824293_DebtInstrumentNumberOfClosings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Number Of Closings</link:label>
    <link:label id="lab_ck0001824293_DebtInstrumentNumberOfClosings_documentation_en-US" xlink:label="lab_ck0001824293_DebtInstrumentNumberOfClosings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Number Of Closings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtInstrumentNumberOfClosings" xlink:href="ck0001824293-20230630.xsd#ck0001824293_DebtInstrumentNumberOfClosings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_DebtInstrumentNumberOfClosings" xlink:to="lab_ck0001824293_DebtInstrumentNumberOfClosings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_26b883d2-fe82-4ed6-92f7-47d7da545eb8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_735c8594-d018-4c6e-a15a-106e7902dc3f_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_CommonStockHeldIntoEscrowAccount_382579b9-a5c0-474f-bb70-21265e2eb511_terseLabel_en-US" xlink:label="lab_ck0001824293_CommonStockHeldIntoEscrowAccount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock placed into escrow (in shares)</link:label>
    <link:label id="lab_ck0001824293_CommonStockHeldIntoEscrowAccount_label_en-US" xlink:label="lab_ck0001824293_CommonStockHeldIntoEscrowAccount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Held Into Escrow Account</link:label>
    <link:label id="lab_ck0001824293_CommonStockHeldIntoEscrowAccount_documentation_en-US" xlink:label="lab_ck0001824293_CommonStockHeldIntoEscrowAccount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Held Into Escrow Account</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_CommonStockHeldIntoEscrowAccount" xlink:href="ck0001824293-20230630.xsd#ck0001824293_CommonStockHeldIntoEscrowAccount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_CommonStockHeldIntoEscrowAccount" xlink:to="lab_ck0001824293_CommonStockHeldIntoEscrowAccount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_636bbac7-e1ca-4f90-b93f-e77b75b4f576_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_31c404dc-8b7e-4c55-a6a7-157455cbf8bf_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchased during period, shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_PaymentOfReverseRecapitalizationCosts_b5a2d888-111f-4bc1-abcd-f5635488096c_negatedTerseLabel_en-US" xlink:label="lab_ck0001824293_PaymentOfReverseRecapitalizationCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of reverse recapitalization costs</link:label>
    <link:label id="lab_ck0001824293_PaymentOfReverseRecapitalizationCosts_label_en-US" xlink:label="lab_ck0001824293_PaymentOfReverseRecapitalizationCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Of Reverse Recapitalization Costs</link:label>
    <link:label id="lab_ck0001824293_PaymentOfReverseRecapitalizationCosts_documentation_en-US" xlink:label="lab_ck0001824293_PaymentOfReverseRecapitalizationCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Of Reverse Recapitalization Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PaymentOfReverseRecapitalizationCosts" xlink:href="ck0001824293-20230630.xsd#ck0001824293_PaymentOfReverseRecapitalizationCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_PaymentOfReverseRecapitalizationCosts" xlink:to="lab_ck0001824293_PaymentOfReverseRecapitalizationCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringInJune2025Member_9d36553f-bd6f-44bf-bade-1806cdd3c0ad_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInJune2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring In June 2025</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInJune2025Member_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInJune2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring In June 2025 [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInJune2025Member_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInJune2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring In June 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInJune2025Member" xlink:href="ck0001824293-20230630.xsd#ck0001824293_WarrantsExpiringInJune2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringInJune2025Member" xlink:to="lab_ck0001824293_WarrantsExpiringInJune2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_080e5f56-6636-4e4b-8941-97b7556747e4_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_e7bbc270-af8a-48b1-9e8b-053667c3b610_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_7bb4d5de-f47e-4102-aead-2e0a284067af_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_aca37e5f-b2f2-4ac8-8ac1-13edf9aa2d91_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_a6fb0400-fff1-4b4a-8ccc-8798cb7a27be_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value as of December 31, 2022</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_8a5b0c56-07fb-4237-b6e4-efd11ca56e2b_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value as of June&#160;30, 2023</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_d1cf70b1-12bd-48a8-a183-f29c4350888d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Discounts and Debt Issuance Costs</link:label>
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtPolicyTextBlock" xlink:to="lab_us-gaap_DebtPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_cb36de4d-04fc-47e9-9a37-990437f5c0a0_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_48be364b-fa9e-4ee1-83c7-ecee905fde72_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt_e6ad32b4-0a57-4371-9fad-c36ea833a60c_terseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for settlement of bridge note (in shares)</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt_label_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Settlement Of Debt</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Settlement Of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt" xlink:href="ck0001824293-20230630.xsd#ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt" xlink:to="lab_ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_47845de7-466e-41e1-a99d-09bd072176ec_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 11)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_0dd3e3ab-0d49-43f9-bd5e-8ce3a4ffffcf_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_6b923ff5-4eed-4bd2-9c3b-6bd7bff3999a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_CommonStockExchangeRatio_847bced9-99b0-4de6-bd35-2fd804cabf31_terseLabel_en-US" xlink:label="lab_ck0001824293_CommonStockExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, exchange ratio</link:label>
    <link:label id="lab_ck0001824293_CommonStockExchangeRatio_label_en-US" xlink:label="lab_ck0001824293_CommonStockExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Exchange Ratio</link:label>
    <link:label id="lab_ck0001824293_CommonStockExchangeRatio_documentation_en-US" xlink:label="lab_ck0001824293_CommonStockExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Exchange Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_CommonStockExchangeRatio" xlink:href="ck0001824293-20230630.xsd#ck0001824293_CommonStockExchangeRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_CommonStockExchangeRatio" xlink:to="lab_ck0001824293_CommonStockExchangeRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2a9b889e-2f18-48cb-b9b6-c5c6e044c929_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_8c1fd2a6-6fb7-4012-953f-745189605936_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuedForRepaymentOfNotesPayable_b7d595db-e7ae-4e5b-81f4-fe6b0ed664c9_terseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuedForRepaymentOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock for repayment of bridge promissory note</link:label>
    <link:label id="lab_ck0001824293_StockIssuedForRepaymentOfNotesPayable_label_en-US" xlink:label="lab_ck0001824293_StockIssuedForRepaymentOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued For Repayment Of Notes Payable</link:label>
    <link:label id="lab_ck0001824293_StockIssuedForRepaymentOfNotesPayable_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuedForRepaymentOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued For Repayment Of Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedForRepaymentOfNotesPayable" xlink:href="ck0001824293-20230630.xsd#ck0001824293_StockIssuedForRepaymentOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuedForRepaymentOfNotesPayable" xlink:to="lab_ck0001824293_StockIssuedForRepaymentOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_8949762a-3c4e-445a-8d95-4ef415a97702_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock in pre-closing financing</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_d42ee3c6-ee4b-49c0-b4bc-2ac1e5d3484e_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_EquityWarrantsMember_505fc1ee-e4e8-4656-9335-ef01762a5133_terseLabel_en-US" xlink:label="lab_ck0001824293_EquityWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Warrants</link:label>
    <link:label id="lab_ck0001824293_EquityWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_EquityWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_EquityWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_EquityWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_EquityWarrantsMember" xlink:href="ck0001824293-20230630.xsd#ck0001824293_EquityWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_EquityWarrantsMember" xlink:to="lab_ck0001824293_EquityWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValueWarrantExercises_c8b8dca8-5368-48bc-9f80-bbefcc2c2533_terseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValueWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant exercise</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValueWarrantExercises_label_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValueWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Warrant Exercises</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValueWarrantExercises_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValueWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValueWarrantExercises" xlink:href="ck0001824293-20230630.xsd#ck0001824293_StockIssuedDuringPeriodValueWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuedDuringPeriodValueWarrantExercises" xlink:to="lab_ck0001824293_StockIssuedDuringPeriodValueWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ccf0ba0c-c687-4744-aff1-e99cba7f9b9d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_15bd4dc7-72ce-4546-8208-3513c24189b5_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of warrant liability</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_e1d521a9-d3cd-43d8-9d9d-3dd78b3871ca_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock vesting</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_cf9fd056-b84c-48ce-8b2b-07e0b47a713f_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ORGANIZATION AND DESCRIPTION OF BUSINESS</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_DebtConversionConvertedInstrumentPrincipalAmountOfDebt_80768780-6c92-4e06-b603-8e8290c0b46c_terseLabel_en-US" xlink:label="lab_ck0001824293_DebtConversionConvertedInstrumentPrincipalAmountOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount of debt to be converted</link:label>
    <link:label id="lab_ck0001824293_DebtConversionConvertedInstrumentPrincipalAmountOfDebt_label_en-US" xlink:label="lab_ck0001824293_DebtConversionConvertedInstrumentPrincipalAmountOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Principal Amount Of Debt</link:label>
    <link:label id="lab_ck0001824293_DebtConversionConvertedInstrumentPrincipalAmountOfDebt_documentation_en-US" xlink:label="lab_ck0001824293_DebtConversionConvertedInstrumentPrincipalAmountOfDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Principal Amount Of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtConversionConvertedInstrumentPrincipalAmountOfDebt" xlink:href="ck0001824293-20230630.xsd#ck0001824293_DebtConversionConvertedInstrumentPrincipalAmountOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_DebtConversionConvertedInstrumentPrincipalAmountOfDebt" xlink:to="lab_ck0001824293_DebtConversionConvertedInstrumentPrincipalAmountOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_98973e0e-f7ca-4c6c-92b3-e796ee366571_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_5776d454-7afa-40aa-ad1b-96940d59173e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible notes interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_2f2919a6-8f61-4407-bc86-d4bcbe638195_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_6ddcf697-9b5d-46c6-b9d1-1b49779d43ef_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from warrant exercise</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_6aeff1f7-fd77-44bd-87c2-b670707a4a66_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity (deficit)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_a557fcb2-e17e-4ec9-b3ca-2fe404b40c7e_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_443c467f-4f8a-4ca3-8a68-f3aa5523b58c_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_605c3540-ad83-4853-985a-9593b731de86_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockSubjectToPutRightMember_7353f6b4-26bf-43b6-b0d3-25829a49f4d6_terseLabel_en-US" xlink:label="lab_ck0001824293_StockSubjectToPutRightMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock subject to put right</link:label>
    <link:label id="lab_ck0001824293_StockSubjectToPutRightMember_label_en-US" xlink:label="lab_ck0001824293_StockSubjectToPutRightMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Subject To Put Right [Member]</link:label>
    <link:label id="lab_ck0001824293_StockSubjectToPutRightMember_documentation_en-US" xlink:label="lab_ck0001824293_StockSubjectToPutRightMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Subject To Put Right</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockSubjectToPutRightMember" xlink:href="ck0001824293-20230630.xsd#ck0001824293_StockSubjectToPutRightMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockSubjectToPutRightMember" xlink:to="lab_ck0001824293_StockSubjectToPutRightMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization_478b5b21-3d55-40db-a005-fe3e9e91b603_negatedLabel_en-US" xlink:label="lab_ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net liabilities assumed in connection with reverse recapitalization</link:label>
    <link:label id="lab_ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization_label_en-US" xlink:label="lab_ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Liabilities Assumed In Connection With Reverse Recapitalization</link:label>
    <link:label id="lab_ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization_documentation_en-US" xlink:label="lab_ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Liabilities Assumed In Connection With Reverse Recapitalization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization" xlink:href="ck0001824293-20230630.xsd#ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization" xlink:to="lab_ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6ee2c6cb-ff8b-4d58-962b-cdcbb7dc222f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_b60c77d6-9c6a-4693-b0ae-b04a66528fbd_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share of common stock, diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_3c8610ec-fdb3-4eeb-b348-2d89e7061269_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock with repurchase rights</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dab71422-9543-41b5-91a1-31cd519d76db_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing_7a09f481-1eca-4129-84da-54591cdd5157_terseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in pre-closing financing</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing_label_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Pre-closing Financing</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Pre-closing Financing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing" xlink:href="ck0001824293-20230630.xsd#ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing" xlink:to="lab_ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9d53e42d-c6f1-4898-a03d-dd8054844d2f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_3d5a837c-8911-4f14-a9e5-4b74a7ceccf8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of the Fair Value of the Warrants</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableMember_8ccac639-0fa7-4286-a30c-2e349829fdb3_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable</link:label>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleNotesPayableMember" xlink:to="lab_us-gaap_ConvertibleNotesPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_e37feda9-7dd1-42a7-b378-c9d81f6491da_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_DebtConversionConvertedInstrumentAmountOfInterest_554d3d30-0c1b-4fdf-a2aa-0e5e13b41c6b_terseLabel_en-US" xlink:label="lab_ck0001824293_DebtConversionConvertedInstrumentAmountOfInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of accrued interest to be converted</link:label>
    <link:label id="lab_ck0001824293_DebtConversionConvertedInstrumentAmountOfInterest_label_en-US" xlink:label="lab_ck0001824293_DebtConversionConvertedInstrumentAmountOfInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount Of Interest</link:label>
    <link:label id="lab_ck0001824293_DebtConversionConvertedInstrumentAmountOfInterest_documentation_en-US" xlink:label="lab_ck0001824293_DebtConversionConvertedInstrumentAmountOfInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount Of Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtConversionConvertedInstrumentAmountOfInterest" xlink:href="ck0001824293-20230630.xsd#ck0001824293_DebtConversionConvertedInstrumentAmountOfInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_DebtConversionConvertedInstrumentAmountOfInterest" xlink:to="lab_ck0001824293_DebtConversionConvertedInstrumentAmountOfInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_cbb4fca4-74e3-45c0-a822-98d9114ee48f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_88f58624-d8df-4aec-abda-320cb21a3087_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentCompanyCommittedCapital_7ff991da-a700-413b-bf03-c2932a69df9e_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentCompanyCommittedCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in cash</link:label>
    <link:label id="lab_us-gaap_InvestmentCompanyCommittedCapital_label_en-US" xlink:label="lab_us-gaap_InvestmentCompanyCommittedCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Company, Committed Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentCompanyCommittedCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentCompanyCommittedCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentCompanyCommittedCapital" xlink:to="lab_us-gaap_InvestmentCompanyCommittedCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d9cf6fab-2ef1-471b-b6b5-c7c9a6e49ea0_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ba406c76-8406-46d0-b234-ca8e5bd64894_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_1c91ed98-655e-4cfd-9021-d2edd802906d_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, measurement input</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_bca9575f-49e6-4a64-95e5-7129087d5e67_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_e97dee00-8b19-416c-8260-04e7d85e5d85_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3592500a-ac25-40ea-8bd6-198058a61cea_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_330bbfc5-93a9-4696-83de-f4f11fa3d5e4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringInApril2028Member_70afe5e1-a8db-42cf-84ab-3245d2d5c5c7_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInApril2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring In April 2028</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInApril2028Member_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInApril2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring In April 2028 [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInApril2028Member_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInApril2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring In April 2028</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInApril2028Member" xlink:href="ck0001824293-20230630.xsd#ck0001824293_WarrantsExpiringInApril2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringInApril2028Member" xlink:to="lab_ck0001824293_WarrantsExpiringInApril2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_1bcf93d1-74fd-4d7e-8747-8a6980ae2358_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_RepaymentOfAdvancesFromEmployees_dfbfeb52-4717-4803-800a-d7561ddb3f25_negatedTerseLabel_en-US" xlink:label="lab_ck0001824293_RepaymentOfAdvancesFromEmployees" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of advances from employees</link:label>
    <link:label id="lab_ck0001824293_RepaymentOfAdvancesFromEmployees_label_en-US" xlink:label="lab_ck0001824293_RepaymentOfAdvancesFromEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment Of Advances From Employees</link:label>
    <link:label id="lab_ck0001824293_RepaymentOfAdvancesFromEmployees_documentation_en-US" xlink:label="lab_ck0001824293_RepaymentOfAdvancesFromEmployees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment Of Advances From Employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_RepaymentOfAdvancesFromEmployees" xlink:href="ck0001824293-20230630.xsd#ck0001824293_RepaymentOfAdvancesFromEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_RepaymentOfAdvancesFromEmployees" xlink:to="lab_ck0001824293_RepaymentOfAdvancesFromEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_a0bda276-a515-4871-a870-7635d4827b84_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_ec78771e-cbc4-47b8-9393-b6db9063f1b8_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_e0a92bac-e4b6-4511-851b-d222c6ccf8d8_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_232876e8-91c0-411d-8f02-2dedb4983c7c_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_703d8a23-7f9d-40fe-8fa8-f285d10c55ba_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PutOptionMember_30425289-abab-4762-99e4-c554f3695d55_terseLabel_en-US" xlink:label="lab_us-gaap_PutOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Put Option</link:label>
    <link:label id="lab_us-gaap_PutOptionMember_label_en-US" xlink:label="lab_us-gaap_PutOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Put Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PutOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PutOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PutOptionMember" xlink:to="lab_us-gaap_PutOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_BridgeSecuritiesPurchaseAgreementMember_52e6cec2-6e3e-495e-8f70-475842e3e1ca_terseLabel_en-US" xlink:label="lab_ck0001824293_BridgeSecuritiesPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridge SPA</link:label>
    <link:label id="lab_ck0001824293_BridgeSecuritiesPurchaseAgreementMember_label_en-US" xlink:label="lab_ck0001824293_BridgeSecuritiesPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridge Securities Purchase Agreement [Member]</link:label>
    <link:label id="lab_ck0001824293_BridgeSecuritiesPurchaseAgreementMember_documentation_en-US" xlink:label="lab_ck0001824293_BridgeSecuritiesPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridge Securities Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_BridgeSecuritiesPurchaseAgreementMember" xlink:href="ck0001824293-20230630.xsd#ck0001824293_BridgeSecuritiesPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_BridgeSecuritiesPurchaseAgreementMember" xlink:to="lab_ck0001824293_BridgeSecuritiesPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_aceda06b-8269-4303-a9a2-4ae84ffdcea2_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders' equity (deficit)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_4d41e7e5-ad9b-4f7e-bdcf-d1a465b7e477_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_8bac0974-2686-4fcf-954c-2e86fd752733_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchased during period, value</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_0dc6f841-c029-4561-ab87-b98157e439a3_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total net liabilities assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a2fd077-38ea-44cd-ae86-649d8267e401_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_f9d321ee-b07d-44d9-9c41-34f4091ceaea_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity (deficit):</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b72571d7-ad18-47e4-a87e-ae6b1125dd76_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_1054a4b0-28ea-4078-913f-8432f27b1d56_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_552a66b4-87f6-4b70-b22a-24628e72dcb6_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2352253f-d01e-4d99-ba41-81b769b04a89_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Beginning Balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1507e864-224c-4093-9de7-68221d0be019_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Ending Balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityEquityAxis_7c57d905-9b02-4b38-bf17-8946feb84d49_terseLabel_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Indexed to Issuer's Equity [Axis]</link:label>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityEquityAxis_label_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Indexed to Issuer's Equity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_ddc936da-925a-4727-87ac-da1e6da53b55_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_WeightedAverageMember_ea85d19a-4df3-4864-bd5d-ac3476b8aa8b_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average</link:label>
    <link:label id="lab_srt_WeightedAverageMember_label_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_WeightedAverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_446363a1-6b93-4a67-b0e8-e7ae2d5c8ef6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common&#160;Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_beac4d6e-3a6c-49a8-a8e3-c749952bdc99_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_16e798f3-9436-40bd-97f8-4fbc5616c34b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Prices in Active Markets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_46d3444c-bfdd-41eb-8730-47881098d6da_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_cf3c41bf-2a17-47bc-8580-a70936095099_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization_39590b86-b494-4c23-992b-f6aded78c5df_terseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock to Vallon stockholders in reverse recapitalization (in shares)</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization_label_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Reverse Recapitalization</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Reverse Recapitalization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization" xlink:href="ck0001824293-20230630.xsd#ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization" xlink:to="lab_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_ef716e2e-7c55-4d65-adeb-790a022f3c56_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_0c712afc-a066-4574-b0c2-7eb4d6c2468f_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant issuance</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_ccd5ebfb-d6a0-4743-a9e9-ec02a7266d59_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_2a41b6fb-67dd-42d3-a09b-755b4f42f7e6_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of bridge promissory note</link:label>
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_daa375e9-c4ee-43f6-972c-e76cace5a9aa_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of notes</link:label>
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_label_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromNotesPayable" xlink:to="lab_us-gaap_ProceedsFromNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_5e0a12b1-e8e0-4024-99c6-d5953b9523f7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_d34f4a16-043b-46ac-9347-0172f328b590_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant exercise price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_e2ac557d-afa2-477f-81be-e5e9ce3f8947_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price per Share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses_dd7bfde0-6c89-47c0-b6d8-4a96d0bb739f_terseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for reverse recapitalization expenses (in shares)</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses_label_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Reverse Recapitalization Expenses</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Reverse Recapitalization Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses" xlink:href="ck0001824293-20230630.xsd#ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses" xlink:to="lab_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_86e7516e-12bb-4949-8762-b52ed14bcb30_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_a825428d-7d23-48ce-91cf-5c7c14844d7c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of the Changes is the Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_a834e2fc-b08c-4c53-802d-be027360114f_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantLiabilityMember_883bc003-67af-41fc-86d0-c0a711d1bdb9_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Liability</link:label>
    <link:label id="lab_ck0001824293_WarrantLiabilityMember_label_en-US" xlink:label="lab_ck0001824293_WarrantLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Liability [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantLiabilityMember_documentation_en-US" xlink:label="lab_ck0001824293_WarrantLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantLiabilityMember" xlink:href="ck0001824293-20230630.xsd#ck0001824293_WarrantLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantLiabilityMember" xlink:to="lab_ck0001824293_WarrantLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_b68ab5e7-c202-4031-b4ba-24a84caf15cf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_9e060070-6511-49e5-86d3-f4916aee52cf_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_11a858b7-635d-4185-ac65-f42964fc2694_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_2dd88318-1ca0-4175-bbcf-8b69d234f477_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_73e1b1df-3562-4e47-98dc-a22bbba3b4f9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_9bbacb3a-dbc0-4c6e-93e5-b137eff2d7fb_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_ae719ed2-c4d2-4391-81f6-abf248f159ec_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Activity of Stock Options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringIn24MonthsAfterRegistrationDateMember_066ff7eb-d334-4627-8c85-ae3c3eaad3d5_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringIn24MonthsAfterRegistrationDateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring in 24 Months After Registration Date</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringIn24MonthsAfterRegistrationDateMember_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringIn24MonthsAfterRegistrationDateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring In 24 Months After Registration Date [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringIn24MonthsAfterRegistrationDateMember_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringIn24MonthsAfterRegistrationDateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring In 24 Months After Registration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringIn24MonthsAfterRegistrationDateMember" xlink:href="ck0001824293-20230630.xsd#ck0001824293_WarrantsExpiringIn24MonthsAfterRegistrationDateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringIn24MonthsAfterRegistrationDateMember" xlink:to="lab_ck0001824293_WarrantsExpiringIn24MonthsAfterRegistrationDateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_COBRABenefitsPaymentPeriod_094e1b4c-8571-41ed-8b0c-13b6c080ef35_terseLabel_en-US" xlink:label="lab_ck0001824293_COBRABenefitsPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COBRA benefits, payment period (in months)</link:label>
    <link:label id="lab_ck0001824293_COBRABenefitsPaymentPeriod_label_en-US" xlink:label="lab_ck0001824293_COBRABenefitsPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COBRA Benefits, Payment Period</link:label>
    <link:label id="lab_ck0001824293_COBRABenefitsPaymentPeriod_documentation_en-US" xlink:label="lab_ck0001824293_COBRABenefitsPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COBRA Benefits, Payment Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_COBRABenefitsPaymentPeriod" xlink:href="ck0001824293-20230630.xsd#ck0001824293_COBRABenefitsPaymentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_COBRABenefitsPaymentPeriod" xlink:to="lab_ck0001824293_COBRABenefitsPaymentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringInDecember2023Member_5f9aef17-ea7f-41ad-a35a-eddfa76a496c_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInDecember2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring In December 2023</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInDecember2023Member_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInDecember2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring In December 2023 [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInDecember2023Member_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInDecember2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring In December 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInDecember2023Member" xlink:href="ck0001824293-20230630.xsd#ck0001824293_WarrantsExpiringInDecember2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringInDecember2023Member" xlink:to="lab_ck0001824293_WarrantsExpiringInDecember2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_d9fd682f-5f24-45aa-a3b7-dd788ed52624_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Warrants Outstanding to Purchase Common Stock</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_6df6fac4-3ee0-4e46-a34a-f9d1f3ada129_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_EmployeeAdvancesCurrent_f191d3f6-fd75-4797-ad19-f926791b201d_verboseLabel_en-US" xlink:label="lab_ck0001824293_EmployeeAdvancesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advances from employees</link:label>
    <link:label id="lab_ck0001824293_EmployeeAdvancesCurrent_label_en-US" xlink:label="lab_ck0001824293_EmployeeAdvancesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Advances, Current</link:label>
    <link:label id="lab_ck0001824293_EmployeeAdvancesCurrent_documentation_en-US" xlink:label="lab_ck0001824293_EmployeeAdvancesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Advances, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_EmployeeAdvancesCurrent" xlink:href="ck0001824293-20230630.xsd#ck0001824293_EmployeeAdvancesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_EmployeeAdvancesCurrent" xlink:to="lab_ck0001824293_EmployeeAdvancesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_a36b02b5-eff0-4955-b7c3-a2e77bc7b427_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_e605fb89-7f8a-4355-96fe-967fedbe8cad_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, non-current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_60b82138-1825-4e84-9b93-34d7905d8d78_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_00be5ff7-34b2-4ad0-9b3a-9b76d8106009_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SeriesA2WarrantsMember_41656155-77e5-4135-a484-bf2370cbb8e2_terseLabel_en-US" xlink:label="lab_ck0001824293_SeriesA2WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A-2 Warrants</link:label>
    <link:label id="lab_ck0001824293_SeriesA2WarrantsMember_label_en-US" xlink:label="lab_ck0001824293_SeriesA2WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A-2 Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_SeriesA2WarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_SeriesA2WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A-2 Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesA2WarrantsMember" xlink:href="ck0001824293-20230630.xsd#ck0001824293_SeriesA2WarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SeriesA2WarrantsMember" xlink:to="lab_ck0001824293_SeriesA2WarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_ca7c915d-aa55-4b21-b460-b64cd12c0701_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of deferred stock issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_ce741ec3-4a0a-435d-95cb-48426959da0e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_3fb606e3-8ec6-46c2-b37b-7322ac20984d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_198dbfb6-7995-4195-89de-7aca667bf12d_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringInFebruary2026Member_0e479bae-6679-4e9d-9775-0f83e9c6160b_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInFebruary2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring In February 2026</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInFebruary2026Member_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInFebruary2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring In February 2026 [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInFebruary2026Member_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInFebruary2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring In February 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInFebruary2026Member" xlink:href="ck0001824293-20230630.xsd#ck0001824293_WarrantsExpiringInFebruary2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringInFebruary2026Member" xlink:to="lab_ck0001824293_WarrantsExpiringInFebruary2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_0d10645f-f443-404c-94e2-9978857bc86a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross" xlink:to="lab_us-gaap_DeferredFinanceCostsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_5a9f563f-a88e-4920-9839-bb8631aea8b7_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_403d42f6-60b7-439c-bdc0-e6b940f4cac8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0f7adaac-a21b-4d47-9a3e-b697cef54327_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_36436e7e-1ad2-4d61-874a-6b7a12719041_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_dd7781be-7527-4d70-a243-5d08d74ac9b8_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_ca3d909f-2e66-483d-8bf7-7349cad0222b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt discounts and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_ebf562f6-b3ff-4ce6-b7be-7d4307de1f7d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses_0d46bab3-3b4c-40cd-9497-f15f9e174d78_negatedLabel_en-US" xlink:label="lab_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses_label_en-US" xlink:label="lab_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accounts Payable And Accrued Expenses</link:label>
    <link:label id="lab_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses_documentation_en-US" xlink:label="lab_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accounts Payable And Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses" xlink:href="ck0001824293-20230630.xsd#ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses" xlink:to="lab_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_9f0e72cb-d2cd-48fe-b416-625a27e9f36e_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity (deficit)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts_3c946216-396c-4942-a7f7-d27f26543e40_terseLabel_en-US" xlink:label="lab_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total net liabilities assumed plus transaction costs</link:label>
    <link:label id="lab_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts_label_en-US" xlink:label="lab_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net, Including Transaction Costs</link:label>
    <link:label id="lab_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts_documentation_en-US" xlink:label="lab_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net, Including Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts" xlink:href="ck0001824293-20230630.xsd#ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts" xlink:to="lab_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_04601ef5-d3bd-40ae-95ea-d13c74187f51_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_b626db00-e825-4a5b-85ad-88fc8f3a4bad_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share of common stock, basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_2aa0f3e8-5799-4c87-8c2a-4f7416e58b40_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_d40aad77-d0fc-45da-ae74-e941fe0a064c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_6f47924f-4d62-4179-9d44-8dfd68007629_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_b54557c1-c832-4765-aee7-aabfbe2845b2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of the Net Liabilities Assumed in the Merger</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashUninsuredAmount_a2bb3ac8-8e0f-41f9-85cb-4997d02fd278_terseLabel_en-US" xlink:label="lab_us-gaap_CashUninsuredAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uninsured cash balances</link:label>
    <link:label id="lab_us-gaap_CashUninsuredAmount_label_en-US" xlink:label="lab_us-gaap_CashUninsuredAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Uninsured Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashUninsuredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashUninsuredAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashUninsuredAmount" xlink:to="lab_us-gaap_CashUninsuredAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_ebaeb288-735a-41d7-ad5d-2a6956d83dd0_terseLabel_en-US" xlink:label="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_label_en-US" xlink:label="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research and Development Costs, Current</link:label>
    <link:label id="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_documentation_en-US" xlink:label="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research and Development Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" xlink:href="ck0001824293-20230630.xsd#ck0001824293_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" xlink:to="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_a9afd6ab-6fdd-425f-b028-d76cd512b405_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_5fef3cb1-a3b2-431d-b344-c31ce3c0e994_terseLabel_en-US" xlink:label="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIQUIDITY</link:label>
    <link:label id="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_label_en-US" xlink:label="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Substantial Doubt about Going Concern [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_d32d4421-2047-4f1c-84bc-7e49e3cced4e_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, outstanding term</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_eed3d000-61ab-4c7c-9692-39da18c2ef43_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_e8c97571-9cbd-45cf-830e-85edcbdb7278_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_27cd88b1-3a7c-40d7-b988-9faa58d93ae4_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_083a24d4-35ff-40b8-a76a-e68dbedc32fb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Common Stock Equivalents Excluded From Diluted Net Loss Per Share Calculation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_928ae9df-255e-41b5-890d-9df2b99cbc2c_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_a9826983-4bb4-437e-89ba-21d69848c002_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_12483e63-01f4-4645-bc35-353ea9522b10_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_NoncashMergerRelatedCostsFinancingActivities_1960e544-56b3-4898-bac2-1b7dce378192_terseLabel_en-US" xlink:label="lab_ck0001824293_NoncashMergerRelatedCostsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger costs included in accounts payable</link:label>
    <link:label id="lab_ck0001824293_NoncashMergerRelatedCostsFinancingActivities_label_en-US" xlink:label="lab_ck0001824293_NoncashMergerRelatedCostsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Merger Related Costs, Financing Activities</link:label>
    <link:label id="lab_ck0001824293_NoncashMergerRelatedCostsFinancingActivities_documentation_en-US" xlink:label="lab_ck0001824293_NoncashMergerRelatedCostsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Merger Related Costs, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_NoncashMergerRelatedCostsFinancingActivities" xlink:href="ck0001824293-20230630.xsd#ck0001824293_NoncashMergerRelatedCostsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_NoncashMergerRelatedCostsFinancingActivities" xlink:to="lab_ck0001824293_NoncashMergerRelatedCostsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_2730e6a9-4339-49a7-a1e1-96fdb042127b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_eaf1b7d8-a162-47ac-846f-a7e59cb1a345_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_6c3e2082-4000-44e8-9a62-0176f83db8de_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6b10c953-397e-4a2d-a34e-02d1cdc7a89d_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities (in usd per share)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_b41b6cfa-0870-4e66-a9d3-f46e1c2a39ee_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_c324fe9a-3453-4c31-985b-26df21bef14e_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5d1d9d58-5f44-470a-9bf8-612c00ad11ef_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_3a0e47f8-16b2-4a4a-9fee-3f66e0ada0c6_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_PercentageOfTargetBonus_72b3b82b-2e5c-4313-8dbe-bf9e23b3fef0_terseLabel_en-US" xlink:label="lab_ck0001824293_PercentageOfTargetBonus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of target bonus (as a percent)</link:label>
    <link:label id="lab_ck0001824293_PercentageOfTargetBonus_label_en-US" xlink:label="lab_ck0001824293_PercentageOfTargetBonus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Target Bonus</link:label>
    <link:label id="lab_ck0001824293_PercentageOfTargetBonus_documentation_en-US" xlink:label="lab_ck0001824293_PercentageOfTargetBonus" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Target Bonus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PercentageOfTargetBonus" xlink:href="ck0001824293-20230630.xsd#ck0001824293_PercentageOfTargetBonus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_PercentageOfTargetBonus" xlink:to="lab_ck0001824293_PercentageOfTargetBonus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_1dea0366-c819-4cdb-bf13-a2c5f6b66c2f_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_ee9e7ed9-cc0f-4500-9627-900e4db270ab_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares authorized</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_6ee51aa8-17dc-4fd5-960b-3f1395489b58_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_3a969425-04e2-4816-b9f7-eef03f2e61f3_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a1e8b175-e1f4-4c46-bc81-aa244475775a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseBorrowings_52bb4ba0-44c0-45d3-989d-e673fb75e54c_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseBorrowings_label_en-US" xlink:label="lab_us-gaap_InterestExpenseBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseBorrowings" xlink:to="lab_us-gaap_InterestExpenseBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_46ccf533-8979-4cca-a5c9-b66b1595b8cd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plus: Transaction costs</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:to="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_e583573a-b61d-4d08-b11a-1e5e7c96dc1b_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_d9ab7c0f-c297-4458-98b7-02d4e5d533a9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_1ef0d678-5c87-4020-9d39-7ddcf0886e17_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_7e641072-5d07-40f0-b193-dda6df53b5d1_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_5c7841cf-8334-49a3-a691-ef554176e623_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_6e6a96a0-02b8-4e1a-8de6-a58303ed9076_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_832cb396-f8c3-4345-944e-465ea6554c25_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuanceCostsOfferingExpenses_d455b439-94c4-421e-ab19-1fdc524f0570_terseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuanceCostsOfferingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering expenses</link:label>
    <link:label id="lab_ck0001824293_StockIssuanceCostsOfferingExpenses_label_en-US" xlink:label="lab_ck0001824293_StockIssuanceCostsOfferingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Costs, Offering Expenses</link:label>
    <link:label id="lab_ck0001824293_StockIssuanceCostsOfferingExpenses_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuanceCostsOfferingExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Costs, Offering Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuanceCostsOfferingExpenses" xlink:href="ck0001824293-20230630.xsd#ck0001824293_StockIssuanceCostsOfferingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuanceCostsOfferingExpenses" xlink:to="lab_ck0001824293_StockIssuanceCostsOfferingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_44409891-d788-429a-a3ec-6c6b8fad30fb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9bd96377-d0fd-492e-a623-38b1fd8b2414_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_AccruedInterestForfeited_5512beb0-7ff4-4bb7-ac64-1d88fd472ae5_terseLabel_en-US" xlink:label="lab_ck0001824293_AccruedInterestForfeited" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest forfeited</link:label>
    <link:label id="lab_ck0001824293_AccruedInterestForfeited_label_en-US" xlink:label="lab_ck0001824293_AccruedInterestForfeited" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Interest Forfeited</link:label>
    <link:label id="lab_ck0001824293_AccruedInterestForfeited_documentation_en-US" xlink:label="lab_ck0001824293_AccruedInterestForfeited" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Interest Forfeited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedInterestForfeited" xlink:href="ck0001824293-20230630.xsd#ck0001824293_AccruedInterestForfeited"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_AccruedInterestForfeited" xlink:to="lab_ck0001824293_AccruedInterestForfeited" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_587c36e8-3d0b-44e3-9f46-c302592b7d0f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_cc565b14-160c-4cf8-9791-55c2d4d00763_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SeriesA1WarrantsMember_c7f83635-8de8-404c-9bb4-3aeb51306b49_terseLabel_en-US" xlink:label="lab_ck0001824293_SeriesA1WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A-1 Warrants</link:label>
    <link:label id="lab_ck0001824293_SeriesA1WarrantsMember_label_en-US" xlink:label="lab_ck0001824293_SeriesA1WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A-1 Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_SeriesA1WarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_SeriesA1WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A-1 Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesA1WarrantsMember" xlink:href="ck0001824293-20230630.xsd#ck0001824293_SeriesA1WarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SeriesA1WarrantsMember" xlink:to="lab_ck0001824293_SeriesA1WarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_2805b0a3-eb70-4929-8d4f-4d8fb85b9540_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, gross</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3c2a23df-ab49-45d8-959a-3f9873fe30d4_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_5554adbc-f7d7-4fb8-af42-af277f4797cd_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_fb4a46e6-baf2-47b0-8818-0d721c1f68f7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_85ab6a8e-1a88-419a-928c-b800368a5002_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_0fe25b95-d0b2-4f7b-8782-8d1907a1255f_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableCurrent_f0fc2912-5828-4a9b-b106-12fe3704a292_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridge promissory note, net</link:label>
    <link:label id="lab_us-gaap_NotesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableCurrent" xlink:to="lab_us-gaap_NotesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_b5dbf3dc-e430-4010-a66f-974006a8ad7a_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_label_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Acquired, Average Cost Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:to="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_27c7ace3-d984-422e-93ba-3db4610f1581_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, 0.0001 par value; 250,000,000 shares authorized as of June&#160;30, 2023 and December&#160;31, 2022; 2,956,354 and 999,748 shares issued and outstanding as of June&#160;30, 2023 and December&#160;31, 2022, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding" xlink:to="lab_us-gaap_CommonStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_1e5509c0-553d-42e4-a042-79a829b1f262_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_1d64fe78-1684-44b2-8fbb-63648aab512d_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_EquityWarrantsExchangeWarrantsAndBankerWarrantsMember_ea836887-8a2a-4753-ab23-b100a0b37914_terseLabel_en-US" xlink:label="lab_ck0001824293_EquityWarrantsExchangeWarrantsAndBankerWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Warrants, Exchange Warrants and Banker Warrants</link:label>
    <link:label id="lab_ck0001824293_EquityWarrantsExchangeWarrantsAndBankerWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_EquityWarrantsExchangeWarrantsAndBankerWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Warrants, Exchange Warrants And Banker Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_EquityWarrantsExchangeWarrantsAndBankerWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_EquityWarrantsExchangeWarrantsAndBankerWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Warrants, Exchange Warrants And Banker Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_EquityWarrantsExchangeWarrantsAndBankerWarrantsMember" xlink:href="ck0001824293-20230630.xsd#ck0001824293_EquityWarrantsExchangeWarrantsAndBankerWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_EquityWarrantsExchangeWarrantsAndBankerWarrantsMember" xlink:to="lab_ck0001824293_EquityWarrantsExchangeWarrantsAndBankerWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b940924d-f2c0-42ac-8794-240fd2c2f3f1_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fd987d78-d4c5-49be-a063-758639cac94c_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_ConvertiblePromissoryNoteMember_bc25e00c-c27a-4379-988a-c1147e0154a2_terseLabel_en-US" xlink:label="lab_ck0001824293_ConvertiblePromissoryNoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible promissory note</link:label>
    <link:label id="lab_ck0001824293_ConvertiblePromissoryNoteMember_label_en-US" xlink:label="lab_ck0001824293_ConvertiblePromissoryNoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Promissory Note [Member]</link:label>
    <link:label id="lab_ck0001824293_ConvertiblePromissoryNoteMember_documentation_en-US" xlink:label="lab_ck0001824293_ConvertiblePromissoryNoteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Promissory Note</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ConvertiblePromissoryNoteMember" xlink:href="ck0001824293-20230630.xsd#ck0001824293_ConvertiblePromissoryNoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_ConvertiblePromissoryNoteMember" xlink:to="lab_ck0001824293_ConvertiblePromissoryNoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_0614c14a-7b00-49dc-b6d5-31bda532f9cd_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse stock split</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_e6982aa0-fd86-452f-b3eb-98cb63c2e171_terseLabel_en-US" xlink:label="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_label_en-US" xlink:label="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued General and Administrative Expenses, Current</link:label>
    <link:label id="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_documentation_en-US" xlink:label="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued General and Administrative Expenses, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:href="ck0001824293-20230630.xsd#ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:to="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants_52818536-dc76-4d1a-9b3d-8c92ea16faab_terseLabel_en-US" xlink:label="lab_ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognition of debt discount and additional paid-in-capital for issuance of warrants in connection with the issuance of promissory notes</link:label>
    <link:label id="lab_ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants_label_en-US" xlink:label="lab_ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Discount And Additional Paid-In-Capital Recognized From Issuance Of Warrants</link:label>
    <link:label id="lab_ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants_documentation_en-US" xlink:label="lab_ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Discount And Additional Paid-In-Capital Recognized From Issuance Of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants" xlink:href="ck0001824293-20230630.xsd#ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants" xlink:to="lab_ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_c6bef462-8184-40b0-a16c-30f1d62c1da0_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term in years</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_2ce8c9bf-c4cc-4a0d-8a4b-6527423a8fca_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain_9dc64290-963e-498f-94f5-5c58e435d560_terseLabel_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain_label_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_62161dc6-9681-470d-9869-d154561f9ce6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_30205dcd-701a-435f-99ec-e989f8e9d80d_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_3ea9b0fd-0e55-45da-a43f-21d0554eca0c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_d1df51ed-fb35-4a57-ae6a-5b2caad30d93_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_bf5518f6-51c3-4779-8dba-965538382499_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_329ec8d1-4027-4873-bb28-6f3cb27f60fb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_952ab40d-8ae5-4a81-96a9-c14fea08e843_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_CommonStockOwnershipPercentage_9989032f-85df-4162-b91c-5359ae8524fe_terseLabel_en-US" xlink:label="lab_ck0001824293_CommonStockOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage in common stock (as a percent)</link:label>
    <link:label id="lab_ck0001824293_CommonStockOwnershipPercentage_label_en-US" xlink:label="lab_ck0001824293_CommonStockOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Ownership Percentage</link:label>
    <link:label id="lab_ck0001824293_CommonStockOwnershipPercentage_documentation_en-US" xlink:label="lab_ck0001824293_CommonStockOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_CommonStockOwnershipPercentage" xlink:href="ck0001824293-20230630.xsd#ck0001824293_CommonStockOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_CommonStockOwnershipPercentage" xlink:to="lab_ck0001824293_CommonStockOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_669b7bdb-5b12-4b4d-882d-86c96c10dc62_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation, weighted average amortization period (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_5788d472-9ef7-45d1-8873-fb158f60fd37_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_5b816fc1-89a8-4d96-b05c-2ff5b77314d9_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_ProceedsFromAdvancesFromEmployees_616f2695-8b41-4854-b125-3aabc4c75e43_verboseLabel_en-US" xlink:label="lab_ck0001824293_ProceedsFromAdvancesFromEmployees" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advances from employees</link:label>
    <link:label id="lab_ck0001824293_ProceedsFromAdvancesFromEmployees_label_en-US" xlink:label="lab_ck0001824293_ProceedsFromAdvancesFromEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Advances From Employees</link:label>
    <link:label id="lab_ck0001824293_ProceedsFromAdvancesFromEmployees_documentation_en-US" xlink:label="lab_ck0001824293_ProceedsFromAdvancesFromEmployees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Advances From Employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ProceedsFromAdvancesFromEmployees" xlink:href="ck0001824293-20230630.xsd#ck0001824293_ProceedsFromAdvancesFromEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_ProceedsFromAdvancesFromEmployees" xlink:to="lab_ck0001824293_ProceedsFromAdvancesFromEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_74e3ac04-3536-4a38-8d37-88cc6fba35dd_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of option on grant date (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_a4d4add2-978c-45a8-9c0d-94666857f28b_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_4d125bd7-e2cf-4970-bcab-c368b90b5230_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_2c394f91-a57e-41fe-924f-988b327e5f0f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_PutOptionSharePrice_0ea0bc57-8d98-45ac-92c0-98d0851b04a8_terseLabel_en-US" xlink:label="lab_ck0001824293_PutOptionSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Put right, share price (in usd per share)</link:label>
    <link:label id="lab_ck0001824293_PutOptionSharePrice_label_en-US" xlink:label="lab_ck0001824293_PutOptionSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Put Option, Share Price</link:label>
    <link:label id="lab_ck0001824293_PutOptionSharePrice_documentation_en-US" xlink:label="lab_ck0001824293_PutOptionSharePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Put Option, Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PutOptionSharePrice" xlink:href="ck0001824293-20230630.xsd#ck0001824293_PutOptionSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_PutOptionSharePrice" xlink:to="lab_ck0001824293_PutOptionSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_7f15986f-9369-4b39-a87f-6a35ac269fad_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_FormerChiefExecutiveOfficerMember_3f4e17c0-30d4-40b3-88d3-5f1d00b5ba04_terseLabel_en-US" xlink:label="lab_ck0001824293_FormerChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Former Chief Executive Officer</link:label>
    <link:label id="lab_ck0001824293_FormerChiefExecutiveOfficerMember_label_en-US" xlink:label="lab_ck0001824293_FormerChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Former Chief Executive Officer [Member]</link:label>
    <link:label id="lab_ck0001824293_FormerChiefExecutiveOfficerMember_documentation_en-US" xlink:label="lab_ck0001824293_FormerChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Former Chief Executive Officer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_FormerChiefExecutiveOfficerMember" xlink:href="ck0001824293-20230630.xsd#ck0001824293_FormerChiefExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_FormerChiefExecutiveOfficerMember" xlink:to="lab_ck0001824293_FormerChiefExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_1053eed1-2b41-49f6-8e98-e447b1852c1a_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant liability</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_fc3dbeab-801e-41bd-90d4-6d732662f944_verboseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outsanding warrants</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsIssued_ff134295-1c03-4d3a-9919-5f868a5f38eb_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of warrants for payment of stock issuance costs</link:label>
    <link:label id="lab_ck0001824293_WarrantsIssued_label_en-US" xlink:label="lab_ck0001824293_WarrantsIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued</link:label>
    <link:label id="lab_ck0001824293_WarrantsIssued_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsIssued" xlink:href="ck0001824293-20230630.xsd#ck0001824293_WarrantsIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsIssued" xlink:to="lab_ck0001824293_WarrantsIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_0501ffcb-e626-45f4-94ee-65bcda654099_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember_324067e6-1e96-4272-b093-71e216f2a113_terseLabel_en-US" xlink:label="lab_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A&amp;R 2918 Plan</link:label>
    <link:label id="lab_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember_label_en-US" xlink:label="lab_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended and Restated 2018 Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember_documentation_en-US" xlink:label="lab_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended and Restated 2018 Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember" xlink:href="ck0001824293-20230630.xsd#ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember" xlink:to="lab_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_3078d439-0471-43e2-9468-0fb8dc7acf42_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_b762f870-63c9-4612-b68e-2c8e0cfed14c_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_2751cdab-3e2b-4ad6-a217-4b08fb57260b_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e13d6f6c-3878-451d-ab55-414ec82b3546_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b4fe9af1-fa39-44b0-b93d-de2dfd6305f7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_e26c536b-0782-4bdd-8285-0f395535c5ca_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_cc85126b-9a6c-4d68-a25b-0ed06de54b2c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, Ending Balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringInNovember2023Member_14bfd6c4-f8b5-45b4-8530-ad8ca66bc88f_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInNovember2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring In November 2023</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInNovember2023Member_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInNovember2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring In November 2023 [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInNovember2023Member_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInNovember2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring In November 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInNovember2023Member" xlink:href="ck0001824293-20230630.xsd#ck0001824293_WarrantsExpiringInNovember2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringInNovember2023Member" xlink:to="lab_ck0001824293_WarrantsExpiringInNovember2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_b596d05e-f4b1-41bb-9ccd-0ec14e2bef1f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise_0069d95b-3df8-4d33-91ba-b8bef21a94d7_terseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant exercise (in shares)</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise_label_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Warrant Exercise</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Warrant Exercise</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise" xlink:href="ck0001824293-20230630.xsd#ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise" xlink:to="lab_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_bd2e23f3-8d6e-4716-90f2-6520589ce540_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_32d7f32b-e9d7-498e-aa61-16cb41b3843a_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discounts and issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_c111d6f9-f223-4ac9-a90f-9299c8e540c6_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_d50fdd52-186d-4fa5-a4d6-60f172f4c2e8_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_dc2038e6-d882-4fbc-a68b-e48184e88228_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts_bc5a516a-16a5-4408-ae85-80cc733f8b70_terseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock for payment of reverse recapitalization costs</link:label>
    <link:label id="lab_ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts_label_en-US" xlink:label="lab_ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued For Payment Of Reverse Recapitalization Costs</link:label>
    <link:label id="lab_ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued For Payment Of Reverse Recapitalization Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts" xlink:href="ck0001824293-20230630.xsd#ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts" xlink:to="lab_ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_DebtInstrumentConvertibleSharesIssuedUponConversion_6a073e84-4cfc-4ecb-8509-3506ed101753_terseLabel_en-US" xlink:label="lab_ck0001824293_DebtInstrumentConvertibleSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares to be issued upon conversion</link:label>
    <link:label id="lab_ck0001824293_DebtInstrumentConvertibleSharesIssuedUponConversion_label_en-US" xlink:label="lab_ck0001824293_DebtInstrumentConvertibleSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Shares Issued Upon Conversion</link:label>
    <link:label id="lab_ck0001824293_DebtInstrumentConvertibleSharesIssuedUponConversion_documentation_en-US" xlink:label="lab_ck0001824293_DebtInstrumentConvertibleSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Shares Issued Upon Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtInstrumentConvertibleSharesIssuedUponConversion" xlink:href="ck0001824293-20230630.xsd#ck0001824293_DebtInstrumentConvertibleSharesIssuedUponConversion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_DebtInstrumentConvertibleSharesIssuedUponConversion" xlink:to="lab_ck0001824293_DebtInstrumentConvertibleSharesIssuedUponConversion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_39b6f1d5-59d2-45e8-9fd5-20eb835f5aa2_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited/Cancelled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_b1601156-1a46-4426-aa45-8f2254169e7f_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_6ab91aff-4a21-4a24-95aa-60751440f818_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll and related</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_ConversionOfStockAdditionalSharesConverted_28ad161a-288f-4a01-af36-1fbbde4d6397_terseLabel_en-US" xlink:label="lab_ck0001824293_ConversionOfStockAdditionalSharesConverted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional shares converted into common stock (in shares)</link:label>
    <link:label id="lab_ck0001824293_ConversionOfStockAdditionalSharesConverted_label_en-US" xlink:label="lab_ck0001824293_ConversionOfStockAdditionalSharesConverted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Additional Shares Converted</link:label>
    <link:label id="lab_ck0001824293_ConversionOfStockAdditionalSharesConverted_documentation_en-US" xlink:label="lab_ck0001824293_ConversionOfStockAdditionalSharesConverted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Additional Shares Converted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ConversionOfStockAdditionalSharesConverted" xlink:href="ck0001824293-20230630.xsd#ck0001824293_ConversionOfStockAdditionalSharesConverted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_ConversionOfStockAdditionalSharesConverted" xlink:to="lab_ck0001824293_ConversionOfStockAdditionalSharesConverted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_26b11fb4-e225-4f6b-b3e6-481cd3a4f23e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_ExchangeWarrantsMember_ddda66c1-b083-4f24-86a9-cb3dc7d73e66_terseLabel_en-US" xlink:label="lab_ck0001824293_ExchangeWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange Warrants</link:label>
    <link:label id="lab_ck0001824293_ExchangeWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_ExchangeWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_ExchangeWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_ExchangeWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ExchangeWarrantsMember" xlink:href="ck0001824293-20230630.xsd#ck0001824293_ExchangeWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_ExchangeWarrantsMember" xlink:to="lab_ck0001824293_ExchangeWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_b07fc743-3257-4c6d-8ebc-f00ebd720372_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_17aedcdb-3790-4a88-a2f6-0628165aca06_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MERGER WITH VALLON</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_dd0bf03e-e2bc-46e6-8030-5c57f2693c19_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_82da996e-3f5a-4efc-8356-62bc386be42a_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_8db03917-208d-443c-87a9-c96a2a2dba50_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_024b78b5-deb7-4eab-a001-f7e53b42e16a_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestorMember_27114f2b-d4df-41f5-9d8e-692145cbe523_terseLabel_en-US" xlink:label="lab_us-gaap_InvestorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investor</link:label>
    <link:label id="lab_us-gaap_InvestorMember_label_en-US" xlink:label="lab_us-gaap_InvestorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investor [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestorMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestorMember" xlink:to="lab_us-gaap_InvestorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_8f7a4361-a839-4404-a35d-a5f3ee5c45a8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of convertible notes to common stock</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_9e7f4ebc-c39c-4ef2-a7de-0db8043b9dfb_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_9496a164-e240-4aea-8a3e-437b095cb846_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_b489f9bc-34cd-463a-994c-d14e012fa8bc_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_ecee7c79-1398-4941-bbab-5aab7bc9b908_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SeriesTWarrantsMember_263b43ac-dbf8-4d12-9163-ddd2e8255015_terseLabel_en-US" xlink:label="lab_ck0001824293_SeriesTWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series T Warrants</link:label>
    <link:label id="lab_ck0001824293_SeriesTWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_SeriesTWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series T Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_SeriesTWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_SeriesTWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series T Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesTWarrantsMember" xlink:href="ck0001824293-20230630.xsd#ck0001824293_SeriesTWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SeriesTWarrantsMember" xlink:to="lab_ck0001824293_SeriesTWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_DebtInstrumentAggregatePurchasePrice_fa319ab5-0913-4052-8f53-49d553c32c0c_terseLabel_en-US" xlink:label="lab_ck0001824293_DebtInstrumentAggregatePurchasePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate purchase price</link:label>
    <link:label id="lab_ck0001824293_DebtInstrumentAggregatePurchasePrice_label_en-US" xlink:label="lab_ck0001824293_DebtInstrumentAggregatePurchasePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Aggregate Purchase Price</link:label>
    <link:label id="lab_ck0001824293_DebtInstrumentAggregatePurchasePrice_documentation_en-US" xlink:label="lab_ck0001824293_DebtInstrumentAggregatePurchasePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Aggregate Purchase Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtInstrumentAggregatePurchasePrice" xlink:href="ck0001824293-20230630.xsd#ck0001824293_DebtInstrumentAggregatePurchasePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_DebtInstrumentAggregatePurchasePrice" xlink:to="lab_ck0001824293_DebtInstrumentAggregatePurchasePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_GRIBioIncMember_ea0a0bbf-07a2-42c5-b780-b8de98332981_terseLabel_en-US" xlink:label="lab_ck0001824293_GRIBioIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GRI Bio, Inc</link:label>
    <link:label id="lab_ck0001824293_GRIBioIncMember_label_en-US" xlink:label="lab_ck0001824293_GRIBioIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GRI Bio, Inc [Member]</link:label>
    <link:label id="lab_ck0001824293_GRIBioIncMember_documentation_en-US" xlink:label="lab_ck0001824293_GRIBioIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GRI Bio, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_GRIBioIncMember" xlink:href="ck0001824293-20230630.xsd#ck0001824293_GRIBioIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_GRIBioIncMember" xlink:to="lab_ck0001824293_GRIBioIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateTwoMember_bfbd2e84-3b60-4df0-b53a-c5add552d465_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring in 60 Months After Registration Date</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateTwoMember_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring In 60 Months After Registration Date Two [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateTwoMember_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring In 60 Months After Registration Date Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateTwoMember" xlink:href="ck0001824293-20230630.xsd#ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateTwoMember" xlink:to="lab_ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_27c52e41-3ac0-43c5-a91a-f5d3e3db36c2_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_2d37cec4-5d38-4c67-8f02-3bd74d7d20df_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of notes payable</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_4c4998fb-fd61-4eae-b65f-79e468e81974_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible notes, converted, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_b133705b-8684-4ecd-99db-d4d16162847d_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt_d5f838d7-82c2-402f-b2a7-1e05e094d41e_terseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for settlement of bridge note</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt_label_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Settlement Of Debt</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Settlement Of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt" xlink:href="ck0001824293-20230630.xsd#ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt" xlink:to="lab_ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_71e7ec06-4367-4a94-a059-52d25a72a657_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringInJuly2027Member_f85f3cbb-51ec-4350-a0c3-adc88417173d_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInJuly2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring In July 2027</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInJuly2027Member_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInJuly2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring In July 2027 [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInJuly2027Member_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInJuly2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring In July 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInJuly2027Member" xlink:href="ck0001824293-20230630.xsd#ck0001824293_WarrantsExpiringInJuly2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringInJuly2027Member" xlink:to="lab_ck0001824293_WarrantsExpiringInJuly2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_bc62e9a0-8a44-4a77-a2c9-d834f1e319f7_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5ee4dccb-37eb-4c54-84af-171e0ade8f34_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_BridgeWarrantsMember_131f21bb-416f-47f1-9bbe-22e235fd1ad2_terseLabel_en-US" xlink:label="lab_ck0001824293_BridgeWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridge Warrants</link:label>
    <link:label id="lab_ck0001824293_BridgeWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_BridgeWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridge Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_BridgeWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_BridgeWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridge Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_BridgeWarrantsMember" xlink:href="ck0001824293-20230630.xsd#ck0001824293_BridgeWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_BridgeWarrantsMember" xlink:to="lab_ck0001824293_BridgeWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_14bef8d5-4344-45bd-b3d6-3d65a20259b8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_038d4f33-bb88-41ee-8846-ce020ff97f0d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateOneMember_7a07e99e-fb93-4cd2-b3aa-a89bb98dc906_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring in 60 Months After Registration Date</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateOneMember_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring In 60 Months After Registration Date One [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateOneMember_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring In 60 Months After Registration Date One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateOneMember" xlink:href="ck0001824293-20230630.xsd#ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateOneMember" xlink:to="lab_ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFDICInsuredAmount_3c731684-66ee-4829-ba79-552df371852c_terseLabel_en-US" xlink:label="lab_us-gaap_CashFDICInsuredAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FDIC insured amount</link:label>
    <link:label id="lab_us-gaap_CashFDICInsuredAmount_label_en-US" xlink:label="lab_us-gaap_CashFDICInsuredAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, FDIC Insured Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFDICInsuredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFDICInsuredAmount" xlink:to="lab_us-gaap_CashFDICInsuredAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_d02d8802-63bf-4d10-8bc8-6fd8f83e2bbb_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_LongTermDebtIncludingInterest_142111bd-deb9-4bee-baca-20d889d327ae_terseLabel_en-US" xlink:label="lab_ck0001824293_LongTermDebtIncludingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, including interest</link:label>
    <link:label id="lab_ck0001824293_LongTermDebtIncludingInterest_label_en-US" xlink:label="lab_ck0001824293_LongTermDebtIncludingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Including Interest</link:label>
    <link:label id="lab_ck0001824293_LongTermDebtIncludingInterest_documentation_en-US" xlink:label="lab_ck0001824293_LongTermDebtIncludingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Including Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_LongTermDebtIncludingInterest" xlink:href="ck0001824293-20230630.xsd#ck0001824293_LongTermDebtIncludingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_LongTermDebtIncludingInterest" xlink:to="lab_ck0001824293_LongTermDebtIncludingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_fb8928b0-379d-4c90-94f4-ac531c9d2119_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_8a6199d2-fe6f-43af-be18-5e2e364817e2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional shares authorized</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_5f1f110a-50a4-4917-80d1-066051fd55b5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_PrivateGRIMember_c2449cf3-646d-4a7d-b58e-a9fbb7f3cc0e_terseLabel_en-US" xlink:label="lab_ck0001824293_PrivateGRIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private GRI</link:label>
    <link:label id="lab_ck0001824293_PrivateGRIMember_label_en-US" xlink:label="lab_ck0001824293_PrivateGRIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private GRI [Member]</link:label>
    <link:label id="lab_ck0001824293_PrivateGRIMember_documentation_en-US" xlink:label="lab_ck0001824293_PrivateGRIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private GRI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PrivateGRIMember" xlink:href="ck0001824293-20230630.xsd#ck0001824293_PrivateGRIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_PrivateGRIMember" xlink:to="lab_ck0001824293_PrivateGRIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5455800f-32b0-4a14-9ed8-a5b087c95511_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_07dd5fda-922e-46c2-b62d-9ce1682f8431_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_d7f155b8-8fa9-46a5-b08c-e4f6915b4924_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in-capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_43d9404d-0f26-4185-88c3-631d8b8101f2_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_1bbc761f-00a1-45d9-867d-0a55cf85cc4d_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional&#160;Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_5851b1bf-0372-4430-a898-246f0b5b141f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_6835dd63-c422-4353-97a9-75484ebaef55_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_75acc861-9e1a-4f78-8feb-1f93456e4ddb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_119c1a74-4040-4dd8-b372-af86614c9cf4_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_e7092222-3332-40ba-b2d6-f1a1bccf7675_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_77d84aeb-40e1-4bd7-8718-7f848140c7dc_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_806cc357-917a-4ad4-8e12-903d0840eed2_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_66dafeda-cc2e-4724-9c3d-d4cbca4e3807_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c378d094-1eb7-4799-bb82-c861712c8b5c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_3351e2a8-b386-400f-8da7-30458f9c4e41_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_ca5949bb-f6e8-4a32-a5e2-92a42a9551d1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_6411b51d-4430-4903-aa12-c1f7adacafe9_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_51fb6ec2-049c-4d69-af94-4945e52d5d56_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_3fa826b3-d242-4dce-a966-5dab52ac691a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_A2018EquityIncentivePlanMember_40f0124a-1aad-4157-af27-9cd64c1ae7ad_terseLabel_en-US" xlink:label="lab_ck0001824293_A2018EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Plan</link:label>
    <link:label id="lab_ck0001824293_A2018EquityIncentivePlanMember_label_en-US" xlink:label="lab_ck0001824293_A2018EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_ck0001824293_A2018EquityIncentivePlanMember_documentation_en-US" xlink:label="lab_ck0001824293_A2018EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_A2018EquityIncentivePlanMember" xlink:href="ck0001824293-20230630.xsd#ck0001824293_A2018EquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_A2018EquityIncentivePlanMember" xlink:to="lab_ck0001824293_A2018EquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_c6d13b92-d160-476d-84b8-ba2df9f2f4de_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_BankerWarrantsMember_d73f8f52-4b35-43f4-b094-d01805a46ffc_terseLabel_en-US" xlink:label="lab_ck0001824293_BankerWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Banker Warrants</link:label>
    <link:label id="lab_ck0001824293_BankerWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_BankerWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Banker Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_BankerWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_BankerWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Banker Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_BankerWarrantsMember" xlink:href="ck0001824293-20230630.xsd#ck0001824293_BankerWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_BankerWarrantsMember" xlink:to="lab_ck0001824293_BankerWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_e6078fa6-d504-49de-a2a1-3f31cc11a841_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5321b2e3-4c2f-472c-afc7-ce8acc849643_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_20640226-bc09-4f2c-a3c9-b737be24405a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_aeb6f8f5-27c9-4aad-8978-ee7bc3b2eda0_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_PrivateGRIPlanMember_e6a2fa9c-a5b6-479d-a23a-8d8123535478_terseLabel_en-US" xlink:label="lab_ck0001824293_PrivateGRIPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2015 Plan</link:label>
    <link:label id="lab_ck0001824293_PrivateGRIPlanMember_label_en-US" xlink:label="lab_ck0001824293_PrivateGRIPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private GRI Plan [Member]</link:label>
    <link:label id="lab_ck0001824293_PrivateGRIPlanMember_documentation_en-US" xlink:label="lab_ck0001824293_PrivateGRIPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private GRI Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PrivateGRIPlanMember" xlink:href="ck0001824293-20230630.xsd#ck0001824293_PrivateGRIPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_PrivateGRIPlanMember" xlink:to="lab_ck0001824293_PrivateGRIPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CallOptionMember_f09f3c90-7eff-435a-aaba-79665c30f5f0_terseLabel_en-US" xlink:label="lab_us-gaap_CallOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Call Option</link:label>
    <link:label id="lab_us-gaap_CallOptionMember_label_en-US" xlink:label="lab_us-gaap_CallOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Call Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CallOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CallOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CallOptionMember" xlink:to="lab_us-gaap_CallOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_2f8f42f7-bef0-45c1-93b5-dd07b25751ed_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_180ef542-809a-443e-95fa-fd70b35fb4e5_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_7bc3f0e6-be8b-452f-987a-b683dff1d435_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f3845671-ee4f-4a76-b2f4-317bed674354_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_3f0adb6f-1fa4-43b7-9d96-9aeca90c1bbf_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_a044a26e-5a0f-470b-814f-e2f1585f4683_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d9877038-686d-4e36-9f22-4bbfcf101d8c_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_ClassOfWarrantOrRightExpirationPeriod_885b6614-9239-4abb-82f9-3f6ef7370c2f_terseLabel_en-US" xlink:label="lab_ck0001824293_ClassOfWarrantOrRightExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration period</link:label>
    <link:label id="lab_ck0001824293_ClassOfWarrantOrRightExpirationPeriod_label_en-US" xlink:label="lab_ck0001824293_ClassOfWarrantOrRightExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Expiration Period</link:label>
    <link:label id="lab_ck0001824293_ClassOfWarrantOrRightExpirationPeriod_documentation_en-US" xlink:label="lab_ck0001824293_ClassOfWarrantOrRightExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ClassOfWarrantOrRightExpirationPeriod" xlink:href="ck0001824293-20230630.xsd#ck0001824293_ClassOfWarrantOrRightExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_ClassOfWarrantOrRightExpirationPeriod" xlink:to="lab_ck0001824293_ClassOfWarrantOrRightExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_fbe4e9be-2bb8-40ad-bbb5-92ad37751c9a_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_CallOptionPrice_bf79ec2d-6318-43da-8563-87c02a9c179e_terseLabel_en-US" xlink:label="lab_ck0001824293_CallOptionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Call option price (in usd per share)</link:label>
    <link:label id="lab_ck0001824293_CallOptionPrice_label_en-US" xlink:label="lab_ck0001824293_CallOptionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Call Option Price</link:label>
    <link:label id="lab_ck0001824293_CallOptionPrice_documentation_en-US" xlink:label="lab_ck0001824293_CallOptionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Call Option Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_CallOptionPrice" xlink:href="ck0001824293-20230630.xsd#ck0001824293_CallOptionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_CallOptionPrice" xlink:to="lab_ck0001824293_CallOptionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_4dfbaa89-aac0-4db6-a43f-b2f9bf42f0d2_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_565a74c3-ee54-4581-9d2a-f807df7f5aee_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockSharesConverted1_59ce5fbf-9ab6-47a9-9036-21e4519df53c_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockSharesConverted1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Shares Converted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesConverted1" xlink:to="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_55ca40ab-d645-4db0-a1b9-383794ddfd85_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0b8b5e67-321e-4d14-99f7-174eda2f1817_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_22f35925-5d57-4153-aa78-a62b08946d64_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7cb60822-c681-4493-80f6-468b5edec5e1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_295bf3fd-4ecd-41bc-beae-a21f76ad7a6c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares reserved for future awards (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_8c8cd7ec-d3b5-4df2-991e-5e9299ef610e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PROPERTY AND EQUIPMENT</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_35612011-d107-4ed1-9ba2-269bb20c8dcb_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_4b526245-bb75-4d52-b234-7e3edc7119c5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_3726dfb0-f581-4bd8-81d4-e4a23b18d316_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_20c25fc4-7950-4dfd-bc30-b8c8ecae80fd_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACCRUED EXPENSES</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_f1a1e15d-2d3d-40a8-b498-6e6e9007bf33_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5bc5b887-d508-48a3-b307-39c57d543031_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual term&#160;(years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization_4698bbb0-37d6-4182-9567-78d065915871_terseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock to Vallon stockholders in reverse recapitalization</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization_label_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Reverse Recapitalization</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Reverse Recapitalization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization" xlink:href="ck0001824293-20230630.xsd#ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization" xlink:to="lab_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_dea1d9e6-1aeb-42c4-bf77-4a169f4285b3_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>ck0001824293-20230630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:03e6aede-a80d-4c93-aec7-6df3e5ac1c16,g:d01e6060-7205-4c9b-8c6f-b994c931683b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/Cover" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_1cbec220-b7bb-48a9-b69d-1d4f152ca681" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_4a535c87-58a1-4ae2-87e6-c54092f25855" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbec220-b7bb-48a9-b69d-1d4f152ca681" xlink:to="loc_dei_DocumentType_4a535c87-58a1-4ae2-87e6-c54092f25855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_0050fdb4-3fd4-40cf-b07e-40280cb902a2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbec220-b7bb-48a9-b69d-1d4f152ca681" xlink:to="loc_dei_DocumentQuarterlyReport_0050fdb4-3fd4-40cf-b07e-40280cb902a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_9ed11a06-18a5-4d83-91ff-0d8c277b05c0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbec220-b7bb-48a9-b69d-1d4f152ca681" xlink:to="loc_dei_DocumentPeriodEndDate_9ed11a06-18a5-4d83-91ff-0d8c277b05c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_7249c593-7aeb-4723-b8fd-b848980b97ea" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbec220-b7bb-48a9-b69d-1d4f152ca681" xlink:to="loc_dei_DocumentTransitionReport_7249c593-7aeb-4723-b8fd-b848980b97ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_3012947a-0048-42e3-9db8-75c289945cf0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbec220-b7bb-48a9-b69d-1d4f152ca681" xlink:to="loc_dei_EntityFileNumber_3012947a-0048-42e3-9db8-75c289945cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_fd8d7fb8-a8f4-4bb8-a825-f5638f3a8105" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbec220-b7bb-48a9-b69d-1d4f152ca681" xlink:to="loc_dei_EntityRegistrantName_fd8d7fb8-a8f4-4bb8-a825-f5638f3a8105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_ec2c1cbc-71bf-4cd2-a57b-84beacc62783" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbec220-b7bb-48a9-b69d-1d4f152ca681" xlink:to="loc_dei_EntityIncorporationStateCountryCode_ec2c1cbc-71bf-4cd2-a57b-84beacc62783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_67f57b3e-f868-4b73-8699-1aafc324197f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbec220-b7bb-48a9-b69d-1d4f152ca681" xlink:to="loc_dei_EntityTaxIdentificationNumber_67f57b3e-f868-4b73-8699-1aafc324197f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_8d36542d-1a03-4049-80dd-486e44b524e7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbec220-b7bb-48a9-b69d-1d4f152ca681" xlink:to="loc_dei_EntityAddressAddressLine1_8d36542d-1a03-4049-80dd-486e44b524e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_42ef1e45-4b8d-4ec4-8188-8885b17fd46d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbec220-b7bb-48a9-b69d-1d4f152ca681" xlink:to="loc_dei_EntityAddressAddressLine2_42ef1e45-4b8d-4ec4-8188-8885b17fd46d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_ee4aa716-cb3d-47a4-b643-ca6c9cd89784" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbec220-b7bb-48a9-b69d-1d4f152ca681" xlink:to="loc_dei_EntityAddressCityOrTown_ee4aa716-cb3d-47a4-b643-ca6c9cd89784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_96870532-f1a5-4a12-ae2b-bc0000ad2d39" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbec220-b7bb-48a9-b69d-1d4f152ca681" xlink:to="loc_dei_EntityAddressStateOrProvince_96870532-f1a5-4a12-ae2b-bc0000ad2d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_5e3c8dea-4475-45b0-84a6-badc22f1ad3d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbec220-b7bb-48a9-b69d-1d4f152ca681" xlink:to="loc_dei_EntityAddressPostalZipCode_5e3c8dea-4475-45b0-84a6-badc22f1ad3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_dd65c81d-7855-46d1-a9ad-f0304bbeab4f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbec220-b7bb-48a9-b69d-1d4f152ca681" xlink:to="loc_dei_CityAreaCode_dd65c81d-7855-46d1-a9ad-f0304bbeab4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_3b8e7d0f-a1e8-40e7-a9e8-0e6f0c148541" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbec220-b7bb-48a9-b69d-1d4f152ca681" xlink:to="loc_dei_LocalPhoneNumber_3b8e7d0f-a1e8-40e7-a9e8-0e6f0c148541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_7c078ba2-15f8-48a6-afed-65f3028cd793" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbec220-b7bb-48a9-b69d-1d4f152ca681" xlink:to="loc_dei_Security12bTitle_7c078ba2-15f8-48a6-afed-65f3028cd793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_76602656-7014-4c5c-b71c-1edea1f8b82f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbec220-b7bb-48a9-b69d-1d4f152ca681" xlink:to="loc_dei_TradingSymbol_76602656-7014-4c5c-b71c-1edea1f8b82f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_b49ffb73-6db4-4119-8eb3-70c1e706b1c9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbec220-b7bb-48a9-b69d-1d4f152ca681" xlink:to="loc_dei_SecurityExchangeName_b49ffb73-6db4-4119-8eb3-70c1e706b1c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_d7ccf6eb-15f9-44d8-9010-3efc53416821" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbec220-b7bb-48a9-b69d-1d4f152ca681" xlink:to="loc_dei_EntityCurrentReportingStatus_d7ccf6eb-15f9-44d8-9010-3efc53416821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_1cbdaeec-9acc-4766-8248-edfd1c70611f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbec220-b7bb-48a9-b69d-1d4f152ca681" xlink:to="loc_dei_EntityInteractiveDataCurrent_1cbdaeec-9acc-4766-8248-edfd1c70611f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_321bc9d7-a4c4-4bdf-8137-bf9b8b47f21c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbec220-b7bb-48a9-b69d-1d4f152ca681" xlink:to="loc_dei_EntityFilerCategory_321bc9d7-a4c4-4bdf-8137-bf9b8b47f21c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_1121a6ff-3b42-4700-ac6e-2cbc79100b03" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbec220-b7bb-48a9-b69d-1d4f152ca681" xlink:to="loc_dei_EntitySmallBusiness_1121a6ff-3b42-4700-ac6e-2cbc79100b03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_0dba2b7d-5749-4a4a-bb06-a6d3ac1a9b71" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbec220-b7bb-48a9-b69d-1d4f152ca681" xlink:to="loc_dei_EntityEmergingGrowthCompany_0dba2b7d-5749-4a4a-bb06-a6d3ac1a9b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_0b8231be-ad5f-4a8d-be09-dd7c34d8e0f4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbec220-b7bb-48a9-b69d-1d4f152ca681" xlink:to="loc_dei_EntityExTransitionPeriod_0b8231be-ad5f-4a8d-be09-dd7c34d8e0f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_9e1aab65-8bfa-4f51-b98f-bf2f1e53ecec" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbec220-b7bb-48a9-b69d-1d4f152ca681" xlink:to="loc_dei_EntityShellCompany_9e1aab65-8bfa-4f51-b98f-bf2f1e53ecec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_22481ab7-e90e-4384-a586-ec75ca833fb3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbec220-b7bb-48a9-b69d-1d4f152ca681" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_22481ab7-e90e-4384-a586-ec75ca833fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_6e3f8adc-5fc2-4ca0-acd4-df2b7e91691f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbec220-b7bb-48a9-b69d-1d4f152ca681" xlink:to="loc_dei_EntityCentralIndexKey_6e3f8adc-5fc2-4ca0-acd4-df2b7e91691f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_75370018-4181-43c1-8be0-d2b1eb4afec6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbec220-b7bb-48a9-b69d-1d4f152ca681" xlink:to="loc_dei_CurrentFiscalYearEndDate_75370018-4181-43c1-8be0-d2b1eb4afec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_ef0e051b-669e-4937-bdac-4546ccc0a163" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbec220-b7bb-48a9-b69d-1d4f152ca681" xlink:to="loc_dei_DocumentFiscalYearFocus_ef0e051b-669e-4937-bdac-4546ccc0a163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_ed2be9f7-2aa8-458c-bf2e-55d997354406" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbec220-b7bb-48a9-b69d-1d4f152ca681" xlink:to="loc_dei_DocumentFiscalPeriodFocus_ed2be9f7-2aa8-458c-bf2e-55d997354406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_e3a1eaf0-6edf-499c-8e0f-ca86efe1c1d4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1cbec220-b7bb-48a9-b69d-1d4f152ca681" xlink:to="loc_dei_AmendmentFlag_e3a1eaf0-6edf-499c-8e0f-ca86efe1c1d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_c3785321-dfc9-438c-9e65-8a46fa76c3c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_d1a0dd31-7c76-4c7a-872f-4db12fb745fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c3785321-dfc9-438c-9e65-8a46fa76c3c1" xlink:to="loc_us-gaap_AssetsAbstract_d1a0dd31-7c76-4c7a-872f-4db12fb745fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_90d85be5-6fb8-4729-bdf2-084433cfe8e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d1a0dd31-7c76-4c7a-872f-4db12fb745fa" xlink:to="loc_us-gaap_AssetsCurrentAbstract_90d85be5-6fb8-4729-bdf2-084433cfe8e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_cb6fe247-6131-4f56-849a-4a95bac4d32f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_90d85be5-6fb8-4729-bdf2-084433cfe8e2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_cb6fe247-6131-4f56-849a-4a95bac4d32f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a0026d50-2b20-4a88-81b8-ce960d99d20b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_90d85be5-6fb8-4729-bdf2-084433cfe8e2" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a0026d50-2b20-4a88-81b8-ce960d99d20b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_8466e97e-486b-43ac-91d7-b411b6a8b356" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_90d85be5-6fb8-4729-bdf2-084433cfe8e2" xlink:to="loc_us-gaap_AssetsCurrent_8466e97e-486b-43ac-91d7-b411b6a8b356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c618210a-9bb5-4b90-b4c7-d00896746aef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d1a0dd31-7c76-4c7a-872f-4db12fb745fa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_c618210a-9bb5-4b90-b4c7-d00896746aef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_7d59b83b-94e9-4fc9-8193-18c3f11ba271" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d1a0dd31-7c76-4c7a-872f-4db12fb745fa" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_7d59b83b-94e9-4fc9-8193-18c3f11ba271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_6c75e894-091c-4556-b88d-9b50f66c7b82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d1a0dd31-7c76-4c7a-872f-4db12fb745fa" xlink:to="loc_us-gaap_Assets_6c75e894-091c-4556-b88d-9b50f66c7b82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7b727984-2276-42a8-92a3-283ee3adbe7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c3785321-dfc9-438c-9e65-8a46fa76c3c1" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7b727984-2276-42a8-92a3-283ee3adbe7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_2da2f086-c214-40c3-b51a-23d89b586855" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7b727984-2276-42a8-92a3-283ee3adbe7e" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_2da2f086-c214-40c3-b51a-23d89b586855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_2356a632-1753-4251-9bfa-17c69b1a83d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2da2f086-c214-40c3-b51a-23d89b586855" xlink:to="loc_us-gaap_AccountsPayableCurrent_2356a632-1753-4251-9bfa-17c69b1a83d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_b7521353-4072-4a4b-a001-5c7d18310ece" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2da2f086-c214-40c3-b51a-23d89b586855" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_b7521353-4072-4a4b-a001-5c7d18310ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_EmployeeAdvancesCurrent_f0af2ee9-ac83-4ce0-972c-8c351877954d" xlink:href="ck0001824293-20230630.xsd#ck0001824293_EmployeeAdvancesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2da2f086-c214-40c3-b51a-23d89b586855" xlink:to="loc_ck0001824293_EmployeeAdvancesCurrent_f0af2ee9-ac83-4ce0-972c-8c351877954d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_db6e1178-96ff-4430-b460-836d3f44b10d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2da2f086-c214-40c3-b51a-23d89b586855" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_db6e1178-96ff-4430-b460-836d3f44b10d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_e99b69b6-2745-4044-a9ba-31b6fd919e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2da2f086-c214-40c3-b51a-23d89b586855" xlink:to="loc_us-gaap_NotesPayableCurrent_e99b69b6-2745-4044-a9ba-31b6fd919e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_bfed5893-812c-4d53-be62-a08a32aaad38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2da2f086-c214-40c3-b51a-23d89b586855" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_bfed5893-812c-4d53-be62-a08a32aaad38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_7c982dc9-f557-40b7-89cc-d6feb64252bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2da2f086-c214-40c3-b51a-23d89b586855" xlink:to="loc_us-gaap_LiabilitiesCurrent_7c982dc9-f557-40b7-89cc-d6feb64252bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9f2e3f5b-cd91-400f-b786-592be3b1e726" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7b727984-2276-42a8-92a3-283ee3adbe7e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9f2e3f5b-cd91-400f-b786-592be3b1e726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_755a6512-bd84-46dd-be85-708571984d09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7b727984-2276-42a8-92a3-283ee3adbe7e" xlink:to="loc_us-gaap_Liabilities_755a6512-bd84-46dd-be85-708571984d09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_90f572a5-d2f4-46fd-afcb-b3eeb7994af0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7b727984-2276-42a8-92a3-283ee3adbe7e" xlink:to="loc_us-gaap_CommitmentsAndContingencies_90f572a5-d2f4-46fd-afcb-b3eeb7994af0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_df30b28c-6924-4a01-a4a7-f63d64a8f90b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7b727984-2276-42a8-92a3-283ee3adbe7e" xlink:to="loc_us-gaap_StockholdersEquityAbstract_df30b28c-6924-4a01-a4a7-f63d64a8f90b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_a1190aa7-c21e-4823-88e9-473e254b7968" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_df30b28c-6924-4a01-a4a7-f63d64a8f90b" xlink:to="loc_us-gaap_CommonStockValueOutstanding_a1190aa7-c21e-4823-88e9-473e254b7968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_77b54139-8fee-44c1-86c4-17cba4c4ed0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_df30b28c-6924-4a01-a4a7-f63d64a8f90b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_77b54139-8fee-44c1-86c4-17cba4c4ed0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8a4c46c2-a9cb-43e8-81f4-55ecbc64f5f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_df30b28c-6924-4a01-a4a7-f63d64a8f90b" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8a4c46c2-a9cb-43e8-81f4-55ecbc64f5f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7fde03b8-a092-4d3f-8b54-07d4891382de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_df30b28c-6924-4a01-a4a7-f63d64a8f90b" xlink:to="loc_us-gaap_StockholdersEquity_7fde03b8-a092-4d3f-8b54-07d4891382de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_22bbc431-b46b-4177-91dc-9ab39c2c69d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_df30b28c-6924-4a01-a4a7-f63d64a8f90b" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_22bbc431-b46b-4177-91dc-9ab39c2c69d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_5790b317-38a8-4b69-b59c-bb81d61c5c53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c3785321-dfc9-438c-9e65-8a46fa76c3c1" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_5790b317-38a8-4b69-b59c-bb81d61c5c53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_a66d5a0c-2ae2-4d5b-99ed-627ef4ae91aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c3785321-dfc9-438c-9e65-8a46fa76c3c1" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_a66d5a0c-2ae2-4d5b-99ed-627ef4ae91aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_988a370c-aa27-4baa-9a96-22702c073263" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_36c7fbb0-e339-4344-a71c-bcbe05a24bcf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_988a370c-aa27-4baa-9a96-22702c073263" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_36c7fbb0-e339-4344-a71c-bcbe05a24bcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_499a3b0b-2ae5-4120-b238-369f3dfa0035" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_988a370c-aa27-4baa-9a96-22702c073263" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_499a3b0b-2ae5-4120-b238-369f3dfa0035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_ff25a62e-973d-4161-b1c9-0983fb887561" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_988a370c-aa27-4baa-9a96-22702c073263" xlink:to="loc_us-gaap_CommonStockSharesIssued_ff25a62e-973d-4161-b1c9-0983fb887561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_24c9f602-f75e-4675-a316-4407100adbd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_988a370c-aa27-4baa-9a96-22702c073263" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_24c9f602-f75e-4675-a316-4407100adbd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#ConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_e685ea99-cd00-4e67-b40f-1927ccd68eb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_af3dd5d2-fd04-455e-b8f7-fb5b46048d76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e685ea99-cd00-4e67-b40f-1927ccd68eb2" xlink:to="loc_us-gaap_OperatingExpensesAbstract_af3dd5d2-fd04-455e-b8f7-fb5b46048d76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_944ece5e-bafa-4eac-a507-53e81ffc8fab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_af3dd5d2-fd04-455e-b8f7-fb5b46048d76" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_944ece5e-bafa-4eac-a507-53e81ffc8fab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_c32df8d5-d83f-4f5c-994c-414030607da9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_af3dd5d2-fd04-455e-b8f7-fb5b46048d76" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_c32df8d5-d83f-4f5c-994c-414030607da9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_93dff797-8779-4f25-93f0-ca607186dbcc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_af3dd5d2-fd04-455e-b8f7-fb5b46048d76" xlink:to="loc_us-gaap_OperatingExpenses_93dff797-8779-4f25-93f0-ca607186dbcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_67ef90ac-63cd-4d40-ae75-b359290ecb37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e685ea99-cd00-4e67-b40f-1927ccd68eb2" xlink:to="loc_us-gaap_OperatingIncomeLoss_67ef90ac-63cd-4d40-ae75-b359290ecb37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ChangeInFairValueOfWarrantLiability_23a23498-f182-4f08-a334-2d2be50dbfd4" xlink:href="ck0001824293-20230630.xsd#ck0001824293_ChangeInFairValueOfWarrantLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e685ea99-cd00-4e67-b40f-1927ccd68eb2" xlink:to="loc_ck0001824293_ChangeInFairValueOfWarrantLiability_23a23498-f182-4f08-a334-2d2be50dbfd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_5057c50c-7c5c-4ab2-ae01-d6dc45b0497d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e685ea99-cd00-4e67-b40f-1927ccd68eb2" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_5057c50c-7c5c-4ab2-ae01-d6dc45b0497d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ba0ae405-7776-4a71-ae28-c9a760a5ac7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e685ea99-cd00-4e67-b40f-1927ccd68eb2" xlink:to="loc_us-gaap_NetIncomeLoss_ba0ae405-7776-4a71-ae28-c9a760a5ac7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_2958895c-6207-4cda-bf63-0534d13739c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e685ea99-cd00-4e67-b40f-1927ccd68eb2" xlink:to="loc_us-gaap_EarningsPerShareBasic_2958895c-6207-4cda-bf63-0534d13739c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1f3f10dc-d90e-4895-a90d-49319ea48861" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e685ea99-cd00-4e67-b40f-1927ccd68eb2" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1f3f10dc-d90e-4895-a90d-49319ea48861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_afe91547-e43e-4618-a2f2-bf11adf27a2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e685ea99-cd00-4e67-b40f-1927ccd68eb2" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_afe91547-e43e-4618-a2f2-bf11adf27a2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9e6eafec-3a6c-46f0-8341-7e0a948e9196" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e685ea99-cd00-4e67-b40f-1927ccd68eb2" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9e6eafec-3a6c-46f0-8341-7e0a948e9196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#ConsolidatedStatementsofChangesinStockholdersEquityDeficit"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_55e82583-1926-4ff4-aa51-238d9db5d571" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_cedd3b61-9766-45d5-8535-5b721fbd7824" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_55e82583-1926-4ff4-aa51-238d9db5d571" xlink:to="loc_us-gaap_StatementTable_cedd3b61-9766-45d5-8535-5b721fbd7824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e771519f-a0d7-4829-97ca-80093461d6d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cedd3b61-9766-45d5-8535-5b721fbd7824" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e771519f-a0d7-4829-97ca-80093461d6d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f5897778-8aac-4bbb-87ce-897aa5635fed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e771519f-a0d7-4829-97ca-80093461d6d3" xlink:to="loc_us-gaap_EquityComponentDomain_f5897778-8aac-4bbb-87ce-897aa5635fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_1add51ae-c9da-413d-9b7e-38dfb5f2af98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f5897778-8aac-4bbb-87ce-897aa5635fed" xlink:to="loc_us-gaap_CommonStockMember_1add51ae-c9da-413d-9b7e-38dfb5f2af98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_bf082b08-5610-4c35-8000-3aea7231bbf4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f5897778-8aac-4bbb-87ce-897aa5635fed" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_bf082b08-5610-4c35-8000-3aea7231bbf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_92d6958a-8c3f-44f4-8acb-bc9189460f6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f5897778-8aac-4bbb-87ce-897aa5635fed" xlink:to="loc_us-gaap_RetainedEarningsMember_92d6958a-8c3f-44f4-8acb-bc9189460f6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_89814d09-5485-49d4-b7d6-9285882b7d24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cedd3b61-9766-45d5-8535-5b721fbd7824" xlink:to="loc_us-gaap_StatementLineItems_89814d09-5485-49d4-b7d6-9285882b7d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_99430293-7458-4c36-aa54-209a433dff31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_89814d09-5485-49d4-b7d6-9285882b7d24" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_99430293-7458-4c36-aa54-209a433dff31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_0d0af341-f9b2-49fa-9efd-840544f8a5e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_99430293-7458-4c36-aa54-209a433dff31" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_0d0af341-f9b2-49fa-9efd-840544f8a5e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_d3b0113e-2ad3-4db8-8d74-d1dc3bf80683" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_99430293-7458-4c36-aa54-209a433dff31" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_d3b0113e-2ad3-4db8-8d74-d1dc3bf80683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_12fdbe09-915b-4581-ac46-8711cb283b62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_99430293-7458-4c36-aa54-209a433dff31" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_12fdbe09-915b-4581-ac46-8711cb283b62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_b3f2909e-c9c5-498f-95dd-77009fbce085" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_99430293-7458-4c36-aa54-209a433dff31" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_b3f2909e-c9c5-498f-95dd-77009fbce085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2059571e-f224-4959-9bd2-f55b89720978" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_89814d09-5485-49d4-b7d6-9285882b7d24" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2059571e-f224-4959-9bd2-f55b89720978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_7d894df8-88a8-4028-af85-0bd4dd53e3b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2059571e-f224-4959-9bd2-f55b89720978" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_7d894df8-88a8-4028-af85-0bd4dd53e3b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8ea002dd-1910-41fa-841a-dce282539e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2059571e-f224-4959-9bd2-f55b89720978" xlink:to="loc_us-gaap_StockholdersEquity_8ea002dd-1910-41fa-841a-dce282539e5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_a31be54a-f424-4803-a98f-a713cda6caf9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2059571e-f224-4959-9bd2-f55b89720978" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_a31be54a-f424-4803-a98f-a713cda6caf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c27681a3-58ae-45fe-ac7b-4bda2229ef6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2059571e-f224-4959-9bd2-f55b89720978" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c27681a3-58ae-45fe-ac7b-4bda2229ef6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_88eb7a37-8b84-4a5e-bb56-b6f37c384e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2059571e-f224-4959-9bd2-f55b89720978" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_88eb7a37-8b84-4a5e-bb56-b6f37c384e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise_2612507a-9e64-42c8-aa9f-2a52cd2bf6fc" xlink:href="ck0001824293-20230630.xsd#ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2059571e-f224-4959-9bd2-f55b89720978" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise_2612507a-9e64-42c8-aa9f-2a52cd2bf6fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValueWarrantExercises_ad3117f6-9125-4a14-a270-1b68fcd36f11" xlink:href="ck0001824293-20230630.xsd#ck0001824293_StockIssuedDuringPeriodValueWarrantExercises"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2059571e-f224-4959-9bd2-f55b89720978" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodValueWarrantExercises_ad3117f6-9125-4a14-a270-1b68fcd36f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing_21a91c78-b9d7-4b4a-8106-46fe6331da9d" xlink:href="ck0001824293-20230630.xsd#ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2059571e-f224-4959-9bd2-f55b89720978" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing_21a91c78-b9d7-4b4a-8106-46fe6331da9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing_119b7577-51a9-4801-be3b-129e528749f7" xlink:href="ck0001824293-20230630.xsd#ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2059571e-f224-4959-9bd2-f55b89720978" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing_119b7577-51a9-4801-be3b-129e528749f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt_7fb3bfd6-9cc0-43b8-b083-af47530638ac" xlink:href="ck0001824293-20230630.xsd#ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2059571e-f224-4959-9bd2-f55b89720978" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt_7fb3bfd6-9cc0-43b8-b083-af47530638ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt_5cc8f6a7-10c5-4f8d-a49e-02b543e35ddd" xlink:href="ck0001824293-20230630.xsd#ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2059571e-f224-4959-9bd2-f55b89720978" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt_5cc8f6a7-10c5-4f8d-a49e-02b543e35ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses_8a5b25f9-db37-4fac-928f-ff9586e7314e" xlink:href="ck0001824293-20230630.xsd#ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2059571e-f224-4959-9bd2-f55b89720978" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses_8a5b25f9-db37-4fac-928f-ff9586e7314e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses_c20342e6-6852-4983-bd81-4fcb8d7ab6fa" xlink:href="ck0001824293-20230630.xsd#ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2059571e-f224-4959-9bd2-f55b89720978" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses_c20342e6-6852-4983-bd81-4fcb8d7ab6fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization_c5bfb067-a871-4b6d-8ac0-851ff48f9390" xlink:href="ck0001824293-20230630.xsd#ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2059571e-f224-4959-9bd2-f55b89720978" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization_c5bfb067-a871-4b6d-8ac0-851ff48f9390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization_2a89f092-a94e-4e73-89d7-d3919e51a92e" xlink:href="ck0001824293-20230630.xsd#ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2059571e-f224-4959-9bd2-f55b89720978" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization_2a89f092-a94e-4e73-89d7-d3919e51a92e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_833737f9-6483-4a95-9e8b-66a77a0b5623" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2059571e-f224-4959-9bd2-f55b89720978" xlink:to="loc_us-gaap_NetIncomeLoss_833737f9-6483-4a95-9e8b-66a77a0b5623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_dee828d7-9fd4-4762-ad22-60e6375a8291" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2059571e-f224-4959-9bd2-f55b89720978" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_dee828d7-9fd4-4762-ad22-60e6375a8291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_63e50c64-4c7b-4d9e-a8ae-214c659b3b54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2059571e-f224-4959-9bd2-f55b89720978" xlink:to="loc_us-gaap_StockholdersEquity_63e50c64-4c7b-4d9e-a8ae-214c659b3b54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_120c81cf-c31b-4cb6-9830-7eed33320b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1cd81631-262b-4c82-a576-57f7fa8b3695" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_120c81cf-c31b-4cb6-9830-7eed33320b9c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1cd81631-262b-4c82-a576-57f7fa8b3695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2fc9839e-7c77-41f3-a072-7bc74e150c70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1cd81631-262b-4c82-a576-57f7fa8b3695" xlink:to="loc_us-gaap_NetIncomeLoss_2fc9839e-7c77-41f3-a072-7bc74e150c70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c5793c21-a854-45fe-acfd-d11ae60a5227" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1cd81631-262b-4c82-a576-57f7fa8b3695" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c5793c21-a854-45fe-acfd-d11ae60a5227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_9ffa2628-b612-4f3b-94b9-eb59636d21a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c5793c21-a854-45fe-acfd-d11ae60a5227" xlink:to="loc_us-gaap_Depreciation_9ffa2628-b612-4f3b-94b9-eb59636d21a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_6e6ec1e4-4c40-4062-8e5d-794bc695ee0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c5793c21-a854-45fe-acfd-d11ae60a5227" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_6e6ec1e4-4c40-4062-8e5d-794bc695ee0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_038f03c1-13ba-4502-b01b-d175f83f0c03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c5793c21-a854-45fe-acfd-d11ae60a5227" xlink:to="loc_us-gaap_ShareBasedCompensation_038f03c1-13ba-4502-b01b-d175f83f0c03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_ee2c2ddf-a4ef-4ca6-a238-e1a8f08c92d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c5793c21-a854-45fe-acfd-d11ae60a5227" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_ee2c2ddf-a4ef-4ca6-a238-e1a8f08c92d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_2e006a43-d8da-4feb-9d73-f03323b444d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c5793c21-a854-45fe-acfd-d11ae60a5227" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_2e006a43-d8da-4feb-9d73-f03323b444d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_56de2b9b-bf48-4df3-b4e6-ae25743f14d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c5793c21-a854-45fe-acfd-d11ae60a5227" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_56de2b9b-bf48-4df3-b4e6-ae25743f14d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d60facb0-d334-44f5-bd79-72de343347a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_56de2b9b-bf48-4df3-b4e6-ae25743f14d0" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d60facb0-d334-44f5-bd79-72de343347a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ade1fd3e-71d6-4578-9719-e10c2f458731" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_56de2b9b-bf48-4df3-b4e6-ae25743f14d0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ade1fd3e-71d6-4578-9719-e10c2f458731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_6f1d1221-9058-4d4a-be14-57839e0b5db1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_56de2b9b-bf48-4df3-b4e6-ae25743f14d0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_6f1d1221-9058-4d4a-be14-57839e0b5db1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_40a6b352-e655-4757-8f6d-bde76536ff86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_56de2b9b-bf48-4df3-b4e6-ae25743f14d0" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_40a6b352-e655-4757-8f6d-bde76536ff86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e95cec52-4ddc-4aeb-8f14-ff7f979f1275" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c5793c21-a854-45fe-acfd-d11ae60a5227" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e95cec52-4ddc-4aeb-8f14-ff7f979f1275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7ba14d6d-6a34-4f14-962e-ca7c26dd7a23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_120c81cf-c31b-4cb6-9830-7eed33320b9c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7ba14d6d-6a34-4f14-962e-ca7c26dd7a23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f5935118-af06-4a90-afd9-2dc1432b4ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7ba14d6d-6a34-4f14-962e-ca7c26dd7a23" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f5935118-af06-4a90-afd9-2dc1432b4ce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_67059bea-3578-4d92-8772-169c52704ff7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7ba14d6d-6a34-4f14-962e-ca7c26dd7a23" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_67059bea-3578-4d92-8772-169c52704ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0e86f96c-6262-4bf4-a16b-eaa5b8eb51c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_120c81cf-c31b-4cb6-9830-7eed33320b9c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0e86f96c-6262-4bf4-a16b-eaa5b8eb51c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ProceedsFromAdvancesFromEmployees_6797f623-3839-4a0b-b05d-e29640f5b38b" xlink:href="ck0001824293-20230630.xsd#ck0001824293_ProceedsFromAdvancesFromEmployees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0e86f96c-6262-4bf4-a16b-eaa5b8eb51c1" xlink:to="loc_ck0001824293_ProceedsFromAdvancesFromEmployees_6797f623-3839-4a0b-b05d-e29640f5b38b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_RepaymentOfAdvancesFromEmployees_dd653e5a-6232-409c-a677-d616c1b19a1f" xlink:href="ck0001824293-20230630.xsd#ck0001824293_RepaymentOfAdvancesFromEmployees"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0e86f96c-6262-4bf4-a16b-eaa5b8eb51c1" xlink:to="loc_ck0001824293_RepaymentOfAdvancesFromEmployees_dd653e5a-6232-409c-a677-d616c1b19a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_661792b4-fe95-4daf-9fb0-b2f7896b3ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0e86f96c-6262-4bf4-a16b-eaa5b8eb51c1" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_661792b4-fe95-4daf-9fb0-b2f7896b3ec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_89238159-1de3-4cd5-b8fb-c17728dfe318" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0e86f96c-6262-4bf4-a16b-eaa5b8eb51c1" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_89238159-1de3-4cd5-b8fb-c17728dfe318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_d6173ae8-ca4d-4a2f-b7c1-5986ce9c2442" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0e86f96c-6262-4bf4-a16b-eaa5b8eb51c1" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_d6173ae8-ca4d-4a2f-b7c1-5986ce9c2442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization_af67e2b7-ef14-4e13-93a2-ab931c301b83" xlink:href="ck0001824293-20230630.xsd#ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0e86f96c-6262-4bf4-a16b-eaa5b8eb51c1" xlink:to="loc_ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization_af67e2b7-ef14-4e13-93a2-ab931c301b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PaymentOfReverseRecapitalizationCosts_93993516-8796-4e58-8962-5ae852bd0c84" xlink:href="ck0001824293-20230630.xsd#ck0001824293_PaymentOfReverseRecapitalizationCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0e86f96c-6262-4bf4-a16b-eaa5b8eb51c1" xlink:to="loc_ck0001824293_PaymentOfReverseRecapitalizationCosts_93993516-8796-4e58-8962-5ae852bd0c84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_a034dcb0-10a6-48fe-8c60-a4c3de9c8fed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0e86f96c-6262-4bf4-a16b-eaa5b8eb51c1" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_a034dcb0-10a6-48fe-8c60-a4c3de9c8fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_9efda478-1b11-4939-b553-e9ae6445fe60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0e86f96c-6262-4bf4-a16b-eaa5b8eb51c1" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_9efda478-1b11-4939-b553-e9ae6445fe60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5588fff1-6928-4676-94e1-0c28c8362f79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0e86f96c-6262-4bf4-a16b-eaa5b8eb51c1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5588fff1-6928-4676-94e1-0c28c8362f79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a3328d36-c758-4d6c-a0b7-0f9bdaa3e125" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_120c81cf-c31b-4cb6-9830-7eed33320b9c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a3328d36-c758-4d6c-a0b7-0f9bdaa3e125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5c1298de-6077-4291-82cd-f71b949340d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_120c81cf-c31b-4cb6-9830-7eed33320b9c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5c1298de-6077-4291-82cd-f71b949340d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_aeb02703-b0b3-471f-b22c-c1507fa37319" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_120c81cf-c31b-4cb6-9830-7eed33320b9c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_aeb02703-b0b3-471f-b22c-c1507fa37319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_4a0ea36f-5f49-4dd8-b360-bf4b3f4972c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_120c81cf-c31b-4cb6-9830-7eed33320b9c" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_4a0ea36f-5f49-4dd8-b360-bf4b3f4972c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedForRepaymentOfNotesPayable_ed8c3805-1b95-4840-b5ed-86ecd6fd981a" xlink:href="ck0001824293-20230630.xsd#ck0001824293_StockIssuedForRepaymentOfNotesPayable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_4a0ea36f-5f49-4dd8-b360-bf4b3f4972c5" xlink:to="loc_ck0001824293_StockIssuedForRepaymentOfNotesPayable_ed8c3805-1b95-4840-b5ed-86ecd6fd981a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants_ac80773a-2003-4613-834d-0d47b77e61ca" xlink:href="ck0001824293-20230630.xsd#ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_4a0ea36f-5f49-4dd8-b360-bf4b3f4972c5" xlink:to="loc_ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants_ac80773a-2003-4613-834d-0d47b77e61ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts_28e2f205-4b71-4b51-b363-f1cc43926c82" xlink:href="ck0001824293-20230630.xsd#ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_4a0ea36f-5f49-4dd8-b360-bf4b3f4972c5" xlink:to="loc_ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts_28e2f205-4b71-4b51-b363-f1cc43926c82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsIssued_024c210b-0e76-4109-aea8-6d721bb1107a" xlink:href="ck0001824293-20230630.xsd#ck0001824293_WarrantsIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_4a0ea36f-5f49-4dd8-b360-bf4b3f4972c5" xlink:to="loc_ck0001824293_WarrantsIssued_024c210b-0e76-4109-aea8-6d721bb1107a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_NoncashMergerRelatedCostsFinancingActivities_f27b30b7-8feb-410b-9eb6-fdfaec8492be" xlink:href="ck0001824293-20230630.xsd#ck0001824293_NoncashMergerRelatedCostsFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_4a0ea36f-5f49-4dd8-b360-bf4b3f4972c5" xlink:to="loc_ck0001824293_NoncashMergerRelatedCostsFinancingActivities_f27b30b7-8feb-410b-9eb6-fdfaec8492be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#ORGANIZATIONANDDESCRIPTIONOFBUSINESS"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_24cbca0f-dd61-4770-819a-a88313897c17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_63bad29f-95f2-4bf6-8512-e30c1019b337" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_24cbca0f-dd61-4770-819a-a88313897c17" xlink:to="loc_us-gaap_NatureOfOperations_63bad29f-95f2-4bf6-8512-e30c1019b337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/LIQUIDITY" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#LIQUIDITY"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/LIQUIDITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_211d89a7-93bd-4d77-9d82-c725ddea2910" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_2c7bfa81-6784-4bb7-bfc7-133544dadd95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_211d89a7-93bd-4d77-9d82-c725ddea2910" xlink:to="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_2c7bfa81-6784-4bb7-bfc7-133544dadd95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ad1cbafc-5030-4fde-a93e-0e849407b858" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_44f468b0-be06-49fc-97c4-89b6f182fe7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ad1cbafc-5030-4fde-a93e-0e849407b858" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_44f468b0-be06-49fc-97c4-89b6f182fe7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/MERGERWITHVALLON" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#MERGERWITHVALLON"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/MERGERWITHVALLON" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_8c471974-3b35-4e6a-b9e8-f96b0f9ce50f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_e7016ea6-0849-418d-a7a6-19466bfe3c81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_8c471974-3b35-4e6a-b9e8-f96b0f9ce50f" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_e7016ea6-0849-418d-a7a6-19466bfe3c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTS" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#FAIRVALUEMEASUREMENTS"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_49731faa-5b6e-4e49-b375-e9612ea6571e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_dac682d8-ed31-4a0d-9783-096dee43ab7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_49731faa-5b6e-4e49-b375-e9612ea6571e" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_dac682d8-ed31-4a0d-9783-096dee43ab7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENT" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#PROPERTYANDEQUIPMENT"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e331b315-e436-4a8e-b764-5bf928d021ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_3f7f8165-5f88-4c0a-84be-88122968600a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e331b315-e436-4a8e-b764-5bf928d021ba" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_3f7f8165-5f88-4c0a-84be-88122968600a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSES" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#ACCRUEDEXPENSES"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ACCRUEDEXPENSES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_2328b4f8-184c-414c-ae3f-0354e74e1977" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_71c02d62-6e46-4d93-aa8b-88bdb4e5a098" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_2328b4f8-184c-414c-ae3f-0354e74e1977" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_71c02d62-6e46-4d93-aa8b-88bdb4e5a098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/PROMISSORYNOTES" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#PROMISSORYNOTES"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/PROMISSORYNOTES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_fea3e511-3f33-44e7-8a30-a8e013d5be21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_331d3424-1128-428e-8489-6dac68c38d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_fea3e511-3f33-44e7-8a30-a8e013d5be21" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_331d3424-1128-428e-8489-6dac68c38d5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#STOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_60d8e60a-98d7-485e-b90f-1d8feba10e71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_f19262ba-2f51-406e-897e-4cdd8dbd904f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_60d8e60a-98d7-485e-b90f-1d8feba10e71" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_f19262ba-2f51-406e-897e-4cdd8dbd904f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#STOCKBASEDCOMPENSATION"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_099cd2a2-bd6e-4cda-9661-7a5a4914180b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_c7c6c33e-c339-45bb-a7a0-630012ea62e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_099cd2a2-bd6e-4cda-9661-7a5a4914180b" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_c7c6c33e-c339-45bb-a7a0-630012ea62e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f9be295b-60cc-40c5-a11c-97507c3011f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0264a115-8b2e-44c9-9194-523c8b0a765f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f9be295b-60cc-40c5-a11c-97507c3011f9" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0264a115-8b2e-44c9-9194-523c8b0a765f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c5df31fe-4b11-4d04-9dc0-6d05508e5358" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_95b47a28-b3ea-4024-88fa-9b1a597102a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c5df31fe-4b11-4d04-9dc0-6d05508e5358" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_95b47a28-b3ea-4024-88fa-9b1a597102a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_76f23dab-09d9-4a14-bf5b-05d83cc081b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c5df31fe-4b11-4d04-9dc0-6d05508e5358" xlink:to="loc_us-gaap_UseOfEstimates_76f23dab-09d9-4a14-bf5b-05d83cc081b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_7a549621-7fc1-43fe-a972-1143cf95c3f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c5df31fe-4b11-4d04-9dc0-6d05508e5358" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_7a549621-7fc1-43fe-a972-1143cf95c3f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_831d60cb-4e7f-4116-ba06-32058738e4d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c5df31fe-4b11-4d04-9dc0-6d05508e5358" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_831d60cb-4e7f-4116-ba06-32058738e4d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock_57d3ec42-c363-4969-a741-46fcfcf3768f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c5df31fe-4b11-4d04-9dc0-6d05508e5358" xlink:to="loc_us-gaap_DeferredChargesPolicyTextBlock_57d3ec42-c363-4969-a741-46fcfcf3768f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtPolicyTextBlock_c702c75b-1f94-4c1b-a4ed-da12a229df0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c5df31fe-4b11-4d04-9dc0-6d05508e5358" xlink:to="loc_us-gaap_DebtPolicyTextBlock_c702c75b-1f94-4c1b-a4ed-da12a229df0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_b304fd64-30ad-4955-b311-622b68332e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c5df31fe-4b11-4d04-9dc0-6d05508e5358" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_b304fd64-30ad-4955-b311-622b68332e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_ea7c66df-06bd-4301-9500-ab6d1f97ca2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c5df31fe-4b11-4d04-9dc0-6d05508e5358" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_ea7c66df-06bd-4301-9500-ab6d1f97ca2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2b3ae4e8-2e5d-47b7-9560-593696105028" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c5df31fe-4b11-4d04-9dc0-6d05508e5358" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2b3ae4e8-2e5d-47b7-9560-593696105028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a38b6626-042e-48c9-a574-bda70f863527" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_359ed4e5-7cf7-45bc-b465-ba98ab605a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a38b6626-042e-48c9-a574-bda70f863527" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_359ed4e5-7cf7-45bc-b465-ba98ab605a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/MERGERWITHVALLONTables" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#MERGERWITHVALLONTables"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/MERGERWITHVALLONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_eb85c886-7d9d-439f-9712-84f18d1fc4a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_e0cde1f7-9555-4bf9-bd07-56b12bd5d29b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_eb85c886-7d9d-439f-9712-84f18d1fc4a8" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_e0cde1f7-9555-4bf9-bd07-56b12bd5d29b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#FAIRVALUEMEASUREMENTSTables"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_fadfbc16-5b66-454c-89d3-dc97b1c6ec89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_55d6113c-e7eb-4462-8872-82f3f8a4a622" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_fadfbc16-5b66-454c-89d3-dc97b1c6ec89" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_55d6113c-e7eb-4462-8872-82f3f8a4a622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_40638da6-fe87-4b14-bd80-7f16d798c016" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_fadfbc16-5b66-454c-89d3-dc97b1c6ec89" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_40638da6-fe87-4b14-bd80-7f16d798c016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_fee31fb1-0c8e-4cbd-a4c0-e8b9a7151200" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_fadfbc16-5b66-454c-89d3-dc97b1c6ec89" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_fee31fb1-0c8e-4cbd-a4c0-e8b9a7151200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTTables" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#PROPERTYANDEQUIPMENTTables"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c3c3bbd6-a8c7-4413-b31d-225312cbc614" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_5a9f070d-52ee-406c-9b21-d97e79b4c696" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c3c3bbd6-a8c7-4413-b31d-225312cbc614" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_5a9f070d-52ee-406c-9b21-d97e79b4c696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#ACCRUEDEXPENSESTables"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_af73d5bd-9f91-450c-885c-6b2cb8cd7194" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_d0e253bb-5795-4695-912d-1dff41f90bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_af73d5bd-9f91-450c-885c-6b2cb8cd7194" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_d0e253bb-5795-4695-912d-1dff41f90bbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYTables" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#STOCKHOLDERSEQUITYTables"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_a5de394d-f15d-4a65-9187-a271e4bf25a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_e3496015-cae2-4dfb-8588-f5d6a16739f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a5de394d-f15d-4a65-9187-a271e4bf25a3" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_e3496015-cae2-4dfb-8588-f5d6a16739f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_aa9f9f60-d3a0-4a6d-a8c4-04c1e1ab7ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a5de394d-f15d-4a65-9187-a271e4bf25a3" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_aa9f9f60-d3a0-4a6d-a8c4-04c1e1ab7ba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#STOCKBASEDCOMPENSATIONTables"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_82c8d14c-eb5c-45ff-bb71-faca367bf69c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_9bc16a15-c628-4e1f-b251-36cb65ae57af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_82c8d14c-eb5c-45ff-bb71-faca367bf69c" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_9bc16a15-c628-4e1f-b251-36cb65ae57af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_fb82af1c-eacc-40b9-91d9-77d2f9ea88c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_82c8d14c-eb5c-45ff-bb71-faca367bf69c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_fb82af1c-eacc-40b9-91d9-77d2f9ea88c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_c7a69ae9-7900-4c60-af41-aa0a1992bc88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_82c8d14c-eb5c-45ff-bb71-faca367bf69c" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_c7a69ae9-7900-4c60-af41-aa0a1992bc88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fc45c18f-ae45-4d8e-a4e2-59def0b2535c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_b178e87c-dbdf-4f8c-b17a-f61eecae1a87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fc45c18f-ae45-4d8e-a4e2-59def0b2535c" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_b178e87c-dbdf-4f8c-b17a-f61eecae1a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_CommonStockExchangeRatio_fa153fae-38bf-4e67-87a5-30399647eafd" xlink:href="ck0001824293-20230630.xsd#ck0001824293_CommonStockExchangeRatio"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fc45c18f-ae45-4d8e-a4e2-59def0b2535c" xlink:to="loc_ck0001824293_CommonStockExchangeRatio_fa153fae-38bf-4e67-87a5-30399647eafd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/LIQUIDITYDetails" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#LIQUIDITYDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/LIQUIDITYDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b964f914-dad3-4c6f-b0e0-296c3fb08f34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0a45d883-1f22-4375-b953-eefbb1a0f974" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b964f914-dad3-4c6f-b0e0-296c3fb08f34" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0a45d883-1f22-4375-b953-eefbb1a0f974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d6ccae43-6813-4dc2-92f0-3f57c2ccaf24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b964f914-dad3-4c6f-b0e0-296c3fb08f34" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d6ccae43-6813-4dc2-92f0-3f57c2ccaf24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f4ba456c-d167-44ad-a50d-72a9eaec7f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b964f914-dad3-4c6f-b0e0-296c3fb08f34" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f4ba456c-d167-44ad-a50d-72a9eaec7f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1b8086d3-aeec-42d6-9a9f-dc35fcfe3691" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f4ba456c-d167-44ad-a50d-72a9eaec7f2b" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1b8086d3-aeec-42d6-9a9f-dc35fcfe3691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_8b83742b-1b30-4489-a545-a8b3d3fc4e94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1b8086d3-aeec-42d6-9a9f-dc35fcfe3691" xlink:to="loc_us-gaap_RelatedPartyDomain_8b83742b-1b30-4489-a545-a8b3d3fc4e94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestorMember_8e0824ca-04f0-415e-82d6-348d163df07f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_8b83742b-1b30-4489-a545-a8b3d3fc4e94" xlink:to="loc_us-gaap_InvestorMember_8e0824ca-04f0-415e-82d6-348d163df07f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_773c6d8a-2829-4bba-9f62-941b1799a9b4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f4ba456c-d167-44ad-a50d-72a9eaec7f2b" xlink:to="loc_dei_LegalEntityAxis_773c6d8a-2829-4bba-9f62-941b1799a9b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_3eeb9cc1-f9ff-4342-b175-dd41dba7ebfb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_773c6d8a-2829-4bba-9f62-941b1799a9b4" xlink:to="loc_dei_EntityDomain_3eeb9cc1-f9ff-4342-b175-dd41dba7ebfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PrivateGRIMember_020651ba-93d3-404f-bab7-543abcff5dfa" xlink:href="ck0001824293-20230630.xsd#ck0001824293_PrivateGRIMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_3eeb9cc1-f9ff-4342-b175-dd41dba7ebfb" xlink:to="loc_ck0001824293_PrivateGRIMember_020651ba-93d3-404f-bab7-543abcff5dfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_79841a28-dbfe-4ec5-8dff-e2255ac3e5ce" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f4ba456c-d167-44ad-a50d-72a9eaec7f2b" xlink:to="loc_srt_CounterpartyNameAxis_79841a28-dbfe-4ec5-8dff-e2255ac3e5ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_71c0c583-6218-4721-a9b3-ce17a70dec79" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_79841a28-dbfe-4ec5-8dff-e2255ac3e5ce" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_71c0c583-6218-4721-a9b3-ce17a70dec79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_GRIBioIncMember_9b31bf4b-4816-4599-b8ed-33d8085ecd6b" xlink:href="ck0001824293-20230630.xsd#ck0001824293_GRIBioIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_71c0c583-6218-4721-a9b3-ce17a70dec79" xlink:to="loc_ck0001824293_GRIBioIncMember_9b31bf4b-4816-4599-b8ed-33d8085ecd6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b8216ae5-52b7-4dca-baf1-b77862d0ac89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f4ba456c-d167-44ad-a50d-72a9eaec7f2b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b8216ae5-52b7-4dca-baf1-b77862d0ac89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f8cb03ba-3653-458f-8283-fb3804b491ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b8216ae5-52b7-4dca-baf1-b77862d0ac89" xlink:to="loc_us-gaap_EquityComponentDomain_f8cb03ba-3653-458f-8283-fb3804b491ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_5fc8bbe2-6219-4168-9465-8165f8583afa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f8cb03ba-3653-458f-8283-fb3804b491ac" xlink:to="loc_us-gaap_CommonStockMember_5fc8bbe2-6219-4168-9465-8165f8583afa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_2a9d5fe8-62d4-4941-af27-9d784acc2cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f4ba456c-d167-44ad-a50d-72a9eaec7f2b" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_2a9d5fe8-62d4-4941-af27-9d784acc2cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentCompanyCommittedCapital_4db452ba-62a1-4694-9036-a9e274e80201" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentCompanyCommittedCapital"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2a9d5fe8-62d4-4941-af27-9d784acc2cd7" xlink:to="loc_us-gaap_InvestmentCompanyCommittedCapital_4db452ba-62a1-4694-9036-a9e274e80201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_40338850-0c0d-49fb-a11c-b826bc1f177b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2a9d5fe8-62d4-4941-af27-9d784acc2cd7" xlink:to="loc_us-gaap_CommonStockSharesIssued_40338850-0c0d-49fb-a11c-b826bc1f177b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_CommonStockHeldIntoEscrowAccount_67a4ecbf-831b-476f-90b9-f6ad3dea5cd5" xlink:href="ck0001824293-20230630.xsd#ck0001824293_CommonStockHeldIntoEscrowAccount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2a9d5fe8-62d4-4941-af27-9d784acc2cd7" xlink:to="loc_ck0001824293_CommonStockHeldIntoEscrowAccount_67a4ecbf-831b-476f-90b9-f6ad3dea5cd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_82771355-9ce7-4c0a-a8b2-ccef4103b804" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2a9d5fe8-62d4-4941-af27-9d784acc2cd7" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_82771355-9ce7-4c0a-a8b2-ccef4103b804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_14864c02-3239-4ba3-bd3d-617ef6cea5a7" xlink:href="ck0001824293-20230630.xsd#ck0001824293_StockIssuanceCostsOfferingExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2a9d5fe8-62d4-4941-af27-9d784acc2cd7" xlink:to="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_14864c02-3239-4ba3-bd3d-617ef6cea5a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_a76b7252-16a6-4638-ac02-c4d765d5fe26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2a9d5fe8-62d4-4941-af27-9d784acc2cd7" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_a76b7252-16a6-4638-ac02-c4d765d5fe26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ConversionOfStockAdditionalSharesConverted_0e2b9e81-af18-4deb-9834-3cef8fee86a0" xlink:href="ck0001824293-20230630.xsd#ck0001824293_ConversionOfStockAdditionalSharesConverted"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2a9d5fe8-62d4-4941-af27-9d784acc2cd7" xlink:to="loc_ck0001824293_ConversionOfStockAdditionalSharesConverted_0e2b9e81-af18-4deb-9834-3cef8fee86a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0fbe2612-5cb1-4e70-afe7-3dfa5347eef9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFDICInsuredAmount_16a1cf59-739f-4bb1-a21f-ff73312f11fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0fbe2612-5cb1-4e70-afe7-3dfa5347eef9" xlink:to="loc_us-gaap_CashFDICInsuredAmount_16a1cf59-739f-4bb1-a21f-ff73312f11fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashUninsuredAmount_17e504a6-ed59-414d-9760-401b7633425b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashUninsuredAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0fbe2612-5cb1-4e70-afe7-3dfa5347eef9" xlink:to="loc_us-gaap_CashUninsuredAmount_17e504a6-ed59-414d-9760-401b7633425b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e96e0416-29c8-4adf-ad5d-e205b7b92e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8ce62d65-b5c0-4df8-a8a3-393540344375" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e96e0416-29c8-4adf-ad5d-e205b7b92e2b" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8ce62d65-b5c0-4df8-a8a3-393540344375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_55e6b29b-db7f-420e-9e60-a6c2fd5db180" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8ce62d65-b5c0-4df8-a8a3-393540344375" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_55e6b29b-db7f-420e-9e60-a6c2fd5db180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_dd242a3a-9ea5-4e5d-94c1-180d1d8d34cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_55e6b29b-db7f-420e-9e60-a6c2fd5db180" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_dd242a3a-9ea5-4e5d-94c1-180d1d8d34cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e54268a7-a695-44f7-809a-3bbefb1a8722" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_dd242a3a-9ea5-4e5d-94c1-180d1d8d34cd" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e54268a7-a695-44f7-809a-3bbefb1a8722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_285b9416-0a72-4c6e-9019-74d63f12a15a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_dd242a3a-9ea5-4e5d-94c1-180d1d8d34cd" xlink:to="loc_us-gaap_WarrantMember_285b9416-0a72-4c6e-9019-74d63f12a15a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_6cf13921-140d-410f-9e87-1af2d1a4342b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_dd242a3a-9ea5-4e5d-94c1-180d1d8d34cd" xlink:to="loc_us-gaap_RestrictedStockMember_6cf13921-140d-410f-9e87-1af2d1a4342b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockSubjectToPutRightMember_0203f5bd-6862-4eed-a1bb-29e72600cec9" xlink:href="ck0001824293-20230630.xsd#ck0001824293_StockSubjectToPutRightMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_dd242a3a-9ea5-4e5d-94c1-180d1d8d34cd" xlink:to="loc_ck0001824293_StockSubjectToPutRightMember_0203f5bd-6862-4eed-a1bb-29e72600cec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ConvertiblePromissoryNoteMember_5769fd83-a605-4d73-93f3-78428c490497" xlink:href="ck0001824293-20230630.xsd#ck0001824293_ConvertiblePromissoryNoteMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_dd242a3a-9ea5-4e5d-94c1-180d1d8d34cd" xlink:to="loc_ck0001824293_ConvertiblePromissoryNoteMember_5769fd83-a605-4d73-93f3-78428c490497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ef97fa5b-acba-4bb6-a5f9-9d09fe9ff7f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8ce62d65-b5c0-4df8-a8a3-393540344375" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ef97fa5b-acba-4bb6-a5f9-9d09fe9ff7f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6c67e785-cea8-44f9-a393-be227be6b232" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ef97fa5b-acba-4bb6-a5f9-9d09fe9ff7f3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6c67e785-cea8-44f9-a393-be227be6b232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#MERGERWITHVALLONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_9c0ad3dc-dbd9-4d27-a35e-83665562fb56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b69adb0f-1bb9-4e84-bd1f-c8f5605059e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_9c0ad3dc-dbd9-4d27-a35e-83665562fb56" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b69adb0f-1bb9-4e84-bd1f-c8f5605059e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_80840bb8-903a-4e82-a281-adafc32aae5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b69adb0f-1bb9-4e84-bd1f-c8f5605059e2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_80840bb8-903a-4e82-a281-adafc32aae5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_f9c31ac0-7dcd-4303-939d-2f45260fe294" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_80840bb8-903a-4e82-a281-adafc32aae5b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_f9c31ac0-7dcd-4303-939d-2f45260fe294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ExchangeWarrantsMember_cfba75e4-1861-405d-a749-8db084c83307" xlink:href="ck0001824293-20230630.xsd#ck0001824293_ExchangeWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_f9c31ac0-7dcd-4303-939d-2f45260fe294" xlink:to="loc_ck0001824293_ExchangeWarrantsMember_cfba75e4-1861-405d-a749-8db084c83307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_cc2b05cc-6ff0-4176-b71b-1541d568ca2f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b69adb0f-1bb9-4e84-bd1f-c8f5605059e2" xlink:to="loc_dei_LegalEntityAxis_cc2b05cc-6ff0-4176-b71b-1541d568ca2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_0e6a1227-500c-4ea8-9385-a22abbc70191" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_cc2b05cc-6ff0-4176-b71b-1541d568ca2f" xlink:to="loc_dei_EntityDomain_0e6a1227-500c-4ea8-9385-a22abbc70191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PrivateGRIMember_9d93492b-f46d-4f23-8123-9b2d96f53d09" xlink:href="ck0001824293-20230630.xsd#ck0001824293_PrivateGRIMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_0e6a1227-500c-4ea8-9385-a22abbc70191" xlink:to="loc_ck0001824293_PrivateGRIMember_9d93492b-f46d-4f23-8123-9b2d96f53d09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_cc6796a0-2ddc-4617-b3ad-393a0549339e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b69adb0f-1bb9-4e84-bd1f-c8f5605059e2" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_cc6796a0-2ddc-4617-b3ad-393a0549339e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1b29c2af-aa46-4d5c-943d-19206a8eec27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cc6796a0-2ddc-4617-b3ad-393a0549339e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1b29c2af-aa46-4d5c-943d-19206a8eec27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_4f84962d-872d-45b1-bb64-97cda69372ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cc6796a0-2ddc-4617-b3ad-393a0549339e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_4f84962d-872d-45b1-bb64-97cda69372ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_CommonStockOwnershipPercentage_ab7fc6bf-0b3d-4c73-9309-563840b052d2" xlink:href="ck0001824293-20230630.xsd#ck0001824293_CommonStockOwnershipPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cc6796a0-2ddc-4617-b3ad-393a0549339e" xlink:to="loc_ck0001824293_CommonStockOwnershipPercentage_ab7fc6bf-0b3d-4c73-9309-563840b052d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_95f83a81-66fb-4e4c-902d-4d802285523d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cc6796a0-2ddc-4617-b3ad-393a0549339e" xlink:to="loc_us-gaap_CommonStockSharesIssued_95f83a81-66fb-4e4c-902d-4d802285523d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses_11121536-ffc6-4ae8-ad3c-41e20aaeb546" xlink:href="ck0001824293-20230630.xsd#ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cc6796a0-2ddc-4617-b3ad-393a0549339e" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses_11121536-ffc6-4ae8-ad3c-41e20aaeb546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_b51b0634-7259-4679-9129-b00f018cdcdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0bbfdcd8-4e1f-4ec7-a7e1-f4a1374a1dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_b51b0634-7259-4679-9129-b00f018cdcdd" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0bbfdcd8-4e1f-4ec7-a7e1-f4a1374a1dbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_bded7499-782d-4f2e-aa66-2a8d2987b929" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0bbfdcd8-4e1f-4ec7-a7e1-f4a1374a1dbd" xlink:to="loc_dei_LegalEntityAxis_bded7499-782d-4f2e-aa66-2a8d2987b929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_14b0f557-47a1-4767-ade8-839dfe48f424" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_bded7499-782d-4f2e-aa66-2a8d2987b929" xlink:to="loc_dei_EntityDomain_14b0f557-47a1-4767-ade8-839dfe48f424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PrivateGRIMember_381d3116-cd50-4e82-b32f-2609879ad31a" xlink:href="ck0001824293-20230630.xsd#ck0001824293_PrivateGRIMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_14b0f557-47a1-4767-ade8-839dfe48f424" xlink:to="loc_ck0001824293_PrivateGRIMember_381d3116-cd50-4e82-b32f-2609879ad31a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_403b6cb1-cb16-446f-a3b5-a7a18d46fe8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0bbfdcd8-4e1f-4ec7-a7e1-f4a1374a1dbd" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_403b6cb1-cb16-446f-a3b5-a7a18d46fe8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_c9f056a1-c9ed-4734-827b-a4a652439b15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_403b6cb1-cb16-446f-a3b5-a7a18d46fe8f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_c9f056a1-c9ed-4734-827b-a4a652439b15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_2ad10dca-d1f0-4e9b-996a-3a7415798639" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_403b6cb1-cb16-446f-a3b5-a7a18d46fe8f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_2ad10dca-d1f0-4e9b-996a-3a7415798639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses_d72e28fd-5ff1-4a70-babd-53fe5ba26790" xlink:href="ck0001824293-20230630.xsd#ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_403b6cb1-cb16-446f-a3b5-a7a18d46fe8f" xlink:to="loc_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses_d72e28fd-5ff1-4a70-babd-53fe5ba26790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_a9df73f8-731e-44a0-b438-4b8890f865c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_403b6cb1-cb16-446f-a3b5-a7a18d46fe8f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_a9df73f8-731e-44a0-b438-4b8890f865c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_de161cb4-fbe5-4e42-b288-9988c47f7255" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_403b6cb1-cb16-446f-a3b5-a7a18d46fe8f" xlink:to="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_de161cb4-fbe5-4e42-b288-9988c47f7255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts_00ad90be-66dd-4bdb-93bb-ca3cf286ddd5" xlink:href="ck0001824293-20230630.xsd#ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_403b6cb1-cb16-446f-a3b5-a7a18d46fe8f" xlink:to="loc_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts_00ad90be-66dd-4bdb-93bb-ca3cf286ddd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails_1" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails_1"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f2fb05b1-67e9-4a01-92b0-7f0e3a453e15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f5a81ec4-222d-41f1-9c18-7e31f13604e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f2fb05b1-67e9-4a01-92b0-7f0e3a453e15" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f5a81ec4-222d-41f1-9c18-7e31f13604e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6ebc41ac-60df-4fcd-bb59-a6cba6a5a45a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f5a81ec4-222d-41f1-9c18-7e31f13604e7" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6ebc41ac-60df-4fcd-bb59-a6cba6a5a45a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b0c0b1d6-8074-4a0c-a2ec-f8c8c9376725" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6ebc41ac-60df-4fcd-bb59-a6cba6a5a45a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b0c0b1d6-8074-4a0c-a2ec-f8c8c9376725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_1179c5ba-14ef-437c-8068-ceadef6a8c14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b0c0b1d6-8074-4a0c-a2ec-f8c8c9376725" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_1179c5ba-14ef-437c-8068-ceadef6a8c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_0a5733a4-5f0e-4c10-b5fc-93394c94e443" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b0c0b1d6-8074-4a0c-a2ec-f8c8c9376725" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_0a5733a4-5f0e-4c10-b5fc-93394c94e443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_3fed1346-540f-4c9f-9c48-66486fa749fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b0c0b1d6-8074-4a0c-a2ec-f8c8c9376725" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_3fed1346-540f-4c9f-9c48-66486fa749fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_33da1d0f-8d46-49cf-854c-d59f1e99a733" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f5a81ec4-222d-41f1-9c18-7e31f13604e7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_33da1d0f-8d46-49cf-854c-d59f1e99a733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_7809fbe5-acab-4f68-bc30-513375fc636a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_33da1d0f-8d46-49cf-854c-d59f1e99a733" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_7809fbe5-acab-4f68-bc30-513375fc636a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_b1d044d6-f6f4-48df-8385-638df4a807d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_33da1d0f-8d46-49cf-854c-d59f1e99a733" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_b1d044d6-f6f4-48df-8385-638df4a807d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4f06e214-52ae-44c2-9a6e-2c39f5246c18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6e302855-63e1-4c21-bb07-899016d8f521" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4f06e214-52ae-44c2-9a6e-2c39f5246c18" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6e302855-63e1-4c21-bb07-899016d8f521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_91ab8480-15c3-4bc2-b84d-6e316b689557" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6e302855-63e1-4c21-bb07-899016d8f521" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_91ab8480-15c3-4bc2-b84d-6e316b689557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_f34c4a7f-fdde-44a8-b68c-0c35410cb6c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_91ab8480-15c3-4bc2-b84d-6e316b689557" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_f34c4a7f-fdde-44a8-b68c-0c35410cb6c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantLiabilityMember_00108544-eaed-46d5-98af-a621208d9d9c" xlink:href="ck0001824293-20230630.xsd#ck0001824293_WarrantLiabilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_f34c4a7f-fdde-44a8-b68c-0c35410cb6c6" xlink:to="loc_ck0001824293_WarrantLiabilityMember_00108544-eaed-46d5-98af-a621208d9d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_125522e7-f7c7-4b01-bb1e-512c58c156c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6e302855-63e1-4c21-bb07-899016d8f521" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_125522e7-f7c7-4b01-bb1e-512c58c156c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_a55f38f7-d375-4eac-8caf-d62a89c5c634" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_125522e7-f7c7-4b01-bb1e-512c58c156c9" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_a55f38f7-d375-4eac-8caf-d62a89c5c634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_e28d0aec-457b-47d9-b75c-bdfc9c760473" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_125522e7-f7c7-4b01-bb1e-512c58c156c9" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_e28d0aec-457b-47d9-b75c-bdfc9c760473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_f9524ddc-be4c-454b-997b-681612bd1da0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_125522e7-f7c7-4b01-bb1e-512c58c156c9" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_f9524ddc-be4c-454b-997b-681612bd1da0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_445cb08c-d55b-41d4-b76b-aab6af5bacb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_9690a931-9517-43d6-9950-a9373c2d31dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_445cb08c-d55b-41d4-b76b-aab6af5bacb9" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_9690a931-9517-43d6-9950-a9373c2d31dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_99a5e71e-9b73-41a0-9a36-b4bc35410727" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_9690a931-9517-43d6-9950-a9373c2d31dd" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_99a5e71e-9b73-41a0-9a36-b4bc35410727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_4002af23-ffcd-436e-8e3f-da24ca2b21c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_99a5e71e-9b73-41a0-9a36-b4bc35410727" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_4002af23-ffcd-436e-8e3f-da24ca2b21c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_ee4673fb-b2de-4ed0-b740-f37607701896" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_4002af23-ffcd-436e-8e3f-da24ca2b21c1" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_ee4673fb-b2de-4ed0-b740-f37607701896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_94f4a53d-84d9-4466-ade3-135ef8700218" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_4002af23-ffcd-436e-8e3f-da24ca2b21c1" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_94f4a53d-84d9-4466-ade3-135ef8700218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_d0dc48bf-b8de-4fd2-a562-6eaa84ce3d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_4002af23-ffcd-436e-8e3f-da24ca2b21c1" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_d0dc48bf-b8de-4fd2-a562-6eaa84ce3d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_d6b3f375-c90c-4b98-9df7-c9c09a89bc6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_4002af23-ffcd-436e-8e3f-da24ca2b21c1" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_d6b3f375-c90c-4b98-9df7-c9c09a89bc6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_abe59681-28b9-4083-b6a5-a351fd379727" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_9690a931-9517-43d6-9950-a9373c2d31dd" xlink:to="loc_srt_RangeAxis_abe59681-28b9-4083-b6a5-a351fd379727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5d607a7b-c5ba-4e73-a6bb-75235c63f8b7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_abe59681-28b9-4083-b6a5-a351fd379727" xlink:to="loc_srt_RangeMember_5d607a7b-c5ba-4e73-a6bb-75235c63f8b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_64f7f2a7-2cc1-4bff-bd65-7585ede780d9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5d607a7b-c5ba-4e73-a6bb-75235c63f8b7" xlink:to="loc_srt_WeightedAverageMember_64f7f2a7-2cc1-4bff-bd65-7585ede780d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_4b409d48-769f-4f71-b3ba-eb1c4915695f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_9690a931-9517-43d6-9950-a9373c2d31dd" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_4b409d48-769f-4f71-b3ba-eb1c4915695f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_07b04a84-5f82-4702-a540-3f1749aa3f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_4b409d48-769f-4f71-b3ba-eb1c4915695f" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_07b04a84-5f82-4702-a540-3f1749aa3f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_96906354-5ca3-4e3e-9a78-380249124467" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f025aef7-f5ef-430d-ab99-d2b7e90a0ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_96906354-5ca3-4e3e-9a78-380249124467" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f025aef7-f5ef-430d-ab99-d2b7e90a0ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7eb928ea-983d-4c4a-aeaa-2aacb3c9b743" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f025aef7-f5ef-430d-ab99-d2b7e90a0ab2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7eb928ea-983d-4c4a-aeaa-2aacb3c9b743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3f5e9b59-12e8-47d5-9fc7-d9a7eb361e13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7eb928ea-983d-4c4a-aeaa-2aacb3c9b743" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3f5e9b59-12e8-47d5-9fc7-d9a7eb361e13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_5cc91dee-ef3a-4915-a305-784c91770fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3f5e9b59-12e8-47d5-9fc7-d9a7eb361e13" xlink:to="loc_us-gaap_ComputerEquipmentMember_5cc91dee-ef3a-4915-a305-784c91770fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_eb141b76-b942-417b-97c5-981e8689d7b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3f5e9b59-12e8-47d5-9fc7-d9a7eb361e13" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_eb141b76-b942-417b-97c5-981e8689d7b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_984193bc-2545-4189-9c70-1f54337a5289" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f025aef7-f5ef-430d-ab99-d2b7e90a0ab2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_984193bc-2545-4189-9c70-1f54337a5289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_d5c82eb3-838c-4864-92a1-573c393f5497" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_984193bc-2545-4189-9c70-1f54337a5289" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_d5c82eb3-838c-4864-92a1-573c393f5497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6c6a4e09-92a1-404d-8990-c6d6abf9df9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_984193bc-2545-4189-9c70-1f54337a5289" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6c6a4e09-92a1-404d-8990-c6d6abf9df9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5fc0a109-002e-4a73-bffc-be836b567921" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_984193bc-2545-4189-9c70-1f54337a5289" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_5fc0a109-002e-4a73-bffc-be836b567921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTNarrativeDetails" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#PROPERTYANDEQUIPMENTNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_30d81733-d7fd-4b95-8f37-47ee3c2afa5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_2546ae35-c3da-4ef6-8fe8-cce1e38a1558" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_30d81733-d7fd-4b95-8f37-47ee3c2afa5a" xlink:to="loc_us-gaap_Depreciation_2546ae35-c3da-4ef6-8fe8-cce1e38a1558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#ACCRUEDEXPENSESDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_b36b438a-c1d8-4b0d-9a39-6bde8695ec63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_9591d1a0-e139-4d6b-9297-3558df50ae35" xlink:href="ck0001824293-20230630.xsd#ck0001824293_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_b36b438a-c1d8-4b0d-9a39-6bde8695ec63" xlink:to="loc_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_9591d1a0-e139-4d6b-9297-3558df50ae35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_cca31037-3918-4d69-9252-4e4879187f6c" xlink:href="ck0001824293-20230630.xsd#ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_b36b438a-c1d8-4b0d-9a39-6bde8695ec63" xlink:to="loc_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_cca31037-3918-4d69-9252-4e4879187f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_7d389b53-9047-4ab9-8ecf-660ebeb1bbd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_b36b438a-c1d8-4b0d-9a39-6bde8695ec63" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_7d389b53-9047-4ab9-8ecf-660ebeb1bbd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_b5e6d837-eaf4-46a6-8a15-ccb1baea2ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_b36b438a-c1d8-4b0d-9a39-6bde8695ec63" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_b5e6d837-eaf4-46a6-8a15-ccb1baea2ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#PROMISSORYNOTESBridgeFinancingDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_cafd81c4-15c9-4048-a0a1-0ec8c7140fd4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_48098f31-66f3-4622-b639-ff72f8a45370" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_cafd81c4-15c9-4048-a0a1-0ec8c7140fd4" xlink:to="loc_us-gaap_DebtInstrumentTable_48098f31-66f3-4622-b639-ff72f8a45370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_48f987f7-ade5-4150-8c3a-6bcae309dee0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_48098f31-66f3-4622-b639-ff72f8a45370" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_48f987f7-ade5-4150-8c3a-6bcae309dee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_aacb88b2-b444-41e1-824d-714cc5da5fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_48f987f7-ade5-4150-8c3a-6bcae309dee0" xlink:to="loc_us-gaap_RelatedPartyDomain_aacb88b2-b444-41e1-824d-714cc5da5fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestorMember_915f3108-859e-4782-9679-d8caa4794a81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_aacb88b2-b444-41e1-824d-714cc5da5fb1" xlink:to="loc_us-gaap_InvestorMember_915f3108-859e-4782-9679-d8caa4794a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_522143f5-cd12-4f9b-af85-359294aff89a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_48098f31-66f3-4622-b639-ff72f8a45370" xlink:to="loc_dei_LegalEntityAxis_522143f5-cd12-4f9b-af85-359294aff89a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_cf5ccf95-e984-4b59-a542-88ad3fac406e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_522143f5-cd12-4f9b-af85-359294aff89a" xlink:to="loc_dei_EntityDomain_cf5ccf95-e984-4b59-a542-88ad3fac406e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PrivateGRIMember_272c0be0-7d63-4907-a84b-44285cfa5287" xlink:href="ck0001824293-20230630.xsd#ck0001824293_PrivateGRIMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_cf5ccf95-e984-4b59-a542-88ad3fac406e" xlink:to="loc_ck0001824293_PrivateGRIMember_272c0be0-7d63-4907-a84b-44285cfa5287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ba4fa794-79b6-4a4d-a9de-7cfaba0b2deb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_48098f31-66f3-4622-b639-ff72f8a45370" xlink:to="loc_us-gaap_DebtInstrumentAxis_ba4fa794-79b6-4a4d-a9de-7cfaba0b2deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_abd714ee-3cdb-449a-866d-22e7c0b34893" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_ba4fa794-79b6-4a4d-a9de-7cfaba0b2deb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_abd714ee-3cdb-449a-866d-22e7c0b34893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_BridgeSecuritiesPurchaseAgreementMember_74169f1e-1b3f-4fb9-aef2-95cb13cabb46" xlink:href="ck0001824293-20230630.xsd#ck0001824293_BridgeSecuritiesPurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_abd714ee-3cdb-449a-866d-22e7c0b34893" xlink:to="loc_ck0001824293_BridgeSecuritiesPurchaseAgreementMember_74169f1e-1b3f-4fb9-aef2-95cb13cabb46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_08386d39-48df-4ac4-969d-0c7c4fc9b073" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_48098f31-66f3-4622-b639-ff72f8a45370" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_08386d39-48df-4ac4-969d-0c7c4fc9b073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_a2a15dea-4b6b-4241-a7fc-a5452dcb32fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_08386d39-48df-4ac4-969d-0c7c4fc9b073" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_a2a15dea-4b6b-4241-a7fc-a5452dcb32fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_BridgeWarrantsMember_e6466a92-d589-46c7-8d89-46a16adb1db3" xlink:href="ck0001824293-20230630.xsd#ck0001824293_BridgeWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a2a15dea-4b6b-4241-a7fc-a5452dcb32fd" xlink:to="loc_ck0001824293_BridgeWarrantsMember_e6466a92-d589-46c7-8d89-46a16adb1db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ExchangeWarrantsMember_fb1ecba8-1165-461c-8038-065a860d2195" xlink:href="ck0001824293-20230630.xsd#ck0001824293_ExchangeWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a2a15dea-4b6b-4241-a7fc-a5452dcb32fd" xlink:to="loc_ck0001824293_ExchangeWarrantsMember_fb1ecba8-1165-461c-8038-065a860d2195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_e9952567-ab09-4bfe-affc-7cdc02612bab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_48098f31-66f3-4622-b639-ff72f8a45370" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_e9952567-ab09-4bfe-affc-7cdc02612bab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_c642794e-623f-4662-957a-bc8ea8074ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_e9952567-ab09-4bfe-affc-7cdc02612bab" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_c642794e-623f-4662-957a-bc8ea8074ba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CallOptionMember_3e2f34e2-225e-472e-b77f-9992ecc8f161" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CallOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_c642794e-623f-4662-957a-bc8ea8074ba7" xlink:to="loc_us-gaap_CallOptionMember_3e2f34e2-225e-472e-b77f-9992ecc8f161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_fa3e330c-2fd1-49bb-be20-bf180956aaad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_48098f31-66f3-4622-b639-ff72f8a45370" xlink:to="loc_us-gaap_DebtInstrumentLineItems_fa3e330c-2fd1-49bb-be20-bf180956aaad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_3458f91f-ca75-4f87-93ce-ce38396a8a53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fa3e330c-2fd1-49bb-be20-bf180956aaad" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_3458f91f-ca75-4f87-93ce-ce38396a8a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtInstrumentAggregatePurchasePrice_ec3609ff-0371-4781-bf63-5af1ae7018e7" xlink:href="ck0001824293-20230630.xsd#ck0001824293_DebtInstrumentAggregatePurchasePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fa3e330c-2fd1-49bb-be20-bf180956aaad" xlink:to="loc_ck0001824293_DebtInstrumentAggregatePurchasePrice_ec3609ff-0371-4781-bf63-5af1ae7018e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtInstrumentNumberOfClosings_dc938bd0-99bd-4550-bde2-cc144cd7d142" xlink:href="ck0001824293-20230630.xsd#ck0001824293_DebtInstrumentNumberOfClosings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fa3e330c-2fd1-49bb-be20-bf180956aaad" xlink:to="loc_ck0001824293_DebtInstrumentNumberOfClosings_dc938bd0-99bd-4550-bde2-cc144cd7d142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_31a69fcb-c802-4fcd-a53d-694250109710" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fa3e330c-2fd1-49bb-be20-bf180956aaad" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_31a69fcb-c802-4fcd-a53d-694250109710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_67b6de13-6fde-41f0-90ad-1cafa4ce0ef5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fa3e330c-2fd1-49bb-be20-bf180956aaad" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_67b6de13-6fde-41f0-90ad-1cafa4ce0ef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_64914d51-c7db-42dc-b3a1-c61109770207" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fa3e330c-2fd1-49bb-be20-bf180956aaad" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_64914d51-c7db-42dc-b3a1-c61109770207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_498e6b46-ccd3-421e-b6f0-dac5177e801c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fa3e330c-2fd1-49bb-be20-bf180956aaad" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_498e6b46-ccd3-421e-b6f0-dac5177e801c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentCompanyCommittedCapital_e7c7064a-18c4-4fdc-babb-207a80f529f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentCompanyCommittedCapital"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fa3e330c-2fd1-49bb-be20-bf180956aaad" xlink:to="loc_us-gaap_InvestmentCompanyCommittedCapital_e7c7064a-18c4-4fdc-babb-207a80f529f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_05e629ef-8e60-4ad9-81b1-a4389c61ca38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fa3e330c-2fd1-49bb-be20-bf180956aaad" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_05e629ef-8e60-4ad9-81b1-a4389c61ca38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_6cb278d3-c1f3-4310-bc92-bb6721e2caf5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fa3e330c-2fd1-49bb-be20-bf180956aaad" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_6cb278d3-c1f3-4310-bc92-bb6721e2caf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_208b9679-5808-41bd-8070-29a3c7920dce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fa3e330c-2fd1-49bb-be20-bf180956aaad" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_208b9679-5808-41bd-8070-29a3c7920dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#PROMISSORYNOTESTEPNoteDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_5df4c4a3-4721-46a6-bbc9-9a629bcb732a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_6a2eb2eb-3268-4db0-a8f2-5e3d607a6e24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5df4c4a3-4721-46a6-bbc9-9a629bcb732a" xlink:to="loc_us-gaap_DebtInstrumentTable_6a2eb2eb-3268-4db0-a8f2-5e3d607a6e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_64e1dd82-41b9-4f80-bde3-5c68de58ee3a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6a2eb2eb-3268-4db0-a8f2-5e3d607a6e24" xlink:to="loc_dei_LegalEntityAxis_64e1dd82-41b9-4f80-bde3-5c68de58ee3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a715b86e-5cd7-47ee-8428-943e0bcfb9be" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_64e1dd82-41b9-4f80-bde3-5c68de58ee3a" xlink:to="loc_dei_EntityDomain_a715b86e-5cd7-47ee-8428-943e0bcfb9be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PrivateGRIMember_7c901227-db39-4c4c-953c-13011bd985c0" xlink:href="ck0001824293-20230630.xsd#ck0001824293_PrivateGRIMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_a715b86e-5cd7-47ee-8428-943e0bcfb9be" xlink:to="loc_ck0001824293_PrivateGRIMember_7c901227-db39-4c4c-953c-13011bd985c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c3502be3-3e30-445d-a3bd-b94df0a39878" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6a2eb2eb-3268-4db0-a8f2-5e3d607a6e24" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c3502be3-3e30-445d-a3bd-b94df0a39878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2c44a0ae-50a8-4ab9-9447-e3009c6b433d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c3502be3-3e30-445d-a3bd-b94df0a39878" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2c44a0ae-50a8-4ab9-9447-e3009c6b433d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_d7dd95cf-e5ad-4b4e-94c5-7f30e02cb930" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2c44a0ae-50a8-4ab9-9447-e3009c6b433d" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_d7dd95cf-e5ad-4b4e-94c5-7f30e02cb930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_af7c09ea-44a4-4532-ba0a-e335deda2209" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6a2eb2eb-3268-4db0-a8f2-5e3d607a6e24" xlink:to="loc_us-gaap_DebtInstrumentAxis_af7c09ea-44a4-4532-ba0a-e335deda2209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_946ccce6-acf1-4274-9f80-5415b9dc4644" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_af7c09ea-44a4-4532-ba0a-e335deda2209" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_946ccce6-acf1-4274-9f80-5415b9dc4644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_TEPNoteMember_ccfb3baa-50a3-4973-aea6-b992530bbc88" xlink:href="ck0001824293-20230630.xsd#ck0001824293_TEPNoteMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_946ccce6-acf1-4274-9f80-5415b9dc4644" xlink:to="loc_ck0001824293_TEPNoteMember_ccfb3baa-50a3-4973-aea6-b992530bbc88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_579285a5-2bbc-466a-a46e-315083e31e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6a2eb2eb-3268-4db0-a8f2-5e3d607a6e24" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_579285a5-2bbc-466a-a46e-315083e31e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_ab10417e-f25b-46a6-9155-668154e07740" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_579285a5-2bbc-466a-a46e-315083e31e5e" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_ab10417e-f25b-46a6-9155-668154e07740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CallOptionMember_93be3bb7-10d5-42d1-8a6c-a23a591b2d86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CallOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_ab10417e-f25b-46a6-9155-668154e07740" xlink:to="loc_us-gaap_CallOptionMember_93be3bb7-10d5-42d1-8a6c-a23a591b2d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_bd0ff465-b1f5-4034-8212-772fb54a66e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6a2eb2eb-3268-4db0-a8f2-5e3d607a6e24" xlink:to="loc_us-gaap_DebtInstrumentLineItems_bd0ff465-b1f5-4034-8212-772fb54a66e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_cb798637-f443-40f5-96cf-043f733aa292" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bd0ff465-b1f5-4034-8212-772fb54a66e9" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_cb798637-f443-40f5-96cf-043f733aa292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_39336a35-9daf-4eb5-afa4-ec5a02cafdcc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bd0ff465-b1f5-4034-8212-772fb54a66e9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_39336a35-9daf-4eb5-afa4-ec5a02cafdcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_86c2432f-b93d-4081-b080-b02e68173224" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bd0ff465-b1f5-4034-8212-772fb54a66e9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_86c2432f-b93d-4081-b080-b02e68173224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_92223f24-83db-43f1-96c6-274ca14a4bcf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bd0ff465-b1f5-4034-8212-772fb54a66e9" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_92223f24-83db-43f1-96c6-274ca14a4bcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_caa70a18-f4c0-4783-9607-39670a8af446" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bd0ff465-b1f5-4034-8212-772fb54a66e9" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_caa70a18-f4c0-4783-9607-39670a8af446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_1994dc81-f55b-4b2b-8c7f-aa9524b2696a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bd0ff465-b1f5-4034-8212-772fb54a66e9" xlink:to="loc_us-gaap_CommonStockSharesIssued_1994dc81-f55b-4b2b-8c7f-aa9524b2696a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_CallOptionPrice_12e67977-a688-4112-961e-0115debd3b10" xlink:href="ck0001824293-20230630.xsd#ck0001824293_CallOptionPrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bd0ff465-b1f5-4034-8212-772fb54a66e9" xlink:to="loc_ck0001824293_CallOptionPrice_12e67977-a688-4112-961e-0115debd3b10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtConversionConvertedInstrumentPrincipalAmountOfDebt_e804bd4a-33c7-490f-893b-cfd44c9423ca" xlink:href="ck0001824293-20230630.xsd#ck0001824293_DebtConversionConvertedInstrumentPrincipalAmountOfDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bd0ff465-b1f5-4034-8212-772fb54a66e9" xlink:to="loc_ck0001824293_DebtConversionConvertedInstrumentPrincipalAmountOfDebt_e804bd4a-33c7-490f-893b-cfd44c9423ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtConversionConvertedInstrumentAmountOfInterest_524abc58-04bb-427b-bfe4-5eaf196df2c5" xlink:href="ck0001824293-20230630.xsd#ck0001824293_DebtConversionConvertedInstrumentAmountOfInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bd0ff465-b1f5-4034-8212-772fb54a66e9" xlink:to="loc_ck0001824293_DebtConversionConvertedInstrumentAmountOfInterest_524abc58-04bb-427b-bfe4-5eaf196df2c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtInstrumentConvertibleSharesIssuedUponConversion_394fbc27-15b2-409e-a26c-794b09b79b2f" xlink:href="ck0001824293-20230630.xsd#ck0001824293_DebtInstrumentConvertibleSharesIssuedUponConversion"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bd0ff465-b1f5-4034-8212-772fb54a66e9" xlink:to="loc_ck0001824293_DebtInstrumentConvertibleSharesIssuedUponConversion_394fbc27-15b2-409e-a26c-794b09b79b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_b1c99be2-a790-471b-97cf-6ab297b1c843" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bd0ff465-b1f5-4034-8212-772fb54a66e9" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_b1c99be2-a790-471b-97cf-6ab297b1c843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_ba2cfe5d-b193-4eb1-a538-0f1c3dd0b1e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bd0ff465-b1f5-4034-8212-772fb54a66e9" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_ba2cfe5d-b193-4eb1-a538-0f1c3dd0b1e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_b2afd63e-053b-479a-8c21-41baeda9c2b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrentAndNoncurrent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bd0ff465-b1f5-4034-8212-772fb54a66e9" xlink:to="loc_us-gaap_InterestPayableCurrentAndNoncurrent_b2afd63e-053b-479a-8c21-41baeda9c2b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_LongTermDebtIncludingInterest_07540518-aeb4-47fd-9949-f1e9586acf07" xlink:href="ck0001824293-20230630.xsd#ck0001824293_LongTermDebtIncludingInterest"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bd0ff465-b1f5-4034-8212-772fb54a66e9" xlink:to="loc_ck0001824293_LongTermDebtIncludingInterest_07540518-aeb4-47fd-9949-f1e9586acf07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_e924195a-60b5-4b9b-b857-cd759dbad981" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bd0ff465-b1f5-4034-8212-772fb54a66e9" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_e924195a-60b5-4b9b-b857-cd759dbad981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_d06cae26-04ac-47d1-9d46-6fc1ef789cd5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bd0ff465-b1f5-4034-8212-772fb54a66e9" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_d06cae26-04ac-47d1-9d46-6fc1ef789cd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_b22db6b7-2660-4c5b-8c52-04fd02e77920" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bd0ff465-b1f5-4034-8212-772fb54a66e9" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_b22db6b7-2660-4c5b-8c52-04fd02e77920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedInterestForfeited_39ad243b-7a8e-48c9-8087-ad29ea54ea10" xlink:href="ck0001824293-20230630.xsd#ck0001824293_AccruedInterestForfeited"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bd0ff465-b1f5-4034-8212-772fb54a66e9" xlink:to="loc_ck0001824293_AccruedInterestForfeited_39ad243b-7a8e-48c9-8087-ad29ea54ea10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseBorrowings_d56e0d57-1e23-4eb6-a32d-8320bd2b9ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseBorrowings"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bd0ff465-b1f5-4034-8212-772fb54a66e9" xlink:to="loc_us-gaap_InterestExpenseBorrowings_d56e0d57-1e23-4eb6-a32d-8320bd2b9ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#STOCKHOLDERSEQUITYNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_abe73b75-398d-447a-8fbf-15c200a7ae99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_42d3c094-3720-4d08-97f2-866eaf19f9cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_abe73b75-398d-447a-8fbf-15c200a7ae99" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_42d3c094-3720-4d08-97f2-866eaf19f9cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e4a3e89c-4f2e-4f26-bbd1-5299fa803264" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_42d3c094-3720-4d08-97f2-866eaf19f9cc" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e4a3e89c-4f2e-4f26-bbd1-5299fa803264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_187d771d-a83a-4055-b81d-8eaa488867f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e4a3e89c-4f2e-4f26-bbd1-5299fa803264" xlink:to="loc_us-gaap_RelatedPartyDomain_187d771d-a83a-4055-b81d-8eaa488867f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestorMember_e79c876c-e28b-442e-8fdc-3deae66230c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_187d771d-a83a-4055-b81d-8eaa488867f5" xlink:to="loc_us-gaap_InvestorMember_e79c876c-e28b-442e-8fdc-3deae66230c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_e8a06195-df62-481a-97e5-5affc59ee4c1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_42d3c094-3720-4d08-97f2-866eaf19f9cc" xlink:to="loc_dei_LegalEntityAxis_e8a06195-df62-481a-97e5-5affc59ee4c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_199df398-f691-4588-8029-88af4ce6ba04" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_e8a06195-df62-481a-97e5-5affc59ee4c1" xlink:to="loc_dei_EntityDomain_199df398-f691-4588-8029-88af4ce6ba04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PrivateGRIMember_ec0e24c9-1e20-44c3-8532-a5a02bd11a0b" xlink:href="ck0001824293-20230630.xsd#ck0001824293_PrivateGRIMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_199df398-f691-4588-8029-88af4ce6ba04" xlink:to="loc_ck0001824293_PrivateGRIMember_ec0e24c9-1e20-44c3-8532-a5a02bd11a0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_593736c3-406c-4805-853a-4efb5860fd36" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_42d3c094-3720-4d08-97f2-866eaf19f9cc" xlink:to="loc_srt_CounterpartyNameAxis_593736c3-406c-4805-853a-4efb5860fd36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8b124c87-6eb3-41d3-8705-2b6ed5147ed8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_593736c3-406c-4805-853a-4efb5860fd36" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8b124c87-6eb3-41d3-8705-2b6ed5147ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_GRIBioIncMember_04abe490-b469-4a82-bc49-aa9a0a4a91d4" xlink:href="ck0001824293-20230630.xsd#ck0001824293_GRIBioIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8b124c87-6eb3-41d3-8705-2b6ed5147ed8" xlink:to="loc_ck0001824293_GRIBioIncMember_04abe490-b469-4a82-bc49-aa9a0a4a91d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1578c88c-fd17-4796-a60d-219b0ae7f3a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_42d3c094-3720-4d08-97f2-866eaf19f9cc" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1578c88c-fd17-4796-a60d-219b0ae7f3a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_55f62138-16cf-4099-90d9-f8040d9432bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1578c88c-fd17-4796-a60d-219b0ae7f3a9" xlink:to="loc_us-gaap_EquityComponentDomain_55f62138-16cf-4099-90d9-f8040d9432bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9bc8db19-2a01-4803-92bb-16d2f2f5e047" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_55f62138-16cf-4099-90d9-f8040d9432bb" xlink:to="loc_us-gaap_CommonStockMember_9bc8db19-2a01-4803-92bb-16d2f2f5e047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_b0fd8993-561a-420f-acea-0e248d67cec5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_55f62138-16cf-4099-90d9-f8040d9432bb" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_b0fd8993-561a-420f-acea-0e248d67cec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_aba0789e-ae35-4b44-8606-3364da358133" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_42d3c094-3720-4d08-97f2-866eaf19f9cc" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_aba0789e-ae35-4b44-8606-3364da358133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_9e10fd55-14b9-43a8-bbdc-3fdf741d0e29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_aba0789e-ae35-4b44-8606-3364da358133" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_9e10fd55-14b9-43a8-bbdc-3fdf741d0e29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PutOptionMember_44710eb1-79f0-4ba0-bf4e-d01c8d6f80aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PutOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_9e10fd55-14b9-43a8-bbdc-3fdf741d0e29" xlink:to="loc_us-gaap_PutOptionMember_44710eb1-79f0-4ba0-bf4e-d01c8d6f80aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_8b2277a4-a8c0-4abe-8d34-ef85c37ac208" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_42d3c094-3720-4d08-97f2-866eaf19f9cc" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_8b2277a4-a8c0-4abe-8d34-ef85c37ac208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_7814e58f-a425-4292-b7ca-709e20cdf913" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_8b2277a4-a8c0-4abe-8d34-ef85c37ac208" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_7814e58f-a425-4292-b7ca-709e20cdf913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_EquityWarrantsMember_aedac41b-62e8-4b45-ade3-776e7b690150" xlink:href="ck0001824293-20230630.xsd#ck0001824293_EquityWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7814e58f-a425-4292-b7ca-709e20cdf913" xlink:to="loc_ck0001824293_EquityWarrantsMember_aedac41b-62e8-4b45-ade3-776e7b690150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesA1WarrantsMember_7c830927-27b2-4a0a-baa3-3985200fed13" xlink:href="ck0001824293-20230630.xsd#ck0001824293_SeriesA1WarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ck0001824293_EquityWarrantsMember_aedac41b-62e8-4b45-ade3-776e7b690150" xlink:to="loc_ck0001824293_SeriesA1WarrantsMember_7c830927-27b2-4a0a-baa3-3985200fed13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesA2WarrantsMember_ea6056cc-c1c8-4ad1-8a16-1f9a7c5d22cb" xlink:href="ck0001824293-20230630.xsd#ck0001824293_SeriesA2WarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ck0001824293_EquityWarrantsMember_aedac41b-62e8-4b45-ade3-776e7b690150" xlink:to="loc_ck0001824293_SeriesA2WarrantsMember_ea6056cc-c1c8-4ad1-8a16-1f9a7c5d22cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesTWarrantsMember_a8035183-f4e6-409d-9ac0-f11e4930cfc7" xlink:href="ck0001824293-20230630.xsd#ck0001824293_SeriesTWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7814e58f-a425-4292-b7ca-709e20cdf913" xlink:to="loc_ck0001824293_SeriesTWarrantsMember_a8035183-f4e6-409d-9ac0-f11e4930cfc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_BridgeWarrantsMember_14c1e2b6-8c0a-4645-affa-40e33aa59fd2" xlink:href="ck0001824293-20230630.xsd#ck0001824293_BridgeWarrantsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7814e58f-a425-4292-b7ca-709e20cdf913" xlink:to="loc_ck0001824293_BridgeWarrantsMember_14c1e2b6-8c0a-4645-affa-40e33aa59fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_BankerWarrantsMember_76f3c348-14ab-4ca4-8382-c8d3ef7de23b" xlink:href="ck0001824293-20230630.xsd#ck0001824293_BankerWarrantsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7814e58f-a425-4292-b7ca-709e20cdf913" xlink:to="loc_ck0001824293_BankerWarrantsMember_76f3c348-14ab-4ca4-8382-c8d3ef7de23b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ExchangeWarrantsMember_db34d1e1-0905-4c05-914f-0699d30d7e49" xlink:href="ck0001824293-20230630.xsd#ck0001824293_ExchangeWarrantsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7814e58f-a425-4292-b7ca-709e20cdf913" xlink:to="loc_ck0001824293_ExchangeWarrantsMember_db34d1e1-0905-4c05-914f-0699d30d7e49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_e16c4385-2706-493b-ae6d-a4b0647eb747" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_42d3c094-3720-4d08-97f2-866eaf19f9cc" xlink:to="loc_us-gaap_ClassOfStockLineItems_e16c4385-2706-493b-ae6d-a4b0647eb747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentCompanyCommittedCapital_8865f77c-262d-4a65-85a1-0b83fe081b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentCompanyCommittedCapital"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e16c4385-2706-493b-ae6d-a4b0647eb747" xlink:to="loc_us-gaap_InvestmentCompanyCommittedCapital_8865f77c-262d-4a65-85a1-0b83fe081b1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_3a07aed2-54b5-4a55-8207-21ec97ba970c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e16c4385-2706-493b-ae6d-a4b0647eb747" xlink:to="loc_us-gaap_CommonStockSharesIssued_3a07aed2-54b5-4a55-8207-21ec97ba970c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_CommonStockHeldIntoEscrowAccount_1e065012-fc13-4b5a-89a9-07552e94281d" xlink:href="ck0001824293-20230630.xsd#ck0001824293_CommonStockHeldIntoEscrowAccount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e16c4385-2706-493b-ae6d-a4b0647eb747" xlink:to="loc_ck0001824293_CommonStockHeldIntoEscrowAccount_1e065012-fc13-4b5a-89a9-07552e94281d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_a3f0728e-de24-4024-93e4-9bced53306b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e16c4385-2706-493b-ae6d-a4b0647eb747" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_a3f0728e-de24-4024-93e4-9bced53306b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_b74ba374-50fe-4582-a1e7-77dfb8384fbf" xlink:href="ck0001824293-20230630.xsd#ck0001824293_StockIssuanceCostsOfferingExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e16c4385-2706-493b-ae6d-a4b0647eb747" xlink:to="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_b74ba374-50fe-4582-a1e7-77dfb8384fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_f5bb7e3f-21d8-4b27-a350-66d76375989f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e16c4385-2706-493b-ae6d-a4b0647eb747" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_f5bb7e3f-21d8-4b27-a350-66d76375989f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ConversionOfStockAdditionalSharesConverted_720ee1e8-78cb-4643-8b78-78c4b23a7420" xlink:href="ck0001824293-20230630.xsd#ck0001824293_ConversionOfStockAdditionalSharesConverted"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e16c4385-2706-493b-ae6d-a4b0647eb747" xlink:to="loc_ck0001824293_ConversionOfStockAdditionalSharesConverted_720ee1e8-78cb-4643-8b78-78c4b23a7420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PutOptionSharePrice_134ff5c1-3ed8-4ac8-b517-3a25b57d8ba7" xlink:href="ck0001824293-20230630.xsd#ck0001824293_PutOptionSharePrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e16c4385-2706-493b-ae6d-a4b0647eb747" xlink:to="loc_ck0001824293_PutOptionSharePrice_134ff5c1-3ed8-4ac8-b517-3a25b57d8ba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_0226e1ca-fc08-41b2-8b0c-465722c33b94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e16c4385-2706-493b-ae6d-a4b0647eb747" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_0226e1ca-fc08-41b2-8b0c-465722c33b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_7504b885-20e7-4f7d-9e2f-58e507870e86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e16c4385-2706-493b-ae6d-a4b0647eb747" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_7504b885-20e7-4f7d-9e2f-58e507870e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_2ae2b5f1-9e5e-4600-a90b-c09f18227f0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e16c4385-2706-493b-ae6d-a4b0647eb747" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_2ae2b5f1-9e5e-4600-a90b-c09f18227f0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7fb118b4-ad59-4fc2-bd51-621a3d296944" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e16c4385-2706-493b-ae6d-a4b0647eb747" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7fb118b4-ad59-4fc2-bd51-621a3d296944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_b69e2c16-36ad-4db7-ade5-e8c57bfdaff3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e16c4385-2706-493b-ae6d-a4b0647eb747" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_b69e2c16-36ad-4db7-ade5-e8c57bfdaff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_752a9f02-c88f-49e6-aa5b-e4e644c72966" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e16c4385-2706-493b-ae6d-a4b0647eb747" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_752a9f02-c88f-49e6-aa5b-e4e644c72966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_71a5ca6c-06d4-45e9-b0ae-239c379bc72c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e16c4385-2706-493b-ae6d-a4b0647eb747" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_71a5ca6c-06d4-45e9-b0ae-239c379bc72c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_b0fbec80-4730-4fbf-ba96-672510093961" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e16c4385-2706-493b-ae6d-a4b0647eb747" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_b0fbec80-4730-4fbf-ba96-672510093961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_e48f898a-146e-4542-b8c0-499b5a56b611" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_08d7d174-f818-4495-a515-bbd4c1f4bf78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e48f898a-146e-4542-b8c0-499b5a56b611" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_08d7d174-f818-4495-a515-bbd4c1f4bf78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1bc42567-d2c6-413b-85b3-80839f4006f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_08d7d174-f818-4495-a515-bbd4c1f4bf78" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1bc42567-d2c6-413b-85b3-80839f4006f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_54b7ce54-b6c5-407d-ad3b-737d2302cc18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1bc42567-d2c6-413b-85b3-80839f4006f9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_54b7ce54-b6c5-407d-ad3b-737d2302cc18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_EquityWarrantsExchangeWarrantsAndBankerWarrantsMember_925c2198-ad5e-40a9-931f-1db6011b4ba9" xlink:href="ck0001824293-20230630.xsd#ck0001824293_EquityWarrantsExchangeWarrantsAndBankerWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_54b7ce54-b6c5-407d-ad3b-737d2302cc18" xlink:to="loc_ck0001824293_EquityWarrantsExchangeWarrantsAndBankerWarrantsMember_925c2198-ad5e-40a9-931f-1db6011b4ba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_4ffd7967-8309-40ab-a8ee-60440daa482e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_08d7d174-f818-4495-a515-bbd4c1f4bf78" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_4ffd7967-8309-40ab-a8ee-60440daa482e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_09f78a13-0aa6-4814-97e1-b1507f4e510f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_4ffd7967-8309-40ab-a8ee-60440daa482e" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_09f78a13-0aa6-4814-97e1-b1507f4e510f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_d52fd909-2dd4-48b9-a166-1d45c363ace8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_09f78a13-0aa6-4814-97e1-b1507f4e510f" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_d52fd909-2dd4-48b9-a166-1d45c363ace8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_97bf6755-a393-4783-a90e-e9cdd9e744be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_09f78a13-0aa6-4814-97e1-b1507f4e510f" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_97bf6755-a393-4783-a90e-e9cdd9e744be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_31037f18-296e-4723-942e-4a2789a3a71a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_09f78a13-0aa6-4814-97e1-b1507f4e510f" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_31037f18-296e-4723-942e-4a2789a3a71a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_40afae91-28e9-4d33-92d8-5d4c30032bad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_09f78a13-0aa6-4814-97e1-b1507f4e510f" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_40afae91-28e9-4d33-92d8-5d4c30032bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_293040d6-746e-4944-9371-5cc4491e8849" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_08d7d174-f818-4495-a515-bbd4c1f4bf78" xlink:to="loc_srt_RangeAxis_293040d6-746e-4944-9371-5cc4491e8849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_62808ff2-a326-4619-92f0-b926ecb70bad" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_293040d6-746e-4944-9371-5cc4491e8849" xlink:to="loc_srt_RangeMember_62808ff2-a326-4619-92f0-b926ecb70bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_c38a4cc1-403e-4ff1-acc5-8bd849e05ed1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_62808ff2-a326-4619-92f0-b926ecb70bad" xlink:to="loc_srt_WeightedAverageMember_c38a4cc1-403e-4ff1-acc5-8bd849e05ed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_f78767cb-3554-4a40-badc-49ea3416de22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_08d7d174-f818-4495-a515-bbd4c1f4bf78" xlink:to="loc_us-gaap_ClassOfStockLineItems_f78767cb-3554-4a40-badc-49ea3416de22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_a3f7244b-c6e0-4526-844a-9aa1770cc6e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f78767cb-3554-4a40-badc-49ea3416de22" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_a3f7244b-c6e0-4526-844a-9aa1770cc6e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_0d2e356d-2ab3-4b15-b983-04708a2176e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_545ef646-79dd-43b5-b172-560874486ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0d2e356d-2ab3-4b15-b983-04708a2176e7" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_545ef646-79dd-43b5-b172-560874486ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_ed2295d8-6604-4390-a94e-caa23139ab60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_545ef646-79dd-43b5-b172-560874486ccd" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_ed2295d8-6604-4390-a94e-caa23139ab60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_8fc2ae7f-4068-4b7a-8f7a-008663415a24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_ed2295d8-6604-4390-a94e-caa23139ab60" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_8fc2ae7f-4068-4b7a-8f7a-008663415a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInNovember2023Member_7fad6166-0b19-4f2e-8178-2caaee13ed2f" xlink:href="ck0001824293-20230630.xsd#ck0001824293_WarrantsExpiringInNovember2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8fc2ae7f-4068-4b7a-8f7a-008663415a24" xlink:to="loc_ck0001824293_WarrantsExpiringInNovember2023Member_7fad6166-0b19-4f2e-8178-2caaee13ed2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInDecember2023Member_f74ac5dc-c6a5-4334-83ea-84778124eb90" xlink:href="ck0001824293-20230630.xsd#ck0001824293_WarrantsExpiringInDecember2023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8fc2ae7f-4068-4b7a-8f7a-008663415a24" xlink:to="loc_ck0001824293_WarrantsExpiringInDecember2023Member_f74ac5dc-c6a5-4334-83ea-84778124eb90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInJune2025Member_b5ebd0d8-0500-4814-ac01-a1ef13d27811" xlink:href="ck0001824293-20230630.xsd#ck0001824293_WarrantsExpiringInJune2025Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8fc2ae7f-4068-4b7a-8f7a-008663415a24" xlink:to="loc_ck0001824293_WarrantsExpiringInJune2025Member_b5ebd0d8-0500-4814-ac01-a1ef13d27811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInFebruary2026Member_c47f0dfe-7f17-4914-9c6d-1c3ffd42969b" xlink:href="ck0001824293-20230630.xsd#ck0001824293_WarrantsExpiringInFebruary2026Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8fc2ae7f-4068-4b7a-8f7a-008663415a24" xlink:to="loc_ck0001824293_WarrantsExpiringInFebruary2026Member_c47f0dfe-7f17-4914-9c6d-1c3ffd42969b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInMay2027Member_b3dc4aca-fca1-4893-a8d5-ef3b8f81653a" xlink:href="ck0001824293-20230630.xsd#ck0001824293_WarrantsExpiringInMay2027Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8fc2ae7f-4068-4b7a-8f7a-008663415a24" xlink:to="loc_ck0001824293_WarrantsExpiringInMay2027Member_b3dc4aca-fca1-4893-a8d5-ef3b8f81653a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInJuly2027Member_2ec68bb9-95a9-4013-ab1e-5d2acb5bf276" xlink:href="ck0001824293-20230630.xsd#ck0001824293_WarrantsExpiringInJuly2027Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8fc2ae7f-4068-4b7a-8f7a-008663415a24" xlink:to="loc_ck0001824293_WarrantsExpiringInJuly2027Member_2ec68bb9-95a9-4013-ab1e-5d2acb5bf276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInApril2028Member_e45a4b0c-7252-492e-817a-9222f828fda8" xlink:href="ck0001824293-20230630.xsd#ck0001824293_WarrantsExpiringInApril2028Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8fc2ae7f-4068-4b7a-8f7a-008663415a24" xlink:to="loc_ck0001824293_WarrantsExpiringInApril2028Member_e45a4b0c-7252-492e-817a-9222f828fda8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateOneMember_126cedcd-ece4-4399-84c1-2bb2b7fe7354" xlink:href="ck0001824293-20230630.xsd#ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateOneMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8fc2ae7f-4068-4b7a-8f7a-008663415a24" xlink:to="loc_ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateOneMember_126cedcd-ece4-4399-84c1-2bb2b7fe7354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateTwoMember_892d7360-d051-491c-8ddb-ec66012c1117" xlink:href="ck0001824293-20230630.xsd#ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateTwoMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8fc2ae7f-4068-4b7a-8f7a-008663415a24" xlink:to="loc_ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateTwoMember_892d7360-d051-491c-8ddb-ec66012c1117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringIn24MonthsAfterRegistrationDateMember_cde8cb4b-a562-4c5f-a785-53b6b19cec02" xlink:href="ck0001824293-20230630.xsd#ck0001824293_WarrantsExpiringIn24MonthsAfterRegistrationDateMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8fc2ae7f-4068-4b7a-8f7a-008663415a24" xlink:to="loc_ck0001824293_WarrantsExpiringIn24MonthsAfterRegistrationDateMember_cde8cb4b-a562-4c5f-a785-53b6b19cec02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_eb448efe-178a-4afd-bbe8-9b3b8117c662" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_545ef646-79dd-43b5-b172-560874486ccd" xlink:to="loc_us-gaap_ClassOfStockLineItems_eb448efe-178a-4afd-bbe8-9b3b8117c662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_2c23181b-574c-4bff-bdc2-db318ba37b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_eb448efe-178a-4afd-bbe8-9b3b8117c662" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_2c23181b-574c-4bff-bdc2-db318ba37b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6663ec19-0344-49bb-b8ba-676d2ac193f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_eb448efe-178a-4afd-bbe8-9b3b8117c662" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6663ec19-0344-49bb-b8ba-676d2ac193f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ClassOfWarrantOrRightExpirationPeriod_c4d1e32a-c215-4d16-882e-07860c1b92c2" xlink:href="ck0001824293-20230630.xsd#ck0001824293_ClassOfWarrantOrRightExpirationPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_eb448efe-178a-4afd-bbe8-9b3b8117c662" xlink:to="loc_ck0001824293_ClassOfWarrantOrRightExpirationPeriod_c4d1e32a-c215-4d16-882e-07860c1b92c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#STOCKBASEDCOMPENSATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dd5639bc-9432-4f70-a72e-ee98a5f387bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8b6d2491-0b51-43a5-9186-3e2ee22d6306" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dd5639bc-9432-4f70-a72e-ee98a5f387bc" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8b6d2491-0b51-43a5-9186-3e2ee22d6306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_7a581c1f-304d-4ead-a7a5-b004588a06f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8b6d2491-0b51-43a5-9186-3e2ee22d6306" xlink:to="loc_us-gaap_PlanNameAxis_7a581c1f-304d-4ead-a7a5-b004588a06f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_b8a78a2a-d955-4d26-8c39-cad794d6b7bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_7a581c1f-304d-4ead-a7a5-b004588a06f7" xlink:to="loc_us-gaap_PlanNameDomain_b8a78a2a-d955-4d26-8c39-cad794d6b7bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PrivateGRIPlanMember_f4460526-3890-41b2-a52d-a61fe0709889" xlink:href="ck0001824293-20230630.xsd#ck0001824293_PrivateGRIPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_b8a78a2a-d955-4d26-8c39-cad794d6b7bc" xlink:to="loc_ck0001824293_PrivateGRIPlanMember_f4460526-3890-41b2-a52d-a61fe0709889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember_72c2931a-0ba5-4a49-b0dd-441351f7c76b" xlink:href="ck0001824293-20230630.xsd#ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_b8a78a2a-d955-4d26-8c39-cad794d6b7bc" xlink:to="loc_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember_72c2931a-0ba5-4a49-b0dd-441351f7c76b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_A2018EquityIncentivePlanMember_9f2747d0-4a22-4989-ab0c-73a48266528d" xlink:href="ck0001824293-20230630.xsd#ck0001824293_A2018EquityIncentivePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_b8a78a2a-d955-4d26-8c39-cad794d6b7bc" xlink:to="loc_ck0001824293_A2018EquityIncentivePlanMember_9f2747d0-4a22-4989-ab0c-73a48266528d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_75227934-9c31-4ca5-9cdb-5a1b4a110a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8b6d2491-0b51-43a5-9186-3e2ee22d6306" xlink:to="loc_us-gaap_AwardTypeAxis_75227934-9c31-4ca5-9cdb-5a1b4a110a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9478b101-88e8-4f46-b4f4-4cebe4507931" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_75227934-9c31-4ca5-9cdb-5a1b4a110a5a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9478b101-88e8-4f46-b4f4-4cebe4507931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f20e074d-58fe-4ca1-b16e-aed7ff92c03d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9478b101-88e8-4f46-b4f4-4cebe4507931" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f20e074d-58fe-4ca1-b16e-aed7ff92c03d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5a5d3116-a542-4285-9af0-98b5b52e3e57" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8b6d2491-0b51-43a5-9186-3e2ee22d6306" xlink:to="loc_srt_RangeAxis_5a5d3116-a542-4285-9af0-98b5b52e3e57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9379951b-1365-48a2-b86b-19843933a23c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5a5d3116-a542-4285-9af0-98b5b52e3e57" xlink:to="loc_srt_RangeMember_9379951b-1365-48a2-b86b-19843933a23c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_152ba797-7fd6-40cb-b929-696591666733" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9379951b-1365-48a2-b86b-19843933a23c" xlink:to="loc_srt_MaximumMember_152ba797-7fd6-40cb-b929-696591666733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e8ededea-06a2-4608-b5a1-83ee4d849163" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8b6d2491-0b51-43a5-9186-3e2ee22d6306" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e8ededea-06a2-4608-b5a1-83ee4d849163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_771bd6b8-70de-4799-a66f-522910d1eb03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e8ededea-06a2-4608-b5a1-83ee4d849163" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_771bd6b8-70de-4799-a66f-522910d1eb03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_d99cf6dc-6d19-49fb-b43d-35569b7faaca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e8ededea-06a2-4608-b5a1-83ee4d849163" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_d99cf6dc-6d19-49fb-b43d-35569b7faaca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_3ed7da2e-c860-4a9d-981d-df8f3f9f811a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e8ededea-06a2-4608-b5a1-83ee4d849163" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_3ed7da2e-c860-4a9d-981d-df8f3f9f811a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_bbd029af-03b6-4137-9745-b1988933b766" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e8ededea-06a2-4608-b5a1-83ee4d849163" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_bbd029af-03b6-4137-9745-b1988933b766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c08ed77e-97c7-4a2e-866a-ca733a9a90f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e8ededea-06a2-4608-b5a1-83ee4d849163" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c08ed77e-97c7-4a2e-866a-ca733a9a90f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_f78a4bd6-28ef-404e-8568-2858551dadb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e8ededea-06a2-4608-b5a1-83ee4d849163" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_f78a4bd6-28ef-404e-8568-2858551dadb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_396154b7-d75e-48ee-bbef-33818af36044" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e8ededea-06a2-4608-b5a1-83ee4d849163" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_396154b7-d75e-48ee-bbef-33818af36044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a7ca0b72-49d4-4010-b306-291b1e99e02e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0ad823ba-8459-416a-81d6-d4e4f6bf2c37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a7ca0b72-49d4-4010-b306-291b1e99e02e" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0ad823ba-8459-416a-81d6-d4e4f6bf2c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_39da766b-9501-49ce-814b-7c5b8a52f782" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0ad823ba-8459-416a-81d6-d4e4f6bf2c37" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_39da766b-9501-49ce-814b-7c5b8a52f782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_35768666-310e-4b8e-8429-923e285b9043" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_39da766b-9501-49ce-814b-7c5b8a52f782" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_35768666-310e-4b8e-8429-923e285b9043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4a652576-6b39-4f22-83ab-73a1e8c751ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_35768666-310e-4b8e-8429-923e285b9043" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4a652576-6b39-4f22-83ab-73a1e8c751ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1a2eabc7-fa3a-4436-8ecb-90f064727064" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_35768666-310e-4b8e-8429-923e285b9043" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1a2eabc7-fa3a-4436-8ecb-90f064727064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d1b69135-a7e9-43d7-a1dc-c03925a80e75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0ad823ba-8459-416a-81d6-d4e4f6bf2c37" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d1b69135-a7e9-43d7-a1dc-c03925a80e75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3fea8e52-bc7b-40d7-8792-e6b9aea2695b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d1b69135-a7e9-43d7-a1dc-c03925a80e75" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_3fea8e52-bc7b-40d7-8792-e6b9aea2695b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6ba5a1e8-889e-4c74-aa8e-e9c8e011b195" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_93f4f329-0488-4920-8039-5d8c9957acc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6ba5a1e8-889e-4c74-aa8e-e9c8e011b195" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_93f4f329-0488-4920-8039-5d8c9957acc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_89e22b71-432c-4d83-94a3-0e4252c31baf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_93f4f329-0488-4920-8039-5d8c9957acc1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_89e22b71-432c-4d83-94a3-0e4252c31baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a69467fc-a897-4753-8467-6c15e45675b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_93f4f329-0488-4920-8039-5d8c9957acc1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a69467fc-a897-4753-8467-6c15e45675b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7d2b9888-1616-44f8-940e-4965c3a75ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_93f4f329-0488-4920-8039-5d8c9957acc1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7d2b9888-1616-44f8-940e-4965c3a75ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_bf9d4e34-8c3c-46eb-a2f3-9e7bea8f31fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_93f4f329-0488-4920-8039-5d8c9957acc1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_bf9d4e34-8c3c-46eb-a2f3-9e7bea8f31fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_579e1475-24dc-4091-a533-5c3f9ffd2789" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_93f4f329-0488-4920-8039-5d8c9957acc1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_579e1475-24dc-4091-a533-5c3f9ffd2789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_edff7381-5eab-424a-b2ed-f635308302f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6ba5a1e8-889e-4c74-aa8e-e9c8e011b195" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_edff7381-5eab-424a-b2ed-f635308302f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e672351f-b96d-4d9c-a01c-d63549962bcf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6ba5a1e8-889e-4c74-aa8e-e9c8e011b195" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e672351f-b96d-4d9c-a01c-d63549962bcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_cf52651b-6b27-4f49-8976-6202d41b15ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e672351f-b96d-4d9c-a01c-d63549962bcf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_cf52651b-6b27-4f49-8976-6202d41b15ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0c5af83b-01bc-49fb-a957-90d475e5914c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e672351f-b96d-4d9c-a01c-d63549962bcf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0c5af83b-01bc-49fb-a957-90d475e5914c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c905e5ef-6d36-4ea7-8e37-42d45bc92a33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e672351f-b96d-4d9c-a01c-d63549962bcf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c905e5ef-6d36-4ea7-8e37-42d45bc92a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_e0ac9cdc-b090-45ce-97cc-66adcff85af8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e672351f-b96d-4d9c-a01c-d63549962bcf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_e0ac9cdc-b090-45ce-97cc-66adcff85af8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_448e3867-8ed4-43d9-80a9-ed284024aceb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e672351f-b96d-4d9c-a01c-d63549962bcf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_448e3867-8ed4-43d9-80a9-ed284024aceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_ca2c684d-0be5-4c3d-9097-041e570693a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6ba5a1e8-889e-4c74-aa8e-e9c8e011b195" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_ca2c684d-0be5-4c3d-9097-041e570693a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_7eed5048-f5fb-4443-bdc3-4696040e42e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6ba5a1e8-889e-4c74-aa8e-e9c8e011b195" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_7eed5048-f5fb-4443-bdc3-4696040e42e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_18fed653-3342-47f1-a42c-66b0ac6b1fb6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_7eed5048-f5fb-4443-bdc3-4696040e42e3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_18fed653-3342-47f1-a42c-66b0ac6b1fb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dcdf8e63-4937-4774-97c9-0ab6a97d1898" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_7eed5048-f5fb-4443-bdc3-4696040e42e3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dcdf8e63-4937-4774-97c9-0ab6a97d1898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_992661df-879f-4142-b329-74d451637f29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e517b0d6-07df-4925-87f2-246cd2a7923e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_992661df-879f-4142-b329-74d451637f29" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e517b0d6-07df-4925-87f2-246cd2a7923e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0fd73c3a-fe62-405d-b6b0-392a9ec4f12a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e517b0d6-07df-4925-87f2-246cd2a7923e" xlink:to="loc_us-gaap_AwardTypeAxis_0fd73c3a-fe62-405d-b6b0-392a9ec4f12a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d51a195d-859a-48e1-b3f4-c6fa2bdb43b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0fd73c3a-fe62-405d-b6b0-392a9ec4f12a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d51a195d-859a-48e1-b3f4-c6fa2bdb43b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2ada04c6-9454-4743-bebe-2f61b3c8c5c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d51a195d-859a-48e1-b3f4-c6fa2bdb43b0" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2ada04c6-9454-4743-bebe-2f61b3c8c5c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0dcd956d-3d13-4d5d-bbfe-040b2fcf5462" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e517b0d6-07df-4925-87f2-246cd2a7923e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0dcd956d-3d13-4d5d-bbfe-040b2fcf5462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7ef47a86-ff35-45a0-890d-6708631173b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0dcd956d-3d13-4d5d-bbfe-040b2fcf5462" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7ef47a86-ff35-45a0-890d-6708631173b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_5089bc03-7eab-408b-af54-0f5be236b17e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0dcd956d-3d13-4d5d-bbfe-040b2fcf5462" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_5089bc03-7eab-408b-af54-0f5be236b17e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3629e965-8525-4464-a770-cdc7590bb8cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0dcd956d-3d13-4d5d-bbfe-040b2fcf5462" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3629e965-8525-4464-a770-cdc7590bb8cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_a1602c34-1f2c-4c6f-8ae3-9fcbf16c9e28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0dcd956d-3d13-4d5d-bbfe-040b2fcf5462" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_a1602c34-1f2c-4c6f-8ae3-9fcbf16c9e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_a2084c9b-def6-4607-aef3-2e932178dad3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0dcd956d-3d13-4d5d-bbfe-040b2fcf5462" xlink:to="loc_us-gaap_SharePrice_a2084c9b-def6-4607-aef3-2e932178dad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="ck0001824293-20230630.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a1c1a820-7da8-429b-88f9-fe408ba72660" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_4f90d5f3-5fec-486c-bd97-26ddfe738aec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a1c1a820-7da8-429b-88f9-fe408ba72660" xlink:to="loc_us-gaap_LossContingenciesTable_4f90d5f3-5fec-486c-bd97-26ddfe738aec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_cd58b33a-b8f6-4917-a5f2-53e1fa17439e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_4f90d5f3-5fec-486c-bd97-26ddfe738aec" xlink:to="loc_srt_TitleOfIndividualAxis_cd58b33a-b8f6-4917-a5f2-53e1fa17439e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_bed2bf16-fb3e-4f35-9d15-e351a941a543" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_cd58b33a-b8f6-4917-a5f2-53e1fa17439e" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_bed2bf16-fb3e-4f35-9d15-e351a941a543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_FormerChiefExecutiveOfficerMember_612f9f79-4dd2-40eb-ba0e-6376842043db" xlink:href="ck0001824293-20230630.xsd#ck0001824293_FormerChiefExecutiveOfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_bed2bf16-fb3e-4f35-9d15-e351a941a543" xlink:to="loc_ck0001824293_FormerChiefExecutiveOfficerMember_612f9f79-4dd2-40eb-ba0e-6376842043db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_bfe76ad1-689e-46cb-8ab9-e1a5ea7dc446" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_4f90d5f3-5fec-486c-bd97-26ddfe738aec" xlink:to="loc_us-gaap_LossContingenciesLineItems_bfe76ad1-689e-46cb-8ab9-e1a5ea7dc446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_COBRABenefitsPaymentPeriod_bd2f15d2-8615-4c99-b9bd-13d0aec88f22" xlink:href="ck0001824293-20230630.xsd#ck0001824293_COBRABenefitsPaymentPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_bfe76ad1-689e-46cb-8ab9-e1a5ea7dc446" xlink:to="loc_ck0001824293_COBRABenefitsPaymentPeriod_bd2f15d2-8615-4c99-b9bd-13d0aec88f22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PercentageOfTargetBonus_9c8816b2-b54b-46b4-8c1b-14398e8ccdba" xlink:href="ck0001824293-20230630.xsd#ck0001824293_PercentageOfTargetBonus"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_bfe76ad1-689e-46cb-8ab9-e1a5ea7dc446" xlink:to="loc_ck0001824293_PercentageOfTargetBonus_9c8816b2-b54b-46b4-8c1b-14398e8ccdba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>ck0001824293-20230630_g1.jpg
<TEXT>
begin 644 ck0001824293-20230630_g1.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M
M   18W!R=    5     S9&5S8P   80   !L=W1P=    ?     48FMP=
M @0    4<EA96@   A@    49UA96@   BP    48EA96@   D     49&UN
M9    E0   !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0    D
M;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P  !#P
M  @,9U120P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@
M*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,
M$G-21T(@245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV-BTR
M+C$
M         %A96B        #S40 !     1;,6%E:(
M  !865H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:
M(        "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W=RYI
M96,N8V@              !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                                    9&5S8P
M       N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@
M+2!S4D="               N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C
M;VQO=7(@<W!A8V4@+2!S4D="                             &1E<V,
M        +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV
M-BTR+C$              "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@
M:6X@245#-C$Y-C8M,BXQ                                  !V:65W
M       3I/X %%\N !#/%  #[<P !!,+  -<G@    %865H@      !,"58
M4    %<?YVUE87,          0                        */     G-I
M9R      0U)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M #(
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M(@LY"U$+:0N "Y@+L O("^$+^0P2#"H,0PQ<#'4,C@RG#, ,V0SS#0T-)@U
M#5H-= V.#:D-PPW>#?@.$PXN#DD.9 Y_#IL.M@[2#NX/"0\E#T$/7@]Z#Y8/
MLP_/#^P0"1 F$$,081!^$)L0N1#7$/41$Q$Q$4\1;1&,$:H1R1'H$@<2)A)%
M$F02A!*C$L,2XQ,#$R,30Q-C$X,3I!/%$^44!A0G%$D4:A2+%*T4SA3P%1(5
M-!56%7@5FQ6]%> 6 Q8F%DD6;!:/%K(6UA;Z%QT701=E%XD7KA?2%_<8&QA
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M.N\[+3MK.ZH[Z#PG/&4\I#SC/2(]83VA/> ^(#Y@/J ^X#\A/V$_HC_B0"-
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M)*75\.*CY6;"@T2D)?%D_]H # ,!  (1 Q$ /P"_P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MF8X8IKIG#BJARY?5<Q=OT6ZJ:.355$<$3T?#7Q$8:X
M
M
M
M
M                      %8KTM'ZK;7OE6<2_F;RJW.YB?SV7?@/->RY92M
M8]J1Z./$EFGIB5L                 )'O!_P#K2>@+Y5G#7YY8UB'?]\R>
MU/P'F_8JG:R?MNWZ./%; Z 9>0
M
M
M
M
M     "L5Z6C]5MKWRK.)?S-Y5;G<Q/Y[+OP'FO9<LI6L>U(]''B2S3TQ*V
M               $CW@__6D] 7RK.&OSRQK$._[YD]J?@/-^Q5.UD_;=OT<>
M*V!T R\@
M
M
M
M                                               %8KTM'ZK;7OE6
M<2_F;RJW.YB?SV7?@/->RY92M8]J1Z./$EFGIB5L                 )'O
M!_\ K2>@+Y5G#7YY8UB'?]\R>U/P'F_8JG:R?MNWZ./%; Z 9>0
M
M
M
M
M                              "L5Z6C]5MKWRK.)?S-Y5;G<Q/Y[+OP
M'FO9<LI6L>U(]''B2S3TQ*V                 $CW@_P#UI/0%\JSAK\\L
M:Q#O^^9/:GX#S?L53M9/VW;]''BM@= ,O(
M
M
M
M
M             !6*]+1^JVU[Y5G$OYF\JMSN8G\]EWX#S7LN64K6/:D>CCQ)
M9IZ8E;                 "1[P?_K2>@+Y5G#7YY8UB'?\ ?,GM3\!YOV*I
MVLG[;M^CCQ6P.@&7D
M
M
M
M                                                         K%>
MEH_5;:]\JSB7\S>56YW,3^>R[\!YKV7+*5K'M2/1QXDLT],2M@
M      !(]X/_ -:3T!?*LX:_/+&L0[_OF3VI^ \W[%4[63]MV_1QXK8'0#+R
M
M
M
M
M                                        5BO2T?JMM>^59Q+^9O*K
M<[F)_/9=^ \U[+EE*UCVI'HX\26:>F)6P                 D>\'_ZTGH"
M^59PU^>6-8AW_?,GM3\!YOV*IVLG[;M^CCQ6P.@&7D
M
M
M
M
M                      K%>EH_5;:]\JSB7\S>56YW,3^>R[\!YKV7+*5K
M'M2/1QXDLT],2M@                !(]X/_P!:3T!?*LX:_/+&L0[_ +YD
M]J?@/-^Q5.UD_;=OT<>*V!T R\@
M
M
M
M
M      %8KTM'ZK;7OE6<2_F;RJW.YB?SV7?@/->RY92M8]J1Z./$EFGIB5L
M                )'O!_P#K2>@+Y5G#7YY8UB'?]\R>U/P'F_8JG:R?MNWZ
M./%; Z 9>0
M
M
M
M                                                 "L5Z6C]5MKW
MRK.)?S-Y5;G<Q/Y[+OP'FO9<LI6L>U(]''B2S3TQ*V                 $
MCW@__6D] 7RK.&OSRQK$._[YD]J?@/-^Q5.UD_;=OT<>*V!T R\@
M
M
M
M
M                               %8KTM'ZK;7OE6<2_F;RJW.YB?SV7?
M@/->RY92M8]J1Z./$EFGIB5L                 )'O!_\ K2>@+Y5G#7YY
M8UB'?]\R>U/P'F_8JG:R?MNWZ./%; Z 9>0
M
M
M
M
M              "L5Z6C]5MKWRK.)?S-Y5;G<Q/Y[+OP'FO9<LI6L>U(]''B
M2S3TQ*V                 $CW@_P#UI/0%\JSAK\\L:Q#O^^9/:GX#S?L5
M3M9/VW;]''BM@= ,O(
M
M
M
M                                                         !6*
M]+1^JVU[Y5G$OYF\JMSN8G\]EWX#S7LN64K6/:D>CCQ)9IZ8E;
M       "1[P?_K2>@+Y5G#7YY8UB'?\ ?,GM3\!YOV*IVLG[;M^CCQ6P.@&7
MD
M
M
M
M                                         K%>EH_5;:]\JSB7\S>5
M6YW,3^>R[\!YKV7+*5K'M2/1QXDLT],2M@                !(]X/_ -:3
MT!?*LX:_/+&L0[_OF3VI^ \W[%4[63]MV_1QXK8'0#+R
M
M
M
M
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MHF>%H2HHUQ@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M0]:TR)G4LGFLO$1$_7;5RWP3.$>;ICCG@CIRY(KHJ\S,3X;GJEOH
M
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M/%)\_P!ZK/?EW+V2/D!W)_%;0_>EKU)VYF_7*^O)],!XI/G^]5GOR[E[)'R
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MY[^,D].>2,81A&$81A'LB_:='TBFJ*J<KEHJB<8F+5&,3Z4Y573EPE4GR
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MF*J:HFFJF8XXJIG"8F.C$QB[<3$QC'$^@XGZ
M    KB^E&\I<F\0^&K@=KXGY%WOC#:*G4YQ;B:FR<=[=L&E9^IBKS4N3:UWC
M)\QK60QF1FQ]U6M*4]2C&IY.>:E)&:$8RP[-N^93HFC:_OBNY'7<IE<[DHT7
M,U=COVJ+U'*B[EXBKD7*:J>5$3,1.&,1,]-3-6KJHRL31,Q/+CBX.A+/ _CN
MZX//*ZJ_G#\N^Z]+'\F.[;XO:'[PROWI;G9[_GZ^O)_'=UP>>5U5_.'Y=]UY
M\F.[;XO:'[PROWH[/?\ /U]>3^.[K@\\KJK^</R[[KSY,=VWQ>T/WAE?O1V>
M_P"?KZ\G\=W7!YY757\X?EWW7GR8[MOB]H?O#*_>CL]_S]?7D_CNZX//*ZJ_
MG#\N^Z\^3'=M\7M#]X97[T=GO^?KZ\G\=W7!YY757\X?EWW7GR8[MOB]H?O#
M*_>CL]_S]?7D_CNZX//*ZJ_G#\N^Z\^3'=M\7M#]X97[T=GO^?KZ\G\=W7!Y
MY757\X?EWW7GR8[MOB]H?O#*_>CL]_S]?7D_CNZX//*ZJ_G#\N^Z\^3'=M\7
MM#]X97[T=GO^?KZ\G\=W7!YY757\X?EWW7GR8[MOB]H?O#*_>CL]_P _7UY/
MX[NN#SRNJOYP_+ONO/DQW;?%[0_>&5^]'9[_ )^OKR?QW=<'GE=5?SA^7?=>
M?)CNV^+VA^\,K]Z.SW_/U]>3^.[K@\\KJK^</R[[KSY,=VWQ>T/WAE?O1V>_
MY^OKR?QW=<'GE=5?SA^7?=>?)CNV^+VA^\,K]Z.SW_/U]>3^.[K@\\KJK^</
MR[[KSY,=VWQ>T/WAE?O1V>_Y^OKR?QW=<'GE=5?SA^7?=>?)CNV^+VA^\,K]
MZ.SW_/U]>3^.[K@\\KJK^</R[[KSY,=VWQ>T/WAE?O1V>_Y^OKR?QW=<'GE=
M5?SA^7?=>?)CNV^+VA^\,K]Z.SW_ #]?7E('X4?63U>[EXE70UJFW]574CM6
MK[#U.<28G/ZWLG.7)V<P&<Q5[MN.HWF,S&'RFT76.R>/NZ,T9*M&M3GIU)8Q
MA-",&*]^6[W8'3]SNTV>R&AZ/8SMK1<U51<MY/+45T51:JF*J*Z;<54U1/#$
MQ,3$\3L92]>G-6XFNJ8FN.C/3:NR#5=P
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M:JIGJNC<OWKOV2NJKP9EY@7HX0
M
M &A]Z'E\1_J<^577^"+C9$WWP#YR=%^ X_&LPN31OL%?H_&A;G:&*P
M           I3>F6_P!FO03[>>H#\0<4I&>]Z_EC:CW-D?J\RH>M^9M^#/C*
M&:3Y;X
M                      #T[T[=:?5ITE9/\*]-?45R[PU-4NZ=[>XK2-VS
M6-U7-7-+M\G-L>F37-;4=FIR=O;"GD+&YI]OJ]WM67M;NZV$V[L]@VPTC(:C
M$4X15>LT57:(GUN]A%VWX-NNF>JYK=^]9G&U553X$^-Q++'2%Z77U4<>3XC7
M.L?AK1NHG6Z7DK:_Y X_\AQ%RO"6I7DC<9;(8NRM,AQALE>WH=Z%*RL\9K<E
M2;L[US+V1C'3O;[F%[$:M%S-[OM0S.D9R<9IL7\<UEN+@IIJF:<S;B9XZZ[F
M8F.A1*IV=8NT\%ZF*HZ<<$^1XBV9T2>-IX=77E-A\#Q/SGB],Y3S$U.A;\)\
MSRVG&W)E?(58R0DQ>!L\G?W&M;WD)X3=Z%+7LGEIX22S330E[LW=T5WD<W#>
MWNPBYFM=TRO,:);X9SF4QS&7BF/IJYIIBY9IZM^W:C'"(QQC&KV,]ELQP458
M5]*>"?Z?"Q2R,%.X                          K%>EH_5;:]\JSB7\S>
M56YW,3^>R[\!YKV7+*5K'M2/1QXDLT],2M@                !(]X/_P!:
M3T!?*LX:_/+&L0[_ +YD]J?@/-^Q5.UD_;=OT<>*V!T R\@
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M.,N/NV_
M                                              &A]Z'E\1_J<^57
M7^"+C9$WWP#YR=%^ X_&LPN31OL%?H_&A;G:&*P                 I3>F
M6_V:]!/MYZ@/Q!Q2D9[WK^6-J/<V1^KS*AZWYFWX,^,H9I/EO@
M
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MR9>>+&:X[%RIBFB]7*OY;/V,SP4SR;G2GQNGXO43)->W=
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M7*O*]*."/_'@XHT68W5
M
M :'WH>7Q'^ISY5=?X(N-D3?? /G)T7X#C\:S"Y-&^P5^C\:%N=H8K
M          "E-Z9;_9KT$^WGJ _$'%*1GO>OY8VH]S9'ZO,J'K?F;?@SXRAF
MD^6^
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MPKHF,:;ENK#&BY1-5%<<--4QPKBMW+=VB*[<Q-$NZ%NOL
M      !6*]+1^JVU[Y5G$OYF\JMSN8G\]EWX#S7LN64K6/:D>CCQ)9IZ8E;
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M'$<C&[R9FFN]7"W,UG[^:X)GDVNE'C]/Q.HAD;#NB
M
M                         T/O0\OB/]3GRJZ_P1<;(F^^ ?.3HOP''XUF
M%R:-]@K]'XT+<[0Q6                 %*;TRW^S7H)]O/4!^(.*4C/>]?
MRQM1[FR/U>94/6_,V_!GQE#-)\M\
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M=FN>5&$U437;PKFZ,KG+6;HQHX*XXXZ,>3'52A,+.V
M   K%>EH_5;:]\JSB7\S>56YW,3^>R[\!YKV7+*5K'M2/1QXDLT],2M@
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MJJF9JGHRXH[SY
M                                                          :'
MWH>7Q'^ISY5=?X(N-D3?? /G)T7X#C\:S"Y-&^P5^C\:%N=H8K
M       "E-Z9;_9KT$^WGJ _$'%*1GO>OY8VH]S9'ZO,J'K?F;?@SXRAFD^6
M^
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M +YD]J?@/-^Q5.UD_;=OT<>*V!T R\@
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M\51'+O1]-F)B)C'DVHIIY55RV<[J->8F;=O&FQ]&?!ZG4ZZMHW!4L
M
M                                       !H?>AY?$?ZG/E5U_@BXV1
M-]\ ^<G1?@./QK,+DT;[!7Z/QH6YVABL                 *4WIEO]FO03
M[>>H#\0<4I&>]Z_EC:CW-D?J\RH>M^9M^#/C*&:3Y;X
M
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M9NS$133F+43$5Q$1%=,TW*(B*IIHNW)9RC-V\>*Y'''CQU)2[L".X
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M.*/'GJ^(AK;".B
M
M  T/O0\OB/\ 4Y\JNO\ !%QLB;[X!\Y.B_ <?C687)HWV"OT?C0MSM#%8
M              4IO3+?[->@GV\]0'X@XI2,][U_+&U'N;(_5YE0];\S;\&?
M&4,TGRWP
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MSAK\\L:Q#O\ OF3VI^ \W[%4[63]MV_1QXK8'0#+R
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M2
M                                                  :'WH>7Q'^I
MSY5=?X(N-D3?? /G)T7X#C\:S"Y-&^P5^C\:%N=H8K                 "
ME-Z9;_9KT$^WGJ _$'%*1GO>OY8VH]S9'ZO,J'K?F;?@SXRAFD^6^
M
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MJVU[Y5G$OYF\JMSN8G\]EWX#S7LN64K6/:D>CCQ)9IZ8E;
M   "1[P?_K2>@+Y5G#7YY8UB'?\ ?,GM3\!YOV*IVLG[;M^CCQ6P.@&7D
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M7M;7*:
M                                                        T/O0
M\OB/]3GRJZ_P1<;(F^^ ?.3HOP''XUF%R:-]@K]'XT+<[0Q6
M     %*;TRW^S7H)]O/4!^(.*4C/>]?RQM1[FR/U>94/6_,V_!GQE#-)\M\
M
M                          !H!^BM>*36Y3X]O_#FYIV.:YWWB/"76R=-
MN7RUUW[K9>)K*;RFP\9PN+NO&M=Y3C.M7A=8NC)WYHZ_6J4I):=#%0[T5_/>
MW)TZ)JU.]S9VSAI>?N1;U"FF."WFI^QYC"(PBG,1')N3.'U^(JF9JO\ !<6D
MYOET]K5SY:/,^!TO"\3P%R)'PK0                "L5Z6C]5MKWRK.)?S
M-Y5;G<Q/Y[+OP'FO9<LI6L>U(]''B2S3TQ*V                 $CW@_\
MUI/0%\JSAK\\L:Q#O^^9/:GX#S?L53M9/VW;]''BM@= ,O(
M                         !1%])]\8N?/Y//>&CTU[7V8+"W<E'JXW; W
M<)OPQG;*XH75EP+C<A;S?R=CK]W0EN-K\E-&:M?0I8N>:G"VR5O7DXYE_-^C
M*V;6^/;"Q_S5RG'2[-<>8HF)B<[53/TUR)Y.6QXJ.5?B)Y=FNF@:KG<9[5M3
MP?33XWD];IJ2B1]0@
M
M       &A]Z'E\1_J<^577^"+C9$WWP#YR=%^ X_&LPN31OL%?H_&A;G:&*P
M                 I3>F6_V:]!/MYZ@/Q!Q2D9[WK^6-J/<V1^KS*AZWYFW
MX,^,H9I/EO@
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M >;]BJ=K)^V[?HX\5L#H!EY
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M1$1$80M.9F9QGC?@<K\
M
M          :'WH>7Q'^ISY5=?X(N-D3?? /G)T7X#C\:S"Y-&^P5^C\:%N=H
M8K                 "E-Z9;_9KT$^WGJ _$'%*1GO>OY8VH]S9'ZO,J'K?
MF;?@SXRAFD^6^
M                                          NJ^B+==\VO[WR[X>^\
MYJ?\%;_0ON<."*-]=TH4;;<=>QUM9\JZABZ=:::YJU]BU*RM,W1MZ791H28+
M(UHR]^O/-&.?GZ;L8S>EY#>MIEN.SY6:<GG9IB<9M7*IG+7:L."(MW9JLS5/
M#,WK5..%,0KFCYC"JK+5<4\,>#T8ZW#X4KZ",!<                "L5Z6
MC]5MKWRK.)?S-Y5;G<Q/Y[+OP'FO9<LI6L>U(]''B2S3TQ*V
M     $CW@_\ UI/0%\JSAK\\L:Q#O^^9/:GX#S?L53M9/VW;]''BM@= ,O(
M                                   !U[RURIH?!W&._<Q<H;#9ZIQW
MQEJ6=W;<MAOY^[;XO7]=Q]?)9&XA)#^4N;F:A0C)0H4X35KBO-)2IRS5)Y98
MU;0M#U3:76LKL_HMJJ_JV=OT6;5NGCJKN5133'4C&<9JG@IC&J9B(F7S773;
MHFNN<*8C&60?XE'7?R%XC75SR5U+;S-?8[$YF[AKG%>E75UZYH<<\38&XNY=
M-T^VA)4J6TMW3HW56^R=2CW:5UF;Z[N)9985N["?'<]NQTG='L%D]CM,Y-=^
MW3V3,WHC"<QFJXCLMV>CAC$46XGAIM46Z)F>3BLW-9BK,WINU<70CI1T(_\
M'1>#&4'7
M
M:'WH>7Q'^ISY5=?X(N-D3?? /G)T7X#C\:S"Y-&^P5^C\:%N=H8K
M         "E-Z9;_ &:]!/MYZ@/Q!Q2D9[WK^6-J/<V1^KS*AZWYFWX,^,H9
MI/EO@
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M^59Q+^9O*K<[F)_/9=^ \U[+EE*UCVI'HX\26:>F)6P
MD>\'_P"M)Z OE6<-?GEC6(=_WS)[4_ >;]BJ=K)^V[?HX\5L#H!EY
M                              *.'I9GB33R2ZEX:G%6=[):TF Y6ZH+
MO'7$(]Z2%23*<4\3WLU.O&,.RI2I[3E+>I2A'U,)/3J?_P 1325<Q7<_$]GW
MQ:Y:X8FO+:=%4?Z.9S4<'5G+6ZHG\)B8\Q*@ZOFN+*T>#5XT>/UE&E):H(
M
M                                                  #0^]#R^(_U
M.?*KK_!%QLB;[X!\Y.B_ <?C687)HWV"OT?C0MSM#%8
M4IO3+?[->@GV\]0'X@XI2,][U_+&U'N;(_5YE0];\S;\&?&4,TGRWP
M
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MRLNY75=KFY7YJ9Q=3JZ^
M
M             &A]Z'E\1_J<^577^"+C9$WWP#YR=%^ X_&LPN31OL%?H_&A
M;G:&*P                 I3>F6_P!FO03[>>H#\0<4I&>]Z_EC:CW-D?J\
MRH>M^9M^#/C*&:3Y;X
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ME6<-?GEC6(=_WS)[4_ >;]BJ=K)^V[?HX\5L#H!EY
M                 *(OI=/7E5RFT<0^'GH><J0QVL4+'G+GVC9S3227&PY6
MVN;+B33;ZK)4ISS?@C!5[W.75K/+/0J1R6+K0CY6AV22<<PO=A38R6?WL:I:
MCLUZ:LGD9GH6Z9B<U=IC^O7%%FFJ)BJ.QWJ>*KAH&L9C&:<M3Q1PSXT>/UE)
M1(^H0
M                                                          #0
M^]#R^(_U.?*KK_!%QLB;[X!\Y.B_ <?C687)HWV"OT?C0MSM#%8
M        4IO3+?[->@GV\]0'X@XI2,][U_+&U'N;(_5YE0];\S;\&?&4,TGR
MWP
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ME1_R.G92W9B<,)KJICZY<JC&<*KMR:KE7#YJJ<%E7KE5Z[5=JXZIQ>?%UN(
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MA>&I_EY=#7S2^ _< ?+1OB^-FTO^*9W[^=JY7UNWZ6/(/HPO#4_R\NAKYI?
M?N /EHWQ?&S:7_%,[]_.U<KZW;]+'D'T87AJ?Y>70U\TO@/W 'RT;XOC9M+_
M (IG?OYVKE?6[?I8\@^C"\-3_+RZ&OFE\!^X ^6C?%\;-I?\4SOW\[5ROK=O
MTL>0?1A>&I_EY=#7S2^ _< ?+1OB^-FTO^*9W[^=JY7UNWZ6/(/HPO#4_P O
M+H:^:7P'[@#Y:-\7QLVE_P 4SOW\[5ROK=OTL>0?1A>&I_EY=#7S2^ _< ?+
M1OB^-FTO^*9W[^=JY7UNWZ6/(/HPO#4_R\NAKYI? ?N /EHWQ?&S:7_%,[]_
M.U<KZW;]+'D'T87AJ?Y>70U\TO@/W 'RT;XOC9M+_BF=^_G:N5];M^ECR'%L
MIX27A?9>\J7UWX?W2'2KU9:<LTF+X$XYPEG"%.26G+Y/'87 6&/HS1EE^^C)
M2EC/-VQF[8QC%W;._C?3E[<6J-JM?FF//9W,5SZ:NNJJ?#G@Z#YG)Y2>'L='
M6A\_Z'_PM?,"Z5/>;T[V-<OR_;[/C3KGON[ZI^=I93UNCK'T/_A:^8%TJ>\W
MIWL:?+]OL^-.N>^[OJCM+*>MT=8^A_\ "U\P+I4]YO3O8T^7[?9\:=<]]W?5
M':64];HZQ]#_ .%KY@72I[S>G>QI\OV^SXTZY[[N^J.TLIZW1UCZ'_PM?,"Z
M5/>;T[V-/E^WV?&G7/?=WU1VEE/6Z.L?0_\ A:^8%TJ>\WIWL:?+]OL^-.N>
M^[OJCM+*>MT=8^A_\+7S NE3WF].]C3Y?M]GQIUSWW=]4=I93UNCK'T/_A:^
M8%TJ>\WIWL:?+]OL^-.N>^[OJCM+*>MT=8^A_P#"U\P+I4]YO3O8T^7[?9\:
M=<]]W?5':64];HZQ]#_X6OF!=*GO-Z=[&GR_;[/C3KGON[ZH[2RGK='6/H?_
M  M?,"Z5/>;T[V-/E^WV?&G7/?=WU1VEE/6Z.L?0_P#A:^8%TJ>\WIWL:?+]
MOL^-.N>^[OJCM+*>MT=8^A_\+7S NE3WF].]C3Y?M]GQIUSWW=]4=I93UNCK
M'T/_ (6OF!=*GO-Z=[&GR_;[/C3KGON[ZH[2RGK='6/H?_"U\P+I4]YO3O8T
M^7[?9\:=<]]W?5':64];HZQ]#_X6OF!=*GO-Z=[&GR_;[/C3KGON[ZH[2RGK
M='6/H?\ PM?,"Z5/>;T[V-/E^WV?&G7/?=WU1VEE/6Z.L^'FO!=\*;/^MO7W
M05TX4/6GEO)?@70[/6^_Y?R7?]<_T=JXKU[W?(P[GEO*>3[9NYW>]-V]K+<X
MG?CE>5V+:C5YY6&/+OS<XL>+LD58<?#AACP8XX03D<I/^SIZSX7T'?A+>8EP
M;_->:]FW9_>4W[?&?4_34>H?G:&3];I/H._"6\Q+@W^:\U[-G[RF_;XSZGZ:
MCU!VAD_6Z3Z#OPEO,2X-_FO->S9^\IOV^,^I^FH]0=H9/UND^@[\);S$N#?Y
MKS7LV?O*;]OC/J?IJ/4':&3];I/H._"6\Q+@W^:\U[-G[RF_;XSZGZ:CU!VA
MD_6Z3Z#OPEO,2X-_FO->S9^\IOV^,^I^FH]0=H9/UND^@[\);S$N#?YKS7LV
M?O*;]OC/J?IJ/4':&3];I/H._"6\Q+@W^:\U[-G[RF_;XSZGZ:CU!VAD_6Z3
MZ#OPEO,2X-_FO->S9^\IOV^,^I^FH]0=H9/UND^@[\);S$N#?YKS7LV?O*;]
MOC/J?IJ/4':&3];I/H._"6\Q+@W^:\U[-G[RF_;XSZGZ:CU!VAD_6Z3Z#OPE
MO,2X-_FO->S9^\IOV^,^I^FH]0=H9/UND^@[\);S$N#?YKS7LV?O*;]OC/J?
MIJ/4':&3];I9I'BW<5<=\(>)+U@\3<3:GBM%XXT3EW)8/4-0P=.K2Q. Q%+%
MXFM3L+"G6JUZLE"2K7GFA":>:/;-'U4QFX?7-6VDW/[/Z[KM^O-:OFLA37=N
MUX3575-54<JK"(C'"(Z"U\Y13;S-=%$84Q5P0CH9;=8                !
MH?>AY?$?ZG/E5U_@BXV1-]\ ^<G1?@./QK,+DT;[!7Z/QH6YVABL
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M:]\JSB7\S>56YW,3^>R[\!YKV7+*5K'M2/1QXDLT],2M@
M !(]X/\ ]:3T!?*LX:_/+&L0[_OF3VI^ \W[%4[63]MV_1QXK8'0#+R
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MJY<KJZ=5=<S55/5F9E58B*8Y-,1$0Y ZC]
M                                            9&/CA_6T==O[<\M^
M)L*GGYMGS$[,?!E/U=:S\_[<N>B14,X.F                 T/O0\OB/\
M4Y\JNO\ !%QLB;[X!\Y.B_ <?C687)HWV"OT?C0MSM#%8
M  4IO3+?[->@GV\]0'X@XI2,][U_+&U'N;(_5YE0];\S;\&?&4,TGRWP
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M%VC&.53C,3$TUT556ZJ*ZK6O6;F7N3;N1A5'T>K'4>7%ZN$
M     !KY^#/N,^]>%7T#YN>M+6FL>F?C;3H3RUJ%Q"63CO$2\?TZ/?MY*=.6
M:WIZQ"G&2,._3C+W)XS3RS1C 9SA=/C3-]^U.6B,.5K.8N\4Q]GJ[/CP]/LF
M./%/'&$3"\LE5RLI;G^K$=;@29,-NT              K%>EH_5;:]\JSB7\
MS>56YW,3^>R[\!YKV7+*5K'M2/1QXDLT],2M@                !(]X/\
M]:3T!?*LX:_/+&L0[_OF3VI^ \W[%4[63]MV_1QXK8'0#+R
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MQT(=K*&^P
M                    &1CXX?UM'7;^W/+?B;"IY^;9\Q.S'P93]76L_/\
MMRYZ)%0S@Z8                #0^]#R^(_U.?*KK_!%QLB;[X!\Y.B_ <?
MC687)HWV"OT?C0MSM#%8                 4IO3+?[->@GV\]0'X@XI2,]
M[U_+&U'N;(_5YE0];\S;\&?&4,TGRWP                $Y7HVOUTW1C_>
M)_PH<ZM:>>!_#KM%_8/TGDG?TSV]1X?U,M5M!\NT
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M5%VU<HG&FNW<IBJBNF>C353,3$]*5HU1-,S35P51+C;N/D
M   !JZ^CI9FKG?!FZ*KVM1IT)Z&&YGPT)*<TTTLU+7>H_F'7Z%:,9O5\I<T<
M9+4GA]R$TT80]3L0;<[;+TY;G#;1VZ9F8FYE*_#N:?E+DQX4U81U(7=ILXY*
MCP_JI38-<7>              5BO2T?JMM>^59Q+^9O*K<[F)_/9=^ \U[+E
ME*UCVI'HX\26:>F)6P                 D>\'_ .M)Z OE6<-?GEC6(=_W
MS)[4_ >;]BJ=K)^V[?HX\5L#H!EY
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MG&9GAF9GCF9Z,RN%_5\@
M                                #(Q\</ZVCKM_;GEOQ-A4\_-L^8G9
MCX,I^KK6?G_;EST2*AG!TP                &A]Z'E\1_J<^577^"+C9$W
MWP#YR=%^ X_&LPN31OL%?H_&A;G:&*P                 I3>F6_V:]!/M
MYZ@/Q!Q2D9[WK^6-J/<V1^KS*AZWYFWX,^,H9I/EO@                )R
MO1M?KINC'^\3_A0YU:T\\#^'7:+^P?I/)._IGMZCP_J9:K:#Y=H
M                                          #/$]+-Z#L?PYU(<<=;
M?'^"DQVG]35I<:CRK+C[2%''V7.&D8ZA-99RX\C3I6MM=\CZ'3IU/)RPC4N+
MW W]W5FFJ5YXI8^8KO/N[0;(9S=OJMV:]0T:J+N6Y4XU3D[U4XT1CC,QE[^,
M8\5-%^U13$13"W-7R_(NQ?ICRM?'X,>3'B2J*M]%&                  :
MKGHVOU+/1C_>)_Q7\ZH/N>!_$5M%_8/T9DEVZ9[1H\/ZJ4Y+6EWP
M     %8KTM'ZK;7OE6<2_F;RJW.YB?SV7?@/->RY92M8]J1Z./$EFGIB5L
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MKU55=ZNJ:JJJIF:JJIG&9F9X9F9X9F>&9X973Q<$<3];C
M                                                           &
M1CXX?UM'7;^W/+?B;"IY^;9\Q.S'P93]76L_/^W+GHD5#.#I@
M     -#[T/+XC_4Y\JNO\$7&R)OO@'SDZ+\!Q^-9A<FC?8*_1^-"W.T,5@
M              !2F],M_LUZ"?;SU ?B#BE(SWO7\L;4>YLC]7F5#UOS-OP9
M\90S2?+?                 3E>C:_73=&/]XG_  H<ZM:>>!_#KM%_8/TG
MDG?TSV]1X?U,M5M!\NT
M          !"]Z01TW6/4KX475'C?P?+>;)PUK5#J-TVYC#O5,5DN&YZNQ;3
M>4)/^W5N^,)L_8]GW>[>1C#MC"$&Q'-5VPN;';\M$O<ODY/4;TY"['GJ<WA;
MMQ/4C,]@K_T'1U&UV7*5QT:8Y4>%_1BR>TYZT0                 &JYZ-
MK]2ST8_WB?\ %?SJ@^YX'\16T7]@_1F27;IGM&CP_JI3DM:7?
M   5BO2T?JMM>^59Q+^9O*K<[F)_/9=^ \U[+EE*UCVI'HX\26:>F)6P
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M;5%BW%JCS,1_XGPWH9:;D
M                                    9&/CA_6T==O[<\M^)L*GGYMG
MS$[,?!E/U=:S\_[<N>B14,X.F                 T/O0\OB/\ 4Y\JNO\
M!%QLB;[X!\Y.B_ <?C687)HWV"OT?C0MSM#%8                 4IO3+?
M[->@GV\]0'X@XI2,][U_+&U'N;(_5YE0];\S;\&?&4,TGRWP
M    $Y7HVOUTW1C_ 'B?\*'.K6GG@?PZ[1?V#])Y)W],]O4>']3+5;0?+M
M                                                  <&Y/T?'\G<
M:<A\;9:G0JXKD+1MMT?)TKJG"M;5,?MF R&!O:=Q2FEGEJT)[:_FA/+&6,)I
M>V'9%4]%U*[HNLY36+$S%_*9FU>IF.">5:KIKC">A.-/ ^:Z8KHFF>*8F&(W
M=6MS8W-Q97MO7L[RSKUK6[M+JC4M[FUN;>I-2KV]Q0JRR5:%>A5DC+/)-"$T
MLT(PC"$8/2#171<HBY;F*K=41,3$XQ,3PQ,3'!,3'%*QGYWV_
M      &JYZ-K]2ST8_WB?\5_.J#[G@?Q%;1?V#]&9)=NF>T:/#^JE.2UI=\
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MG'@PNW;U%48T1*Y-(RW(MSF*O-5<7@?TSXD+<C0U6
M                                                         &1C
MXX?UM'7;^W/+?B;"IY^;9\Q.S'P93]76L_/^W+GHD5#.#I@
M   -#[T/+XC_ %.?*KK_  1<;(F^^ ?.3HOP''XUF%R:-]@K]'XT+<[0Q6
M               %*;TRW^S7H)]O/4!^(.*4C/>]?RQM1[FR/U>94/6_,V_!
MGQE#-)\M\                !.5Z-K]=-T8_P!XG_"ASJUIYX'\.NT7]@_2
M>2=_3/;U'A_4RU6T'R[0
M            &(GR?_:5R'[>=M_'^0>D31?R/E/<UKZBE8M7FI\%P94WR
M              U7/1M?J6>C'^\3_BOYU0?<\#^(K:+^P?HS)+MTSVC1X?U4
MIR6M+O@             *Q7I:/U6VO?*LXE_,WE5N=S$_GLN_ >:]ERRE:Q[
M4CT<>)+-/3$K8                 2/>#_]:3T!?*LX:_/+&L0[_OF3VI^
M\W[%4[63]MV_1QXK8'0#+R                                 <0Y!W
M3#\;Z%N_(FPU/(X#0M0V7=,Y5[TLGDL/JV&O<YDZG?F^]D[EE8SQ[8^I#L=_
M2M.S&L:IEM)RD8YK-9BW9HCIUW*XHI^C5#YJJBFF:IXHC%B7[IMN:W[<=LWO
M9+B6[V+==ESNVY^ZEA/++<YK8\I=9C*W$LM2>K4A+6OKRI-"$TTT?5]6,?NO
M1WIV0RVEZ?8TS)QR<IEK-%JB.E1;IBBF.AQ4Q"QZIFJJ:IXYEQEW7R
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M,44Q33P4Q&$.6N@_0
M                                &1CXX?UM'7;^W/+?B;"IY^;9\Q.S
M'P93]76L_/\ MRYZ)%0S@Z8                #0^]#R^(_U.?*KK_!%QLB
M;[X!\Y.B_ <?C687)HWV"OT?C0MSM#%8                 4IO3+?[->@G
MV\]0'X@XI2,][U_+&U'N;(_5YE0];\S;\&?&4,TGRWP                $
MY7HVOUTW1C_>)_PH<ZM:>>!_#KM%_8/TGDG?TSV]1X?U,M5M!\NT
M                                            !B)\G_VE<A^WG;?Q
M_D'I$T7\CY3W-:^HI6+5YJ?!<&5-\@                -5ST;7ZEGHQ_O$
M_P"*_G5!]SP/XBMHO[!^C,DNW3/:-'A_52G):TN^              K%>EH_
M5;:]\JSB7\S>56YW,3^>R[\!YKV7+*5K'M2/1QXDLT],2M@
M   !(]X/_P!:3T!?*LX:_/+&L0[_ +YD]J?@/-^Q5.UD_;=OT<>*V!T R\@
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M+@
M                   9&/CA_6T==O[<\M^)L*GGYMGS$[,?!E/U=:S\_P"W
M+GHD5#.#I@                -#[T/+XC_4Y\JNO\$7&R)OO@'SDZ+\!Q^-
M9A<FC?8*_1^-"W.T,5@                !2F],M_LUZ"?;SU ?B#BE(SWO
M7\L;4>YLC]7F5#UOS-OP9\90S2?+?                 3E>C:_73=&/]XG
M_"ASJUIYX'\.NT7]@_2>2=_3/;U'A_4RU6T'R[0
M                               &(GR?_:5R'[>=M_'^0>D31?R/E/<U
MKZBE8M7FI\%P94WR                 U7/1M?J6>C'^\3_ (K^=4'W/ _B
M*VB_L'Z,R2[=,]HT>']5*<EK2[X             "L5Z6C]5MKWRK.)?S-Y5
M;G<Q/Y[+OP'FO9<LI6L>U(]''B2S3TQ*V                 $CW@__ %I/
M0%\JSAK\\L:Q#O\ OF3VI^ \W[%4[63]MV_1QXK8'0#+R
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M,.">7CU5WZ=:[%E*(Z,QC/A_T8)E&O;N@
M                                                 ,C'QP_K:.NW
M]N>6_$V%3S\VSYB=F/@RGZNM9^?]N7/1(J&<'3                 :'WH>
M7Q'^ISY5=?X(N-D3?? /G)T7X#C\:S"Y-&^P5^C\:%N=H8K
M    "E-Z9;_9KT$^WGJ _$'%*1GO>OY8VH]S9'ZO,J'K?F;?@SXRAFD^6^
M               G*]&U^NFZ,?[Q/^%#G5K3SP/X==HO[!^D\D[^F>WJ/#^I
MEJMH/EV@
M,1/D_P#M*Y#]O.V_C_(/2)HOY'RGN:U]12L6KS4^"X,J;Y
M   :KGHVOU+/1C_>)_Q7\ZH/N>!_$5M%_8/T9DEVZ9[1H\/ZJ4Y+6EWP
M         %8KTM'ZK;7OE6<2_F;RJW.YB?SV7?@/->RY92M8]J1Z./$EFGIB
M5L                 )'O!_^M)Z OE6<-?GEC6(=_WS)[4_ >;]BJ=K)^V[
M?HX\5L#H!EY                                 *;/ICV]?@_IQZ,>-
M/7,TO]+>;>0]Z]:=M'NU_P!'>B6. ]<QEFN):\9K7]*'=A&6E/)#RT>]/)&,
MD*DA'>^M,[+M=M%K.'V#3;%G'AX.SWJJ\.+#A[6QXXG@X(GAPHNM586Z*.G5
M,]:/Z5 !*>MT                 !VQP-Q9D><^<N&.$\//5IY;F'E?CKBS
M%U*%.%6O3R/(.WX?4K*>C2FA&%2K+<Y>6,LL?4C'U%"VHUNSLSLUJ.T>8PFQ
MI^1OYFK'@CDV+5=V<9Z6%,ONW1-RY3;CCJF(Z\MK+6M=PVGZYK^I:Y8TL9KV
MKX3%:[@L;0A&%#'X;"6%#&8NQHPCVQA2M+&VDIR__J5YSLYF\QJ&<NY_-U37
MF[]RJY75/'5775-554]69F97Q$13&$<4/MNL_0
M                                                      &1CXX?
MUM'7;^W/+?B;"IY^;9\Q.S'P93]76L_/^W+GHD5#.#I@
M-#[T/+XC_4Y\JNO\$7&R)OO@'SDZ+\!Q^-9A<FC?8*_1^-"W.T,5@
M         !2F],M_LUZ"?;SU ?B#BE(SWO7\L;4>YLC]7F5#UOS-OP9\90S2
M?+?                 3E>C:_73=&/]XG_"ASJUIYX'\.NT7]@_2>2=_3/;
MU'A_4RU6T'R[0
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M/+&L0[_OF3VI^ \W[%4[63]MV_1QXK8'0#+R
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MQ1PQWM-HY><HCH1,SUH\EJ](-%W
M                                             ,C'QP_K:.NW]N>6
M_$V%3S\VSYB=F/@RGZNM9^?]N7/1(J&<'3                 :'WH>7Q'^
MISY5=?X(N-D3?? /G)T7X#C\:S"Y-&^P5^C\:%N=H8K
M"E-Z9;_9KT$^WGJ _$'%*1GO>OY8VH]S9'ZO,J'K?F;?@SXRAFD^6^
M           G*]&U^NFZ,?[Q/^%#G5K3SP/X==HO[!^D\D[^F>WJ/#^IEJMH
M/EV@
M                               *Q7I:/U6VO?*LXE_,WE5N=S$_GLN_
M >:]ERRE:Q[4CT<>)+-/3$K8                 2/>#_\ 6D] 7RK.&OSR
MQK$._P"^9/:GX#S?L53M9/VW;]''BM@= ,O(
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MCF:JNE1XLPT9T1RY0
M                                  &1CXX?UM'7;^W/+?B;"IY^;9\Q
M.S'P93]76L_/^W+GHD5#.#I@                -#[T/+XC_4Y\JNO\$7&R
M)OO@'SDZ+\!Q^-9A<FC?8*_1^-"W.T,5@                !2F],M_LUZ"
M?;SU ?B#BE(SWO7\L;4>YLC]7F5#UOS-OP9\90S2?+?
M3E>C:_73=&/]XG_"ASJUIYX'\.NT7]@_2>2=_3/;U'A_4RU6T'R[0
M
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M57J%VJ.'Z6,G11/2X>5<ZL8=")X:]HE/#<J]#'BKT:,Y7@
M
M   &1CXX?UM'7;^W/+?B;"IY^;9\Q.S'P93]76L_/^W+GHD5#.#I@
M         -#[T/+XC_4Y\JNO\$7&R)OO@'SDZ+\!Q^-9A<FC?8*_1^-"W.T,
M5@                !2F],M_LUZ"?;SU ?B#BE(SWO7\L;4>YLC]7F5#UOS
M-OP9\90S2?+?                 3E>C:_73=&/]XG_  H<ZM:>>!_#KM%_
M8/TGDG?TSV]1X?U,M5M!\NT
M                                                  !6*]+1^JVU
M[Y5G$OYF\JMSN8G\]EWX#S7LN64K6/:D>CCQ)9IZ8E;
M"1[P?_K2>@+Y5G#7YY8UB'?]\R>U/P'F_8JG:R?MNWZ./%; Z 9>0
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MG^M'B+DR/=6@
M                             &1CXX?UM'7;^W/+?B;"IY^;9\Q.S'P9
M3]76L_/^W+GHD5#.#I@                -#[T/+XC_ %.?*KK_  1<;(F^
M^ ?.3HOP''XUF%R:-]@K]'XT+<[0Q6                 %*;TRW^S7H)]O
M/4!^(.*4C/>]?RQM1[FR/U>94/6_,V_!GQE#-)\M\                !.5
MZ-K]=-T8_P!XG_"ASJUIYX'\.NT7]@_2>2=_3/;U'A_4RU6T'R[0
M
M                   %8KTM'ZK;7OE6<2_F;RJW.YB?SV7?@/->RY92M8]J
M1Z./$EFGIB5L                 )'O!_\ K2>@+Y5G#7YY8UB'?]\R>U/P
M'F_8JG:R?MNWZ./%; Z 9>0                                #+<])
MV^N(Y_\ :-P+\#6FIKN9C_#_ *5[ISOXW=6IJGMVKP(\2%?UM2IP
M         #0^]#R^(_U.?*KK_!%QLB;[X!\Y.B_ <?C687)HWV"OT?C0MSM#
M%8
M                    9&/CA_6T==O[<\M^)L*GGYMGS$[,?!E/U=:S\_[<
MN>B14,X.F                 T/O0\OB/\ 4Y\JNO\ !%QLB;[X!\Y.B_ <
M?C687)HWV"OT?C0MSM#%8                 4IO3+?[->@GV\]0'X@XI2,
M][U_+&U'N;(_5YE0];\S;\&?&4,TGRWP                $Y7HVOUTW1C_
M 'B?\*'.K6GG@?PZ[1?V#])Y)W],]O4>']3+5;0?+M
M
M          5BO2T?JMM>^59Q+^9O*K<[F)_/9=^ \U[+EE*UCVI'HX\26:>F
M)6P                 D>\'_P"M)Z OE6<-?GEC6(=_WS)[4_ >;]BJ=K)^
MV[?HX\5L#H!EY                                 ,MSTG;ZXCG_P!H
MW OP-::FNYF/\/\ I7NG._C=U:FJ>W:O CQ(5_6U*G
M-#[T/+XC_4Y\JNO\$7&R)OO@'SDZ+\!Q^-9A<FC?8*_1^-"W.T,5@
M
M          !D8^.'];1UV_MSRWXFPJ>?FV?,3LQ\&4_5UK/S_MRYZ)%0S@Z8
M                #0^]#R^(_P!3GRJZ_P $7&R)OO@'SDZ+\!Q^-9A<FC?8
M*_1^-"W.T,5@                !2F],M_LUZ"?;SU ?B#BE(SWO7\L;4>Y
MLC]7F5#UOS-OP9\90S2?+?                 3E>C:_73=&/\ >)_PH<ZM
M:>>!_#KM%_8/TGDG?TSV]1X?U,M5M!\NT
M
M!6*]+1^JVU[Y5G$OYF\JMSN8G\]EWX#S7LN64K6/:D>CCQ)9IZ8E;
M          "1[P?_ *TGH"^59PU^>6-8AW_?,GM3\!YOV*IVLG[;M^CCQ6P.
M@&7D                                 RZ_2@L;>V/C <UW5U1\E0S/
M''!.2QL_E*4_KFRI<6Z]AZE;NTZD\]'NY'%7%/NU(23Q\GWH0[LTLT9JN9;>
MMW=P.FT43C5;SF=IJX^"9S-RO#J^5JIG@QCAPXXF%J:K&&=J\"/$5[FUJG
M                - 7T.+.>N.FKK)UKU_Y3\$\Y:'G/P9V__P '_2'0:]AZ
M_P"[W?4_"7]&/)]O;'M]:_<AV>K%=WP7+<C;'9[.<G#LFF7Z.5T^QWXJY/\
MH]DQ_P!)<6BS]:KC^M'B+D"/E6@
M                                            &1CXX?UM'7;^W/+?
MB;"IY^;9\Q.S'P93]76L_/\ MRYZ)%0S@Z8                #0^]#R^(_
MU.?*KK_!%QLB;[X!\Y.B_ <?C687)HWV"OT?C0MSM#%8
M 4IO3+?[->@GV\]0'X@XI2,][U_+&U'N;(_5YE0];\S;\&?&4,TGRWP
M           $Y7HVOUTW1C_>)_PH<ZM:>>!_#KM%_8/TGDG?TSV]1X?U,M5M
M!\NT
M                               !6*]+1^JVU[Y5G$OYF\JMSN8G\]EW
MX#S7LN64K6/:D>CCQ)9IZ8E;                 "1[P?\ ZTGH"^59PU^>
M6-8AW_?,GM3\!YOV*IVLG[;M^CCQ6P.@&7D
M        S+_2M\-5Q?BMWM]4K4ZLFQ].G#F9H222S0FMJ5"OM^O1HU8S>I/4
MFK8&>I",/4[M2$/NPBF3YCF8IO;C:;<1,39U?-T3U9F+5S&/"KB/!A:^KQAF
M_!IA6J;B*6                  O&^AF[;W:_B"Z+7JS1C4H]-.VXNA"E1A
M++Y&?G'#YVK4K]Z%Q--/ZXQT)).R:2$)9H]LL8_?1J]\,R&-.RFITQQ3J%JJ
M<9Z/:==$8<70N8SQ\7'T*]HD_9*?0^.O,(TE>
M                                                       9&/CA
M_6T==O[<\M^)L*GGYMGS$[,?!E/U=:S\_P"W+GHD5#.#I@
M  -#[T/+XC_4Y\JNO\$7&R)OO@'SDZ+\!Q^-9A<FC?8*_1^-"W.T,5@
M           !2F],M_LUZ"?;SU ?B#BE(SWO7\L;4>YLC]7F5#UOS-OP9\90
MS2?+?                 3E>C:_73=&/]XG_"ASJUIYX'\.NT7]@_2>2=_3
M/;U'A_4RU6T'R[0
M                                          %8KTM'ZK;7OE6<2_F;
MRJW.YB?SV7?@/->RY92M8]J1Z./$EFGIB5L                 )'O!_P#K
M2>@+Y5G#7YY8UB'?]\R>U/P'F_8JG:R?MNWZ./%; Z 9>0
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M3/#P81RL:QHU6&8JIZ='B3#1;1)+D
M                                               9&/CA_6T==O[<
M\M^)L*GGYMGS$[,?!E/U=:S\_P"W+GHD5#.#I@                -#[T/+
MXC_4Y\JNO\$7&R)OO@'SDZ+\!Q^-9A<FC?8*_1^-"W.T,5@
M   !2F],M_LUZ"?;SU ?B#BE(SWO7\L;4>YLC]7F5#UOS-OP9\90S2?+?
M              3E>C:_73=&/]XG_"ASJUIYX'\.NT7]@_2>2=_3/;U'A_4R
MU6T'R[0
M                                  %8KTM'ZK;7OE6<2_F;RJW.YB?S
MV7?@/->RY92M8]J1Z./$EFGIB5L                 )'O!_P#K2>@+Y5G#
M7YY8UB'?]\R>U/P'F_8JG:R?MNWZ./%; Z 9>0
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MD9RCI3C'7CR6K0@Z7:
M                                    R,?'#^MHZ[?VYY;\385//S;/
MF)V8^#*?JZUGY_VY<]$BH9P=,                !H?>AY?$?ZG/E5U_@BX
MV1-]\ ^<G1?@./QK,+DT;[!7Z/QH6YVABL                 *4WIEO]FO
M03[>>H#\0<4I&>]Z_EC:CW-D?J\RH>M^9M^#/C*&:3Y;X
M "<KT;7ZZ;HQ_O$_X4.=6M// _AUVB_L'Z3R3OZ9[>H\/ZF6JV@^7:
M
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M9C+WLIF*\KF:9HS%JNJBJF>.FJF9BJ)ZL3$Q*]XF)C&.)])POT
M
M      !D8^.'];1UV_MSRWXFPJ>?FV?,3LQ\&4_5UK/S_MRYZ)%0S@Z8
M            #0^]#R^(_P!3GRJZ_P $7&R)OO@'SDZ+\!Q^-9A<FC?8*_1^
M-"W.T,5@                !2F],M_LUZ"?;SU ?B#BE(SWO7\L;4>YLC]7
MF5#UOS-OP9\90S2?+?                 3E>C:_73=&/\ >)_PH<ZM:>>!
M_#KM%_8/TGDG?TSV]1X?U,M5M!\NT
M                                                        !6*]
M+1^JVU[Y5G$OYF\JMSN8G\]EWX#S7LN64K6/:D>CCQ)9IZ8E;
M      "1[P?_ *TGH"^59PU^>6-8AW_?,GM3\!YOV*IVLG[;M^CCQ6P.@&7D
M                                 K5>E;\>S;IX4EYLD)._#B/J+X<Y
M"FF[9X>2ER5#;^*._P#>75O+'MFY.A+]])7E^^_U(1[*E/</F-ZM&G;\:<GC
M[?TC-V/2S:S/2G\&Z<>#T)I>KT\K*8]*J)\6/'9EZ91:X
M   #6Q\"?J1I=3_A7=).Y7%[Z[V30^/Z/!>Y25*TMQ>T,]PE<5>/+.ODJLL9
MHS7V?U7"8W+31FC&I-)D)9I_OHQ01<YO9"K8O?=KVGTT\G)YK-SG;7!A$T9R
M.SS%,>=HNUW+7!P8VYB.!>&0N]ERE%71B,)\+@\3A2Z,"NX
M
M    R,?'#^MHZ[?VYY;\385//S;/F)V8^#*?JZUGY_VY<]$BH9P=,
M         !H?>AY?$?ZG/E5U_@BXV1-]\ ^<G1?@./QK,+DT;[!7Z/QH6YVA
MBL                 *4WIEO]FO03[>>H#\0<4I&>]Z_EC:CW-D?J\RH>M^
M9M^#/C*&:3Y;X                "<KT;7ZZ;HQ_O$_X4.=6M// _AUVB_L
M'Z3R3OZ9[>H\/ZF6JV@^7:
M                                                  K%>EH_5;:]
M\JSB7\S>56YW,3^>R[\!YKV7+*5K'M2/1QXDLT],2M@                !
M(]X/_P!:3T!?*LX:_/+&L0[_ +YD]J?@/-^Q5.UD_;=OT<>*V!T R\@
M                           $5OC>\71Y@\)OKLU&6WFNIL9P7F.3)*,D
MTLDT:G"F6PW,U.I+WJ=7OS4)]"A/"2$.]/W>[+&6:,)H9OYMNM]P-^NS&?QY
M,5ZG1E\?=E->4ZG'V?#'H<<X\3J9^CEY.Y']7'K</C,BQ/0LX
M       !=R]#UZLY,?L74_T2;#E>Y2V&TQ/49QACZUQ&G1_"V(EQ^A<L6]M2
MJ=M.O?9+$U=8N))*<99X4,;<3QA/++&-.-[G_P"PDW<IHN\C*48U6JJLAF:H
MCAY-?*OY69GH4TU1F*9F>#&Y3'!,\-=T:]A-=B>CY:/$GQE[-&2KX
M
M         #(Q\</ZVCKM_;GEOQ-A4\_-L^8G9CX,I^KK6?G_ &Y<]$BH9P=,
M                !H?>AY?$?ZG/E5U_@BXV1-]\ ^<G1?@./QK,+DT;[!7Z
M/QH6YVABL                 *4WIEO]FO03[>>H#\0<4I&>]Z_EC:CW-D?
MJ\RH>M^9M^#/C*&:3Y;X                "<KT;7ZZ;HQ_O$_X4.=6M//
M_AUVB_L'Z3R3OZ9[>H\/ZF6JV@^7:
M                                                         K%>
MEH_5;:]\JSB7\S>56YW,3^>R[\!YKV7+*5K'M2/1QXDLT],2M@
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MT[.7M/S]NJUGK%VJW<HJC"JBNBJ::Z*HZ%5-43$QT)A>D3%4153PQ+[KK/T
M
M              !D8^.'];1UV_MSRWXFPJ>?FV?,3LQ\&4_5UK/S_MRYZ)%0
MS@Z8                #0^]#R^(_P!3GRJZ_P $7&R)OO@'SDZ+\!Q^-9A<
MFC?8*_1^-"W.T,5@                !2F],M_LUZ"?;SU ?B#BE(SWO7\L
M;4>YLC]7F5#UOS-OP9\90S2?+?                 3E>C:_73=&/\ >)_P
MH<ZM:>>!_#KM%_8/TGDG?TSV]1X?U,M5M!\NT
M
M    !6*]+1^JVU[Y5G$OYF\JMSN8G\]EWX#S7LN64K6/:D>CCQ)9IZ8E;
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M.9[)9[!5YNCB\#^CBZRUBT=5<
M                                        !D8^.'];1UV_MSRWXFPJ
M>?FV?,3LQ\&4_5UK/S_MRYZ)%0S@Z8                #0^]#R^(_U.?*K
MK_!%QLB;[X!\Y.B_ <?C687)HWV"OT?C0MSM#%8                 4IO3
M+?[->@GV\]0'X@XI2,][U_+&U'N;(_5YE0];\S;\&?&4,TGRWP
M      $Y7HVOUTW1C_>)_P *'.K6GG@?PZ[1?V#])Y)W],]O4>']3+5;0?+M
M
M                            5BO2T?JMM>^59Q+^9O*K<[F)_/9=^ \U
M[+EE*UCVI'HX\26:>F)6P                 D>\'_ZTGH"^59PU^>6-8AW
M_?,GM3\!YOV*IVLG[;M^CCQ6P.@&7D
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MRB[;BY1.-,P[F6\^P
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M77,4Q%,355.$1$<40CT_BOZI?.4Y^]^/D3W1KP[@:#^!93[C;]2VI^1#<O\
M%#9?_"LC]X/XK^J7SE.?O?CY$]T9W T'\"RGW&WZD^1#<O\ %#9?_"LC]X/X
MK^J7SE.?O?CY$]T9W T'\"RGW&WZD^1#<O\ %#9?_"LC]X/XK^J7SE.?O?CY
M$]T9W T'\"RGW&WZD^1#<O\ %#9?_"LC]X/XK^J7SE.?O?CY$]T9W T'\"RG
MW&WZD^1#<O\ %#9?_"LC]X/XK^J7SE.?O?CY$]T9W T'\"RGW&WZD^1#<O\
M%#9?_"LC]X6B?1X.4N3>3M.ZI:_)/(V]\A5\/LW%5+$UMXV[8-LJXNE>8O>I
M[RECJF>R%_/94[J>WIQJ2THRPGC3EC-V]V'9@K?#D,CD<SD(R5FU9BJB[CR*
M*:,<)HPQY,1CAT,4,O?6-B]CMCM?V+M[(Z3IFE6\QD]2F[&3RMC+1<FBYDXI
MFY%FBB*YIBJJ*9JQPY4X88RL>L,HE
M                                           %8KTM'ZK;7OE6<2_F
M;RJW.YB?SV7?@/->RY92M8]J1Z./$EFGIB5L                 )'O!_\
MK2>@+Y5G#7YY8UB'?]\R>U/P'F_8JG:R?MNWZ./%; Z 9>0
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M&,)I9H1[81A]U$!,3$X3QKF?Z?@
M                                         R,?'#^MHZ[?VYY;\385
M//S;/F)V8^#*?JZUGY_VY<]$BH9P=,                !H?>AY?$?ZG/E5
MU_@BXV1-]\ ^<G1?@./QK,+DT;[!7Z/QH6YVABL                 *4WI
MEO\ 9KT$^WGJ _$'%*1GO>OY8VH]S9'ZO,J'K?F;?@SXRAFD^6^
M        G*]&U^NFZ,?[Q/\ A0YU:T\\#^'7:+^P?I/)._IGMZCP_J9:K:#Y
M=H    #/B\7[ZR#JC]M6J?!KI3;W=W^I>0^UU^R5O4US#?X2-B_<69_2&;1L
M+T;=@    +9GHU']2>K;VU<0_BCD!K_OK]M:?]KO>+;0==][_6+87W%JGLN1
M6>&#D-X
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MCA5T
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M\4<@-?\ ?7[:T_[7>\6V@Z[[W^L6PON+5/9<BL\,'(;P
M                                                         %8K
MTM'ZK;7OE6<2_F;RJW.YB?SV7?@/->RY92M8]J1Z./$EFGIB5L
M       )'O!_^M)Z OE6<-?GEC6(=_WS)[4_ >;]BJ=K)^V[?HX\5L#H!EY
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MJ9B:9<B=1^@
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MV]M7$/XHY :_[Z_;6G_:[WBVT'7?>_UBV%]Q:I[+D5GA@Y#>
M
M  K%>EH_5;:]\JSB7\S>56YW,3^>R[\!YKV7+*5K'M2/1QXDLT],2M@
M           !(]X/_P!:3T!?*LX:_/+&L0[_ +YD]J?@/-^Q5.UD_;=OT<>*
MV!T R\@                                  %4'TM#H[FY?Z+N/NK#6
ML9+<;9TJ;O+8[96H6\9KJMQ%RY=XC6\I6JSTHQJW$N W^UP-2G)-+-);VUY>
M5>])"$_>WFYB>\"- WB9O87.5X9'7,MRK43/!&:RL57*8C'@CEV)OQ,XXU54
M6Z<)X,*1K%GEV(O1QT3]"?Z<&<PEQ6T                      E7\.+QC
M.L[PS\[2M.'=SI[CPS?Y+U_M73[R)/=YGC;+SUJD\U]?Z_3DKT\KH&R7,*LT
M\U_AZUO"YJRTXWM&\ITY:3!^]WF^[O-\>6FO:#+SE]H::.3:SUC"C,48<5-?
M!R;]N,,.1=BKDQCV.JW,S4[F6SM_*SY2<:.E/%_1X2^_T ^D6>'WUMVV%U7:
MMTI=+'.-]+9VM?C/F[+8W$:[F<O<34Z,;?C_ )6FC::=LU*M>5I*-M;WTV&S
M-U4F[*>/FEEC.BZWI\TG>KNWKN9[(Y:=;V:IQF,QDZ:JKE%$8SC?RW#=MS$1
M,U54=ELTQQW8F<%P9?4LM?X)GD7.E/C3Q>)/43UTJM*O2IUJ-2G6HUJ<E6E5
MI3RU*56E4EA/3J4ZDD8R3TYY(PC",(QA&$>V#5ZJFJFJ::HF*HG"8GCB50?T
M?@
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MZ_;6G_:[WBVT'7?>_P!8MA?<6J>RY%9X8.0W@
M                                                  *Q7I:/U6VO
M?*LXE_,WE5N=S$_GLN_ >:]ERRE:Q[4CT<>)+-/3$K8
M2/>#_P#6D] 7RK.&OSRQK$._[YD]J?@/-^Q5.UD_;=OT<>*V!T R\@
M                            '5/.O#>E=0_"_*O!'(UC^$-%Y@X_VSCG
M:;>66E&XEP^W82\PMW>8^>M3JR6N6QTMYZXLZ\(=^WNJ5.K)&$\DL85S9G:'
M4=D]HLCM/I%7(U/3\W:S%J>'#EVJXKB*L,,::L.373Q54S-,\$R^+E%-RB;=
M7F:HPZ[&;ZD.!]XZ7^>^7^GCDBSJ6>[<.<@;-H.=[UO4MJ-_5U_)U[.TSF.D
MJS3QJ8;8L?)1O[&K":>2O9W-*I)--+/":/H8V0VGTW;39?3]K-'JBK3=0REN
M_1PXS3%=,3-%6'T]NK&BN."::Z:HF(F,%E7;=5JY5;J\U3.#I1<;C
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M;TRW^S7H)]O/4!^(.*4C/>]?RQM1[FR/U>94/6_,V_!GQE#-)\M\
M        !.5Z-K]=-T8_WB?\*'.K6GG@?PZ[1?V#])Y)W],]O4>']3+5;0?+
MM     9\7B_?60=4?MJU3X-=*;>[N_U+R'VNOV2MZFN8;_"1L7[BS/Z0S:-A
M>C;L    !;,]&H_J3U;>VKB'\4<@-?\ ?7[:T_[7>\6V@Z[[W^L6PON+5/9<
MBL\,'(;P
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MQ;ICBPM7JJ;D=&>V*^A0M[6,OR:XS%/%5P3X,<77CQ%,A(<H@
M
M                                          #0^]#R^(_U.?*KK_!%
MQLB;[X!\Y.B_ <?C687)HWV"OT?C0MSM#%8                 4IO3+?[-
M>@GV\]0'X@XI2,][U_+&U'N;(_5YE0];\S;\&?&4,TGRWP
M  $Y7HVOUTW1C_>)_P *'.K6GG@?PZ[1?V#])Y)W],]O4>']3+5;0?+M
M 9\7B_?60=4?MJU3X-=*;>[N_P!2\A]KK]DK>IKF&_PD;%^XLS^D,VC87HV[
M     6S/1J/ZD]6WMJXA_%'(#7_?7[:T_P"UWO%MH.N^]_K%L+[BU3V7(K/#
M!R&\
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M%43A+KY57R
M
M   T/O0\OB/]3GRJZ_P1<;(F^^ ?.3HOP''XUF%R:-]@K]'XT+<[0Q6
M            %*;TRW^S7H)]O/4!^(.*4C/>]?RQM1[FR/U>94/6_,V_!GQE
M#-)\M\                !.5Z-K]=-T8_WB?\*'.K6GG@?PZ[1?V#])Y)W]
M,]O4>']3+5;0?+M     9\7B_?60=4?MJU3X-=*;>[N_U+R'VNOV2MZFN8;_
M  D;%^XLS^D,VC87HV[     6S/1J/ZD]6WMJXA_%'(#7_?7[:T_[7>\6V@Z
M[[W^L6PON+5/9<BL\,'(;P
M                                   %8KTM'ZK;7OE6<2_F;RJW.YB?
MSV7?@/->RY92M8]J1Z./$EFGIB5L                 )'O!_\ K2>@+Y5G
M#7YY8UB'?]\R>U/P'F_8JG:R?MNWZ./%; Z 9>0
M               "AOZ63X;,^N[7JGB3<5X'LP>XSX+B_J8ML=;PA)CMNM+6
M3&<8\G7=.A0FFEH;)B+277LC<U)Y*-*ZL<5)+":M>U)HR>\Q;?!&;R-_<_K=
MW_F<O%>9TZ:I\U:F>5F<O&,\=NJ>SVZ8B9FFN_,X4VXA;^KY7"8S5'%/!5X/
M0GQNLI1)&E#
M
M    :'WH>7Q'^ISY5=?X(N-D3?? /G)T7X#C\:S"Y-&^P5^C\:%N=H8K
M             "E-Z9;_ &:]!/MYZ@/Q!Q2D9[WK^6-J/<V1^KS*AZWYFWX,
M^,H9I/EO@                )RO1M?KINC'^\3_ (4.=6M// _AUVB_L'Z3
MR3OZ9[>H\/ZF6JV@^7:     SXO%^^L@ZH_;5JGP:Z4V]W=_J7D/M=?LE;U-
M<PW^$C8OW%F?TAFT;"]&W8    "V9Z-1_4GJV]M7$/XHY :_[Z_;6G_:[WBV
MT'7?>_UBV%]Q:I[+D5GA@Y#>
M                                      K%>EH_5;:]\JSB7\S>56YW
M,3^>R[\!YKV7+*5K'M2/1QXDLT],2M@                !(]X/_P!:3T!?
M*LX:_/+&L0[_ +YD]J?@/-^Q5.UD_;=OT<>*V!T R\@
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M75HJ\S,Q'+MS1<B,*X6;F+%67O3:KZ'T8Z$O&;(;@
M
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M)ZMO;5Q#^*.0&O\ OK]M:?\ :[WBVT'7?>_UBV%]Q:I[+D5GA@Y#>
M
M       K%>EH_5;:]\JSB7\S>56YW,3^>R[\!YKV7+*5K'M2/1QXDLT],2M@
M                !(]X/_UI/0%\JSAK\\L:Q#O^^9/:GX#S?L53M9/VW;]'
M'BM@= ,O(                                     !7L](5\*"7Q#^F
M*')_$F MKCJQZ<<7E]@X\A;4(29+E#0>[-D=PX=KUZ4._=Y"[\C'(ZY"K"I+
M2S%.:UDC;T\G=UY=KN:AOSG=-MGW%UZ[,;"ZO711?QGRN6O^9M9N(GBIC'L>
M8PPQM3%<\N;-%,T[4<IVS:Y=$?7J>+JQT8\CJ^"R\Z]"O:UZUK=4:MM<VU6I
M0N+>O3GHUZ%>C/&G5HUJ52$M2E5I5)8RS2S0A&6,.R/JIIZ:J:Z8KHF)HF,8
MF.&)B>*8GHQ*U7\7T_
M
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MVN]XMM!UWWO]8MA?<6J>RY%9X8.0W@
M                                           *Q7I:/U6VO?*LXE_,
MWE5N=S$_GLN_ >:]ERRE:Q[4CT<>)+-/3$K8                 2/>#_\
M6D] 7RK.&OSRQK$._P"^9/:GX#S?L53M9/VW;]''BM@= ,O(
M                          !GY^DX^#K5X=W/->(OTXZSV<3\BYVE-U*Z
M;AK6;R7'7).=NI*-OREC[:WIQDHZ;R-DJT*>5A&$L+#8*LM2$T]/)0DM)4^9
MGS@:=H-.M[I-KKW_ /=REJ>Y]VN>',9>B,9RU4SQW<O3&-KS]B)C")LXW+=U
M3)<BKMFU'E)GRT=*>GX$^+X*G,D$44
M
M                    !H?>AY?$?ZG/E5U_@BXV1-]\ ^<G1?@./QK,+DT;
M[!7Z/QH6YVABL                 *4WIEO]FO03[>>H#\0<4I&>]Z_EC:C
MW-D?J\RH>M^9M^#/C*&:3Y;X                "<KT;7ZZ;HQ_O$_X4.=6
MM// _AUVB_L'Z3R3OZ9[>H\/ZF6JV@^7:     SXO%^^L@ZH_;5JGP:Z4V]W
M=_J7D/M=?LE;U-<PW^$C8OW%F?TAFT;"]&W8    "V9Z-1_4GJV]M7$/XHY
M:_[Z_;6G_:[WBVT'7?>_UBV%]Q:I[+D5GA@Y#>
M                                                    K%>EH_5;
M:]\JSB7\S>56YW,3^>R[\!YKV7+*5K'M2/1QXDLT],2M@
M !(]X/\ ]:3T!?*LX:_/+&L0[_OF3VI^ \W[%4[63]MV_1QXK8'0#+R
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MH,&S#H
M                                                        -#[T
M/+XC_4Y\JNO\$7&R)OO@'SDZ+\!Q^-9A<FC?8*_1^-"W.T,5@
M     !2F],M_LUZ"?;SU ?B#BE(SWO7\L;4>YLC]7F5#UOS-OP9\90S2?+?
M                3E>C:_73=&/]XG_"ASJUIYX'\.NT7]@_2>2=_3/;U'A_
M4RU6T'R[0    &?%XOWUD'5'[:M4^#72FWN[O]2\A]KK]DK>IKF&_P )&Q?N
M+,_I#-HV%Z-NP    %LST:C^I/5M[:N(?Q1R U_WU^VM/^UWO%MH.N^]_K%L
M+[BU3V7(K/#!R&\
M                            !6*]+1^JVU[Y5G$OYF\JMSN8G\]EWX#S
M7LN64K6/:D>CCQ)9IZ8E;                 "1[P?_ *TGH"^59PU^>6-8
MAW_?,GM3\!YOV*IVLG[;M^CCQ6P.@&7D
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M:[%SAFU<PC'"JBK"NBNF+2S>4KRESDU<-$\4]/\ IZ:+AFMU
M
M                                     &A]Z'E\1_J<^577^"+C9$WW
MP#YR=%^ X_&LPN31OL%?H_&A;G:&*P                 I3>F6_P!FO03[
M>>H#\0<4I&>]Z_EC:CW-D?J\RH>M^9M^#/C*&:3Y;X                "<
MKT;7ZZ;HQ_O$_P"%#G5K3SP/X==HO[!^D\D[^F>WJ/#^IEJMH/EV@    ,^+
MQ?OK(.J/VU:I\&NE-O=W?ZEY#[77[)6]37,-_A(V+]Q9G](9M&PO1MV
MMF>C4?U)ZMO;5Q#^*.0&O^^OVUI_VN]XMM!UWWO]8MA?<6J>RY%9X8.0W@
M
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M9NV*Y\Q=BF(Q\I7%-<32M/-Y2YE*^35PT3Q3T_Z>HBM9O=0
M
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MHU']2>K;VU<0_BCD!K_OK]M:?]KO>+;0==][_6+87W%JGLN16>&#D-X
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M?@/-^Q5.UD_;=OT<>*V!T R\@
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MFJNS,S=M1$S]<MTS<6QG<A<RL\NGRUGI]+P?)XD"#:)3@
M
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MK;VU<0_BCD!K_OK]M:?]KO>+;0==][_6+87W%JGLN16>&#D-X
M                                  "GYZ0)\<GC3Y,NF_"GS.V"W4?J
M[>]VU^Q64XW>S_F(U;]K<U^C]+08,GI$     $Y_H_?QR>2_DR[E\*?##&&]
M?]7;/NVCV*\CO[YA\Q&D_M;E?T?JBX&U]0<@                  *Q7I:/
MU6VO?*LXE_,WE5N=S$_GLN_ >:]ERRE:Q[4CT<>)+-/3$K8
M    2/>#_P#6D] 7RK.&OSRQK$._[YD]J?@/-^Q5.UD_;=OT<>*V!T R\@
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MJIJB8F*HF8F)QB5#F)B<)X)A\ESOP
M
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MG_:[WBVT'7?>_P!8MA?<6J>RY%9X8.0W@
M                  *?GI GQR>-/DRZ;\*?,[8+=1^KM[W;7[%93C=[/^8C
M5OVMS7Z/TM!@R>D0     3G^C]_')Y+^3+N7PI\,,8;U_P!7;/NVCV*\CO[Y
MA\Q&D_M;E?T?JBX&U]0<@                  *Q7I:/U6VO?*LXE_,WE5N
M=S$_GLN_ >:]ERRE:Q[4CT<>)+-/3$K8                 2/>#_\ 6D]
M7RK.&OSRQK$._P"^9/:GX#S?L53M9/VW;]''BM@= ,O(
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MT=..+^CPT73-;J
M                                                          -#
M[T/+XC_4Y\JNO\$7&R)OO@'SDZ+\!Q^-9A<FC?8*_1^-"W.T,5@
M       !2F],M_LUZ"?;SU ?B#BE(SWO7\L;4>YLC]7F5#UOS-OP9\90S2?+
M?                 3E>C:_73=&/]XG_"ASJUIYX'\.NT7]@_2>2=_3/;U'
MA_4RU6T'R[0    &?%XOWUD'5'[:M4^#72FWN[O]2\A]KK]DK>IKF&_PD;%^
MXLS^D,VC87HV[     6S/1J/ZD]6WMJXA_%'(#7_ 'U^VM/^UWO%MH.N^]_K
M%L+[BU3V7(K/#!R&\
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M,\C,VOMMBO"Y3&/!%?)FW5/F*ZHX5"OY:]EYPNTS'5Z$^&\3LCN
M
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M4GJV]M7$/XHY :_[Z_;6G_:[WBVT'7?>_P!8MA?<6J>RY%9X8.0W@
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M1.,3''$CPOS7X87AX]1'KZMS!T9=.^UY7)=OKW:*'&6N:ON]QV]G^MO>H6>
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MK\\L:M'?]\R>U/P'F_8JG+D_;=OT<>*V!T R\@
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M8X8F."8='BX)?F?;\
M                                                        :'WH
M>7Q'^ISY5=?X(N-D3?? /G)T7X#C\:S"Y-&^P5^C\:%N=H8K
M     "E-Z9;_ &:]!/MYZ@/Q!Q2D9[WK^6-J/<V1^KS*AZWYFWX,^,H9I/EO
M@                )RO1M?KINC'^\3_ (4.=6M// _AUVB_L'Z3R3OZ9[>H
M\/ZF6JV@^7:     SXO%^^L@ZH_;5JGP:Z4V]W=_J7D/M=?LE;U-<PW^$C8O
MW%F?TAFT;"]&W8    "V9Z-1_4GJV]M7$/XHY :_[Z_;6G_:[WBVT'7?>_UB
MV%]Q:I[+D5GA@Y#>
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M<]PX5YB]7=F,>A3RZIBBGI4TQ%,1$1$1$/JBW;M1R;=,4QU(P=S+>?8
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MJ(Y-=,Q/!Q<'4XNM@F8:\NZ
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M;2[.[39;MS9S/Y+/Y28\WEK]N_1Z:W55'T71KMUVYPKIFF>K&#JU6WP
M
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M]6WMJXA_%'(#7_?7[:T_[7>\6V@Z[[W^L6PON+5/9<BL\,'(;P
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MT5U3%,353$S,88S$8XS"VFP*A6
M
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M0C&G7MKB2G6HU(0C]R:6$7?M7;=ZW%VS537:JC&)IF)B8ZDQP2_.+C?D<C\
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M7_?7[:T_[7>\6V@Z[[W^L6PON+5/9<BL\,'(;P
M
M
M
M                         &1CXX?UM'7;^W/+?B;"IY^;9\Q.S'P93]76
ML_/^W+GHD5#.#I@                -#[T/+XC_ %.?*KK_  1<;(F^^ ?.
M3HOP''XUF%R:-]@K]'XT+<[0Q6
M         &?%XOWUD'5'[:M4^#72FWN[O]2\A]KK]DK>IKF&_P )&Q?N+,_I
M#-HV%Z-NP    %LST:C^I/5M[:N(?Q1R U_WU^VM/^UWO%MH.N^]_K%L+[BU
M3V7(K/#!R&\
M
M
M                                                          !D
M8^.'];1UV_MSRWXFPJ>?FV?,3LQ\&4_5UK/S_MRYZ)%0S@Z8
M    #0^]#R^(_P!3GRJZ_P $7&R)OO@'SDZ+\!Q^-9A<FC?8*_1^-"W.T,5@
M                                          !GQ>+]]9!U1^VK5/@U
MTIM[N[_4O(?:Z_9*WJ:YAO\ "1L7[BS/Z0S:-A>C;L    !;,]&H_J3U;>VK
MB'\4<@-?]]?MK3_M=[Q;:#KOO?ZQ;"^XM4]ER*SPP<AO
M
M
M
M                                8_'C 9C\.>*3U^WOX0_"?D.JSF7#
M^N?+>7\G_1[<LE@/P?W^V/=_!/X,]:]S_P#Q^1[GJ=U/SN"R_:VY/9:WR.1C
MH>4KPPP^R6J:^5_I<KE8]'''HK-SDXYNYZ.?%1PLO.J
MT6?0^<--0\/SJ'V&-Q+-)E.L;9\-+:PIQA-1FP/"G"-]/<1J]^,)Y;F&QRRP
ME[L.[Y*,>V/>]2)+G^YB*MZNDY3#AHV?MUX]/EYS.1AAU.Q_1ZBY=&C_ )>J
M?Z_C0MF-%57                                           9\7B_?
M60=4?MJU3X-=*;>[N_U+R'VNOV2MZFN8;_"1L7[BS/Z0S:-A>C;L    !;,]
M&H_J3U;>VKB'\4<@-?\ ?7[:T_[7>\6V@Z[[W^L6PON+5/9<BL\,'(;P
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M0
M
M                #%]ZX=QEY$ZU.K_D"2K-6EWGJBZ@-QEK3R6U*:M+LW+&
MVYJ%6:G9U*UG3FJ0O>V,M*>:E",>R6,9>R+T0[M=/G2=W6@:5,83EM$R-K#A
MG#L>5M48<.$]#HQ$]/A63?JY5^NKIUS/T7EQ>SA                 :2GH
MC&%_!?AB\D7WKGR_]).LCE+->2\CY+UEY#BC@C7?6W?\K4]<=[\ ^6[_ &4^
MSRO<[OWO>FA_Y^>8[/OGR=K##L.SV6HQQQQQS.=N8\7!YO##AXL<>'"+FT>,
M,K/5KGQ(6D6E"K                                           ,^+
MQ?OK(.J/VU:I\&NE-O=W?ZEY#[77[)6]37,-_A(V+]Q9G](9M&PO1MV
MMF>C4?U)ZMO;5Q#^*.0&O^^OVUI_VN]XMM!UWWO]8MA?<6J>RY%9X8.0W@
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MFJM MX_\_D\,YDN3&'EJ[MCE3EXF9PB,U18JF8X*9C"9]TK5:U@
M
M
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M]2>K;VU<0_BCD!K_ +Z_;6G_ &N]XMM!UWWO]8MA?<6J>RY%9X8.0W@
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M^J11FKU-7!PV+,T4Y;+83CR*[5F+\4SR:KU?#,QF+V;A
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MI%CAH/,33/)JX)A_T?@
M
M                           "'+Q^.=;?@/PENL#-0N_(9?D?0[;@K VT
MM2%*MD[CFG-8_0,_:49H^I-ZWTC,Y6[J2_\ :H6T\(>K&#8+FM;,U[4[]M R
MW)QR^3S4YVN>.*8RE%5^B9\&]1:ICI550Z6H7.QY.N>C,8=?@\1DSIU5H
M               -:SP$]%CQWX0G0W@(T9J'X0XOS6]=R;RW;-#E#D;=N2X5
MH>7KW$_=N8;;Y2'9-"3LF^\EDE[))8(^=#J?=;?YM+FL<>1G:+/0_P#QLO9R
M^'!$<78L.GP<,S/#-X:?3R<G;CJ8]>9E+RP([@
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M.#9?<U^K%_W?7[%8>A7O37\.FM?MKG/T9HZ 5EI*      L1^C?_ !IN<_V
M5OA%TEAW?/\ D+*^Z_\ AUHI>^V?,MLW^U$?B&<7(6N" 0
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MW+U,<I(0M!JP
M
M                    H\^F&=6%K+C^EWHDP&2FGO:MYE>I/DNQHUX2RVUK
M;T,OQWQ/0N):?>FJS7M6ZVFO4I5(R0IPH6]3NS]^2:22?F ;"US=UO>1FJ,+
M<4TZ?EZICCF9HOYJ8Z6$1EHB8QQY5<8QA,30M9O>8L1Z*?$CQU&!)@H
M             #:/Z+^-YN'.CWI3XDJ4?6];C'IPX1T&YI1A2[\+O4>--9P-
MY-5C1J5J4]>I=6$\U2>$\_?GC&;O3=O;'SL[Q-8C:#;_ %S7HG&G.ZOG+\3P
M\5W,7*XPQPG#"J,(PC".#"%[V*>19HHZ5,1]!Z66<Y0
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MTW.?[ *WPBZ2P[OG_(65]U_\.M%+WVSYEMF_VHC\0SBY"UP0"
M    /A;/M&MZ5KV9VW<,]A]7U?7L?<97/;%L&1M,1A</C+2G&K<W^2R5]5H6
MEE:4*<.V:>I/++#_ /+EL6+V:O4Y?+457+]<Q%--,3-4S/%$1'#,JEHVC:OM
M%JN7T/0<KF,[K6;NTVK-BQ;JNW;MRJ<*:+=NB)JKJF>**8F54WQ"_'GS.Q39
MWB/H@N;O7\!'R^,S74#?V-2UV/,4IH1I7%/C'"Y*A)7UJRJ4XQEER]]2ADH]
MZ,UM0LYY*=Q/GS8_=1;L\C4=J(BN]QTY>)QICI=EJCS4_P!2F>3YZ:HF:8FU
MYJW>R]/TJ,MMUSC:*,UJGE;EG1**XJL6ICAIG4+UNJ:<Q7$\,Y6S5.7C#"]<
MOTU5VJ:S>7S&6V#*9#.9[*9'-YK+WEQD<KF,O>W.2RF3R%W4FK75]D,A>5:U
MW>WES6GC/4JU)YIYYHQC&,8Q9MMV[=FW%JU333:IC"(B(B(B.*(B."(CI0F#
MR&0R.EY*UINF6;66TZQ;IHMVK5%-NW;HIC"FBBBB(IHHIB(BFFF(B(X(C!\Y
M]NV                       ^EALSF-=RV-SVOY;)8+.X:]MLEB,UAKZZQ
M>6Q61LZLM>SR&-R-E5H7EC>VM>26>G5I3RU))X0C+&$8/BY:MWK=5J]337:J
MB8FF8B8F)XXF)X)B>C$NGJ&GY#5LC>TS5;%G,Z;F+=5N[:NT4W+5RW7')JHN
M6ZXFBNBJ)F*J:HFF8G"8F%F3P]O'IS.OU,)Q+UP7-SL&!C&CCL-U 8^PFN-A
MPU.'93MZ?)F"Q=O-5V.PIR=DL<M848Y&7NPFN*%Y//4N),);8;J+5Z*M0V7B
M*+O'5EYGRL_:JI\S/]2J>3YV:8B(F'SG4=[*T_5*,SMSS<:*,KJ?#<NZ)77%
M-B[/'5.GWKE6%BN9X8RUZOL$XS%JY8IIIM56L-7VK6=WUW#[=INP8;:M6V&P
MH93!;'KV2L\QA,QCKF7O4+W&Y.PK5[.\MJL/N3TYYI>V'9]V# =_+W\K>JR^
M9HJMWZ)PJIJB8JB8Z$Q/#$H3-:T76-G-5S&A;097,9+6LK=FW>L7[=5J]:N4
M\=%RW7%-5%4=&*HB7WG$I@
M
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M<Q<F;E^[PQ$X57:JN1%7#3;Y%'%3"S,S>G,7JKL]&>#J1T/H/%S(K@
M           >B^D#B*?G_JOZ:.#I;?UU)RYSSQ+QU=THTX5:<N.V_>\%@\I7
MN))I9I/6EICKVK5K1FA&66E)-&/J0BM';[7HV6V&UG:69Y,Y#2\UF(GB\M:L
MUUTQ'5FJ(B.K,.6S1V2]3;\]5$=>6TT\ZR]P
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M&*,Q.
M
M        _E7KT+6A6NKJM2MK:VI5*]Q<5ZDE&A0H49(U*U:M6J1EITJ5*G+&
M::::,(2PAVQ]1]4TU5U111$S7,X1$<,S,\41'1F1GB>DA^-GB>J?-9#H1Z5-
MJI97IYTC8J%SS9R;@,A"OA^;]YUZ[M[K%ZIK=S;PEI9'C+0<W;1KSW<)ZMMG
M<S1HW%O#UK8VMS>2Q<T+FXW]B,O1O.VXL31M9F;,QD\O73A7D[-R)BJ[<B>&
MG,7Z)Y,4X159LS517Y>[71;MS4\]%V>U[,_6XGAGISY$?1E4:;YJ,
M           GR]&AX.FYG\6_@S*7%E+?8/@W5N2^<<_2F[>RE+K^JW.GZK>P
MFA_JS6'(F]86M#_\QD[/]+5SGC;2QL[N'U.Q15R<SJ=_+Y.B>GR[L7;L?Z5B
MS>CPU1TNWR\Y3/0IB9\;Q9AJ9H2UU@
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M.6:6>66:6:$TLT(32S2QA&6:6,.V$TL8=L(PC"/J18 0?S$TSR:N"8?]'X
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M:V*W?92+.6C"K,9BO"K,YR_$83?S-W")KKGAY-,13:M4SR+5%%$12\S*VS"
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MEFJW=K]R+6:W@
M
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M<<,38IKB*KMVF>&+]RFF:9B)MV[=4<J;=SFIW,Q$V[6--GZ,^#Y"M W'4L
M                !>D]#CZ>)Z6(ZQNK#)V';3OLCH_3QI64[D(=V?%VT>2>
M3[#RD>V:/?ES&H5.R'9"'=[8]O;#NQG=\%VLBJ_L_L+9KX::+V?O4^BGM?+5
M?ZF:C_QPU_1;?!7>GJ1'BSXR\"C95T
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M73+5,1&;B(FJ[G<I1'!&:B,:\Q8IC#-1C=MQVSRJ<S;<:^(+P
M%+7TC3X[G%OR5](^%OG!LON:_5B_[OK]BL/0KWIK^'36OVUSGZ,T= *RTE
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M9'):;E:,CIUFUE\E:C"BW;HIHHHCI4T4Q%-,=2(B'0F9JG&J<9? =I^
M               -:KP(NE^KTH>%MTMZ3E<?^#]QW_4:G.N]R3RS27<=@YDN
M9MTQMID:,\E.:WR6OZ5?XG%5Z<8=LE2PC+&,8PC&,$G.<VTC;G?9K>I6*^7I
M^5S':5GI<C*1V&J:9Z--=ZF[=IGHQ7BO#3[78<I13/FIC&?#X?$2]L!NX
M                                         SXO%^^L@ZH_;5JGP:Z4
MV]W=_J7D/M=?LE;U-<PW^$C8OW%F?TAFT;"]&W8    "V9Z-1_4GJV]M7$/X
MHY :_P"^OVUI_P!KO>+;0==][_6+87W%JGLN16>&#D-X
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M4PT"[7-S6<E:IX,M<KJ\MJ-BBG_\>Y5,=MVZ8^L7)G,1]9KN]@LT,(H>0
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MP]GD9.Q'*OWZHI[/G,Q5$1<S.8JIB.5<KPB(CS-NW31:MQ3;HIB/-JM,N
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M:[F8_P /^E>Z<[^-W5J:I[=J\"/$A7];4J<
M
M                       ]T>&CTHWO6WUU]-'393LJ]Y@=^Y+P]QR#-0[\
MDUEQ9J<*NX<GWL*\)8R6]>GHV"OY+:,\999[N>E3[>]/+".,]\>W-O=ONRUG
M;":HIS65R=<6,>CF;N%K+1AT8[-71-6'%3%4\42[&5L]GS%-KH3/#X''/T&Q
MQ0H4+6A1M;6C2MK:VI4Z%O;T*<E&A0H49(4Z-&C1IPEITJ5*G+"6666$(2PA
MV0]1Y]JJJJZIKKF9KF<9F>&9F>.9GHS*]']7R
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MBS.\#4J;=[5<W3'!7>B)Y&6LU3'*[5RO*JHM8X3<KJNYB::)N]CHCH7DVP
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M:TU-=S,?X?\ 2O=.=_&[JU-4]NU>!'B0K^MJ5.
M
M                          7F?1!>BB>G1Y]Z^]NQ522%QW^G;AFM=T(2
MRU*-.?#[;RWLEE+7AWZDD:TN#Q5K=T80D[U/)6_>C&%266-'G\[QHFK2]UN0
MKC@_Y_-Q$]'R]K*VYPZG9KE5,\/#9KPXIFO:-8\UF)]#'BSXWT5XQ&LKP
M                                         #/B\7[ZR#JC]M6J?!KI
M3;W=W^I>0^UU^R5O4US#?X2-B_<69_2&;1L+T;=@    +9GHU']2>K;VU<0_
MBCD!K_OK]M:?]KO>+;0==][_ %BV%]Q:I[+D5GA@Y#>
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MCM+I=B*=7M6Z>',Y*B,*,[A3PU7LE3Y6]5,535E,*JJJ:,I$56_&NR!P
M                        !EN>D[?7$<_^T;@7X&M-37<S'^'_ $KW3G?Q
MNZM35/;M7@1XD*_K:E3@
M
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M-JGBIC__ &?#EZD62Y0
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MB:H[/DIJG'&O)7*XHIQFJJK+UY>Y75RZZHB3I8[3D
M        !EN>D[?7$<_^T;@7X&M-37<S'^'_ $KW3G?QNZM35/;M7@1XD*_K
M:E3@
M                                                  %S;T37PY:^
M\<F[CXC')F%__P"2XHJ9CC'I[M[^VDFIYODS,XOUKR!O=K"K/+/ZTT74\I#%
M6M2%.I1N+[,W,9)Y*^-FA&/+GU;W*=-T;+[H]&N?\_GHHS.>FF?,9>BK&Q9G
M#HWKM/9:HQB::+5&,33>A6](RW*KG,U>9C@CP>C/A>/U%^]%JN$
M                                    !GQ>+]]9!U1^VK5/@UTIM[N[
M_4O(?:Z_9*WJ:YAO\)&Q?N+,_I#-HV%Z-NP    %LST:C^I/5M[:N(?Q1R U
M_P!]?MK3_M=[Q;:#KOO?ZQ;"^XM4]ER*SPP<AO
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MUQ'/_M&X%^!K34UW,Q_A_P!*]TYW\;NK4U3V[5X$>)"OZVI4X
M
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M&H_J3U;>VKB'\4<@-?\ ?7[:T_[7>\6V@Z[[W^L6PON+5/9<BL\,'(;P
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M_5R8\I:U*WAVY1.'%VQRJ,W3-4XUW+F8BF.3:3H,6(V@
M          &6YZ3M]<1S_P"T;@7X&M-37<S'^'_2O=.=_&[JU-4]NU>!'B0K
M^MJ5.
M                                                  ?ZEEFGFEDD
MEFGGGFA+))+",TTTTT>R6666';&:::,>R$(?=?DS$1C/$-.+T=+PE*W0'T\5
M^>.;=9EQ_5CU&X3'7N>QN3LH4\SP]Q5/4I936N+YO+QFN,?L68JRT<MLM/NT
M)Y+V%M85:<9\9"K4AFYVV_>G>EM9&R^S=[E["Z1<JBBJF?*9O,\--S,\'!5;
MHC&UEYX8FCEW:9PO<F+ITW)]KV^R7(^O5?0CI>3_ $+(+4)4P
M                                   &?%XOWUD'5'[:M4^#72FWN[O]
M2\A]KK]DK>IKF&_PD;%^XLS^D,VC87HV[     6S/1J/ZD]6WMJXA_%'(#7_
M 'U^VM/^UWO%MH.N^]_K%L+[BU3V7(K/#!R&\
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M .E=MU>5SNHVY^P3,>:L9"K&F:<>37G(KJFF>U[%Q8A8=13
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MP-::FNYF/\/^E>Z<[^-W5J:I[=J\"/$A7];4J<
M
M                       N/>C0^"]<\N[;K/B)]3^I5:?$VBY>7*=,^AY^
MQEEH\F[WAKN:6CRQE+.ZEC-6T?0LI;QCAY8R0ER>;HPK][UM8QDO(^N>-SB*
M- R%[=+L7?B==S5ODZC>HJX<O9KCARM,QQ7K],_79Q^MV9Y.'+NXVZUI>1Y<
MQF;L>4CS,=.>GX$=#JM =%:N(
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M%%-.;JKG,VJ>#DTQ:SE.8IHMT\%%F;7!3$Q"458K3$
M       !EN>D[?7$<_\ M&X%^!K34UW,Q_A_TKW3G?QNZM35/;M7@1XD*_K:
ME3@
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MJIF9F9F9G%=$1%,81P1#[+KOT
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M975-A=K]4V*UNGDZOI.H9C)WHC'#LF6NUV:YIQ^EFJB9IGHTS$QP2YVZBV@
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MBU5-54<,Q1FZ,I%$3P4]FN3$Q-4Q5<T:V//P
M  RW/2=OKB.?_:-P+\#6FIKN9C_#_I7NG._C=U:FJ>W:O CQ(5_6U*G
M
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M>C4?U)ZMO;5Q#^*.0&O^^OVUI_VN]XMM!UWWO]8MA?<6J>RY%9X8.0W@
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M<AJEV;NU.S-<:7F9JG&NNU:HIJR5Z>&9F*\K-%J:ZIY5=ZQ>JGIS$@R"WH
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MNG._C=U:FJ>W:O CQ(5_6U*G
M
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MZZYFJJNNJJ9JJJJJF9JJF9F9G&5Q1$4QA'!$/MNL_0
M                               &?%XOWUD'5'[:M4^#72FWN[O]2\A]
MKK]DK>IKF&_PD;%^XLS^D,VC87HV[     6S/1J/ZD]6WMJXA_%'(#7_ 'U^
MVM/^UWO%MH.N^]_K%L+[BU3V7(K/#!R&\
M  !\;8]?P^VZ]G=5V*PH937]FPV4U_.XRYE[]MD</F;&OC<G87$O_:H7=E<S
MTYX?Z99HN2S>N9>]1F+,S3>HJBJF8Z$TSC$^%,*AI.JY_0]5RVMZ5=JLZID\
MQ;OV;E/!5;NVJXN6ZZ9Z=-=,51U89H74IPSE.GCG[E_A'+QJU+GC/?\ 8]6M
MKNM#NSY3#6.0JQU[-PAW*<?)9W 5+:\I]LLL?)UX=L(1]2&[6BZE;UC2,MJE
MOS-^S35,=*9CRU/^C5C'A/7_ +H=X&2WJ[K]!WBY#DQ9UC2[&9JICBMW:Z([
M/9XYX;-Z+EJKAGAHGAGC=(JFR,     L=^CA<NS8'GSG7A.ZN?)V/)'&>)WK
M'4ZU2'DY\_QGGY<;ZTM*<T8QENKW![_=UZG<A"$]*P^_C_)R089WSZ=V72<I
MJ=,>7LWYHGT-VG'&>I%5N(\&KJRB6[[5L)&I[L-FMXEBC',Z1K%W)W)B.&+&
MH6.R<JJ?.T7LE;HIQXJKWE?-5+A+71 F      I:^D:?'<XM^2OI'PM\X-E]
MS7ZL7_=]?L5AZ%>]-?PZ:U^VN<_1FCH!66DH     "Q'Z-_\:;G/]@%;X1=)
M8=WS_D+*^Z_^'6BE[[9\RVS?[41^(9Q<A:X(!      '@[Q.N7IN$.@WJ8W>
MWN(VN4N^.;[1,'6IS1EN:6:Y.N[/CO'W=GV??1N<94V:-W+'U>["WC-&'9+%
M=>P^G=U-J\CE9C&W%Z+E72Y-J)N3$]2>3AX;9GF<;!QO&YS.Q^SMVCEY*C5J
M,[>B?,S9T^FK/5TU?U;D9?L4]/EQ$<,PSK&XSU>      +N?@"].U+BGHZO.
M8<G8PH;5U%;9>;#"O4I2T[J30M)N<CJNG65:$:<M;R=3)RYC(THQFC+/0R-.
M:6$.WMCK#O;UF<_M'&G43CE\G;BGJ=DKB*ZYZW(IGJTR\Z'?0-Z]>V^_VWL%
MD[G*T39/(TV,(G&F<[FZ;>9S5<<.&,6^U;%7!$Q78JB9GH3HL6(V0
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M5MW+]=J(C@B;<TQP0D%6@U:                         9;GI.WUQ'/\
M[1N!?@:TU-=S,?X?]*]TYW\;NK4U3V[5X$>)"OZVI4X
M
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MO%^^L@ZH_;5JGP:Z4V]W=_J7D/M=?LE;U-<PW^$C8OW%F?TAFT;"]&W8
M"V9Z-1_4GJV]M7$/XHY :_[Z_;6G_:[WBVT'7?>_UBV%]Q:I[+D5GA@Y#>
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MTU_#IK7[:YS]&:.@%9:2@     +$?HW_ ,:;G/\ 8!6^$726'=\_Y"RONO\
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MNG._C=U:FJ>W:O CQ(5_6U*G
M
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MO:R]'(M1A'T9\&7KQ8+F
M             9\7B_?60=4?MJU3X-=*;>[N_P!2\A]KK]DK>IKF&_PD;%^X
MLS^D,VC87HV[     6S/1J/ZD]6WMJXA_%'(#7_?7[:T_P"UWO%MH.N^]_K%
ML+[BU3V7(K/#!R&\                              !7_P#2)N+I=IZ1
M..N3;6SA6R7%7,>-H7=WW8=ZRU7?L%EL/E.R;[L(7&S8["2QA]R/J?\ X@RY
MN<SW8-HKV1JG"C,9:<(Z=5NJ)C_5FM*)WJ/;.=%W[:ML=>N<G*:WH%R::?/Y
MG)7K5VWP?U<O<S<X^2I=ME7H1     <[XMW2YXWY-XZY$LIJDEYH6]ZCNEI/
M1EEFJR7.K;!C\Y0FI2S_ 'DU26K8PC+"/J1C]UU<_EJ<[D;V3J\S=M5T3X%5
M,T^.MK;39ZSM=L=JVRF8B)R^IZ9FLI5$\$33F;%=FK'#APPKG'!J"T:U*XI4
MJ]"K3K4*U.2M1K49Y:E*M2J2PGIU:522,TE2G4DFA&6:$8PC"/;!HS,3$X3P
M3#QHUT5VJYM78FFY3,Q,3&$Q,<$Q,3PQ,3P3$\3^C\?(    "EKZ1I\=SBWY
M*^D?"WS@V7W-?JQ?]WU^Q6'H5[TU_#IK7[:YS]&:.@%9:2@     +$?HW_QI
MN<_V 5OA%TEAW?/^0LK[K_X=:*7OMGS+;-_M1'XAG%R%K@@$      4^?21M
MZJY'J"Z>.-/*SS4-0X=S>[R4O*5)J=*XY#W2^P=>:%*,D*-.K4H\9TN]&$T9
MYI82]Z$(0EC-L7N7RL4:1G,[T;F9IH^YT15_Q93U=Z/V:HRFZW:O:_DQ%W/Z
M_9R<SA&,TY'*47HX<<9B)U"K")C")FK"9F9PK@LS):P    $FO@\\54^6/$/
MZ>K"\HQJXK2,YE^5<E/++WXVU3CG 9+9-<K=WU(=DVYVN,IQC&,.["IVP[8P
MA+&R-XV?G3]C\Y73/UR[3%J.KV2J*:O]2:FG?/WVUKV'YJFU69R]7)SVHY:U
MIMN.+E1G[]O+WX]Z59BKJ\G#@B<8T#VHKRW
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MK::>5=T_:*K+8X3,TT9W*7KE4XQ&$4S7DK=,S,QY::(C&97%VN* H
M                 !EN>D[?7$<_^T;@7X&M-37<S'^'_2O=.=_&[JU-4]NU
M>!'B0K^MJ5.
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MHBF.!6\OD<OEN&B,:^G/#/\ 1X25Y@QW
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M7NG._C=U:FJ>W:O CQ(5_6U*G
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M$XTTW+D]BHF>/L5BGDV;6/1[';IB>BJMJQ9L1A:IBGQ>OQO4RR'*
M                                                 SXO%^^L@ZH_
M;5JGP:Z4V]W=_J7D/M=?LE;U-<PW^$C8OW%F?TAFT;"]&W8    "V9Z-1_4G
MJV]M7$/XHY :_P"^OVUI_P!KO>+;0==][_6+87W%JGLN16>&#D-X
M                      #I/J6UJ&Y].//^GS4IZ\NU\)\JZU-1IVU2]J5H
M9W1,]BXTI+.E/3JW<]2%UV0I2S2S5(Q[L(PC'M5/1+_:VLY3,\78\U:JX\/,
MUTSQ]#BXV1-T&KSL_O9V7U^)BF<CM%IN8QFJ*(CL.<LW,9KF)BF(Y./*F)BG
MCF)P9D[=Y[$0     &C#X:.8GSO0'TDWM2%6$U#A'2\/"%:M&O/W-=L(:_2C
M">:$(RTHTL9"-.3[E.3LDAZDK3?;:W%K:W4*8Z.:KGTT\KQWDYYW^0ITWG/[
M=9>CDX5;1YN[P1R8QOU]GG@Z>-R>5/TTXU=%[C6LUP     4M?2-/CN<6_)7
MTCX6^<&R^YK]6+_N^OV*P]"O>FOX=-:_;7.?HS1T K+24     !8C]&_^--S
MG^P"M\(NDL.[Y_R%E?=?_#K12]]L^9;9O]J(_$,XN0M<$ @     #/5\6[-3
MY[Q&>J>^J37$TU#>,/A81N:T:U3N:WH^JZ[2EEGFC-&6WEIXN$*,GW*=*$LL
M.R$.QM_N]M1:V-R%,8<-J:N#^M775X_#U7JCYB^GTZ9S3=BLM1R8BK3;MWRL
M81CF,YF;\\'GL;D\J?IJL:NBCE7DVR     6V?1J]=IVW&_57ML).RKF]WXP
MUV>?R=6'>IZO@=NR=.3RL9XT9^Y-N$\>[++":7O=LT8PFEA#7W?7>FK.Y#+]
M"FU=J]-51'_T(,N^\ZM5>VMV)T.9\IEM.U&_$8QQYF]E;<\&&,8]JQPS.$X<
M$1,3C9K800[@                              *TOI)^L2W?$/3#N<:$
M)I\#R1O>L2W79;=ZC+MVL8G*ST(1F_\ &0A<QTF6:/D_Y+^2AY3[[R;-FY6_
MR=1SV6QX*[%%6'#])5,>!P<OP>'@Z*7WO1.LS8V\VRV?Y6%.:TC)YCD^6X>U
M<Q=MQ5P>5\KVW,</EO+>5X.6J*MA4[     "0CPI<O-A/$0Z4[V6:VEC6Y)_
M!';=QC+2C+L&NYW S2R1A5I?^)GER4848=L>VM&6'=F_U8VAM];[+L=GZ>'@
MLX\']6JFKK<'#U&K'/;R$:CS4]MLO,5S%.D=E\KQ_6+]F]P\$^5CL>-?!YCE
M<,<<:'C3UY40                        %9;Q*/1M]*\1CJXWSJNS75CM
M/%60WC":-AJNE8OB/$[99XZ72=0Q&I4KBGF[O?L#7N9LA3Q,*\TL;:3R<T\9
M81FA#O1W*W/<[_4=T>P>5V&R^A6,]:RUR]7%ZK-56IJ[-=KNS'(BQ7$<GE8>
M:G'#'@XE+S6F4YF]-Z:YC'#@PQXHPZ;P?]C2XU\_;>?F_P" _>LR?_,*UCXK
MY;W]7_=G7[B4^N3UOZ3[&EQKY^V\_-_P'[UC^85K'Q7RWOZO^['<2GUR>M_2
M?8TN-?/VWGYO^ _>L?S"M8^*^6]_5_W8[B4^N3UOZ3[&EQKY^V\_-_P'[UC^
M85K'Q7RWOZO^['<2GUR>M_2?8TN-?/VWGYO^ _>L?S"M8^*^6]_5_P!V.XE/
MKD];^D^QI<:^?MO/S?\  ?O6/YA6L?%?+>_J_P"['<2GUR>M_2X35]#$I1JU
M(T?$@GIT8SSQI4ZO2#+6JR4HS1C3DJ59.J"A+5GEE[(1FA))":/J]V'W%1I[
MX?.$<K9")JPX<-5P^AW.G#KSX+Y[B?[W_5_\S_'V,/\ ^R/_ )/?_E*_?YA_
M_P /_P"J_P#MIW$_WO\ J_\ F/L8?_V1_P#)[_\ *4_F'_\ P_\ ZK_[:=Q/
M][_J_P#F/L8?_P!D?_)[_P#*4_F'_P#P_P#ZK_[:=Q/][_J_^8^QA_\ V1_\
MGO\ \I3^8?\ _#_^J_\ MIW$_P![_J_^8^QA_P#V1_\ )[_\I3^8?_\ #_\
MJO\ [:=Q/][_ *O_ )C[&'_]D?\ R>__ "E/YA__ ,/_ .J_^VG<3_>_ZO\
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MOKSZD^R!>)7^N_H:]\KGS_IG/W^]SOYMVE][Y+_N)W&S7GK?7GU)]D"\2O\
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MI\.7:IIIIC"F(B.HY:Z#Z
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M\AR>&ULC9N<K'C[+J.HTX8=3L4SCCP\KJ<-A!B!%B
M            K]^D;V-K4Z,>)<E/2[;VTZGM5L;>MWZD/)VN0XJYAKWE+R<)
MX4I_+5<90CWII8S2]SLEC"$9NW+FYFJJ-I<Q1]+.1KGPXNV</%E*/WIC,WJ>
M<'KN4IG_ )>O8W,UU1A'#51J6E4TSCAC&$7*XPB<)QX8G",*7[95Z#@    '
MM+PY/CY](G[?^-/SEL5M;9_JGJ/N2Y]3+7KG9_PS;=_LOJ'XO6T<FF;R7@
M
M
M                                                           ,
M_#QC\=<8OQ*.I^VN8TXU*N<T#(R^2FC-+ZWR_$7'^6M(1C&66,*D+6]D[\.S
MLA/VPA&,(=L=NMV]<5[%9&JGBY-R.M>N1/T8>I'F!9JUG.:'L;>LX\B,MG:.
M'@\M:U3/6JO"Y5$X=.,)X.)&4O=N(     MF>C4?U)ZMO;5Q#^*.0&O^^OVU
MI_VN]XMM!UWWO]8MA?<6J>RY%9X8.0W@
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M-%X!][76_P#T1_G/:S\XYO[I5Y)^]GSFOCWM1_B&8]6?1Q]!GFB\ ^]KK?\
MZ(_SGM9^<<W]TJ\D_>SYS7Q[VH_Q#,>K/HX^@SS1> ?>UUO_ -$?YSVL_..;
M^Z5>2?O9\YKX][4?XAF/5O0G$_"O$G!&NWNH\,\<ZAQCJ^1S5SL=_@=*P=E@
M,5=YZ\L<;C+K+W%G84J5&ID+C'X>UHSU8P[T:=O)+V]DL%'U#4]0U6]&8U*]
M<OWZ:8IBJNJ:IBF)F8C&>AC,SATYEBS;C>'MUO+U:WKN\#5L_K.LVLO38HO9
MN]7?N4V::[ERFU377,S%%-=VY7%/%%5=4\<R[/=%9H
M            " ;TC3XD?%ORJ-(^"3G!EO<U^L]_W!7[+82@=Z:_B+UK]BLY
M^D]'4M&RST*@    /:7AR?'SZ1/V_P#&GYRV*VML_P!4]1]R7/J9:]<[/^&;
M;O\ 9?4/Q>MHY-,WDO
M
M
M                    4(/&_P 9-8>);S[=1K0J0S6+X?R<LD)(RQMY:7#&
M@8?R,TT9IO*1FFQ,:G;V0]2>$.SU.V.V.Z^OE[$Y2G#S-5Z/_6N3X[TY][DS
MD9GF@[,68IPG+WM4MS./FL=6SMW'J?9>3AP\6/1P1-,@-X@    %I;T://24
M\AUAZQ5K5XU+JSX-SUC;]^2-M3DL*_*^/RM:%.:K"I+7K39*SEC&62,L9:<.
M]-",)(38)WV6IFC3K\1&$3?IF>CP]BF/$J0N=]^TRJK*[ ZS133R:+FL6:ZL
M)Y4S7&FUVXQPPPCL=V<)F)QJX(G&J8M7,"(30
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M]YMGR67GN\K0U3CKCK7)[7^EO)6[WMK<WMK@,/&\GDM,=86=C9UKO(Y&X_\
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MGB:*S3AY00
M
M
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ME;69RF;IJGI?9;=BGACZ;@F.*;G[6IY\0
M   'B#Q*=TDT'H'ZL\_/4A1C<\);IJ5&K&,\L9+KD''QT&SFIS21EFDK0NME
MD\G-"/J3]D5T;%9:<WM9I]F.AFJ*_"MSV2?H4MC>:'L]5M1SG=AM+ICE11M'
ME,U,<'#3D:^W:\<>"8Y.7GE1T8Q9S3<EZR      &E5T5ZU'3NCSI7U>I0C;
MW.$Z=^&K*_I34Z]&>&3DX]UZ;*SST;G^7H5*V1FJSS23=D9)IHR]D.SLAI5M
M-?[9VCS]^)QIJSEZ8\#LE6'%U,'D,YPVL1K^_O;76::N7:S&U>JUT3C$QV.<
M]?['$33P3$6^3$3''$8XSCB]-*&PZ     I:^D:?'<XM^2OI'PM\X-E]S7ZL
M7_=]?L5AZ%>]-?PZ:U^VN<_1FCH!66DH     "Q'Z-_\:;G/]@%;X1=)8=WS
M_D+*^Z_^'6BE[[9\RVS?[41^(9Q<A:X(!      $ ?I%GAV<N^(-T38*PX!L
M?Z1\P<!\B2\K8+0O7OK2XY#UV?6<WKVV:O@9:]:CC:NWPH7]O?8Z6O-+&OZS
MJVM*:%6YEA-M-S2=[6@[J=X]V[M35V'0-4RG:U=_#&+%SLE%RU<KPB:HM8TU
M47.3YGETUU1R:)PIVI9:O,V/K?#73..'3_I4'>FGP:?$:ZE>;,)PSC>E/G'C
M+RN>L<9NW('+O%NZ<=Z'QOB:E_"URN>V3.[=B<)97$V,M:=:O3Q]I4K9'(>0
MFDM:-6?[DHVV/.%W1[';.7-H;VN:9G<+4U6;&5S-F_?S%7)QIHMT6JJYCE3A
M$W*HBW1C$UU4PM^UDLS=N<B**HZ<S$Q$-;'0=/L./=%TK0<57N;K%Z/J6N:?
MC;F\C)&\N;#6L/9X6SKW<:4LE*-S6M[*6:IW982]Z,>R$(((M4U"[JVIYG5+
M\13>S-^Y=JB.**KE<US$8]")G@ZB[Z:>33%,<41@Y:Z#Z4+O3)Y=WARET,3W
M7X3_ $;S:!S1+@H332QPW]-Y=BT2.V>3DDCWI<G' SX7OQJ0A"-+N>3[>RIV
M2@=[WG3>XFTT4<CNQVUE.7Y_L/8[W8O]'E]FPPZ../06_K7*Y=OSN$]?@_H4
MJTBZAK/GHEU+>)O$_P!DJ:S+=_T8I=+W*'Z1IZ<:DMG#7JFU<<PPLES&$849
MJ\VZ0QL:4L>V?LEGC+#LEGC#2_GV5:;&Y:S&<Y/;LZUENU^GV3L68Y>'1P[#
MV3'H<6/'"JZ1RNVIPXN1./T/':5*'A<X
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M3Y[#C7]&I3R_
M
M
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M9HY>;R61MZA1.$S-$:??M9N]5&'_ /S6K],S/!%-4SP<<:#[4)Y9
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MIJJI\I-%44S%-<S$Q''E<]8S<S3;QBN.A/\ XE+JP*[@
M             "BEX\?)DN_^(1M^ HUZ=>UXBX\X[XVH3T9H34_*U<7<<BY&
MGWI8QEFKVV3Y K4*G^F6>E&2/JRMJ=U.1[4V0MWIC"K,7KESZ/8XZ\6XF/!>
ME3O9VQ\[+\UC(:I<IFF_KNJY[/S$\>$7*<C1/@56\C173TXJBJ."4-#)"0$
M   !/1Z/!ID^?ZV]QVFI3CZTT/@7;[^G7[)XRRY;/;5I&O6=O'N5Z4(1KXR^
MOIX1FEJR_P E&'=A-&6>7%&^',]BV8MV(\U=S=$>%3175/T8IZ7&C*[ZQM!3
MIG-UT_1:)^OZGM/E:)C@^Q6<MG+]=7#$\5RBS'!-,^6X\(FF;KC65YWP
M
M
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M5=)U',Y.]&&'UW+7J[-S@X>#E43APSP=&7-W56X
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M%<VW;7:#E]CNT[/9NQ;JX,:;V<MSD[$QCP8Q>S%$QCCP]">*='5IF\EH
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M)M6-0SUVG'C[+7E\OEZII_J]AS,1/#CRIB,,)QM&,%(8P
M
M
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M0B*[M41$<$1A$1$<"\<C7->4MU5<?)PZW!XR4MA-VP
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MJ?\ 0S.;OT3Q>6IGP9E]8[:'
M
M
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ME?G/T<F)FJK)UTQ;U"W&'%33;BWFZY\[E,(X^&\^U9>;0
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M1'!$1$1P1#LETEH@
M
M
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M9N-IVUUFQV/:S:ZNWG*N5&%=&0HIF-/MSTHKHKN9O@XZ<U135PT81">R:D1
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M7C<KM7+<533%RJNNBJW5RKE454Q35=-SU>9B;=W[)3&./3CR5FIIJJ@
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M3$\GM&UF:<8X.551$\$X3?I:F/,,
M
M
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M<C&BJ:Z8HJGDU2K&EY.Y8Y5Z[&%5481'1PZJW T.5@
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MM,V9R79,Q$3P=OY^*+M5-41P53:RE&6FF<9FFJ_>HPIGE<JPBQ BP
M
M
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MPQPBN_<JN333CQ44<KD41]+1333'!#L-TUJ
M
M
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M3R]>&,3V?,4U9BJF<*J>U;%7#3=X;;;7Q!B
M
M
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M(X8GCIKHJC&FY:N4S%=J[1-5NY;JIKHJFF8EV2Z2T0
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M^7L[LS<FYG9HJQHNZG<HPY$X8Q/:-FJ;7'$TW[V9MUQC;C"PPP^BL
M 4M?2-/CN<6_)7TCX6^<&R^YK]6+_N^OV*P]"O>FOX=-:_;7.?HS1T K+24
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MZ)GA['E[%%NS1,\,TT1-6-4S+O-2F-@
M
M
M                                     %?SQY.AJ?FWANRZH^/L1&ZY
M,X'Q-Q0W6TL+:2>]VKAZ:YJ7^0KU)I98UJ]SQQ?5ZV2I2]L)9<?<Y":/>GEI
M2LN;J-J8TS4IT+.589'-U>4F9X*+V&$>%<C"F?ZT4=5*-WLWG(T[NMO[FYC:
MJ_R-C]IK]-64JKJF*,MJG)BBB(QG"FG/T4T9>J<)F;]O*Q&%,URI?-E7H/
M     26^'!XDG)'01R%4E[F1W7@G;[^A/R1QA+=R2S^5[E.VEW/2IKNI)9XK
M=,=;4Y99H334[;*6U.6VN8RQEMKFULK;/8O);69/Z6UJMN/K=W#P^17APS1,
M^'3/EJ?IJ:M0.=MS1MDN<YLK$XVM.WEY"U,9#4>3.&&,U=J9ODQ-5S*5U3,Q
MA%5S+7*INV8F*KMJ]>YX,YWXKZD>--?Y:X;V[';CI6Q4(36]]95(2W>-OY*5
M&I>X'/XZ>,+S![#BXUY9;FSN)9*U*,81C",LTLTVJFJZ5G]%SM>GZE;JMYJB
M>*>*8Z%5,\55,]"8X)>:3>3NTVUW1[7YK8;;_(W=/VBRE7EJ*X\K<HF9BB]8
MN1Y6]8N83-N[1,T51$QCRHJB.WE.6(                    @A\5CQ>-;Z
M6\7G^!NGS+X[9>I*_MI\?G,];PMLI@.%;>[ISR5;K(][RUGD^1):<81L\7/+
M/2LIIH7%[",):=K<Y6V!W>7M=N4:MJ]-5&BQ.--/#%5[#H1T8M].KCJXJ>C5
M3)?S)>8CJ^^C.Y7>9O2L7<GNBM5\NS9JY5N_JU5,Q,4V^*NWD<?LN8B8JO1$
MVLO.,UWK-*W-YO,[+F<KL6Q97(YW/YW(WN7S>;R][<9'*Y?*Y&XJ7>0R62R%
MW4K75[?WMU6GJ5:M2>:>I/-&::,8QC%LQ:M6[%NFS9IIHLT4Q%-,1$1$1&$1
M$1P1$1P1$/0UIVG:?I&GV-*TJQ:RVEY:U1:LV;5%-NU:M6Z8IHMVZ*8BFBBB
MF(IIIIB(IB(B(B(?+?;N      />?AQ=&>8ZW>IK4^,9J5Y;\=8*-/<^7\];
MPK4H8S0L1>6\+W&6U[3[(6V<VVZJT\98QA&,]*I<37'<FIV]7LM3;/:6WLOH
M=S/<$YROREFGIW)B<)F.C31'EJNGAAQS#67G:<X'(<W/<[GML8JMU[69G'*:
M79JPGLF=NTU<BY51/FK.6IBK,7L<(JIHBURHKNT8Z'^%PV)US#XG7L!C;+#8
M+!8VPPV%Q&-MJ5GCL5B<7:TK''8W'V="62A:V5C9T)*5*G)+"22G+"6$(0@T
M\NW+EZY5>NU35=KJF:IF<9F9G&9F>C,SPS+RH:AJ&>U;/W]5U.]<S&I9F]7=
MO7;E4UW+EVY5-=RY75.,U5UUS-554S,S5,S/#+Z3X=,       !2U](T^.YQ
M;\E?2/A;YP;+[FOU8O\ N^OV*P]"O>FOX=-:_;7.?HS1T K+24     !8C]&
M_P#C3<Y_L K?"+I+#N^?\A97W7_PZT4O?;/F6V;_ &HC\0SBY"UP0"
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MNQ7"SDP>AS
M
M
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M4SO.T*FWE]2IX(JS%,Q,9?/TQ'!AF::*HO<G"*,S1=B**+=5GE14+];L@
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M5VK?B<9IHN1C5.5S/)B9JR]VJ9QBJ;-R];CLD^^5I-80
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M.KN4[OM*Y>5TJU/*C&S%7US.5T3AR;V<KB+DXTTU46:;%FO&JS-54DRRFHH
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MC/9W-Q$9N]=NQ3Q<NNJK#'CPQF<'Y%,1Q1$/O.J_0
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MLT5\FK,YJYA7F\Y=IC#LN9O81-4QC5R+=,46;7*JBU;HBJK'RXKK,X
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MHS,ON.)30
M
M
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M^5MY'(6K=C)6:*:+=NW3%%%%%,84T444Q%---,1$4TTQ$1$81&#\3Z=@
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MB>3.8O3]=S%<8\JN8HB>Q6K44^WUKM<@
M
M
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MW/Y^[<OYZ_<JN7+ERJJNY<N5U3577775,U5UUU3-5554S555,S,S,OVOEUP
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M9S-4<JJU3:G#8N1Q
M
M
M                             *^7C$^%%3ZAL7FNI_IXP="CSGKV)JWG
M(.CXNS[L_,F$Q-KWI<ABJ%K)VUN2\18V_DZ4G<FGS-O));PCZXI4):N7MW.W
M\Z/<IT+6*IG2JZL+=<S]AJF>*<?]G,\?G)QGBF<)3>8-SW:]U6=R^YK>KF:J
MMVV;OQ1D<Y<JX-*O7:O,7*JIX-/NUU<JJ<8C*7)JNX=BKNS13,JTJM"K5H5Z
M52C7HU)Z5:C5DFIU:56G-&2I2JTYX0GIU*<\(PFEC"$81AV1;)Q,3&,<,2]
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MS>-Q^ZJJB[L!LOH^G9VWAR<Q38INYJ,.+_F[_9<S/AW9Z?&\OJXS*
M   _[++---"66$9IIHPEEEEA&,TTT8]D(0A#U8QC$?DS%,8SP1"WGX-WA+U>
M+9,#U9=3^KPI\E5Z=EF.&.,\W;S0K\<V]22>M0WK;\;7EA"GO=W3J4Y\9959
M>]A*?\M6EAD)Y)+#7C>1O C/\O9_0[G_ "48Q>NT_P"T_J43ZW'TU4>;XH\I
MC-<$//\ N?)1MI5FMQ^YO.X[(4S7:U;4+-7!GZHF(JR>5N1QY*F8F,Q>IG#.
M3];MSVK355FK*#"J(D
M
M
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MBNBJ(JIKHJIF::J:J9B::HF8F)B8G!^1^N<
M    !(_X=WAP<K=>G($DN/I7NG\':ME;:AR9RM6MZ?D+*'DY+R?5=0HW7\GG
M=UR%I-+W9)9:EOCJ=62XNXPEGH4KBS-L=L]/V3RGE\+FJ7*9[%:Z?0Y5>'F:
M(GPZIB8IXIF-2>=;SMMB.;+LM,YJJWG]Y&=L55:?IL53C7PS3&9S4T\-G*45
M8XS,TUWZJ:K5C&:;E=J^=PCPCQET[<9:OQ#Q#J]EJ6C:E90M,;C;2'?N+JXG
M^_OLQF+Z?MN<MG<M<QFKW=W7FFK5ZTT9IH_<A#5'5-4SVLYZYJ.HW)N9JY.,
MS/0Z41'%%,1P1$<$0\R^\7>+MCO7VQSNW>W>=N9[:3/7.5<N5<%--,<%%JU1
M'E;5FU3A1:M41%-%,1$1QS/:ZGK(            4M?2-/CN<6_)7TCX6^<&
MR^YK]6+_ +OK]BL/0KWIK^'36OVUSGZ,T= *RTE      6(_1O\ XTW.?[ *
MWPBZ2P[OG_(65]U_\.M%+WVSYEMF_P!J(_$,XN0M<$ @          #(X\;[
MIISO2UXHG5SI>3L;NVP>^<I;!SKH5Y7I5)+3*:5S;D;KD*R_!5:I]]>6.NY?
M-7N#GJ]LT?76*K23333231C/)S;=L<MMMN5T'4;-5,YG*Y*C)7XB>&F]DZ8L
M3RHZ%5RBBB]$>=NTS$1$PL_/6IM9NNF>*9QCP)X?Z$4+.;I@ +,WHI_33G>7
MO$PM^<H6-2.F]*?&&Z[AELK4I5*EC#<.3]>S7$VFZ]/-+"-.3)9+%;)G,E;^
M4AW>YA:LT(PJ2R--N?#MCEM W.3LURH[H:YG;-JFG'RW8LM<HS5VYZ&FJW9M
MU8=&]3'%,JII-J:\UV3Z6B)GPYX(\?K-+]#BN@!#7XAG@4=!7B-[#7Y'Y-U+
M9.+>;KFA;6^0YHX4R.)U;;=FI6-&E;V-/>L7E\'L.H[I4MK6A3MY;R\Q\<M)
M:4J=O3O*=&G3DDV$W3\YK>ANBRD:1HU^SG=FZ9F:<IG*:KMJW-4XU=AJIKMW
M;.,S-7(HK[%-4S7-N:IF9Z69R&7S,\JJ)BYTX\?IHVN%?1%^@C0]PM-DY;Y>
MY]YTPF.NZ=S1T*\R.M<=ZSEJ<D\LT;+9K[4L3'<+RTJ2PC";\'93$U?5_P!?
ML]2.8-H^?IO1U33ZLGH.0TO3,S73A-^*;E^Y3U;=-VKL43]LMW8ZCJT:/EZ9
MQKJJJCI<7B<*S]QCQAQYPMH&J<5\3:9KO'G'.C8BA@=2TS5,9;8? 8'%6\9Y
MY;:QL;622G+-6KU9ZU:I-WJMQ7J3U:LT]2>>>.EVM:UJVT6JW]<UW,7LWJ^9
MN37=O7:IKKKJGHU53THPB(XJ:8BFF(B(A5:**:*8HHB(ICH.=J8^@  &1_XQ
M_B2<@^(]UB<A[O<[1DJW N@;)G=*Z=-%HWUQ#6,'Q_A\A5QUKN%/%2UI[*.W
M\D2V<N5RM[&%2O-Y:E:2U8VEG:TZ<\7-\W0:5NAW?Y33:+-$;49JS1>S]Z:8
M[)7?KIBJ;7*PQ[%E\9M6J."G@JN<GEW*YFS\[F:LS>FK'ZW$X4QU.GX,HFF=
M733(>"'XD'(/A[=:O&E[3V')3\ <R;=K'&W/VC5<A<2Z_>:ULF4H82QY"IXZ
M/E;27:^,[O(PR5K<2TY;BM:4[FQ\I3I7E2:&OG.1W0Z5O7W<YRW-JC_-.GY>
MYF,C>BF.R1<MTS7-CE<$]BS$4]CJIQY,531=PFJW$.[D<S5EK\3C];JG"8\?
MPFLJ@K7>ZJYV_L0YD_95R'^:.7=_2ORIEO=%OZN%Z[M?G&T#X;R/XU:9B#>)
M[(              'Z+2TNK^ZMK&QMKB]O;VXHVEG9VE&I<W5W=7-26C;VUM
M;T99ZU>XKUIX2R22PC---&$(0C&+\JJIHIFNN8BF(QF9X(B(Z,N*_?LY6S7F
M<S73;R]NF:JZZIBFFFFF,:JJJIPBFFF(F9F9B(B,96[/"7\&Z3BVKJ_4_P!6
M6!IU^2J<+?-\9\,9BRDJ6_'->$TM?&[?O5"M/4IW>]TX0EJV6,GI^3PDW=K5
MN_D(226&O.\#>1V_%S0]GZ\,EYF[>B?LG3HHZ5OH55?3\4>4QFN"7GR<_P"J
MVTHSNYO<?FIIV0GE6=0U:U7,59^.*YE<G5$1-.2GAIO9B)QSD8V[?)RO*JS5
ME!A5$2
M
M
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M:+E7#;S6J1'!CF,)QM92>&:,I$_7(F*\SC5R;5F<5BY'
M
M
M
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MFWYIHSN5G@BJJ;<3]>L<J8BC,VN5:JQBFJ;=WE6Z?$JYVQ0
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M*\WFZZ[N:NUU5UUUU357775,S5555,S-554S,U53,S,S,S.+]+Y<(
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MM?9G+W)JR>F6)FG*9:)QB*IC@G,9CDS,59F]C7.-5-N+5J8MT^Y5K-;@
M
M
M
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M+U++W**OIN3>F<O<HCJ53<HJF.#AMTSCP835-(KFG-<CH54S]#A:7:'-=
M  #JKG;^Q#F3]E7(?YHY=W]*_*F6]T6_JX7KNU^<;0/AO(_C5IF(-XGL@
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MU3/!$1Q0Y X5+
M
M
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MKJKKKKJFJNNNJ9JJKKJJF:JJJJIF:JIF9F9F9G%^M\N
M!2U](T^.YQ;\E?2/A;YP;+[FOU8O^[Z_8K#T*]Z:_ATUK]M<Y^C-'0"LM)0
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M[';IFO")KFJKA>@%(8N
M
M
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M&I7KN8S]ZN:[EV[75<N7*ZIQJKKKJF:JJJIX9JJF9F>&9?0?#J@
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MJGD6;>/%;M4T6XZ%,.U'064
M
M
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MC3X[G%OR5](^%OG!LON:_5B_[OK]BL/0KWIK^'36OVUSGZ,T= *RTE
M6(_1O_C3<Y_L K?"+I+#N^?\A97W7_PZT4O?;/F6V;_:B/Q#.+D+7! (
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MFI3&P
M
M
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MU3/17RN5VQF[][E<KS6/9+E6/*^FQX^B[!=-:P
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M35551PX\G&(F/9"VV
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
9                             '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_0.jpg
MB5!.1PT*&@H    -24A$4@  #+(   "=" (   "5""<;   '8DE$051X7NW:
M,0T , S L/(GW?YCL,@^@R&S            A,P;            ^)DM#
M        (,46!@          D&(+ P          2+&% 0          I-C"
M            4FQA            *;8P          " %%L8          !
MBBT,           @Q18&          "08@L#          !(L84!
M  "DV,(           !2;&$            IMC           ( 46Q@
M     $"*+0P          "#%%@8          )!B"P,          $BQA0$
M         *38P@           %)L80           "FV,           @!1;
M&           0(HM#           (,46!@          D&(+ P
M2+&% 0          I-C"            4FQA            *;8P
M  " %%L8          ! BBT,           @Q18&          "08@L#
M      !(L84!          "DV,(           !2;&$            IMC
M         ( 46Q@          $"*+0P          "#%%@8          )!B
M"P,          $BQA0$          *38P@           %)L80
M "FV,           @!1;&           0(HM#           (,46!@
M    D&(+ P          2+&% 0          I-C"            4FQA
M        *;8P          " %%L8          ! BBT,           @Q18&
M          "08@L#          !(L84!          "DV,(           !2
M;&$            IMC           ( 46Q@          $"*+0P
M "#%%@8          )!B"P,          $BQA0$          *38P@
M     %)L80           "FV,           @!1;&           0(HM#
M        (,46!@          D&(+ P          2+&% 0          I-C"
M            4FQA            *;8P          " %%L8          !
MBBT,           @Q18&          "08@L#          !(L84!
M  "DV,(           !2;&$            IMC           ( 46Q@
M     $"*+0P          "#%%@8          )!B"P,          $BQA0$
M         *38P@           %)L80           "FV,           @!1;
M&           0(HM#           (,46!@          D&(+ P
M2+&% 0          I-C"            4FQA            *;8P
M  " %%L8          ! BBT,           @Q18&          "08@L#
M      !(L84!          "DV,(           !2;&$            IMC
M         ( 46Q@          $"*+0P          "#%%@8          )!B
M"P,          $BQA0$          *38P@           %)L80
M "FV,           @!1;&           0(HM#           (,46!@
M    D&(+ P          2+&% 0          I-C"            4FQA
M        *;8P          " %%L8          ! BBT,           @Q18&
M          "08@L#          !(L84!          "DV,(           !2
M;&$            IMC           ( 46Q@          $"*+0P
M "#%%@8          )!B"P,          $BQA0$          *38P@
M     %)L80           "FV,           @!1;&           0(HM#
M        (,46!@          D&(+ P          2+&% 0          I-C"
M            4FQA            *;8P          " %%L8          !
MBBT,           @Q18&          "08@L#          !(.;TM?XX>UR/:
,     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139954756513664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Aug. 06, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GRI BIO, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-4369909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2223 Avenida de la Playa<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">#208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">La Jolla<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">400-1170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GRI<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,956,354<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001824293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139954752544368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 4,799<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">793<span></span>
</td>
<td class="nump">303<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">5,592<span></span>
</td>
<td class="nump">312<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">5,642<span></span>
</td>
<td class="nump">383<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">307<span></span>
</td>
<td class="nump">1,294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">1,193<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_EmployeeAdvancesCurrent', window );">Advances from employees</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="nump">63<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Bridge promissory note, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">602<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">1,604<span></span>
</td>
<td class="nump">1,994<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,604<span></span>
</td>
<td class="nump">2,008<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 11)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common stock, 0.0001 par value; 250,000,000 shares authorized as of June&#160;30, 2023 and December&#160;31, 2022; 2,956,354 and 999,748 shares issued and outstanding as of June&#160;30, 2023 and December&#160;31, 2022, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in-capital</a></td>
<td class="nump">31,430<span></span>
</td>
<td class="nump">16,871<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(27,392)<span></span>
</td>
<td class="num">(18,496)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity (deficit)</a></td>
<td class="nump">4,038<span></span>
</td>
<td class="num">(1,625)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity (deficit)</a></td>
<td class="nump">$ 5,642<span></span>
</td>
<td class="nump">$ 383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_EmployeeAdvancesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee Advances, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_EmployeeAdvancesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139954756386976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">2,956,354<span></span>
</td>
<td class="nump">999,748<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">2,956,354<span></span>
</td>
<td class="nump">999,748<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139954752324064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 880<span></span>
</td>
<td class="nump">$ 59<span></span>
</td>
<td class="nump">$ 997<span></span>
</td>
<td class="nump">$ 119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">5,054<span></span>
</td>
<td class="nump">130<span></span>
</td>
<td class="nump">5,926<span></span>
</td>
<td class="nump">268<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">5,934<span></span>
</td>
<td class="nump">189<span></span>
</td>
<td class="nump">6,923<span></span>
</td>
<td class="nump">387<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(5,934)<span></span>
</td>
<td class="num">(189)<span></span>
</td>
<td class="num">(6,923)<span></span>
</td>
<td class="num">(387)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_ChangeInFairValueOfWarrantLiability', window );">Change in fair value of warrant liability</a></td>
<td class="nump">122<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">122<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest expense, net</a></td>
<td class="num">(934)<span></span>
</td>
<td class="num">(106)<span></span>
</td>
<td class="num">(2,095)<span></span>
</td>
<td class="num">(210)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (6,746)<span></span>
</td>
<td class="num">$ (295)<span></span>
</td>
<td class="num">$ (8,896)<span></span>
</td>
<td class="num">$ (597)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share of common stock, basic (in usd per share)</a></td>
<td class="num">$ (2.79)<span></span>
</td>
<td class="num">$ (0.35)<span></span>
</td>
<td class="num">$ (5.23)<span></span>
</td>
<td class="num">$ (0.70)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share of common stock, diluted (in usd per share)</a></td>
<td class="num">$ (2.79)<span></span>
</td>
<td class="num">$ (0.35)<span></span>
</td>
<td class="num">$ (5.23)<span></span>
</td>
<td class="num">$ (0.70)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding, basic (in shares)</a></td>
<td class="nump">2,417,785<span></span>
</td>
<td class="nump">851,419<span></span>
</td>
<td class="nump">1,701,864<span></span>
</td>
<td class="nump">851,419<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">2,417,785<span></span>
</td>
<td class="nump">851,419<span></span>
</td>
<td class="nump">1,701,864<span></span>
</td>
<td class="nump">851,419<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_ChangeInFairValueOfWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Fair Value Of Warrant Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_ChangeInFairValueOfWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139954752073904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders&#8217; Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common&#160;Stock</div></th>
<th class="th"><div>Additional&#160;Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">7,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="nump">7,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">$ 124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">851,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2021</a></td>
<td class="num">(4,848)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 10,430<span></span>
</td>
<td class="num">$ (15,278)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(302)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(302)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">851,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Mar. 31, 2022</a></td>
<td class="num">$ (5,150)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">10,430<span></span>
</td>
<td class="num">(15,580)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">7,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="nump">7,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">$ 124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">851,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2021</a></td>
<td class="num">(4,848)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">10,430<span></span>
</td>
<td class="num">(15,278)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(597)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">851,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Jun. 30, 2022</a></td>
<td class="num">$ (5,445)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">10,430<span></span>
</td>
<td class="num">(15,875)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2022</a></td>
<td class="nump">7,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Mar. 31, 2022</a></td>
<td class="nump">$ 124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="nump">7,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">$ 124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">851,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Mar. 31, 2022</a></td>
<td class="num">(5,150)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">10,430<span></span>
</td>
<td class="num">(15,580)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(295)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(295)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">851,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Jun. 30, 2022</a></td>
<td class="num">$ (5,445)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">10,430<span></span>
</td>
<td class="num">(15,875)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">999,748<span></span>
</td>
<td class="nump">999,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2022</a></td>
<td class="num">$ (1,625)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">16,871<span></span>
</td>
<td class="num">(18,496)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Warrant issuance</a></td>
<td class="nump">532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(2,150)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,150)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Mar. 31, 2023</a></td>
<td class="num">$ (3,230)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">17,416<span></span>
</td>
<td class="num">(20,646)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">999,748<span></span>
</td>
<td class="nump">999,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2022</a></td>
<td class="num">$ (1,625)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">16,871<span></span>
</td>
<td class="num">(18,496)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (8,896)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2023</a></td>
<td class="nump">2,956,354<span></span>
</td>
<td class="nump">2,956,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Jun. 30, 2023</a></td>
<td class="nump">$ 4,038<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">31,430<span></span>
</td>
<td class="num">(27,392)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Mar. 31, 2023</a></td>
<td class="num">(3,230)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">17,416<span></span>
</td>
<td class="num">(20,646)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise', window );">Warrant exercise (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedDuringPeriodValueWarrantExercises', window );">Warrant exercise</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing', window );">Issuance of common stock in pre-closing financing (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,214,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing', window );">Issuance of common stock in pre-closing financing</a></td>
<td class="nump">11,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt', window );">Issuance of common stock for settlement of bridge note (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt', window );">Issuance of common stock for settlement of bridge note</a></td>
<td class="nump">3,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses', window );">Issuance of common stock for reverse recapitalization expenses (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses', window );">Issuance of common stock for reverse recapitalization expenses</a></td>
<td class="nump">1,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization', window );">Issuance of common stock to Vallon stockholders in reverse recapitalization (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">448,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization', window );">Issuance of common stock to Vallon stockholders in reverse recapitalization</a></td>
<td class="num">(2,940)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,940)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (6,746)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,746)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2023</a></td>
<td class="nump">2,956,354<span></span>
</td>
<td class="nump">2,956,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Jun. 30, 2023</a></td>
<td class="nump">$ 4,038<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 31,430<span></span>
</td>
<td class="num">$ (27,392)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Pre-closing Financing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Reverse Recapitalization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Reverse Recapitalization Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Settlement Of Debt</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Warrant Exercise</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Pre-closing Financing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Reverse Recapitalization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Reverse Recapitalization Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Settlement Of Debt</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuedDuringPeriodValueWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Warrant Exercises</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuedDuringPeriodValueWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139954755464144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (8,896)<span></span>
</td>
<td class="num">$ (597)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discounts and issuance costs</a></td>
<td class="nump">2,104<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="nump">63<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Reduction in operating right of use assets</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(750)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">4,179<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">1,157<span></span>
</td>
<td class="nump">409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(30)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash used in operating activities</a></td>
<td class="num">(2,119)<span></span>
</td>
<td class="num">(116)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(8)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Cash used in investing activities</a></td>
<td class="num">(8)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_ProceedsFromAdvancesFromEmployees', window );">Advances from employees</a></td>
<td class="nump">190<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_RepaymentOfAdvancesFromEmployees', window );">Repayment of advances from employees</a></td>
<td class="num">(195)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock in pre-closing financing</a></td>
<td class="nump">12,250<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from issuance of bridge promissory note</a></td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrant exercise</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization', window );">Net liabilities assumed in connection with reverse recapitalization</a></td>
<td class="num">(2,939)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_PaymentOfReverseRecapitalizationCosts', window );">Payment of reverse recapitalization costs</a></td>
<td class="num">(2,984)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of deferred stock issuance costs</a></td>
<td class="num">(517)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment of debt issuance costs</a></td>
<td class="num">(150)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Cash provided by financing activities</a></td>
<td class="nump">6,917<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">4,790<span></span>
</td>
<td class="num">(81)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">4,799<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of non-cash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedForRepaymentOfNotesPayable', window );">Issuance of stock for repayment of bridge promissory note</a></td>
<td class="nump">3,333<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants', window );">Recognition of debt discount and additional paid-in-capital for issuance of warrants in connection with the issuance of promissory notes</a></td>
<td class="nump">532<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts', window );">Issuance of stock for payment of reverse recapitalization costs</a></td>
<td class="nump">1,875<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_WarrantsIssued', window );">Issuance of warrants for payment of stock issuance costs</a></td>
<td class="nump">18<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_NoncashMergerRelatedCostsFinancingActivities', window );">Merger costs included in accounts payable</a></td>
<td class="nump">$ 72<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Discount And Additional Paid-In-Capital Recognized From Issuance Of Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Liabilities Assumed In Connection With Reverse Recapitalization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_NoncashMergerRelatedCostsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash Merger Related Costs, Financing Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_NoncashMergerRelatedCostsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_PaymentOfReverseRecapitalizationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment Of Reverse Recapitalization Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_PaymentOfReverseRecapitalizationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_ProceedsFromAdvancesFromEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Advances From Employees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_ProceedsFromAdvancesFromEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_RepaymentOfAdvancesFromEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayment Of Advances From Employees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_RepaymentOfAdvancesFromEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued For Payment Of Reverse Recapitalization Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuedForRepaymentOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued For Repayment Of Notes Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuedForRepaymentOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_WarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_WarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139954758253536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND DESCRIPTION OF BUSINESS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">ORGANIZATION AND DESCRIPTION OF BUSINESS</a></td>
<td class="text">ORGANIZATION AND DESCRIPTION OF BUSINESS<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GRI Bio, Inc. (GRI or the Company), based in La Jolla, CA, was incorporated in Delaware in May 2009, which is the date of inception.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GRI is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies that target serious diseases associated with dysregulated immune responses leading to inflammatory, fibrotic, and autoimmune disorders. The Company&#8217;s goal is to be an industry leader in developing therapies to treat these diseases and to improve the lives of patients suffering from such diseases. The Company&#8217;s lead product candidate, GRI-0621, is an oral inhibitor of type 1 Natural Killer T (iNKT I) cells and is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis (IPF). The Company&#8217;s product candidate portfolio also includes GRI-0803 and a proprietary library of 500+ compounds. GRI-0803, the lead molecule selected from the library, is a novel oral agonist of type 2 Natural Killer T (NKT II) cells and is being developed for the treatment of autoimmune disorders, with much of its preclinical work in Systemic Lupus Erythematosus Disease (SLE) or lupus and multiple sclerosis (MS).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reverse Merger with Vallon Pharmaceuticals, Inc.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 21, 2023, the Company (formerly Vallon Pharmaceuticals, Inc.(Vallon)) consummated a merger with GRI Bio Operations, Inc. (formerly GRI Bio, Inc.) (Private GRI) pursuant to an Agreement and Plan of Merger, as amended (the Merger Agreement), by and among the Company, Private GRI and Vallon Merger Sub, Inc. (Merger Sub), a Delaware corporation and wholly-owned subsidiary of the Company (Note 4). The Merger Agreement provided for the merger of Merger Sub with and into Private GRI, with Private GRI surviving the merger as a wholly-owned subsidiary of the Company (the Merger). In connection with the closing of the Merger (the Closing), the Company amended its certificate of incorporation and bylaws to change its name from &#8220;Vallon Pharmaceuticals, Inc.&#8221; to &#8220;GRI Bio, Inc.&#8221; In addition, prior to the effective time of the Merger (the Effective Time), the Company effected a reverse stock split of the Company&#8217;s common stock at a ratio of 1 for 30 (the Reverse Stock Split). At the Effective Time, each share of Private GRI&#8217;s common stock outstanding immediately prior to the Effective Time automatically converted solely into the right to receive a number of shares of the Company's common stock equal to 0.0374 (the Exchange Ratio).</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as otherwise indicated or as the context requires, references herein to &#8220;GRI Bio,&#8221; the &#8220;Company,&#8221; or the &#8220;Combined Company,&#8221; refer to GRI Bio, Inc. on a post-Merger basis, and references to &#8220;Private GRI&#8221; refer to the business of  GRI Bio, Inc. prior to the completion of the Merger. References to &#8220;Vallon&#8221; refer to Vallon Pharmaceuticals, Inc. prior to the completion of the Merger.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 4, the Merger was accounted for as reverse recapitalization under which the historical financial statements of the Company prior to the Merger are the historical financial statements of the accounting acquirer, Private GRI. All common stock, per share and related information presented in the consolidated financial statements and notes prior to the Merger has been retroactively adjusted to reflect the Exchange Ratio and Reverse Stock Split for all periods presented, to the extent applicable.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139954758187712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIQUIDITY<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">LIQUIDITY</a></td>
<td class="text">LIQUIDITYThese financial statements have been prepared on the basis that the Company is a going concern, which contemplates, among other things, the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has not generated any significant revenues from operations since inception and does not expect to do so in the foreseeable future. The Company has incurred operating losses since its inception in 2009 and as a result has incurred $27,392 in accumulated deficit through June&#160;30, 2023. The Company has financed its working capital requirements to date through the issuance of equity and debt securities. As of June&#160;30, 2023, the Company had cash of approximately $4,799. <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with signing the Merger Agreement, Vallon, Private GRI and the Investor entered the Equity SPA pursuant to which the Investor agreed to invest $12,250 in cash and cancel any outstanding principal and accrued interest on the Bridge Notes in return for the issuance of shares of Private GRI common stock immediately prior to the consummation of the Merger. Pursuant to the Equity SPA, immediately prior to the Closing, Private GRI issued 6,787,219 shares of Private GRI common stock (the Initial Shares) to the Investor and 27,148,877 shares of Private GRI common stock (the Additional Shares) into escrow with an escrow agent for net proceeds of $11,704, after deducting offering expenses of $546.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the closing, pursuant to the Merger, the Initial Shares converted into an aggregate of 253,842 shares of the Company&#8217;s common stock and the Additional Shares converted into an aggregate of 1,015,368 shares of the Company&#8217;s common stock. On May 8, 2023, in accordance with the terms of the Equity SPA, the Company and the Investor authorized the escrow agent to, subject to beneficial ownership limitations, disburse to the Investor all of the shares of the Company&#8217;s common stock issued in exchange for the Additional Shares. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the Company&#8217;s current operating plan, the Company believes that its existing cash and cash equivalents, which include the proceeds from the Equity SPA, will be sufficient to fund its operating expenses and capital expenditure requirements for twelve months from the date of the Merger (Note 4), not including the exercise of the Series T Warrants (the Series T Warrant Exercises). </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to continue as a going concern is dependent on its ability to raise additional capital to fund its business activities, including its research and development program. The Company intends to raise capital through additional issuances of common stock and/or short-term or long-term notes, but there can be no assurances any such financing will be available when needed or that the Company&#8217;s research and development efforts will be successful. If the Company is not able to obtain additional financing on acceptable terms and in the amounts necessary to fully fund its future operating requirements, it may be forced to reduce or discontinue its operations entirely. Therefore, there is substantial doubt about the Company&#8217;s ability to continue as a going concern. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from this uncertainty.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205-40/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139954758180752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial periods and pursuant to the rules of the Securities and Exchange Commission (the SEC). Any reference in the accompanying unaudited interim financial statements to &#8220;authoritative guidance&#8221; is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB). The December&#160;31, 2022 balance sheet was derived from the Company&#8217;s audited financial statements.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the unaudited interim financial statements furnished herein include all normal and recurring adjustments considered necessary to present fairly the Company&#8217;s financial position as of June&#160;30, 2023, and the results of operations and stockholders&#8217; deficit for the three and six months ended June&#160;30, 2023 and 2022 and cash flows for the three and six months ended June&#160;30, 2023 and 2022. Results of operations for the three and six months ended June&#160;30, 2023, are not necessarily indicative of the operating results that may be expected for the year ending December 31, 2023. The unaudited interim financial statements, presented herein, do not contain the required disclosures under GAAP for annual financial statements. The accompanying unaudited interim financial statements should be read in conjunction with the annual audited financial statements and related notes as of and for the year ended December&#160;31, 2022, which are included as Exhibit 99.2 of Amendment No. 2 to the Current Report on Form 8-K filed with the SEC on July 6, 2023. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates and assumptions are primarily made in relation to the valuation of share options, the embedded derivative of convertible notes, warrant issuance and subsequent revaluations, valuation allowances relating to deferred tax assets, revenue recognition, accrued expenses and estimation of the incremental borrowing rate for the finance lease. If actual results differ from the Company&#8217;s estimates, or to the extent these estimates are adjusted </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in future periods, the Company&#8217;s results of operations could either benefit from, or be adversely affected by, any such change in estimate.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents are highly-liquid investments that are readily convertible into cash with original maturities of three months or less when purchased and as of June&#160;30, 2023 and  December&#160;31, 2022 included investments in money market funds. The Company maintains its cash and cash equivalent balances at domestic financial institutions. Bank deposits with US banks are insured up to $250 by the Federal Deposits Insurance Corporation. The Company had an uninsured cash balances of $4,302 at June&#160;30, 2023. The Company&#8217;s cash balance as of December&#160;31, 2022 was fully insured.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (ASC 820) establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The three levels of fair value hierarchy defined by ASC 820 are described below:</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:67.5pt;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liabilities.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2023, the Company&#8217;s financial instruments included cash, cash equivalents, prepaid expenses and other current assets, accounts payable, accrued expenses and certain liability classified warrants. The carrying amounts reported in the balance sheets for cash, cash equivalents, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair value based on the short-term maturity of these instruments. The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. At June&#160;30, 2023, there were no financial assets or liabilities measured at fair value on a recurring basis other than the liability classified warrants.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, Vallon issued warrants in connection with a securities purchase agreement. Vallon evaluated the warrants in accordance with ASC 815-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 815-40), and concluded that a provision in the warrants related to the reduction of the exercise price in certain circumstances precludes the warrants from being accounted for as components of equity. As a result, the warrants are recorded as a liability on the balance sheet. Vallon recorded the fair value of the warrants upon issuance using a Black-Scholes valuation model. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to revalue the warrants at each reporting date with any changes in fair value recorded in its statement of operations. The valuation of the warrants is considered under Level 3 of the fair value hierarchy due to the need to use assumptions in the valuation that are both significant to the fair value measurement and unobservable. The change in the fair value of the Level 3 warrants liabilities is reflected in the statement of operations for the six months ended June&#160;30, 2023.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred Stock Issuance Costs</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred stock issuance costs represent incremental legal costs incurred that are directly attributable to proposed offerings of securities. The costs are charged against the gross proceeds of the respective offering upon closing.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt Discounts</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The relative fair values of warrants and common shares issued and call option rights assigned in connection with principal advances under promissory notes, the increases in fair values of embedded conversion options in connection with convertible promissory note </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">modifications, and the intrinsic values of non-contingent beneficial conversion features were recorded as debt discounts that are amortized as additional interest expense over the estimated terms of the notes using the effective interest method.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt Issuance Costs</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt issuance costs represent incremental legal costs and other costs incurred that are directly attributable to issuing debt. The costs are included as a direct reduction of the carrying amount of the respective liability and are amortized as additional interest expense over the estimated term of the debt using the effective interest method.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes expense for employee and non-employee stock-based compensation in accordance with ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 718). ASC 718 requires that such transactions be accounted for using a fair value-based method. The estimated fair value of the options is amortized over the vesting period, based on the fair value of the options on the date granted, and is calculated using the Black-Scholes option-pricing model. The Company accounts for forfeitures as incurred. In considering the fair value of the underlying stock when the Company granted options, the Company considered several factors including the fair values established by market transactions. Stock option-based compensation includes estimates and judgments of when stock options might be exercised and stock price volatility. The timing of option exercises is out of the Company's control and depends upon a number of factors including the Company's market value and the financial objectives of the option holders. These estimates can have a material impact on the stock compensation expense but will have no impact on the cash flows. The estimation of share-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from original estimates, such </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amounts are recorded as a cumulative adjustment in the period the estimates are revised. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the expected term, rather than the contractual term, for both employee and consultant options issued.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Loss Per Common Share</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per common share are calculated by dividing the net loss by the applicable weighted-average number of common shares outstanding during the period. As the Company had a net loss in each of the three and six months ended June&#160;30, 2023 and 2022, diluted net loss per common share is the same as basic net loss per common share for the period because the effects of potentially dilutive securities are antidilutive.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock equivalents excluded from the diluted net loss per common share calculations are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,459&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,472&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,688,449&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,067&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock with repurchase rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,038&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,038&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock subject to put right</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible promissory note</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,952,946&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">414,937&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considered the applicability and impact of all ASUs issued during the quarter ended June&#160;30, 2023 and each was determined to be either not applicable or expected to have minimal impact on these financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139954761079568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MERGER WITH VALLON<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">MERGER WITH VALLON</a></td>
<td class="text">MERGER WITH VALLON<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 21, 2023, pursuant to the Merger Agreement, Merger Sub was merged with and into Private GRI, with Private GRI surviving the Merger as a wholly owned subsidiary of the Company. In connection with the Closing, the Company amended its certificate of incorporation and bylaws to change its name from &#8220;Vallon Pharmaceuticals, Inc.&#8221; to &#8220;GRI Bio, Inc.&#8221;</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the Effective Time:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Each share of Private GRI&#8217;s common stock outstanding immediately prior to the Effective Time, including any shares of Private GRI&#8217;s common stock  issued pursuant to the Equity SPA automatically converted solely into the right to receive a number of shares of the Company&#8217;s common stock equal to the Exchange Ratio.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Each option to purchase shares of Private GRI&#8217;s common stock (each, a GRI Option) outstanding and unexercised immediately prior to the Effective Time under the GRI Bio, Inc. 2015 Equity Incentive Plan (the GRI Plan), whether or not vested, converted into and became an option to purchase shares of the Company&#8217;s common stock, and the Company assumed the GRI Plan and each such GRI Option in accordance with the terms of the GRI Plan (the Assumed Options). The number of shares of he Company&#8217;s common stock subject to each Assumed Option was determined by multiplying (i) the number of shares of Private GRI&#8217;s common stock that were subject to such GRI Option, as in effect immediately prior to the Effective Time, by (ii) the Exchange Ratio, and rounding the resulting number down to the nearest whole number of shares of he Company&#8217;s common stock. The per share exercise price for the he Company&#8217;s common stock issuable upon exercise of each Assumed Option was determined by dividing (A) the per share exercise price of such Assumed Option, as in effect immediately prior to the Effective Time, by (B) the Exchange Ratio and rounding the resulting per share exercise price up to the nearest whole cent. Any restriction on the exercise of any Assumed Option continued in full force and effect and the term, exercisability, vesting schedule, and any other provisions of such Assumed Option otherwise remained unchanged.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Each warrant to purchase shares of Private GRI&#8217;s common stock outstanding immediately prior to the Effective Time other than the Bridge Warrants (as defined below) (the GRI Warrants), was assumed by the Company and converted into a warrant to purchase shares of the Company&#8217;s common stock (the Assumed Warrants) and thereafter (i) each Assumed Warrant became exercisable solely for shares of the Company&#8217;s common stock; (ii) the number of shares of the Company&#8217;s common stock subject to each Assumed Warrant was determined by multiplying (A) the number of shares of Private GRI&#8217;s common stock that were subject to such GRI Warrant, as in effect immediately prior to the Effective Time, by (B) the Exchange Ratio, and rounding the resulting number down to the nearest whole number of shares of the Company&#8217;s common stock; (iii) the per share exercise price for shares of the Company&#8217;s common stock issuable upon exercise of each Assumed Warrant was determined by dividing (A) the exercise price per share of Private GRI&#8217;s common stock subject to such GRI Warrant, as in effect immediately prior to the Effective Time, by (B) the Exchange Ratio, and rounding the resulting exercise price up to the nearest whole cent. </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Bridge Warrants (Note 8) were exchanged for warrants (the Exchange Warrants) to purchase an aggregate of 421,589 shares of the Company&#8217;s common stock. The Exchange Warrants contain substantively similar terms to the Bridge Warrants, and have an initial exercise price equal to $14.73 per share.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All rights with respect to Private GRI restricted stock awards were assumed by the Company and converted into Company restricted stock awards with the number of shares subject to each restricted stock award multiplied by the Exchange Ratio and rounding the resulting number down to the nearest whole number of shares of the Company&#8217;s common stock. The term, exercisability, vesting schedule and other provisions of the Private GRI restricted stock awards otherwise remained unchanged.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Merger is accounted for as a reverse recapitalization under U.S. GAAP because the primary assets of Vallon were cash and cash equivalents. For accounting purposes, GRI has been determined to be the accounting acquirer based upon the terms of the Merger and other factors including: (i)  the equity holders of Private GRI immediately prior to the Merger owned, or held rights to acquire, in the aggregate approximately 85% of the outstanding shares of the Company&#8217;s common stock and the Company&#8217;s stockholders immediately prior to the Merger owned approximately 15% of the outstanding shares of the Company&#8217;s common stock (ii) Private GRI holds the majority (4 out of 5) of board seats of the combined company, and (iii) Private GRI&#8217;s management holds the majority of </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">key positions in the management of the combined company. Immediately after the Merger, there were 2,956,354 shares of the Company&#8217;s common stock outstanding.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the net liabilities assumed in the Merger:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">April 21, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">941&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,190)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net liabilities assumed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,939)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plus: Transaction costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,984)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net liabilities assumed plus transaction costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,923)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>In addition to the transactions costs noted above, at the Effective Time, 30,542 shares of the Company&#8217;s common stock were issued to Private GRI&#8217;s financial advisor for services related to the Merger.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//805/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139954758170624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the guidance in ASC 820 to account for financial assets and liabilities measured on a recurring basis. Fair value is measured as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses a fair value hierarchy, which distinguishes between assumptions based on market data (observable inputs) and an entity's own assumptions (unobservable inputs). The guidance requires that fair value measurements be classified and disclosed in one of the following 3 categories:</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:67.5pt;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liabilities; and</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each reporting period. There were no transfers between Level 1, 2 and 3 during the six months ended June&#160;30, 2023.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents, for each of the fair value hierarchy levels required under ASC 820, the Company&#8217;s liabilities that are measured at fair value on a recurring basis at June&#160;30, 2023:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.098%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets (Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Other Observable Inputs (Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Other Unobservable Inputs (Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes is the fair value of the Level 3 liability:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.984%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Warrant Liability </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value as of December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.6pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(122)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value as of June&#160;30, 2023</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.6pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes valuation model was used to estimate the fair value of the warrants with the following weighted-average assumptions:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.288%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167.1&#160;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139.9&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.68&#160;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.32&#160;%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139954760078256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text">PROPERTY AND EQUIPMENT<div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.512%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense related to property and equipment was $2 and $1 for the six months ended June&#160;30, 2023 and 2022, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139954760322128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCRUED EXPENSES</a></td>
<td class="text">ACCRUED EXPENSES<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following:</span></div><div style="margin-bottom:8pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and related</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">862</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,193&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139954758162960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROMISSORY NOTES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">PROMISSORY NOTES</a></td>
<td class="text">PROMISSORY NOTES<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bridge Financing</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with signing the Merger Agreement, Private GRI entered into a Securities Purchase Agreement, dated as of December 13, 2022 (Bridge SPA), with Altium Growth Fund, LP (the Investor), pursuant to which Private GRI issued senior secured promissory notes (Bridge Notes) in the aggregate principal amount of $3,333, in exchange for an aggregate purchase price of $2,500. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Bridge Notes were issued in two closings: (i) the first closing for $1,667 in aggregate principal amount (in exchange for an aggregate purchase price of $1,250) closed on December 14, 2022; and (ii) the second closing for $1,667 in aggregate principal amount (in exchange for an aggregate purchase price of $1,250) closed on March 9, 2023. The Bridge Notes were secured by a lien on all of the Company&#8217;s assets. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, upon the funding of each tranche, the Investor received warrants to purchase an aggregate of 1,252,490 shares of the Company&#8217;s common stock (the Bridge Warrants). The Bridge Warrants had an exercise price of $1.33 per share, were exercisable at any time on or after the applicable issuance date and had a term of 60 months from the date all shares underlying the Bridge Warrants were freely tradable. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $1,250 of proceeds from the first closing were allocated to the Bridge Notes and Bridge Warrants based on their relative fair values as of the commitment date, resulting in an allocation of $679 and $571, respectively. The $1,250 of proceeds from the second closing were allocated to the Bridge Notes and Bridge Warrants based on their relative fair values as of the commitment date, resulting in an allocation of $718 and $532, respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the Bridge SPA, and also in connection with signing the Merger Agreement, Vallon, Private GRI and the Investor entered into the Equity SPA (Note 9) pursuant to which the Investor agreed to invest $12,250 in cash and cancel any outstanding principal and accrued interest on the Bridge Notes in return for the issuance of shares of Private GRI&#8217;s common stock immediately prior to the consummation of the Merger. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 21, 2023, the Company completed the Merger and the outstanding principal and accrued interest on the Bridge Notes was cancelled and the Bridge Warrants were exchanged for the Exchange Warrants. The Exchange Warrants contain substantively similar terms to the Bridge Warrants, and have an initial exercise price equal to $14.73 per share subject to adjustments for splits and recapitalization events.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Bridge Notes were accounted for as share-settled debt under the accounting guidance in ASC 835-30 and, as such, the initial net carrying amounts were accreted to the redemption amounts using the effective interest method. The Company incurred debt issuance costs of $205 during the year ended December&#160;31, 2022 and $90 during the six months ended June&#160;30, 2023 related to its issuance of debt under the Bridge SPA. Unamortized debt discounts and debt issuance costs totaled $1,065 as of December&#160;31, 2022. Interest expense stemming from amortization of debt discounts and issuance costs was $1,161 and $2,104 for the three and six months ended June&#160;30, 2023, respectively.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">TEP Note</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, Private GRI and TEP Biotech, LLC (TEP) entered into a convertible note and warrant purchase agreement pursuant to which TEP agreed to fund up to $5,000 to Private GRI in exchange for a convertible promissory note (the TEP Note) and a warrant to purchase up to 25,245 shares of Private GRI&#8217;s common stock at an exercise price of $0.27 per share. The TEP Note was secured by Private GRI&#8217;s assets and accrued simple interest on the outstanding principal balance at a rate of 12% per annum. The total outstanding principal and accrued interest balance was initially due on the earlier of Private GRI&#8217;s next financing, as defined, and May 2, 2020. The initial $2,500 tranche under the TEP Note was funded upon execution of the agreement in November 2018. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, Private GRI and TEP amended the TEP Note. In lieu of TEP funding the second $2,500 tranche, TEP made a first additional advance of $500 to Private GRI in exchange for a convertible promissory note, a warrant to purchase up to 17,269 shares of Private GRI&#8217;s common stock at an exercise price of $0.27 per share, and the assignment of Private GRI&#8217;s rights under a certain call option agreement. The call option agreement, which was entered into in 2015, provided Private GRI with the right to repurchase up to 39,720 shares of Private GRI&#8217;s common stock held by the counterparty for $26.74 per share at any time before April 1, 2025. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, the TEP Note maturity date was extended to August 31, 2020, and in March 2021, TEP agreed to forbear on its available right to exercise remedies on account of Private GRI&#8217;s failure to pay the past due principal and accrued interest balance until October 31, 2021.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, Private GRI and TEP amended the TEP Note, and TEP agreed to make a second additional advance of $500 to Private GRI in exchange for a convertible promissory note with separate, modified conversion options. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, Private GRI and TEP further amended the TEP Note, and TEP agreed to make a third additional advance of $125 to Private GRI in exchange for a convertible promissory note and a warrant to purchase up to 1,169 shares of Private GRI&#8217;s common stock at an exercise price of $0.27 per share.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, Private GRI and TEP entered into a conversion agreement pursuant to which, effective upon the full execution of the Merger Agreement (Note 4), $3,500 of outstanding principal under the TEP Note together with $650 of related accrued interest was to </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">automatically convert into 155,210 shares of Private GRI&#8217;s common stock at a conversion price of $26.74 per share. Further, upon the closing of the first tranche of the Bridge Notes, Private GRI was to repay, in cash, the $125 third additional advance under the TEP Note along with the $15 of related accrued interest. Upon issuance of the 155,210 conversion shares and payment of the $140 principal and accrued interest balance, Private GRI would fully satisfy all of its obligations under the TEP Note.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, upon the full execution of the Merger Agreement and the closing of the first tranche of the Bridge Notes Private GRI issued the 155,210 conversion shares and paid the $140 principal and accrued interest balance as per the terms of the conversion agreement. The share numbers and exercise or conversion prices in this section of Note 8 entitled &#8220;TEP Note&#8221; reflect the Exchange Ratio retroactively.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the conversion, the $4,150 of converted principal and accrued interest, along with $863 of related forfeited accrued interest through the conversion date, were credited to stockholders&#8217; deficit. Interest expense recognized on the TEP Note was $107 and $210 for the three and six months ended June&#160;30, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139954759932656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITY <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with signing the Merger Agreement, Vallon, Private GRI and the Investor entered the Equity SPA pursuant to which the Investor agreed to invest $12,250 in cash and cancel any outstanding principal and accrued interest on the Bridge Notes in return for the issuance of shares of Private GRI&#8217;s common stock immediately prior to the consummation of the Merger. Pursuant to the Equity SPA, immediately prior to the Closing, Private GRI issued 6,787,219 shares of Private GRI&#8217;s common stock (the Initial Shares) to the Investor and 27,148,877 shares of Private GRI&#8217;s common stock (the Additional Shares) into escrow with an escrow agent for net proceeds of $11,704, after deducting offering expenses of $546.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the closing, pursuant to the Merger, the Initial Shares converted into an aggregate of 253,842 shares of the Company&#8217;s common stock and the Additional Shares converted into an aggregate of 1,015,368 shares of the Company&#8217;s common stock. On May 8, 2023, in accordance with the terms of the Equity SPA, the Company and the Investor authorized the escrow agent to, subject to beneficial ownership limitations, disburse to the Investor all of the shares of the Company&#8217;s common stock issued in exchange for the Additional Shares. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Redeemable Common Stock</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, Private GRI entered into an agreement with a stockholder pursuant to which the stockholder had the right to require Private GRI to purchase all or a portion of 7,816 shares of Private GRI&#8217;s common stock held by the stockholder for $15.88 per share (the Put Right). The Put Right was exercisable (i) for a period commencing thirty days prior to the day Private GRI completed an equity or debt financing and ending fifteen business days thereafter, or (ii) at any time following a breach of the agreement by Private GRI.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management assessed the Put Right and determined that (i) it was not freestanding and, therefore, was not required to be classified as a liability and (ii) it could be exercised by the stockholder at any time, which was not within Private GRI&#8217;s control. Therefore, the common shares subject to the Put Right were classified in mezzanine equity. In December 2022, the stockholder exercised the Put Right and Private GRI redeemed the 7,816 shares of Private GRI&#8217;s common stock for $124 ($15.88 per share). The redeemed shares were retired by Private GRI. The share numbers and exercise or conversion prices in this section of Note 9 entitled &#8220;Redeemable Common Stock&#8221; reflect the Exchange Ratio retroactively.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Warrants</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Equity SPA, on May 8, 2023, the Company issued to the Investor (i) Series A-1 Warrants to purchase 1,269,210 shares of the Company&#8217;s common stock at an exercise price of $13.51, (ii) Series A-2 Warrants to purchase 1,142,289 shares of the Company&#8217;s common stock at an exercise price of $14.74 , and (iii) Series T Warrants to purchase (x) 814,467 shares of the Company&#8217;s common stock at an exercise price of $12.28 and (y) upon exercise of the Series T Warrants, 814,467 additional Series </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A-1 Warrants and Series A-2 Warrants, each to purchase 814,467 shares of the Company&#8217;s common stock at an exercise price of $13.51 and $14.74, respectively (collectively, the Equity Warrants). </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Series A-1 Warrants have a term of 60 months from the date all shares underlying the Series A-1 Warrants are freely tradable. The A-2 warrants have a 2-year term and expire in June 2025. Series T Warrants have a term of 24 months from the date all shares underlying Series T Warrants are freely tradable. The Company may force the exercise of the Series T Warrants subject to the satisfaction of certain equity conditions. The Equity Warrants include certain contingent cashless exercise features and contain certain other rights with regard to asset distributions and fundamental transactions. The exercise price of the Series A-1 Warrants is subject to adjustment for certain dilutive issuances, and all of the Equity Warrants are subject to standard antidilution adjustments. All of the Equity Warrants were outstanding as of June&#160;30, 2023. The Equity Warrants were classified as equity and the allocated fair value of $5,675 is included in additional paid in capital.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Bridge SPA, upon the funding of each tranche of the Bridge Note, the Investor  received the Bridge Warrants. The Bridge Warrants had an exercise price of $1.33 per share, were exercisable at any time on or after the applicable issuance date and had a term of 60 months from the date all shares underlying the Bridge Warrants are freely tradable. Upon the completion of the Merger the Bridge Warrants were exchanged for the Exchange Warrants to purchase an aggregate of 421,589 shares of the Company&#8217;s common stock. The Exchange Warrants contain substantively similar terms to the Bridge Warrants, and have an initial exercise price equal to $14.73 per share subject to adjustments for splits and recapitalization events. All of the Bridge Warrants were outstanding as of June&#160;30, 2023. The Bridge Warrants were classified as equity and the allocated fair value of $2,860 is included in additional paid in capital.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Closing, Private GRI granted its financial advisor warrants (the Advisor Warrants) to purchase shares of Private GRI&#8217;s common stock, which, at the Effective Time, became exercisable for an aggregate of 2,402 shares of the Company&#8217;s common stock at an exercise price of $61.39 per share. The Advisor Warrants have a five-year term. All of the Advisor Warrants were outstanding as of June 30, 2023. The Advisor Warrants were classified as equity and the fair value of $18 is included in additional paid in capital. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes option-pricing model was used to estimate the fair value of the Equity Warrants, the Exchange Warrants and the Advisor Warrants with the following weighted-average assumptions:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167.6&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.69</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.37&#160;%</span></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2023, the Company had the following warrants outstanding to purchase common stock. </span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercise Price per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expiration Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,629</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$34.76</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,438</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$34.76</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,142,289</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$14.74</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,758</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$300.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,667</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$28.15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2027</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,168</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0.01</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,402</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$61.39</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2028</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">421,590</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$14.73</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60 months after registration date</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,269,210</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$13.51</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60 months after registration date</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">814,467</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$12.28</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24 months after registration date</span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139954758239712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text">STOCK-BASED COMPENSATION<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2015 Equity Incentive Plan</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Private GRI adopted the GRI Bio, Inc. 2015 Equity Incentive Plan, as amended (the Private GRI Plan), that provided Private GRI with the ability to grant stock options, restricted stock awards and other equity-based awards to employees, directors, and consultants. Stock options granted under the Private GRI Plan generally had a contractual life of up to 10 years. Upon completion of the Merger, the Company assumed the Private GRI Plan and the outstanding and unexercised options issued thereunder, and ceased granting awards under the Private GRI Plan.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amended and Restated 2018 Equity Incentive Plan</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 21, 2023, the stockholders of the Company approved the Amended and Restated GRI Bio, Inc. 2018 Equity Incentive Plan, formerly the Vallon Pharmaceuticals, Inc. 2018 Equity Incentive Plan (the A&amp;R 2018 Plan). The A&amp;R 2018 Plan had previously been approved by the Company&#8217;s board of directors, subject to stockholder approval. The A&amp;R 2018 Plan became effective on April 21, 2023, with the stockholders approving the amendment to the A&amp;R 2018 Plan to, among other things, (i) to increase the aggregate number of shares by </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">168,905 shares to 216,666 shares of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company&#8217;s common stock </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for issuance as awards under the A&amp;R 2018 Plan, (ii) to extend the term of the A&amp;R 2018 Plan through January 1, 2033, (iii) to prohibit any action that would be treated as a &#8220;repricing&#8221; of an award without further approval by the stockholders of Company, and (iv) to revise the limits on awards to non-employee directors.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The A&amp;R 2018 Plan provides the Company with the ability to grant stock options, restricted stock and other equity-based awards to employees, directors and consultants. Stock options granted by Vallon generally have a contractual life of up to 10 years. As of June&#160;30, 2023, 100,459 shares of the Company's common stock were authorized to be issued under the A&amp;R 2018 Plan, and 116,207 shares were reserved for future awards under the A&amp;R 2018 Plan. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation related to stock options issued under the A&amp;R 2018 Plan in the following expense categories of its accompanying statements of operations for the three and six months ended June&#160;30, 2023 and 2022:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures equity-based awards granted to employees, and non-employees based on their fair value on the date of the grant and recognizes compensation expense for those awards over the requisite service period or performance-based period, which is generally the vesting period of the respective award. The measurement date for service-based equity awards is the date of grant, and equity-based compensation costs are recognized as expense over the requisite service period, which is the vesting period for certain </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">performance-based awards. The Company records expense for performance-based awards if it concludes that it is probable that the performance condition will be achieved.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below represents the activity of stock options granted to employees and non-employees for the six months ended June&#160;30, 2023:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted average remaining contractual term&#160;(years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,612</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.77&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.71</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/Cancelled</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,153)</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.84</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,459</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.75</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.73</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2023</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,459</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.75</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.73</span></td></tr></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes option-pricing model was used to estimate the grant date fair value of each stock option grant at the time of grant using the following weighted-average assumptions:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.98</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of option on grant date</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No options were granted during the six months ended June&#160;30, 2023. </span></div>As of June&#160;30, 2023, the unrecognized compensation cost related to unvested stock options expected to vest was $280. This unrecognized compensation is expected to be recognized over a weighted-average amortization period of 3.35 years.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139954756344336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employment Agreements</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into employment contracts with its officers that provide for severance and continuation of benefits in the event of termination of employment by the Company without cause or by the employee for good reason. In addition, in the event of termination of employment following a change in control, the vesting of certain equity awards may be accelerated.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Separation and Release Agreement</span></div>In connection with the resignation of David Baker, the Company&#8217;s Former Chief Executive Officer, pursuant to the Merger, the Company and Mr. Baker entered into a Separation and Release Agreement on April 21, 2023 (the Separation Agreement). Pursuant to the terms of the Separation Agreement and his employment agreement, Mr. Baker will receive continuation of his current salary and certain COBRA benefits for 18 months payable in accordance with the Company&#8217;s payroll practices. Mr. Baker also received a lump sum payment equal to 150% of his target bonus and agreed to reduce amounts payable with respect to certain future milestone payments.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139954752292112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Accounting</a></td>
<td class="text">The accompanying unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial periods and pursuant to the rules of the Securities and Exchange Commission (the SEC). Any reference in the accompanying unaudited interim financial statements to &#8220;authoritative guidance&#8221; is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB). The December&#160;31, 2022 balance sheet was derived from the Company&#8217;s audited financial statements.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates and assumptions are primarily made in relation to the valuation of share options, the embedded derivative of convertible notes, warrant issuance and subsequent revaluations, valuation allowances relating to deferred tax assets, revenue recognition, accrued expenses and estimation of the incremental borrowing rate for the finance lease. If actual results differ from the Company&#8217;s estimates, or to the extent these estimates are adjusted </span></div>in future periods, the Company&#8217;s results of operations could either benefit from, or be adversely affected by, any such change in estimate.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents are highly-liquid investments that are readily convertible into cash with original maturities of three months or less when purchased and as of June&#160;30, 2023 and  December&#160;31, 2022 included investments in money market funds. The Company maintains its cash and cash equivalent balances at domestic financial institutions. Bank deposits with US banks are insured up to $250 by the Federal Deposits Insurance Corporation. The Company had an uninsured cash balances of $4,302 at June&#160;30, 2023. The Company&#8217;s cash balance as of December&#160;31, 2022 was fully insured.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (ASC 820) establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The three levels of fair value hierarchy defined by ASC 820 are described below:</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:67.5pt;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liabilities.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2023, the Company&#8217;s financial instruments included cash, cash equivalents, prepaid expenses and other current assets, accounts payable, accrued expenses and certain liability classified warrants. The carrying amounts reported in the balance sheets for cash, cash equivalents, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair value based on the short-term maturity of these instruments. The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. At June&#160;30, 2023, there were no financial assets or liabilities measured at fair value on a recurring basis other than the liability classified warrants.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, Vallon issued warrants in connection with a securities purchase agreement. Vallon evaluated the warrants in accordance with ASC 815-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 815-40), and concluded that a provision in the warrants related to the reduction of the exercise price in certain circumstances precludes the warrants from being accounted for as components of equity. As a result, the warrants are recorded as a liability on the balance sheet. Vallon recorded the fair value of the warrants upon issuance using a Black-Scholes valuation model. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to revalue the warrants at each reporting date with any changes in fair value recorded in its statement of operations. The valuation of the warrants is considered under Level 3 of the fair value hierarchy due to the need to use assumptions in the valuation that are both significant to the fair value measurement and unobservable. The change in the fair value of the Level 3 warrants liabilities is reflected in the statement of operations for the six months ended June&#160;30, 2023.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Stock Issuance Costs</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred Stock Issuance Costs</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred stock issuance costs represent incremental legal costs incurred that are directly attributable to proposed offerings of securities. The costs are charged against the gross proceeds of the respective offering upon closing.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Debt Discounts and Debt Issuance Costs</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt Discounts</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The relative fair values of warrants and common shares issued and call option rights assigned in connection with principal advances under promissory notes, the increases in fair values of embedded conversion options in connection with convertible promissory note </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">modifications, and the intrinsic values of non-contingent beneficial conversion features were recorded as debt discounts that are amortized as additional interest expense over the estimated terms of the notes using the effective interest method.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt Issuance Costs</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt issuance costs represent incremental legal costs and other costs incurred that are directly attributable to issuing debt. The costs are included as a direct reduction of the carrying amount of the respective liability and are amortized as additional interest expense over the estimated term of the debt using the effective interest method.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes expense for employee and non-employee stock-based compensation in accordance with ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 718). ASC 718 requires that such transactions be accounted for using a fair value-based method. The estimated fair value of the options is amortized over the vesting period, based on the fair value of the options on the date granted, and is calculated using the Black-Scholes option-pricing model. The Company accounts for forfeitures as incurred. In considering the fair value of the underlying stock when the Company granted options, the Company considered several factors including the fair values established by market transactions. Stock option-based compensation includes estimates and judgments of when stock options might be exercised and stock price volatility. The timing of option exercises is out of the Company's control and depends upon a number of factors including the Company's market value and the financial objectives of the option holders. These estimates can have a material impact on the stock compensation expense but will have no impact on the cash flows. The estimation of share-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from original estimates, such </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amounts are recorded as a cumulative adjustment in the period the estimates are revised. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the expected term, rather than the contractual term, for both employee and consultant options issued.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Loss Per Common Share</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per common share are calculated by dividing the net loss by the applicable weighted-average number of common shares outstanding during the period. As the Company had a net loss in each of the three and six months ended June&#160;30, 2023 and 2022, diluted net loss per common share is the same as basic net loss per common share for the period because the effects of potentially dilutive securities are antidilutive.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considered the applicability and impact of all ASUs issued during the quarter ended June&#160;30, 2023 and each was determined to be either not applicable or expected to have minimal impact on these financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139954751843696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Common Stock Equivalents Excluded From Diluted Net Loss Per Share Calculation</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock equivalents excluded from the diluted net loss per common share calculations are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,459&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,472&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,688,449&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,067&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock with repurchase rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,038&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,038&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock subject to put right</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible promissory note</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,952,946&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">414,937&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139954759265504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MERGER WITH VALLON (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Schedule of the Net Liabilities Assumed in the Merger</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the net liabilities assumed in the Merger:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">April 21, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">941&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,190)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net liabilities assumed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,939)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plus: Transaction costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,984)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net liabilities assumed plus transaction costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,923)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139954755532000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents, for each of the fair value hierarchy levels required under ASC 820, the Company&#8217;s liabilities that are measured at fair value on a recurring basis at June&#160;30, 2023:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.098%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets (Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Other Observable Inputs (Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Other Unobservable Inputs (Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of the Changes is the Fair Value</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes is the fair value of the Level 3 liability:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.984%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Warrant Liability </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value as of December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.6pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(122)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value as of June&#160;30, 2023</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.6pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of the Fair Value of the Warrants</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes valuation model was used to estimate the fair value of the warrants with the following weighted-average assumptions:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.288%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167.1&#160;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139.9&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.68&#160;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.32&#160;%</span></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes option-pricing model was used to estimate the fair value of the Equity Warrants, the Exchange Warrants and the Advisor Warrants with the following weighted-average assumptions:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167.6&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.69</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.37&#160;%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139954756628048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.512%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139954759251392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following:</span></div><div style="margin-bottom:8pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and related</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">862</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,193&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139954758247952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of the Fair Value of the Warrants</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes valuation model was used to estimate the fair value of the warrants with the following weighted-average assumptions:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.288%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167.1&#160;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139.9&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.68&#160;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.32&#160;%</span></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes option-pricing model was used to estimate the fair value of the Equity Warrants, the Exchange Warrants and the Advisor Warrants with the following weighted-average assumptions:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167.6&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.69</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.37&#160;%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Warrants Outstanding to Purchase Common Stock</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2023, the Company had the following warrants outstanding to purchase common stock. </span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercise Price per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expiration Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,629</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$34.76</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,438</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$34.76</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,142,289</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$14.74</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,758</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$300.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,667</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$28.15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2027</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,168</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0.01</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,402</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$61.39</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2028</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">421,590</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$14.73</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60 months after registration date</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,269,210</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$13.51</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60 months after registration date</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">814,467</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$12.28</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24 months after registration date</span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139954756483488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-based Compensation Expense</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation related to stock options issued under the A&amp;R 2018 Plan in the following expense categories of its accompanying statements of operations for the three and six months ended June&#160;30, 2023 and 2022:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Activity of Stock Options</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below represents the activity of stock options granted to employees and non-employees for the six months ended June&#160;30, 2023:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted average remaining contractual term&#160;(years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,612</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.77&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.71</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/Cancelled</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,153)</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.84</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,459</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.75</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.73</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2023</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,459</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.75</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.73</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Valuation Assumptions</a></td>
<td class="text"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes option-pricing model was used to estimate the grant date fair value of each stock option grant at the time of grant using the following weighted-average assumptions:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.98</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of option on grant date</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139954751838960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)<br></strong></div></th>
<th class="th"><div>Apr. 21, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split</a></td>
<td class="nump">0.0333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_CommonStockExchangeRatio', window );">Common stock, exchange ratio</a></td>
<td class="nump">0.0374<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_CommonStockExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock Exchange Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_CommonStockExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139954751943808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIQUIDITY (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 21, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (27,392)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (18,496)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,956,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">999,748<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock in pre-closing financing</a></td>
<td class="nump">$ 11,704<span></span>
</td>
<td class="nump">$ 12,250<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuanceCostsOfferingExpenses', window );">Offering expenses</a></td>
<td class="nump">$ 546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common&#160;Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of stock (in shares)</a></td>
<td class="nump">253,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_ConversionOfStockAdditionalSharesConverted', window );">Additional shares converted into common stock (in shares)</a></td>
<td class="nump">1,015,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ck0001824293_GRIBioIncMember', window );">GRI Bio, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_CommonStockHeldIntoEscrowAccount', window );">Common stock placed into escrow (in shares)</a></td>
<td class="nump">27,148,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentCompanyCommittedCapital', window );">Investment in cash</a></td>
<td class="nump">$ 12,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor | Private GRI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">6,787,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_CommonStockHeldIntoEscrowAccount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock Held Into Escrow Account</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_CommonStockHeldIntoEscrowAccount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_ConversionOfStockAdditionalSharesConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of Stock, Additional Shares Converted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_ConversionOfStockAdditionalSharesConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuanceCostsOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issuance Costs, Offering Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuanceCostsOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentCompanyCommittedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of funds committed to investment company from investors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480737/946-205-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentCompanyCommittedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ck0001824293_GRIBioIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ck0001824293_GRIBioIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ck0001824293_PrivateGRIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ck0001824293_PrivateGRIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139954755512704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">FDIC insured amount</a></td>
<td class="nump">$ 250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashUninsuredAmount', window );">Uninsured cash balances</a></td>
<td class="nump">$ 4,302<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashUninsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashUninsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139954755618784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Diluted Net Loss Per Common Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in usd per share)</a></td>
<td class="nump">3,952,946<span></span>
</td>
<td class="nump">414,937<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in usd per share)</a></td>
<td class="nump">100,459<span></span>
</td>
<td class="nump">89,472<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in usd per share)</a></td>
<td class="nump">3,688,449<span></span>
</td>
<td class="nump">10,067<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted stock with repurchase rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in usd per share)</a></td>
<td class="nump">164,038<span></span>
</td>
<td class="nump">164,038<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ck0001824293_StockSubjectToPutRightMember', window );">Stock subject to put right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in usd per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,816<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ck0001824293_ConvertiblePromissoryNoteMember', window );">Convertible promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in usd per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">143,544<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ck0001824293_StockSubjectToPutRightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ck0001824293_StockSubjectToPutRightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ck0001824293_ConvertiblePromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ck0001824293_ConvertiblePromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139954752279984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>MERGER WITH VALLON - Narrative (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Apr. 21, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Apr. 20, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Nov. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_CommonStockOwnershipPercentage', window );">Ownership percentage in common stock (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,956,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">999,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses', window );">Issuance of common stock for reverse recapitalization expenses (in shares)</a></td>
<td class="nump">30,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=ck0001824293_PrivateGRIMember', window );">Private GRI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,169<span></span>
</td>
<td class="nump">17,269<span></span>
</td>
<td class="nump">25,245<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.27<span></span>
</td>
<td class="nump">$ 0.27<span></span>
</td>
<td class="nump">$ 0.27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_CommonStockOwnershipPercentage', window );">Ownership percentage in common stock (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_ExchangeWarrantsMember', window );">Exchange Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted (in shares)</a></td>
<td class="nump">421,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="nump">$ 14.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_CommonStockOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Ownership Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_CommonStockOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Reverse Recapitalization Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ck0001824293_PrivateGRIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ck0001824293_PrivateGRIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_ExchangeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_ExchangeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139954755522080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>MERGER WITH VALLON - Schedule of the Net Liabilities Assumed in the Merger (Details) - Private GRI<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Apr. 21, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 941<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid and other assets</a></td>
<td class="nump">310<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(4,190)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total net liabilities assumed</a></td>
<td class="num">(2,939)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts', window );">Plus: Transaction costs</a></td>
<td class="num">(2,984)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts', window );">Total net liabilities assumed plus transaction costs</a></td>
<td class="num">$ (5,923)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accounts Payable And Accrued Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net, Including Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ck0001824293_PrivateGRIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ck0001824293_PrivateGRIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139954755223456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Schedule of Fair Value, Liabilities Measured on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="nump">$ 63<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Other Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="nump">63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">$ 63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139954751906288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Liability Measured at Estimated Fair Value (Details) - Warrant Liability<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value as of December 31, 2022</a></td>
<td class="nump">$ 185<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in valuation</a></td>
<td class="num">(122)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value as of June&#160;30, 2023</a></td>
<td class="nump">$ 63<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=ck0001824293_WarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=ck0001824293_WarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139954755847120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Derivative Liability Measurement Inputs (Details) - Weighted Average<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">1.671<span></span>
</td>
<td class="nump">1.399<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">0.000<span></span>
</td>
<td class="nump">0.000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">0.0468<span></span>
</td>
<td class="nump">0.0432<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139954752016800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(24)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139954758157264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139954751850304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED EXPENSES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent', window );">Research and development</a></td>
<td class="nump">$ 143<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent', window );">General and administrative</a></td>
<td class="nump">188<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and related</a></td>
<td class="nump">862<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 1,193<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued General and Administrative Expenses, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Research and Development Costs, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_AccruedResearchAndDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139954750961712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROMISSORY NOTES - Bridge Financing (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 21, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 09, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 14, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 13, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 08, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from issuance of notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt discounts and debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discounts and issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,161<span></span>
</td>
<td class="nump">2,104<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_BridgeWarrantsMember', window );">Bridge Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from issuance of notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 532<span></span>
</td>
<td class="nump">$ 571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_ExchangeWarrantsMember', window );">Exchange Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted (in shares) | shares</a></td>
<td class="nump">421,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share) | $ / shares</a></td>
<td class="nump">$ 14.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ck0001824293_BridgeSecuritiesPurchaseAgreementMember', window );">Bridge SPA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,667<span></span>
</td>
<td class="nump">1,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_DebtInstrumentAggregatePurchasePrice', window );">Aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_DebtInstrumentNumberOfClosings', window );">Number of closings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from issuance of notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 718<span></span>
</td>
<td class="nump">$ 679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=ck0001824293_PrivateGRIMember', window );">Private GRI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,169<span></span>
</td>
<td class="nump">17,269<span></span>
</td>
<td class="nump">25,245<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.27<span></span>
</td>
<td class="nump">$ 0.27<span></span>
</td>
<td class="nump">$ 0.27<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentCompanyCommittedCapital', window );">Investment in cash</a></td>
<td class="nump">$ 12,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor | Bridge Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,252,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">421,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants, outstanding term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor | Exchange Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor | Private GRI | Bridge SPA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_DebtInstrumentAggregatePurchasePrice', window );">Aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_DebtInstrumentAggregatePurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Aggregate Purchase Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_DebtInstrumentAggregatePurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_DebtInstrumentNumberOfClosings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Number Of Closings</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_DebtInstrumentNumberOfClosings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentCompanyCommittedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of funds committed to investment company from investors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480737/946-205-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentCompanyCommittedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_BridgeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_BridgeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_ExchangeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_ExchangeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ck0001824293_BridgeSecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ck0001824293_BridgeSecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ck0001824293_PrivateGRIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ck0001824293_PrivateGRIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139954752377520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROMISSORY NOTES - TEP Note (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="6">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Oct. 31, 2022</div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Nov. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from issuance of bridge promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">999,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,956,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=ck0001824293_PrivateGRIMember', window );">Private GRI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,269<span></span>
</td>
<td class="nump">25,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.27<span></span>
</td>
<td class="nump">$ 0.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_DebtInstrumentConvertibleSharesIssuedUponConversion', window );">Number of shares to be issued upon conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Convertible notes, converted, shares issued (in shares)</a></td>
<td class="nump">155,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=ck0001824293_PrivateGRIMember', window );">Private GRI | Call Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,720<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_CallOptionPrice', window );">Call option price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26.74<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=ck0001824293_PrivateGRIMember', window );">Private GRI | Convertible Notes Payable | TEP Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Convertible notes interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from issuance of bridge promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_DebtConversionConvertedInstrumentPrincipalAmountOfDebt', window );">Principal amount of debt to be converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_DebtConversionConvertedInstrumentAmountOfInterest', window );">Amount of accrued interest to be converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_LongTermDebtIncludingInterest', window );">Long-term debt, including interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payment of notes payable</a></td>
<td class="nump">$ 140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of convertible notes to common stock</a></td>
<td class="nump">4,150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_AccruedInterestForfeited', window );">Accrued interest forfeited</a></td>
<td class="nump">$ 863,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseBorrowings', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 107,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_AccruedInterestForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Interest Forfeited</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_AccruedInterestForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_CallOptionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Call Option Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_CallOptionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_DebtConversionConvertedInstrumentAmountOfInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Conversion, Converted Instrument, Amount Of Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_DebtConversionConvertedInstrumentAmountOfInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_DebtConversionConvertedInstrumentPrincipalAmountOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Conversion, Converted Instrument, Principal Amount Of Debt</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_DebtConversionConvertedInstrumentPrincipalAmountOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_DebtInstrumentConvertibleSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Shares Issued Upon Conversion</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_DebtInstrumentConvertibleSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_LongTermDebtIncludingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt, Including Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_LongTermDebtIncludingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount of interest expense on all borrowings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.7,8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ck0001824293_PrivateGRIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ck0001824293_PrivateGRIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_CallOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_CallOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ck0001824293_TEPNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ck0001824293_TEPNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139954749169360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 21, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>May 08, 2023</div></th>
<th class="th"><div>Mar. 09, 2023</div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Nov. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">999,748<span></span>
</td>
<td class="nump">2,956,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 11,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,250<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuanceCostsOfferingExpenses', window );">Offering expenses</a></td>
<td class="nump">$ 546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Outsanding warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_BankerWarrantsMember', window );">Banker Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants, outstanding term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_ExchangeWarrantsMember', window );">Exchange Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted (in shares)</a></td>
<td class="nump">421,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="nump">$ 14.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common&#160;Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of stock (in shares)</a></td>
<td class="nump">253,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_ConversionOfStockAdditionalSharesConverted', window );">Additional shares converted into common stock (in shares)</a></td>
<td class="nump">1,015,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ck0001824293_GRIBioIncMember', window );">GRI Bio, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_CommonStockHeldIntoEscrowAccount', window );">Common stock placed into escrow (in shares)</a></td>
<td class="nump">27,148,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=ck0001824293_PrivateGRIMember', window );">Private GRI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Stock repurchased during period, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Stock repurchased during period, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Purchase price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,169<span></span>
</td>
<td class="nump">17,269<span></span>
</td>
<td class="nump">25,245<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.27<span></span>
</td>
<td class="nump">$ 0.27<span></span>
</td>
<td class="nump">$ 0.27<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=ck0001824293_PrivateGRIMember', window );">Private GRI | Put Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,816<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_PutOptionSharePrice', window );">Put right, share price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.88<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentCompanyCommittedCapital', window );">Investment in cash</a></td>
<td class="nump">$ 12,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor | Series A-1 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,269,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants, outstanding term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor | Series A-2 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,142,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants, outstanding term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor | Series T Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">814,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants, outstanding term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor | Bridge Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">421,589<span></span>
</td>
<td class="nump">1,252,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.33<span></span>
</td>
<td class="nump">$ 1.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants, outstanding term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 months<span></span>
</td>
<td class="text">60 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor | Exchange Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor | Common&#160;Stock | Series A-1 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">814,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor | Common&#160;Stock | Series A-2 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">814,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor | Additional&#160;Paid-in Capital | Equity Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Outsanding warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor | Additional&#160;Paid-in Capital | Bridge Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Outsanding warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor | Additional&#160;Paid-in Capital | Banker Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Outsanding warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor | Private GRI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">6,787,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_CommonStockHeldIntoEscrowAccount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock Held Into Escrow Account</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_CommonStockHeldIntoEscrowAccount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_ConversionOfStockAdditionalSharesConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of Stock, Additional Shares Converted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_ConversionOfStockAdditionalSharesConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_PutOptionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Put Option, Share Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_PutOptionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuanceCostsOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issuance Costs, Offering Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuanceCostsOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentCompanyCommittedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of funds committed to investment company from investors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480737/946-205-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentCompanyCommittedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total cost of shares repurchased divided by the total number of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockAcquiredAverageCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_BankerWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_BankerWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_ExchangeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_ExchangeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ck0001824293_GRIBioIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ck0001824293_GRIBioIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ck0001824293_PrivateGRIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ck0001824293_PrivateGRIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_PutOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_PutOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesA1WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesA1WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesA2WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesA2WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesTWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesTWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_BridgeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_BridgeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_EquityWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_EquityWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139954756355392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY - Estimate of the Fair Value of the Warrants and Assumptions (Details) - Weighted Average<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">1.671<span></span>
</td>
<td class="nump">1.399<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">0.000<span></span>
</td>
<td class="nump">0.000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">0.0468<span></span>
</td>
<td class="nump">0.0432<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_EquityWarrantsExchangeWarrantsAndBankerWarrantsMember', window );">Equity Warrants, Exchange Warrants and Banker Warrants | Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">1.676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_EquityWarrantsExchangeWarrantsAndBankerWarrantsMember', window );">Equity Warrants, Exchange Warrants and Banker Warrants | Expected term in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">1.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_EquityWarrantsExchangeWarrantsAndBankerWarrantsMember', window );">Equity Warrants, Exchange Warrants and Banker Warrants | Dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">0.000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_EquityWarrantsExchangeWarrantsAndBankerWarrantsMember', window );">Equity Warrants, Exchange Warrants and Banker Warrants | Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">0.0437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_EquityWarrantsExchangeWarrantsAndBankerWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_EquityWarrantsExchangeWarrantsAndBankerWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139954752575328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY - Schedule of Warrants Outstanding to Purchase Common Stock (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInNovember2023Member', window );">Warrants Expiring In November 2023</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares | shares</a></td>
<td class="nump">8,629<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 34.76<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInDecember2023Member', window );">Warrants Expiring In December 2023</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares | shares</a></td>
<td class="nump">1,438<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 34.76<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInJune2025Member', window );">Warrants Expiring In June 2025</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares | shares</a></td>
<td class="nump">1,142,289<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 14.74<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInFebruary2026Member', window );">Warrants Expiring In February 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares | shares</a></td>
<td class="nump">3,758<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 300.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInMay2027Member', window );">Warrants Expiring In May 2027</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares | shares</a></td>
<td class="nump">24,667<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 28.15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInJuly2027Member', window );">Warrants Expiring In July 2027</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares | shares</a></td>
<td class="nump">1,168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInApril2028Member', window );">Warrants Expiring In April 2028</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares | shares</a></td>
<td class="nump">2,402<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 61.39<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateOneMember', window );">Warrants Expiring in 60 Months After Registration Date</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares | shares</a></td>
<td class="nump">421,590<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 14.73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_ClassOfWarrantOrRightExpirationPeriod', window );">Expiration period</a></td>
<td class="text">60 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateTwoMember', window );">Warrants Expiring in 60 Months After Registration Date</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares | shares</a></td>
<td class="nump">1,269,210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 13.51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_ClassOfWarrantOrRightExpirationPeriod', window );">Expiration period</a></td>
<td class="text">60 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringIn24MonthsAfterRegistrationDateMember', window );">Warrants Expiring in 24 Months After Registration Date</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares | shares</a></td>
<td class="nump">814,467<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 12.28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_ClassOfWarrantOrRightExpirationPeriod', window );">Expiration period</a></td>
<td class="text">24 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_ClassOfWarrantOrRightExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Expiration Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_ClassOfWarrantOrRightExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInNovember2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInNovember2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInDecember2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInDecember2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInJune2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInJune2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInFebruary2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInFebruary2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInMay2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInMay2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInJuly2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInJuly2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInApril2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInApril2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringIn24MonthsAfterRegistrationDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringIn24MonthsAfterRegistrationDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139954752577904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 21, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 280<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation, weighted average amortization period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 4 months 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ck0001824293_PrivateGRIPlanMember', window );">2015 Plan | Stock options | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock awards, contractual life (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember', window );">A&amp;R 2918 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized</a></td>
<td class="nump">168,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="nump">216,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common shares reserved for future awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,207<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember', window );">A&amp;R 2918 Plan | Stock options | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock awards, contractual life (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ck0001824293_A2018EquityIncentivePlanMember', window );">2018 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,459<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ck0001824293_PrivateGRIPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ck0001824293_PrivateGRIPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ck0001824293_A2018EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ck0001824293_A2018EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139954755225008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Schedule of Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139954754979280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Activity of Stock Options (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Beginning Balance (in shares)</a></td>
<td class="nump">112,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited/Cancelled (in shares)</a></td>
<td class="num">(12,153)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Ending Balance (in shares)</a></td>
<td class="nump">100,459<span></span>
</td>
<td class="nump">112,612<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable, Ending Balance (in shares)</a></td>
<td class="nump">100,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Beginning Balance (in usd per share)</a></td>
<td class="nump">$ 39.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in usd per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in usd per share)</a></td>
<td class="nump">130.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Ending Balance (in usd per share)</a></td>
<td class="nump">28.75<span></span>
</td>
<td class="nump">$ 39.77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, Ending Balance (in usd per share)</a></td>
<td class="nump">$ 28.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted average remaining contractual term&#160;(years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding (years)</a></td>
<td class="text">4 years 8 months 23 days<span></span>
</td>
<td class="text">4 years 8 months 15 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable (years)</a></td>
<td class="text">4 years 8 months 23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139954759170608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Assumptions Used to Estimate Fair Value of Options (Details) - Stock options<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">90.39%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years</a></td>
<td class="text">5 years 11 months 23 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair value of option on grant date (in usd per share)</a></td>
<td class="nump">$ 3.86<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139954761018496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details) - Former Chief Executive Officer<br></strong></div></th>
<th class="th"><div>Apr. 21, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_COBRABenefitsPaymentPeriod', window );">COBRA benefits, payment period (in months)</a></td>
<td class="text">18 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_PercentageOfTargetBonus', window );">Percentage of target bonus (as a percent)</a></td>
<td class="nump">150.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_COBRABenefitsPaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>COBRA Benefits, Payment Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_COBRABenefitsPaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_PercentageOfTargetBonus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Target Bonus</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_PercentageOfTargetBonus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ck0001824293_FormerChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ck0001824293_FormerChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>ck0001824293-20230630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:ck0001824293="http://www.vallon-pharma.com/20230630"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ck0001824293-20230630.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2023-08-06</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2023-04-21</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2023-04-21</startDate>
            <endDate>2023-04-21</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-21</startDate>
            <endDate>2023-04-21</endDate>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-21</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ck0001824293:GRIBioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-21</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-21</startDate>
            <endDate>2023-04-21</endDate>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ck0001824293:StockSubjectToPutRightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ck0001824293:StockSubjectToPutRightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ck0001824293:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ck0001824293:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:ExchangeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-21</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-20</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2023-04-20</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-21</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ck0001824293:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ck0001824293:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ck0001824293:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-13</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-13</startDate>
            <endDate>2022-12-13</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-13</startDate>
            <endDate>2022-12-13</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-14</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-14</startDate>
            <endDate>2022-12-14</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-09</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-09</startDate>
            <endDate>2023-03-09</endDate>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:BridgeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-09</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:BridgeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-14</startDate>
            <endDate>2022-12-14</endDate>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:BridgeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-09</startDate>
            <endDate>2023-03-09</endDate>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:TEPNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-30</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-30</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:TEPNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:TEPNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:TEPNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:CallOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-12-31</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:TEPNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:TEPNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:TEPNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:TEPNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:TEPNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:TEPNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:TEPNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:PutOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-30</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesA1WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-08</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesA2WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-08</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesTWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-08</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesA1WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-08</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesA2WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-08</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:EquityWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:BridgeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-08</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:ExchangeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-08</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:BridgeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:BankerWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:BankerWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-08</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:BankerWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:EquityWarrantsExchangeWarrantsAndBankerWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:EquityWarrantsExchangeWarrantsAndBankerWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:EquityWarrantsExchangeWarrantsAndBankerWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:EquityWarrantsExchangeWarrantsAndBankerWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInNovember2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInDecember2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInJune2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInFebruary2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInMay2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInJuly2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInApril2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringIn60MonthsAfterRegistrationDateOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringIn60MonthsAfterRegistrationDateOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringIn60MonthsAfterRegistrationDateTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringIn60MonthsAfterRegistrationDateTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringIn24MonthsAfterRegistrationDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringIn24MonthsAfterRegistrationDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ck0001824293:PrivateGRIPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ck0001824293:AmendedAndRestated2018EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-21</startDate>
            <endDate>2023-04-21</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ck0001824293:AmendedAndRestated2018EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-21</instant>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ck0001824293:AmendedAndRestated2018EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ck0001824293:A2018EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ck0001824293:AmendedAndRestated2018EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ck0001824293:FormerChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-21</startDate>
            <endDate>2023-04-21</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-29">0001824293</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-30">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-31">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-32">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-33">false</dei:AmendmentFlag>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="c-41" decimals="4" id="f-259" unitRef="number">0.0333</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentType contextRef="c-1" id="f-2">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-3">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-4">2023-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-5">2023-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-6">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-7">001-40034</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-8">GRI BIO, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-9">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-10">82-4369909</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-11">2223 Avenida de la Playa</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-12">#208</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-13">La Jolla</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-14">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-15">92037</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-16">619</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-17">400-1170</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-18">Common Stock, par value $0.0001per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-19">GRI</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-20">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-21">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-22">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-23">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-24">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-25">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="c-1" id="f-26">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany contextRef="c-1" id="f-27">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-28" unitRef="shares">2956354</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-34" unitRef="usd">4799000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-35" unitRef="usd">9000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-3" decimals="-3" id="f-36" unitRef="usd">793000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-37" unitRef="usd">303000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-3" decimals="-3" id="f-38" unitRef="usd">5592000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-39" unitRef="usd">312000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-3" id="f-40" unitRef="usd">9000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-41" unitRef="usd">4000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-3" decimals="-3" id="f-42" unitRef="usd">41000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-43" unitRef="usd">67000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets contextRef="c-3" decimals="-3" id="f-44" unitRef="usd">5642000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-45" unitRef="usd">383000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-3" decimals="-3" id="f-46" unitRef="usd">307000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-3" id="f-47" unitRef="usd">1294000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-48" unitRef="usd">1193000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-49" unitRef="usd">36000</us-gaap:AccruedLiabilitiesCurrent>
    <ck0001824293:EmployeeAdvancesCurrent contextRef="c-3" decimals="-3" id="f-50" unitRef="usd">0</ck0001824293:EmployeeAdvancesCurrent>
    <ck0001824293:EmployeeAdvancesCurrent contextRef="c-4" decimals="-3" id="f-51" unitRef="usd">5000</ck0001824293:EmployeeAdvancesCurrent>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="c-3" decimals="-3" id="f-52" unitRef="usd">63000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="c-4" decimals="-3" id="f-53" unitRef="usd">0</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:NotesPayableCurrent contextRef="c-3" decimals="-3" id="f-54" unitRef="usd">0</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="c-4" decimals="-3" id="f-55" unitRef="usd">602000</us-gaap:NotesPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="-3" id="f-56" unitRef="usd">41000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-57" unitRef="usd">57000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-58" unitRef="usd">1604000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-59" unitRef="usd">1994000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-60" unitRef="usd">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-61" unitRef="usd">14000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="c-3" decimals="-3" id="f-62" unitRef="usd">1604000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-63" unitRef="usd">2008000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-3" id="f-64" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-65" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-66"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-67"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-68" unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-69" unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-3" decimals="INF" id="f-70" unitRef="shares">2956354</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-71" unitRef="shares">2956354</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="INF" id="f-72" unitRef="shares">999748</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-73" unitRef="shares">999748</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValueOutstanding contextRef="c-3" decimals="-3" id="f-74" unitRef="usd">0</us-gaap:CommonStockValueOutstanding>
    <us-gaap:CommonStockValueOutstanding contextRef="c-4" decimals="-3" id="f-75" unitRef="usd">0</us-gaap:CommonStockValueOutstanding>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-3" decimals="-3" id="f-76" unitRef="usd">31430000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-4" decimals="-3" id="f-77" unitRef="usd">16871000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-3" id="f-78" unitRef="usd">-27392000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-79" unitRef="usd">-18496000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-80" unitRef="usd">4038000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-81" unitRef="usd">-1625000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-3" decimals="-3" id="f-82" unitRef="usd">5642000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-83" unitRef="usd">383000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-5" decimals="-3" id="f-84" unitRef="usd">880000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-6" decimals="-3" id="f-85" unitRef="usd">59000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-86" unitRef="usd">997000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-7" decimals="-3" id="f-87" unitRef="usd">119000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-5" decimals="-3" id="f-88" unitRef="usd">5054000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-6" decimals="-3" id="f-89" unitRef="usd">130000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-90" unitRef="usd">5926000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-7" decimals="-3" id="f-91" unitRef="usd">268000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c-5" decimals="-3" id="f-92" unitRef="usd">5934000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-6" decimals="-3" id="f-93" unitRef="usd">189000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-94" unitRef="usd">6923000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-7" decimals="-3" id="f-95" unitRef="usd">387000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-5" decimals="-3" id="f-96" unitRef="usd">-5934000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-6" decimals="-3" id="f-97" unitRef="usd">-189000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-98" unitRef="usd">-6923000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-7" decimals="-3" id="f-99" unitRef="usd">-387000</us-gaap:OperatingIncomeLoss>
    <ck0001824293:ChangeInFairValueOfWarrantLiability contextRef="c-5" decimals="-3" id="f-100" unitRef="usd">122000</ck0001824293:ChangeInFairValueOfWarrantLiability>
    <ck0001824293:ChangeInFairValueOfWarrantLiability contextRef="c-6" decimals="-3" id="f-101" unitRef="usd">0</ck0001824293:ChangeInFairValueOfWarrantLiability>
    <ck0001824293:ChangeInFairValueOfWarrantLiability contextRef="c-1" decimals="-3" id="f-102" unitRef="usd">122000</ck0001824293:ChangeInFairValueOfWarrantLiability>
    <ck0001824293:ChangeInFairValueOfWarrantLiability contextRef="c-7" decimals="-3" id="f-103" unitRef="usd">0</ck0001824293:ChangeInFairValueOfWarrantLiability>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-5" decimals="-3" id="f-104" unitRef="usd">-934000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-6" decimals="-3" id="f-105" unitRef="usd">-106000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-1" decimals="-3" id="f-106" unitRef="usd">-2095000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-7" decimals="-3" id="f-107" unitRef="usd">-210000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-108" unitRef="usd">-6746000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-109" unitRef="usd">-295000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-110" unitRef="usd">-8896000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-111" unitRef="usd">-597000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-5"
      decimals="2"
      id="f-112"
      unitRef="usdPerShare">-2.79</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-5"
      decimals="2"
      id="f-113"
      unitRef="usdPerShare">-2.79</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-6"
      decimals="2"
      id="f-114"
      unitRef="usdPerShare">-0.35</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-6"
      decimals="2"
      id="f-115"
      unitRef="usdPerShare">-0.35</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-116"
      unitRef="usdPerShare">-5.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-117"
      unitRef="usdPerShare">-5.23</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-7"
      decimals="2"
      id="f-118"
      unitRef="usdPerShare">-0.70</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-7"
      decimals="2"
      id="f-119"
      unitRef="usdPerShare">-0.70</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-5" decimals="0" id="f-120" unitRef="shares">2417785</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-5" decimals="0" id="f-121" unitRef="shares">2417785</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-6" decimals="0" id="f-122" unitRef="shares">851419</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-6" decimals="0" id="f-123" unitRef="shares">851419</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-124" unitRef="shares">1701864</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-125" unitRef="shares">1701864</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-7" decimals="0" id="f-126" unitRef="shares">851419</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-7" decimals="0" id="f-127" unitRef="shares">851419</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:TemporaryEquitySharesOutstanding contextRef="c-8" decimals="INF" id="f-128" unitRef="shares">7816</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-8" decimals="-3" id="f-129" unitRef="usd">124000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-9" decimals="INF" id="f-130" unitRef="shares">851419</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-9" decimals="-3" id="f-131" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-10" decimals="-3" id="f-132" unitRef="usd">10430000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-11" decimals="-3" id="f-133" unitRef="usd">-15278000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-8" decimals="-3" id="f-134" unitRef="usd">-4848000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-12" decimals="-3" id="f-135" unitRef="usd">-302000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-3" id="f-136" unitRef="usd">-302000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c-14"
      decimals="INF"
      id="f-137"
      unitRef="shares">7816</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-14" decimals="-3" id="f-138" unitRef="usd">124000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-15"
      decimals="INF"
      id="f-139"
      unitRef="shares">851419</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-15" decimals="-3" id="f-140" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-16" decimals="-3" id="f-141" unitRef="usd">10430000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-17" decimals="-3" id="f-142" unitRef="usd">-15580000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-14" decimals="-3" id="f-143" unitRef="usd">-5150000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-18" decimals="-3" id="f-144" unitRef="usd">-295000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-145" unitRef="usd">-295000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c-19"
      decimals="INF"
      id="f-146"
      unitRef="shares">7816</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-19" decimals="-3" id="f-147" unitRef="usd">124000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-20"
      decimals="INF"
      id="f-148"
      unitRef="shares">851419</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-20" decimals="-3" id="f-149" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-21" decimals="-3" id="f-150" unitRef="usd">10430000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-22" decimals="-3" id="f-151" unitRef="usd">-15875000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-19" decimals="-3" id="f-152" unitRef="usd">-5445000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-23"
      decimals="INF"
      id="f-153"
      unitRef="shares">999748</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-23" decimals="-3" id="f-154" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-24" decimals="-3" id="f-155" unitRef="usd">16871000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-25" decimals="-3" id="f-156" unitRef="usd">-18496000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-157" unitRef="usd">-1625000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-26" decimals="-3" id="f-158" unitRef="usd">13000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-27" decimals="-3" id="f-159" unitRef="usd">13000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="c-28"
      decimals="INF"
      id="f-160"
      unitRef="shares">467</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c-26" decimals="-3" id="f-161" unitRef="usd">532000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c-27" decimals="-3" id="f-162" unitRef="usd">532000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:NetIncomeLoss contextRef="c-29" decimals="-3" id="f-163" unitRef="usd">-2150000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-27" decimals="-3" id="f-164" unitRef="usd">-2150000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-30"
      decimals="INF"
      id="f-165"
      unitRef="shares">1000215</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-30" decimals="-3" id="f-166" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-31" decimals="-3" id="f-167" unitRef="usd">17416000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-32" decimals="-3" id="f-168" unitRef="usd">-20646000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-33" decimals="-3" id="f-169" unitRef="usd">-3230000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-34" decimals="-3" id="f-170" unitRef="usd">13000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-5" decimals="-3" id="f-171" unitRef="usd">13000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="c-35"
      decimals="INF"
      id="f-172"
      unitRef="shares">164038</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <ck0001824293:StockIssuedDuringPeriodSharesWarrantExercise
      contextRef="c-35"
      decimals="INF"
      id="f-173"
      unitRef="shares">43682</ck0001824293:StockIssuedDuringPeriodSharesWarrantExercise>
    <ck0001824293:StockIssuedDuringPeriodValueWarrantExercises contextRef="c-34" decimals="-3" id="f-174" unitRef="usd">12000</ck0001824293:StockIssuedDuringPeriodValueWarrantExercises>
    <ck0001824293:StockIssuedDuringPeriodValueWarrantExercises contextRef="c-5" decimals="-3" id="f-175" unitRef="usd">12000</ck0001824293:StockIssuedDuringPeriodValueWarrantExercises>
    <ck0001824293:StockIssuedDuringPeriodSharesPreClosingFinancing
      contextRef="c-35"
      decimals="INF"
      id="f-176"
      unitRef="shares">1214912</ck0001824293:StockIssuedDuringPeriodSharesPreClosingFinancing>
    <ck0001824293:StockIssuedDuringPeriodValuePreClosingFinancing contextRef="c-34" decimals="-3" id="f-177" unitRef="usd">11721000</ck0001824293:StockIssuedDuringPeriodValuePreClosingFinancing>
    <ck0001824293:StockIssuedDuringPeriodValuePreClosingFinancing contextRef="c-5" decimals="-3" id="f-178" unitRef="usd">11721000</ck0001824293:StockIssuedDuringPeriodValuePreClosingFinancing>
    <ck0001824293:StockIssuedDuringPeriodSharesSettlementOfDebt
      contextRef="c-35"
      decimals="INF"
      id="f-179"
      unitRef="shares">54298</ck0001824293:StockIssuedDuringPeriodSharesSettlementOfDebt>
    <ck0001824293:StockIssuedDuringPeriodValueSettlementOfDebt contextRef="c-34" decimals="-3" id="f-180" unitRef="usd">3333000</ck0001824293:StockIssuedDuringPeriodValueSettlementOfDebt>
    <ck0001824293:StockIssuedDuringPeriodValueSettlementOfDebt contextRef="c-5" decimals="-3" id="f-181" unitRef="usd">3333000</ck0001824293:StockIssuedDuringPeriodValueSettlementOfDebt>
    <ck0001824293:StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses
      contextRef="c-35"
      decimals="INF"
      id="f-182"
      unitRef="shares">30542</ck0001824293:StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses>
    <ck0001824293:StockIssuedDuringPeriodValueReverseRecapitalizationExpenses contextRef="c-34" decimals="-3" id="f-183" unitRef="usd">1875000</ck0001824293:StockIssuedDuringPeriodValueReverseRecapitalizationExpenses>
    <ck0001824293:StockIssuedDuringPeriodValueReverseRecapitalizationExpenses contextRef="c-5" decimals="-3" id="f-184" unitRef="usd">1875000</ck0001824293:StockIssuedDuringPeriodValueReverseRecapitalizationExpenses>
    <ck0001824293:StockIssuedDuringPeriodSharesReverseRecapitalization
      contextRef="c-35"
      decimals="INF"
      id="f-185"
      unitRef="shares">448667</ck0001824293:StockIssuedDuringPeriodSharesReverseRecapitalization>
    <ck0001824293:StockIssuedDuringPeriodValueReverseRecapitalization contextRef="c-34" decimals="-3" id="f-186" unitRef="usd">-2940000</ck0001824293:StockIssuedDuringPeriodValueReverseRecapitalization>
    <ck0001824293:StockIssuedDuringPeriodValueReverseRecapitalization contextRef="c-5" decimals="-3" id="f-187" unitRef="usd">-2940000</ck0001824293:StockIssuedDuringPeriodValueReverseRecapitalization>
    <us-gaap:NetIncomeLoss contextRef="c-36" decimals="-3" id="f-188" unitRef="usd">-6746000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-189" unitRef="usd">-6746000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-37"
      decimals="INF"
      id="f-190"
      unitRef="shares">2956354</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-37" decimals="-3" id="f-191" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-38" decimals="-3" id="f-192" unitRef="usd">31430000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-39" decimals="-3" id="f-193" unitRef="usd">-27392000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-194" unitRef="usd">4038000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-195" unitRef="usd">-8896000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-196" unitRef="usd">-597000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation contextRef="c-1" decimals="-3" id="f-197" unitRef="usd">2000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-7" decimals="-3" id="f-198" unitRef="usd">1000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-1" decimals="-3" id="f-199" unitRef="usd">2104000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-7" decimals="-3" id="f-200" unitRef="usd">0</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-201" unitRef="usd">26000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-7" decimals="-3" id="f-202" unitRef="usd">0</us-gaap:ShareBasedCompensation>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-1" decimals="-3" id="f-203" unitRef="usd">63000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-7" decimals="-3" id="f-204" unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-1" decimals="-3" id="f-205" unitRef="usd">26000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-7" decimals="-3" id="f-206" unitRef="usd">23000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-207" unitRef="usd">750000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-7" decimals="-3" id="f-208" unitRef="usd">8000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-209" unitRef="usd">4179000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-7" decimals="-3" id="f-210" unitRef="usd">79000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-1" decimals="-3" id="f-211" unitRef="usd">1157000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-7" decimals="-3" id="f-212" unitRef="usd">409000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-213" unitRef="usd">-30000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-7" decimals="-3" id="f-214" unitRef="usd">-23000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-215" unitRef="usd">-2119000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-7" decimals="-3" id="f-216" unitRef="usd">-116000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-217" unitRef="usd">8000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-7" decimals="-3" id="f-218" unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-219" unitRef="usd">-8000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-7" decimals="-3" id="f-220" unitRef="usd">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <ck0001824293:ProceedsFromAdvancesFromEmployees contextRef="c-1" decimals="-3" id="f-221" unitRef="usd">190000</ck0001824293:ProceedsFromAdvancesFromEmployees>
    <ck0001824293:ProceedsFromAdvancesFromEmployees contextRef="c-7" decimals="-3" id="f-222" unitRef="usd">35000</ck0001824293:ProceedsFromAdvancesFromEmployees>
    <ck0001824293:RepaymentOfAdvancesFromEmployees contextRef="c-1" decimals="-3" id="f-223" unitRef="usd">195000</ck0001824293:RepaymentOfAdvancesFromEmployees>
    <ck0001824293:RepaymentOfAdvancesFromEmployees contextRef="c-7" decimals="-3" id="f-224" unitRef="usd">0</ck0001824293:RepaymentOfAdvancesFromEmployees>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-1" decimals="-3" id="f-225" unitRef="usd">12250000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-7" decimals="-3" id="f-226" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromNotesPayable contextRef="c-1" decimals="-3" id="f-227" unitRef="usd">1250000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable contextRef="c-7" decimals="-3" id="f-228" unitRef="usd">0</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c-1" decimals="-3" id="f-229" unitRef="usd">12000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c-7" decimals="-3" id="f-230" unitRef="usd">0</us-gaap:ProceedsFromWarrantExercises>
    <ck0001824293:NetLiabilitiesAssumedInConnectionWithReverseRecapitalization contextRef="c-1" decimals="-3" id="f-231" unitRef="usd">2939000</ck0001824293:NetLiabilitiesAssumedInConnectionWithReverseRecapitalization>
    <ck0001824293:NetLiabilitiesAssumedInConnectionWithReverseRecapitalization contextRef="c-7" decimals="-3" id="f-232" unitRef="usd">0</ck0001824293:NetLiabilitiesAssumedInConnectionWithReverseRecapitalization>
    <ck0001824293:PaymentOfReverseRecapitalizationCosts contextRef="c-1" decimals="-3" id="f-233" unitRef="usd">2984000</ck0001824293:PaymentOfReverseRecapitalizationCosts>
    <ck0001824293:PaymentOfReverseRecapitalizationCosts contextRef="c-7" decimals="-3" id="f-234" unitRef="usd">0</ck0001824293:PaymentOfReverseRecapitalizationCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-1" decimals="-3" id="f-235" unitRef="usd">517000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-7" decimals="-3" id="f-236" unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-1" decimals="-3" id="f-237" unitRef="usd">150000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-7" decimals="-3" id="f-238" unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-239" unitRef="usd">6917000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-7" decimals="-3" id="f-240" unitRef="usd">35000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-241" unitRef="usd">4790000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-7" decimals="-3" id="f-242" unitRef="usd">-81000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-243" unitRef="usd">9000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-8" decimals="-3" id="f-244" unitRef="usd">90000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-3" id="f-245" unitRef="usd">4799000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-19" decimals="-3" id="f-246" unitRef="usd">9000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <ck0001824293:StockIssuedForRepaymentOfNotesPayable contextRef="c-1" decimals="-3" id="f-247" unitRef="usd">3333000</ck0001824293:StockIssuedForRepaymentOfNotesPayable>
    <ck0001824293:StockIssuedForRepaymentOfNotesPayable contextRef="c-7" decimals="-3" id="f-248" unitRef="usd">0</ck0001824293:StockIssuedForRepaymentOfNotesPayable>
    <ck0001824293:DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants contextRef="c-1" decimals="-3" id="f-249" unitRef="usd">532000</ck0001824293:DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants>
    <ck0001824293:DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants contextRef="c-7" decimals="-3" id="f-250" unitRef="usd">0</ck0001824293:DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants>
    <ck0001824293:StockIssuedForPaymentOfReverseRecapitalizationCosts contextRef="c-1" decimals="-3" id="f-251" unitRef="usd">1875000</ck0001824293:StockIssuedForPaymentOfReverseRecapitalizationCosts>
    <ck0001824293:StockIssuedForPaymentOfReverseRecapitalizationCosts contextRef="c-7" decimals="-3" id="f-252" unitRef="usd">0</ck0001824293:StockIssuedForPaymentOfReverseRecapitalizationCosts>
    <ck0001824293:WarrantsIssued contextRef="c-1" decimals="-3" id="f-253" unitRef="usd">18000</ck0001824293:WarrantsIssued>
    <ck0001824293:WarrantsIssued contextRef="c-7" id="f-254" unitRef="usd" xsi:nil="true"/>
    <ck0001824293:NoncashMergerRelatedCostsFinancingActivities contextRef="c-1" decimals="-3" id="f-255" unitRef="usd">72000</ck0001824293:NoncashMergerRelatedCostsFinancingActivities>
    <ck0001824293:NoncashMergerRelatedCostsFinancingActivities contextRef="c-7" decimals="-3" id="f-256" unitRef="usd">0</ck0001824293:NoncashMergerRelatedCostsFinancingActivities>
    <us-gaap:NatureOfOperations contextRef="c-1" id="f-257">ORGANIZATION AND DESCRIPTION OF BUSINESS&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;GRI Bio, Inc. (GRI or the Company), based in La Jolla, CA, was incorporated in Delaware in May 2009, which is the date of inception.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;GRI is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies that target serious diseases associated with dysregulated immune responses leading to inflammatory, fibrotic, and autoimmune disorders. The Company&#x2019;s goal is to be an industry leader in developing therapies to treat these diseases and to improve the lives of patients suffering from such diseases. The Company&#x2019;s lead product candidate, GRI-0621, is an oral inhibitor of type 1 Natural Killer T (iNKT I) cells and is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis (IPF). The Company&#x2019;s product candidate portfolio also includes GRI-0803 and a proprietary library of 500+ compounds. GRI-0803, the lead molecule selected from the library, is a novel oral agonist of type 2 Natural Killer T (NKT II) cells and is being developed for the treatment of autoimmune disorders, with much of its preclinical work in Systemic Lupus Erythematosus Disease (SLE) or lupus and multiple sclerosis (MS).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reverse Merger with Vallon Pharmaceuticals, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 21, 2023, the Company (formerly Vallon Pharmaceuticals, Inc.(Vallon)) consummated a merger with GRI Bio Operations, Inc. (formerly GRI Bio, Inc.) (Private GRI) pursuant to an Agreement and Plan of Merger, as amended (the Merger Agreement), by and among the Company, Private GRI and Vallon Merger Sub, Inc. (Merger Sub), a Delaware corporation and wholly-owned subsidiary of the Company (Note 4). The Merger Agreement provided for the merger of Merger Sub with and into Private GRI, with Private GRI surviving the merger as a wholly-owned subsidiary of the Company (the Merger). In connection with the closing of the Merger (the Closing), the Company amended its certificate of incorporation and bylaws to change its name from &#x201c;Vallon Pharmaceuticals, Inc.&#x201d; to &#x201c;GRI Bio, Inc.&#x201d; In addition, prior to the effective time of the Merger (the Effective Time), the Company effected a reverse stock split of the Company&#x2019;s common stock at a ratio of 1 for 30 (the Reverse Stock Split). At the Effective Time, each share of Private GRI&#x2019;s common stock outstanding immediately prior to the Effective Time automatically converted solely into the right to receive a number of shares of the Company's common stock equal to 0.0374 (the Exchange Ratio).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Except as otherwise indicated or as the context requires, references herein to &#x201c;GRI Bio,&#x201d; the &#x201c;Company,&#x201d; or the &#x201c;Combined Company,&#x201d; refer to GRI Bio, Inc. on a post-Merger basis, and references to &#x201c;Private GRI&#x201d; refer to the business of  GRI Bio, Inc. prior to the completion of the Merger. References to &#x201c;Vallon&#x201d; refer to Vallon Pharmaceuticals, Inc. prior to the completion of the Merger.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in Note 4, the Merger was accounted for as reverse recapitalization under which the historical financial statements of the Company prior to the Merger are the historical financial statements of the accounting acquirer, Private GRI. All common stock, per share and related information presented in the consolidated financial statements and notes prior to the Merger has been retroactively adjusted to reflect the Exchange Ratio and Reverse Stock Split for all periods presented, to the extent applicable.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <ck0001824293:CommonStockExchangeRatio contextRef="c-40" decimals="4" id="f-258" unitRef="number">0.0374</ck0001824293:CommonStockExchangeRatio>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="c-1" id="f-260">LIQUIDITYThese financial statements have been prepared on the basis that the Company is a going concern, which contemplates, among other things, the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has not generated any significant revenues from operations since inception and does not expect to do so in the foreseeable future. The Company has incurred operating losses since its inception in 2009 and as a result has incurred $27,392 in accumulated deficit through June&#160;30, 2023. The Company has financed its working capital requirements to date through the issuance of equity and debt securities. As of June&#160;30, 2023, the Company had cash of approximately $4,799. &lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with signing the Merger Agreement, Vallon, Private GRI and the Investor entered the Equity SPA pursuant to which the Investor agreed to invest $12,250 in cash and cancel any outstanding principal and accrued interest on the Bridge Notes in return for the issuance of shares of Private GRI common stock immediately prior to the consummation of the Merger. Pursuant to the Equity SPA, immediately prior to the Closing, Private GRI issued 6,787,219 shares of Private GRI common stock (the Initial Shares) to the Investor and 27,148,877 shares of Private GRI common stock (the Additional Shares) into escrow with an escrow agent for net proceeds of $11,704, after deducting offering expenses of $546.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the closing, pursuant to the Merger, the Initial Shares converted into an aggregate of 253,842 shares of the Company&#x2019;s common stock and the Additional Shares converted into an aggregate of 1,015,368 shares of the Company&#x2019;s common stock. On May 8, 2023, in accordance with the terms of the Equity SPA, the Company and the Investor authorized the escrow agent to, subject to beneficial ownership limitations, disburse to the Investor all of the shares of the Company&#x2019;s common stock issued in exchange for the Additional Shares. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on the Company&#x2019;s current operating plan, the Company believes that its existing cash and cash equivalents, which include the proceeds from the Equity SPA, will be sufficient to fund its operating expenses and capital expenditure requirements for twelve months from the date of the Merger (Note 4), not including the exercise of the Series T Warrants (the Series T Warrant Exercises). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s ability to continue as a going concern is dependent on its ability to raise additional capital to fund its business activities, including its research and development program. The Company intends to raise capital through additional issuances of common stock and/or short-term or long-term notes, but there can be no assurances any such financing will be available when needed or that the Company&#x2019;s research and development efforts will be successful. If the Company is not able to obtain additional financing on acceptable terms and in the amounts necessary to fully fund its future operating requirements, it may be forced to reduce or discontinue its operations entirely. Therefore, there is substantial doubt about the Company&#x2019;s ability to continue as a going concern. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from this uncertainty.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-3" id="f-261" unitRef="usd">-27392000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-262" unitRef="usd">4799000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:InvestmentCompanyCommittedCapital contextRef="c-42" decimals="-3" id="f-263" unitRef="usd">12250000</us-gaap:InvestmentCompanyCommittedCapital>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-43"
      decimals="INF"
      id="f-264"
      unitRef="shares">6787219</us-gaap:CommonStockSharesIssued>
    <ck0001824293:CommonStockHeldIntoEscrowAccount
      contextRef="c-44"
      decimals="INF"
      id="f-265"
      unitRef="shares">27148877</ck0001824293:CommonStockHeldIntoEscrowAccount>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-41" decimals="-3" id="f-266" unitRef="usd">11704000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ck0001824293:StockIssuanceCostsOfferingExpenses contextRef="c-41" decimals="-3" id="f-267" unitRef="usd">546000</ck0001824293:StockIssuanceCostsOfferingExpenses>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c-45"
      decimals="INF"
      id="f-268"
      unitRef="shares">253842</us-gaap:ConversionOfStockSharesConverted1>
    <ck0001824293:ConversionOfStockAdditionalSharesConverted
      contextRef="c-45"
      decimals="INF"
      id="f-269"
      unitRef="shares">1015368</ck0001824293:ConversionOfStockAdditionalSharesConverted>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-270">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial periods and pursuant to the rules of the Securities and Exchange Commission (the SEC). Any reference in the accompanying unaudited interim financial statements to &#x201c;authoritative guidance&#x201d; is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB). The December&#160;31, 2022 balance sheet was derived from the Company&#x2019;s audited financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the opinion of management, the unaudited interim financial statements furnished herein include all normal and recurring adjustments considered necessary to present fairly the Company&#x2019;s financial position as of June&#160;30, 2023, and the results of operations and stockholders&#x2019; deficit for the three and six months ended June&#160;30, 2023 and 2022 and cash flows for the three and six months ended June&#160;30, 2023 and 2022. Results of operations for the three and six months ended June&#160;30, 2023, are not necessarily indicative of the operating results that may be expected for the year ending December 31, 2023. The unaudited interim financial statements, presented herein, do not contain the required disclosures under GAAP for annual financial statements. The accompanying unaudited interim financial statements should be read in conjunction with the annual audited financial statements and related notes as of and for the year ended December&#160;31, 2022, which are included as Exhibit 99.2 of Amendment No. 2 to the Current Report on Form 8-K filed with the SEC on July 6, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates and assumptions are primarily made in relation to the valuation of share options, the embedded derivative of convertible notes, warrant issuance and subsequent revaluations, valuation allowances relating to deferred tax assets, revenue recognition, accrued expenses and estimation of the incremental borrowing rate for the finance lease. If actual results differ from the Company&#x2019;s estimates, or to the extent these estimates are adjusted &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in future periods, the Company&#x2019;s results of operations could either benefit from, or be adversely affected by, any such change in estimate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents are highly-liquid investments that are readily convertible into cash with original maturities of three months or less when purchased and as of June&#160;30, 2023 and  December&#160;31, 2022 included investments in money market funds. The Company maintains its cash and cash equivalent balances at domestic financial institutions. Bank deposits with US banks are insured up to $250 by the Federal Deposits Insurance Corporation. The Company had an uninsured cash balances of $4,302 at June&#160;30, 2023. The Company&#x2019;s cash balance as of December&#160;31, 2022 was fully insured.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, (ASC 820) establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The three levels of fair value hierarchy defined by ASC 820 are described below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:6pt;padding-left:63pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:6pt;padding-left:67.5pt;text-indent:-40.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:6pt;padding-left:63pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2023, the Company&#x2019;s financial instruments included cash, cash equivalents, prepaid expenses and other current assets, accounts payable, accrued expenses and certain liability classified warrants. The carrying amounts reported in the balance sheets for cash, cash equivalents, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair value based on the short-term maturity of these instruments. The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. At June&#160;30, 2023, there were no financial assets or liabilities measured at fair value on a recurring basis other than the liability classified warrants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2022, Vallon issued warrants in connection with a securities purchase agreement. Vallon evaluated the warrants in accordance with ASC 815-40, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging &#x2014; Contracts in Entity&#x2019;s Own Equity &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASC 815-40), and concluded that a provision in the warrants related to the reduction of the exercise price in certain circumstances precludes the warrants from being accounted for as components of equity. As a result, the warrants are recorded as a liability on the balance sheet. Vallon recorded the fair value of the warrants upon issuance using a Black-Scholes valuation model. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is required to revalue the warrants at each reporting date with any changes in fair value recorded in its statement of operations. The valuation of the warrants is considered under Level 3 of the fair value hierarchy due to the need to use assumptions in the valuation that are both significant to the fair value measurement and unobservable. The change in the fair value of the Level 3 warrants liabilities is reflected in the statement of operations for the six months ended June&#160;30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deferred Stock Issuance Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred stock issuance costs represent incremental legal costs incurred that are directly attributable to proposed offerings of securities. The costs are charged against the gross proceeds of the respective offering upon closing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Debt Discounts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The relative fair values of warrants and common shares issued and call option rights assigned in connection with principal advances under promissory notes, the increases in fair values of embedded conversion options in connection with convertible promissory note &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;modifications, and the intrinsic values of non-contingent beneficial conversion features were recorded as debt discounts that are amortized as additional interest expense over the estimated terms of the notes using the effective interest method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Debt Issuance Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt issuance costs represent incremental legal costs and other costs incurred that are directly attributable to issuing debt. The costs are included as a direct reduction of the carrying amount of the respective liability and are amortized as additional interest expense over the estimated term of the debt using the effective interest method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes expense for employee and non-employee stock-based compensation in accordance with ASC Topic 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-Based Compensation &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASC 718). ASC 718 requires that such transactions be accounted for using a fair value-based method. The estimated fair value of the options is amortized over the vesting period, based on the fair value of the options on the date granted, and is calculated using the Black-Scholes option-pricing model. The Company accounts for forfeitures as incurred. In considering the fair value of the underlying stock when the Company granted options, the Company considered several factors including the fair values established by market transactions. Stock option-based compensation includes estimates and judgments of when stock options might be exercised and stock price volatility. The timing of option exercises is out of the Company's control and depends upon a number of factors including the Company's market value and the financial objectives of the option holders. These estimates can have a material impact on the stock compensation expense but will have no impact on the cash flows. The estimation of share-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from original estimates, such &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;amounts are recorded as a cumulative adjustment in the period the estimates are revised. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the expected term, rather than the contractual term, for both employee and consultant options issued.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Loss Per Common Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted net loss per common share are calculated by dividing the net loss by the applicable weighted-average number of common shares outstanding during the period. As the Company had a net loss in each of the three and six months ended June&#160;30, 2023 and 2022, diluted net loss per common share is the same as basic net loss per common share for the period because the effects of potentially dilutive securities are antidilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common stock equivalents excluded from the diluted net loss per common share calculations are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.177%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.985%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,688,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock with repurchase rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock subject to put right&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible promissory note&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,952,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;414,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considered the applicability and impact of all ASUs issued during the quarter ended June&#160;30, 2023 and each was determined to be either not applicable or expected to have minimal impact on these financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-271">The accompanying unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial periods and pursuant to the rules of the Securities and Exchange Commission (the SEC). Any reference in the accompanying unaudited interim financial statements to &#x201c;authoritative guidance&#x201d; is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB). The December&#160;31, 2022 balance sheet was derived from the Company&#x2019;s audited financial statements.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-272">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates and assumptions are primarily made in relation to the valuation of share options, the embedded derivative of convertible notes, warrant issuance and subsequent revaluations, valuation allowances relating to deferred tax assets, revenue recognition, accrued expenses and estimation of the incremental borrowing rate for the finance lease. If actual results differ from the Company&#x2019;s estimates, or to the extent these estimates are adjusted &lt;/span&gt;&lt;/div&gt;in future periods, the Company&#x2019;s results of operations could either benefit from, or be adversely affected by, any such change in estimate.</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c-1" id="f-273">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents are highly-liquid investments that are readily convertible into cash with original maturities of three months or less when purchased and as of June&#160;30, 2023 and  December&#160;31, 2022 included investments in money market funds. The Company maintains its cash and cash equivalent balances at domestic financial institutions. Bank deposits with US banks are insured up to $250 by the Federal Deposits Insurance Corporation. The Company had an uninsured cash balances of $4,302 at June&#160;30, 2023. The Company&#x2019;s cash balance as of December&#160;31, 2022 was fully insured.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashFDICInsuredAmount contextRef="c-3" decimals="-3" id="f-274" unitRef="usd">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:CashUninsuredAmount contextRef="c-3" decimals="-3" id="f-275" unitRef="usd">4302000</us-gaap:CashUninsuredAmount>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c-1" id="f-276">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, (ASC 820) establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The three levels of fair value hierarchy defined by ASC 820 are described below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:6pt;padding-left:63pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:6pt;padding-left:67.5pt;text-indent:-40.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:6pt;padding-left:63pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2023, the Company&#x2019;s financial instruments included cash, cash equivalents, prepaid expenses and other current assets, accounts payable, accrued expenses and certain liability classified warrants. The carrying amounts reported in the balance sheets for cash, cash equivalents, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair value based on the short-term maturity of these instruments. The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. At June&#160;30, 2023, there were no financial assets or liabilities measured at fair value on a recurring basis other than the liability classified warrants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2022, Vallon issued warrants in connection with a securities purchase agreement. Vallon evaluated the warrants in accordance with ASC 815-40, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging &#x2014; Contracts in Entity&#x2019;s Own Equity &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASC 815-40), and concluded that a provision in the warrants related to the reduction of the exercise price in certain circumstances precludes the warrants from being accounted for as components of equity. As a result, the warrants are recorded as a liability on the balance sheet. Vallon recorded the fair value of the warrants upon issuance using a Black-Scholes valuation model. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is required to revalue the warrants at each reporting date with any changes in fair value recorded in its statement of operations. The valuation of the warrants is considered under Level 3 of the fair value hierarchy due to the need to use assumptions in the valuation that are both significant to the fair value measurement and unobservable. The change in the fair value of the Level 3 warrants liabilities is reflected in the statement of operations for the six months ended June&#160;30, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:DeferredChargesPolicyTextBlock contextRef="c-1" id="f-277">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deferred Stock Issuance Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred stock issuance costs represent incremental legal costs incurred that are directly attributable to proposed offerings of securities. The costs are charged against the gross proceeds of the respective offering upon closing.&lt;/span&gt;&lt;/div&gt;</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:DebtPolicyTextBlock contextRef="c-1" id="f-278">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Debt Discounts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The relative fair values of warrants and common shares issued and call option rights assigned in connection with principal advances under promissory notes, the increases in fair values of embedded conversion options in connection with convertible promissory note &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;modifications, and the intrinsic values of non-contingent beneficial conversion features were recorded as debt discounts that are amortized as additional interest expense over the estimated terms of the notes using the effective interest method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Debt Issuance Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt issuance costs represent incremental legal costs and other costs incurred that are directly attributable to issuing debt. The costs are included as a direct reduction of the carrying amount of the respective liability and are amortized as additional interest expense over the estimated term of the debt using the effective interest method.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-279">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes expense for employee and non-employee stock-based compensation in accordance with ASC Topic 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-Based Compensation &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASC 718). ASC 718 requires that such transactions be accounted for using a fair value-based method. The estimated fair value of the options is amortized over the vesting period, based on the fair value of the options on the date granted, and is calculated using the Black-Scholes option-pricing model. The Company accounts for forfeitures as incurred. In considering the fair value of the underlying stock when the Company granted options, the Company considered several factors including the fair values established by market transactions. Stock option-based compensation includes estimates and judgments of when stock options might be exercised and stock price volatility. The timing of option exercises is out of the Company's control and depends upon a number of factors including the Company's market value and the financial objectives of the option holders. These estimates can have a material impact on the stock compensation expense but will have no impact on the cash flows. The estimation of share-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from original estimates, such &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;amounts are recorded as a cumulative adjustment in the period the estimates are revised. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the expected term, rather than the contractual term, for both employee and consultant options issued.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-280">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Loss Per Common Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted net loss per common share are calculated by dividing the net loss by the applicable weighted-average number of common shares outstanding during the period. As the Company had a net loss in each of the three and six months ended June&#160;30, 2023 and 2022, diluted net loss per common share is the same as basic net loss per common share for the period because the effects of potentially dilutive securities are antidilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-281">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common stock equivalents excluded from the diluted net loss per common share calculations are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.177%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.985%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,688,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock with repurchase rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock subject to put right&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible promissory note&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,952,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;414,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-46" decimals="0" id="f-282" unitRef="shares">100459</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-47" decimals="0" id="f-283" unitRef="shares">89472</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-48" decimals="0" id="f-284" unitRef="shares">3688449</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-49" decimals="0" id="f-285" unitRef="shares">10067</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-50" decimals="0" id="f-286" unitRef="shares">164038</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-51" decimals="0" id="f-287" unitRef="shares">164038</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-52" decimals="0" id="f-288" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-53" decimals="0" id="f-289" unitRef="shares">7816</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-54" decimals="0" id="f-290" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-55" decimals="0" id="f-291" unitRef="shares">143544</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="0" id="f-292" unitRef="shares">3952946</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-7" decimals="0" id="f-293" unitRef="shares">414937</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-294">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considered the applicability and impact of all ASUs issued during the quarter ended June&#160;30, 2023 and each was determined to be either not applicable or expected to have minimal impact on these financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="c-1" id="f-295">MERGER WITH VALLON&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 21, 2023, pursuant to the Merger Agreement, Merger Sub was merged with and into Private GRI, with Private GRI surviving the Merger as a wholly owned subsidiary of the Company. In connection with the Closing, the Company amended its certificate of incorporation and bylaws to change its name from &#x201c;Vallon Pharmaceuticals, Inc.&#x201d; to &#x201c;GRI Bio, Inc.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the Effective Time:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"&gt;Each share of Private GRI&#x2019;s common stock outstanding immediately prior to the Effective Time, including any shares of Private GRI&#x2019;s common stock  issued pursuant to the Equity SPA automatically converted solely into the right to receive a number of shares of the Company&#x2019;s common stock equal to the Exchange Ratio.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Each option to purchase shares of Private GRI&#x2019;s common stock (each, a GRI Option) outstanding and unexercised immediately prior to the Effective Time under the GRI Bio, Inc. 2015 Equity Incentive Plan (the GRI Plan), whether or not vested, converted into and became an option to purchase shares of the Company&#x2019;s common stock, and the Company assumed the GRI Plan and each such GRI Option in accordance with the terms of the GRI Plan (the Assumed Options). The number of shares of he Company&#x2019;s common stock subject to each Assumed Option was determined by multiplying (i) the number of shares of Private GRI&#x2019;s common stock that were subject to such GRI Option, as in effect immediately prior to the Effective Time, by (ii) the Exchange Ratio, and rounding the resulting number down to the nearest whole number of shares of he Company&#x2019;s common stock. The per share exercise price for the he Company&#x2019;s common stock issuable upon exercise of each Assumed Option was determined by dividing (A) the per share exercise price of such Assumed Option, as in effect immediately prior to the Effective Time, by (B) the Exchange Ratio and rounding the resulting per share exercise price up to the nearest whole cent. Any restriction on the exercise of any Assumed Option continued in full force and effect and the term, exercisability, vesting schedule, and any other provisions of such Assumed Option otherwise remained unchanged.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"&gt;Each warrant to purchase shares of Private GRI&#x2019;s common stock outstanding immediately prior to the Effective Time other than the Bridge Warrants (as defined below) (the GRI Warrants), was assumed by the Company and converted into a warrant to purchase shares of the Company&#x2019;s common stock (the Assumed Warrants) and thereafter (i) each Assumed Warrant became exercisable solely for shares of the Company&#x2019;s common stock; (ii) the number of shares of the Company&#x2019;s common stock subject to each Assumed Warrant was determined by multiplying (A) the number of shares of Private GRI&#x2019;s common stock that were subject to such GRI Warrant, as in effect immediately prior to the Effective Time, by (B) the Exchange Ratio, and rounding the resulting number down to the nearest whole number of shares of the Company&#x2019;s common stock; (iii) the per share exercise price for shares of the Company&#x2019;s common stock issuable upon exercise of each Assumed Warrant was determined by dividing (A) the exercise price per share of Private GRI&#x2019;s common stock subject to such GRI Warrant, as in effect immediately prior to the Effective Time, by (B) the Exchange Ratio, and rounding the resulting exercise price up to the nearest whole cent. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;The Bridge Warrants (Note 8) were exchanged for warrants (the Exchange Warrants) to purchase an aggregate of 421,589 shares of the Company&#x2019;s common stock. The Exchange Warrants contain substantively similar terms to the Bridge Warrants, and have an initial exercise price equal to $14.73 per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(e)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"&gt;All rights with respect to Private GRI restricted stock awards were assumed by the Company and converted into Company restricted stock awards with the number of shares subject to each restricted stock award multiplied by the Exchange Ratio and rounding the resulting number down to the nearest whole number of shares of the Company&#x2019;s common stock. The term, exercisability, vesting schedule and other provisions of the Private GRI restricted stock awards otherwise remained unchanged.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Merger is accounted for as a reverse recapitalization under U.S. GAAP because the primary assets of Vallon were cash and cash equivalents. For accounting purposes, GRI has been determined to be the accounting acquirer based upon the terms of the Merger and other factors including: (i)  the equity holders of Private GRI immediately prior to the Merger owned, or held rights to acquire, in the aggregate approximately 85% of the outstanding shares of the Company&#x2019;s common stock and the Company&#x2019;s stockholders immediately prior to the Merger owned approximately 15% of the outstanding shares of the Company&#x2019;s common stock (ii) Private GRI holds the majority (4 out of 5) of board seats of the combined company, and (iii) Private GRI&#x2019;s management holds the majority of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;key positions in the management of the combined company. Immediately after the Merger, there were 2,956,354 shares of the Company&#x2019;s common stock outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the net liabilities assumed in the Merger:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:81.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.568%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;April 21, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,190)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,939)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plus: Transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,984)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net liabilities assumed plus transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,923)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;In addition to the transactions costs noted above, at the Effective Time, 30,542 shares of the Company&#x2019;s common stock were issued to Private GRI&#x2019;s financial advisor for services related to the Merger.</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-56"
      decimals="INF"
      id="f-296"
      unitRef="shares">421589</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-56"
      decimals="2"
      id="f-297"
      unitRef="usdPerShare">14.73</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ck0001824293:CommonStockOwnershipPercentage contextRef="c-57" decimals="2" id="f-298" unitRef="number">0.85</ck0001824293:CommonStockOwnershipPercentage>
    <ck0001824293:CommonStockOwnershipPercentage contextRef="c-58" decimals="2" id="f-299" unitRef="number">0.15</ck0001824293:CommonStockOwnershipPercentage>
    <us-gaap:CommonStockSharesIssued contextRef="c-3" decimals="INF" id="f-300" unitRef="shares">2956354</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-301" unitRef="shares">2956354</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock contextRef="c-1" id="f-302">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the net liabilities assumed in the Merger:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:81.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.568%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;April 21, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,190)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,939)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plus: Transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,984)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net liabilities assumed plus transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,923)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="c-59" decimals="-3" id="f-303" unitRef="usd">941000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets contextRef="c-59" decimals="-3" id="f-304" unitRef="usd">310000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <ck0001824293:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses contextRef="c-59" decimals="-3" id="f-305" unitRef="usd">4190000</ck0001824293:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="c-59" decimals="-3" id="f-306" unitRef="usd">-2939000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts contextRef="c-59" decimals="-3" id="f-307" unitRef="usd">2984000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <ck0001824293:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts contextRef="c-59" decimals="-3" id="f-308" unitRef="usd">-5923000</ck0001824293:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts>
    <ck0001824293:StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses
      contextRef="c-41"
      decimals="INF"
      id="f-309"
      unitRef="shares">30542</ck0001824293:StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-310">FAIR VALUE MEASUREMENTS&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies the guidance in ASC 820 to account for financial assets and liabilities measured on a recurring basis. Fair value is measured as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses a fair value hierarchy, which distinguishes between assumptions based on market data (observable inputs) and an entity's own assumptions (unobservable inputs). The guidance requires that fair value measurements be classified and disclosed in one of the following 3 categories:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:6pt;padding-left:63pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:6pt;padding-left:67.5pt;text-indent:-40.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liabilities; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:6pt;padding-left:63pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each reporting period. There were no transfers between Level 1, 2 and 3 during the six months ended June&#160;30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents, for each of the fair value hierarchy levels required under ASC 820, the Company&#x2019;s liabilities that are measured at fair value on a recurring basis at June&#160;30, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.594%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.098%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets (Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs (Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant Other Unobservable Inputs (Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes is the fair value of the Level 3 liability:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.984%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Warrant Liability &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.6pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(122)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value as of June&#160;30, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.6pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Black-Scholes valuation model was used to estimate the fair value of the warrants with the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.288%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.430%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167.1&#160;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139.9&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.68&#160;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.32&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c-1" id="f-311">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents, for each of the fair value hierarchy levels required under ASC 820, the Company&#x2019;s liabilities that are measured at fair value on a recurring basis at June&#160;30, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.594%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.098%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets (Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs (Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant Other Unobservable Inputs (Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="c-60" decimals="-3" id="f-312" unitRef="usd">0</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="c-61" decimals="-3" id="f-313" unitRef="usd">0</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="c-62" decimals="-3" id="f-314" unitRef="usd">63000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-60" decimals="-3" id="f-315" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-61" decimals="-3" id="f-316" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-62" decimals="-3" id="f-317" unitRef="usd">63000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="c-1" id="f-318">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes is the fair value of the Level 3 liability:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.984%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Warrant Liability &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.6pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(122)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value as of June&#160;30, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.6pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-63" decimals="-3" id="f-319" unitRef="usd">185000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-64" decimals="-3" id="f-320" unitRef="usd">-122000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-65" decimals="-3" id="f-321" unitRef="usd">63000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="c-1" id="f-322">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Black-Scholes valuation model was used to estimate the fair value of the warrants with the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.288%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.430%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167.1&#160;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139.9&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.68&#160;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.32&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Black-Scholes option-pricing model was used to estimate the fair value of the Equity Warrants, the Exchange Warrants and the Advisor Warrants with the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.012%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167.6&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.69&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.37&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-66" decimals="3" id="f-323" unitRef="number">1.671</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-67" decimals="3" id="f-324" unitRef="number">1.399</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-68" decimals="1" id="f-325" unitRef="number">2.5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-69" decimals="1" id="f-326" unitRef="number">2.5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c-70"
      decimals="INF"
      id="f-327"
      unitRef="number">0.000</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c-71"
      decimals="INF"
      id="f-328"
      unitRef="number">0.000</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-72" decimals="4" id="f-329" unitRef="number">0.0468</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-73" decimals="4" id="f-330" unitRef="number">0.0432</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c-1" id="f-331">PROPERTY AND EQUIPMENT&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.122%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.511%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.512%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense related to property and equipment was $2 and $1 for the six months ended June&#160;30, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-332">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.122%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.511%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.512%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-74" decimals="-3" id="f-333" unitRef="usd">21000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-75" decimals="-3" id="f-334" unitRef="usd">13000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-76" decimals="-3" id="f-335" unitRef="usd">12000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-77" decimals="-3" id="f-336" unitRef="usd">13000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-3" decimals="-3" id="f-337" unitRef="usd">33000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-4" decimals="-3" id="f-338" unitRef="usd">26000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-3" decimals="-3" id="f-339" unitRef="usd">24000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-340" unitRef="usd">22000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-3" id="f-341" unitRef="usd">9000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-342" unitRef="usd">4000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation contextRef="c-1" decimals="-3" id="f-343" unitRef="usd">2000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-7" decimals="-3" id="f-344" unitRef="usd">1000</us-gaap:Depreciation>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="c-1" id="f-345">ACCRUED EXPENSES&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.791%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll and related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;862&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-346">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.791%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll and related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;862&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <ck0001824293:AccruedResearchAndDevelopmentCostsCurrent contextRef="c-3" decimals="-3" id="f-347" unitRef="usd">143000</ck0001824293:AccruedResearchAndDevelopmentCostsCurrent>
    <ck0001824293:AccruedResearchAndDevelopmentCostsCurrent contextRef="c-4" decimals="-3" id="f-348" unitRef="usd">0</ck0001824293:AccruedResearchAndDevelopmentCostsCurrent>
    <ck0001824293:AccruedGeneralAndAdministrativeExpensesCurrent contextRef="c-3" decimals="-3" id="f-349" unitRef="usd">188000</ck0001824293:AccruedGeneralAndAdministrativeExpensesCurrent>
    <ck0001824293:AccruedGeneralAndAdministrativeExpensesCurrent contextRef="c-4" decimals="-3" id="f-350" unitRef="usd">0</ck0001824293:AccruedGeneralAndAdministrativeExpensesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-351" unitRef="usd">862000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-352" unitRef="usd">36000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-353" unitRef="usd">1193000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-354" unitRef="usd">36000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-355">PROMISSORY NOTES&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Bridge Financing&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with signing the Merger Agreement, Private GRI entered into a Securities Purchase Agreement, dated as of December 13, 2022 (Bridge SPA), with Altium Growth Fund, LP (the Investor), pursuant to which Private GRI issued senior secured promissory notes (Bridge Notes) in the aggregate principal amount of $3,333, in exchange for an aggregate purchase price of $2,500. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Bridge Notes were issued in two closings: (i) the first closing for $1,667 in aggregate principal amount (in exchange for an aggregate purchase price of $1,250) closed on December 14, 2022; and (ii) the second closing for $1,667 in aggregate principal amount (in exchange for an aggregate purchase price of $1,250) closed on March 9, 2023. The Bridge Notes were secured by a lien on all of the Company&#x2019;s assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, upon the funding of each tranche, the Investor received warrants to purchase an aggregate of 1,252,490 shares of the Company&#x2019;s common stock (the Bridge Warrants). The Bridge Warrants had an exercise price of $1.33 per share, were exercisable at any time on or after the applicable issuance date and had a term of 60 months from the date all shares underlying the Bridge Warrants were freely tradable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The $1,250 of proceeds from the first closing were allocated to the Bridge Notes and Bridge Warrants based on their relative fair values as of the commitment date, resulting in an allocation of $679 and $571, respectively. The $1,250 of proceeds from the second closing were allocated to the Bridge Notes and Bridge Warrants based on their relative fair values as of the commitment date, resulting in an allocation of $718 and $532, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the Bridge SPA, and also in connection with signing the Merger Agreement, Vallon, Private GRI and the Investor entered into the Equity SPA (Note 9) pursuant to which the Investor agreed to invest $12,250 in cash and cancel any outstanding principal and accrued interest on the Bridge Notes in return for the issuance of shares of Private GRI&#x2019;s common stock immediately prior to the consummation of the Merger. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 21, 2023, the Company completed the Merger and the outstanding principal and accrued interest on the Bridge Notes was cancelled and the Bridge Warrants were exchanged for the Exchange Warrants. The Exchange Warrants contain substantively similar terms to the Bridge Warrants, and have an initial exercise price equal to $14.73 per share subject to adjustments for splits and recapitalization events.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Bridge Notes were accounted for as share-settled debt under the accounting guidance in ASC 835-30 and, as such, the initial net carrying amounts were accreted to the redemption amounts using the effective interest method. The Company incurred debt issuance costs of $205 during the year ended December&#160;31, 2022 and $90 during the six months ended June&#160;30, 2023 related to its issuance of debt under the Bridge SPA. Unamortized debt discounts and debt issuance costs totaled $1,065 as of December&#160;31, 2022. Interest expense stemming from amortization of debt discounts and issuance costs was $1,161 and $2,104 for the three and six months ended June&#160;30, 2023, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;TEP Note&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2018, Private GRI and TEP Biotech, LLC (TEP) entered into a convertible note and warrant purchase agreement pursuant to which TEP agreed to fund up to $5,000 to Private GRI in exchange for a convertible promissory note (the TEP Note) and a warrant to purchase up to 25,245 shares of Private GRI&#x2019;s common stock at an exercise price of $0.27 per share. The TEP Note was secured by Private GRI&#x2019;s assets and accrued simple interest on the outstanding principal balance at a rate of 12% per annum. The total outstanding principal and accrued interest balance was initially due on the earlier of Private GRI&#x2019;s next financing, as defined, and May 2, 2020. The initial $2,500 tranche under the TEP Note was funded upon execution of the agreement in November 2018. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, Private GRI and TEP amended the TEP Note. In lieu of TEP funding the second $2,500 tranche, TEP made a first additional advance of $500 to Private GRI in exchange for a convertible promissory note, a warrant to purchase up to 17,269 shares of Private GRI&#x2019;s common stock at an exercise price of $0.27 per share, and the assignment of Private GRI&#x2019;s rights under a certain call option agreement. The call option agreement, which was entered into in 2015, provided Private GRI with the right to repurchase up to 39,720 shares of Private GRI&#x2019;s common stock held by the counterparty for $26.74 per share at any time before April 1, 2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2020, the TEP Note maturity date was extended to August 31, 2020, and in March 2021, TEP agreed to forbear on its available right to exercise remedies on account of Private GRI&#x2019;s failure to pay the past due principal and accrued interest balance until October 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, Private GRI and TEP amended the TEP Note, and TEP agreed to make a second additional advance of $500 to Private GRI in exchange for a convertible promissory note with separate, modified conversion options. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2022, Private GRI and TEP further amended the TEP Note, and TEP agreed to make a third additional advance of $125 to Private GRI in exchange for a convertible promissory note and a warrant to purchase up to 1,169 shares of Private GRI&#x2019;s common stock at an exercise price of $0.27 per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2022, Private GRI and TEP entered into a conversion agreement pursuant to which, effective upon the full execution of the Merger Agreement (Note 4), $3,500 of outstanding principal under the TEP Note together with $650 of related accrued interest was to &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;automatically convert into 155,210 shares of Private GRI&#x2019;s common stock at a conversion price of $26.74 per share. Further, upon the closing of the first tranche of the Bridge Notes, Private GRI was to repay, in cash, the $125 third additional advance under the TEP Note along with the $15 of related accrued interest. Upon issuance of the 155,210 conversion shares and payment of the $140 principal and accrued interest balance, Private GRI would fully satisfy all of its obligations under the TEP Note.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2022, upon the full execution of the Merger Agreement and the closing of the first tranche of the Bridge Notes Private GRI issued the 155,210 conversion shares and paid the $140 principal and accrued interest balance as per the terms of the conversion agreement. The share numbers and exercise or conversion prices in this section of Note 8 entitled &#x201c;TEP Note&#x201d; reflect the Exchange Ratio retroactively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the conversion, the $4,150 of converted principal and accrued interest, along with $863 of related forfeited accrued interest through the conversion date, were credited to stockholders&#x2019; deficit. Interest expense recognized on the TEP Note was $107 and $210 for the three and six months ended June&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-78" decimals="-3" id="f-356" unitRef="usd">3333000</us-gaap:DebtInstrumentFaceAmount>
    <ck0001824293:DebtInstrumentAggregatePurchasePrice contextRef="c-79" decimals="-3" id="f-357" unitRef="usd">2500000</ck0001824293:DebtInstrumentAggregatePurchasePrice>
    <ck0001824293:DebtInstrumentNumberOfClosings
      contextRef="c-80"
      decimals="INF"
      id="f-358"
      unitRef="number">2</ck0001824293:DebtInstrumentNumberOfClosings>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-81" decimals="-3" id="f-359" unitRef="usd">1667000</us-gaap:DebtInstrumentFaceAmount>
    <ck0001824293:DebtInstrumentAggregatePurchasePrice contextRef="c-82" decimals="-3" id="f-360" unitRef="usd">1250000</ck0001824293:DebtInstrumentAggregatePurchasePrice>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-83" decimals="-3" id="f-361" unitRef="usd">1667000</us-gaap:DebtInstrumentFaceAmount>
    <ck0001824293:DebtInstrumentAggregatePurchasePrice contextRef="c-84" decimals="-3" id="f-362" unitRef="usd">1250000</ck0001824293:DebtInstrumentAggregatePurchasePrice>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-85"
      decimals="INF"
      id="f-363"
      unitRef="shares">1252490</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-85"
      decimals="2"
      id="f-364"
      unitRef="usdPerShare">1.33</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-85" id="f-365">P60M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <ck0001824293:DebtInstrumentAggregatePurchasePrice contextRef="c-82" decimals="-3" id="f-366" unitRef="usd">1250000</ck0001824293:DebtInstrumentAggregatePurchasePrice>
    <us-gaap:ProceedsFromNotesPayable contextRef="c-82" decimals="-3" id="f-367" unitRef="usd">679000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable contextRef="c-86" decimals="-3" id="f-368" unitRef="usd">571000</us-gaap:ProceedsFromNotesPayable>
    <ck0001824293:DebtInstrumentAggregatePurchasePrice contextRef="c-84" decimals="-3" id="f-369" unitRef="usd">1250000</ck0001824293:DebtInstrumentAggregatePurchasePrice>
    <us-gaap:ProceedsFromNotesPayable contextRef="c-84" decimals="-3" id="f-370" unitRef="usd">718000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable contextRef="c-87" decimals="-3" id="f-371" unitRef="usd">532000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:InvestmentCompanyCommittedCapital contextRef="c-42" decimals="-3" id="f-372" unitRef="usd">12250000</us-gaap:InvestmentCompanyCommittedCapital>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-56"
      decimals="2"
      id="f-373"
      unitRef="usdPerShare">14.73</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DeferredFinanceCostsGross contextRef="c-88" decimals="-3" id="f-374" unitRef="usd">205000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DeferredFinanceCostsGross contextRef="c-89" decimals="-3" id="f-375" unitRef="usd">90000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet contextRef="c-4" decimals="-3" id="f-376" unitRef="usd">1065000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-5" decimals="-3" id="f-377" unitRef="usd">1161000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-1" decimals="-3" id="f-378" unitRef="usd">2104000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-90" decimals="INF" id="f-379" unitRef="usd">5000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-91"
      decimals="INF"
      id="f-380"
      unitRef="shares">25245</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-91"
      decimals="2"
      id="f-381"
      unitRef="usdPerShare">0.27</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-90"
      decimals="INF"
      id="f-382"
      unitRef="number">0.12</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromNotesPayable contextRef="c-92" decimals="-3" id="f-383" unitRef="usd">2500000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-93" decimals="INF" id="f-384" unitRef="usd">2500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromNotesPayable contextRef="c-94" decimals="-3" id="f-385" unitRef="usd">500000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-95"
      decimals="INF"
      id="f-386"
      unitRef="shares">17269</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-95"
      decimals="2"
      id="f-387"
      unitRef="usdPerShare">0.27</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-96"
      decimals="INF"
      id="f-388"
      unitRef="shares">39720</us-gaap:CommonStockSharesIssued>
    <ck0001824293:CallOptionPrice
      contextRef="c-96"
      decimals="2"
      id="f-389"
      unitRef="usdPerShare">26.74</ck0001824293:CallOptionPrice>
    <us-gaap:ProceedsFromNotesPayable contextRef="c-97" decimals="-3" id="f-390" unitRef="usd">500000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable contextRef="c-98" decimals="-3" id="f-391" unitRef="usd">125000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-99"
      decimals="INF"
      id="f-392"
      unitRef="shares">1169</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-99"
      decimals="2"
      id="f-393"
      unitRef="usdPerShare">0.27</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ck0001824293:DebtConversionConvertedInstrumentPrincipalAmountOfDebt contextRef="c-100" decimals="-3" id="f-394" unitRef="usd">3500000</ck0001824293:DebtConversionConvertedInstrumentPrincipalAmountOfDebt>
    <ck0001824293:DebtConversionConvertedInstrumentAmountOfInterest contextRef="c-100" decimals="-3" id="f-395" unitRef="usd">650000</ck0001824293:DebtConversionConvertedInstrumentAmountOfInterest>
    <ck0001824293:DebtInstrumentConvertibleSharesIssuedUponConversion
      contextRef="c-101"
      decimals="INF"
      id="f-396"
      unitRef="shares">155210</ck0001824293:DebtInstrumentConvertibleSharesIssuedUponConversion>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c-101"
      decimals="2"
      id="f-397"
      unitRef="usdPerShare">26.74</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-102" decimals="-3" id="f-398" unitRef="usd">125000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:InterestPayableCurrentAndNoncurrent contextRef="c-102" decimals="-3" id="f-399" unitRef="usd">15000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <ck0001824293:DebtInstrumentConvertibleSharesIssuedUponConversion
      contextRef="c-101"
      decimals="INF"
      id="f-400"
      unitRef="shares">155210</ck0001824293:DebtInstrumentConvertibleSharesIssuedUponConversion>
    <ck0001824293:LongTermDebtIncludingInterest contextRef="c-102" decimals="-3" id="f-401" unitRef="usd">140000</ck0001824293:LongTermDebtIncludingInterest>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="c-103"
      decimals="INF"
      id="f-402"
      unitRef="shares">155210</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:RepaymentsOfNotesPayable contextRef="c-104" decimals="-3" id="f-403" unitRef="usd">140000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c-104" decimals="-3" id="f-404" unitRef="usd">4150000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <ck0001824293:AccruedInterestForfeited contextRef="c-104" decimals="-3" id="f-405" unitRef="usd">863000</ck0001824293:AccruedInterestForfeited>
    <us-gaap:InterestExpenseBorrowings contextRef="c-105" decimals="-3" id="f-406" unitRef="usd">107000</us-gaap:InterestExpenseBorrowings>
    <us-gaap:InterestExpenseBorrowings contextRef="c-106" decimals="-3" id="f-407" unitRef="usd">210000</us-gaap:InterestExpenseBorrowings>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-408">STOCKHOLDERS&#x2019; EQUITY &lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with signing the Merger Agreement, Vallon, Private GRI and the Investor entered the Equity SPA pursuant to which the Investor agreed to invest $12,250 in cash and cancel any outstanding principal and accrued interest on the Bridge Notes in return for the issuance of shares of Private GRI&#x2019;s common stock immediately prior to the consummation of the Merger. Pursuant to the Equity SPA, immediately prior to the Closing, Private GRI issued 6,787,219 shares of Private GRI&#x2019;s common stock (the Initial Shares) to the Investor and 27,148,877 shares of Private GRI&#x2019;s common stock (the Additional Shares) into escrow with an escrow agent for net proceeds of $11,704, after deducting offering expenses of $546.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the closing, pursuant to the Merger, the Initial Shares converted into an aggregate of 253,842 shares of the Company&#x2019;s common stock and the Additional Shares converted into an aggregate of 1,015,368 shares of the Company&#x2019;s common stock. On May 8, 2023, in accordance with the terms of the Equity SPA, the Company and the Investor authorized the escrow agent to, subject to beneficial ownership limitations, disburse to the Investor all of the shares of the Company&#x2019;s common stock issued in exchange for the Additional Shares. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Redeemable Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2018, Private GRI entered into an agreement with a stockholder pursuant to which the stockholder had the right to require Private GRI to purchase all or a portion of 7,816 shares of Private GRI&#x2019;s common stock held by the stockholder for $15.88 per share (the Put Right). The Put Right was exercisable (i) for a period commencing thirty days prior to the day Private GRI completed an equity or debt financing and ending fifteen business days thereafter, or (ii) at any time following a breach of the agreement by Private GRI.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management assessed the Put Right and determined that (i) it was not freestanding and, therefore, was not required to be classified as a liability and (ii) it could be exercised by the stockholder at any time, which was not within Private GRI&#x2019;s control. Therefore, the common shares subject to the Put Right were classified in mezzanine equity. In December 2022, the stockholder exercised the Put Right and Private GRI redeemed the 7,816 shares of Private GRI&#x2019;s common stock for $124 ($15.88 per share). The redeemed shares were retired by Private GRI. The share numbers and exercise or conversion prices in this section of Note 9 entitled &#x201c;Redeemable Common Stock&#x201d; reflect the Exchange Ratio retroactively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Equity SPA, on May 8, 2023, the Company issued to the Investor (i) Series A-1 Warrants to purchase 1,269,210 shares of the Company&#x2019;s common stock at an exercise price of $13.51, (ii) Series A-2 Warrants to purchase 1,142,289 shares of the Company&#x2019;s common stock at an exercise price of $14.74 , and (iii) Series T Warrants to purchase (x) 814,467 shares of the Company&#x2019;s common stock at an exercise price of $12.28 and (y) upon exercise of the Series T Warrants, 814,467 additional Series &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A-1 Warrants and Series A-2 Warrants, each to purchase 814,467 shares of the Company&#x2019;s common stock at an exercise price of $13.51 and $14.74, respectively (collectively, the Equity Warrants). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Series A-1 Warrants have a term of 60 months from the date all shares underlying the Series A-1 Warrants are freely tradable. The A-2 warrants have a 2-year term and expire in June 2025. Series T Warrants have a term of 24 months from the date all shares underlying Series T Warrants are freely tradable. The Company may force the exercise of the Series T Warrants subject to the satisfaction of certain equity conditions. The Equity Warrants include certain contingent cashless exercise features and contain certain other rights with regard to asset distributions and fundamental transactions. The exercise price of the Series A-1 Warrants is subject to adjustment for certain dilutive issuances, and all of the Equity Warrants are subject to standard antidilution adjustments. All of the Equity Warrants were outstanding as of June&#160;30, 2023. The Equity Warrants were classified as equity and the allocated fair value of $5,675 is included in additional paid in capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Bridge SPA, upon the funding of each tranche of the Bridge Note, the Investor  received the Bridge Warrants. The Bridge Warrants had an exercise price of $1.33 per share, were exercisable at any time on or after the applicable issuance date and had a term of 60 months from the date all shares underlying the Bridge Warrants are freely tradable. Upon the completion of the Merger the Bridge Warrants were exchanged for the Exchange Warrants to purchase an aggregate of 421,589 shares of the Company&#x2019;s common stock. The Exchange Warrants contain substantively similar terms to the Bridge Warrants, and have an initial exercise price equal to $14.73 per share subject to adjustments for splits and recapitalization events. All of the Bridge Warrants were outstanding as of June&#160;30, 2023. The Bridge Warrants were classified as equity and the allocated fair value of $2,860 is included in additional paid in capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Closing, Private GRI granted its financial advisor warrants (the Advisor Warrants) to purchase shares of Private GRI&#x2019;s common stock, which, at the Effective Time, became exercisable for an aggregate of 2,402 shares of the Company&#x2019;s common stock at an exercise price of $61.39 per share. The Advisor Warrants have a five-year term. All of the Advisor Warrants were outstanding as of June 30, 2023. The Advisor Warrants were classified as equity and the fair value of $18 is included in additional paid in capital. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Black-Scholes option-pricing model was used to estimate the fair value of the Equity Warrants, the Exchange Warrants and the Advisor Warrants with the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.012%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167.6&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.69&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.37&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2023, the Company had the following warrants outstanding to purchase common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Exercise Price per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Expiration Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,629&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$34.76&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;November 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,438&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$34.76&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;December 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,142,289&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$14.74&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,758&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$300.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,667&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$28.15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;May 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,168&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$0.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,402&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$61.39&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;421,590&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$14.73&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60 months after registration date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,269,210&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$13.51&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60 months after registration date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;814,467&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$12.28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24 months after registration date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:InvestmentCompanyCommittedCapital contextRef="c-42" decimals="-3" id="f-409" unitRef="usd">12250000</us-gaap:InvestmentCompanyCommittedCapital>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-43"
      decimals="INF"
      id="f-410"
      unitRef="shares">6787219</us-gaap:CommonStockSharesIssued>
    <ck0001824293:CommonStockHeldIntoEscrowAccount
      contextRef="c-44"
      decimals="INF"
      id="f-411"
      unitRef="shares">27148877</ck0001824293:CommonStockHeldIntoEscrowAccount>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-41" decimals="-3" id="f-412" unitRef="usd">11704000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ck0001824293:StockIssuanceCostsOfferingExpenses contextRef="c-41" decimals="-3" id="f-413" unitRef="usd">546000</ck0001824293:StockIssuanceCostsOfferingExpenses>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c-45"
      decimals="INF"
      id="f-414"
      unitRef="shares">253842</us-gaap:ConversionOfStockSharesConverted1>
    <ck0001824293:ConversionOfStockAdditionalSharesConverted
      contextRef="c-45"
      decimals="INF"
      id="f-415"
      unitRef="shares">1015368</ck0001824293:ConversionOfStockAdditionalSharesConverted>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-107"
      decimals="INF"
      id="f-416"
      unitRef="shares">7816</us-gaap:CommonStockSharesIssued>
    <ck0001824293:PutOptionSharePrice
      contextRef="c-107"
      decimals="2"
      id="f-417"
      unitRef="usdPerShare">15.88</ck0001824293:PutOptionSharePrice>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="c-103"
      decimals="INF"
      id="f-418"
      unitRef="shares">7816</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue contextRef="c-103" decimals="-3" id="f-419" unitRef="usd">124000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="c-103"
      decimals="2"
      id="f-420"
      unitRef="usdPerShare">15.88</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-108"
      decimals="INF"
      id="f-421"
      unitRef="shares">1269210</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-108"
      decimals="2"
      id="f-422"
      unitRef="usdPerShare">13.51</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-109"
      decimals="INF"
      id="f-423"
      unitRef="shares">1142289</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-109"
      decimals="2"
      id="f-424"
      unitRef="usdPerShare">14.74</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-110"
      decimals="INF"
      id="f-425"
      unitRef="shares">814467</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-110"
      decimals="2"
      id="f-426"
      unitRef="usdPerShare">12.28</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-111"
      decimals="INF"
      id="f-427"
      unitRef="shares">814467</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-112"
      decimals="INF"
      id="f-428"
      unitRef="shares">814467</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-111"
      decimals="INF"
      id="f-429"
      unitRef="shares">814467</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-112"
      decimals="INF"
      id="f-430"
      unitRef="shares">814467</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-111"
      decimals="2"
      id="f-431"
      unitRef="usdPerShare">13.51</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-112"
      decimals="2"
      id="f-432"
      unitRef="usdPerShare">14.74</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-108" id="f-433">P60M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-109" id="f-434">P2Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-110" id="f-435">P24M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="c-113" decimals="-3" id="f-436" unitRef="usd">5675000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-114"
      decimals="2"
      id="f-437"
      unitRef="usdPerShare">1.33</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-114" id="f-438">P60M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-114"
      decimals="INF"
      id="f-439"
      unitRef="shares">421589</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-115"
      decimals="2"
      id="f-440"
      unitRef="usdPerShare">14.73</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="c-116" decimals="-3" id="f-441" unitRef="usd">2860000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-117"
      decimals="INF"
      id="f-442"
      unitRef="shares">2402</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-117"
      decimals="2"
      id="f-443"
      unitRef="usdPerShare">61.39</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-118" id="f-444">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="c-119" decimals="-3" id="f-445" unitRef="usd">18000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-120" decimals="3" id="f-446" unitRef="number">1.676</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-121" decimals="2" id="f-447" unitRef="number">1.69</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-122" decimals="2" id="f-448" unitRef="number">0.000</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-123" decimals="5" id="f-449" unitRef="number">0.0437</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="c-1" id="f-450">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2023, the Company had the following warrants outstanding to purchase common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Exercise Price per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Expiration Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,629&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$34.76&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;November 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,438&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$34.76&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;December 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,142,289&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$14.74&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,758&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$300.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,667&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$28.15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;May 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,168&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$0.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,402&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$61.39&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;421,590&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$14.73&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60 months after registration date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,269,210&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$13.51&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60 months after registration date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;814,467&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$12.28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24 months after registration date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-124"
      decimals="INF"
      id="f-451"
      unitRef="shares">8629</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-124"
      decimals="2"
      id="f-452"
      unitRef="usdPerShare">34.76</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-125"
      decimals="INF"
      id="f-453"
      unitRef="shares">1438</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-125"
      decimals="2"
      id="f-454"
      unitRef="usdPerShare">34.76</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-126"
      decimals="INF"
      id="f-455"
      unitRef="shares">1142289</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-126"
      decimals="2"
      id="f-456"
      unitRef="usdPerShare">14.74</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-127"
      decimals="INF"
      id="f-457"
      unitRef="shares">3758</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-127"
      decimals="2"
      id="f-458"
      unitRef="usdPerShare">300.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-128"
      decimals="INF"
      id="f-459"
      unitRef="shares">24667</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-128"
      decimals="2"
      id="f-460"
      unitRef="usdPerShare">28.15</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-129"
      decimals="INF"
      id="f-461"
      unitRef="shares">1168</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-129"
      decimals="2"
      id="f-462"
      unitRef="usdPerShare">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-130"
      decimals="INF"
      id="f-463"
      unitRef="shares">2402</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-130"
      decimals="2"
      id="f-464"
      unitRef="usdPerShare">61.39</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-131"
      decimals="INF"
      id="f-465"
      unitRef="shares">421590</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-131"
      decimals="2"
      id="f-466"
      unitRef="usdPerShare">14.73</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ck0001824293:ClassOfWarrantOrRightExpirationPeriod contextRef="c-132" id="f-467">P60M</ck0001824293:ClassOfWarrantOrRightExpirationPeriod>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-133"
      decimals="INF"
      id="f-468"
      unitRef="shares">1269210</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-133"
      decimals="2"
      id="f-469"
      unitRef="usdPerShare">13.51</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ck0001824293:ClassOfWarrantOrRightExpirationPeriod contextRef="c-134" id="f-470">P60M</ck0001824293:ClassOfWarrantOrRightExpirationPeriod>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-135"
      decimals="INF"
      id="f-471"
      unitRef="shares">814467</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-135"
      decimals="2"
      id="f-472"
      unitRef="usdPerShare">12.28</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ck0001824293:ClassOfWarrantOrRightExpirationPeriod contextRef="c-136" id="f-473">P24M</ck0001824293:ClassOfWarrantOrRightExpirationPeriod>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-474">STOCK-BASED COMPENSATION&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2015 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Private GRI adopted the GRI Bio, Inc. 2015 Equity Incentive Plan, as amended (the Private GRI Plan), that provided Private GRI with the ability to grant stock options, restricted stock awards and other equity-based awards to employees, directors, and consultants. Stock options granted under the Private GRI Plan generally had a contractual life of up to 10 years. Upon completion of the Merger, the Company assumed the Private GRI Plan and the outstanding and unexercised options issued thereunder, and ceased granting awards under the Private GRI Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Amended and Restated 2018 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 21, 2023, the stockholders of the Company approved the Amended and Restated GRI Bio, Inc. 2018 Equity Incentive Plan, formerly the Vallon Pharmaceuticals, Inc. 2018 Equity Incentive Plan (the A&amp;amp;R 2018 Plan). The A&amp;amp;R 2018 Plan had previously been approved by the Company&#x2019;s board of directors, subject to stockholder approval. The A&amp;amp;R 2018 Plan became effective on April 21, 2023, with the stockholders approving the amendment to the A&amp;amp;R 2018 Plan to, among other things, (i) to increase the aggregate number of shares by &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;168,905 shares to 216,666 shares of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the Company&#x2019;s common stock &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for issuance as awards under the A&amp;amp;R 2018 Plan, (ii) to extend the term of the A&amp;amp;R 2018 Plan through January 1, 2033, (iii) to prohibit any action that would be treated as a &#x201c;repricing&#x201d; of an award without further approval by the stockholders of Company, and (iv) to revise the limits on awards to non-employee directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The A&amp;amp;R 2018 Plan provides the Company with the ability to grant stock options, restricted stock and other equity-based awards to employees, directors and consultants. Stock options granted by Vallon generally have a contractual life of up to 10 years. As of June&#160;30, 2023, 100,459 shares of the Company's common stock were authorized to be issued under the A&amp;amp;R 2018 Plan, and 116,207 shares were reserved for future awards under the A&amp;amp;R 2018 Plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation related to stock options issued under the A&amp;amp;R 2018 Plan in the following expense categories of its accompanying statements of operations for the three and six months ended June&#160;30, 2023 and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.261%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.261%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.261%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.264%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures equity-based awards granted to employees, and non-employees based on their fair value on the date of the grant and recognizes compensation expense for those awards over the requisite service period or performance-based period, which is generally the vesting period of the respective award. The measurement date for service-based equity awards is the date of grant, and equity-based compensation costs are recognized as expense over the requisite service period, which is the vesting period for certain &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;performance-based awards. The Company records expense for performance-based awards if it concludes that it is probable that the performance condition will be achieved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below represents the activity of stock options granted to employees and non-employees for the six months ended June&#160;30, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.625%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted average remaining contractual term&#160;(years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,612&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.71&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited/Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,153)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130.84&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,459&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.75&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.73&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,459&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.75&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.73&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Black-Scholes option-pricing model was used to estimate the grant date fair value of each stock option grant at the time of grant using the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.98&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of option on grant date&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No options were granted during the six months ended June&#160;30, 2023. &lt;/span&gt;&lt;/div&gt;As of June&#160;30, 2023, the unrecognized compensation cost related to unvested stock options expected to vest was $280. This unrecognized compensation is expected to be recognized over a weighted-average amortization period of 3.35 years.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-137" id="f-475">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-138"
      decimals="INF"
      id="f-476"
      unitRef="shares">168905</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-139"
      decimals="INF"
      id="f-477"
      unitRef="shares">216666</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-140" id="f-478">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-141"
      decimals="INF"
      id="f-479"
      unitRef="shares">100459</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-142"
      decimals="INF"
      id="f-480"
      unitRef="shares">116207</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-481">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation related to stock options issued under the A&amp;amp;R 2018 Plan in the following expense categories of its accompanying statements of operations for the three and six months ended June&#160;30, 2023 and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.261%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.261%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.261%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.264%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-143" decimals="-3" id="f-482" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-144" decimals="-3" id="f-483" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-145" decimals="-3" id="f-484" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-146" decimals="-3" id="f-485" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-147" decimals="-3" id="f-486" unitRef="usd">13000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-148" decimals="-3" id="f-487" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-149" decimals="-3" id="f-488" unitRef="usd">26000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-150" decimals="-3" id="f-489" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-5" decimals="-3" id="f-490" unitRef="usd">13000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-6" decimals="-3" id="f-491" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-492" unitRef="usd">26000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-7" decimals="-3" id="f-493" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-494">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below represents the activity of stock options granted to employees and non-employees for the six months ended June&#160;30, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.625%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted average remaining contractual term&#160;(years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,612&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.71&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited/Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,153)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130.84&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,459&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.75&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.73&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,459&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.75&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.73&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-4" decimals="INF" id="f-495" unitRef="shares">112612</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-496"
      unitRef="usdPerShare">39.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-151" id="f-497">P4Y8M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="INF" id="f-498" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-499"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-1" decimals="INF" id="f-500" unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-501"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c-1" decimals="INF" id="f-502" unitRef="shares">12153</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-503"
      unitRef="usdPerShare">130.84</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-3" decimals="INF" id="f-504" unitRef="shares">100459</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-3"
      decimals="2"
      id="f-505"
      unitRef="usdPerShare">28.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-506">P4Y8M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c-3" decimals="INF" id="f-507" unitRef="shares">100459</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-3"
      decimals="2"
      id="f-508"
      unitRef="usdPerShare">28.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-509">P4Y8M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-510">&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Black-Scholes option-pricing model was used to estimate the grant date fair value of each stock option grant at the time of grant using the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.98&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of option on grant date&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-152" decimals="4" id="f-511" unitRef="number">0.9039</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-152" id="f-512">P5Y11M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-152" decimals="4" id="f-513" unitRef="number">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-152" decimals="4" id="f-514" unitRef="number">0.0200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharePrice
      contextRef="c-153"
      decimals="2"
      id="f-515"
      unitRef="usdPerShare">3.86</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="INF" id="f-516" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-3" decimals="-3" id="f-517" unitRef="usd">280000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-154" id="f-518">P3Y4M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-519">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Employment Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into employment contracts with its officers that provide for severance and continuation of benefits in the event of termination of employment by the Company without cause or by the employee for good reason. In addition, in the event of termination of employment following a change in control, the vesting of certain equity awards may be accelerated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Separation and Release Agreement&lt;/span&gt;&lt;/div&gt;In connection with the resignation of David Baker, the Company&#x2019;s Former Chief Executive Officer, pursuant to the Merger, the Company and Mr. Baker entered into a Separation and Release Agreement on April 21, 2023 (the Separation Agreement). Pursuant to the terms of the Separation Agreement and his employment agreement, Mr. Baker will receive continuation of his current salary and certain COBRA benefits for 18 months payable in accordance with the Company&#x2019;s payroll practices. Mr. Baker also received a lump sum payment equal to 150% of his target bonus and agreed to reduce amounts payable with respect to certain future milestone payments.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <ck0001824293:COBRABenefitsPaymentPeriod contextRef="c-155" id="f-520">P18M</ck0001824293:COBRABenefitsPaymentPeriod>
    <ck0001824293:PercentageOfTargetBonus
      contextRef="c-155"
      decimals="INF"
      id="f-521"
      unitRef="number">1.50</ck0001824293:PercentageOfTargetBonus>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>62
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
M.7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7<LW(QU2ODRG8
M.9_ [/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD6R4)RU3393>*
M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W<DOJMI2^M28X
M2O2QS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-MNIW<.CB>F)&Y
M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_#
M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0
MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR
ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC
MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYN<KGHB=OJ7
M=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(CE1P&%A<RY%#N
MDI &$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>TB42%(JP# 4A
M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF
M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y,M\Y<-LZW@->
MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_
M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]!
MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MAZ7-C19E?=YX*[06>7VY910^(&, [S<"Q'QW8XXPVR/K]7]02P,$%     @
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M-,U%9YH'P[AKC0'F##S-&P,L&&C3W,QVR1OWZ(W[P]XD65ZI/?65[KC7N6.
MF=PQP$SN&-DNN7/<0^+>C='T:WTXH\DMV4+-AXIX,$:IAY-%)86$Q1X6O],,
M:MZ:S?'T9=C'PV$4=.W1@5& ?=Q=(PPX/'1P%/I=A[Y+>.[1<7>'^[=W_\6C
MTTSJ<\F_UB4=:'9)QUUPZ;N$C4OVR3&UH'Q=?Q\0(+TJ97-&:9^VWR#>UR?O
MSO,[/)IAP_.Y^F91'XN/],T'CT^$KS,XR.9T!4U!DD-G>?,-H;F1;%,?DI^8
MA"-W?9E2DE"N /!^Q9@\W*@&VB\YTW\!4$L#!!0    ( !5!#E=!E$85Z@D
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M_;$/F@MSBLF@8JH62P*,[ 1HM;CD#X* N/B[.CQ.+?U?N\X6E]5FS<VKP5,
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M$G%.YQ(%2??-E>1"VDZMMC0;A7GVH>3Q1N>2*OP%UY&2>U--R/>2%KKS\[K
MY=%&<:@-.YMK(TNVT2MLVTPKZ@F8%ZS+H2[8LWD66IZ%PV!"?::YZJS.2"@8
MY.NW)M2EM)U:;6D:!JE/+1FVNI\48,U9!DA6I&Q/_(&I-9V4TGF[/GF$T+@C
M-)8_89@_'Q5][G5RZ[3';T#L(<5H/FY#=J6ZDLDR)PPSYP-G,2%)#?+8M2OX
MJCO.5"\G=,.LIX6*:C]6:S.=>.M#"GJ-<2DT@M!I!#QB7=98HH5AHNVV9L5I
MHKH\58HR]9CQ/<B9]/8)T$/$'O2N5!=Z2\,P3,.GZ ^=/GDA/*;^E0ET239J
MK_X\,EU(+0W#, V;707;).BFL,RJZJE6\GF]";BC<J/6]EO"%0^HM2PNJ,1I
MO6[TFN,CZCEJ$[5'K,LBR](PO*1]L/.V"W'W4A:ZRU2%>]9>S'K$NG!;GH6O
M\*S%G9 U43UZ<IBRKZ[ H8=MQU&[Y?1(=:&V? O#?'N">B7/P>HAV\B=E6?3
M+;)TB\++6M,;J+JQI8GR[6IOB]\K_0%R5ZN3N>->CU07#R%+EBA,EGI^TCSF
MIIM_GY#JZH.9G]H<W8B9"]V-;7&J-^*\)K@D.9HZ5.J1ZL\ZMIB0Y5(4YM)E
M%U" )5B19YKG.@:ZOR2<LL2+WV7,=C'QB73E3&.;.<RJ0>Q$KZF#J#TKU>G<
M >Y*=2P$D>5/- JVED]E4:3FC &G9D-/\7W)#8'F+.\;:WSI[]]##W+UFS?1
M+Z3MU#.6FU&8F^\;O4157]>, ][L]\YO,9!+R4C]:P?X;.)&EKA1F+@?2<R>
M<^K=N#4)BY/$O%7QUSM!?:JC;EC0&-QLJ>H&1?A87V[(B6S+*?YBX]+Z&+6[
M&8]0EU,L]Z,P]_MC6_R?C@"Y5!_-INV&WB/598QM"%"X(;CW1:AES[D- G*I
M/VJO<,-P_/,2A*:D;2)0N(GX0OBSWIC4Z#7;I652M:#XC-W 6G?S6&OJY)HK
MTP[/H'&VFVD\^LA; //]ZI3T^/1XK'YK#I-;S^^BJV5U.&[55&?U7S!77"=
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MM '?5P:IUKZ0@OZGGHM_ 5!+ P04    "  500Y7EZ.39?$/  !J+   &
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MIT2*;)IPD3T)N0 XDS$&<:E UH-"NBMN]A@9J ]>[(Z@HO=-D> =[4>5+>B
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M;_F-P:=>K252*616Z4P8F)^WIH.3RS'-YPF?%:QLX[<@3V9:?Z6'Z^B\U2=
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M8&X2]TAW)Z(M.^)*AK&PJ)LQ-@)'LH-WI^B&3E.TCP01?A7(MM8A=HJG2E/
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M-:+LNW>NL;-6S%Q^FQGKE2V)RHE$>691L-X]E[YX1"=;EY7B_;[N%&_$\7B
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M;BT-^==-"WHP4=D .L^E-(>%3= ]P<D?4$L#!!0    ( !5!#E<4B<[A@@H
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M+* N_5P(Z.TU;H#W,P6*^@=DT'[DO_HO4$L#!!0    ( !5!#E<&$U561@H
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M:F$?U.X;'NJY<GR)$L;_PJ[QO8H#2&IC57D 4P8EE\T_>S[TX01P$[T!B ^
MV.?=!/)9WC++1@.M=J"=-[&YA2_5HRDY+MVEK*PF*R><'4WO%HOY>C%;KE<P
M7M["]&ZYGB^_SI;3^6PU""V%<(YA<J";-'3Q&W37L%#2%@9F,L7T7WQ(J;7Y
MQ<?\)O%9PN^U[$ WNH XBKMG^+IMO5W/UWVK7E66W-)460-,IC"E=+G,428<
M#=QRDPAE:HWP>[PQ5M/0_'FM"TV0WNM!W$/JFXHE. SHI1C46PQ&'S]<7D>?
MSY30:TOHG6-__Y7]!QW,RDJHO>L7C'.-V'1N72!UKJR8W$/!#- A:DR!2ZL
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MRI)L^65!WPG4SH'LF5+VN'$!VB_/Z"]02P,$%     @ %4$.5P]#2QJ>#@
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M:R!!QAUE5;]>&^L'5_)F$GK-B%Z[]4X9$C^1DVEN!14X#S@];*:J@]TT[+0
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MAH, OC"EF&72=?O#H1N&(XIP_?X -DB'S1/+I>9]XB8E/RI*E:3D!Z#LPR?
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MM@7\L+!O#BJWP,YOI#0O@>N#]A5+_@)02P,$%     @ %4$.5V'PZHYR!0
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M[J P"7I_P[DZ!*87^I?,_P-02P,$%     @ %4$.5XBN["T_!   OQ0  !D
M  !X;"]W;W)K<VAE971S+W-H965T,CDN>&ULS5A=;^(X%/TK5E8:S4B[S2<!
MNH $E,YFU5)$VAFM5OM@$@/>)G'&=J#S[]=.TH1 R"QJ1NH+)([OX=QS3ZS+
M'>P)?69;A#AX"8.(#94MY_&UJC)OBT+(KDB,(O%D36@(N;BE&Y7%%$$_#0H#
MU= T6PTACI31(%U;T-& )#S $5I0P)(PA/3[! 5D/U1TY75AB3=;+A?4T2"&
M&^0B_A0OJ+A3"Q0?ARABF$2 HO50&>O74[TO ](=7S#:LX-K(%-9$?(L;QQ_
MJ&B2$0J0QR4$%%\[-$5!()$$CV\YJ%+\I@P\O'Y%OTV3%\FL($-3$GS%/M\.
ME9X"?+2&2<"79/\'RA/J2#R/!"S]!/M\KZ8 +V&<A'FP8!#B*/N&+[D0!P$"
MIS[ R .,XP#K3("9!YAIHAFS-*T;R.%H0,D>4+E;H,F+5)LT6F2#(UE&EU/Q
M%(LX/IJ,7<<%#[=@L9RYL_GC^-%YF(/Q_ :X3_?WX^5?\IGK?)X[M\YT/'\$
MX^GTX6G^Z,P_@\7#G3-U9B[X#;C"7GX2($#6X 8'"4<^F L3WA'&P )1,"5A
M**KF;B%%X.,-XA '[).(9'*%#50NDI&45"\G/LF(&V>(V^">1'S+P"SRD5^-
M5X4(A1+&JQ(3HQ'PSR2Z J;V*S TPZSA,_W_X48#';,HC)GBF6?PQA''OE12
MN!RXR$LHYAB)=%^\(!$9@S4EH90U3CA,WP@A_0S2"$>;3/),Z[_O!#!P. K9
M/W4J9RRL>A;R$+EF,?304!&G!$-TAY31AU]T6_N]3J*6P"J"685@5A-Z53!6
M"O811R!A/HB%)*G9/M7)D&%W4FQY].U&9K]C]"U[H.X.,SS=9^E6W^P6VRK<
M.P7W3B-WEQ/O&9!8UK'V76@,O[1*+8%5,K6+3.UW86N[3<%: JL(UBT$Z_Y$
M6W=/[*IKFM7I'[GZ=%NO;W6->E/W"N:]1N9?(:4PXK5^;HR\M#PM@562[!=)
M]M^%G_MM"M826$4P72L[#NTG.CH'KYS4=J]G6<>>KMDHO&^?.:GU@X9);Z2_
M1(Q3[,D.AZ7']A[SK>AHXX1Z6]%0 BH[Q_J.IA'YTBJVA5;5P2AU,-Z%\W,:
M;8G6$EI5M+*ITQM;H+=ZWSRUM&UI9N_8^C_<5Z5?MEAZ<X^5]2DL6?TK_H4!
M3H"H;>;W6KJ-8!=7KB6T:NIEAZ9WWH?=6VWUVD*KBE8V>WIC:_16N]LG-M:.
MG7ZZI=O3[3,^+WLNO;GIFI)HARC'*_&/-A9UQ8P1^AU$A*-:HHUH%]>L);1J
M[F77IO?>A]%;[0';0JN*5G:!>F//]%:C]W]L]-,MNF5V+.O(ZNK!*"A$=)-.
MR!CP2!+Q;!92K!93N'$Z>SI:G\CI7#IB*F&RT=X]I!L<,1"@M8#4KKJ"%,VF
M9=D-)W$Z<%H1SDF87FX1]!&5&\3S-1'O47XC?Z"868[^ U!+ P04    "  5
M00Y7*UU%ML,$  !K)   &0   'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6R]
MFEEOXS841O\*H19%!IA:BR4OJ6T@L;84F4R06?)0](&1Z9B(MB%I.^VO+RG)
MBN4HBHW>]B5:S.]<*3J@2$*3;<:>^(H0@9Z3..53;25$?J[K/%J1!/->EI-4
M_K+,6(*%/&2/.L\9P8LBE,2Z91@#/<$TU6:3XMPMFTVRM8AI2FX9XNLDP>RO
M2Q)GVZEF:KL3=_1Q)=0)?3;)\2/Y0L2W_);)([VF+&A"4DZS%#&RG&H7YGEH
MVBI0M/A.R9;O[2-U*P]9]J0.KA93S5!71&(2"87 <K,A<Q+'BB2OXT<%U>J:
M*KB_OZ/[Q<W+FWG G,RS^)XNQ&JJC32T($N\CL5=M@U)=4..XD59S(N_:%NV
M'3H:BM9<9$D5EE>0T+3<XN?J'[$7D#?:'K"J@'5LH%\%^L<&["I@'QMPJH!S
M;&!0!0;'!H958'AL8%0%1L73+1]'\2Q=+/!LPK(M8JJUI*F=0H@B+1\A396[
M7P23OU*9$[-/WEW@W:'[JZ\A^GYQ??WY!OV*;C!C6#F%SEPB,(WY!WGV9Z0C
MOL*,\(DN9&D%T*.JS&59QGJCS$7.>L@R/R++L/HM\7EW_/=UVD-]X\VX>TSU
MM^->=]PED:Q>7KS5$O??N_BX,QX<7=T<M\3#[OA-MMG]Z\Q1,ZY+5VIAK%H8
MJ^#UW^!=KKD\PSFZB'ZL*:=%#_3'M3R'K@1)^)]M<I1(NQVINN=SGN.(3#79
M_W+"-D2;_?*3.3!^:U,%$N9"PCQ(F \)"R!A(1"LH5^_UJ_?19]]WJ:$\17-
M44Y81%(A7["(IBC*DD2**/O+Z F=88[PKL&'-B$[BYPJ)"3,+6&F4=#4R&,S
M,WJF,]$W^Z9!EO0A80$D+ 2"-4RS:]/L3M/F>T9]K%Y\B'*^)@MT)HTKS[3:
MU0D^U:X2YNSY8(V=0=^QFTJXD$6]UT7'X_'0'C5K^I U TA8" 1KF./4YCB=
MYEQ)27 :$90MF_V2G&K(\?Y&=F!$;B.<4X%C^C<NWJ'D6<Y'N'3L';F<5X^F
M;SBVU7PR\\XK/+5/@H1YD# ?$A9 PD(@6$/ 02W@H%/ 6T8W6! 4W%VU&=09
M/K5[@H2YD# /$N9#P@)(6 @$:X@VK$4;PD\&AI#Z0<)<2)@'"?,A80$D+ 2"
M-?0;U?J-.ONY>[5.D0J.'M7F_7%9)^U4\R!A+B3,@X3YHU?##=,<C)NCC:"E
MT= Z;!6^;F4YEOTRM6DX,*X=&!_C@!P^R>D>E0.KG%$Y]%(FK/E"30)+(UJ%
MZ$2?*@0DS(6$>9 POX2-&O-3:W@@Q#&-PG<:-70PC9<%3>/_6"'HKG*J&Z T
MMZ(=+!*,#A<)0(OZH+0 E!9"T9K*[:VAFYW*><_1"J=2L]T+J56H3L;)0D'2
M7%":!TKS06D!*"V$HC6]>UF*-_^#M7@3=#$>E.:"TCQ0F@]*"T!I(12MZ>'+
MFKS9O2A_ZCB\PNV/!&W+=$8' \9Y=]F3Y8*D>: T'Y06@-)"*%I3KI=E>+-[
M'?Y?#? K]OX8T[1[P_ZA:)!KSRXHS0.E^:"T )060M%*T?2]CR+49SB?,'ND
M*4<Q64J\T5/?K;#RRY;R0&1Y\9W$0R9$EA2[*X(7A*D&\O=EEHG=@?KTHOZ^
M:/8/4$L#!!0    ( !5!#E>T-<X:W (  !<'   9    >&PO=V]R:W-H965T
M<R]S:&5E=#,Q+GAM;)V5VV[:0!"&7V7D1E4B-3&8,P5+Y- $B:0(:')1]6*Q
M![S*VNOLKB%Y^\[:Q**-055O8$_S_]_L83S82O6L(T0#K[%(]-")C$G[KJN#
M"&.F+V2*"<VLI(J9H:Y:NSI5R,(\*!:N5ZNUW9CQQ/$'^=A4^0.9&<$3G"K0
M61PS]7:)0FZ'3MUY'YCQ=63L@.L/4K;&.9H?Z511SRU50AYCHKE,0.%JZ(SJ
M_<NN79\O>.2XU7MML)DLI7RVG7$X=&H6" 4&QBHP^MO@%0IAA0CC9:?IE)8V
M<+_]KOXMSYUR63*-5U(\\=!$0Z?K0(@KE@DSD]L[W.73LGJ!%#K_A>UN;<V!
M(--&QKM@(HAY4ORSU]T^[ 5XWH$ ;Q?@Y=R%44YYS0SS!TIN0=G5I&8;>:IY
M-,'QQ![*W"B:Y11G_/N;V>W-#)[&BSMX'$TFWQ_@'.9T]&$F$.0*3(3P0)=C
MPMF2"VXX:AAI.D,,@2?Y]#VJ-2HXO4;#N-!GI#!5?,,,PNUL#"=VW2*2F69)
MJ >N(6QK[@8[Q,L"T3N .$K5!7CU+^#5O ;\F%_#Z<G9GS(N95VF[I6I>[EN
MXX#N9:9I1%,ZP4O&-<]OR<\)C<'88*Q_5:$6DLUJ2?N"^CIE 0X=>B(:U08=
M__.G>KOV]0APHP1N'%/WKYB.@/80 MM @MXP@8FIW--"JIU+V9>Y\7O-^L#=
M5/@W2__F4?^IPI3Q,$>0=/ *F-98;5\HM?;L&_5:M7VKM&\=M1\%@<PH6TC9
M&UO2[;0<+ A41E<17ZE,::QD:7U@.6_6>P=HVB5-^RC-0AHF(*&7(?9>!BM>
M1A5%^R.%UVOTJBDZ)47G^)&(3/=AH5BB65'F JFK3Z13Y=]M5OMW2__N_^\"
MI$0'YE_@NA]NZWFKYS7^@G/WZIS]9-PSM>:)!H$KBJM=="@[593AHF-DFI>^
MI3142/-F1%\N5'8!S:^D-.\=6TW+;Z'_&U!+ P04    "  500Y7>$/$Y(P#
M  #O$   &0   'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6S-6-MNVS@0_15"
M6RP2H(UNMG-96X!SPV:1M*D=IP^+?:"EL4V$(KTD9;=_OZ2DRM9&86-'#WFQ
M2(ES9LX9CCQ4?\W%DUP */0]I4P.G(52RS/7E?$"4BR/^!*8?C+C(L5*3\7<
ME4L!.,F-4NH&GM=S4TR8$_7S>_<BZO-,4<+@7B"9I2D6/\Z!\O7 \9V?-T9D
MOE#FAAOUEW@.8U"3Y;W0,[="24@*3!+.D(#9P!GZ9Q=^UQCD*QX)K.76&!DJ
M4\Z?S.0F&3B>B0@HQ,I 8'U9P050:I!T'/^6H$[ETQANCW^B7^?D-9DIEG#!
MZ3>2J,7 .7%0 C.<437BZS^A))0'&',J\U^T+M=Z#HHSJ7A:&NL(4L***_Y>
M"K%EX'=>, A*@^"U!F%I$.9$B\AR6I=8X:@O^!H)LUJCF4&N36ZMV1!FTCA6
M0C\EVDY%U\.;$7H<WDZNT-W5<#P97=U=?7X8HT]HK'=,DE% ?(:N,1'H$=,,
M/J);@J>$$D5 HCO ,A.0()V0$<29$(3-T3F61**#2U"84'FHL2;C2W3PX1!]
M0(2AAP7/)&:)[+M*,S!QN'$9[7D1;?!"M']E[ B%WD<4>$'88'YA-[^$6)O[
MN7E0-W>U;I5X025>D..%+XFW)<M02E 2:5ZO4,BL^LR9^)]D?]]J!^A&02K_
M:1*GB*;3'(TI^#.YQ#$,'%W1$L0*G.CWW_R>]T>35"V!U80+*^%"&WKT#0N!
MF4*T5.I'$]L"HI=#F+?1*NKIG*^V.3Q?XE4K:H%UJL ZUL"^9ESI9-T+$NOD
MZ<TZS%\SZ Z+)Y/>@UM8 47^85/ 5NA=T],26$V%;J5"]UWMZVZ;PK4$5A.N
M5PG7>_N^+B"ZC9NVH&!ULB>%XXK"L97" U>85@1TJILH'/^2@M7)GA1.*@HG
M5@IC,F=D1F*3B2]J 0)]F1H?>*K_S6[8,ML4<M!8R%;X7?=C2V U)4XK)4[?
M52&?MBE<2V UX7QOTQ=Y;R_E$L-6"'8W^]+8:N_\MY=SB6&E876S+XU-H^5;
MVY&&DIXP_E)1AXU%;?>PZ^9L"ZVNQZ9_\L-W5=B^M9_;6;R6T.KB;7H\W][D
MO:ZT.\]JXEG[:?>S+X]-E^9;>YE7UG;WUVVTW<^N/-RMTZCY%*![YSEA$E&8
M:7COZ%A[$\7INI@HOLP/J%.N]'$W'RX )R#, OU\QG537D[,F;?ZQA']!U!+
M P04    "  500Y7.HYU9[X"  !"!@  &0   'AL+W=O<FMS:&5E=',O<VAE
M970S,RYX;6R556%OVC 0_2NGK)HZJ6U"*%G5020H5&,J4P6E_3#M@Y,<B57'
MSFP'VG\_VX&4;11I7XC/N??NW<.^]#="/JL"4<-+R;@:>(76U;7OJ[3 DJ@+
M42$W;U9"ED2;4.:^JB22S(%*YH=!$/DEH=R+^V[O7L9]46M&.=Y+4'59$ODZ
M0B8V Z_C[3;F-"^TW?#C?D5R7*!>5O?21'[+DM$2N:*"@\35P!MVKD>1S7<)
MCQ0W:F\-MI-$B&<;3+.!%UA!R##5EH&8QQIOD#%+9&3\VG)Z;4D+W%_OV&]=
M[Z:7A"B\$>R)9KH8>%<>9+@B-=-SL?F*VWYZEB\53+E?V&QS P_26FE1;L%&
M04EY\R0O6Q_V &'X#B#< D*GNRGD5(Z))G%?B@U(FVW8[,*UZM!&'.7V3UEH
M:=Y2@]/Q[7 ZA\?AW7("L\EPL9Q/9I/O#PLXASM*$LJH?H49$E5+S(!HF"A-
MC1<FN"54PB-A-<+I&#6A3'TRL"<B)>%Z#WX"E,-#(6I%>*;ZOC:R;7$_W4H<
M-1+#=R1&,!-<%PHF/,/L3[QOVFU[#G<]C\*CA-]J?@'=X S"(.S"<C&&TY-/
M1WB[K9==Q]M]S\O6D;.V?8KJS3]S"N>8UE)2GL.(**K.8,E%HE"N2<(0IKRJ
MM<T1/#5HX@[NCSM3!Z8:2_7SD'N-J,O#HNREOE8527'@F5MK*Z$7?_S0B8(O
M1UJ^;%N^/,;>M+QVAX H$"L88XIE@A*Z'>=O>$AQPQDY3CLUUG'GJM?WUP>$
M]%HAO:-";@K"<[0GS:IQQAVJW)#T]BJ?=ZS&0Z6CMG3T?QZ8\X6-P[M#=DA*
M](\)4?<O(?[>O2Y1YFYZ*4A%S75SQ=O==D .F[GPEMY,UQF1.>4*&*X,-+CX
M;#R0S<1J BTJ-R42H<W,<<O"#'F4-L&\7PFA=X$MT'XVXM]02P,$%     @
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M7!0B/12E \5C<ZZXXPI/*>9RC0=)$+H GR\Y5\\#?53)CZ;#/U!+ P04
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MVWW'#=YM,H:&R"HQ](H8>LUN\-Y6WSGV1FMNE]AN?6^>%"I/=JJ\3%E,1,I
MRYR1)S6NE;>3YZT+TQ!9Q;)MO7R@K7?LT)R\H22:8JM&43JKV,UV:<Y7_LC8
MSD:;UM5L]JE9.F"IT^TU9G,2<Q3"3(*LXZ[L<I8=&+.)H(D^<]U3(4]P>KB0
MAVQ@JD#>GU$JUA-UC"N.[=Y?4$L#!!0    ( !5!#E>5W OG<0(  +8%   9
M    >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;*U4;4_;,!#^*Z<,32 QDJ9=
MF5@;J6\33()E!39-TSZXR;6Q2.Q@.RW\^YV=-"NLH'W8E\1WON>Y>RZY&VRD
MNM,9HH&'(A=ZZ&7&E&>^KY,,"Z9/9(F";I92%<R0J5:^+A6RU(&*W ^#H.\7
MC LO&CA?K**!K$S.!<8*=%443#V.,9>;H=?QMHXY7V7&.OQH4+(57J.Y+6-%
MEM^RI+Q H;D4H' Y]$:=LTG/QKN ;QPW>N<,5LE"RCMK7*1#+[ %88Z)L0R,
M7FN<8)Y;(BKCON'TVI06N'O>LG]RVDG+@FF<R/P[3TTV]#YXD.*25;F9R\TY
M-GK>6[Y$YMH]85/'G@8>))4VLFC 5$'!1?UF#TT?=@#$LQ\0-H#P.:#W J#;
M +I.:%V9DS5EAD4#)3>@;#2QV8/KC4.3&B[L5[PVBFXYX4P4S[_$L_G-#QA=
M36'V]?8BOIQ=W< [N&)*,=MB.)RB83S71^2]O9["X<$1'  7<)/)2C.1ZH%O
MJ!1+Z"=-VG&=-GPA;1\NI3"9AIE(,7V*]TE"JR/<ZAB'KQ)^KL0)=(-C"(.P
MNZ>>R;_#PU?*Z;9M[3J^[DMM531GRCP>0YPS88"Z!+/[BI<T  9^CA;:*/J#
M?^WK7,W<V\]LI_I,ERS!H4=CJU&MT8O>ONGT@X_[9/\GLB=-Z+5-Z+W&'DV1
M2!/.W+SB RT>C?L$URQ]QV*WSCJB3[#>5?%W1*>-J$OS=T:@0+5RFT%#(BMA
MZK^H];;+9^1F[IE_3$NIWB%_:.J-=LG4B@L-.2Z),C@YI9%6]9:H#2-+-V@+
M:6ALW3&CQ8K*!M#]4DJS-6R"=E5'OP%02P,$%     @ %4$.5X7.:X6; @
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M1REX;O63F$%B)HE9)&:_8.,-5AU7/MVJVFAPW7_:K^KCA0Z6<,DQ>23FDUA
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M[LG>W9.]O>?_XY)I>A.+TX?HUW$Z&4:Z0S4#U4Q4LU#-1C4'U5Q4\U#-1[4
MU4)*:T\$3>A.EX?NP.-X-**':@:JF:AFH9J-:@ZJN;7VQI5U/;13']4"5 LI
MK5W[3?9.EU\W;>]H8.]O6)L3]:]<4%6NGEWH: 0/U4Q4LU#-1C4'U5Q4\U#-
M1[4 U4)*:\\'301/G[ '!>@EV5#-0#43U2Q4LU'-0347U3Q4\U$M0+60TMH3
M09/9T^69O7,OJ"KGSIX(T-0>JIFUMI\_UO7#4U86VJ>-:@ZJN:CFH9J/:@&J
MA936+O FC:?+K_=VSH57Y=39Q8TF\5#-U(^O+Z>-!H/#XD83=JCFH)J+:AZJ
M^:@6H%I(:2_%W<\70A1&5$2WURN1S<6=6"YS95IMC&]ZU=G]W;-*)AZJBSV^
M_Z#U^D?/V^I[1ZV>[S?,[?5C-!=AE,W+S;VR% \E.;B8C'I*%L\7NU^*]/&F
MI_:4;VE1I*O-PX6(9B*K%BC__R%-B^TO50?/:?;;9MBW_P502P,$%     @
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M&X#2-"A-A](,*,V$TBPHC4)I-I3FH&AML36.!.7_9DF0DSOK#FI=@-)T*,V
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MHN&<\N(!=7_!F'P\*1+4>][3_P%02P,$%     @ %4$.5R0CX\*4!    Q@
M !D   !X;"]W;W)K<VAE971S+W-H965T-#,N>&ULQ5CO3^LV%/U7KK*G)Y"
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MUOZ!:'2T&(*+#2>YFO*N"1<SHUI&@$.@4D \GQ/"-QNIH/HKPOD#4$L#!!0
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M]99JZB;+368M:8)8#>-<,/EO(.W$:/YC-OUV/1G/[V[1=';_>/<P'__X,GM
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MN$A XJKO#!JWPZZQSPQ>.1[4V1A,) LAMF9R'_8=SPC"")?:(##Z['&$462
M2,;O'-,I*(WC^?B$?I?%3K$LF,*1B'[P4&_Z3M>!$%=L%^DG<?B">3PM@[<4
MD<K^X9#;>@XL=TJ+.'<F!3%/[)>]Y7DX<_#;%QS\W,'/=%NB3.68:1;TI#B
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M+H2FGIL--_3(H30&M+\20I\FAJ!X-H,_4$L#!!0    ( !5!#E<>&LNI60(
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MVK6_P?#"N-GVZUQ,I'1-TTG=E8N9:7JZH;/6!Q .D1MSN!&,8S$W AB6!W.
M<2P+R_,_C6> CL=BF+>!$QF@G '*L2P7,C$?+(^;D^C#/=(DB:(XQF9T,G$Z
MF&#S%L?P=:MAWH"!Y8%,?S?7^&KC%?)\'6!K^ER%8"/%*Q$;*3[7@+CG#1A)
MXEYM+ \PL%7 :@?RN_- 3;DY402KBGG#[F <21(,@5ITUV@<([,3P\>]/MA=
M$D5)XD8 <SN((@R!NQ%', ?@ 4.BR+P'#]Y'P?8]%>Q^AQW_ 5!+ P04
M"  500Y7EXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">
M, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]
M$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<
MUYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A
M(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X
M4$L#!!0    ( !5!#E<=0O',%@0  (T?   /    >&PO=V]R:V)O;VLN>&UL
MQ9E=<Z,V%$#_BH:G]"&U^4AV-[/>&8))PM0&"CAM^I*108XUBY%'DI/M_OH*
MO&[D+K[3%YDG6P*+PY6Y1[I\?F/\ZY*QK^C;IF[$Q%I+N;T9C42Y)ALL?F5;
MTJ@C*\8W6*HF?QF)+2>X$FM"Y*8>.>/Q]6B#:6-]^7P8*^4CO<$D*25EC>IL
M.QXI>1/OQ]LF>J6"+FE-Y=\3J_M>$PMM:$,W]#NI)M;80F+-WAX8I]]9(W&=
MEYS5]<2R]P<>"9>T_*D[;R$+O!1=C\3+#"N0B74]5@.N*!>R.Z,;'RO&5Z).
MWK=VDMW16A(^Q9+<<[;;TN:E'4;=Q4B[C2X.A\]]$&_X_PDC6ZUH2::LW&U(
M(_=QY*1N 1NQIEMAH09OR,0*V"OA[?VH"T35_MZD@M(BQ6^H.L"CJL,SB=((
M5M-*7;U"M[C&34E0%T*A 3H H#,8(+I(L0;I I#N&2'S%J+]@4!LA9+MT51[
M *0W&&2PQHT&>05 7@T'B<5:@[P&(*_-0B;9O1]'?_E%E,3(CZ=H&N9!%J5=
M.[G3(#\ D!_,0LZBWQ?1-"J>-)R/ ,Y'LSBW?A[E*C@HS<(\C(OWX.6+^=S7
M(#\!D)_,0L[#[#[,T!]1\8 >_=DLB?4L/8;2]-@LV9T?92W2(D3ST,\763A7
M0<QU/- BAC629DD:9L53-Z&A^N.E+9Y.!RG$-NP0/PBR1:C _DS#. ^/H@99
MPS:L#16U>93G2?:$XJ0XYH)$81LV15XDP6\/R6P:9OES-YU'6<2&_& ;%D3'
M=JFRB9K/()FW$]JE$IT/4H-MV V*:1X5W</9/0Q!$A=1?!_&070\P9 :;,-N
M )/QLZ-C0LJPAW3&LZMC0M*PSVX-=*%V'341O^AK:$@?SC#Z.'#JF)!&G$$T
MTAM-<$MR9I_T D)B<0R+I2^!]T)"EG'.89F>3/X#5,>$A.,8%@ZXV#_*E0[D
M'<>P=_Y=[J.+*9&8UL<3#=G&&=0VGHX)V<89U#97.B9D&^?\MKE$,>8<M]4N
MI!=$(..XAHW3BYFK@:M=31#3,2'CN(:-<TJ,/UAU3,@XKF'CG,:<4;RD.B98
M!C/LG=.84\+IJXX)F<<U;)X3RXS#_U/'A,SC&C;/2<S]TZYC0N9Q#9OGY]50
MCX!<2$"N80']=Y^M0GC+:?5"T!UMCBJ?+B0@U[" >C"+,$4QDZ2-J8X)"<@U
M+*#>Q>6[@O1B-R0@S[" 3F"&0E(UF!Y-#Q*09UA )S /IM0Q(0%YA@5T<K&^
MGW@=$Q*0=XZ-3S]F&U$=$WP3,]36YQ+YI=1U[D$"\@:JM;680NB>]" !>4.6
MW-"%C@E9R.LL-#J\_JW(BC:DBM4EA.HO<5VF'+4?^WJV=]46G5:[N@Y47]+,
M&*X.;Y,/;\*__ -02P,$%     @ %4$.5[DCVC>R 0  5!P  !H   !X;"]?
M<F5L<R]W;W)K8F]O:RYX;6PN<F5L<\W9.V["0!2%X:T@+R##?4!"%%*EH8W8
M@ 7#0P%L>28*[#X("CA6BC1H3F7-6+[^JT_6^.TS[NJ\;0YILVW3X+C?'=*T
MVN3<OH:0%INXK]-3T\;#^<ZJZ?9U/B^[=6CKQ5>]CD&'PW'H[F=4[V_W,P?S
M4QO_,[%9K;:+^-$LOO?QD/\8''Z:[BMM8LS58%YWZYBG53CN;MLI7"[R=)Y<
M#6;+:=7-EE*%TD$*05H^R"#(R@<Y!'GYH!$$C<H'C2%H7#[H&8*>RP>]0-!+
M^: )!$W*!\D091P2)/6P)M!:D&LA\%H0;"$06Y!L(3!;$&TA4%N0;2%P6Q!N
M(9!;D&XAL%L0;R'06U%O)=!;46\ET%M[']L$>BOJK01Z*^JM!'HKZJT$>BOJ
MK01Z*^JM!'HKZJT$>BOJK01Z&^IM!'H;ZFT$>AOJ;01Z6^^PA$!O0[V-0&]#
MO8U ;T.]C4!O0[V-0&]#O8U ;T.]C4!O1[V=0&]'O9U ;T>]G4!O1[V=0&_O
M'783Z.VHMQ/H[:BW$^CMJ+<_4N^43[N8;CW7-;[_D53G\[/Q]OK+\KK98^>"
M<X"?B.^_4$L#!!0    ( !5!#E=EX9FUMP$  &4<   3    6T-O;G1E;G1?
M5'EP97-=+GAM;,W9R6[",!0%T%]!V2)B/)0. C9MMRV+_H";/$A$$ENVH?#W
M=<(@M:*HB$J]FT2)[7=?;.EL,G[;6O*]35TU?I(4(=@'QGQ64*U]:BPU<61N
M7*U#?'0+9G6VU MB8C@<L<PT@9HP"&V-9#I^HKE>5:'WO(FO?6F:2>*H\DGO
M<3>QS9HDVMJJS'2(XVS=Y-]2!ON$-*[LYOBBM+X?)R3L9$([\G/ ?MWKFIPK
M<^K-M LONHZSV*9B/FPK\NGY$B=Z-/-YF5%NLE4=EZ3>.M*Y+XA"7:6[HOWS
MR2'N,.VN_.K\KLRYP#ASYHSU\<0<71YW.))V]<#&0N1">?X3CXFQ]-7?1^UI
MYY3_,CMN[X=QR^X\/.MNU^_QUS,^UK^P#P'2AP3I0X'T<0/2QPBDCUN0/NY
M^K@'Z8,/41I!$96CD,I13.4HJ'(453D*JQS%58X"*T>15:#(*E!D%2BR"A19
M!8JL D56@2*K0)%5H,@J4&25*+)*%%DEBJP215:)(JM$D56BR"I19)4HLDH4
M616*K I%5H4BJT*15:'(JE!D52BRJO^4]=V8Y5__^&KO::W+YI#/NK^+TT]0
M2P$"% ,4    "  500Y7!T%-8H$   "Q    $               @ $
M9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( !5!#E='0/2T[P   "L"   1
M              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    (
M !5!#E>97)PC$ 8  )PG   3              "  <T!  !X;"]T:&5M92]T
M:&5M93$N>&UL4$L! A0#%     @ %4$.5\U+8^KV!0  D"   !@
M     ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    (
M !5!#E?$)[I?D 4  +X6   8              " @3H.  !X;"]W;W)K<VAE
M971S+W-H965T,BYX;6Q02P$"% ,4    "  500Y7,; 8):("  !@!P  &
M            @($ %   >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#
M%     @ %4$.5Z:[[:YV!   U1$  !@              ("!V!8  'AL+W=O
M<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( !5!#E=!E$85Z@D  .!:
M   8              " @80;  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q0
M2P$"% ,4    "  500Y71_2@X"8'  "0(   &               @(&D)0
M>&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ %4$.5UX]D5&[
M!P  Z!(  !@              ("! "T  'AL+W=O<FMS:&5E=',O<VAE970W
M+GAM;%!+ 0(4 Q0    ( !5!#E>5!W(;80<  /81   8              "
M@?$T  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    "  500Y7
MEZ.39?$/  !J+   &               @(&(/   >&PO=V]R:W-H965T<R]S
M:&5E=#DN>&UL4$L! A0#%     @ %4$.5\&F/.@@"   :!H  !D
M     ("!KTP  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !5!#E<&$U561@H  %H>   9              "
M@7]K  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ %4$.
M5S_53:KO!P   Q4  !D              ("!_'4  'AL+W=O<FMS:&5E=',O
M<VAE970Q-BYX;6Q02P$"% ,4    "  500Y75;(C ?$"  "%!@  &0
M        @($B?@  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0
M   ( !5!#E</0TL:G@X  '@J   9              " @4J!  !X;"]W;W)K
M<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ %4$.5PNT'((P P  >@8
M !D              ("!'Y   'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q0
M2P$"% ,4    "  500Y7M6N#Z]$"   6!@  &0              @(&&DP
M>&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( !5!#E>+>;FZ
M0P0  .8*   9              " @8Z6  !X;"]W;W)K<VAE971S+W-H965T
M,C$N>&UL4$L! A0#%     @ %4$.5U5Q.V-X @  5P4  !D
M ("!")L  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    "  5
M00Y71,(U9Y("  "2!0  &0              @(&WG0  >&PO=V]R:W-H965T
M<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( !5!#E>E$":+&00  ($)   9
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M970R."YX;6Q02P$"% ,4    "  500Y7B*[L+3\$  "_%   &0
M    @(%KM   >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    (
M !5!#E<K746VPP0  &LD   9              " @>&X  !X;"]W;W)K<VAE
M971S+W-H965T,S N>&UL4$L! A0#%     @ %4$.5[0USAK< @  %P<  !D
M             ("!V[T  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"
M% ,4    "  500Y7>$/$Y(P#  #O$   &0              @('NP   >&PO
M=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( !5!#E<ZCG5GO@(
M $(&   9              " @;'$  !X;"]W;W)K<VAE971S+W-H965T,S,N
M>&UL4$L! A0#%     @ %4$.5R68A/5/ P  I@X  !D              ("!
MIL<  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    "  500Y7
M6@FUP0T#  #""P  &0              @($LRP  >&PO=V]R:W-H965T<R]S
M:&5E=#,U+GAM;%!+ 0(4 Q0    ( !5!#E>5W OG<0(  +8%   9
M      " @7#.  !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%
M  @ %4$.5X7.:X6; @  WP8  !D              ("!&-$  'AL+W=O<FMS
M:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    "  500Y7\"OP5.8*   MF0
M&0              @('JTP  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+
M 0(4 Q0    ( !5!#E>T\S&TZ@@  (]C   9              " @0??  !X
M;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ %4$.5V2+X-?C
M#P  !O0  !D              ("!*.@  'AL+W=O<FMS:&5E=',O<VAE970T
M,"YX;6Q02P$"% ,4    "  500Y7@7K"G40$   Z&@  &0
M@(%"^   >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( !5!
M#E?O%1@O+ 4  /\>   9              " @;W\  !X;"]W;W)K<VAE971S
M+W-H965T-#(N>&UL4$L! A0#%     @ %4$.5R0CX\*4!    Q@  !D
M         ("!( (! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4
M    "  500Y7^.4SVX$#  "6$   &0              @('K!@$ >&PO=V]R
M:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( !5!#E<(_#IF$@0  !03
M   9              " @:,* 0!X;"]W;W)K<VAE971S+W-H965T-#4N>&UL
M4$L! A0#%     @ %4$.5Q<7W%8  P  0@<  !D              ("![ X!
M 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    "  500Y7'AK+
MJ5D"  #M!   &0              @($C$@$ >&PO=V]R:W-H965T<R]S:&5E
M=#0W+GAM;%!+ 0(4 Q0    ( !5!#E=&00[+3 ,  )05   -
M  "  ;,4 0!X;"]S='EL97,N>&UL4$L! A0#%     @ %4$.5Y>*NQS
M$P(   L              ( !*A@! %]R96QS+RYR96QS4$L! A0#%     @
M%4$.5QU"\<P6!   C1\   \              ( !$QD! 'AL+W=O<FMB;V]K
M+GAM;%!+ 0(4 Q0    ( !5!#E>Y(]HWL@$  %0<   :              "
M 58= 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( !5!
M#E=EX9FUMP$  &4<   3              "  4 ? 0!;0V]N=&5N=%]4>7!E
<<UTN>&UL4$L%!@     W #< ^ X  "@A 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>155</ContextCount>
  <ElementCount>222</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>53</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="ck0001824293-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ck0001824293-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ck0001824293-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ck0001824293-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ck0001824293-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Statements of Changes in Stockholders??? Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders??? Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ck0001824293-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ck0001824293-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS</Role>
      <ShortName>ORGANIZATION AND DESCRIPTION OF BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ck0001824293-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - LIQUIDITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/LIQUIDITY</Role>
      <ShortName>LIQUIDITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ck0001824293-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ck0001824293-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - MERGER WITH VALLON</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/MERGERWITHVALLON</Role>
      <ShortName>MERGER WITH VALLON</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ck0001824293-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTS</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ck0001824293-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENT</Role>
      <ShortName>PROPERTY AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ck0001824293-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - ACCRUED EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ACCRUEDEXPENSES</Role>
      <ShortName>ACCRUED EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ck0001824293-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - PROMISSORY NOTES</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.vallon-pharma.com/role/PROMISSORYNOTES</Role>
      <ShortName>PROMISSORY NOTES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ck0001824293-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITY</Role>
      <ShortName>STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ck0001824293-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ck0001824293-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ck0001824293-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9954701 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ck0001824293-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9954702 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</Role>
      <ShortName>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="ck0001824293-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9954703 - Disclosure - MERGER WITH VALLON (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/MERGERWITHVALLONTables</Role>
      <ShortName>MERGER WITH VALLON (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/MERGERWITHVALLON</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="ck0001824293-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9954704 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTS</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="ck0001824293-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9954705 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENT</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="ck0001824293-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9954706 - Disclosure - ACCRUED EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables</Role>
      <ShortName>ACCRUED EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/ACCRUEDEXPENSES</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="ck0001824293-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9954707 - Disclosure - STOCKHOLDERS??? EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYTables</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITY</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ck0001824293-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9954708 - Disclosure - STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables</Role>
      <ShortName>STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ck0001824293-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9954709 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails</Role>
      <ShortName>ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ck0001824293-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9954710 - Disclosure - LIQUIDITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/LIQUIDITYDetails</Role>
      <ShortName>LIQUIDITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/LIQUIDITY</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ck0001824293-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9954711 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails</Role>
      <ShortName>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ck0001824293-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9954712 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Diluted Net Loss Per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails</Role>
      <ShortName>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Diluted Net Loss Per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="ck0001824293-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9954713 - Disclosure - MERGER WITH VALLON - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails</Role>
      <ShortName>MERGER WITH VALLON - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="ck0001824293-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954714 - Disclosure - MERGER WITH VALLON - Schedule of the Net Liabilities Assumed in the Merger (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails</Role>
      <ShortName>MERGER WITH VALLON - Schedule of the Net Liabilities Assumed in the Merger (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="ck0001824293-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954715 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Fair Value, Liabilities Measured on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Schedule of Fair Value, Liabilities Measured on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="ck0001824293-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954716 - Disclosure - FAIR VALUE MEASUREMENTS - Liability Measured at Estimated Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Liability Measured at Estimated Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="ck0001824293-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954717 - Disclosure - FAIR VALUE MEASUREMENTS - Derivative Liability Measurement Inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Derivative Liability Measurement Inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="ck0001824293-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954718 - Disclosure - PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="ck0001824293-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954719 - Disclosure - PROPERTY AND EQUIPMENT - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTNarrativeDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="ck0001824293-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954720 - Disclosure - ACCRUED EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails</Role>
      <ShortName>ACCRUED EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ck0001824293-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954721 - Disclosure - PROMISSORY NOTES - Bridge Financing (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails</Role>
      <ShortName>PROMISSORY NOTES - Bridge Financing (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="ck0001824293-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954722 - Disclosure - PROMISSORY NOTES - TEP Note (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails</Role>
      <ShortName>PROMISSORY NOTES - TEP Note (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="ck0001824293-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954723 - Disclosure - STOCKHOLDERS??? EQUITY - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails</Role>
      <ShortName>STOCKHOLDERS??? EQUITY - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="ck0001824293-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954724 - Disclosure - STOCKHOLDERS??? EQUITY - Estimate of the Fair Value of the Warrants and Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails</Role>
      <ShortName>STOCKHOLDERS??? EQUITY - Estimate of the Fair Value of the Warrants and Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="ck0001824293-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954725 - Disclosure - STOCKHOLDERS??? EQUITY - Schedule of Warrants Outstanding to Purchase Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails</Role>
      <ShortName>STOCKHOLDERS??? EQUITY - Schedule of Warrants Outstanding to Purchase Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="ck0001824293-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954726 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="ck0001824293-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954727 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Schedule of Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ck0001824293-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954728 - Disclosure - STOCK-BASED COMPENSATION - Activity of Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Activity of Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ck0001824293-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954729 - Disclosure - STOCK-BASED COMPENSATION - Assumptions Used to Estimate Fair Value of Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Assumptions Used to Estimate Fair Value of Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ck0001824293-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954730 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES</ParentRole>
      <Position>47</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="ck0001824293-20230630.htm">ck0001824293-20230630.htm</File>
    <File>ck0001824293-20230630.xsd</File>
    <File>ck0001824293-20230630_cal.xml</File>
    <File>ck0001824293-20230630_def.xml</File>
    <File>ck0001824293-20230630_lab.xml</File>
    <File>ck0001824293-20230630_pre.xml</File>
    <File>ex106_aagroemploymentagree.htm</File>
    <File>ex311_ceo302cert63023.htm</File>
    <File>ex312_cfo302cert63023.htm</File>
    <File>ex321_ceosection906cert630.htm</File>
    <File>ex322_cfosection906cert630.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ck0001824293-20230630_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="414">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="33">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>68
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ck0001824293-20230630.htm": {
   "axisCustom": 0,
   "axisStandard": 18,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 414,
    "http://xbrl.sec.gov/dei/2023": 33
   },
   "contextCount": 155,
   "dts": {
    "calculationLink": {
     "local": [
      "ck0001824293-20230630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ck0001824293-20230630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "ck0001824293-20230630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ck0001824293-20230630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ck0001824293-20230630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ck0001824293-20230630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    }
   },
   "elementCount": 368,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2023": 1,
    "http://xbrl.sec.gov/dei/2023": 5,
    "total": 6
   },
   "keyCustom": 42,
   "keyStandard": 180,
   "memberCustom": 29,
   "memberStandard": 23,
   "nsprefix": "ck0001824293",
   "nsuri": "http://www.vallon-pharma.com/20230630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.vallon-pharma.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - MERGER WITH VALLON",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.vallon-pharma.com/role/MERGERWITHVALLON",
     "shortName": "MERGER WITH VALLON",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - FAIR VALUE MEASUREMENTS",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTS",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - PROPERTY AND EQUIPMENT",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENT",
     "shortName": "PROPERTY AND EQUIPMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - ACCRUED EXPENSES",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.vallon-pharma.com/role/ACCRUEDEXPENSES",
     "shortName": "ACCRUED EXPENSES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - PROMISSORY NOTES",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.vallon-pharma.com/role/PROMISSORYNOTES",
     "shortName": "PROMISSORY NOTES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - STOCKHOLDERS\u2019 EQUITY",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITY",
     "shortName": "STOCKHOLDERS\u2019 EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - STOCK-BASED COMPENSATION",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION",
     "shortName": "STOCK-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954701 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "menuCat": "Policies",
     "order": "18",
     "role": "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954702 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "menuCat": "Tables",
     "order": "19",
     "role": "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables",
     "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-3",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-3",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954703 - Disclosure - MERGER WITH VALLON (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://www.vallon-pharma.com/role/MERGERWITHVALLONTables",
     "shortName": "MERGER WITH VALLON (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954704 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSTables",
     "shortName": "FAIR VALUE MEASUREMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954705 - Disclosure - PROPERTY AND EQUIPMENT (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTTables",
     "shortName": "PROPERTY AND EQUIPMENT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954706 - Disclosure - ACCRUED EXPENSES (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables",
     "shortName": "ACCRUED EXPENSES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954707 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYTables",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954708 - Disclosure - STOCK-BASED COMPENSATION (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables",
     "shortName": "STOCK-BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-40",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "ck0001824293:CommonStockExchangeRatio",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954709 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)",
     "menuCat": "Details",
     "order": "26",
     "role": "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails",
     "shortName": "ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-40",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "ck0001824293:CommonStockExchangeRatio",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-3",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954710 - Disclosure - LIQUIDITY (Details)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
     "shortName": "LIQUIDITY (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-3",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFDICInsuredAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954711 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
     "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-3",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFDICInsuredAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-1",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954712 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Diluted Net Loss Per Common Share (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails",
     "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Diluted Net Loss Per Common Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-1",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-3",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-58",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "ck0001824293:CommonStockOwnershipPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954713 - Disclosure - MERGER WITH VALLON - Narrative (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails",
     "shortName": "MERGER WITH VALLON - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-58",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "ck0001824293:CommonStockOwnershipPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-59",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954714 - Disclosure - MERGER WITH VALLON - Schedule of the Net Liabilities Assumed in the Merger (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails",
     "shortName": "MERGER WITH VALLON - Schedule of the Net Liabilities Assumed in the Merger (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-59",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-3",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WarrantsAndRightsOutstanding",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954715 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Fair Value, Liabilities Measured on Recurring Basis (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Schedule of Fair Value, Liabilities Measured on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-60",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:WarrantsAndRightsOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-63",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954716 - Disclosure - FAIR VALUE MEASUREMENTS - Liability Measured at Estimated Fair Value (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Liability Measured at Estimated Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-63",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-66",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954717 - Disclosure - FAIR VALUE MEASUREMENTS - Derivative Liability Measurement Inputs (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Derivative Liability Measurement Inputs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-3",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954718 - Disclosure - PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails",
     "shortName": "PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-3",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-1",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954719 - Disclosure - PROPERTY AND EQUIPMENT - Narrative (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTNarrativeDetails",
     "shortName": "PROPERTY AND EQUIPMENT - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-3",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ck0001824293:AccruedResearchAndDevelopmentCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954720 - Disclosure - ACCRUED EXPENSES (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails",
     "shortName": "ACCRUED EXPENSES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-3",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ck0001824293:AccruedResearchAndDevelopmentCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-1",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromNotesPayable",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954721 - Disclosure - PROMISSORY NOTES - Bridge Financing (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails",
     "shortName": "PROMISSORY NOTES - Bridge Financing (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-4",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-1",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromNotesPayable",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954722 - Disclosure - PROMISSORY NOTES - TEP Note (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails",
     "shortName": "PROMISSORY NOTES - TEP Note (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-101",
      "decimals": "INF",
      "lang": "en-US",
      "name": "ck0001824293:DebtInstrumentConvertibleSharesIssuedUponConversion",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-5",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Consolidated Statements of Operations",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-5",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-4",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954723 - Disclosure - STOCKHOLDERS\u2019 EQUITY - Narrative (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
     "shortName": "STOCKHOLDERS\u2019 EQUITY - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-117",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-66",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954724 - Disclosure - STOCKHOLDERS\u2019 EQUITY - Estimate of the Fair Value of the Warrants and Assumptions (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails",
     "shortName": "STOCKHOLDERS\u2019 EQUITY - Estimate of the Fair Value of the Warrants and Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-120",
      "decimals": "3",
      "lang": "en-US",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-124",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954725 - Disclosure - STOCKHOLDERS\u2019 EQUITY - Schedule of Warrants Outstanding to Purchase Common Stock (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails",
     "shortName": "STOCKHOLDERS\u2019 EQUITY - Schedule of Warrants Outstanding to Purchase Common Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-124",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-1",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954726 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
     "shortName": "STOCK-BASED COMPENSATION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-3",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-5",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954727 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock-based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails",
     "shortName": "STOCK-BASED COMPENSATION - Schedule of Stock-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-5",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-4",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954728 - Disclosure - STOCK-BASED COMPENSATION - Activity of Stock Options (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails",
     "shortName": "STOCK-BASED COMPENSATION - Activity of Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-1",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-152",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954729 - Disclosure - STOCK-BASED COMPENSATION - Assumptions Used to Estimate Fair Value of Options (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails",
     "shortName": "STOCK-BASED COMPENSATION - Assumptions Used to Estimate Fair Value of Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-152",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-155",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ck0001824293:COBRABenefitsPaymentPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954730 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-155",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ck0001824293:COBRABenefitsPaymentPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-8",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Consolidated Statements of Changes in Stockholders\u2019 Equity (Deficit)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit",
     "shortName": "Consolidated Statements of Changes in Stockholders\u2019 Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-12",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-1",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-1",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000007 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS",
     "shortName": "ORGANIZATION AND DESCRIPTION OF BUSINESS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - LIQUIDITY",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.vallon-pharma.com/role/LIQUIDITY",
     "shortName": "LIQUIDITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 53,
   "tag": {
    "ck0001824293_A2018EquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2018 Equity Incentive Plan",
        "label": "2018 Equity Incentive Plan [Member]",
        "terseLabel": "2018 Plan"
       }
      }
     },
     "localname": "A2018EquityIncentivePlanMember",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued General and Administrative Expenses, Current",
        "label": "Accrued General and Administrative Expenses, Current",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "AccruedGeneralAndAdministrativeExpensesCurrent",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ck0001824293_AccruedInterestForfeited": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Interest Forfeited",
        "label": "Accrued Interest Forfeited",
        "terseLabel": "Accrued interest forfeited"
       }
      }
     },
     "localname": "AccruedInterestForfeited",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ck0001824293_AccruedResearchAndDevelopmentCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Research and Development Costs, Current",
        "label": "Accrued Research and Development Costs, Current",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentCostsCurrent",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended and Restated 2018 Equity Incentive Plan",
        "label": "Amended and Restated 2018 Equity Incentive Plan [Member]",
        "terseLabel": "A&amp;R 2918 Plan"
       }
      }
     },
     "localname": "AmendedAndRestated2018EquityIncentivePlanMember",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ck0001824293_BankerWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Banker Warrants",
        "label": "Banker Warrants [Member]",
        "terseLabel": "Banker Warrants"
       }
      }
     },
     "localname": "BankerWarrantsMember",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ck0001824293_BridgeSecuritiesPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bridge Securities Purchase Agreement",
        "label": "Bridge Securities Purchase Agreement [Member]",
        "terseLabel": "Bridge SPA"
       }
      }
     },
     "localname": "BridgeSecuritiesPurchaseAgreementMember",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ck0001824293_BridgeWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bridge Warrants",
        "label": "Bridge Warrants [Member]",
        "terseLabel": "Bridge Warrants"
       }
      }
     },
     "localname": "BridgeWarrantsMember",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accounts Payable And Accrued Expenses",
        "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accounts Payable And Accrued Expenses",
        "negatedLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net, Including Transaction Costs",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net, Including Transaction Costs",
        "terseLabel": "Total net liabilities assumed plus transaction costs"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ck0001824293_COBRABenefitsPaymentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COBRA Benefits, Payment Period",
        "label": "COBRA Benefits, Payment Period",
        "terseLabel": "COBRA benefits, payment period (in months)"
       }
      }
     },
     "localname": "COBRABenefitsPaymentPeriod",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ck0001824293_CallOptionPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Call Option Price",
        "label": "Call Option Price",
        "terseLabel": "Call option price (in usd per share)"
       }
      }
     },
     "localname": "CallOptionPrice",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ck0001824293_ChangeInFairValueOfWarrantLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Fair Value Of Warrant Liability",
        "label": "Change In Fair Value Of Warrant Liability",
        "terseLabel": "Change in fair value of warrant liability"
       }
      }
     },
     "localname": "ChangeInFairValueOfWarrantLiability",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ck0001824293_ClassOfWarrantOrRightExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Expiration Period",
        "label": "Class Of Warrant Or Right, Expiration Period",
        "terseLabel": "Expiration period"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExpirationPeriod",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ck0001824293_CommonStockExchangeRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Exchange Ratio",
        "label": "Common Stock Exchange Ratio",
        "terseLabel": "Common stock, exchange ratio"
       }
      }
     },
     "localname": "CommonStockExchangeRatio",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ck0001824293_CommonStockHeldIntoEscrowAccount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Held Into Escrow Account",
        "label": "Common Stock Held Into Escrow Account",
        "terseLabel": "Common stock placed into escrow (in shares)"
       }
      }
     },
     "localname": "CommonStockHeldIntoEscrowAccount",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ck0001824293_CommonStockOwnershipPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Ownership Percentage",
        "label": "Common Stock, Ownership Percentage",
        "terseLabel": "Ownership percentage in common stock (as a percent)"
       }
      }
     },
     "localname": "CommonStockOwnershipPercentage",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ck0001824293_ConversionOfStockAdditionalSharesConverted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of Stock, Additional Shares Converted",
        "label": "Conversion of Stock, Additional Shares Converted",
        "terseLabel": "Additional shares converted into common stock (in shares)"
       }
      }
     },
     "localname": "ConversionOfStockAdditionalSharesConverted",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ck0001824293_ConvertiblePromissoryNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Promissory Note",
        "label": "Convertible Promissory Note [Member]",
        "terseLabel": "Convertible promissory note"
       }
      }
     },
     "localname": "ConvertiblePromissoryNoteMember",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ck0001824293_DebtConversionConvertedInstrumentAmountOfInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Conversion, Converted Instrument, Amount Of Interest",
        "label": "Debt Conversion, Converted Instrument, Amount Of Interest",
        "terseLabel": "Amount of accrued interest to be converted"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmountOfInterest",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ck0001824293_DebtConversionConvertedInstrumentPrincipalAmountOfDebt": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Conversion, Converted Instrument, Principal Amount Of Debt",
        "label": "Debt Conversion, Converted Instrument, Principal Amount Of Debt",
        "terseLabel": "Principal amount of debt to be converted"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentPrincipalAmountOfDebt",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Discount And Additional Paid-In-Capital Recognized From Issuance Of Warrants",
        "label": "Debt Discount And Additional Paid-In-Capital Recognized From Issuance Of Warrants",
        "terseLabel": "Recognition of debt discount and additional paid-in-capital for issuance of warrants in connection with the issuance of promissory notes"
       }
      }
     },
     "localname": "DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ck0001824293_DebtInstrumentAggregatePurchasePrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Aggregate Purchase Price",
        "label": "Debt Instrument Aggregate Purchase Price",
        "terseLabel": "Aggregate purchase price"
       }
      }
     },
     "localname": "DebtInstrumentAggregatePurchasePrice",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ck0001824293_DebtInstrumentConvertibleSharesIssuedUponConversion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Convertible, Shares Issued Upon Conversion",
        "label": "Debt Instrument, Convertible, Shares Issued Upon Conversion",
        "terseLabel": "Number of shares to be issued upon conversion"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleSharesIssuedUponConversion",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ck0001824293_DebtInstrumentNumberOfClosings": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Number Of Closings",
        "label": "Debt Instrument, Number Of Closings",
        "terseLabel": "Number of closings"
       }
      }
     },
     "localname": "DebtInstrumentNumberOfClosings",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ck0001824293_EmployeeAdvancesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Advances, Current",
        "label": "Employee Advances, Current",
        "verboseLabel": "Advances from employees"
       }
      }
     },
     "localname": "EmployeeAdvancesCurrent",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ck0001824293_EquityWarrantsExchangeWarrantsAndBankerWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Warrants, Exchange Warrants And Banker Warrants",
        "label": "Equity Warrants, Exchange Warrants And Banker Warrants [Member]",
        "terseLabel": "Equity Warrants, Exchange Warrants and Banker Warrants"
       }
      }
     },
     "localname": "EquityWarrantsExchangeWarrantsAndBankerWarrantsMember",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ck0001824293_EquityWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Warrants",
        "label": "Equity Warrants [Member]",
        "terseLabel": "Equity Warrants"
       }
      }
     },
     "localname": "EquityWarrantsMember",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ck0001824293_ExchangeWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exchange Warrants",
        "label": "Exchange Warrants [Member]",
        "terseLabel": "Exchange Warrants"
       }
      }
     },
     "localname": "ExchangeWarrantsMember",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ck0001824293_FormerChiefExecutiveOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Former Chief Executive Officer",
        "label": "Former Chief Executive Officer [Member]",
        "terseLabel": "Former Chief Executive Officer"
       }
      }
     },
     "localname": "FormerChiefExecutiveOfficerMember",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ck0001824293_GRIBioIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GRI Bio, Inc",
        "label": "GRI Bio, Inc [Member]",
        "terseLabel": "GRI Bio, Inc"
       }
      }
     },
     "localname": "GRIBioIncMember",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ck0001824293_LongTermDebtIncludingInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Debt, Including Interest",
        "label": "Long-Term Debt, Including Interest",
        "terseLabel": "Long-term debt, including interest"
       }
      }
     },
     "localname": "LongTermDebtIncludingInterest",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization": {
     "auth_ref": [],
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Liabilities Assumed In Connection With Reverse Recapitalization",
        "label": "Net Liabilities Assumed In Connection With Reverse Recapitalization",
        "negatedLabel": "Net liabilities assumed in connection with reverse recapitalization"
       }
      }
     },
     "localname": "NetLiabilitiesAssumedInConnectionWithReverseRecapitalization",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ck0001824293_NoncashMergerRelatedCostsFinancingActivities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash Merger Related Costs, Financing Activities",
        "label": "Noncash Merger Related Costs, Financing Activities",
        "terseLabel": "Merger costs included in accounts payable"
       }
      }
     },
     "localname": "NoncashMergerRelatedCostsFinancingActivities",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ck0001824293_PaymentOfReverseRecapitalizationCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment Of Reverse Recapitalization Costs",
        "label": "Payment Of Reverse Recapitalization Costs",
        "negatedTerseLabel": "Payment of reverse recapitalization costs"
       }
      }
     },
     "localname": "PaymentOfReverseRecapitalizationCosts",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ck0001824293_PercentageOfTargetBonus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage Of Target Bonus",
        "label": "Percentage Of Target Bonus",
        "terseLabel": "Percentage of target bonus (as a percent)"
       }
      }
     },
     "localname": "PercentageOfTargetBonus",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ck0001824293_PrivateGRIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Private GRI",
        "label": "Private GRI [Member]",
        "terseLabel": "Private GRI"
       }
      }
     },
     "localname": "PrivateGRIMember",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails",
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ck0001824293_PrivateGRIPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Private GRI Plan",
        "label": "Private GRI Plan [Member]",
        "terseLabel": "2015 Plan"
       }
      }
     },
     "localname": "PrivateGRIPlanMember",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ck0001824293_ProceedsFromAdvancesFromEmployees": {
     "auth_ref": [],
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Advances From Employees",
        "label": "Proceeds From Advances From Employees",
        "verboseLabel": "Advances from employees"
       }
      }
     },
     "localname": "ProceedsFromAdvancesFromEmployees",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ck0001824293_PutOptionSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Put Option, Share Price",
        "label": "Put Option, Share Price",
        "terseLabel": "Put right, share price (in usd per share)"
       }
      }
     },
     "localname": "PutOptionSharePrice",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ck0001824293_RepaymentOfAdvancesFromEmployees": {
     "auth_ref": [],
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repayment Of Advances From Employees",
        "label": "Repayment Of Advances From Employees",
        "negatedTerseLabel": "Repayment of advances from employees"
       }
      }
     },
     "localname": "RepaymentOfAdvancesFromEmployees",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ck0001824293_SeriesA1WarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A-1 Warrants",
        "label": "Series A-1 Warrants [Member]",
        "terseLabel": "Series A-1 Warrants"
       }
      }
     },
     "localname": "SeriesA1WarrantsMember",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ck0001824293_SeriesA2WarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A-2 Warrants",
        "label": "Series A-2 Warrants [Member]",
        "terseLabel": "Series A-2 Warrants"
       }
      }
     },
     "localname": "SeriesA2WarrantsMember",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ck0001824293_SeriesTWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series T Warrants",
        "label": "Series T Warrants [Member]",
        "terseLabel": "Series T Warrants"
       }
      }
     },
     "localname": "SeriesTWarrantsMember",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ck0001824293_StockIssuanceCostsOfferingExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issuance Costs, Offering Expenses",
        "label": "Stock Issuance Costs, Offering Expenses",
        "terseLabel": "Offering expenses"
       }
      }
     },
     "localname": "StockIssuanceCostsOfferingExpenses",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Pre-closing Financing",
        "label": "Stock Issued During Period, Shares, Pre-closing Financing",
        "terseLabel": "Issuance of common stock in pre-closing financing (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesPreClosingFinancing",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Reverse Recapitalization",
        "label": "Stock Issued During Period, Shares, Reverse Recapitalization",
        "terseLabel": "Issuance of common stock to Vallon stockholders in reverse recapitalization (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesReverseRecapitalization",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Reverse Recapitalization Expenses",
        "label": "Stock Issued During Period, Shares, Reverse Recapitalization Expenses",
        "terseLabel": "Issuance of common stock for reverse recapitalization expenses (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit",
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Settlement Of Debt",
        "label": "Stock Issued During Period, Shares, Settlement Of Debt",
        "terseLabel": "Issuance of common stock for settlement of bridge note (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesSettlementOfDebt",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Warrant Exercise",
        "label": "Stock Issued During Period, Shares, Warrant Exercise",
        "terseLabel": "Warrant exercise (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantExercise",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Pre-closing Financing",
        "label": "Stock Issued During Period, Value, Pre-closing Financing",
        "terseLabel": "Issuance of common stock in pre-closing financing"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValuePreClosingFinancing",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Reverse Recapitalization",
        "label": "Stock Issued During Period, Value, Reverse Recapitalization",
        "terseLabel": "Issuance of common stock to Vallon stockholders in reverse recapitalization"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueReverseRecapitalization",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Reverse Recapitalization Expenses",
        "label": "Stock Issued During Period, Value, Reverse Recapitalization Expenses",
        "terseLabel": "Issuance of common stock for reverse recapitalization expenses"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueReverseRecapitalizationExpenses",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Settlement Of Debt",
        "label": "Stock Issued During Period, Value, Settlement Of Debt",
        "terseLabel": "Issuance of common stock for settlement of bridge note"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueSettlementOfDebt",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ck0001824293_StockIssuedDuringPeriodValueWarrantExercises": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Warrant Exercises",
        "label": "Stock Issued During Period, Value, Warrant Exercises",
        "terseLabel": "Warrant exercise"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueWarrantExercises",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued For Payment Of Reverse Recapitalization Costs",
        "label": "Stock Issued For Payment Of Reverse Recapitalization Costs",
        "terseLabel": "Issuance of stock for payment of reverse recapitalization costs"
       }
      }
     },
     "localname": "StockIssuedForPaymentOfReverseRecapitalizationCosts",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ck0001824293_StockIssuedForRepaymentOfNotesPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued For Repayment Of Notes Payable",
        "label": "Stock Issued For Repayment Of Notes Payable",
        "terseLabel": "Issuance of stock for repayment of bridge promissory note"
       }
      }
     },
     "localname": "StockIssuedForRepaymentOfNotesPayable",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ck0001824293_StockSubjectToPutRightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Subject To Put Right",
        "label": "Stock Subject To Put Right [Member]",
        "terseLabel": "Stock subject to put right"
       }
      }
     },
     "localname": "StockSubjectToPutRightMember",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ck0001824293_TEPNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TEP Note",
        "label": "TEP Note [Member]",
        "terseLabel": "TEP Note"
       }
      }
     },
     "localname": "TEPNoteMember",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ck0001824293_WarrantLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant Liability",
        "label": "Warrant Liability [Member]",
        "terseLabel": "Warrant Liability"
       }
      }
     },
     "localname": "WarrantLiabilityMember",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ck0001824293_WarrantsExpiringIn24MonthsAfterRegistrationDateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Expiring In 24 Months After Registration Date",
        "label": "Warrants Expiring In 24 Months After Registration Date [Member]",
        "terseLabel": "Warrants Expiring in 24 Months After Registration Date"
       }
      }
     },
     "localname": "WarrantsExpiringIn24MonthsAfterRegistrationDateMember",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Expiring In 60 Months After Registration Date One",
        "label": "Warrants Expiring In 60 Months After Registration Date One [Member]",
        "terseLabel": "Warrants Expiring in 60 Months After Registration Date"
       }
      }
     },
     "localname": "WarrantsExpiringIn60MonthsAfterRegistrationDateOneMember",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Expiring In 60 Months After Registration Date Two",
        "label": "Warrants Expiring In 60 Months After Registration Date Two [Member]",
        "terseLabel": "Warrants Expiring in 60 Months After Registration Date"
       }
      }
     },
     "localname": "WarrantsExpiringIn60MonthsAfterRegistrationDateTwoMember",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ck0001824293_WarrantsExpiringInApril2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Expiring In April 2028",
        "label": "Warrants Expiring In April 2028 [Member]",
        "terseLabel": "Warrants Expiring In April 2028"
       }
      }
     },
     "localname": "WarrantsExpiringInApril2028Member",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ck0001824293_WarrantsExpiringInDecember2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Expiring In December 2023",
        "label": "Warrants Expiring In December 2023 [Member]",
        "terseLabel": "Warrants Expiring In December 2023"
       }
      }
     },
     "localname": "WarrantsExpiringInDecember2023Member",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ck0001824293_WarrantsExpiringInFebruary2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Expiring In February 2026",
        "label": "Warrants Expiring In February 2026 [Member]",
        "terseLabel": "Warrants Expiring In February 2026"
       }
      }
     },
     "localname": "WarrantsExpiringInFebruary2026Member",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ck0001824293_WarrantsExpiringInJuly2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Expiring In July 2027",
        "label": "Warrants Expiring In July 2027 [Member]",
        "terseLabel": "Warrants Expiring In July 2027"
       }
      }
     },
     "localname": "WarrantsExpiringInJuly2027Member",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ck0001824293_WarrantsExpiringInJune2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Expiring In June 2025",
        "label": "Warrants Expiring In June 2025 [Member]",
        "terseLabel": "Warrants Expiring In June 2025"
       }
      }
     },
     "localname": "WarrantsExpiringInJune2025Member",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ck0001824293_WarrantsExpiringInMay2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Expiring In May 2027",
        "label": "Warrants Expiring In May 2027 [Member]",
        "terseLabel": "Warrants Expiring In May 2027"
       }
      }
     },
     "localname": "WarrantsExpiringInMay2027Member",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ck0001824293_WarrantsExpiringInNovember2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Expiring In November 2023",
        "label": "Warrants Expiring In November 2023 [Member]",
        "terseLabel": "Warrants Expiring In November 2023"
       }
      }
     },
     "localname": "WarrantsExpiringInNovember2023Member",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ck0001824293_WarrantsIssued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Issued",
        "label": "Warrants Issued",
        "terseLabel": "Issuance of warrants for payment of stock issuance costs"
       }
      }
     },
     "localname": "WarrantsIssued",
     "nsuri": "http://www.vallon-pharma.com/20230630",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails",
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails",
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r149",
      "r150",
      "r208",
      "r236",
      "r348",
      "r463",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r190",
      "r191",
      "r192",
      "r193",
      "r259",
      "r353",
      "r378",
      "r393",
      "r394",
      "r449",
      "r450",
      "r451",
      "r452",
      "r456",
      "r460",
      "r461",
      "r469",
      "r475",
      "r479",
      "r484",
      "r523",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r190",
      "r191",
      "r192",
      "r193",
      "r251",
      "r259",
      "r290",
      "r291",
      "r292",
      "r352",
      "r353",
      "r378",
      "r393",
      "r394",
      "r449",
      "r450",
      "r451",
      "r452",
      "r456",
      "r460",
      "r461",
      "r469",
      "r475",
      "r479",
      "r484",
      "r487",
      "r517",
      "r523",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails",
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r190",
      "r191",
      "r192",
      "r193",
      "r251",
      "r259",
      "r290",
      "r291",
      "r292",
      "r352",
      "r353",
      "r378",
      "r393",
      "r394",
      "r449",
      "r450",
      "r451",
      "r452",
      "r456",
      "r460",
      "r461",
      "r469",
      "r475",
      "r479",
      "r484",
      "r487",
      "r517",
      "r523",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails",
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r149",
      "r150",
      "r208",
      "r236",
      "r348",
      "r464",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r515",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_WeightedAverageMember": {
     "auth_ref": [
      "r460",
      "r461",
      "r561",
      "r563",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average [Member]",
        "terseLabel": "Weighted Average"
       }
      }
     },
     "localname": "WeightedAverageMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "ACCRUED EXPENSES"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r14",
      "r483"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails",
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r40",
      "r131",
      "r374"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in-capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r299",
      "r300",
      "r301",
      "r390",
      "r512",
      "r513",
      "r514",
      "r551",
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional\u00a0Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r56",
      "r57",
      "r262"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r7",
      "r42",
      "r104"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Warrant issuance"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r294",
      "r307"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r226",
      "r341",
      "r473",
      "r474",
      "r508"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt discounts and issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities (in usd per share)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r110",
      "r133",
      "r148",
      "r176",
      "r178",
      "r180",
      "r182",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r313",
      "r315",
      "r334",
      "r369",
      "r415",
      "r483",
      "r495",
      "r521",
      "r522",
      "r559"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r127",
      "r137",
      "r148",
      "r182",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r313",
      "r315",
      "r334",
      "r483",
      "r521",
      "r522",
      "r559"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r265",
      "r266",
      "r267",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails",
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Accounting"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.",
        "label": "Business Acquisition, Transaction Costs",
        "negatedTerseLabel": "Plus: Transaction costs"
       }
      }
     },
     "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails",
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r107",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "MERGER WITH VALLON"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/MERGERWITHVALLON"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid and other assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r60",
      "r61"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "totalLabel": "Total net liabilities assumed"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CallOptionMember": {
     "auth_ref": [
      "r453",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial contract between two parties, the buyer and the seller of the option, where the buyer has the right but not the obligation to buy an agreed quantity of a particular commodity or financial instrument (the underlying instrument) from the seller of the option for a certain price (the strike price). Seller is obligated to sell the asset to the buyer, if the buyer exercises the option.",
        "label": "Call Option [Member]",
        "terseLabel": "Call Option"
       }
      }
     },
     "localname": "CallOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r29",
      "r129",
      "r462"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets",
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r29",
      "r91",
      "r145"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r1",
      "r91"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFDICInsuredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.",
        "label": "Cash, FDIC Insured Amount",
        "terseLabel": "FDIC insured amount"
       }
      }
     },
     "localname": "CashFDICInsuredAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashUninsuredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.",
        "label": "Cash, Uninsured Amount",
        "terseLabel": "Uninsured cash balances"
       }
      }
     },
     "localname": "CashUninsuredAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [
      "r134",
      "r135",
      "r136",
      "r175",
      "r234",
      "r235",
      "r236",
      "r238",
      "r241",
      "r246",
      "r248",
      "r385",
      "r386",
      "r387",
      "r388",
      "r475",
      "r503",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Warrant exercise price (in usd per share)",
        "verboseLabel": "Exercise Price per Share (in usd per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrants granted (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Number of Shares",
        "verboseLabel": "Number of shares (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r22",
      "r73",
      "r370",
      "r402"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 11)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r98",
      "r187",
      "r188",
      "r459",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common shares reserved for future awards (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r485",
      "r486",
      "r487",
      "r489",
      "r490",
      "r491",
      "r492",
      "r512",
      "r513",
      "r551",
      "r569",
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common\u00a0Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit",
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets",
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r81",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets",
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r7",
      "r81",
      "r403",
      "r421",
      "r570",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValueOutstanding": {
     "auth_ref": [
      "r81",
      "r403"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.",
        "label": "Common Stock, Value, Outstanding",
        "terseLabel": "Common stock, 0.0001 par value; 250,000,000 shares authorized as of June\u00a030, 2023 and December\u00a031, 2022; 2,956,354 and 999,748 shares issued and outstanding as of June\u00a030, 2023 and December\u00a031, 2022, respectively"
       }
      }
     },
     "localname": "CommonStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "auth_ref": [
      "r31",
      "r32",
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Converted",
        "terseLabel": "Conversion of stock (in shares)"
       }
      }
     },
     "localname": "ConversionOfStockSharesConverted1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertibleNotesPayableMember": {
     "auth_ref": [
      "r77",
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.",
        "label": "Convertible Notes Payable [Member]",
        "terseLabel": "Convertible Notes Payable"
       }
      }
     },
     "localname": "ConvertibleNotesPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r31",
      "r33"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Conversion of convertible notes to common stock"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "auth_ref": [
      "r31",
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "terseLabel": "Convertible notes, converted, shares issued (in shares)"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r99",
      "r146",
      "r204",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r220",
      "r227",
      "r228",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "PROMISSORY NOTES"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r12",
      "r77",
      "r78",
      "r111",
      "r112",
      "r151",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r211",
      "r216",
      "r217",
      "r218",
      "r219",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r342",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r12",
      "r112",
      "r231"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Long-term debt, gross"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r100",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Conversion price (in usd per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r67",
      "r69",
      "r205",
      "r342",
      "r471",
      "r472"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt instrument, face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r20",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Convertible notes interest rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [
      "r151",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r211",
      "r216",
      "r217",
      "r218",
      "r219",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r229",
      "r342",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r21",
      "r151",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r211",
      "r216",
      "r217",
      "r218",
      "r219",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r342",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r21",
      "r47",
      "r50",
      "r66",
      "r67",
      "r69",
      "r74",
      "r102",
      "r103",
      "r151",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r211",
      "r216",
      "r217",
      "r218",
      "r219",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r229",
      "r342",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-Term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r68",
      "r216",
      "r232",
      "r471",
      "r472"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "terseLabel": "Unamortized debt discounts and debt issuance costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtPolicyTextBlock": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.",
        "label": "Debt, Policy [Policy Text Block]",
        "terseLabel": "Debt Discounts and Debt Issuance Costs"
       }
      }
     },
     "localname": "DebtPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.",
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "terseLabel": "Deferred Stock Issuance Costs"
       }
      }
     },
     "localname": "DeferredChargesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "auth_ref": [
      "r68"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Gross",
        "terseLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsGross",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r4",
      "r39"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r260",
      "r264",
      "r295",
      "r296",
      "r298",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "STOCK-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r143",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r165",
      "r167",
      "r169",
      "r170",
      "r171",
      "r173",
      "r325",
      "r326",
      "r367",
      "r377",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share of common stock, basic (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r143",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r167",
      "r169",
      "r170",
      "r171",
      "r173",
      "r325",
      "r326",
      "r367",
      "r377",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share of common stock, diluted (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r34",
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Common Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Payroll and related"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation, weighted average amortization period (in years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r550"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails",
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails",
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r7",
      "r125",
      "r140",
      "r141",
      "r142",
      "r152",
      "r153",
      "r154",
      "r156",
      "r162",
      "r164",
      "r174",
      "r183",
      "r184",
      "r250",
      "r299",
      "r300",
      "r301",
      "r309",
      "r310",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r324",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r345",
      "r379",
      "r380",
      "r381",
      "r390",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit",
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r0",
      "r4"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment of Warrants",
        "verboseLabel": "Change in fair value of warrant liability"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [
      "r328",
      "r329",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r328",
      "r329",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Schedule of the Fair Value of the Warrants"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSTables",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r218",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r329",
      "r349",
      "r350",
      "r351",
      "r471",
      "r472",
      "r476",
      "r477",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r65",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r218",
      "r252",
      "r257",
      "r329",
      "r349",
      "r476",
      "r477",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted Prices in Active Markets (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r218",
      "r252",
      "r257",
      "r329",
      "r350",
      "r471",
      "r472",
      "r476",
      "r477",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Significant Other Observable Inputs (Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r218",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r329",
      "r351",
      "r471",
      "r472",
      "r476",
      "r477",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Significant Other Unobservable Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r9",
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r9",
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of the Changes is the Fair Value"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r332"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Change in valuation"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r9"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Fair value as of June\u00a030, 2023",
        "periodStartLabel": "Fair value as of December 31, 2022"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r218",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r349",
      "r350",
      "r351",
      "r471",
      "r472",
      "r476",
      "r477",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r89",
      "r425"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r185",
      "r186",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r186",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r3"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r3"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Change in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r504",
      "r507"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r3"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Temporary Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpenseBorrowings": {
     "auth_ref": [
      "r115"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate amount of interest expense on all borrowings.",
        "label": "Interest Expense, Borrowings",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "terseLabel": "Interest expense, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r72",
      "r568"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.",
        "label": "Interest Payable",
        "terseLabel": "Accrued interest"
       }
      }
     },
     "localname": "InterestPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentCompanyCommittedCapital": {
     "auth_ref": [
      "r391"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of funds committed to investment company from investors.",
        "label": "Investment Company, Committed Capital",
        "terseLabel": "Investment in cash"
       }
      }
     },
     "localname": "InvestmentCompanyCommittedCapital",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestorMember": {
     "auth_ref": [
      "r555",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value.",
        "label": "Investor [Member]",
        "terseLabel": "Investor"
       }
      }
     },
     "localname": "InvestorMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r17",
      "r148",
      "r182",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r314",
      "r315",
      "r316",
      "r334",
      "r401",
      "r467",
      "r495",
      "r521",
      "r559",
      "r560"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r86",
      "r113",
      "r373",
      "r483",
      "r511",
      "r516",
      "r554"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity (deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders' equity (deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r19",
      "r128",
      "r148",
      "r182",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r314",
      "r315",
      "r316",
      "r334",
      "r483",
      "r521",
      "r559",
      "r560"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Liabilities, Fair Value Disclosure",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-Term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r21",
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-Term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [
      "r189",
      "r190",
      "r191",
      "r194",
      "r519",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r189",
      "r190",
      "r191",
      "r194",
      "r519",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "auth_ref": [
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.",
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "terseLabel": "Dividend rate"
       }
      }
     },
     "localname": "MeasurementInputExpectedDividendRateMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Measurement Input, Expected Term [Member]",
        "terseLabel": "Expected term in years"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input, Price Volatility [Member]",
        "terseLabel": "Volatility"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r116",
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "ORGANIZATION AND DESCRIPTION OF BUSINESS"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r144"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r144"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r91",
      "r92",
      "r93"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r87",
      "r93",
      "r114",
      "r126",
      "r138",
      "r139",
      "r142",
      "r148",
      "r155",
      "r157",
      "r158",
      "r159",
      "r160",
      "r163",
      "r164",
      "r168",
      "r176",
      "r177",
      "r179",
      "r181",
      "r182",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r326",
      "r334",
      "r376",
      "r423",
      "r441",
      "r442",
      "r468",
      "r493",
      "r521"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss)",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit",
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Notes Payable, Current",
        "terseLabel": "Bridge promissory note, net"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r176",
      "r177",
      "r179",
      "r181",
      "r468"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r344"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities, current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r344"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, non-current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r343"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r508"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "terseLabel": "Reduction in operating right of use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityEquityAxis": {
     "auth_ref": [
      "r43",
      "r62",
      "r63",
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of options indexed to an issuer's equity.",
        "label": "Option Indexed to Issuer's Equity [Axis]",
        "terseLabel": "Option Indexed to Issuer's Equity [Axis]"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityEquityAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding.",
        "label": "Option Indexed to Issuer's Equity, Type [Domain]",
        "terseLabel": "Option Indexed to Issuer's Equity, Type [Domain]"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedTerseLabel": "Payment of debt issuance costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedTerseLabel": "Payment of deferred stock issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r505"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r2"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock in pre-closing financing",
        "verboseLabel": "Proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.",
        "label": "Proceeds from Notes Payable",
        "terseLabel": "Proceeds from issuance of bridge promissory note",
        "verboseLabel": "Proceeds from issuance of notes"
       }
      }
     },
     "localname": "ProceedsFromNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r506"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from warrant exercise"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r96",
      "r119",
      "r122",
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "PROPERTY AND EQUIPMENT"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r97",
      "r130",
      "r375"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r5",
      "r368",
      "r375",
      "r483"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets",
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PutOptionMember": {
     "auth_ref": [
      "r453",
      "r454",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A financial contract between two parties, the buyer and the seller (writer) of the option, where the buyer has the right but not the obligation to sell a commodity or financial instrument (the underlying instrument) to the seller (writer) at a certain time for a certain price (the strike price). The seller (writer) has the obligation to purchase the underlying asset at that strike price, if the buyer exercises the option.",
        "label": "Put Option [Member]",
        "terseLabel": "Put Option"
       }
      }
     },
     "localname": "PutOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r258",
      "r346",
      "r347",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r420",
      "r422",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party, Type [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [
      "r426",
      "r427",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r258",
      "r346",
      "r347",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r420",
      "r422",
      "r448",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party, Type [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r27"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "terseLabel": "Payment of notes payable"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r75",
      "r308",
      "r567"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted stock with repurchase rights"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r83",
      "r104",
      "r372",
      "r382",
      "r383",
      "r389",
      "r404",
      "r483"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated undistributed earnings (deficit).",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets",
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r125",
      "r152",
      "r153",
      "r154",
      "r156",
      "r162",
      "r164",
      "r183",
      "r184",
      "r299",
      "r300",
      "r301",
      "r309",
      "r310",
      "r317",
      "r319",
      "r320",
      "r322",
      "r324",
      "r379",
      "r381",
      "r390",
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated undistributed earnings (deficit).",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Common Stock Equivalents Excluded From Diluted Net Loss Per Share Calculation"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r58",
      "r59",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails",
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "auth_ref": [
      "r58",
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "terseLabel": "Schedule of the Net Liabilities Assumed in the Merger"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r328",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value, Liabilities Measured on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r70",
      "r71",
      "r426",
      "r427",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r261",
      "r263",
      "r265",
      "r266",
      "r267",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r10",
      "r11",
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Activity of Stock Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r44",
      "r45",
      "r46",
      "r47",
      "r48",
      "r49",
      "r50",
      "r102",
      "r103",
      "r104",
      "r134",
      "r135",
      "r136",
      "r175",
      "r234",
      "r235",
      "r236",
      "r238",
      "r241",
      "r246",
      "r248",
      "r385",
      "r386",
      "r387",
      "r388",
      "r475",
      "r503",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of Warrants Outstanding to Purchase Common Stock"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r3"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [
      "r261",
      "r263",
      "r265",
      "r266",
      "r267",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of additional shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted average remaining contractual term\u00a0(years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable, Ending Balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "periodEndLabel": "Exercisable, Ending Balance (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited/Cancelled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails",
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r269",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, Ending Balance (in shares)",
        "periodStartLabel": "Outstanding, Beginning Balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r269",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, Ending Balance (in usd per share)",
        "periodStartLabel": "Outstanding, Beginning Balance (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r265",
      "r266",
      "r267",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "All Award Types"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails",
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r260",
      "r268",
      "r287",
      "r288",
      "r289",
      "r290",
      "r293",
      "r302",
      "r303",
      "r304",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Fair value of option on grant date (in usd per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Stock awards, contractual life (up to)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term in years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r7",
      "r24",
      "r125",
      "r140",
      "r141",
      "r142",
      "r152",
      "r153",
      "r154",
      "r156",
      "r162",
      "r164",
      "r174",
      "r183",
      "r184",
      "r250",
      "r299",
      "r300",
      "r301",
      "r309",
      "r310",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r324",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r345",
      "r379",
      "r380",
      "r381",
      "r390",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit",
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [
      "r152",
      "r153",
      "r154",
      "r174",
      "r354",
      "r384",
      "r392",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r403",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r422",
      "r424",
      "r425",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r443",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r152",
      "r153",
      "r154",
      "r174",
      "r354",
      "r384",
      "r392",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r403",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r422",
      "r424",
      "r425",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r443",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r7",
      "r80",
      "r81",
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Restricted stock vesting"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r7",
      "r80",
      "r81",
      "r104",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r7",
      "r80",
      "r81",
      "r104",
      "r388",
      "r443",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "terseLabel": "Stock repurchased during period, shares"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r7",
      "r80",
      "r81",
      "r104",
      "r390",
      "r443",
      "r457",
      "r494"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Value",
        "terseLabel": "Stock repurchased during period, value"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r81",
      "r84",
      "r85",
      "r95",
      "r405",
      "r421",
      "r444",
      "r445",
      "r483",
      "r495",
      "r511",
      "r516",
      "r554",
      "r570"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.",
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total stockholders\u2019 equity (deficit)"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets",
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity (deficit):"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r101",
      "r147",
      "r233",
      "r235",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r247",
      "r250",
      "r323",
      "r446",
      "r447",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for equity.",
        "label": "Equity [Text Block]",
        "terseLabel": "STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITY"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Reverse stock split"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.",
        "label": "Substantial Doubt about Going Concern [Text Block]",
        "terseLabel": "LIQUIDITY"
       }
      }
     },
     "localname": "SubstantialDoubtAboutGoingConcernTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITY"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash financing activities:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [
      "r195",
      "r197",
      "r198",
      "r199",
      "r202",
      "r203",
      "r306",
      "r371"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockAcquiredAverageCostPerShare": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.",
        "label": "Shares Acquired, Average Cost Per Share",
        "terseLabel": "Purchase price (in usd per share)"
       }
      }
     },
     "localname": "TreasuryStockAcquiredAverageCostPerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r36",
      "r37",
      "r38",
      "r117",
      "r118",
      "r120",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [
      "r485",
      "r486",
      "r489",
      "r490",
      "r491",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [],
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "Warrants and Rights Outstanding",
        "terseLabel": "Warrant liability",
        "verboseLabel": "Outsanding warrants"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets",
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "terseLabel": "Warrants outstanding, measurement input"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Warrants, outstanding term"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r166",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares outstanding, diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r165",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares outstanding, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org//1943274/2147481766/480-10-25-13",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org//505/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "https://asc.fasb.org//805/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.7,8)",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org//275/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org//718/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.E.Q2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(iii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(iv)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(i)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(e)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(f)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(14))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(15))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(17))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(19))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(8))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "63",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org//1943274/2147481620/480-10-55-63",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(9))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r496": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r497": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r498": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r499": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r501": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r502": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org//450/tableOfContent",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "40",
   "Topic": "205",
   "URI": "https://asc.fasb.org//205-40/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org//235/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org//360/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org//440/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org//470/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>69
<FILENAME>0001824293-23-000147-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001824293-23-000147-xbrl.zip
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M'X=W3R-41'G34<?T$=*I*<<G-$]/32QSYKL)CIG*8^CG9X,X(D2S,3(M?-5
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MNKD@.\J;2SE#7B-OE)^P1+$GM:1^\_J60]*#;ZS(F6CO1*W]BUAFE%#;C<J
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M+=E:L-CQ_H>_O<J@6^V)T4XO^Z P@TS^+%JMG!+OD3S^1&D2.[' J5+[]V2
MF XLO?A&ZVN(_T:V+#Q,9LIAZ#B6-G9I-/S9? "^,.*Z;$I];/ ?E\^3/;GO
M(/7VM>A*H1HC5/M;A"J+PE!_<6^!VFQLRD\I16HI4H\K4ON;16HX2,*D:HHI
M%<T-\WE*6B]I_=BT+C;V(_;MC1&;.!ZH46TUXVKS2H+/DN SVGNNB3M=Y\^D
MK3\S(/,FD'F[*G5[^1NA>>H2\Y+1SIW1(E[HX?BL51FTJKU6[MFLT!,ADI'(
MNH$0NVZW*+ZT;\#OO^V= A0EZ/8%W:%"1R5F2M"5H,L9Z!(46>9IQ-LA_" I
MHS[MS79ET&Q$9_VF[M->T&&^YTXGS:SHI),C.KF@W +ANVPI4R^G0#I\1+08
M3)"VAT+KR"D%S>ZZE(*4Y=AE "F7['F1 :14BJ=U^#2&9B\^C>&,6>Q8V12E
M.MFH3MK'3*;HKT^F.&-*+Y5)J4SB^2WC!(Y68WT"1\E?)7]= G]%AM%F?<C7
M$M?FC)0\5O)807DL72@NZ6C-#+A-HJDK[5Z4VW)VIEXR6LEHF3-:)/1P.$9K
M5@;MJMC./9^5N2MI6K.>14R#^S1[M?\\L=3/ONENB=EB8?; F3\EX9PKX928
M+3%;8K;$;(XQF\ZI29J0ORV1I]6J#*1^=.I1ZD2>DK;.A;8BT=]=2:M="-*Z
MI.RQO[D&$9J-S)+'CC2T))<')VMR ;8U5L@ZM:S5.4AJV9$F?9PR_)L]\>:-
M[W<-#N\'F6*R<YR1M:511!9):ZWN 9+6BLR\^4MI*Y7<*F-(C2,FO+5Z!TIX
M*S*7E"JN5'%9J#AIS_8PFU/I^@=*I2LYM^3<B^?<2.N;K+,9VHW#).F5W%MR
M[SER;ZH@JY2T8CL#/A9I^E^ONT\HMF3ADH5+%MX2'CH<"TN86-AJ%9R#-P]S
MCAW_R#97#I8L!TOF::WEL,9S66LY6#*?@R7%7CE8LAPL60Z6+ =+'I(DRL&2
M!QPLR5P=X8H#=F7 _";97TZ87#^<;Z_]7@30TDW'.Y+2+"=,EA,FSY:'R@F3
MQ\WCC9\PN3ZA]^*&H>W3=;CL+5 .7#H>.1TKW?'B1$#:E,;F$5,:V\W*H-_O
M5[LQ4TY*F57*K*/G$D7:@F>8!=ANE1,12V+/$;%O:46<P6E]NS(0.]5>5RP)
M/A\I*Y>3E")%>J,>+BFE V3>J[;ZT=+#G+6[*AFM9+2L&>UX7>7:6")8[4C9
M)7_EI9*^>%WE*#9K8]DFN,79G!BVC*@H)R1FWZ.C!%U>^Z25F"F)N@3=*7S7
M+9W9ARKF-\^(X=C/9I "A,D_(X.G_M#H)=5@-R$%]DC -K$UASP1ZU53R /L
MQ50?B6*^&/0M_Y!UE\19)SAUIYF-HWOAE%#.RCP&"T7ZKI^>A?JQ++1;C[^R
M)58BDGDDMF-I"B;^V6C3"Z_P!UA[%@&Z2Y$Y&1YMEJ#+ZZEP$3&3]NRWM^7L
MEWK](]MVB?K%M0 :3+2S<^! DM#;AF^RI=X1YW[RU;0F1'-<^L7(&7"G41FT
M.MVCG!"<.[YSPHDEZ'9NM54\FW.W1LSQAE(N^JV56#H$EBX@)OZ[;%FRX0@:
M*$A,3RUCX67$HUB@*V/A><5,";J+ MVQ8^%<=3'7+B8RUQ$K@W93.FYT^RQ#
MM'O-+2GH!(GB8>G8@?2M_"?%\U\9&C_EY,0R%%)&D7()NC(4GE?,E* K05?&
M*[/.]4_:@')E4E>Z].-.LS*0LAEJ78:]<TE&$4/^(&34RA4974!<WI_Z]EVV
ME*G7):)9#D2_E$FJ!\1FWF@]>;U2NKV7%)R/:-N!#W$N3/2ES(]J'G/<5P>+
MIZNP_:HD1BO>SIC62VE]WM(ZC4G>/.18KDXGL[%<)7^5_)673:?BKX,/S^I@
MT7:WVMI_+G/)8R6/Y673J>)*S>.-N.KT*@.I4>VT]FE%4C):R6AYV70Z1HNT
M;SL<H_4K@V95BAD)F3,^NX \C=2]2#)K"E>,*,=>N?_YT (9'F*5F"TD9@^<
M]5(2SKD23HG9$K-G@=E4EO"6WJXG:.[1;631W*,DU/P3:BF"SA6S:410I/_N
MZ2606!@)= %96:D;#YUEH5%9#E9BZ2+3B(I'!&F3A=J';Z:4+J.H*^$XAE:U
MT8Q.VSD?TCY+VCL[ 51BJ<12B:422_G%T@4<G'H-J\@[L13-7M^PZBQKPT[>
M$JVLX+M$+)W^(+-X1)"5ZZ7\A&6*/:DE]9N;_2\N&F^Y9$SM:C4K@U:SVNGM
MW;(EQY1\EJ1V=O+F++&4Q5EH$F% CQ)69($==[30J@S$DM<+1D4EKQ<!2QD<
M.F;*ZNV<L?H%G!6.>$=EP9Q@AN_,-/B9H68(<XO4%-VT82O"1#/@MO(0L8QH
ME5@J#Q'S2 3']V0?+'+#Q.-73SJF]F9QP'55$EO5_OZ:+\<$?984=W9BYRRQ
M=%2'=F>1$+*"L:Q;K'8E\8SE05[><?$4OZ];EP7!]W)(\!=P1KG6]0/T"39Q
M')U@$C%>'EN:^D($PW3*D\PRCE5BJ3S)S!\1'-__>_)EY/WD"QD[J9V_?F70
M;E6E_MY)HSDFY;.DM;,3.&>)I:-Z?KL)@\ *[C6P[4FSF54551ZI+"_ON'AJ
MW]?KVYO8Q?P1^R4?]J''9Q%8J4W@OPJK$=7^18M"!?*.!:)D_;"FLPRBE,'=
M$DOY#(R6)W\G]_P>F:Q\7!&5MUQ2IG4$>Q*HPT:UW2J/  M&>F<G?\X22T=U
M!#.1#2%3N8D9 KUN5H,*\DAT>7G'Q1/_OGYAUK3?RA_M7_+!H&,*@&;=^YVW
M^<54T77.8WE:6.B 78FE(F"I/"TLL,^8VE=L5P:M5J_:Z71S%#PM!<\E"IZS
MQ%*ZN0@1;W%E+L*^IG-JD[F#,W#[K9S,P,WCZ5])^5E0?L15/#7A=W-%^!=P
MFGA''$$W[?)<L-C!MQ)+1<#2@<\%\Q*!+=]Q <R9SL+N))P\!NIH9"CFC'P#
MG93:>NA5!IUJ-XOA?GF4'B49;3-7LZ&B?JZHZ *.*C[+.IY45(6_N081FHVJ
M(#6D9@;CZ=BFKIL >M5TQSIABO2<1DYD,4QD+S"=.*AP,DK(&Q,E'W^:)61*
MWL@Q;^3H;.ER!'+:,ZGNEC$(-_3LGL;>V!'4O>O8CFRH.S0JZ3=H>*W=J3;;
MK6P'_1293TH=4NJ03+(.NYMG>FT;JSW1WHE:^Q>QS!BWI"_Z"JWDW))S2\[-
ME'-[^W'N]JA"'ZL#Q&JK&3W:*KFWY-Z2>_<*+_<3!@8SX.,FF-#=:K,?K?))
M?41=LG#)PF?,PJDX^.#ZMU499#+:+P>\2X\$/CHR? [^JVJO@U_@'V_),]EZ
MT0QO98@J_A>Z&FF9C10"6+"RI@^QX1$(?>,US0A2-I.,A"3S1(@@*XHY@]4L
M $RT69F-)0NN(;NJAM-P-5RQ-D,"HG"5\8^\L[6LPQ[@#W1N<EWPD;H*(_[1
M?J_>[\-2YZ9-)R-?6T27'>V5?'K35&?JT7'H00[51O"(/(95N,[Z1Z+X."+\
M-T*[O0R?\+^X?N0<C:C=+I%;DW&KUVZ)1!WW.Z+4[DG*N*VT&^/N/Z5>Q7MH
M:GD[F,LOI#:VB/RS)D]@@]>R_B8O[,K'9<@ 6/B".AP3B8&X'F23R<% QC '
M0L:T:'K;-<@%8N%=L!PY-VL1IA9*U;]L1UZW,GA&,8)%0C<HD(%M?ODH#^((
M(X2-XQ-P-Y: ?WL<"9\ULRJ,#*6^EMGSLMJ;L,!Z\L44A;UL3X6ONOEFYWX7
M5YHA.%/3A7>H]H?\+_>'ISC6KW6KQH2U4VT;: &JWF$/NCRWR;7WPR=5L^>Z
MO+C6#+H2^M"GY=>WYQ'M3F'%+@<"L-Y@0I ?_?,O\\MU>FG%5F'7NIVZ*$EK
M+S?JXMIKFUXKPH+$]8]N>NWF:\UV^S"+30:#+>D56\^^^I%;8YP5Q@&GL<WC
MV>))>Q>^PUU36[@%O:'ZJ1=+=O"^P DYEDD-XMR"C7+CQKR4-+N]*)!):8@J
MWPE-_42>[_V<H%$&_@OZF*_@*!#[.@G=;/$V]R2H(^0/)%UA1I45U'WNYIL8
MUE58[)W+F;>-)@^!Q>WP1*&L9%M+%8T6CY&EVF]7!KUJKY^3+-6,<IU+GCA3
MGHAD1B3CB2C9=RJ#=C]:-%_DU.PB*+&A^H=K.RQ>X9C8(<8T% T\8H-K-_RK
M@E$,UZ8Q6L',V@;*BZ5S<'M&;.:;%KZ0.>!?6^HKNQ-B8V#0\F!PLBS/9##8
MRQY8%GEA<,9)/"R)CLB[+."=1<W;N>)L2R;?-ISA,*3-.,M2=^1=8 QG)JR%
M-Z(V)P#9L2.HFJW _D"?R 8H#*];F6+:SOIB])0 .D?*W")-PK"^G_CCO&X0
MK$-#_>)!/;6_T<?4<;$131O/BTX_5X1O$46[(7Q3JK'4:*Q/-=Y/B!78ZJ$I
M*+6QC.8M)BB U5-:0-G(+%K7\ADA>Q,";!QABB"$HA&/TA@ZJ01:A[[D\D8Z
ME+PIL-%T,Y6-%X*>]$36+.$5NRRA\?0F6Y9L@-.MR6--UYQ%:2SM+'B^ F1I
M^ZH@O'$_^9T!.";Z)#6:E4$G.NZFM(!.*G^V8#&Y&&J59D\$3X]$=1F&EF)Z
ME)Y0'+DV$63;)AN<MH+U+3FZ%/)/B[\14**/^)'[R0^;#!&L8?.>=V"/(]UV
MK&%T49VS+EP*9D%%V'9TBWK;(ON\!#AXGFS&X['N/+<%GZF1&SHNHMJ$1@4]
M&[<\.DIJ3?3SC>\'B\QE3?6G$5(LF\Z46(+B6A8.JK]$8V*_]))E/3 R% LU
MP!?"_CLR.-"_D D!$*M<_@\-]1X!3_5#K+/3K0RZ[7TZ\>;8GBC):(LYD1T9
M]2J#:-%=X?,U\BYIAPH_79O+"ZQ"**-$&4I4#[@/#+8IS]*D1A]K4<5NOXPD
MY<N'2H#I"#+%!JC)+9B\)!,/(&:Y1-T^<+ITZ7<2/ C<;X%?E%;VB").XQ/;
MT13*\A0M?[(G@NPH/B70)8VLY4^!#9^@]D9',(9C")=F QVD:B%*I\N11X]<
M%W'$VL01V=N=@=+L.5'Z_5[(;<5&CS\<S!*2VOF61#?;TN'W"7(5HV7N::NK
M$ $/EOFJJ43]O/@!F C1\]!'0VH3JDU3(<6HTDT=U<A'CZ\,@V872Y8I"IP2
MDV64\CI@O(L9E/P=H3^5XS<#XD!E37OR7YJ<_Q46>BQ=,MX;&:_$SJ1Z[  >
M:N;ON*!"P@?74J;HEYD386ZA5>0LZ"D@^=/5YIB[57IINT>,'N0%K=%\-H<*
MP-,B#QS$#[IL.$-#O?6@'*==NHE.:DKG[*AQH30H39SJ*/9.D.I8*']-BU%
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MTW7 B#.H-01Z@JAH0P$C+X%G^1M4IX!\0 3 G4 P&.-'*@/M!W^@9(N/T0,
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MH%G)WH>I0-.!9%C&$O=@\28+Z8&>7/BP1FW'?XQ_+GR20>EH1C-B>%"?2T$
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MO/.^!7<'W\4,@#<6G0F[YBI:BO347W[G8*YZR7O4'>=S#:K^8?=23)+30^@
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MZE)R01(<*YAC^/HK.OA5SP]5-5!D#J@@>K_W6Y6212A]B)_CH3DDL!0PWK+
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M@!MXVVV,>A=<#$;GK;O,WZ6, QV:I6,Y_DQ@LWS8$P<;Z595#&%Y=@2S, W
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M=-]$6-,2P.]C*?*<112RNX1+$'<VP_(#E$>@5\#3'FA?Q-X#E%J>-0/N&(3
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M[M @3@^%UT. &3//!0 ";EO\XM@OE_N]5L:HI2N+=[M@W.1>XX2 YP$]X4V
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M W[<+9"$/8;S":Q[,,T)G+1O(%B?0!8DGHC /" JV],@B!@YZ. O2\#!IJ?
M3&'(AH&9N\#(!*L>)Z"8PBOTW/S=;/8N>;JYL(?=DT!;YK!6'+/9G"Y'O>SL
MCE.W*=X8$ EHFESQ TSG$BY&;X$PH@#G08LC>!%%.];B- Y.X7]4MRO%?JA+
MC2V>RXL.48"Z6DB<9?UJ2/T.T3S,T0*&?V/-&H,92HO+N?)J$33)A[N 6&8
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M&&FXR!4$HKJ0(?HJ2-00$!M]QN=3ETTP@T5HOU>8DL-X!C#_[DNJ$,GO9"!
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M+].$MKW'WG;W6+.+.VN1^UC[PA,]:Y]]R76@+"78SY2"5"-* Y8AGDRFL,K
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ME.?YS@:;F!N!K^O^E)]SIR@WFZJOG]<.JR\1(6P]6&!3 +3+^!2=M\^7F-]
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M_PMC6[>9KD:R3GLT'X@L#4S2;H+^C,-[6UX-QV&<2-+M23??0O%RV!VG7H/
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M^7@?-2K;C,TKZR)G')Q#!ZHH Y$^TB@QHM*,QKV6UNA!\O:!E.J1TW83UW9
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M!G4P9T:2N-Q>M:?84C(M&'@("B;S!:-E>VO)6J%#AY!04A<Z?@F5DU"S*^>
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M0,^Y ^VZC1."U:#;;%G2U_TA9MRE;J\T!HBZ<T"#(N$P6D7(HA<*:&BNEP]
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M#R2PA5*QHD;<@F+P60_85>@<7"08+JV%H:B'XA*2DFVJ!5SS9!)<HMX;'+/
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M)'@J$BF8-,42T;R%:9+5'=@R%DS#,H!T(!@ Y1R 0L5$57>6&O8V:*#ESZM
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MB8A&I1WLK)?KX9$P6C-UEST7V255J)VCS84@:1F&I*\A['9B/%=T_[ENR+A
MFO2>H'@ZD G,Y]H/KC*5&9#'E102(_*,">E>+=^4,8&_'^?;VU]HD:[G(MU+
M_U;'JK%4"U=@/$-Y9R]O+R!17O: )B]?Y.XF)A[OC#A[P6"CHK2.ZMNGFW*L
MK;<2@]V+V53:*/^H';)">A&^%F8VY+A:LS)V::AMGU5O)*RWB=F%1&;ZWG?4
M,#ZS$Q&6L)(PB>D]X8B>C5@-'K!DRNQ[K -?[32:'3;"^?>&_$2J-Z8=PQQY
MMC,.Y31VGOVOJL+%Z_CS9@2ZF9U]/QV-Y]TXF-S%EM=/P,9KA,CI6^T1IYZ8
M!ZSVGW#<&8NI"\XYRS[<XQWG;084GG"<[SSZN/R&1+3=[)G.^YW"L^_K=NLD
MEN5V'4)6SGJ[AD/'BY)O[@/#E+0[5/))N=@O#NJU'NXTKP'!D0T;]:$:GE*+
MJ"-%F'@O8J+XV*GV8MBR*N?HWKI<G5P\PN"8-_?@W;"UHQUEOJ U[$U+/"7&
M^-*00?7X]Q%(J=YB!UO8D\8MF<:#BQV20&."E1$ =<:G=<PT_SL/&A=>2=44
MY=$N[1;59_#M!FM'I,Z+'N SUN;- ^)*SNC;L)C*[R$RY!4:FY,T V*XY%KI
M+)>C0F&TH._\3ZODC:-YL_%4XVV]X;TOQMV;O0/&,L(-9BE0#%77OH,09A*F
MZ"M#8,^'1F\^O"6%X_&1T MB6'[S8:3=N%8-TBK3G,[>\(6Y.UB[18D76N2D
M@^G#TKT-'CK?8YE4H[5AHC>C%*'75N2FJM@QW7)6W[FCJ47?V4T\2?PLTYOU
M;SZ[U>D7'A8H5=;W%D\(*NQU:S20<+A:V9:I51"*D &*!BAU#)@.?P Z58X8
MP!P\6UWT+YLA^W3>B,JY(_K- C2(8S[Z$*Q:6=4R[C42PII6"%QWN>"/3X?<
M0:KZ8V(YN1<4^&"3U <G'(7"!K5D!_/)(S;X9J^:Z+V1HF+36DGH0G5,[5NZ
M*8%\VY**O2G/)_">;CJ&=-)<C<7?+%E.?G*5AK@_4/X^J[\4]J;FP8.C8$9[
M&+>J;G:1ZNQ3=>AT_!R^HP,8,XNSG?L?S[%G-_ 6Z>= 4A;%QHG\BK-X"X(U
M"ZN?+@FEP=,ES3%W4O2A>M_2Y)%.W]X3*HGH,P*!>/JXE0PGN 0#1!O"&)//
M)D;[FA'5PHZ+&MAP,R6G6_H95>1+!LS@Q-X!?:B1-KSNQ6O[V>V%"$NJHD2#
MLCW9'76W=0S-]4S<:X9%(9/3^D+^.CAJ<VQ#_4A50Z"6NGZ&+YEXOEL_Y&I4
MO4]R\)7QI3,-@<\:!Y)X0-"N0I.)'UHBJK!8K[#Y3O)K@\%[FDZ-@Q>4"'2/
M 33R%FHJZ^ZAB6;:JZCKIK##G,B49*]?,)$U2;[=U%]\NRRF._/=#?LD,%J#
M]#Z[)J?DJZ8Y79SW1(6U-$6C^TD6;68S,% HU_3'I$MZFVV!&GILF=W(?*/J
M'[%*>JSR=BA09:)\;[X753-F3*;5X]?8&S+P=._"6&\U:."$,6QJ4',U=65]
M.WELFR'[ $1:5G;HGV@T=A2W'Q-4?<EJW_9K@ .2_)]/(D/5&9[F1[>HJ[/[
MMSX2-DZ#S>*B G]:Z,Y/ZJ8]!,GV0=9&II;YF(+R6E3%BZ@!2@HT&/\\J@=O
M3$&T32W>4UQHE[XNW3]E&I9?N/'5J(_C.;*WI5T'4^B<5+OUR]#=*3*1V1Q[
MY?U$'.9:CBC)HBPS3\&(BYDG-+7<V!N^]FRP""\HI[:V(GSO5>D]:\7C;R<]
M!SUH!NCT&71:R)$+#*T *M2\31]'KJY#[]V)D@S!HD\X^O8R?,Z(<PVKN_FJ
MQ!)G TR2OQ%9DK6>6UUU:@1(WU"59 24-9OK_LPU-;GATSC%G-PI8Z9,W6**
MWQXV3R$PP*[,MS4!K[N1.ZE]F')Q<O_F&QFROJF1L;!^3J^._O=()^/+]\#Y
M HT2=(0?3!)V-=CSEKGA@W!H3?/@Q\F):CBU!:LZ9:DK>+U%/08:R@9VKPOQ
M9JTYKVEV]A;H[S1QO[&YW(V!I.A>[->6\"2[H<&(DFC(T#$=20BX>7WG5K%B
M;X/6F^O?$KWJ)G?D45FXL3:OPXZ6ONF[3/4>Z*B)\(4?IW+&()%#EO.%3%CR
M]YWUR@)9<@%'_EO/<FH*[]G:6,*2BM0*Q .,A_33(:V^MQ"C [76M_4L:C;N
M/=*M_@Z+!N26Q!,R1K46[Z89U1#I7D?X -4)G=RT(OF/2+\$^6L37(W]L1TS
M =PM4.H)AWY81MNQ1M7'C;8%TBQG>]WBR F'F$;%;FW^0:/4*22XU\\N+K8>
MA@2]FTUG.':*9(0S\_[V>T'9^,;6UO3O'M"5*C0<YM!]-)%^T#.XLK>_OQXI
M-.H'8P59;L2RQH-F6Y.6Z^0\(E;;CN:6=@Z/PF':2>Q*S?4J_%[C^DK5QG1+
M\#AON7:H:\1F,.(XHJXFKR7$3AAF#SJ<V L9A:V[5/LF#(G4W*V':P!..+0=
M'8!3U41.32+NV.^PFEVS)S]*:5[F'.-SK!7"G'#DD4CB:Z/,LQA+4*1JA/V.
M0U@F>WAR.W;E FDLJ2NRB\D\Y8+%9UU2N/H<;=F#3US@O8:XOQ-CN:+[+]/_
MD.DS%G5B$3>5E0>V+1S^DNLS.#C87> )!GLR0C1MAVV&;?M0Z><1<![*H,3C
M_'MIOZ#T;D7=0EG=^S[J^M=:M72?IZP Z$R;UZBE9%965M]=,P6%1@4%9?FL
MK*D,IK?;:5+O,M(R.#@2K[L5.2/ E.OLRP.,UT4\W-%8 [K5-ZP[GD*(TF(&
M0''O%$(F+4\A!'JXK+;Q"4*HX_$(I6/>E$\00K*CSF-;M5+'+]=O7%S,F 5W
M85:Z7H1W'IH-DE9K,D[AC YGG=;T"<[23S@R?>WJ-8S#/M$9.V020X^,GJX[
MA3-/IBP<_ G.FDBG<,;:&PJ8_01G ?4\VYZ'<K=.X:S,@1K0!_P$9Y^I>PIG
MN;O8,L<)F-PIG*&WVC'HL%,X6Y/Z!&?4B."<O4]P-K+2##B->^=;PT_AC$FT
MV^S[!&=QCGLQ6^T;Y;-=G^!L-D)BB;GK8' *9VZUT-FBO$]PIG_"T:%"=,S%
M:B$^T=F_'/-/[!AJ.BFA/EXIEUQ;*%N_7X9))YQ3WL16S1RQ]V<@@1+M^GI$
M.=\ 7MZ,]!F4E0Z<# %:O!HM,U)T0[KPAR.B1@K;9EBV4OE07!;F0FYFDG#:
M0RXNH=O/GR?=1HK44M%;;?OKQR<<AF?C@7DK(,QA=48I,/D7H=9#B^ZC><_^
M>D2 RF+ZUO3^CYJF82<<\#<[K)':%*V_AHBOV=[?*229!L_X,J466S=_"WVU
M=[QEO=).1=P,^XD-G*R(73%P>+7<,4ZT9*;._[2FMW&T4#:> =U^M/?%2%ZS
M-^<8JE9O.*O>[C38]7TQF3I[P'"OEV4MO5@_0]6.'Q*IE8&G4A0BJ*>QLNA,
MLWC7#JXKPKY]4'3Z+#3R2KDVW&9+W,?M"'H::C_77??]I>EC*8^(3?*"\0A]
MGQ4.T\KDY,G3'L,#]D+DGGQF62XU^Y/MX7>$);0B:RT0ZVR'5I&_:*3N$O(/
M>IG%&O^R^_^?=@=(.0K47S70\$3HVX=L]&\2/$PHA8"!=\EU5'3N.6AOBF?"
M\ BHF<6"%:*X, 2;5$:QBE>?$5_!-5J>H_)RLQW1!U3&[RA9G/7QY>M/P\7D
M;\.E-F>K+6]\OG'-8V-Y5GO62^4M*6^TS%_[JF*7@2,^8OLX@"FIE:-]-5EK
M+. XN!%Q+F(Y.VZWI AN<V0]O-=E]WK?[]!&\P#6M3=\<4GBH,)'?)*6->^Y
MY>X["X 6?/Y<+'NP,B^!W[V0Q,BM/ZTU&<O97-!%R3GAR'T[UI!7[389(0W&
MH.HM@O]5Y_]]==JW]T0MC!?+OH7KS1Z-%Q-_'-[+\!I03R#@/BI4)]()]&TY
M^XQ$1<,:>>6R(1L;/9E7=ZTEMZI%I5W&\2JX1#9<X&S)P1<4M$5V256$H_'[
ML=X;RX$V<?$0ZC!O,<M805,3#4[^\KI=+\F^U@U'9"@9@GI6K[O2<G _?3ZQ
MEUB>]]N(55PE"0?^$-085M\F:!#PUB=L_C[ GX8X'LQGTKM;?MRE%6DE.1 )
MJ&;S5M.2XA +R-T!Y&HA?QG-X3U=>/1X1JC,5J,<7M';4ZYV 1618!V6UL.7
M<)74S V"8<Q[>,'X5"6G:Q,QJCJ:^K(ET"H)RGN<"Q]&HO'5J\C?07 *Y]]
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M-IJ@]41=7ZZ'=5>-!>ZC*E)@ I)7/)^L5D#O"64.3GS[PYOLWIF\JD167PC
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M$[%I8&T#$J22WWGN'\N><*CDTEFDVRYK5F%:DKV$8Z!4:GU5L?Y BTAR:3X
MPL 9R:B;3R/[=+Z/<IYI=RWCZVBNP9C&LV>(3",>$T,CD*6]&4^?D2)-00FD
MP,4EJ* 0I2WF+,HW&?.C,$!+0>V$X[*6*[XI#)#9YEQU9V(TOCQ0\TDOJ(7!
M.NH2T=_@#>E *"%74V8,U--\V#);U0+)+.F2(+=*O''BZ'+S.05=>F1VIV6@
M (!_N]OV9>TDY*I+&6.F0,JM.+Y PH<H[1\/Z; $?AURXW81A.(3CR.3+RS-
MX*=-ML^Y/\,#M*\[## E?OW#G?7OI/N@>WTW>4MM'4]:?4A[G[WR4]CT7/T7
M+5/6T:T%X4_K=:?NC2Q?L/A=&=/L/IEC.OR[[8W^LY.7)!YU(9CKM'Y$MN@6
M+)W3=D/YD&\M34%O??R/:^=Q=HX0^FJ I06H7YV9R4WRS-UYOIIA*VY$#2,S
M(Q9=)STE:HH::7Z5U21^)LQ8@># :U5U-V0FJ=ZF4.(6]OZ52YN6&V,CN>IB
M!.,=Y>!.?H>(:=M^B2)5F1GL$@QYXTY\ )=@=JIJ>,2-TTGQ"<?7S:]F]@*W
MR0&L@HY=(;GS3:N\-W0;RC]7Z<\[XXKGX69>F/-LU_3&&#] :3D\4UIF) U>
M.?I6Q2][E1;<-AG-R/AR"GIU(U+<A33:C9KR7#?3@3"["Q,P$+^*5EMF:I+K
MX?AICQO8W6YH.62T^?<N,86=X^+B.AF&1TKO,<:VPI)JEI/B&6Y5'OS$$+YE
M6[-WFWU3,( /.B5.Y/%/?[P]_Z/\8T?V,U7J0;.=C^9]<W;+7OO<:#_^:MKG
MQDB)0!$)IBG9Y>ZPR.=8L<*902FP&4,<13K1^@G)K38[+!2[88;,5S"*D0KQ
M#';4'?9&=WEA:GU+Y_D.:X-]=+^1OZ+[=:!AT[J/+?[<,B,VG8B&)%V#VE)!
M^!?09"7#R0]Y!76O=S<(LEFAOL5L.6H*$=N.]HYIO!!)O%E5-1#,;P:B^? [
MF!+4GJ1X=:976(U-LJ>DK]]D+(NAC0=%I7LV=FHNQC,H017PF.9%\P[W4KYX
MPOK;!EG;'$DR/',C@P!ZV ;71+\4C[WF$.S3%\%0\9C,/.$X2OYNWC6'];D'
M_JRU]F><PI%7I( 7'=*D!M?8-EV[V%F<=;C&LY(>5/JHMTYG]#E%BO"/[P?[
MDU.V,,GND?H8=?VWQ3(#P>Q>Z]<#%86PZ6V7[&^F97UC?9QG"#ZD=9T,1?M.
M4"-7L)N;MRLX<X*VV:< =?FNB*YR!X=>H"3??TS?)N1);=M4BA;WY9UO=O5/
M:WNR =-,\E1Z4=<^<W>'"3.LL)4(\?^EE747=CX^(V1/,/%H5)]B26%20.YX
M&[+U3+'IJQZT!TT>:1;D1L\AH^_NP24H&11#,R/%IM.K[]KI!XV+I^G!OXG3
M>6,W-W^,RD=H_1_NJ'\O_]@#B^,\;O_&: B=M!)6/;%2,X,]O%+?73=[Z=N"
M\!!]'F^*$$+(V[VM*D8V%UQ$Q3LZ][\A* 1ZSP>;Y(N=%[6YN[/8I>B2EU>T
MY*)2.*U"*+)-ZDI'0V&#1>)\9&AQ#GGH[<?GE&!(F1+P GW1?"I:_MQ,<F8#
MKI3A#[P0"KBVZ+=K6O?T#N_O;/^3HOH7S!IR&UKDK'_248==_MO!A9P0F@TJ
M)'BD0F#OH&*W-M*^A=GZQ.?Z3>TT*A4=_6WKO6A5(YO)FEY3K#1#'&7%*)?A
M-!^R]Y0JVY?!D18&AS>MR3X8=3S5W,PP2)2/!L&<<^$O<K[ANF$?./S2D^A7
M),KW1&32A!EY/30Q**#5WL!7P=&E1"V[TC/'LM#>'CX3*[BF_,TDVUX%6!&5
M+FEK$&*<R+!=RM4'#%E:9R]6Q[FBKE2_S1/J\FG1&Q5^]V1;PW":&3$*2%6
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MZE)J-798\Q?\S1#WS(&5*7!(;J1761JT?/F,3-M+-_FDH8[FX#>K@3#E OD
M0?%4>^79I["[KQ9VJH4=9'31Q(@H_]V.$=/#BK_^!X6^8&O%AJE54=>XIL]5
MB1AJVOXRY.&,&S:H7+_J!MLZEIE:X'V,ABOM ,86H@V#HNGPNT#3<1'?\V_(
M2VFSB01"Q/119A_,=N0#H ]L@O,N"DZX8LG]X8T):T-E1G62GHD!F7!'@>SM
MLLT-6V2K_&.=:3;;;D2CURU8P+>KKO 3#L[QA\D%$=FL1M]PF^FBQ3,H[\+\
M$*$ .1='^X\RT./O4:\\ACQ*[4%MT*\&^KH $G@O7I \)6U">JUIN#^VF _1
M/TNI$2)EH]T:3$8NGO-/:GUH$@" 8G+&&B1*DK^:<,ZD/I@2PE1:ENX;93O8
M[&20YH*JM$2LW0&6IHQ HQ#NUV#^SOJBA=#S>EYW;.KP,2V>0^RK-#TLQD#:
MF)O+VSV1-F0 T"LX%PC6NRFJZ#*X4-X.R.N"P*JSCO2W1F@1RW8XMCT1GR&%
MQX*".ACF6VYN(*OG16J*30_N_Z*>W/V?=8/_G3QQF8K=*@\:/@AHCQ!KP.9E
MNW<8=X3Q 1D#91O'(]2Y%X\[+V5^7N#_X%8:[O2YH:/ T6LG'*%YJ_F=!/#L
MSX?JR[S;G+TP\4C#[2UAD?YV4+F(['_-\/O ^.2GIT0M-A3AHI;U;FJ75+P4
M<9E<%]LO3$HL\,W$(SR]%>_L:IFTV!KHYUV?AS)3]/VQ =>>O+F]4^L2Y#M6
M?,L^>B19=90R,I#O*Y-1[8#X?]A[[[@FLVU_F#G.#%88!Q&DCJ(@W4CO,Z@@
M-4,)D18&D5!"[X22<104": @H8?1"#$)(5)""T5Z#0@!0N\]A-XA\.JYG_=S
MQ[GGS)V?]WVO]W?/?#_Y+WL_:^VUU[.?M?;>:ZV[C%(NA(@/+O62:&A%L"M6
MJ#KDM!-?>+'->+\SX7@JW+(\)J='N>.KD8>[&LI0L5Y979O5=UAU]V%U?\[7
M/3W;,9 <&2E/XJ05 SR\&8+OF1]7RN!7,HT@JQ]F96+=U9W!#Y\O=!*,B62J
M!(^?C/2\X=+R]OT"?FH_LK+7#7U7=CYI\D14C8QEZ5D!BM+KAF >YP85\TD
M0)Y^"V2-?[) )EF6)I4J+NEPZW8N-)I,UR_\+O\7W^Z.W)+<,H0[[-C,+%':
M)0?N-.FNRM5J%5%W)2%V]=M5EJK&?K X#06#P^O$&V[75AE?WQ9#TEKE';Y(
M'_?;H2F-DE6<D2I6[7>7SS7V+RSNK&SLBRJO @7LN4ZU7@%+BGL@"&=[Q_02
MSE"^_W>RGV=)_-KJ,)YD 5)-7;TY;03F2DC=OSD?PA,]/WD'<[E[W%.TFM#A
MC9HVB)KK0G89/,4TI^2@KF?I9:=FZ?.6?9-&&8Y0$:U-F:EI:/  BZ"K=,7,
M>@D$+1^X>G2R&0KI-/\AS.>9@ FHY4VC +2[>SG 9J@N.%59/?/ESZ(TW-O?
M,2,M,E8Q-^<C:^U'1K\JH[S(]Q;65]+,I[JJ9EVUJ%ESTG)8,-!9ZEH^H^ *
ML3.>/)UX8IQW!HOB*960N['B]Q1K:A,A?766JWU4;[@"7*3U4W8[PL.!3V8X
M7;)URG4\ZLE*NLR,2^868%JZHQ_+FP8"Y:NZ@U<H(7QN&ZJ^4[I@(LTYK";T
M0BU+V3NWN':(JU$5R[V*QKB<,N3(Q-Y]?3<OH&*I:6AD:%?9R#^Q;8J@K4#R
M7%H 5U:6I+K2N5U[T"Z37"&ZA0.'= 9/T0.7]<#U >I>7BYS(!N/S3K[+ON)
MPR]/Q)\XOTP7?YF<?8E'D.)GE7VU^.RY1FW!G!>5OY?&G\,%WIUQEKM@P.'0
MVFC4&]SL3/\Z5X'PUV:;_CD'1VS%,O#+YG(/LG_;X[\M0<67TW#%*ELE':T1
ML8.KO@2KX#$$!^46Z\$&6F^4IE&A^VCS>H\[>^M'T0C_'#?%D)D1'O<G(FBB
M0/-X.O?]!27DHJ^:F/'0,U_CQ!.K@_);72#*NP";AX4SI7'":^?<7@^,U@@>
ML=T9:O5\&I]AR0R-<=NE+H?MY4X7M2,W>FR'G[6#;I4?0I2#+59K9 >QT05]
M#:Z8Z"1#NBLTF90(!*H]QRK .+?RZC65[FMU-<]Z=RO&:@X&A'$&5M\CA[4:
M],GQ9=.),]+8@M:?%#40%[V?4.WS \B:AR/[_,\*<3HYSS8=T;>K5?;"$5?P
M4U(+J>X#LBZ[:>:V9)^HAE3F>WOO99D3QLB\S1"H;Q%C(M]& W]E(J.XI/G]
M1[(GD#!9*82,%>@<?HO,YR?V(G(F5/XR5IYFH" =^/K0GCYG@81NAF91!>Z1
MQ1X-/:3I?+.I]HU[^Z"LL76Z8N=@-O2NAZ/DRI++KD&"T+F>A_X7 UT*8O7C
M.!>R%,]X!_[\[Y0^2TZJ8QC5]%D!3L-A5=^D'RGJA0OCRM9/ BL-*@IQZBZ-
M8HHO<N_)622[RAGP&O&7#S.SU/2OURYCB5:6]@L-I](<%&$*1=;6V6YH ]ZV
M!16&2E"F6K^'V4VZAOXE*&[^IF')TE"T!;Y4W;RNPS(Z=K)HMIA)<1TI(NRE
MV&+\^M;3/)H3",>U<W4U\J:6"BY$[SU]A#N9E'*J)5&D?R&@;<, .W6]#*+=
MD/(L^VJS8TZGZS"@WNC\_).KV)KL2^>-S!1 "D"!UAA*W.\"O+YJ8@F1V,H1
M:H,P0;_-ZE?FI>,EW454OR.VZA!CU6_R9TZH9ZA%<YB.KB;9A?G6QP/E16LG
M&&8/TRZOU2R4B];5)*J_"O7-G=4+A$I64#0&H7<5'YW :&20P1QF+RRLZDWJ
M4^9L2[EB(>I9RG;31JDC&=CZ-CF>R18_$6P/&FN '?,>W8HX>;[PZL! 9Y:[
MN[M^QH<R05,8[8B3U[4S^.3?&_*%\Z99QG<,I/)KOD%]L_CH=30?'E^6738#
M+4V'.D5"G6*A<#G)");==W_N#?T]3B-#O0Z+8BD(CV#/NC[S]76WW:C^N ?B
M>V6]X8C!)(UO)2Y4TS[2]/^VS6F?"GZ[W#2,\#+7X3F5'J+ZBM8CVY>'U7O
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MZX<SV]9>PC*%MF:=M_+;%^6C$U0U8\QMJ/::%C,!9>I$==ZZ!BMJ:'K0-4K
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M&%(N*1??BQO"RH83];!I12X8WG<%*4,SF!2"RFL(!:$$$< O@4#^/0]O 6)
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MRE6#X!$#F$?S#F*WN+K&IVT6&@2/H_FVHH!G6BI.!Q$Z,2J03Y^'?YV#Z3_
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M#02>N;5>3[/Z6H^2J.2H6%LN4"G:R&>V=90@"Y?I;!364;U&7\>BPR>6<$'
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M F^]^08LSS?2W:8&4(.7J"F3S):6&C$MSVHWLI$'GMLX8L-F1T?"_#]QMOX
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M!7(%#;+QI>7QA<*(8H('G/"KF*79+U_2)1]F9>5*/W/9=MCXY>^[V3^"WS]
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M+[<VABO6@E*.UQ_R8XM@ 19O:XY&U"W=8T*+,@,G3UDCG_W3SKDRE?U@3O&
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MZD-[MI+OY_W)%B/;R'WM\"']MV&5T?UQ:.WOJIJ.#^Q)C)MJ-3*EGMF$)F:
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ME0>3#F<H>>G.4E[W+=;V,(4X:GM3S:BIV<?=5DR?!E@)*+#'RF3/U>40P&_
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M1/@"/8A^R8:K(XVJ+UXLCZ(PT+AK.C*C@4VL9EG7TA6S1 TC?DVSYU3B<^6
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M+KV\G/0X$I<$ L_TM#FK)S# .;U[KO.,FG&@U/J;X%O6'NWE0XR>/GXK#_\
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M(ZUCK-R$Z8-.&VUSU!57:GT<>QK&#),@#80Y3"D66B<30A&->;CR^9/T@#8
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M-7I@OQKVR/?>NO H24$2DU$KXS1,'TAV\Z@A<KO(MH\>!-?8'<ARK!OMM76
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MY";2?#*H*>9*>4OU:K9<DZ[OU92Z')K^@4A*)5%_??!3OI<+.\7SUZNPQ2T
MS^, F54Y5=;VJH_5'^S1^<&6CX8 0.Z7'].E'?MK'4L&=D3T:D--FL/T&1,Y
MP=L'G"$48S+([]<X4&&:[!9+QW'/QK3I ,*1JNP(8OFFGE5F?9XZ=OTV_,7P
MH:(=JCY1*;V:!VN,](IT8J?=LX%/[ALH&T^5F-H";+6V</8A=E98=F]Y@S=]
MK0(.<"+]_!@2^(&.)+>I3B1I9BV-^@"!@(XN#.+%C<5$]B:3XF+@&YJ30HGZ
M@<42)5+S](3+%W8G-!"$1BM3U85JZ\]^!'QNKU.2"6MM%QP,>!R3%<'_\_]2
M[C]KOS!T$L_&?[9_JWN_T[]"S1OU^8HD)7*4.XZ2*$<K">@-U1BN&]D]$45:
MU/<L*$:NL5ZGQ)!N[85A:[V7AXD*L(?]0<""/O"K(05&,"P6_ZDX'JT*@>CK
M8OJ^!B@#KE10&5T;ER./W6&NP<$I1-72T1A(.3-1TZLH]RD1@*5%#R&8P&M:
MZU8QC2H.C58J5@;LEA/3T.YR5DJ=NER 7\>)6/P'@UF+F34I@Z;/XPMOK$/&
M%P^(R[=]3^]/%*7<7[?$FQIK"Z):1V)D2D@6=0-K26W+87*N<A2>,$N"#FVE
M,(X(XME-"Y*(K2C._OAB-X81EMW+.:Q=YEO8MC0G^-XY+3>%6=)\[LSY%VBB
M_ /-Y,C^8UM#(##JX$_35 >P3X)?&<W^_W@9X=VXG_5X%?V7#&%%\.AZ8O-F
MN?UM!?I,VV%/(MJFX;^S]]Y1;299WC"]'9RA,<8F,S8V-&# ,CE/8T*3!X0(
M(C5@)!#)('+L:8-M0(!-1H!HP$B6A(0)0@@1VB8C! 8ALL $D446F/S:,[/[
M[;X[Y\RWY[S?['N^L_>/^JOJJ;J_Y]:MWZVJYSXMX->H)OI*WJXY7/P1+$TV
M87-E".L7MFJPFA3(T<2.%SI7B[@QQ]BNZ1U8AH0M%] VC&[XR!X<+NC4R_5Z
M+O[3DG[?0?@)NPY6M:H"1 ?Q=A"M'.QJ Z47/ 1Z:@O+>_='G"5?XW"!SK.%
MZ@'S+@Y1\7E'N-G JH8VR=XFF;JA_EF_ 054T+6(R_:%5H5%21IV#:/AZW=)
M>/MVM@]-8J\D3O<*$I!+:C:K@V:^GB 1E[50_4N8V]C)!==T$8B&+[%$U\A5
MZ B@(\"OPZ>NS9Y";9'YZAW"92(+Y&HFD@"TVO B& VR/I^DOD-^^X(:&(GY
M59YLK[8Q:-0+*],5*@?\YVN?_P?E#+3V@50*7ETER?OYP4#R4RX.V'LB-WZP
MR525MR> 7WMCS'+D0CI]T<@'B6^?^\>9,%68KC9&_,HN_?S\;<K*'?SBPJ]0
M,J^?ST.35TM47RZ;5%CB<ATPQ5*>I7!Z4>$OW08MDH4'Q=$;TVNW<'X1:ENY
MN2:(.C%6G=] Q*7522A<Q6?*N6VD7HVLGME!OU*8=OJ"-MC$::A6"8! ^CJM
ME5PU'+)J0Z3EJ"$RSXHZCF2R;LP*.M6JVKCG45UO<NC6NK>@I/6!D;E(*$;/
M,$[8SK<%]N _J"A#&RS]N$(IZ6A]^C#OINW,SY_4[1=:@@>&"LDUV8UG>#AF
ME?P6*;E*]^@N'+E9IW_2:36P1X*CU(8Z^S<D@=5&+D7]F 2EK++H6&IU^'I"
MA2=]>8LIKCBCI&FQ)YM<(MJ1#X,DDD;^(=;_%UY6^5>INY"XB6 M7I^W7\FJ
MO(:,:?K6=_GG!D9QO>CR0-B?L2H_.'NJ2EAT3YUR^R]'E8K84R:X4O:]OJ\Q
M,2HC,Y\*742;KDTPPA7]"K6-;Y737*HMGH &D9SVX,^EU*^1*SM3@H_<]7@/
M6&G&(Q&QSDD]'2(5 '72-9$.(6"T#LD!#HZ[<5@XN$A\O(R6I?*#G")39\#-
M_IJ0W"AOI%.I2JV!@+E*=:(WTK&M7L#\LZ-Z@)!:-?KE^P2 RH T\=+S4\E?
M_E63R^ CXQ+Q?H5#^17)*[$?Q^/H\97N!W'Q'1[+#LVJ)UI^[O64@4&DUE=.
MOG_9=+MOLCQSXDL9V/_*>?:6J0=K]\R@][CJ3-RG8K,^EN8_PS&,OUWDDD2\
M^,V_@?75G!6E<7-V(S&2>A3<G;/4'T"9<74*[A*:4^0LKU/[/:=-I>Q5YNT%
M;[\8J;8A6/GG6A$T5\ ].C6F]_R0=0IK+L<*-<ATYM*Q@XP8HEG(DE8K8?]B
M>[6D JT!37^"EO;RI-3O^DQNA$Q"SYS'S;P42KTIJDO<*W5,S=AB'/I)UU5M
M1<\-02-$LZJ1@[0T#D>&I)(#/K3B^@D43&6Z;7<(1GD=OK"YN#."["=YL /"
M=&]]I1LD_\AU>%L A+^7EO.#@2.3H,-4W)1KZYUBXNT!Q:2C[P9\"]5?(IX5
MFDBG:^%0(FOX 0==X163&R;? K[?8U(4.@,/GHC>\O,DQV6G:OJ\K^ST;)+K
M6U)J]U#?57^23*3,+C#X+?%V W>8-VSXS?MZ)Q_\PO/W9*_$C.6PJV02BT6P
MXX7',!V/EP^OZ&:X-R69%[M'CGI3R\,B*@,<*3!@TL;##14/%O;N\ 8!%@XB
MX\TJ:P8N*S;_YDLU>8FW'G[#MM%188H)VM@+&=E9&W@1=( "8E>-6IJ[ \]Y
M$@H%8SS5GV:G'FI5$SN.'F  6:T]2-\^;Z*'3FKV?)M%A_T&D*TXZ"J@0M^-
M%E@;?7[$F9N,HQDUEE9MYL-N*!Q*I81HBMS2EL[*1=30=&%QF<X@^FK4Y>I-
MKYVZY1ZS.?>%57/CQ6*_:' YR5GFS3HQ/F3\#7(GQWIDH]W#,G@O2K6+8:.,
M".Y4Z;,XS%N2IV<%1=5Q*F+TZ^I R/&B#J#](UMR("[DD.JB8;C%O E7,?GV
MA 2BVUGGEN%S8>3PUA %"/GO@_A_1+9;':;_X"H9>OO- #G,J!\<)!KE9Y;G
MJ&M 6!AO^6F26GQX%_-F>^0RRB2HGX&:<[1%+>9@*@.@*'Y*E7&)_U:W\]>-
MA-;I\/B'HH)HB'(^*"G"4U,XQCV@SZ&'9'+A*E U9/7%3C93AU=T/%4SLI-C
M(VZ5X9SV1\E;DC]M%FOM=/DW\3&>:?^\,EKAWZS=9]5F0#BM:Z+VY3LC@TO=
MNA)H'FM38ZN-%:>7T)DMK2F-#1BXE>]"<W-3N<X/P&Q.&]QPO'C,K;;NV-V5
MX![ Z0,%>A9P7"J"VP0\D7-RU/""V=0#6;1O?C(YD&736QBAB9WJ,YPDI:G%
M(S[I&=1=Z[+]_3_@\>V*+J\>2J;BQ9HH_FKQ\P#M]?0,1F=.]H:!^/AV^. "
MROKMSBL.4O<0+I)DU1UN(#X]MK_?1A5F;;E6IE2MG[T?KWJ&5()N I<QI!UF
M A:9<?)D=,\Y5G :]=HD5>_AU@_C#G_\1R_EO[C;=K-O#Z:/U76.@<U)=HC]
M,GK*/?:S/G;=O#G!2]U,J'2^LJ$ ' ^1UWD0(OKOE/U&E:O^,7GHG,<NMJO;
MA4/>T=?UFYR1<I^OT31W#?IY?@QFKZXQI2;_M9GS52OK-*7=[TMMV_CO0G+1
M9E%-=0S+2Z5*CU_VB$CL<EE7+&LKO-?9\KU.R2^06 HM'XDF"J>^$H,O13:N
M\$QMQD)CJ?ECU^3#D;RO:H4)R*$ %W)@90?B(,#!DD8.LE;D-!ND.G9$0.[X
MTMI#/*6N!F/98C/E0;\[W)B_%O2FY><.T([@O<3#IN_RW@*3^A(V<)TY2>A:
M%1_3<QY82;R Y5DRV^4FF8$W/(V1R<4!CL!XS-,V9.OV!PA'NX7== R:QZ^C
MGL;/R&G<GZ:/H:R- <3*KJM[<FT7=VMV-V:7ASGU0P[XW\*\B!"9C&SD1->3
MN5@4^9Z^?9"4<8O#E:: 8,)JN &L9KQG=;_SQCG/!SR;/)J'OTA?X3+$A<O6
M07MR9>GU>J*R/KH'A,L<NT&2*%\AC?&NMTH>Z]QGL;>HP.IAOUV>M6"5&&Y#
M[T9^&_F+[W6'JDJ/3U5Y/D,H'P:F-.1>_<.CBHN/6B]G.8>X:6>L&%3>XTIC
M[H%K(XX][D*?/_:"/R:3:C2Q+UKMO93T-Q7ZNMRFIM9FQ5U$K]7H[D[[44U
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MBJY"2)W_QNU+A!KM>)&9-("#W2)G'>^;NU#(,A<-,P#D/MADX%6*6S"PL8&
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M8DJ]Y)=XL)OQW)J\F 5%=&56N-0]B.%Q3\'/)\FL>M.!<#F\0(M5C&K.O7(
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M;R\-1!X'O D2#0S3)0UO(SI+D;@%H'*&%TG(QG/8VOC^.#HU6%<((SSK5J\
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MF'>X9P_+-&C6CJ[?9W3Z!KQ>G[KV;+Q1#?HC.8<H1=XX#=D[YW'SZIL?*GN
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MX5\0XO^5(J\UU_5)P6YCA5WTZ=6V3B$4_X$E[V"'-]H7B:!9NV_X[+Z@HFU
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MVN<#/YRZ&YK7(S,4GT[QW%F'HVJ+8&UQ\82))QWV<9*22\> =V1+H?&@ZLR
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M;8YXO)>B)Q$ZWH,UAB@QA,"\0G=Z36)#+GW1CO%H.<03F/'>7F^VZ&[![TU
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M6I9Z?^U^;T:I/;JT*?J\+.:)YSD]LFR,.;&+"":?[9LBZ9'YIPL-R#))C<A
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M,/MO)$\8:"!'<2(P=KNJ*$0\-SRY?<]7]M/U%(I-=%%M6M(*<G;_P7LUD6-
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M"Y9!1.F.("!=#+WH'*4,)2 EE 2"$$D@@4 2>IT9400"C" M0!A@2" A04J
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MUOY[P0HDGHAKP1 P*JD>548#V0D.O0CCSW>SSM?HUT9F\G</=,6(UL""^J$
MF"Z!4CJ,S@E3-_'8[5+(.C#W?O?BQ8LMZ6G$R?"$F(O['RR#K:IQ+HDXOZG7
MTT2Y<9Q6C4V*=[XI?')E='%T(@1XJ5.A#T>?VQ9ZH(Z'B=CB;Y[=:[O[GK:Q
M< B!*W3:W7,#9)*RDI<'$G'#E-LKA18-N=4?*B?Y%8?R\'H Y)]T3QK(2KTY
MH\LXM#LM8%ZA$:4D==%&9]-=VPLEWONO78[_;OX6=0C[.2>;@=5.^'+*;EA<
M\@B5XR<"P?B)>CL(\4H<GE\&M7Z(*BD?>EWY[.?V3IO&\;U2DOF?*7L6 @D'
MY;'\-?Q;W#\'*O1,WE5!F.8>V6-C/?-JH.="KN.5VKY;9++&. ,]:9U;<(U(
M=N'EE$G=;I(I_6VXI^2=YOBFY=Q%<F:$0MV/4]KZXTR5YVC1JB%TQ75A&'3Y
M@)L8)/'EE+C[^H92FYE\63CFV1!M@6:+WMGFX;E #:X)P.2T;KL74R7O;=*@
M=UV@NHE='2!(X4630DYK'4"XQ?2!-(MA9.1OY"XH*"'0+N,R\JH&Y!*1HS<I
M===V%#CQ;WW^'X]#FG;/J5E'?K]UM);XY51I=:\#([^I+N(63>RZL%KP@:,#
M2P6%K @:SL<D]OO>W=>@F(UII"W9K1*<VH0>?.+W)O,3J=U<>UA&=Q^\K.A9
MO5Q.A'BJD;6M)].E*=C985>W9U$W@D/OS%],ZZ41VM1)MSN!FI[OBXGG2/-!
MI;2Z$N*Y DJMG+0'[L"W><CI1"FUY'?>K9HZW<TC217!#@-5G=BIL?HMQI'H
MW&J)6*@RS?#A:9SV5#-;X,C1XG5MBF%EM+S#";CFJ2PA9@RKKQ>3,(5JZ 2;
M:5/5XDTJO7C3?=ZOP;AZR#=9+Q<B[]$ M7O0,;LS+J=37H/&.99\.?40D-UH
M]"$4B7B3%0FKCOW/A=3_F7RW,%?NM+JN)!_3/6[;V#*/V<\L+4H,,=%0PXP)
M(-,SJM/RE3T)&G1?*O 6_V5,N%SD!-.5^HI?H^-"\O (LQ/"6S]3'3;5S^;B
MJ@,EG@6"^SS7![#\@ \#)^S&BDDT32/+0/>LZ_H8N/733^2TC\'J8HR[$K .
M"/HE^'U51:?AKB%.-QS/Z+0X=V]+HR(]?6==H<V-33#_%VT:Z\ A*M'.LGO9
MX7/KH89CK$6:I67[,P,IH5'2FM:(?'WDE%=VY.^S;8[.@Q7,#I*\2('?6,&<
MP\<03 W(SMC&0%VCQUJ (KF[_G6HWWI'".@1R7_Q/4<QP]$W98G)0U&*R>)O
M3=C@ %^58);>+C8"]9*J,1##4U7%,E3]JV[%A,O8:4^(1*[*7/!F R\%^F;G
MS&6V:Z90*TRM?/M.=VP6GE_HEQEIL&'6[6=QCM=Y2T&D^8'5M$]] YUQ!$KG
MB"5D2*5-PIZ+5IE?R=-_U:3ST>\>+R/[I[^="\&G[_>'UE2S]*1G)R;1#ZYE
M+ZA K)O#+NJ!Y@K#98^7/$/]*N9I,\I3S'S)8(O"WYE%4#/8^>#^ZA3U%$U/
MPO7>]1W=$2UBJV:;KF7]'BI7^7;F+-?PLHJ;G)R>QE8=L'/^!K-KO[57S;0;
MH1($S.I?2734!UAI $7-EZAJ7SV+V)>=?6VY -'MO,HS EVU!'SZZBZ/3U13
MM5M<VJ0!'Y+0H/F>9W\.J3$S4FZ_V]Q%D+^<^A 6?=W)\36#G0]67]L*#%K+
MT/0S>!V+".L5/,E,KGYOY<BBB7YJ10,Z ^F57<2B8(1HLAE0:+K^RZG]4>U8
M$W:#I%"P,R2GM+IO22ALU>A3SG"AJR;/J-WJ+C.B"&.H5/L5P#7[&,3_<:+*
M?_WPQVWK)=N/8"RP464RY-7F>OGOXQ\WT,.,W/"2<!>5G/TLJ7OC&I.NSXLH
M6U96S\XMU&9;C.Z*7XBZNSP/OF<A&HY/"8_/S=@Y3'G6DQ!), R[@ [W4K.!
M.71/,7'6A(7S?A,LD"-Z;BGKW>KP.L^URSNK;>ZZW.UDFI76,>T5-6/"WD2C
M)Q1-DKSQW>7/_B5/7H(N+M,3]306DEC,F4=+^V3^@WW/"2W(.,!S:]N&9NW8
MSP@++.G.FM+&]U3-5[]9T='W+C0T3VWOFN2M0R!FX&7&>6'ER&D_ ;@VK%(T
MD3I>WZJ%O>9-!.JT/VG$75: <R0")^DATC*_9;;5S1,4*,7SY1[S'K.0&I&>
MHTNEU>>7\GX-O)1^$#X=E;.C2QD>JG5,9$CI-K^='"CTB\Q*=6H&SZ"K)7*5
MHF=ENU>#=Y!OITRLV83E]W^Z+QN?\,.+'E6/LTU1#$N9^\4+JO-*)#DX05\6
M9P\A(6)?HK/B;[<O>3^;0_*U:%PD41%VQC[P:!@=UW_&S(7-<_S1R;%WIG;F
M(D+UC%TE,Z7WRZD ?K4E+;VF:#F]!F!;2Q@D0CRZ'CWC]U11P]J:P/LV9(,J
M>+HF?QB];3=%XL]JW3"GJT![78BN8WCO2C@?@-T=P\.D@'7(62X>NT+P:I,K
MSNCU.-(-UX12X^_A=T2S<6^3&^,;];?DK,-B'22>MCC5C2DET**3/EKM6>D-
M!D;X['ZFT<6>55_+-:CN?##H],#-!;Z^Y1@8"3URZI9:E3/U_$1#WX=K$#1Z
MIST!^P4OXC<69*K57*@7Y)B$SS1FGCX\.\#T04Z( X/S4!M+=U3U3GKE;WIL
M($PXDDJ6FH(O-Z;3ZFZL6.LF\T/5W/]:P+E(<OS;/5Z+KE5LV+4.]R)T9D+:
M'J]B/EH2H:Z0&\$OVSV]^JMI#I:18=I1M64.:0X$7-D\NW+BXA^\^EP^N$RE
M<)QE+-J3ITA99%Q'QM_N<:;44>B$<!7["2827AS'!#I\NLH%*=)SBQW#&MY$
M/R]YGR?F*&=:5_5O\H9"]-+I0&/K5WHO>6%!(W?OU?+J(IOZ,!7=#TIE? ,[
M#UL92:;R)B'<-3+N2()7#*/-XN'XX7U'[2J6+%YNPX>^&*#0L5BCF3WP[/,<
MU)%\K3CKQ:8N"$NF"EJRS^S3@@$.;>AD?78D>$0&/)[38I<Q9YI.MNKDN;)P
M(IO<L6U %/,%7JG&3PT*D,A1VNN.,SGQ];W R>\AJ-$[X.KO!TD/=2OF,2$7
M5)Z)F"!KF#Z<M0M!>H.O7L? Q#*T,^Z:*=^\S (D[:Z$AFN^9>F "[(H)4M&
M)H![5Q_D49%9DD+F/2O@W X&:79K7XU/#REF(..8V))E.R  \$[C_72#3MOF
MON"':*'ISSF8"._V\:A8F.VK\A3PW@&Q,?E-9Z"(R0\$9 :T?"N5H_T6:/ !
MSR_'@^^7(%!#@0('S_HJW-BNG9LH"K*YJ?U,4F+C^.3\U-IP98WH9YA^*3*K
M= T#2)8KY1QL .^=-FBP_ J\3L"7ONP@^,?_8/[_'\FW*5*_7_[6%!_6W8X=
MUFH+$]M_1% %N--PY^12QB-73,@HLJ]#T-9!%6OK,6TS.*U0V5V4ZL;1Z%]+
M#O,E\J5H$Q/:#GDN,^'R0=[-A1UE8HMYP.X7R[8[D*FZJ0#?9.T5UL5LIC"2
MI53B4GYU)M$FM1?H7,H !?AG\Q J-LG"UZ2E_?'2Y[. _Z(1OO=<7BGUC:<Z
MLT?E:$I-_7F'\QQ&5__\KDI9^9A!8*L^2^!0GV!GX3"UWKN,3U/H4W;72.T^
MVV3X.F*RQG@B$,P2!-45>'B$>'C SL4EO6JF$CN?[!JDK6D_8ABO/O?@!:U/
MT*4IJA"F)==5F&L@; <":/"$WJ@#K@QP_U@O+C=\O%/3^GG$&_KVX&%J<^>O
MLRZ^EV65_>M?TLTL;M0X _U,G&49-?7L].M[V&!//&8_?7OO(7N4JT+MI_O,
MLZ(M*?*ON8Z*DY]6 OT'#%UDNOIV"Z 6S!XTPK#6=0>ESVH$1G951OD]05L!
MQK#7YU%=(\)6!I3B0G%MA.C!$;5J1L?PEQJGJW\W5=^8-$I*T9XL"U#-/SM2
MYR+#VPVU)F8#+-P@0S%[NI?,V+7YCBE;53/*X8@\R4@8*@8O%_N$H2XLGV(X
MSJ[TE5O1"@M(S,,?'?CW+L!5K:U4VD=GFN,(7TYQ7Q#E_[3:ZYU!\N$SWA.N
M\';8.(=.G\+2[=U=1<\K9'+7^LR5"EA9#9?T</9VCA=%C.0KD$8_?=4I.AR%
MRI[(#M?7#]L/#@Y<@H#')VQ+H//S\VPS[T<U-?GFSI3A,G!I?[J9; R<X-7T
M0RQJBU*02:!DQGNH9Q&??G5>YW"06R-(P^FK]U*^7O8FR8A22G*DI:6__G\V
M2=3;9J#OC.U295&OP/19VWR3PY]F>J3N>^Q6R3YC1W;+F/NL?X@TN0(T:+"^
M6>NI1FW>(.TJ1HX>C2XY#")3:2@FS4Z4H :E>+?WFJ85&"A*9VX2'VH?UL?O
MLQHBBZ8T>"!G7SL0VS7)D4!60'OT6L6U7Q*[6[TZT"J%B-<AIMF(Q)P8_[^[
MA7IY.A#E&^F+\0SW>[#5N_4,!6%94#365>@TN@+'G,UN/5_19\X^OT/&5W9J
MR"@/MMW!RYQM**:S EN[<1J37V&\AW]FYG3<_R;OTADP[IPZ/76EGE4-XM>H
MOM I>![U?LOR64\ A/,VWG\D.*5II1&ZX?">4VG)6Y]G$K="5YJ*<@8G[=?[
M'(3Z;J5:Y%2A<>+[_7?524N'%L2<4KO.),XUG&:+O[]Q#X<Z(G-!6J&I44FD
M5<>HUU"O0E1O(0U4VUZ"#TF]'+#S:;#/RO V$E0%S0ZQ2*QU=*RG/EA02IY9
M<[Q>-MPW!>YTR*TV172-]S]W\^Z"#)09ZJI6:%]WO&*7C!5J@G:H$WEKU2-K
MO5&:AJ^'*@E)09F9).H^DGX[KEG,EPOHJ+'L,>)H+9&RB!+J02KC#+BN5DD\
MK'B#09_]I]N?OESKF[O:T^X](5&J[7.X"3\A'X*;WD/[IFY#R%&A2S]ZPPN=
M;N_[A.A<MM"T]&EBM2=]L*D($I_)]!Y("=NV2]<'<,1] G+Q;X/R,H>I!<,/
M[\/W+"I&W@!9&>_E>GJ.U%37KH()M=*93(!]J_K=1:0#A?6*<GLF+FX%<W3I
M&JBS 6QVM(/40\Y&X3Y83:/_R?N0%19V!EA5#07-&=9U0>)%/@NGM>55HL2"
MOIT_-J\>0G2@)^ .B:7I]VPUZ9BALI4':>!K-3]D..B^]TUZ6:F?,A10NA:T
M8#\L-P510?H3J)DL]-SX^QRY4"U?.TU@B#NPDV&MJ$C'(_4\*73X$L6 8P"8
M"9PK>2 T DE<AZ"_^^>0%FT#V4B.Y^W0_'2K5[/T7N.]8:_%YN^NJ&<VEIP-
M*R<CDBI+; V)94_H\WF_<Y!9AV)PDZPR_2RV,36@71(T2;E=D'>IY$442!T(
ML/]@!%!?7ACT^W![OM=CK%HU[Y,#.DO'X[GM\=ODVK<@;NV^=E9AF1E&(W,R
M:9NQ%M;;]XJS5E.--3.<5:%.S-SFX0<G()V7QA:R#'^;1S#7<L8.=8&4CGV$
M%RD>?NRQ-K%CHWUG:VB,@9RK\V((X6VZXNF6[IHC!C:H*1[ 42FKQB!>3S F
M4KC 4')#=,K^@\Q?V(SO W5-3T</R0L\?CV1EG$3%6)AB.:^"ME6>/G\\LV4
M4<T>8SVQX^MHWM[YO2JZ?/NCBM?LZH[^+8=7R$=EAKZ*"YZ<F8?\[U&R51.B
MVMYC0).U(%)KU_SL7!G76I7@Q81J*S&PDR"-UBXJ/9[&ZV+:@RSM0%P<;][#
MEW\HJYYDJ+/E@/2F%/]-X+ZL'1@X%,08]+.J+^S35U99OS6H.;X;^%GSJ^&/
M9">W<)WQ7$:)04Y_V62/CV/Z#K7/2@CHAYI#M4F.VYD(TX@#96O?5\+,RO'
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MH(T1K_G:.M=^@JG>/+I"4:&&&AS5OTW+G.4GQ5K_937AQ/MWJ4'X6-DP8C3
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M5[MNH:HU%^>[U.;%&]C6!?,"<M/K96,JS.38U9XHV$J?U"ZX8EYE>MFN9A>
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MZ-CH[F_91"T=G-W?'96ZYI00]QQE_4#Y#'C-XGMP#W&B*"#^R,ZAX&F  WI
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MRQ[17*,C_Y5=PG>VA?W]><J$US7MKIW.,>_216B%J@I$$*[H\ZJ^^ \<Q$-
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M7".C7L7 ^K"WY*_M+S _IT6C2WI!IF#[?XXVI?=8%\%=JOBC#VO$H$59](D
M5WIR<LJ6H96;Q_-NQZM>!:NIVQ_;)NCMYE"V9$N/O<+3V_\N#OZOV.F/K+HZ
M3EU]32/S920JTJ*"(:S@JX>OTC$T 3XG-C9%TI>8@Y:D.,KX9?E;NY6F>4M'
MW$51J>@42D%*<4ARAN%)6AD*W4-U^RY14[<A?^S6!+GTZ$( TO;V]I9?:R];
MSUW89X2)X_KN_IAG@'^LWUAXEL?8C+U[U=-NLB*H8NR^5Y%G=CH]H'?4V?VP
MB"\R*D<X _AP\1",] #-JZ@7%[CWB/%\U3Q38@Z=L>P[K<96B.T9R[01$S5
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MQ5!%Q9"D^O*VN;XL1+C325<=8C1>^BZ6A>H,-Y>]G-G.QVG=ZKWF/ 9"!%D
M2TNO95N[@D;'UVUJUM@R:;N1!F(R["%LNZE'PQ+M0M1'KM_I6;!8N]CEQJ7F
M__A_I7PQPA YQ<9Q_**/]L=HDQ&/[!X#?2?:3U/C?JH8;>O^TH#H +>'D9]J
ML\;[^SY"2FDW-ZT9ZD-[+O,)@X.,APD[:A-'JJ_Q30-CJ74SKU$AYNX[3H9?
M=ZJ?UJ[\LT_^(;HX.'E,(;"0MU?:8V,6Y-PY2OMAO%WJ-H<ZIR5\OY1$]6%'
M:X ["T4+^?E$D,LP4S=Q>0"B)X#<-'Z]+%YDW#.+;DSG$^P/C',G6$QAN)P'
MHURO0DH<!W7/]@FWEQ N=Z*4'54=I*0@Y,KXV&O.H!"O\H>Y=U;6>E?F<FK<
MM 4"K4V?8/PR\=IR_L(0S(8BEJ@W8YJ?YI4:>;W>;&0K;E@]PC$R^E:-51R^
MQHB6#R/T>))NK[ ([RV%NND>J6'M5S&AU%3H0@JU@Y>R#/@#).*C@K:MJL+Y
M U[G,Z=LE!#M([48_2;?D959?&$]1G]B[ON\\[Z/])HLGO!98_WI3XP?-%,<
MZQB3613;_EI%%(8XX#:,N=8XGU.XT^U?8WD,C(JF9)I81J,;U4.2J=<X/:.%
MR!P^,^R@B")R9]=%3T#AMCR8X:Z'T.48WV Z(-I\WNW5;"HA3&3+-6@T8_TL
M*OS<?T/AY[[Y4:A[]=KG*IIW%7Z7_7/[NZPAV2=OILK+3B0_^SPZ..&YYHHF
M9K;4X8>8K$[-OPZ<WUM'!L'RNR' 29;+B6AO!9S0S>Y>![\G7K#P] <N(Q?A
MP,J R+4Y1N&:C^AHCPX!>K!C5G$G^7>)>(U&;R!1R24 G?II\/\SNOY_L^C8
M<H<<PR^GRNG?CD7=BR<KUQ80XEO<,WJ5:YE&%Z]'=SC5?\[ U \KF<DL.6;6
M5P)-\%<&3G#CG'"51'0+ .EIL(TJYW:#H$RJKR&RH*4AY ,]><O%\9<.\=9$
M)\DP&4)P[,I(1M 17["76;T%%.955LU5;\%4TN8<9@7#FT.J9Y-2%I.HXSB0
M9\K.U4HK@/ZTJ@DQZL.)+&S.C720$MEKV2LLEHBH,Z$2L>H@Q#,&_LI0^_QK
M)D3-*?WSZ;OI--NUKNDK/!%FB2?=XL;V?3*-<B<YN@M6T='G6-$!M3/RAL1T
MH(T%U4^::BQ^&4JHF3#O"@KRWEZ="H3Z $S,**ZISQU/:X][(46$VK;>&SN$
M9Q!:+<(4OYB?G-_B5Y;S[>[OKC)2>5F/B8NO\8X$R3[L0<M&,!_9J?YCF-%8
M-"=K]/2MTVJB26.$0POC/-MVDZ?GF_:0*%_-ET&,GN&*377[5A_P)'UK7, X
M'0]O"- 2!)!72_Z0H^KU3@]4UK<E:U9;8%\7;\$?(41N'J2&>=9$),^01 W3
M5'2&6HM/<'YRAG0BL4%F^Z?2ES:7.\R"?6C"=$.GJMIY/D#L7 WWOMK]FXP#
M*:NV=XFV.4HR*GC2O=/6*%):O]V^L7SVT-]7*>-7 5"<[U)&X7OZHXS9XW,!
M+[;W7UYLG(T=W J=0P08U4^2"D/H%5(&D6>X2+_L7WL\:6<RI%,"_=23DE+(
M=9_XC$+#K:RHH]P=4Z\]KBRIIGF110VAI V':_*?1%X.ES%1=$_0T=U9[B^-
M#C"-S5EPE GXD7*FT]G-+\'WR>6>AS7XQS[EI!AA!$YO0^ )L.](-#N[X"C1
M<4%1@*ZS04?(>G!J3'S)\WJ<?_)ZI.X<T"##; =3\%OZ#61*R9.4F6L:Y'-E
M5%1^GGXX]/\Z\E=ILKQ9W#S/6.TUIV/]*(S@=XN'THI[<&EA!U,]6M&](TK#
MJ/LA1+Y<5/U(TZN-RBR:=:FM9PV\OQXO_W;\R*#JVIH )BG2VC7-,#6@<6\M
M;<8 >YWSB0I&&?J"K?BYV*;'P0>TZ(J\MPXV")5&;33K+770.3\3>#7*1 4]
M&Q)Z9WL(!/26"F"(=Z7@=GC3J0-//?+VI#U?J*K*!X_+-NLD357H?U[SN/A
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M-@^253)1K9:J&)O\KC*/QJ"T:*0]\:)#Q%^P[6?D&GVHH1'+R231$IK>$,!
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M:HO GE+ZXG. A.X&.17/W:QS3IP5TH0O9V]F.1F1M_S?/W+TKF9WC*ZD<^S
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M=WTYU7%9_,RR:9]1SP(0XA#K'9'+(@43ASK'>VSPLQ\=G'7:G3*M"_)G#X(
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M5BL_J8(*)%)CYM:5*]Z>!,5>(PW4?JE3CV;'D'XXG+(/^</MQ]O5A[H.JR/
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M+8<HRR]'!7N\Y1TC:6<=?=31M+Z41%P3)2"^Q#8,B&@4*P-A9$>M8#?.V?F
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M,_5[&^'U@N;Y+K'0_?J3V5Z]U_RST0- T\V,LS@5$@D8(,4API) 0K5_2$B
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M\-%^Y.4WNE=%V;/0W5(/0;WH-D<GG_5$*(5>CG,S)S[(68)Q*E""(*9*<T9
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MDD0D5F'[9]J?VJ#7ZE7!3X[1OR]@L_,#>H Q\(#>XS# ^=,9LWT%[;YH?=P
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M14Z-T3[SKU)L%\4N0*W]KIK-4VN1K:Z@VY&:7R@'9K%:V1M0J'L((/CE2Y%
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MCR4%+N7FD 9+0\#38IN#S=X$EW.DZWP<5UKI^>KR22_RZ#FG7%M_ W;V@P8
M%^*<)_#!7'EIY^O#^5VLZOQ_0-=?T-ETX-76<JW*_;Z7<3:X#[Z"LU*BXT'M
MZ0W\_<G2J^?](]7!T^VO="V:J7VVCT_FK?S3//_;N[64=TOM4\A\\XENY"Q
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M)$M2%3B-  PA!04A$"28DS227CF!6DG7&GU-;0I74@:W( H:06U",;IQ-=B
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M5,Q9\(K7P4\E^%^#. UOY,_4/QUU-O!&L27^K[<E_^=_BK+PKTEX$ZC/MKQ
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MJ9G)>NW?"VE("]<)HJY;9 _-.!Z1+BH6?E"WZ@-<H*,&1_9^NM4Y=7S./#?
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M*]@K%C2:!>KS"EJZJ<R'':&B5*_*&1^P#W VY)KG]U<82-\W &..H?E]@F/
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MWP] \S!S*L/J^US488&8O<XM3W#CQ14<97BNG:BC)>L_1HJ.">RNB\?H=3J
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MEC(:L#\;)!0S)YZ9 ,HRY,01"DXX#5GQJ(0SV58O+CLPF_8:L5IWJ*JDB@9
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M&[H(3I((FCF;7 HZL^Z>:NY :+]70_U#MGOM-@#A[5@[^C&<#:@WQ"@4H\-
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MY8+SZ%NC/^(#)R IYQH/$,551P-KUM+3B)_X^C!9/^SF<)TU@+][,EQS43;
M XL(@8=65AD/+8,AGBE-EA3'+X7#HRS6OG;<3-'/;S#K8+"BWJK57721K5N;
MU+AA_OI&Y&Y^/)L/+TN6_4X:':5[=EJ\X^S._H)XC62.R$0E1C'L8:X4_P0&
MUJD$+'";)1,*/82?,9FS><\O-OGG\<3/TO1[<8X6/GM)RH\#_BMW]P!$)4Y*
M<PC<E8FBY\Y*ZQJBP5A+J(H&9;2I9>-!\JG$0R,NP:'H>]8E[4/5#7@%]^Y^
M;TW,HCW3XLK74N>-, 2H#!R$1\GBWR,@DU1Y9:R4G>4BUQ'4" A[P<KS:9T#
M%=<2"@^7[&-QW+29YB((IS/D&!?EJ>BL*Q. !"X%)<&K4'M81^=,-;(;#@=@
M=S:Y AI:><BRBD7O.8++&V=""<82 I(KK]U4E&!-:=^H&&7$1!MMV*MF<_UZ
MC6"N#62L*].LH*8_ET&^BX(IDY*QI"'KH-$FD'+<T022LB!-H%(]GH[:D@UN
M[2:W*2>D+YBTM%7NY8;^/IQ_?<+O["'#LXM'ET4K@['XK(&3,G.3-42NRW,%
M%\ $M!=1,6=LD$'QSNH&:C+RISDO]L3G%G4PKPN6O7?,MV4;PKF;SGO=-\](
MXC<\O3],9K/ENX843\8WHQX'B9E(7 H@I/8@=+3@M0S@8PXV:$6$[BQUV#5S
M?YK#J-_]U2VH_K2G5+:2B=+GU)=&N$**TA  Q:$,593Y2*.K_;JWOU.J^^J2
MGWT7U0/+@:?4\3CVD:UZEQ8]P(;?;S5Y?4^"2XEUE:S:9>V.<U5[B^%54E5"
M!D],R;U*M-LT"K3;RH-S7KDLO0N^LR"TT7='Y=\O \(4OHZ'_WV55K4^5EGB
M+*=@)44;PJ/"'2L)X/<T#RQR6KU;;Y?\-!*+'(K*+JJJJD"@ 3?GL9WYA/]N
M>1]MG4P:SS_K-4<!.P+6<05>^.7-GJX^G^@Y6AJ!8>]HF72@ND8AN+I<%H0P
M5X;-Y;R8=:H2F,0Q3G=,!,<\HZ%V&<#SU/0+PSK:W@)">XB^01 MAB+]QV2$
M^KF75$A)*,VS!\]*LB)%@J>&() YQI]:H_=H:R<UMR*L/6CM@X(7P'6X2AK$
M66E<%I8=;"YO9F6*+)SD$8R(MC0N4:4Q,@?*9<I&HT2KUW:]3%6_UUZOA+ #
ME=$PO-X-OP\CAGH7;IY6G$42@S ^@S=EX^3(P$G%0"7GC B)1QY>"69/J>OW
M?NB5X7:@<AJ$W<5P]E_OIRF=C'&--)O?YTQYGDO6)-@R6]A; Z61'?XU$.N,
M]4'5GIZ[/77]MAY\)=A54DZ/L)M-YX,+-_ZR=&#Q^](J0X&9,E&8& X8PTMP
M7-(<N;9;1IKXJ??0A'^[0]*#!1O) +423NZOC!80M *^C.@L.NUA\5!=)(R$
MG/(>M&2\9'.S\=4PU*?+?H"R'JM[#\GUK/"_I_*D+,6C[VGJ;AE0(NO,G 86
M D6;E_'0C4HB T:FF+0A<:O[Z1=4OW;QGD&PCPHG->79@.O2D3V]RPL*+XB-
MPH!6MG1QT10\1SDG3X.P5"HK:T]RZ9JG1K*WK9R 34*I@:VUZ3'O8Z=T0+0G
M F,;D-DP$)J4B$<0X)EJ89WCF=2."W:A[T^90]@363N\V3Y(S4WWNCV_.#L_
MOOCTCZ/3=\?__OGD?)&(O^T(>CZ=?$O3^;5;3LKY5@10H1!A_T7K52!48KQ2
MZ<'->N<CA.#1O45O,[W%HBLN$7'!<?1N> +KM %N"$-H,R%4[43DBT35&WK[
M[%*KYB&$29<P@L]RT7N+1'#>6HC,ZX0G'7&>569^6]KZM:AU<?/\7-N*^FG@
M1'^6FS?7M_E$G;QE)CFPAD<HCWO )>> .1<\#];KZCW2MB"KE6FX-?$PZ58Y
M+>/MWM4H1U'9TA:3LF1*7; $FX.&B+LU>:YHHJ^&MU:2_=6AL"W4]M1+ U![
M.[E$_S1-;UFYN1P)P=*8$J3,'11?&!PG$K01^ .M2?:U*ZZ?(:512.VK\DE]
M^3< H_=7T_%PCB$/BNC]\$?Y:G93J>"IH%XK\%9@Z$.U!ZM#>99*DU'&1NVK
MOXIYEII^DQA=@ZF2%AK T[.2NHO=K1'4<A^ 22&1(V/!!DV 9BDXUTXR4[O
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M(IR]5VIUPY".W%@O.5@BT!5PWH))(8-2)/GDJ?>QML_T(E$]1W65X=:-+AH
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M[O+W( DVX!H\M(*+W>"=R X/*M#6*Q .ST&'#A)HI-X[4EK+^<KNP5,J^KW
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M\<K\Y9+4^Z^+E-:DFQR9T8P+*(E+(,$".!\\,*NU0*^$X_D@]^>I+W<16#5
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M@'D.04L)=&@47TJ=B-U;J\9AT<5@C1J_X%XY#B9'1A<O9WWLE>W=6I]CMDK
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MHO7U+%??]RI<KE^M4M8N2AD@NGKP>DX'KRX"M$1> K=*^IV2#/2%6R"BGVX
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MTXO$O([$LEF 0E5LR;3ZY]Z@GP@? P'BA\6V!(TW@S,(HHU?1A%&0QJ^WJ/
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MK!M1[WVG:[T$@^ESL.>W%^SY3ED-)ZF"D[UOCD WBM]OU#:.UJ/TUG#=PGO
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MA?,GDI@H8+3'!:].EJ=%:*$)E11BUOHZ"805IJ=PL177&#^+%\2:BT*JZ*H
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MC(IL%]L8N8'PAL[EE6@-1LDB#T;WOHS+4VV:3FXLC(>V1NJQFS1]8ZEU1Q=
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M'36V!9Y\>^!9:9$;+H2!1AQB187L:2"5L,9Z/#>;3\%BYPH 1;&2+9\JUZ
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M]Y>]?D -W=:>IP[L=T</Z#NK_P!02P,$%     @ %4$.5Y35<$5<"   LBH
M !D   !E>#,Q,E]C9F\S,#)C97)T-C,P,C,N:'1M[5IM4QLY$OY^OT('=5FH
MLHW'+X -294#SBYW.<@:4[OWZ4J>Z?&HT(QFI1D;WZ^_5FO\AFUBLB0Q6\D'
MA[%:K5;WTT^W-#Z/LEB^.X^ !^_^=O[W<IE=*C^/(<F8KX%G$+#<B&3(?@O
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MW7VT,I8%3 FE^!&JQ2S4G48+BV'IS1.3VD[-:Z=/=;)[3@GZ^WOOKJ7ER.3
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M2[9NO+7?^3\D]NT_0OX%4$L#!!0    ( !5!#E<+T(C_M@4  /H8   >
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MSO,-I-'-@@5,0]UW_/ZQT2]]VO%L W&(T:/RJT,^N1?R<#2=C<_'P\%L/+F
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M/ [[) R+5MNTV46'_Z [!VSAT7(B=&F=<;1L&G9<G@I%M\?!]A>,@%N[();
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MV\.Q_<WC/U!+ 0(4 Q0    ( !5!#E?JP@HS"M0  $<I"@ 9
M  "  0    !C:S P,#$X,C0R.3,M,C R,S V,S N:'1M4$L! A0#%     @
M%4$.5V@Q;N=U#P  U:8  !D              ( !0=0  &-K,# P,3@R-#(Y
M,RTR,#(S,#8S,"YX<V102P$"% ,4    "  500Y7%#WXQDD2  !2I0  '0
M            @ 'MXP  8VLP,# Q.#(T,CDS+3(P,C,P-C,P7V-A;"YX;6Q0
M2P$"% ,4    "  500Y7XM10_&Q$  #Y]P( '0              @ %Q]@
M8VLP,# Q.#(T,CDS+3(P,C,P-C,P7V1E9BYX;6Q02P$"% ,4    "  500Y7
M6#\$3Q-* @#Q8 , '               @ $8.P$ 8VLP,# Q.#(T,CDS+3(P
M,C,P-C,P7V<Q+FIP9U!+ 0(4 Q0    ( !5!#E>:+R%GD*<  "8U!P =
M          "  66% P!C:S P,#$X,C0R.3,M,C R,S V,S!?;&%B+GAM;%!+
M 0(4 Q0    ( !5!#E=C=/BL8G   +$"!0 =              "  3 M! !C
M:S P,#$X,C0R.3,M,C R,S V,S!?<')E+GAM;%!+ 0(4 Q0    ( !5!#E=M
MGUD!FS@  (-/ 0 >              "  <V=! !E>#$P-E]A86=R;V5M<&QO
M>6UE;G1A9W)E92YH=&U02P$"% ,4    "  500Y7? W_HF0(  "Z*@  &0
M            @ &DU@0 97@S,3%?8V5O,S R8V5R=#8S,#(S+FAT;5!+ 0(4
M Q0    ( !5!#E>4U7!%7 @  +(J   9              "  3_?! !E>#,Q
M,E]C9F\S,#)C97)T-C,P,C,N:'1M4$L! A0#%     @ %4$.5RX@ZQC#!0
M#QD  !X              ( !TN<$ &5X,S(Q7V-E;W-E8W1I;VXY,#9C97)T
M-C,P+FAT;5!+ 0(4 Q0    ( !5!#E<+T(C_M@4  /H8   >
M  "  ='M! !E>#,R,E]C9F]S96-T:6]N.3 V8V5R=#8S,"YH=&U02P4&
/  P # !V P  P_,$

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
